Chr	Start	End	Ref	Alt	Func.refGene	Gene.refGene	GeneDetail.refGene	ExonicFunc.refGene	AAChange.refGene	pLi.refGene	pRec.refGene	pNull.refGene	Gene_full_name.refGene	Function_description.refGene	Disease_description.refGene	Tissue_specificity(Uniprot).refGene	Expression(egenetics).refGene	Expression(GNF/Atlas).refGene	P(HI).refGene	P(rec).refGene	RVIS.refGene	RVIS_percentile.refGene	GDI.refGene	GDI-Phred.refGene	avsnp150	CLNALLELEID	CLNDN	CLNDISDB	CLNREVSTAT	CLNSIG	SIFT_score	SIFT_converted_rankscore	SIFT_pred	LRT_score	LRT_converted_rankscore	LRT_pred	MutationTaster_score	MutationTaster_converted_rankscore	MutationTaster_pred	MutationAssessor_score	MutationAssessor_score_rankscore	MutationAssessor_pred	FATHMM_score	FATHMM_converted_rankscore	FATHMM_pred	PROVEAN_score	PROVEAN_converted_rankscore	PROVEAN_pred	MetaSVM_score	MetaSVM_rankscore	MetaSVM_pred	MetaLR_score	MetaLR_rankscore	MetaLR_pred	M-CAP_score	M-CAP_rankscore	M-CAP_pred	MutPred_score	MutPred_rankscore	fathmm-MKL_coding_score	fathmm-MKL_coding_rankscore	fathmm-MKL_coding_pred	Eigen_coding_or_noncoding	Eigen-raw	Eigen-PC-raw	GenoCanyon_score	GenoCanyon_score_rankscore	integrated_fitCons_score	integrated_fitCons_score_rankscore	integrated_confidence_value	GERP++_RS	GERP++_RS_rankscore	phyloP100way_vertebrate	phyloP100way_vertebrate_rankscore	phyloP20way_mammalian	phyloP20way_mammalian_rankscore	phastCons100way_vertebrate	phastCons100way_vertebrate_rankscore	phastCons20way_mammalian	phastCons20way_mammalian_rankscore	SiPhy_29way_logOdds	SiPhy_29way_logOdds_rankscore	Interpro_domain	GTEx_V6p_gene	GTEx_V6p_tissue	dbscSNV_ADA_SCORE	dbscSNV_RF_SCORE	gnomAD_genome_ALL	gnomAD_genome_AFR	gnomAD_genome_AMR	gnomAD_genome_ASJ	gnomAD_genome_EAS	gnomAD_genome_FIN	gnomAD_genome_NFE	gnomAD_genome_OTH	gnomAD_exome_ALL	gnomAD_exome_AFR	gnomAD_exome_AMR	gnomAD_exome_ASJ	gnomAD_exome_EAS	gnomAD_exome_FIN	gnomAD_exome_NFE	gnomAD_exome_OTH	gnomAD_exome_SAS	FORMAT	AB_sample	PVS1_contrib	PS1_contrib	PS2_contrib_merged	PS3_contrib	PS4_contrib	PM1_contrib	PM2_contrib	PM4_contrib	PM5_contrib	PP2_contrib	PP3_contrib	PP5_contrib	BS1_contrib	BS2_contrib	BS3_contrib	BP1_contrib	BP3_contrib	BP4_contrib	BP6_contrib	BP7_contrib	BA_1_contrib	Probability_Path	Prediction_ACMG_tapes
11	532698	532698	T	A	exonic	HRAS	.	stopgain	HRAS:NM_001130442:exon5:c.A508T:p.K170X,HRAS:NM_005343:exon5:c.A508T:p.K170X,HRAS:NM_001318054:exon6:c.A271T:p.K91X	0.00794104930284198	0.785285637637198	0.20677331305996	Harvey_rat_sarcoma_viral_oncogene_homolog	FUNCTION:_Ras_proteins_bind_GDP/GTP_and_possess_intrinsic_GTPase_activity._{ECO:0000269|PubMed:12740440,_ECO:0000269|PubMed:14500341,_ECO:0000269|PubMed:9020151}.\x3b_	DISEASE:_Costello_syndrome_(CSTLO)_[MIM:218040]:_A_rare_condition_characterized_by_prenatally_increased_growth,_postnatal_growth_deficiency,_mental_retardation,_distinctive_facial_appearance,_cardiovascular_abnormalities_(typically_pulmonic_stenosis,_hypertrophic_cardiomyopathy_and/or_atrial_tachycardia),_tumor_predisposition,_skin_and_musculoskeletal_abnormalities._{ECO:0000269|PubMed:16170316,_ECO:0000269|PubMed:16329078,_ECO:0000269|PubMed:16443854,_ECO:0000269|PubMed:17054105,_ECO:0000269|PubMed:18039947,_ECO:0000269|PubMed:18247425,_ECO:0000269|PubMed:19995790}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Congenital_myopathy_with_excess_of_muscle_spindles_(CMEMS)_[MIM:218040]:_Variant_of_Costello_syndrome._{ECO:0000269|PubMed:17412879}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hurthle_cell_thyroid_carcinoma_(HCTC)_[MIM:607464]:_A_rare_type_of_thyroid_cancer_accounting_for_only_about_3-10%_of_all_differentiated_thyroid_cancers._These_neoplasms_are_considered_a_variant_of_follicular_carcinoma_of_the_thyroid_and_are_referred_to_as_follicular_carcinoma,_oxyphilic_type._{ECO:0000269|PubMed:12727991}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dMutations_which_change_positions_12,_13_or_61_activate_the_potential_of_HRAS_to_transform_cultured_cells_and_are_implicated_in_a_variety_of_human_tumors._{ECO:0000269|PubMed:3670300}.\x3b_DISEASE:_Bladder_cancer_(BLC)_[MIM:109800]:_A_malignancy_originating_in_tissues_of_the_urinary_bladder._It_often_presents_with_multiple_tumors_appearing_at_different_times_and_at_different_sites_in_the_bladder._Most_bladder_cancers_are_transitional_cell_carcinomas_that_begin_in_cells_that_normally_make_up_the_inner_lining_of_the_bladder._Other_types_of_bladder_cancer_include_squamous_cell_carcinoma_(cancer_that_begins_in_thin,_flat_cells)_and_adenocarcinoma_(cancer_that_begins_in_cells_that_make_and_release_mucus_and_other_fluids)._Bladder_cancer_is_a_complex_disorder_with_both_genetic_and_environmental_influences._{ECO:0000269|PubMed:6298635,_ECO:0000269|PubMed:6844927}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Schimmelpenning-Feuerstein-Mims_syndrome_(SFM)_[MIM:163200]:_A_disease_characterized_by_sebaceous_nevi,_often_on_the_face,_associated_with_variable_ipsilateral_abnormalities_of_the_central_nervous_system,_ocular_anomalies,_and_skeletal_defects._Many_oral_manifestations_have_been_reported,_not_only_including_hypoplastic_and_malformed_teeth,_and_mucosal_papillomatosis,_but_also_ankyloglossia,_hemihyperplastic_tongue,_intraoral_nevus,_giant_cell_granuloma,_ameloblastoma,_bone_cysts,_follicular_cysts,_oligodontia,_and_odontodysplasia._Sebaceous_nevi_follow_the_lines_of_Blaschko_and_these_can_continue_as_linear_intraoral_lesions,_as_in_mucosal_papillomatosis._{ECO:0000269|PubMed:22683711}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Widely_expressed._{ECO:0000269|PubMed:14500341}.\x3b_	ovary\x3bdevelopmental\x3bcolon\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3boptic_nerve\x3bwhole_body\x3boesophagus\x3bendometrium\x3bthyroid\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bhypothalamus\x3bblood\x3blens\x3bskeletal_muscle\x3blung\x3bplacenta\x3bvisual_apparatus\x3bhypopharynx\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bcerebellum\x3b	whole_brain\x3bmedulla_oblongata\x3btrigeminal_ganglion\x3b	0.99944	0.99980	-0.339715008	30.06605331	4.91473	0.18207	rs372936166	48917	Costello_syndrome|not_specified	MedGen:C0587248,OMIM:218040,Orphanet:ORPHA3071,SNOMED_CT:309776008|MedGen:CN169374	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	.	.	.	0.129	0.187	U	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.992	0.934	D	c	0.673	0.501	1.000	0.747	0.722	0.854	0	3.94	0.446	4.127	0.575	1.058	0.762	1.000	0.715	0.999	0.750	12.411	0.546	.	.	.	.	.	3.233e-05	0.0001	0	0	0	0	0	0	3.271e-05	0	0	0	0	0	7.256e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,611	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
12	103237423	103237423	C	G	splicing	PAH	NM_000277:exon11:c.1199+1G>C	.	.	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62509015	108293	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	.	.	.	.	.	.	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.997	0.983	D	c	1.149	0.995	1.000	0.747	0.061	0.009	0	5.34	0.759	7.905	0.864	0.892	0.403	1.000	0.715	0.977	0.480	19.048	0.930	.	.	.	1.0000	0.94	.	.	.	.	.	.	.	.	8.129e-06	0	0	0	0	0	8.962e-06	0	3.249e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,658	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
16	68845757	68845757	C	T	exonic	CDH1	.	stopgain	CDH1:NM_001317184:exon7:c.C1003T:p.R335X,CDH1:NM_004360:exon7:c.C1003T:p.R335X	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	rs587780784	139767	Hereditary_cancer-predisposing_syndrome|Hereditary_diffuse_gastric_cancer|not_provided	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708349,OMIM:137215,Orphanet:ORPHA26106|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	0.000	0.445	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.844	0.432	D	c	0.625	0.472	1.000	0.517	0.632	0.406	0	3.22	0.359	1.335	0.332	0.935	0.490	1.000	0.715	1.000	0.888	13.393	0.601	Cadherin|Cadherin-like	.	.	.	.	3.23e-05	0	0	0	0	0	6.665e-05	0	8.129e-06	0	0	0	0	0	8.965e-06	0	3.249e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,899	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
10	89720876	89720876	G	A	splicing	PTEN	NM_001304718:exon8:c.435+1G>A\x3bNM_001304717:exon9:c.1545+1G>A\x3bNM_000314:exon8:c.1026+1G>A	.	.	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs786201041	183060	Hereditary_cancer-predisposing_syndrome|Cowden_syndrome_1	MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN072330,OMIM:158350	criteria_provided,_single_submitter	Likely_pathogenic	.	.	.	.	.	.	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.985	0.838	D	c	1.221	1.076	1.0	0.983	0.295	0.044	0	5.37	0.769	9.468	0.968	0.998	0.613	1.000	0.715	1.000	0.888	19.092	0.932	C2_domain|Tensin_phosphatase,_C2_domain	.	.	1.0000	0.934	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,590	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
10	89725043	89725043	G	A	splicing	PTEN	NM_001304718:exon9:c.436-1G>A\x3bNM_001304717:exon10:c.1546-1G>A\x3bNM_000314:exon9:c.1027-1G>A	.	.	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs1057517809	359852	Hereditary_cancer-predisposing_syndrome|not_provided	MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	.	.	.	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.998	0.995	D	c	1.228	1.083	1.000	0.747	0.106	0.022	0	5.31	0.750	9.556	0.972	0.902	0.416	1.000	0.715	1.000	0.888	19.412	0.946	.	.	.	1.0000	0.932	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,592	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
12	103249059	103249059	C	T	exonic	PAH	.	stopgain	PAH:NM_000277:exon6:c.G561A:p.W187X	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62507336	108472	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	.	.	.	0.000	0.843	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.987	0.859	D	c	0.857	0.713	1.000	0.747	0.638	0.428	0	5.73	0.897	7.905	0.864	0.935	0.490	1.000	0.715	0.328	0.242	19.899	0.970	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	8.128e-06	0	0	0	0	0	1.793e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,767	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
16	68844245	68844245	G	T	splicing	CDH1	NM_004360:exon6:c.832+1G>T\x3bNM_001317186:exon6:UTR5\x3bNM_001317185:exon6:UTR5\x3bNM_001317184:exon6:c.832+1G>T	.	.	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	rs878854697	242465	Hereditary_diffuse_gastric_cancer	MedGen:C1708349,OMIM:137215,Orphanet:ORPHA26106	criteria_provided,_single_submitter	Likely_pathogenic	.	.	.	.	.	.	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.982	0.799	D	c	1.080	0.918	1.000	0.747	0.295	0.044	0	5.06	0.677	8.888	0.920	1.048	0.713	1.000	0.715	0.973	0.468	17.562	0.878	.	.	.	1.0000	0.94	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,898	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
13	20763650	20763650	C	T	exonic	GJB2	.	stopgain	GJB2:NM_004004:exon2:c.G71A:p.W24X	1.02863295453376e-11	0.00164377442881105	0.998356225560903	gap_junction_protein_beta_2	FUNCTION:_One_gap_junction_consists_of_a_cluster_of_closely_packed_pairs_of_transmembrane_channels,_the_connexons,_through_which_materials_of_low_MW_diffuse_from_one_cell_to_a_neighboring_cell.\x3b_	DISEASE:_Deafness,_autosomal_recessive,_1A_(DFNB1A)_[MIM:220290]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10830906,_ECO:0000269|PubMed:11313763,_ECO:0000269|PubMed:11439000,_ECO:0000269|PubMed:12121355,_ECO:0000269|PubMed:12239718,_ECO:0000269|PubMed:12786758,_ECO:0000269|PubMed:14722929,_ECO:0000269|PubMed:15666300,_ECO:0000269|PubMed:15994881,_ECO:0000269|PubMed:17660464,_ECO:0000269|PubMed:17666888,_ECO:0000269|PubMed:19384972,_ECO:0000269|PubMed:23680645,_ECO:0000269|PubMed:9328482,_ECO:0000269|PubMed:9336442,_ECO:0000269|PubMed:9471561,_ECO:0000269|PubMed:9529365}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_dominant,_3A_(DFNA3A)_[MIM:601544]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10807696,_ECO:0000269|PubMed:11313763,_ECO:0000269|PubMed:11439000,_ECO:0000269|PubMed:12786758,_ECO:0000269|PubMed:19384972,_ECO:0000269|PubMed:9620796}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Vohwinkel_syndrome_(VS)_[MIM:124500]:_VS_is_an_autosomal_dominant_disease_characterized_by_hyperkeratosis,_constriction_on_fingers_and_toes_and_congenital_deafness._{ECO:0000269|PubMed:10369869,_ECO:0000269|PubMed:15954104,_ECO:0000269|PubMed:18688874}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Keratoderma,_palmoplantar,_with_deafness_(PPKDFN)_[MIM:148350]:_An_autosomal_dominant_disorder_characterized_by_the_association_of_palmoplantar_hyperkeratosis_with_progressive,_bilateral,_high-frequency,_sensorineural_deafness._{ECO:0000269|PubMed:10633135,_ECO:0000269|PubMed:10757647,_ECO:0000269|PubMed:12372058,_ECO:0000269|PubMed:15996214,_ECO:0000269|PubMed:17993581,_ECO:0000269|PubMed:9856479}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Keratitis-ichthyosis-deafness_syndrome_(KID_syndrome)_[MIM:148210]:_An_autosomal_dominant_form_of_ectodermal_dysplasia._Ectodermal_dysplasia_defines_a_heterogeneous_group_of_disorders_due_to_abnormal_development_of_two_or_more_ectodermal_structures._Keratitis-ichthyosis-deafness_syndrome_is_characterized_by_the_association_of_hyperkeratotic_skin_lesions_with_vascularizing_keratitis_and_profound_sensorineural_hearing_loss._Clinical_features_include_deafness,_ichthyosis,_photophobia,_absent_or_decreased_eyebrows,_sparse_or_absent_scalp_hair,_decreased_sweating_and_dysplastic_finger_and_toenails._{ECO:0000269|PubMed:11912510,_ECO:0000269|PubMed:12548749,_ECO:0000269|PubMed:12752120}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bart-Pumphrey_syndrome_(BPS)_[MIM:149200]:_An_autosomal_dominant_disorder_characterized_by_sensorineural_hearing_loss,_palmoplantar_keratoderma,_knuckle_pads,_and_leukonychia,_It_shows_considerable_phenotypic_variability._{ECO:0000269|PubMed:15482471,_ECO:0000269|PubMed:15952212}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ichthyosis_hystrix-like_with_deafness_syndrome_(HID_syndrome)_[MIM:602540]:_An_autosomal_dominant_keratinizing_disorder_characterized_by_sensorineural_deafness_and_spiky_hyperkeratosis_affecting_the_entire_skin._HID_syndrome_is_considered_to_differ_from_the_similar_KID_syndrome_in_the_extent_and_time_of_occurrence_of_skin_symptoms_and_the_severity_of_the_associated_keratitis._{ECO:0000269|PubMed:12072059}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	.	.	0.42941	0.50569	0.663285274	84.55414013	794.09383	5.55726	rs104894396	32041	Hearing_impairment|Mutilating_keratoderma|Knuckle_pads,_deafness_AND_leukonychia_syndrome|Keratoderma_palmoplantar_deafness|Keratitis-ichthyosis-deafness_syndrome,_autosomal_dominant|Deafness,_X-linked_2|Hystrix-like_ichthyosis_with_deafness|Deafness,_autosomal_recessive_1A|Deafness,_autosomal_dominant_3a|Nonsyndromic_hearing_loss_and_deafness|not_provided	Human_Phenotype_Ontology:HP:0000365,MedGen:C0018772|MedGen:C0265964,OMIM:124500,Orphanet:ORPHA494,SNOMED_CT:24559001|MedGen:C0266004,OMIM:149200,Orphanet:ORPHA2698,SNOMED_CT:1271009|MedGen:C1835672,OMIM:148350,Orphanet:ORPHA2202|MedGen:C1835678,OMIM:148210|MedGen:C1844678,OMIM:304400,Orphanet:ORPHA383|MedGen:C1865234,OMIM:602540|MedGen:C2673759,OMIM:220290|MedGen:C2675750,OMIM:601544|MedGen:CN043648,Orphanet:ORPHA87884|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	0.000	0.843	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.971	0.727	D	c	0.840	0.679	1.0	0.983	0.534	0.214	0	5.21	0.719	7.854	0.852	0.852	0.362	1.000	0.715	0.977	0.480	19.121	0.933	Connexin,_N-terminal	.	.	.	.	6.459e-05	0.0001	0	0	0	0	6.666e-05	0	0.0006	6.534e-05	2.978e-05	0	0	0	6.35e-05	0.0005	0.0045	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,871	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
12	103234176	103234176	A	G	splicing	PAH	NM_000277:exon12:c.1315+2T>C	.	.	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs1799970	108324	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_single_submitter	Likely_pathogenic	.	.	.	.	.	.	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.987	0.862	D	c	1.077	0.908	1.000	0.402	0.061	0.009	0	5.33	0.756	8.813	0.915	1.199	0.960	1.000	0.715	0.996	0.625	14.569	0.676	.	.	.	0.9911	0.624	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,642	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
12	103234177	103234177	C	T	splicing	PAH	NM_000277:exon12:c.1315+1G>A	.	.	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs5030861	15615	Inborn_genetic_diseases|Phenylketonuria|not_provided	MeSH:D030342,MedGen:C0950123|MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	.	.	.	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.980	0.789	D	c	1.097	0.930	1.000	0.747	0.061	0.009	0	5.33	0.756	7.458	0.797	0.935	0.490	1.000	0.715	0.996	0.625	18.147	0.895	.	.	.	1.0000	0.93	0.0004	0.0001	0	0	0	0	0.0007	0	0.0004	0.0001	2.982e-05	0	0	0	0.0008	0.0002	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,643	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
12	103237476	103237476	G	A	exonic	PAH	.	stopgain	PAH:NM_000277:exon11:c.C1147T:p.Q383X	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs1037293795	358085	Phenylketonuria	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006	criteria_provided,_single_submitter	Likely_pathogenic	.	.	.	0.000	0.843	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.992	0.926	D	c	1.137	0.962	1.000	0.747	0.693	0.558	0	5.34	0.759	9.999	0.994	0.998	0.613	1.000	0.715	0.989	0.536	19.048	0.930	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,663	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
10	89720741	89720741	C	T	exonic	PTEN	.	stopgain	PTEN:NM_000314:exon8:c.C892T:p.Q298X,PTEN:NM_001304718:exon8:c.C301T:p.Q101X,PTEN:NM_001304717:exon9:c.C1411T:p.Q471X	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs371387815	183051	Hereditary_cancer-predisposing_syndrome|PTEN_hamartoma_tumor_syndrome|not_provided	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	0.000	0.469	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.976	0.760	D	c	1.024	0.865	1.000	0.747	0.732	0.924	0	5.13	0.696	2.692	0.464	0.892	0.403	1.000	0.715	1.000	0.888	18.563	0.910	C2_domain|Tensin_phosphatase,_C2_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,586	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
12	103237559	103237559	T	A	splicing	PAH	NM_000277:exon11:c.1066-2A>T	.	.	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs281865447	125852	Phenylketonuria	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006	no_assertion_criteria_provided	Likely_pathogenic	.	.	.	.	.	.	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.997	0.985	D	c	0.929	0.722	1.000	0.480	0.075	0.013	0	5.08	0.682	8.001	0.879	1.061	0.807	1.000	0.715	0.790	0.333	14.848	0.698	.	.	.	1.0000	0.906	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,673	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
12	103306568	103306568	C	T	splicing	PAH	NM_000277:exon2:c.168+1G>A	.	.	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62514898	108340	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_single_submitter	Likely_pathogenic	.	.	.	.	.	.	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.929	0.567	D	c	1.060	0.897	1.000	0.747	0.075	0.013	0	5.46	0.799	5.034	0.637	0.935	0.490	1.000	0.715	0.953	0.430	16.241	0.822	.	.	.	1.0000	0.93	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,831	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
12	103245464	103245464	C	T	splicing	PAH	NM_000277:exon8:c.912+1G>A	.	.	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62514956	98659	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	.	.	.	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.972	0.729	D	c	1.202	1.060	1.000	0.747	0.075	0.013	0	5.51	0.817	7.568	0.814	0.935	0.490	1.000	0.715	0.997	0.653	19.779	0.964	.	.	.	1.0000	0.938	.	.	.	.	.	.	.	.	1.221e-05	0	0	0	0	0	1.796e-05	0	3.249e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,687	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
12	103288669	103288669	C	A	exonic	PAH	.	stopgain	PAH:NM_000277:exon3:c.G196T:p.E66X	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs281865454	125864	Phenylketonuria	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006	no_assertion_criteria_provided	Likely_pathogenic	.	.	.	0.000	0.843	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.985	0.831	D	c	1.237	1.115	1.000	0.747	0.615	0.372	0	6.17	0.997	7.033	0.761	0.935	0.490	1.000	0.715	1.000	0.888	20.879	0.999	ACT_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,818	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
12	103288534	103288534	G	A	exonic	PAH	.	stopgain	PAH:NM_000277:exon3:c.C331T:p.R111X	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs76296470	15620	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	0.000	0.843	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.962	0.678	D	c	0.829	0.716	1.000	0.747	0.615	0.372	0	5.27	0.737	4.797	0.620	0.100	0.199	1.000	0.715	0.996	0.625	14.458	0.669	ACT_domain\x3bACT_domain|Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	3.249e-05	0.0002	0	0	0	0	3.583e-05	0	3.249e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,807	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
12	103246592	103246592	C	T	splicing	PAH	NM_000277:exon7:c.842+1G>A	.	.	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs5030852	15638	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	.	.	.	.	.	.	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.984	0.826	D	c	1.137	0.980	1.000	0.747	0.075	0.013	0	5.73	0.897	7.905	0.864	0.935	0.490	1.000	0.715	0.980	0.490	19.896	0.969	.	.	.	1.0000	0.932	3.228e-05	0	0	0	0	0	6.661e-05	0	3.658e-05	0	0	0	0	0	8.072e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,707	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
12	103260442	103260442	C	T	splicing	PAH	NM_000277:exon5:c.442-1G>A	.	.	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62514907	15633	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	.	.	.	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.964	0.686	D	c	1.186	1.057	0.995	0.338	0.061	0.009	0	6.08	0.990	5.240	0.650	0.935	0.490	1.000	0.715	0.962	0.444	17.819	0.885	.	.	.	1.0000	0.938	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,795	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
12	103246654	103246654	G	A	exonic	PAH	.	stopgain	PAH:NM_000277:exon7:c.C781T:p.R261X	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs5030850	15649	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	0.000	0.843	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.943	0.603	D	c	0.689	0.551	0.982	0.302	0.638	0.428	0	3.79	0.426	2.806	0.474	1.048	0.713	1.000	0.715	1.000	0.888	14.330	0.660	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	3.23e-05	0.0001	0	0	0	0	0	0	2.032e-05	0	2.979e-05	0	0	0	2.689e-05	0.0002	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,739	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
10	89720813	89720813	A	T	exonic	PTEN	.	stopgain	PTEN:NM_000314:exon8:c.A964T:p.K322X,PTEN:NM_001304718:exon8:c.A373T:p.K125X,PTEN:NM_001304717:exon9:c.A1483T:p.K495X	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs786202004	183056	Hereditary_cancer-predisposing_syndrome|not_provided	MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	0.000	0.843	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.970	0.718	D	c	1.149	1.001	1.000	0.747	0.707	0.730	0	5.37	0.769	8.823	0.916	1.140	0.893	1.000	0.715	1.000	0.888	15.354	0.740	C2_domain|Tensin_phosphatase,_C2_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,588	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
12	103246708	103246708	G	A	exonic	PAH	.	stopgain	PAH:NM_000277:exon7:c.C727T:p.R243X	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs5030846	15627	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	0.000	0.843	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.979	0.780	D	c	0.580	0.448	0.983	0.304	0.638	0.428	0	3.03	0.339	8.100	0.893	0.112	0.206	1.000	0.715	0.995	0.604	9.935	0.405	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	6.46e-05	0.0002	0	0	0	0	0	0	4.068e-05	0	0	0	0	0	8.98e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,752	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
10	89685300	89685300	C	G	exonic	PTEN	.	stopgain	PTEN:NM_000314:exon3:c.C195G:p.Y65X,PTEN:NM_001304717:exon4:c.C714G:p.Y238X	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs878853936	240873	PTEN_hamartoma_tumor_syndrome	MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498	criteria_provided,_single_submitter	Pathogenic	.	.	.	0.000	0.843	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.949	0.625	D	c	0.885	0.705	1.000	0.747	0.742	0.980	0	3.6	0.402	1.854	0.388	0.935	0.490	1.000	0.715	1.000	0.888	11.159	0.475	Protein-tyrosine_phosphatase,_catalytic|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain\x3bProtein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,528	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
21	36231783	36231783	G	A	exonic	RUNX1	.	stopgain	RUNX1:NM_001001890:exon3:c.C520T:p.R174X,RUNX1:NM_001122607:exon3:c.C520T:p.R174X,RUNX1:NM_001754:exon6:c.C601T:p.R201X	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	rs1057519748	362897	Acute_myeloid_leukemia	Human_Phenotype_Ontology:HP:0004808,MeSH:D015470,MedGen:C0023467,OMIM:601626,Orphanet:ORPHA519,SNOMED_CT:17788007	no_assertion_criteria_provided	Likely_pathogenic	.	.	.	0.000	0.843	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.875	0.467	D	c	0.680	0.531	1.000	0.747	0.707	0.730	0	4.21	0.488	4.537	0.601	1.048	0.713	1.000	0.715	1.000	0.888	12.147	0.531	Runt_domain|p53-like_transcription_factor,_DNA-binding|p53/RUNT-type_transcription_factor,_DNA-binding_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,961	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
21	36259139	36259139	C	G	splicing	RUNX1	NM_001754:exon4:c.351+1G>C\x3bNM_001001890:exon1:c.270+1G>C\x3bNM_001122607:exon1:c.270+1G>C	.	.	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	rs1060502579	403732	Familial_platelet_disorder_with_associated_myeloid_malignancy	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290	criteria_provided,_single_submitter	Likely_pathogenic	.	.	.	.	.	.	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.970	0.717	D	c	1.085	0.909	1.0	0.983	0.167	0.032	0	4.44	0.530	7.392	0.790	0.852	0.362	1.000	0.715	1.000	0.888	16.859	0.858	.	.	.	1.0000	0.954	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,977	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
10	89653781	89653781	G	C	splicing	PTEN	NM_001304718:exon2:UTR5\x3bNM_001304717:exon3:c.599-1G>C\x3bNM_000314:exon2:c.80-1G>C	.	.	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs786204914	187328	not_provided	MedGen:CN517202	criteria_provided,_single_submitter	Pathogenic	.	.	.	.	.	.	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.984	0.820	D	c	1.201	1.047	1.000	0.747	0.164	0.030	0	5.19	0.713	9.418	0.967	1.048	0.713	1.000	0.715	0.992	0.562	17.468	0.875	.	.	.	0.9999	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,520	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
16	68867259	68867259	G	T	exonic	CDH1	.	stopgain	CDH1:NM_001317184:exon15:c.G2323T:p.E775X,CDH1:NM_001317186:exon15:c.G541T:p.E181X,CDH1:NM_001317185:exon16:c.G958T:p.E320X,CDH1:NM_004360:exon16:c.G2506T:p.E836X	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	.	477938	Hereditary_cancer-predisposing_syndrome	MedGen:C0027672,SNOMED_CT:699346009	criteria_provided,_single_submitter	Likely_pathogenic	.	.	.	0.000	0.523	D	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.995	0.962	D	c	1.286	1.164	1.000	0.747	0.632	0.406	0	6.04	0.980	10.003	0.997	1.048	0.713	1.000	0.715	0.998	0.697	20.190	0.982	Cadherin,_cytoplasmic_domain\x3bCadherin,_cytoplasmic_domain|Catenin_binding_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,922	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
10	89711893	89711893	C	T	exonic	PTEN	.	stopgain	PTEN:NM_000314:exon6:c.C511T:p.Q171X,PTEN:NM_001304717:exon7:c.C1030T:p.Q344X	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs786204864	187361	Hereditary_cancer-predisposing_syndrome|Bannayan-Riley-Ruvalcaba_syndrome|PTEN_hamartoma_tumor_syndrome|not_provided	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0265326,OMIM:153480,Orphanet:ORPHA109|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	0.000	0.629	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.950	0.630	D	c	1.200	1.066	1.000	0.747	0.722	0.854	0	5.74	0.900	7.464	0.798	0.892	0.403	1.000	0.715	1.000	0.888	19.931	0.971	Protein-tyrosine_phosphatase,_catalytic|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,561	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
21	36171704	36171704	G	T	exonic	RUNX1	.	stopgain	RUNX1:NM_001001890:exon5:c.C780A:p.Y260X,RUNX1:NM_001754:exon8:c.C861A:p.Y287X	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	rs121912499	29506	Familial_platelet_disorder_with_associated_myeloid_malignancy	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290	no_assertion_criteria_provided	Pathogenic	.	.	.	0.000	0.629	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.963	0.681	D	c	0.867	0.760	1.000	0.747	0.706	0.609	0	5.78	0.914	3.072	0.495	1.048	0.713	1.000	0.715	1.000	0.888	13.872	0.630	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,953	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
21	36253011	36253011	C	T	splicing	RUNX1	NM_001754:exon5:c.352-1G>A\x3bNM_001001890:exon2:c.271-1G>A\x3bNM_001122607:exon2:c.271-1G>A	.	.	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	.	430421	Familial_platelet_disorder_with_associated_myeloid_malignancy	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290	criteria_provided,_single_submitter	Pathogenic	.	.	.	.	.	.	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.989	0.881	D	c	1.180	1.030	1.0	0.983	0.156	0.027	0	5.31	0.750	7.568	0.814	0.935	0.490	1.000	0.715	0.948	0.423	19.335	0.943	.	.	.	1.0000	0.94	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,975	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
6	76538307	76538307	C	T	exonic	MYO6	.	stopgain	MYO6:NM_001300899:exon4:c.C238T:p.R80X,MYO6:NM_004999:exon4:c.C238T:p.R80X	0.0177883990936548	0.982211600378647	5.27698444208756e-10	myosin_VI	FUNCTION:_Myosins_are_actin-based_motor_molecules_with_ATPase_activity._Unconventional_myosins_serve_in_intracellular_movements._Myosin_6_is_a_reverse-direction_motor_protein_that_moves_towards_the_minus-end_of_actin_filaments._Has_slow_rate_of_actin-activated_ADP_release_due_to_weak_ATP_binding._Functions_in_a_variety_of_intracellular_processes_such_as_vesicular_membrane_trafficking_and_cell_migration._Required_for_the_structural_integrity_of_the_Golgi_apparatus_via_the_p53-dependent_pro-survival_pathway._Appears_to_be_involved_in_a_very_early_step_of_clathrin-mediated_endocytosis_in_polarized_epithelial_cells._May_act_as_a_regulator_of_F-actin_dynamics._May_play_a_role_in_transporting_DAB2_from_the_plasma_membrane_to_specific_cellular_targets._Required_for_structural_integrity_of_inner_ear_hair_cells_(By_similarity)._{ECO:0000250,_ECO:0000269|PubMed:10519557,_ECO:0000269|PubMed:11447109,_ECO:0000269|PubMed:16507995,_ECO:0000269|PubMed:16949370}.\x3b_	DISEASE:_Deafness,_autosomal_dominant,_22_(DFNA22)_[MIM:606346]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._DFNA22_is_progressive_and_postlingual,_with_onset_during_childhood._By_the_age_of_approximately_50_years,_affected_individuals_invariably_have_profound_sensorineural_deafness._{ECO:0000269|PubMed:11468689}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_recessive,_37_(DFNB37)_[MIM:607821]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:12687499}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_sensorineural,_with_hypertrophic_cardiomyopathy_(DFNHCM)_[MIM:606346]:_An_autosomal_dominant_sensorineural_deafness_associated_with_hypertrophic_cardiomyopathy._{ECO:0000269|PubMed:15060111}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_most_tissues_examined_including_heart,_brain,_placenta,_pancreas,_spleen,_thymus,_prostate,_testis,_ovary,_small_intestine_and_colon._Highest_levels_in_brain,_pancreas,_testis_and_small_intestine._Also_expressed_in_fetal_brain_and_cochlea._Isoform_1_and_isoform_2,_containing_the_small_insert,_and_isoform_4,_containing_neither_insert,_are_expressed_in_unpolarized_epithelial_cells._{ECO:0000269|PubMed:9259267}.\x3b_	.	.	0.26137	0.31948	-0.369255208	28.25548478	419.15519	4.27823	rs727504567	174003	Nonsyndromic_hearing_loss_and_deafness|not_specified|not_provided	MedGen:CN043648,Orphanet:ORPHA87884|MedGen:CN169374|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	.	.	.	0.000	0.843	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.961	0.673	D	c	0.865	0.751	1.000	0.446	0.732	0.924	0	5.51	0.817	4.458	0.596	0.935	0.490	1.000	0.715	1.000	0.888	19.415	0.947	Myosin_head,_motor_domain|P-loop_containing_nucleoside_triphosphate_hydrolase	.	.	.	.	.	.	.	.	.	.	.	.	4.07e-06	0	0	0	0	0	8.983e-06	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,485	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
10	89685269	89685269	G	A	splicing	PTEN	NM_001304717:exon4:c.684-1G>A\x3bNM_000314:exon3:c.165-1G>A	.	.	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs786203847	183017	Hereditary_cancer-predisposing_syndrome|not_provided	MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	.	.	.	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.994	0.951	D	c	1.235	1.092	1.000	0.747	0.295	0.044	0	5.45	0.796	9.286	0.950	1.048	0.713	1.000	0.715	1.000	0.888	19.279	0.940	.	.	.	1.0000	0.936	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,525	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
21	36253011	36253011	C	A	splicing	RUNX1	NM_001754:exon5:c.352-1G>T\x3bNM_001001890:exon2:c.271-1G>T\x3bNM_001122607:exon2:c.271-1G>T	.	.	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	rs587776809	29502	Familial_platelet_disorder_with_associated_myeloid_malignancy	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290	no_assertion_criteria_provided	Pathogenic	.	.	.	.	.	.	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.991	0.914	D	c	1.180	1.030	1.0	0.983	0.156	0.027	0	5.31	0.750	7.568	0.814	0.935	0.490	1.000	0.715	0.948	0.423	19.335	0.943	.	.	.	1.0000	0.94	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,974	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
10	89717741	89717741	G	T	exonic	PTEN	.	stopgain	PTEN:NM_000314:exon7:c.G766T:p.E256X,PTEN:NM_001304718:exon7:c.G175T:p.E59X,PTEN:NM_001304717:exon8:c.G1285T:p.E429X	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs121909228	22867	Bannayan-Riley-Ruvalcaba_syndrome	MedGen:C0265326,OMIM:153480,Orphanet:ORPHA109	no_assertion_criteria_provided	Pathogenic	.	.	.	0.000	0.843	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.988	0.870	D	c	1.201	1.049	1.000	0.747	0.706	0.609	0	5.15	0.702	9.525	0.971	0.902	0.416	1.000	0.715	1.000	0.888	18.616	0.912	C2_domain|Tensin_phosphatase,_C2_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,580	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
10	89711873	89711873	A	G	splicing	PTEN	NM_001304718:exon6:UTR5\x3bNM_001304717:exon7:c.1012-2A>G\x3bNM_000314:exon6:c.493-2A>G	.	.	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs587781784	151199	Hereditary_cancer-predisposing_syndrome|Cowden_syndrome_1|not_provided	MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN072330,OMIM:158350|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	.	.	.	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.963	0.681	D	c	1.180	1.045	1.000	0.747	0.257	0.036	0	5.74	0.900	8.820	0.916	1.140	0.893	1.000	0.715	0.999	0.750	16.045	0.804	.	.	.	1.0000	0.93	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,556	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
10	89693010	89693010	T	G	splicing	PTEN	NM_001304718:exon4:UTR5\x3bNM_001304717:exon6:c.1011+2T>G\x3bNM_000314:exon5:c.492+2T>G	.	.	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs587776668	22860	Cowden_syndrome_1	MedGen:CN072330,OMIM:158350	no_assertion_criteria_provided	Pathogenic	.	.	.	.	.	.	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.985	0.834	D	c	1.080	0.920	1.000	0.747	0.164	0.030	0	5.09	0.685	7.615	0.821	0.964	0.580	1.000	0.715	0.996	0.625	14.868	0.699	.	.	.	1.0000	0.928	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,555	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
10	89692985	89692985	G	T	exonic	PTEN	.	stopgain	PTEN:NM_000314:exon5:c.G469T:p.E157X,PTEN:NM_001304717:exon6:c.G988T:p.E330X	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs121909220	22853	Lhermitte-Duclos_disease	MedGen:C0391826,Orphanet:ORPHA65285	no_assertion_criteria_provided	Pathogenic	.	.	.	0.000	0.843	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.991	0.918	D	c	1.190	1.037	1.000	0.747	0.722	0.854	0	5.09	0.685	9.525	0.971	0.953	0.551	1.000	0.715	1.000	0.888	18.493	0.908	Dual_specificity_phosphatase,_catalytic_domain|Protein-tyrosine_phosphatase,_catalytic|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain\x3bDual_specificity_phosphatase,_catalytic_domain|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,553	1	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9986	Pathogenic
12	103288698	103288698	T	C	splicing	PAH	NM_000277:exon3:c.169-2A>G	.	.	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	.	.	.	.	.	.	.	.	.	.	.	.	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.979	0.776	D	c	1.086	0.931	1.000	0.747	0.162	0.029	0	6.17	0.997	7.131	0.767	1.061	0.807	1.000	0.715	0.864	0.361	16.822	0.856	.	.	.	1.0000	0.932	.	.	.	.	.	.	.	.	8.163e-06	0	0	0	0	0	0	0	6.498e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,827	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
16	68846113	68846114	GT	G	exonic	CDH1	.	frameshift_deletion	CDH1:NM_001317184:exon8:c.1085delT:p.V362fs,CDH1:NM_004360:exon8:c.1085delT:p.V362fs	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	.	477802	Hereditary_cancer-predisposing_syndrome	MedGen:C0027672,SNOMED_CT:699346009	criteria_provided,_single_submitter	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,903	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
21	36252912	36252920	GGCTGCGGT	G	exonic	RUNX1	.	frameshift_deletion	RUNX1:NM_001001890:exon2:c.361_368del:p.T121fs,RUNX1:NM_001122607:exon2:c.361_368del:p.T121fs,RUNX1:NM_001754:exon5:c.442_449del:p.T148fs	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	rs587776811	29509	Familial_platelet_disorder_with_associated_myeloid_malignancy	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290	no_assertion_criteria_provided	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,969	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
12	103260379	103260380	GT	G	exonic	PAH	.	frameshift_deletion	PAH:NM_000277:exon5:c.503delA:p.Y168fs	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475661	108441	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	4.063e-06	0	0	0	0	0	8.958e-06	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,782	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
12	103260379	103260379	G	T	exonic	PAH	.	stopgain	PAH:NM_000277:exon5:c.C504A:p.Y168X	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs281865455	125871	Phenylketonuria	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006	no_assertion_criteria_provided	Likely_pathogenic	.	.	.	0.000	0.843	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.925	0.556	D	c	0.458	0.309	0.001	0.076	0.554	0.246	0	3.27	0.364	3.102	0.497	0.142	0.226	1.000	0.715	0.998	0.697	8.700	0.333	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,781	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
12	103288514	103288515	TG	T	exonic	PAH	.	frameshift_deletion	PAH:NM_000277:exon3:c.350delC:p.T117fs	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs281865428	125868	Phenylketonuria	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006	no_assertion_criteria_provided	Likely_pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,805	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
12	103310860	103310862	CAG	C	exonic	PAH	.	frameshift_deletion	PAH:NM_000277:exon1:c.47_48del:p.S16fs	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62642906	108432	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	4.062e-06	0	0	0	0	0	8.955e-06	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,846	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
12	103306571	103306572	CA	C	exonic	PAH	.	frameshift_deletion	PAH:NM_000277:exon2:c.165delT:p.F55fs	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475566	15650	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1.219e-05	0	0	0	0	0	2.688e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,832	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
12	103306610	103306610	C	A	exonic	PAH	.	stopgain	PAH:NM_000277:exon2:c.G127T:p.E43X	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	.	.	.	.	.	.	.	.	.	0.000	0.843	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.920	0.545	D	c	1.092	0.947	1.000	0.747	0.638	0.428	0	5.46	0.799	5.034	0.637	0.935	0.490	1.000	0.715	1.000	0.888	16.222	0.820	ACT_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,839	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
12	103310851	103310851	G	A	exonic	PAH	.	stopgain	PAH:NM_000277:exon1:c.C58T:p.Q20X	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475585	108480	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_single_submitter	Likely_pathogenic	.	.	.	0.044	0.237	N	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.889	0.488	D	c	0.832	0.675	1.000	0.747	0.405	0.054	1	5.2	0.716	4.095	0.572	1.048	0.713	1.000	0.715	0.336	0.243	14.428	0.667	.	.	.	0.9987	0.87	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,845	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
21	36206833	36206833	C	A	exonic	RUNX1	.	stopgain	RUNX1:NM_001001890:exon4:c.G598T:p.E200X,RUNX1:NM_001122607:exon4:c.G598T:p.E200X,RUNX1:NM_001754:exon7:c.G679T:p.E227X	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	.	.	.	.	.	.	.	.	.	0.000	0.629	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.910	0.524	D	c	1.035	0.872	1.000	0.747	0.732	0.924	0	4.86	0.625	6.185	0.718	0.935	0.490	1.000	0.715	1.000	0.888	17.989	0.890	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,956	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
13	20763744	20763744	T	G	splicing	GJB2	NM_004004:exon2:UTR5	.	.	1.02863295453376e-11	0.00164377442881105	0.998356225560903	gap_junction_protein_beta_2	FUNCTION:_One_gap_junction_consists_of_a_cluster_of_closely_packed_pairs_of_transmembrane_channels,_the_connexons,_through_which_materials_of_low_MW_diffuse_from_one_cell_to_a_neighboring_cell.\x3b_	DISEASE:_Deafness,_autosomal_recessive,_1A_(DFNB1A)_[MIM:220290]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10830906,_ECO:0000269|PubMed:11313763,_ECO:0000269|PubMed:11439000,_ECO:0000269|PubMed:12121355,_ECO:0000269|PubMed:12239718,_ECO:0000269|PubMed:12786758,_ECO:0000269|PubMed:14722929,_ECO:0000269|PubMed:15666300,_ECO:0000269|PubMed:15994881,_ECO:0000269|PubMed:17660464,_ECO:0000269|PubMed:17666888,_ECO:0000269|PubMed:19384972,_ECO:0000269|PubMed:23680645,_ECO:0000269|PubMed:9328482,_ECO:0000269|PubMed:9336442,_ECO:0000269|PubMed:9471561,_ECO:0000269|PubMed:9529365}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_dominant,_3A_(DFNA3A)_[MIM:601544]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10807696,_ECO:0000269|PubMed:11313763,_ECO:0000269|PubMed:11439000,_ECO:0000269|PubMed:12786758,_ECO:0000269|PubMed:19384972,_ECO:0000269|PubMed:9620796}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Vohwinkel_syndrome_(VS)_[MIM:124500]:_VS_is_an_autosomal_dominant_disease_characterized_by_hyperkeratosis,_constriction_on_fingers_and_toes_and_congenital_deafness._{ECO:0000269|PubMed:10369869,_ECO:0000269|PubMed:15954104,_ECO:0000269|PubMed:18688874}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Keratoderma,_palmoplantar,_with_deafness_(PPKDFN)_[MIM:148350]:_An_autosomal_dominant_disorder_characterized_by_the_association_of_palmoplantar_hyperkeratosis_with_progressive,_bilateral,_high-frequency,_sensorineural_deafness._{ECO:0000269|PubMed:10633135,_ECO:0000269|PubMed:10757647,_ECO:0000269|PubMed:12372058,_ECO:0000269|PubMed:15996214,_ECO:0000269|PubMed:17993581,_ECO:0000269|PubMed:9856479}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Keratitis-ichthyosis-deafness_syndrome_(KID_syndrome)_[MIM:148210]:_An_autosomal_dominant_form_of_ectodermal_dysplasia._Ectodermal_dysplasia_defines_a_heterogeneous_group_of_disorders_due_to_abnormal_development_of_two_or_more_ectodermal_structures._Keratitis-ichthyosis-deafness_syndrome_is_characterized_by_the_association_of_hyperkeratotic_skin_lesions_with_vascularizing_keratitis_and_profound_sensorineural_hearing_loss._Clinical_features_include_deafness,_ichthyosis,_photophobia,_absent_or_decreased_eyebrows,_sparse_or_absent_scalp_hair,_decreased_sweating_and_dysplastic_finger_and_toenails._{ECO:0000269|PubMed:11912510,_ECO:0000269|PubMed:12548749,_ECO:0000269|PubMed:12752120}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bart-Pumphrey_syndrome_(BPS)_[MIM:149200]:_An_autosomal_dominant_disorder_characterized_by_sensorineural_hearing_loss,_palmoplantar_keratoderma,_knuckle_pads,_and_leukonychia,_It_shows_considerable_phenotypic_variability._{ECO:0000269|PubMed:15482471,_ECO:0000269|PubMed:15952212}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ichthyosis_hystrix-like_with_deafness_syndrome_(HID_syndrome)_[MIM:602540]:_An_autosomal_dominant_keratinizing_disorder_characterized_by_sensorineural_deafness_and_spiky_hyperkeratosis_affecting_the_entire_skin._HID_syndrome_is_considered_to_differ_from_the_similar_KID_syndrome_in_the_extent_and_time_of_occurrence_of_skin_symptoms_and_the_severity_of_the_associated_keratitis._{ECO:0000269|PubMed:12072059}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	.	.	0.42941	0.50569	0.663285274	84.55414013	794.09383	5.55726	rs201895089	362175	Deafness,_autosomal_recessive_1A|not_specified|not_provided	MedGen:C2673759,OMIM:220290|MedGen:CN169374|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1.0000	0.924	0.0004	0.0001	0	0.0033	0	0	0.0006	0	0.0006	6.548e-05	0.0002	0.0046	0	4.485e-05	0.0008	0.0004	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,874	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
16	68835596	68835596	C	T	exonic	CDH1	.	stopgain	CDH1:NM_001317184:exon3:c.C187T:p.R63X,CDH1:NM_004360:exon3:c.C187T:p.R63X	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	rs587783047	166261	Hereditary_cancer-predisposing_syndrome|Hereditary_diffuse_gastric_cancer	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708349,OMIM:137215,Orphanet:ORPHA26106	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	0.085	0.207	N	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.177	0.197	N	c	0.378	0.132	1.000	0.747	0.707	0.730	0	4.37	0.517	0.477	0.217	0.935	0.490	0.000	0.063	0.087	0.184	14.645	0.682	Cadherin_prodomain|Cadherin-like	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,889	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
16	68835692	68835692	C	T	exonic	CDH1	.	stopgain	CDH1:NM_001317184:exon3:c.C283T:p.Q95X,CDH1:NM_004360:exon3:c.C283T:p.Q95X	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	rs781409616	465844	Hereditary_diffuse_gastric_cancer	MedGen:C1708349,OMIM:137215,Orphanet:ORPHA26106	criteria_provided,_single_submitter	Pathogenic	.	.	.	0.124	0.189	N	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.387	0.258	N	c	0.087	-0.169	1.000	0.467	0.707	0.730	0	3.42	0.381	1.713	0.373	0.103	0.200	0.751	0.289	0.007	0.100	15.160	0.723	Cadherin_prodomain|Cadherin-like	.	.	.	.	.	.	.	.	.	.	.	.	4.064e-06	0	0	0	0	0	8.965e-06	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,891	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
16	68835787	68835788	GC	G	exonic	CDH1	.	frameshift_deletion	CDH1:NM_001317184:exon3:c.379delC:p.P127fs,CDH1:NM_004360:exon3:c.379delC:p.P127fs	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	.	477827	Hereditary_cancer-predisposing_syndrome|Hereditary_diffuse_gastric_cancer	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708349,OMIM:137215,Orphanet:ORPHA26106	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,893	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
16	68863687	68863688	AT	A	exonic	CDH1	.	frameshift_deletion	CDH1:NM_001317184:exon14:c.2244delT:p.N748fs,CDH1:NM_001317186:exon14:c.462delT:p.N154fs,CDH1:NM_001317185:exon15:c.879delT:p.N293fs,CDH1:NM_004360:exon15:c.2427delT:p.N809fs	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	rs786203752	184466	Hereditary_cancer-predisposing_syndrome|Hereditary_diffuse_gastric_cancer|not_provided	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708349,OMIM:137215,Orphanet:ORPHA26106|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,921	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
16	68863655	68863656	TC	T	exonic	CDH1	.	frameshift_deletion	CDH1:NM_001317184:exon14:c.2212delC:p.P738fs,CDH1:NM_001317186:exon14:c.430delC:p.P144fs,CDH1:NM_001317185:exon15:c.847delC:p.P283fs,CDH1:NM_004360:exon15:c.2395delC:p.P799fs	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	rs587783048	166262	Hereditary_cancer-predisposing_syndrome|Hereditary_diffuse_gastric_cancer	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708349,OMIM:137215,Orphanet:ORPHA26106	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,918	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
16	68855984	68855984	C	T	exonic	CDH1	.	stopgain	CDH1:NM_001317184:exon11:c.C1609T:p.R537X,CDH1:NM_001317185:exon12:c.C244T:p.R82X,CDH1:NM_004360:exon12:c.C1792T:p.R598X	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	rs121964877	27280	Hereditary_cancer-predisposing_syndrome|Hereditary_diffuse_gastric_cancer|not_provided	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708349,OMIM:137215,Orphanet:ORPHA26106|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	0.105	0.197	N	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.991	0.918	D	c	0.729	0.547	1.000	0.747	0.707	0.730	0	5.34	0.759	5.425	0.660	0.927	0.437	1.000	0.715	0.685	0.306	18.699	0.915	Cadherin-like\x3bCadherin|Cadherin-like	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,913	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
1	215932085	215932085	G	T	exonic	USH2A	.	stopgain	USH2A:NM_206933:exon58:c.C11241A:p.Y3747X	3.68100336207458e-43	0.999989235571568	1.07644284322941e-05	Usher_syndrome_2A_(autosomal_recessive,_mild)	FUNCTION:_Involved_in_hearing_and_vision.\x3b_	DISEASE:_Usher_syndrome_2A_(USH2A)_[MIM:276901]:_USH_is_a_genetically_heterogeneous_condition_characterized_by_the_association_of_retinitis_pigmentosa_with_sensorineural_deafness._Age_at_onset_and_differences_in_auditory_and_vestibular_function_distinguish_Usher_syndrome_type_1_(USH1),_Usher_syndrome_type_2_(USH2)_and_Usher_syndrome_type_3_(USH3)._USH2_is_characterized_by_congenital_mild_hearing_impairment_with_normal_vestibular_responses._{ECO:0000269|PubMed:10729113,_ECO:0000269|PubMed:10738000,_ECO:0000269|PubMed:10909849,_ECO:0000269|PubMed:11311042,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:12525556,_ECO:0000269|PubMed:14970843,_ECO:0000269|PubMed:15015129,_ECO:0000269|PubMed:15025721,_ECO:0000269|PubMed:15241801,_ECO:0000269|PubMed:15325563,_ECO:0000269|PubMed:17085681,_ECO:0000269|PubMed:17405132,_ECO:0000269|PubMed:18273898,_ECO:0000269|PubMed:18452394,_ECO:0000269|PubMed:19683999,_ECO:0000269|PubMed:19737284,_ECO:0000269|PubMed:20309401,_ECO:0000269|PubMed:20440071,_ECO:0000269|PubMed:20507924,_ECO:0000269|PubMed:21593743,_ECO:0000269|PubMed:21686329,_ECO:0000269|PubMed:22004887,_ECO:0000269|PubMed:23737954,_ECO:0000269|PubMed:9624053}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Retinitis_pigmentosa_39_(RP39)_[MIM:613809]:_A_retinal_dystrophy_belonging_to_the_group_of_pigmentary_retinopathies._Retinitis_pigmentosa_is_characterized_by_retinal_pigment_deposits_visible_on_fundus_examination_and_primary_loss_of_rod_photoreceptor_cells_followed_by_secondary_loss_of_cone_photoreceptors._Patients_typically_have_night_vision_blindness_and_loss_of_midperipheral_visual_field._As_their_condition_progresses,_they_lose_their_far_peripheral_visual_field_and_eventually_central_vision_as_well._{ECO:0000269|PubMed:10775529,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:12427073,_ECO:0000269|PubMed:15325563,_ECO:0000269|PubMed:16098008,_ECO:0000269|PubMed:17296898,_ECO:0000269|PubMed:20507924,_ECO:0000269|PubMed:21686329,_ECO:0000269|PubMed:22334370,_ECO:0000269|PubMed:24227914}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Present_in_the_basement_membrane_of_many,_but_not_all_tissues._Expressed_in_retina,_cochlea,_small_and_large_intestine,_pancreas,_bladder,_prostate,_esophagus,_trachea,_thymus,_salivary_glands,_placenta,_ovary,_fallopian_tube,_uterus_and_testis._Absent_in_many_other_tissues_such_as_heart,_lung,_liver,_kidney_and_brain._In_the_retina,_it_is_present_in_the_basement_membranes_in_the_Bruch's_layer_choroid_capillary_basement_membranes,_where_it_localizes_just_beneath_the_retinal_pigment_epithelial_cells_(at_protein_level)._Weakly_expressed._Isoform_2_is_expressed_in_fetal_eye,_cochlea_and_heart,_and_at_very_low_level_in_brain,_CNS,_intestine,_skeleton,_tongue,_kidney_and_lung._Isoform_2_is_not_expressed_in_stomach_and_liver._In_adult_tissues,_isoform_2_is_expressed_in_neural_retina_and_testis,_and_at_low_level_in_brain,_heart,_kidney_and_liver._Isoform_1_displays_a_similar_pattern_of_expression_but_is_expressed_at_very_low_level_in_fetal_cochlea._{ECO:0000269|PubMed:11788194,_ECO:0000269|PubMed:12433396,_ECO:0000269|PubMed:15015129,_ECO:0000269|PubMed:9624053}.\x3b_	unclassifiable_(Anatomical_System)\x3bliver\x3btestis\x3bretina\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3badrenal_gland\x3btemporal_lobe\x3bciliary_ganglion\x3batrioventricular_node\x3btrigeminal_ganglion\x3bskin\x3bskeletal_muscle\x3bcerebellum\x3b	0.15836	.	4.179636958	99.70511913	6401.91635	16.71188	rs777465132	496182	Usher_syndrome,_type_2A	MedGen:C1848634,OMIM:276901	criteria_provided,_single_submitter	Pathogenic	.	.	.	0.001	0.389	U	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.943	0.605	D	c	0.439	0.238	0.000	0.041	0.487	0.133	0	1.84	0.242	2.214	0.423	0.100	0.199	1.000	0.715	0.996	0.625	9.634	0.388	Fibronectin_type_III|Immunoglobulin-like_fold	.	.	.	.	3.23e-05	0.0001	0	0	0	0	0	0	1.22e-05	0.0002	0	0	0	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,450	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
12	103245493	103245493	G	C	exonic	PAH	.	stopgain	PAH:NM_000277:exon8:c.C884G:p.S295X	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62642910	108620	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	.	.	.	0.000	0.629	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.983	0.817	D	c	1.250	1.112	1.000	0.747	0.638	0.428	0	5.51	0.817	9.602	0.976	1.048	0.713	1.000	0.715	0.999	0.750	19.779	0.964	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,697	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
12	103248987	103248988	TG	T	exonic	PAH	.	frameshift_deletion	PAH:NM_000277:exon6:c.632delC:p.P211fs	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62514929	108503	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_single_submitter	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	8.127e-06	0	0	0.0001	0	0	8.962e-06	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,763	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
10	89720832	89720836	CAAAT	C	exonic	PTEN	.	frameshift_deletion	PTEN:NM_000314:exon8:c.984_987del:p.A328fs,PTEN:NM_001304718:exon8:c.393_396del:p.A131fs,PTEN:NM_001304717:exon9:c.1503_1506del:p.A501fs	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs587782304	187386	Hereditary_cancer-predisposing_syndrome|not_provided	MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,589	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
1	216363621	216363623	CAG	C	exonic	USH2A	.	frameshift_deletion	USH2A:NM_007123:exon20:c.4338_4339del:p.L1446fs,USH2A:NM_206933:exon20:c.4338_4339del:p.L1446fs	3.68100336207458e-43	0.999989235571568	1.07644284322941e-05	Usher_syndrome_2A_(autosomal_recessive,_mild)	FUNCTION:_Involved_in_hearing_and_vision.\x3b_	DISEASE:_Usher_syndrome_2A_(USH2A)_[MIM:276901]:_USH_is_a_genetically_heterogeneous_condition_characterized_by_the_association_of_retinitis_pigmentosa_with_sensorineural_deafness._Age_at_onset_and_differences_in_auditory_and_vestibular_function_distinguish_Usher_syndrome_type_1_(USH1),_Usher_syndrome_type_2_(USH2)_and_Usher_syndrome_type_3_(USH3)._USH2_is_characterized_by_congenital_mild_hearing_impairment_with_normal_vestibular_responses._{ECO:0000269|PubMed:10729113,_ECO:0000269|PubMed:10738000,_ECO:0000269|PubMed:10909849,_ECO:0000269|PubMed:11311042,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:12525556,_ECO:0000269|PubMed:14970843,_ECO:0000269|PubMed:15015129,_ECO:0000269|PubMed:15025721,_ECO:0000269|PubMed:15241801,_ECO:0000269|PubMed:15325563,_ECO:0000269|PubMed:17085681,_ECO:0000269|PubMed:17405132,_ECO:0000269|PubMed:18273898,_ECO:0000269|PubMed:18452394,_ECO:0000269|PubMed:19683999,_ECO:0000269|PubMed:19737284,_ECO:0000269|PubMed:20309401,_ECO:0000269|PubMed:20440071,_ECO:0000269|PubMed:20507924,_ECO:0000269|PubMed:21593743,_ECO:0000269|PubMed:21686329,_ECO:0000269|PubMed:22004887,_ECO:0000269|PubMed:23737954,_ECO:0000269|PubMed:9624053}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Retinitis_pigmentosa_39_(RP39)_[MIM:613809]:_A_retinal_dystrophy_belonging_to_the_group_of_pigmentary_retinopathies._Retinitis_pigmentosa_is_characterized_by_retinal_pigment_deposits_visible_on_fundus_examination_and_primary_loss_of_rod_photoreceptor_cells_followed_by_secondary_loss_of_cone_photoreceptors._Patients_typically_have_night_vision_blindness_and_loss_of_midperipheral_visual_field._As_their_condition_progresses,_they_lose_their_far_peripheral_visual_field_and_eventually_central_vision_as_well._{ECO:0000269|PubMed:10775529,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:12427073,_ECO:0000269|PubMed:15325563,_ECO:0000269|PubMed:16098008,_ECO:0000269|PubMed:17296898,_ECO:0000269|PubMed:20507924,_ECO:0000269|PubMed:21686329,_ECO:0000269|PubMed:22334370,_ECO:0000269|PubMed:24227914}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Present_in_the_basement_membrane_of_many,_but_not_all_tissues._Expressed_in_retina,_cochlea,_small_and_large_intestine,_pancreas,_bladder,_prostate,_esophagus,_trachea,_thymus,_salivary_glands,_placenta,_ovary,_fallopian_tube,_uterus_and_testis._Absent_in_many_other_tissues_such_as_heart,_lung,_liver,_kidney_and_brain._In_the_retina,_it_is_present_in_the_basement_membranes_in_the_Bruch's_layer_choroid_capillary_basement_membranes,_where_it_localizes_just_beneath_the_retinal_pigment_epithelial_cells_(at_protein_level)._Weakly_expressed._Isoform_2_is_expressed_in_fetal_eye,_cochlea_and_heart,_and_at_very_low_level_in_brain,_CNS,_intestine,_skeleton,_tongue,_kidney_and_lung._Isoform_2_is_not_expressed_in_stomach_and_liver._In_adult_tissues,_isoform_2_is_expressed_in_neural_retina_and_testis,_and_at_low_level_in_brain,_heart,_kidney_and_liver._Isoform_1_displays_a_similar_pattern_of_expression_but_is_expressed_at_very_low_level_in_fetal_cochlea._{ECO:0000269|PubMed:11788194,_ECO:0000269|PubMed:12433396,_ECO:0000269|PubMed:15015129,_ECO:0000269|PubMed:9624053}.\x3b_	unclassifiable_(Anatomical_System)\x3bliver\x3btestis\x3bretina\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3badrenal_gland\x3btemporal_lobe\x3bciliary_ganglion\x3batrioventricular_node\x3btrigeminal_ganglion\x3bskin\x3bskeletal_muscle\x3bcerebellum\x3b	0.15836	.	4.179636958	99.70511913	6401.91635	16.71188	rs111033367	17392	Usher_syndrome,_type_2A|USH2A-Related_Disorders	MedGen:C1848634,OMIM:276901|MedGen:CN239332	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	4.074e-06	0	0	0	0	0	8.989e-06	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,456	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
1	216373231	216373233	AAT	A	exonic	USH2A	.	frameshift_deletion	USH2A:NM_007123:exon17:c.3547_3548del:p.I1183fs,USH2A:NM_206933:exon17:c.3547_3548del:p.I1183fs	3.68100336207458e-43	0.999989235571568	1.07644284322941e-05	Usher_syndrome_2A_(autosomal_recessive,_mild)	FUNCTION:_Involved_in_hearing_and_vision.\x3b_	DISEASE:_Usher_syndrome_2A_(USH2A)_[MIM:276901]:_USH_is_a_genetically_heterogeneous_condition_characterized_by_the_association_of_retinitis_pigmentosa_with_sensorineural_deafness._Age_at_onset_and_differences_in_auditory_and_vestibular_function_distinguish_Usher_syndrome_type_1_(USH1),_Usher_syndrome_type_2_(USH2)_and_Usher_syndrome_type_3_(USH3)._USH2_is_characterized_by_congenital_mild_hearing_impairment_with_normal_vestibular_responses._{ECO:0000269|PubMed:10729113,_ECO:0000269|PubMed:10738000,_ECO:0000269|PubMed:10909849,_ECO:0000269|PubMed:11311042,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:12525556,_ECO:0000269|PubMed:14970843,_ECO:0000269|PubMed:15015129,_ECO:0000269|PubMed:15025721,_ECO:0000269|PubMed:15241801,_ECO:0000269|PubMed:15325563,_ECO:0000269|PubMed:17085681,_ECO:0000269|PubMed:17405132,_ECO:0000269|PubMed:18273898,_ECO:0000269|PubMed:18452394,_ECO:0000269|PubMed:19683999,_ECO:0000269|PubMed:19737284,_ECO:0000269|PubMed:20309401,_ECO:0000269|PubMed:20440071,_ECO:0000269|PubMed:20507924,_ECO:0000269|PubMed:21593743,_ECO:0000269|PubMed:21686329,_ECO:0000269|PubMed:22004887,_ECO:0000269|PubMed:23737954,_ECO:0000269|PubMed:9624053}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Retinitis_pigmentosa_39_(RP39)_[MIM:613809]:_A_retinal_dystrophy_belonging_to_the_group_of_pigmentary_retinopathies._Retinitis_pigmentosa_is_characterized_by_retinal_pigment_deposits_visible_on_fundus_examination_and_primary_loss_of_rod_photoreceptor_cells_followed_by_secondary_loss_of_cone_photoreceptors._Patients_typically_have_night_vision_blindness_and_loss_of_midperipheral_visual_field._As_their_condition_progresses,_they_lose_their_far_peripheral_visual_field_and_eventually_central_vision_as_well._{ECO:0000269|PubMed:10775529,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:12427073,_ECO:0000269|PubMed:15325563,_ECO:0000269|PubMed:16098008,_ECO:0000269|PubMed:17296898,_ECO:0000269|PubMed:20507924,_ECO:0000269|PubMed:21686329,_ECO:0000269|PubMed:22334370,_ECO:0000269|PubMed:24227914}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Present_in_the_basement_membrane_of_many,_but_not_all_tissues._Expressed_in_retina,_cochlea,_small_and_large_intestine,_pancreas,_bladder,_prostate,_esophagus,_trachea,_thymus,_salivary_glands,_placenta,_ovary,_fallopian_tube,_uterus_and_testis._Absent_in_many_other_tissues_such_as_heart,_lung,_liver,_kidney_and_brain._In_the_retina,_it_is_present_in_the_basement_membranes_in_the_Bruch's_layer_choroid_capillary_basement_membranes,_where_it_localizes_just_beneath_the_retinal_pigment_epithelial_cells_(at_protein_level)._Weakly_expressed._Isoform_2_is_expressed_in_fetal_eye,_cochlea_and_heart,_and_at_very_low_level_in_brain,_CNS,_intestine,_skeleton,_tongue,_kidney_and_lung._Isoform_2_is_not_expressed_in_stomach_and_liver._In_adult_tissues,_isoform_2_is_expressed_in_neural_retina_and_testis,_and_at_low_level_in_brain,_heart,_kidney_and_liver._Isoform_1_displays_a_similar_pattern_of_expression_but_is_expressed_at_very_low_level_in_fetal_cochlea._{ECO:0000269|PubMed:11788194,_ECO:0000269|PubMed:12433396,_ECO:0000269|PubMed:15015129,_ECO:0000269|PubMed:9624053}.\x3b_	unclassifiable_(Anatomical_System)\x3bliver\x3btestis\x3bretina\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3badrenal_gland\x3btemporal_lobe\x3bciliary_ganglion\x3batrioventricular_node\x3btrigeminal_ganglion\x3bskin\x3bskeletal_muscle\x3bcerebellum\x3b	0.15836	.	4.179636958	99.70511913	6401.91635	16.71188	rs397518013	57665	Usher_syndrome,_type_2A|Retinitis_pigmentosa_39|USH2A-Related_Disorders	MedGen:C1848634,OMIM:276901|MedGen:C3151138,OMIM:613809|MedGen:CN239332	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	4.069e-06	0	0	0	0	0	8.987e-06	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,457	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
7	107312637	107312637	C	CT	exonic	SLC26A4	.	frameshift_insertion	SLC26A4:NM_000441:exon4:c.360dupT:p.A120fs	6.36692519367205e-13	0.204987783815785	0.795012216183578	solute_carrier_family_26_member_4	FUNCTION:_Sodium-independent_transporter_of_chloride_and_iodide._{ECO:0000269|PubMed:10192399}.\x3b_	DISEASE:_Deafness,_autosomal_recessive,_4_(DFNB4)_[MIM:600791]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._DFNB4_is_associated_with_an_enlarged_vestibular_aqueduct._{ECO:0000269|PubMed:10190331,_ECO:0000269|PubMed:10700480,_ECO:0000269|PubMed:11748854,_ECO:0000269|PubMed:12676893,_ECO:0000269|PubMed:14508505,_ECO:0000269|PubMed:14679580,_ECO:0000269|PubMed:19204907,_ECO:0000269|PubMed:20108392,_ECO:0000269|PubMed:20597900,_ECO:0000269|PubMed:9500541}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_High_expression_in_adult_thyroid,_lower_expression_in_adult_and_fetal_kidney_and_fetal_brain._Not_expressed_in_other_tissues.\x3b_	unclassifiable_(Anatomical_System)\x3bheart\x3bhypothalamus\x3badrenal_cortex\x3bparathyroid\x3bskeletal_muscle\x3bskin\x3buterus\x3blung\x3badrenal_gland\x3bthyroid\x3bhead_and_neck\x3bkidney\x3bbrain\x3bpineal_gland\x3b	superior_cervical_ganglion\x3bthyroid\x3batrioventricular_node\x3btrigeminal_ganglion\x3bskeletal_muscle\x3b	0.51161	0.43881	1.139030387	92.34489266	1009.39813	6.11806	rs1064797340	186730	Pendred's_syndrome|not_provided	MedGen:C0271829,OMIM:274600,Orphanet:ORPHA705,SNOMED_CT:70348004|MedGen:CN517202	criteria_provided,_single_submitter	Likely_pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1.219e-05	0	0	0	0	0	1.791e-05	0	3.249e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,490	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
10	89624262	89624262	C	CA	exonic	PTEN	.	frameshift_insertion	PTEN:NM_000314:exon1:c.37dupA:p.N12fs,PTEN:NM_001304717:exon2:c.556dupA:p.N185fs	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs587776671	22873	Cowden_syndrome_1	MedGen:CN072330,OMIM:158350	no_assertion_criteria_provided	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,513	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
10	89692782	89692782	C	CT	exonic	PTEN	.	frameshift_insertion	PTEN:NM_000314:exon5:c.267dupT:p.P89fs,PTEN:NM_001304717:exon6:c.786dupT:p.P262fs	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	.	419711	Hereditary_cancer-predisposing_syndrome	MedGen:C0027672,SNOMED_CT:699346009	criteria_provided,_single_submitter	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,534	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
10	89711886	89711887	TC	T	exonic	PTEN	.	frameshift_deletion	PTEN:NM_000314:exon6:c.505delC:p.P169fs,PTEN:NM_001304717:exon7:c.1024delC:p.P342fs	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs587776673	22882	Proteus-like_syndrome|PTEN_hamartoma_tumor_syndrome	MedGen:C1866398,Orphanet:ORPHA2969|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498	no_assertion_criteria_provided	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,558	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
10	89711893	89711893	C	CA	exonic	PTEN	.	frameshift_insertion	PTEN:NM_000314:exon6:c.512dupA:p.Q171fs,PTEN:NM_001304717:exon7:c.1031dupA:p.Q344fs	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	.	419737	Hereditary_cancer-predisposing_syndrome	MedGen:C0027672,SNOMED_CT:699346009	criteria_provided,_single_submitter	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,560	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
10	89711946	89711946	T	A	exonic	PTEN	.	stopgain	PTEN:NM_000314:exon6:c.T564A:p.Y188X,PTEN:NM_001304717:exon7:c.T1083A:p.Y361X	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs606231170	22870	Prostate_cancer,_somatic	MedGen:C4015779	no_assertion_criteria_provided	Pathogenic	.	.	.	0.000	0.629	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.839	0.427	D	c	0.734	0.537	0.999	0.395	0.722	0.854	0	1.78	0.238	1.202	0.317	0.110	0.204	1.000	0.715	1.000	0.888	7.320	0.255	C2_domain|Protein-tyrosine_phosphatase-like|Tensin_phosphatase,_C2_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,567	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
10	89711967	89711968	TC	T	exonic	PTEN	.	frameshift_deletion	PTEN:NM_000314:exon6:c.586delC:p.H196fs,PTEN:NM_001304717:exon7:c.1105delC:p.H369fs	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs587776670	22862	Bannayan-Riley-Ruvalcaba_syndrome	MedGen:C0265326,OMIM:153480,Orphanet:ORPHA109	no_assertion_criteria_provided	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,568	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
10	89717670	89717671	CA	C	exonic	PTEN	.	frameshift_deletion	PTEN:NM_000314:exon7:c.696delA:p.T232fs,PTEN:NM_001304718:exon7:c.105delA:p.T35fs,PTEN:NM_001304717:exon8:c.1215delA:p.T405fs	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs587776669	22861	Cowden_syndrome_1	MedGen:CN072330,OMIM:158350	no_assertion_criteria_provided	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,571	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
10	89717734	89717739	CAAAGT	C	exonic	PTEN	.	frameshift_deletion	PTEN:NM_000314:exon7:c.760_764del:p.K254fs,PTEN:NM_001304718:exon7:c.169_173del:p.K57fs,PTEN:NM_001304717:exon8:c.1279_1283del:p.K427fs	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs606231169	22869	Prostate_cancer,_somatic	MedGen:C4015779	no_assertion_criteria_provided	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,579	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
21	36259274	36259274	T	TCC	exonic	RUNX1	.	frameshift_insertion	RUNX1:NM_001001890:exon1:c.135_136insGG:p.S46fs,RUNX1:NM_001122607:exon1:c.135_136insGG:p.S46fs,RUNX1:NM_001754:exon4:c.216_217insGG:p.S73fs	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	.	471192	Familial_platelet_disorder_with_associated_myeloid_malignancy	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290	criteria_provided,_single_submitter	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,984	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
12	103237555	103237555	G	T	exonic	PAH	.	stopgain	PAH:NM_000277:exon11:c.C1068A:p.Y356X	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62516095	98636	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	0.000	0.843	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.964	0.688	D	c	0.468	0.241	0.000	0.060	0.638	0.428	0	2.43	0.287	1.311	0.329	0.143	0.228	1.000	0.715	0.887	0.373	9.379	0.373	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	1.221e-05	0	0	0	0.0002	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,672	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
12	103238154	103238155	GC	G	exonic	PAH	.	frameshift_deletion	PAH:NM_000277:exon10:c.1024delG:p.A342fs	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs63581460	108211	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,678	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
12	103246628	103246629	GA	G	exonic	PAH	.	frameshift_deletion	PAH:NM_000277:exon7:c.806delT:p.I269fs	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62508687	108580	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3.229e-05	0	0	0	0	0	6.661e-05	0	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,725	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
12	103246621	103246621	C	A	exonic	PAH	.	stopgain	PAH:NM_000277:exon7:c.G814T:p.G272X	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62514952	15635	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	0.001	0.407	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.386	0.258	N	c	0.728	0.547	0.932	0.270	0.638	0.428	0	5.73	0.897	0.394	0.204	0.935	0.490	0.031	0.203	0.997	0.653	13.371	0.600	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	0.0002	0.0001	0	0	0	0	0.0003	0	3.657e-05	0	0	0	0	0	6.273e-05	0.0004	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,720	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
12	103246597	103246598	CG	C	exonic	PAH	.	frameshift_deletion	PAH:NM_000277:exon7:c.837delC:p.P279fs	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs281865429	125882	Phenylketonuria	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006	no_assertion_criteria_provided	Likely_pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,710	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
12	103246592	103246592	C	A	splicing	PAH	NM_000277:exon7:c.842+1G>T	.	.	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs5030852	108605	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	.	.	.	.	.	.	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.988	0.868	D	c	1.137	0.980	1.000	0.747	0.075	0.013	0	5.73	0.897	7.905	0.864	0.935	0.490	1.000	0.715	0.980	0.490	19.896	0.969	.	.	.	1.0000	0.932	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,706	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
12	103245536	103245536	T	A	splicing	PAH	NM_000277:exon8:c.843-2A>T	.	.	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62509019	108609	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	.	.	.	.	.	.	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.972	0.733	D	c	1.145	1.000	1.000	0.747	0.075	0.013	0	5.51	0.817	7.674	0.830	1.061	0.807	1.000	0.715	0.998	0.697	15.919	0.792	.	.	.	1.0000	0.95	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,703	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
1	216348710	216348710	C	CT	exonic	USH2A	.	frameshift_insertion	USH2A:NM_007123:exon21:c.4510dupA:p.R1504fs,USH2A:NM_206933:exon21:c.4510dupA:p.R1504fs	3.68100336207458e-43	0.999989235571568	1.07644284322941e-05	Usher_syndrome_2A_(autosomal_recessive,_mild)	FUNCTION:_Involved_in_hearing_and_vision.\x3b_	DISEASE:_Usher_syndrome_2A_(USH2A)_[MIM:276901]:_USH_is_a_genetically_heterogeneous_condition_characterized_by_the_association_of_retinitis_pigmentosa_with_sensorineural_deafness._Age_at_onset_and_differences_in_auditory_and_vestibular_function_distinguish_Usher_syndrome_type_1_(USH1),_Usher_syndrome_type_2_(USH2)_and_Usher_syndrome_type_3_(USH3)._USH2_is_characterized_by_congenital_mild_hearing_impairment_with_normal_vestibular_responses._{ECO:0000269|PubMed:10729113,_ECO:0000269|PubMed:10738000,_ECO:0000269|PubMed:10909849,_ECO:0000269|PubMed:11311042,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:12525556,_ECO:0000269|PubMed:14970843,_ECO:0000269|PubMed:15015129,_ECO:0000269|PubMed:15025721,_ECO:0000269|PubMed:15241801,_ECO:0000269|PubMed:15325563,_ECO:0000269|PubMed:17085681,_ECO:0000269|PubMed:17405132,_ECO:0000269|PubMed:18273898,_ECO:0000269|PubMed:18452394,_ECO:0000269|PubMed:19683999,_ECO:0000269|PubMed:19737284,_ECO:0000269|PubMed:20309401,_ECO:0000269|PubMed:20440071,_ECO:0000269|PubMed:20507924,_ECO:0000269|PubMed:21593743,_ECO:0000269|PubMed:21686329,_ECO:0000269|PubMed:22004887,_ECO:0000269|PubMed:23737954,_ECO:0000269|PubMed:9624053}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Retinitis_pigmentosa_39_(RP39)_[MIM:613809]:_A_retinal_dystrophy_belonging_to_the_group_of_pigmentary_retinopathies._Retinitis_pigmentosa_is_characterized_by_retinal_pigment_deposits_visible_on_fundus_examination_and_primary_loss_of_rod_photoreceptor_cells_followed_by_secondary_loss_of_cone_photoreceptors._Patients_typically_have_night_vision_blindness_and_loss_of_midperipheral_visual_field._As_their_condition_progresses,_they_lose_their_far_peripheral_visual_field_and_eventually_central_vision_as_well._{ECO:0000269|PubMed:10775529,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:12427073,_ECO:0000269|PubMed:15325563,_ECO:0000269|PubMed:16098008,_ECO:0000269|PubMed:17296898,_ECO:0000269|PubMed:20507924,_ECO:0000269|PubMed:21686329,_ECO:0000269|PubMed:22334370,_ECO:0000269|PubMed:24227914}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Present_in_the_basement_membrane_of_many,_but_not_all_tissues._Expressed_in_retina,_cochlea,_small_and_large_intestine,_pancreas,_bladder,_prostate,_esophagus,_trachea,_thymus,_salivary_glands,_placenta,_ovary,_fallopian_tube,_uterus_and_testis._Absent_in_many_other_tissues_such_as_heart,_lung,_liver,_kidney_and_brain._In_the_retina,_it_is_present_in_the_basement_membranes_in_the_Bruch's_layer_choroid_capillary_basement_membranes,_where_it_localizes_just_beneath_the_retinal_pigment_epithelial_cells_(at_protein_level)._Weakly_expressed._Isoform_2_is_expressed_in_fetal_eye,_cochlea_and_heart,_and_at_very_low_level_in_brain,_CNS,_intestine,_skeleton,_tongue,_kidney_and_lung._Isoform_2_is_not_expressed_in_stomach_and_liver._In_adult_tissues,_isoform_2_is_expressed_in_neural_retina_and_testis,_and_at_low_level_in_brain,_heart,_kidney_and_liver._Isoform_1_displays_a_similar_pattern_of_expression_but_is_expressed_at_very_low_level_in_fetal_cochlea._{ECO:0000269|PubMed:11788194,_ECO:0000269|PubMed:12433396,_ECO:0000269|PubMed:15015129,_ECO:0000269|PubMed:9624053}.\x3b_	unclassifiable_(Anatomical_System)\x3bliver\x3btestis\x3bretina\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3badrenal_gland\x3btemporal_lobe\x3bciliary_ganglion\x3batrioventricular_node\x3btrigeminal_ganglion\x3bskin\x3bskeletal_muscle\x3bcerebellum\x3b	0.15836	.	4.179636958	99.70511913	6401.91635	16.71188	rs727503731	172390	Retinitis_pigmentosa|Usher_syndrome,_type_2A|not_provided	Human_Phenotype_Ontology:HP:0000547,MeSH:D012174,MedGen:C0035334,OMIM:268000,Orphanet:ORPHA791,SNOMED_CT:28835009|MedGen:C1848634,OMIM:276901|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1.222e-05	0	0	0	0	0	2.699e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,455	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
12	103237533	103237534	GC	G	exonic	PAH	.	frameshift_deletion	PAH:NM_000277:exon11:c.1089delG:p.K363fs	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs5030654	108254	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,670	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
12	103240709	103240711	CAG	C	exonic	PAH	.	frameshift_deletion	PAH:NM_000277:exon9:c.931_932del:p.L311fs	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs281865430	125891	Phenylketonuria	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006	no_assertion_criteria_provided	Likely_pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,684	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
12	103237555	103237555	G	C	exonic	PAH	.	stopgain	PAH:NM_000277:exon11:c.C1068G:p.Y356X	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62516095	15634	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	.	.	.	0.000	0.843	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.966	0.695	D	c	0.468	0.241	0.000	0.060	0.638	0.428	0	2.43	0.287	1.311	0.329	0.143	0.228	1.000	0.715	0.887	0.373	9.379	0.373	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	3.232e-05	0	0	0	0	0	6.672e-05	0	1.627e-05	0	0	0	0	0	3.591e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,671	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
12	103238123	103238124	AC	A	exonic	PAH	.	frameshift_deletion	PAH:NM_000277:exon10:c.1055delG:p.G352fs	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62516094	108234	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,676	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
19	4110574	4110574	G	T	exonic	MAP2K2	.	nonsynonymous_SNV	MAP2K2:NM_030662:exon3:c.C383A:p.P128Q	0.86326115931858	0.136320885012997	0.00041795566842237	mitogen-activated_protein_kinase_kinase_2	FUNCTION:_Catalyzes_the_concomitant_phosphorylation_of_a_threonine_and_a_tyrosine_residue_in_a_Thr-Glu-Tyr_sequence_located_in_MAP_kinases._Activates_the_ERK1_and_ERK2_MAP_kinases_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Cardiofaciocutaneous_syndrome_4_(CFC4)_[MIM:615280]:_A_form_of_cardiofaciocutaneous_syndrome,_a_multiple_congenital_anomaly_disorder_characterized_by_a_distinctive_facial_appearance,_heart_defects_and_mental_retardation._Heart_defects_include_pulmonic_stenosis,_atrial_septal_defects_and_hypertrophic_cardiomyopathy._Some_affected_individuals_present_with_ectodermal_abnormalities_such_as_sparse,_friable_hair,_hyperkeratotic_skin_lesions_and_a_generalized_ichthyosis-like_condition._Typical_facial_features_are_similar_to_Noonan_syndrome._They_include_high_forehead_with_bitemporal_constriction,_hypoplastic_supraorbital_ridges,_downslanting_palpebral_fissures,_a_depressed_nasal_bridge,_and_posteriorly_angulated_ears_with_prominent_helices._{ECO:0000269|PubMed:16439621,_ECO:0000269|PubMed:18042262,_ECO:0000269|PubMed:20358587}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	medulla_oblongata\x3bsmooth_muscle\x3bovary\x3bsalivary_gland\x3bsympathetic_chain\x3bcolon\x3bparathyroid\x3bskin\x3buterus\x3bprostate\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bmuscle\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbile_duct\x3bpancreas\x3blung\x3badrenal_gland\x3bplacenta\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	amygdala\x3bprefrontal_cortex\x3btestis\x3bpons\x3bcingulate_cortex\x3b	0.88489	0.51187	-0.800872469	12.33191791	40.94266	1.19949	rs267607230	23314	Cardio-facio-cutaneous_syndrome|Cardiofaciocutaneous_syndrome_4|not_provided	MedGen:C1275081,Orphanet:ORPHA1340,SNOMED_CT:403770008|MedGen:C3809007,OMIM:615280|MedGen:CN517202	reviewed_by_expert_panel	Pathogenic	0.001	0.784	D	0.000	0.843	D	1	0.810	D	2.175	0.612	M	-3.43	0.944	D	-5.98	0.900	D	1.022	0.976	D	0.907	0.969	D	0.716	0.977	D	0.955	0.995	0.965	0.695	D	c	0.710	0.612	1.000	0.747	0.722	0.854	0	5.3	0.746	9.865	0.984	0.949	0.536	1.000	0.715	0.150	0.205	17.509	0.876	Protein_kinase_domain|Protein_kinase-like_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,935	0	0	0	1	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	112926910	112926910	G	C	exonic	PTPN11	.	nonsynonymous_SNV	PTPN11:NM_001330437:exon13:c.G1542C:p.Q514H,PTPN11:NM_002834:exon13:c.G1530C:p.Q510H	0.999877230878678	0.000122769057470549	6.38519788034449e-11	protein_tyrosine_phosphatase,_non-receptor_type_11	FUNCTION:_Acts_downstream_of_various_receptor_and_cytoplasmic_protein_tyrosine_kinases_to_participate_in_the_signal_transduction_from_the_cell_surface_to_the_nucleus._Dephosphorylates_ROCK2_at_Tyr-722_resulting_in_stimulatation_of_its_RhoA_binding_activity._{ECO:0000269|PubMed:10655584,_ECO:0000269|PubMed:18559669,_ECO:0000269|PubMed:18829466}.\x3b_	DISEASE:_LEOPARD_syndrome_1_(LPRD1)_[MIM:151100]:_A_disorder_characterized_by_lentigines,_electrocardiographic_conduction_abnormalities,_ocular_hypertelorism,_pulmonic_stenosis,_abnormalities_of_genitalia,_retardation_of_growth,_and_sensorineural_deafness._{ECO:0000269|PubMed:12058348,_ECO:0000269|PubMed:14961557,_ECO:0000269|PubMed:15121796,_ECO:0000269|PubMed:15389709,_ECO:0000269|PubMed:15520399,_ECO:0000269|PubMed:15690106,_ECO:0000269|PubMed:16679933,_ECO:0000269|PubMed:24891296}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Noonan_syndrome_1_(NS1)_[MIM:163950]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._Some_patients_with_NS1_develop_multiple_giant_cell_lesions_of_the_jaw_or_other_bony_or_soft_tissues,_which_are_classified_as_pigmented_villonodular_synovitis_(PVNS)_when_occurring_in_the_jaw_or_joints._{ECO:0000269|PubMed:11704759,_ECO:0000269|PubMed:11992261,_ECO:0000269|PubMed:12161469,_ECO:0000269|PubMed:12325025,_ECO:0000269|PubMed:12529711,_ECO:0000269|PubMed:12634870,_ECO:0000269|PubMed:12717436,_ECO:0000269|PubMed:12739139,_ECO:0000269|PubMed:12960218,_ECO:0000269|PubMed:15384080,_ECO:0000269|PubMed:15948193,_ECO:0000269|PubMed:19020799,_ECO:0000269|PubMed:24891296}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry._Mutations_in_PTPN11_account_for_more_than_50%_of_the_cases.\x3b_DISEASE:_Leukemia,_juvenile_myelomonocytic_(JMML)_[MIM:607785]:_An_aggressive_pediatric_myelodysplastic_syndrome/myeloproliferative_disorder_characterized_by_malignant_transformation_in_the_hematopoietic_stem_cell_compartment_with_proliferation_of_differentiated_progeny._Patients_have_splenomegaly,_enlarged_lymph_nodes,_rashes,_and_hemorrhages._{ECO:0000269|PubMed:12717436}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Metachondromatosis_(MC)_[MIM:156250]:_A_skeletal_disorder_with_radiologic_features_of_both_multiple_exostoses_and_Ollier_disease,_characterized_by_the_presence_of_exostoses,_commonly_of_the_bones_of_the_hands_and_feet,_and_enchondromas_of_the_metaphyses_of_long_bones_and_iliac_crest._{ECO:0000269|PubMed:20577567}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Widely_expressed,_with_highest_levels_in_heart,_brain,_and_skeletal_muscle._{ECO:0000269|PubMed:1280823,_ECO:0000269|PubMed:7681589,_ECO:0000269|PubMed:8216283}.\x3b_	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3bfrontal_lobe\x3bendometrium\x3boesophagus\x3blarynx\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bpineal_gland\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bpineal_body\x3burinary\x3badrenal_cortex\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3blung\x3bcornea\x3badrenal_gland\x3bplacenta\x3bvisual_apparatus\x3bhippocampus\x3bhypopharynx\x3bliver\x3bhead_and_neck\x3bcervix\x3bkidney\x3bmammary_gland\x3baorta\x3bstomach\x3b	amygdala\x3btestis_-_interstitial\x3bthalamus\x3bmedulla_oblongata\x3bsuperior_cervical_ganglion\x3boccipital_lobe\x3bhypothalamus\x3bspinal_cord\x3bcaudate_nucleus\x3bpons\x3bskeletal_muscle\x3bsubthalamic_nucleus\x3bprefrontal_cortex\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bparietal_lobe\x3b	0.26245	0.72890	-0.427900189	25.14744043	19.44641	0.66817	rs397507550	49037	LEOPARD_syndrome_1|Rasopathy|not_provided	MedGen:CN074218,OMIM:151100|MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN517202	reviewed_by_expert_panel	Pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	D	3.48	0.927	M	-6.37	0.997	D	-4.43	0.775	D	1.083	0.990	D	0.989	0.997	D	0.749	0.980	D	0.934	0.990	0.966	0.700	D	c	0.605	0.476	0.087	0.160	0.722	0.854	0	2.29	0.275	3.711	0.543	1.048	0.713	1.000	0.715	1.000	0.888	9.290	0.367	PTP_type_protein_phosphatase|Protein-tyrosine_phosphatase,_catalytic|Protein-tyrosine_phosphatase-like|Tyrosine_specific_protein_phosphatases_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,860	0	0	0	1	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
10	89720649	89720649	A	T	splicing	PTEN	NM_001304718:exon8:c.211-2A>T\x3bNM_001304717:exon9:c.1321-2A>T\x3bNM_000314:exon8:c.802-2A>T	.	.	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs587782455	152137	Hereditary_cancer-predisposing_syndrome|Cowden_syndrome_1|not_provided	MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN072330,OMIM:158350|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	.	.	.	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.997	0.983	D	c	1.116	0.957	1.000	0.747	0.089	0.018	0	5.13	0.696	8.807	0.915	1.140	0.893	1.000	0.715	0.986	0.517	14.923	0.704	.	.	.	1.0000	0.928	4.922e-05	0	0	0	0	0	9.397e-05	0	4.534e-05	0	0.0001	0	0.0002	0.0002	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,582	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
11	533553	533553	T	C	exonic	HRAS	.	nonsynonymous_SNV	HRAS:NM_001130442:exon4:c.A350G:p.K117R,HRAS:NM_001318054:exon4:c.A31G:p.S11G,HRAS:NM_005343:exon4:c.A350G:p.K117R,HRAS:NM_176795:exon4:c.A350G:p.K117R	0.00794104930284198	0.785285637637198	0.20677331305996	Harvey_rat_sarcoma_viral_oncogene_homolog	FUNCTION:_Ras_proteins_bind_GDP/GTP_and_possess_intrinsic_GTPase_activity._{ECO:0000269|PubMed:12740440,_ECO:0000269|PubMed:14500341,_ECO:0000269|PubMed:9020151}.\x3b_	DISEASE:_Costello_syndrome_(CSTLO)_[MIM:218040]:_A_rare_condition_characterized_by_prenatally_increased_growth,_postnatal_growth_deficiency,_mental_retardation,_distinctive_facial_appearance,_cardiovascular_abnormalities_(typically_pulmonic_stenosis,_hypertrophic_cardiomyopathy_and/or_atrial_tachycardia),_tumor_predisposition,_skin_and_musculoskeletal_abnormalities._{ECO:0000269|PubMed:16170316,_ECO:0000269|PubMed:16329078,_ECO:0000269|PubMed:16443854,_ECO:0000269|PubMed:17054105,_ECO:0000269|PubMed:18039947,_ECO:0000269|PubMed:18247425,_ECO:0000269|PubMed:19995790}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Congenital_myopathy_with_excess_of_muscle_spindles_(CMEMS)_[MIM:218040]:_Variant_of_Costello_syndrome._{ECO:0000269|PubMed:17412879}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hurthle_cell_thyroid_carcinoma_(HCTC)_[MIM:607464]:_A_rare_type_of_thyroid_cancer_accounting_for_only_about_3-10%_of_all_differentiated_thyroid_cancers._These_neoplasms_are_considered_a_variant_of_follicular_carcinoma_of_the_thyroid_and_are_referred_to_as_follicular_carcinoma,_oxyphilic_type._{ECO:0000269|PubMed:12727991}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dMutations_which_change_positions_12,_13_or_61_activate_the_potential_of_HRAS_to_transform_cultured_cells_and_are_implicated_in_a_variety_of_human_tumors._{ECO:0000269|PubMed:3670300}.\x3b_DISEASE:_Bladder_cancer_(BLC)_[MIM:109800]:_A_malignancy_originating_in_tissues_of_the_urinary_bladder._It_often_presents_with_multiple_tumors_appearing_at_different_times_and_at_different_sites_in_the_bladder._Most_bladder_cancers_are_transitional_cell_carcinomas_that_begin_in_cells_that_normally_make_up_the_inner_lining_of_the_bladder._Other_types_of_bladder_cancer_include_squamous_cell_carcinoma_(cancer_that_begins_in_thin,_flat_cells)_and_adenocarcinoma_(cancer_that_begins_in_cells_that_make_and_release_mucus_and_other_fluids)._Bladder_cancer_is_a_complex_disorder_with_both_genetic_and_environmental_influences._{ECO:0000269|PubMed:6298635,_ECO:0000269|PubMed:6844927}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Schimmelpenning-Feuerstein-Mims_syndrome_(SFM)_[MIM:163200]:_A_disease_characterized_by_sebaceous_nevi,_often_on_the_face,_associated_with_variable_ipsilateral_abnormalities_of_the_central_nervous_system,_ocular_anomalies,_and_skeletal_defects._Many_oral_manifestations_have_been_reported,_not_only_including_hypoplastic_and_malformed_teeth,_and_mucosal_papillomatosis,_but_also_ankyloglossia,_hemihyperplastic_tongue,_intraoral_nevus,_giant_cell_granuloma,_ameloblastoma,_bone_cysts,_follicular_cysts,_oligodontia,_and_odontodysplasia._Sebaceous_nevi_follow_the_lines_of_Blaschko_and_these_can_continue_as_linear_intraoral_lesions,_as_in_mucosal_papillomatosis._{ECO:0000269|PubMed:22683711}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Widely_expressed._{ECO:0000269|PubMed:14500341}.\x3b_	ovary\x3bdevelopmental\x3bcolon\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3boptic_nerve\x3bwhole_body\x3boesophagus\x3bendometrium\x3bthyroid\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bhypothalamus\x3bblood\x3blens\x3bskeletal_muscle\x3blung\x3bplacenta\x3bvisual_apparatus\x3bhypopharynx\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bcerebellum\x3b	whole_brain\x3bmedulla_oblongata\x3btrigeminal_ganglion\x3b	0.99944	0.99980	-0.339715008	30.06605331	4.91473	0.18207	rs104894227	27644	Costello_syndrome|not_provided	MedGen:C0587248,OMIM:218040,Orphanet:ORPHA3071,SNOMED_CT:309776008|MedGen:CN517202	reviewed_by_expert_panel	Pathogenic	0.004	0.654	D	0.000	0.843	D	1	0.810	A	4.27	0.982	H	-2.22	0.871	D	-2.67	0.587	D	1.056	0.982	D	0.879	0.960	D	0.393	0.933	D	0.914	0.984	0.989	0.882	D	c	0.935	0.774	1.000	0.747	0.722	0.854	0	4.08	0.467	4.136	0.575	1.061	0.807	1.000	0.715	1.000	0.888	12.54	0.553	P-loop_containing_nucleoside_triphosphate_hydrolase|Small_GTP-binding_protein_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,616	0	0	0	1	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
11	533881	533881	C	T	exonic	HRAS	.	nonsynonymous_SNV	HRAS:NM_001130442:exon3:c.G175A:p.A59T,HRAS:NM_005343:exon3:c.G175A:p.A59T,HRAS:NM_176795:exon3:c.G175A:p.A59T	0.00794104930284198	0.785285637637198	0.20677331305996	Harvey_rat_sarcoma_viral_oncogene_homolog	FUNCTION:_Ras_proteins_bind_GDP/GTP_and_possess_intrinsic_GTPase_activity._{ECO:0000269|PubMed:12740440,_ECO:0000269|PubMed:14500341,_ECO:0000269|PubMed:9020151}.\x3b_	DISEASE:_Costello_syndrome_(CSTLO)_[MIM:218040]:_A_rare_condition_characterized_by_prenatally_increased_growth,_postnatal_growth_deficiency,_mental_retardation,_distinctive_facial_appearance,_cardiovascular_abnormalities_(typically_pulmonic_stenosis,_hypertrophic_cardiomyopathy_and/or_atrial_tachycardia),_tumor_predisposition,_skin_and_musculoskeletal_abnormalities._{ECO:0000269|PubMed:16170316,_ECO:0000269|PubMed:16329078,_ECO:0000269|PubMed:16443854,_ECO:0000269|PubMed:17054105,_ECO:0000269|PubMed:18039947,_ECO:0000269|PubMed:18247425,_ECO:0000269|PubMed:19995790}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Congenital_myopathy_with_excess_of_muscle_spindles_(CMEMS)_[MIM:218040]:_Variant_of_Costello_syndrome._{ECO:0000269|PubMed:17412879}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hurthle_cell_thyroid_carcinoma_(HCTC)_[MIM:607464]:_A_rare_type_of_thyroid_cancer_accounting_for_only_about_3-10%_of_all_differentiated_thyroid_cancers._These_neoplasms_are_considered_a_variant_of_follicular_carcinoma_of_the_thyroid_and_are_referred_to_as_follicular_carcinoma,_oxyphilic_type._{ECO:0000269|PubMed:12727991}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dMutations_which_change_positions_12,_13_or_61_activate_the_potential_of_HRAS_to_transform_cultured_cells_and_are_implicated_in_a_variety_of_human_tumors._{ECO:0000269|PubMed:3670300}.\x3b_DISEASE:_Bladder_cancer_(BLC)_[MIM:109800]:_A_malignancy_originating_in_tissues_of_the_urinary_bladder._It_often_presents_with_multiple_tumors_appearing_at_different_times_and_at_different_sites_in_the_bladder._Most_bladder_cancers_are_transitional_cell_carcinomas_that_begin_in_cells_that_normally_make_up_the_inner_lining_of_the_bladder._Other_types_of_bladder_cancer_include_squamous_cell_carcinoma_(cancer_that_begins_in_thin,_flat_cells)_and_adenocarcinoma_(cancer_that_begins_in_cells_that_make_and_release_mucus_and_other_fluids)._Bladder_cancer_is_a_complex_disorder_with_both_genetic_and_environmental_influences._{ECO:0000269|PubMed:6298635,_ECO:0000269|PubMed:6844927}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Schimmelpenning-Feuerstein-Mims_syndrome_(SFM)_[MIM:163200]:_A_disease_characterized_by_sebaceous_nevi,_often_on_the_face,_associated_with_variable_ipsilateral_abnormalities_of_the_central_nervous_system,_ocular_anomalies,_and_skeletal_defects._Many_oral_manifestations_have_been_reported,_not_only_including_hypoplastic_and_malformed_teeth,_and_mucosal_papillomatosis,_but_also_ankyloglossia,_hemihyperplastic_tongue,_intraoral_nevus,_giant_cell_granuloma,_ameloblastoma,_bone_cysts,_follicular_cysts,_oligodontia,_and_odontodysplasia._Sebaceous_nevi_follow_the_lines_of_Blaschko_and_these_can_continue_as_linear_intraoral_lesions,_as_in_mucosal_papillomatosis._{ECO:0000269|PubMed:22683711}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Widely_expressed._{ECO:0000269|PubMed:14500341}.\x3b_	ovary\x3bdevelopmental\x3bcolon\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3boptic_nerve\x3bwhole_body\x3boesophagus\x3bendometrium\x3bthyroid\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bhypothalamus\x3bblood\x3blens\x3bskeletal_muscle\x3blung\x3bplacenta\x3bvisual_apparatus\x3bhypopharynx\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bcerebellum\x3b	whole_brain\x3bmedulla_oblongata\x3btrigeminal_ganglion\x3b	0.99944	0.99980	-0.339715008	30.06605331	4.91473	0.18207	rs727503093	48905	Non-small_cell_lung_cancer|Costello_syndrome	Human_Phenotype_Ontology:HP:0030358,MeSH:D002289,MedGen:C0007131,SNOMED_CT:254637007|MedGen:C0587248,OMIM:218040,Orphanet:ORPHA3071,SNOMED_CT:309776008	reviewed_by_expert_panel	Likely_pathogenic	0.011	0.555	D	0.000	0.843	D	1	0.810	D	3.86	0.959	H	-2.42	0.886	D	-3.71	0.709	D	0.693	0.931	D	0.717	0.903	D	0.333	0.918	D	0.775	0.901	0.973	0.735	D	c	0.215	0.107	1.000	0.747	0.722	0.854	0	3.64	0.407	7.768	0.840	0.852	0.362	1.000	0.715	0.256	0.229	14.843	0.697	P-loop_containing_nucleoside_triphosphate_hydrolase|Small_GTP-binding_protein_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,621	0	0	0	1	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
11	533883	533883	G	A	exonic	HRAS	.	nonsynonymous_SNV	HRAS:NM_001130442:exon3:c.C173T:p.T58I,HRAS:NM_005343:exon3:c.C173T:p.T58I,HRAS:NM_176795:exon3:c.C173T:p.T58I	0.00794104930284198	0.785285637637198	0.20677331305996	Harvey_rat_sarcoma_viral_oncogene_homolog	FUNCTION:_Ras_proteins_bind_GDP/GTP_and_possess_intrinsic_GTPase_activity._{ECO:0000269|PubMed:12740440,_ECO:0000269|PubMed:14500341,_ECO:0000269|PubMed:9020151}.\x3b_	DISEASE:_Costello_syndrome_(CSTLO)_[MIM:218040]:_A_rare_condition_characterized_by_prenatally_increased_growth,_postnatal_growth_deficiency,_mental_retardation,_distinctive_facial_appearance,_cardiovascular_abnormalities_(typically_pulmonic_stenosis,_hypertrophic_cardiomyopathy_and/or_atrial_tachycardia),_tumor_predisposition,_skin_and_musculoskeletal_abnormalities._{ECO:0000269|PubMed:16170316,_ECO:0000269|PubMed:16329078,_ECO:0000269|PubMed:16443854,_ECO:0000269|PubMed:17054105,_ECO:0000269|PubMed:18039947,_ECO:0000269|PubMed:18247425,_ECO:0000269|PubMed:19995790}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Congenital_myopathy_with_excess_of_muscle_spindles_(CMEMS)_[MIM:218040]:_Variant_of_Costello_syndrome._{ECO:0000269|PubMed:17412879}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hurthle_cell_thyroid_carcinoma_(HCTC)_[MIM:607464]:_A_rare_type_of_thyroid_cancer_accounting_for_only_about_3-10%_of_all_differentiated_thyroid_cancers._These_neoplasms_are_considered_a_variant_of_follicular_carcinoma_of_the_thyroid_and_are_referred_to_as_follicular_carcinoma,_oxyphilic_type._{ECO:0000269|PubMed:12727991}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dMutations_which_change_positions_12,_13_or_61_activate_the_potential_of_HRAS_to_transform_cultured_cells_and_are_implicated_in_a_variety_of_human_tumors._{ECO:0000269|PubMed:3670300}.\x3b_DISEASE:_Bladder_cancer_(BLC)_[MIM:109800]:_A_malignancy_originating_in_tissues_of_the_urinary_bladder._It_often_presents_with_multiple_tumors_appearing_at_different_times_and_at_different_sites_in_the_bladder._Most_bladder_cancers_are_transitional_cell_carcinomas_that_begin_in_cells_that_normally_make_up_the_inner_lining_of_the_bladder._Other_types_of_bladder_cancer_include_squamous_cell_carcinoma_(cancer_that_begins_in_thin,_flat_cells)_and_adenocarcinoma_(cancer_that_begins_in_cells_that_make_and_release_mucus_and_other_fluids)._Bladder_cancer_is_a_complex_disorder_with_both_genetic_and_environmental_influences._{ECO:0000269|PubMed:6298635,_ECO:0000269|PubMed:6844927}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Schimmelpenning-Feuerstein-Mims_syndrome_(SFM)_[MIM:163200]:_A_disease_characterized_by_sebaceous_nevi,_often_on_the_face,_associated_with_variable_ipsilateral_abnormalities_of_the_central_nervous_system,_ocular_anomalies,_and_skeletal_defects._Many_oral_manifestations_have_been_reported,_not_only_including_hypoplastic_and_malformed_teeth,_and_mucosal_papillomatosis,_but_also_ankyloglossia,_hemihyperplastic_tongue,_intraoral_nevus,_giant_cell_granuloma,_ameloblastoma,_bone_cysts,_follicular_cysts,_oligodontia,_and_odontodysplasia._Sebaceous_nevi_follow_the_lines_of_Blaschko_and_these_can_continue_as_linear_intraoral_lesions,_as_in_mucosal_papillomatosis._{ECO:0000269|PubMed:22683711}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Widely_expressed._{ECO:0000269|PubMed:14500341}.\x3b_	ovary\x3bdevelopmental\x3bcolon\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3boptic_nerve\x3bwhole_body\x3boesophagus\x3bendometrium\x3bthyroid\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bhypothalamus\x3bblood\x3blens\x3bskeletal_muscle\x3blung\x3bplacenta\x3bvisual_apparatus\x3bhypopharynx\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bcerebellum\x3b	whole_brain\x3bmedulla_oblongata\x3btrigeminal_ganglion\x3b	0.99944	0.99980	-0.339715008	30.06605331	4.91473	0.18207	rs121917758	27649	Costello_syndrome	MedGen:C0587248,OMIM:218040,Orphanet:ORPHA3071,SNOMED_CT:309776008	reviewed_by_expert_panel	Pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	A	3.4	0.918	M	-2.31	0.878	D	-5.8	0.883	D	0.901	0.957	D	0.825	0.941	D	0.231	0.883	D	0.964	0.996	0.980	0.790	D	c	0.639	0.430	1.000	0.747	0.722	0.854	0	2.72	0.310	9.802	0.982	0.953	0.551	1.000	0.715	0.575	0.284	10.277	0.425	P-loop_containing_nucleoside_triphosphate_hydrolase|Small_GTP-binding_protein_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,622	0	0	0	1	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103249094	103249094	G	A	exonic	PAH	.	stopgain	PAH:NM_000277:exon6:c.C526T:p.R176X	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475575	108459	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	0.015	0.285	N	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.338	0.247	N	c	0.444	0.252	0.001	0.082	0.554	0.246	0	3.76	0.422	0.975	0.288	1.048	0.713	0.018	0.193	0.957	0.436	11.129	0.474	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	3.23e-05	0.0001	0	0	0	0	0	0	1.22e-05	6.536e-05	0	0	0	0	1.795e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,773	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0.9941	Pathogenic
11	534289	534289	C	T	exonic	HRAS	.	nonsynonymous_SNV	HRAS:NM_001130442:exon2:c.G34A:p.G12S,HRAS:NM_005343:exon2:c.G34A:p.G12S,HRAS:NM_176795:exon2:c.G34A:p.G12S	0.00794104930284198	0.785285637637198	0.20677331305996	Harvey_rat_sarcoma_viral_oncogene_homolog	FUNCTION:_Ras_proteins_bind_GDP/GTP_and_possess_intrinsic_GTPase_activity._{ECO:0000269|PubMed:12740440,_ECO:0000269|PubMed:14500341,_ECO:0000269|PubMed:9020151}.\x3b_	DISEASE:_Costello_syndrome_(CSTLO)_[MIM:218040]:_A_rare_condition_characterized_by_prenatally_increased_growth,_postnatal_growth_deficiency,_mental_retardation,_distinctive_facial_appearance,_cardiovascular_abnormalities_(typically_pulmonic_stenosis,_hypertrophic_cardiomyopathy_and/or_atrial_tachycardia),_tumor_predisposition,_skin_and_musculoskeletal_abnormalities._{ECO:0000269|PubMed:16170316,_ECO:0000269|PubMed:16329078,_ECO:0000269|PubMed:16443854,_ECO:0000269|PubMed:17054105,_ECO:0000269|PubMed:18039947,_ECO:0000269|PubMed:18247425,_ECO:0000269|PubMed:19995790}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Congenital_myopathy_with_excess_of_muscle_spindles_(CMEMS)_[MIM:218040]:_Variant_of_Costello_syndrome._{ECO:0000269|PubMed:17412879}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hurthle_cell_thyroid_carcinoma_(HCTC)_[MIM:607464]:_A_rare_type_of_thyroid_cancer_accounting_for_only_about_3-10%_of_all_differentiated_thyroid_cancers._These_neoplasms_are_considered_a_variant_of_follicular_carcinoma_of_the_thyroid_and_are_referred_to_as_follicular_carcinoma,_oxyphilic_type._{ECO:0000269|PubMed:12727991}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dMutations_which_change_positions_12,_13_or_61_activate_the_potential_of_HRAS_to_transform_cultured_cells_and_are_implicated_in_a_variety_of_human_tumors._{ECO:0000269|PubMed:3670300}.\x3b_DISEASE:_Bladder_cancer_(BLC)_[MIM:109800]:_A_malignancy_originating_in_tissues_of_the_urinary_bladder._It_often_presents_with_multiple_tumors_appearing_at_different_times_and_at_different_sites_in_the_bladder._Most_bladder_cancers_are_transitional_cell_carcinomas_that_begin_in_cells_that_normally_make_up_the_inner_lining_of_the_bladder._Other_types_of_bladder_cancer_include_squamous_cell_carcinoma_(cancer_that_begins_in_thin,_flat_cells)_and_adenocarcinoma_(cancer_that_begins_in_cells_that_make_and_release_mucus_and_other_fluids)._Bladder_cancer_is_a_complex_disorder_with_both_genetic_and_environmental_influences._{ECO:0000269|PubMed:6298635,_ECO:0000269|PubMed:6844927}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Schimmelpenning-Feuerstein-Mims_syndrome_(SFM)_[MIM:163200]:_A_disease_characterized_by_sebaceous_nevi,_often_on_the_face,_associated_with_variable_ipsilateral_abnormalities_of_the_central_nervous_system,_ocular_anomalies,_and_skeletal_defects._Many_oral_manifestations_have_been_reported,_not_only_including_hypoplastic_and_malformed_teeth,_and_mucosal_papillomatosis,_but_also_ankyloglossia,_hemihyperplastic_tongue,_intraoral_nevus,_giant_cell_granuloma,_ameloblastoma,_bone_cysts,_follicular_cysts,_oligodontia,_and_odontodysplasia._Sebaceous_nevi_follow_the_lines_of_Blaschko_and_these_can_continue_as_linear_intraoral_lesions,_as_in_mucosal_papillomatosis._{ECO:0000269|PubMed:22683711}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Widely_expressed._{ECO:0000269|PubMed:14500341}.\x3b_	ovary\x3bdevelopmental\x3bcolon\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3boptic_nerve\x3bwhole_body\x3boesophagus\x3bendometrium\x3bthyroid\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bhypothalamus\x3bblood\x3blens\x3bskeletal_muscle\x3blung\x3bplacenta\x3bvisual_apparatus\x3bhypopharynx\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bcerebellum\x3b	whole_brain\x3bmedulla_oblongata\x3btrigeminal_ganglion\x3b	0.99944	0.99980	-0.339715008	30.06605331	4.91473	0.18207	rs104894229	27641	Acute_myeloid_leukemia|Pancreatic_adenocarcinoma|Squamous_cell_carcinoma_of_the_skin|Transitional_cell_carcinoma_of_the_bladder|Multiple_myeloma|Carcinoma_of_esophagus|Lung_adenocarcinoma|Neoplasm_of_the_breast|Neoplasm_of_the_thyroid_gland|Glioblastoma|Squamous_cell_carcinoma_of_the_head_and_neck|Papillary_renal_cell_carcinoma,_sporadic|Malignant_melanoma_of_skin|Uterine_cervical_neoplasms|Adenoid_cystic_carcinoma|Myelodysplastic_syndrome|Nasopharyngeal_Neoplasms|Colorectal_Neoplasms|Adenocarcinoma_of_prostate|Malignant_neoplasm_of_body_of_uterus|Adenocarcinoma_of_stomach|Ovarian_Serous_Cystadenocarcinoma|Uterine_Carcinosarcoma|Costello_syndrome|Nevus_sebaceous|Myopathy,_congenital,_with_excess_of_muscle_spindles|Hepatocellular_carcinoma|Epidermal_nevus_with_urothelial_cancer,_somatic|Rasopathy|not_specified|Nevus,_woolly_hair|not_provided	Human_Phenotype_Ontology:HP:0004808,MeSH:D015470,MedGen:C0023467,OMIM:601626,Orphanet:ORPHA519,SNOMED_CT:17788007|Human_Phenotype_Ontology:HP:0006725,MedGen:C0281361|Human_Phenotype_Ontology:HP:0006739,MedGen:C0553723|Human_Phenotype_Ontology:HP:0006740,MedGen:C0279680|Human_Phenotype_Ontology:HP:0006775,MeSH:D009101,MedGen:C0026764,OMIM:254500,Orphanet:ORPHA29073,SNOMED_CT:109989006,SNOMED_CT:55921005|Human_Phenotype_Ontology:HP:0011459,MedGen:C0152018,Orphanet:ORPHA70482|Human_Phenotype_Ontology:HP:0030078,MeSH:C538231,MedGen:C0152013|Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|Human_Phenotype_Ontology:HP:0100031,MeSH:D013964,MedGen:C0040136,Orphanet:ORPHA100087|Human_Phenotype_Ontology:HP:0100843,MeSH:D005909,MedGen:C0017636,SNOMED_CT:63634009|MeSH:C535575,MedGen:C1168401,OMIM:275355,Orphanet:ORPHA67037|MeSH:C538614,MedGen:C1336078|MeSH:C562393,MedGen:C0151779,SNOMED_CT:93655004|MeSH:D002583,MedGen:CN236667|MeSH:D003528,MedGen:C0010606|MeSH:D009190,MedGen:C3463824,OMIM:614286,Orphanet:ORPHA52688|MeSH:D009303,MedGen:C0027439|MeSH:D015179,MedGen:CN236642|MedGen:C0007112|MedGen:C0153574,Orphanet:ORPHA213569|MedGen:C0278701|MedGen:C0279663|MedGen:C0280630|MedGen:C0587248,OMIM:218040,Orphanet:ORPHA3071,SNOMED_CT:309776008|MedGen:C0853032|MedGen:C1968782|MedGen:C2239176,OMIM:114550,Orphanet:ORPHA88673,SNOMED_CT:187769009,SNOMED_CT:25370001|MedGen:C3277679|MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374|MedGen:CN231320|MedGen:CN517202	reviewed_by_expert_panel	Pathogenic	0.028	0.473	D	0.000	0.843	D	1	0.810	D	0.73	0.189	N	-1.01	0.762	T	-4.49	0.782	D	-0.174	0.784	T	0.370	0.730	T	0.179	0.855	D	0.951	0.994	0.993	0.944	D	c	0.135	0.059	1.000	0.747	0.767	0.994	0	3.0	0.336	6.086	0.708	0.852	0.362	1.000	0.715	0.563	0.282	14.152	0.648	P-loop_containing_nucleoside_triphosphate_hydrolase|Small_GTP-binding_protein_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,626	0	0	0	1	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	25398304	25398304	T	A	exonic	KRAS	.	nonsynonymous_SNV	KRAS:NM_004985:exon2:c.A15T:p.K5N,KRAS:NM_033360:exon2:c.A15T:p.K5N	0.00106119304255182	0.603148256118395	0.395790550839053	Kirsten_rat_sarcoma_viral_oncogene_homolog	FUNCTION:_Ras_proteins_bind_GDP/GTP_and_possess_intrinsic_GTPase_activity._Plays_an_important_role_in_the_regulation_of_cell_proliferation_(PubMed:23698361,_PubMed:22711838)._{ECO:0000269|PubMed:22711838,_ECO:0000269|PubMed:23698361,_ECO:0000305}.\x3b_	DISEASE:_Leukemia,_acute_myelogenous_(AML)_[MIM:601626]:_A_subtype_of_acute_leukemia,_a_cancer_of_the_white_blood_cells._AML_is_a_malignant_disease_of_bone_marrow_characterized_by_maturational_arrest_of_hematopoietic_precursors_at_an_early_stage_of_development._Clonal_expansion_of_myeloid_blasts_occurs_in_bone_marrow,_blood,_and_other_tissue._Myelogenous_leukemias_develop_from_changes_in_cells_that_normally_produce_neutrophils,_basophils,_eosinophils_and_monocytes._{ECO:0000269|PubMed:8955068}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Leukemia,_juvenile_myelomonocytic_(JMML)_[MIM:607785]:_An_aggressive_pediatric_myelodysplastic_syndrome/myeloproliferative_disorder_characterized_by_malignant_transformation_in_the_hematopoietic_stem_cell_compartment_with_proliferation_of_differentiated_progeny._Patients_have_splenomegaly,_enlarged_lymph_nodes,_rashes,_and_hemorrhages._{ECO:0000269|PubMed:17332249}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Noonan_syndrome_3_(NS3)_[MIM:609942]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._{ECO:0000269|PubMed:16474405,_ECO:0000269|PubMed:16773572,_ECO:0000269|PubMed:17056636,_ECO:0000269|PubMed:17468812,_ECO:0000269|PubMed:19396835}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Gastric_cancer_(GASC)_[MIM:613659]:_A_malignant_disease_which_starts_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._The_term_gastric_cancer_or_gastric_carcinoma_refers_to_adenocarcinoma_of_the_stomach_that_accounts_for_most_of_all_gastric_malignant_tumors._Two_main_histologic_types_are_recognized,_diffuse_type_and_intestinal_type_carcinomas._Diffuse_tumors_are_poorly_differentiated_infiltrating_lesions,_resulting_in_thickening_of_the_stomach._In_contrast,_intestinal_tumors_are_usually_exophytic,_often_ulcerating,_and_associated_with_intestinal_metaplasia_of_the_stomach,_most_often_observed_in_sporadic_disease._{ECO:0000269|PubMed:14534542,_ECO:0000269|PubMed:3034404,_ECO:0000269|PubMed:7773929}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dDefects_in_KRAS_are_a_cause_of_pylocytic_astrocytoma_(PA)._Pylocytic_astrocytomas_are_neoplasms_of_the_brain_and_spinal_cord_derived_from_glial_cells_which_vary_from_histologically_benign_forms_to_highly_anaplastic_and_malignant_tumors._{ECO:0000269|PubMed:16247081}.\x3b_DISEASE:_Cardiofaciocutaneous_syndrome_2_(CFC2)_[MIM:615278]:_A_form_of_cardiofaciocutaneous_syndrome,_a_multiple_congenital_anomaly_disorder_characterized_by_a_distinctive_facial_appearance,_heart_defects_and_mental_retardation._Heart_defects_include_pulmonic_stenosis,_atrial_septal_defects_and_hypertrophic_cardiomyopathy._Some_affected_individuals_present_with_ectodermal_abnormalities_such_as_sparse,_friable_hair,_hyperkeratotic_skin_lesions_and_a_generalized_ichthyosis-like_condition._Typical_facial_features_are_similar_to_Noonan_syndrome._They_include_high_forehead_with_bitemporal_constriction,_hypoplastic_supraorbital_ridges,_downslanting_palpebral_fissures,_a_depressed_nasal_bridge,_and_posteriorly_angulated_ears_with_prominent_helices._CFC2_patients_often_do_not_have_the_skin_abnormalities,_such_as_ichthyosis,_hyperkeratosis,_and_hemangioma_observed_in_CFC1._{ECO:0000269|PubMed:16474404,_ECO:0000269|PubMed:16474405,_ECO:0000269|PubMed:17056636,_ECO:0000269|PubMed:21797849}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dKRAS_mutations_are_involved_in_cancer_development._{ECO:0000269|PubMed:14534542,_ECO:0000269|PubMed:1553789,_ECO:0000269|PubMed:16533793,_ECO:0000269|PubMed:3034404,_ECO:0000269|PubMed:3627975,_ECO:0000269|PubMed:6092920,_ECO:0000269|PubMed:6695174,_ECO:0000269|PubMed:7773929}.\x3b_	.	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bfrontal_lobe\x3bcochlea\x3bendometrium\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bspinal_ganglion\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bspinal_cord\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bbile_duct\x3bpancreas\x3blung\x3bcornea\x3bplacenta\x3bvisual_apparatus\x3bliver\x3bcervix\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bperipheral_nerve\x3b	dorsal_root_ganglion\x3bwhole_brain\x3bamygdala\x3boccipital_lobe\x3bsuperior_cervical_ganglion\x3batrioventricular_node\x3bpons\x3bsubthalamic_nucleus\x3bprefrontal_cortex\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3bcerebellum\x3b	0.99997	0.53296	-0.141298762	42.87567823	3.46519	0.12617	rs104894361	27633	Noonan_syndrome|Inborn_genetic_diseases|Cardiofaciocutaneous_syndrome_2|not_specified	MeSH:D009634,MedGen:C0028326,Orphanet:ORPHA648,SNOMED_CT:205824006|MeSH:D030342,MedGen:C0950123|MedGen:C3809005,OMIM:615278|MedGen:CN169374	reviewed_by_expert_panel	Pathogenic	0.0	0.912	D	0.000	0.843	D	1.000	0.810	A	2.925	0.847	M	-2.06	0.859	D	-3.6	0.806	D	0.723	0.935	D	0.726	0.906	D	0.200	0.867	D	0.746	0.878	0.885	0.481	D	c	0.615	0.564	1.000	0.747	0.732	0.924	0	4.55	0.553	0.726	0.255	0.134	0.217	1.000	0.715	1.000	0.888	8.897	0.344	P-loop_containing_nucleoside_triphosphate_hydrolase\x3bP-loop_containing_nucleoside_triphosphate_hydrolase|Small_GTP-binding_protein_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,641	0	0	0	1	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
11	534286	534286	C	A	exonic	HRAS	.	nonsynonymous_SNV	HRAS:NM_001130442:exon2:c.G37T:p.G13C,HRAS:NM_005343:exon2:c.G37T:p.G13C,HRAS:NM_176795:exon2:c.G37T:p.G13C	0.00794104930284198	0.785285637637198	0.20677331305996	Harvey_rat_sarcoma_viral_oncogene_homolog	FUNCTION:_Ras_proteins_bind_GDP/GTP_and_possess_intrinsic_GTPase_activity._{ECO:0000269|PubMed:12740440,_ECO:0000269|PubMed:14500341,_ECO:0000269|PubMed:9020151}.\x3b_	DISEASE:_Costello_syndrome_(CSTLO)_[MIM:218040]:_A_rare_condition_characterized_by_prenatally_increased_growth,_postnatal_growth_deficiency,_mental_retardation,_distinctive_facial_appearance,_cardiovascular_abnormalities_(typically_pulmonic_stenosis,_hypertrophic_cardiomyopathy_and/or_atrial_tachycardia),_tumor_predisposition,_skin_and_musculoskeletal_abnormalities._{ECO:0000269|PubMed:16170316,_ECO:0000269|PubMed:16329078,_ECO:0000269|PubMed:16443854,_ECO:0000269|PubMed:17054105,_ECO:0000269|PubMed:18039947,_ECO:0000269|PubMed:18247425,_ECO:0000269|PubMed:19995790}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Congenital_myopathy_with_excess_of_muscle_spindles_(CMEMS)_[MIM:218040]:_Variant_of_Costello_syndrome._{ECO:0000269|PubMed:17412879}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hurthle_cell_thyroid_carcinoma_(HCTC)_[MIM:607464]:_A_rare_type_of_thyroid_cancer_accounting_for_only_about_3-10%_of_all_differentiated_thyroid_cancers._These_neoplasms_are_considered_a_variant_of_follicular_carcinoma_of_the_thyroid_and_are_referred_to_as_follicular_carcinoma,_oxyphilic_type._{ECO:0000269|PubMed:12727991}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dMutations_which_change_positions_12,_13_or_61_activate_the_potential_of_HRAS_to_transform_cultured_cells_and_are_implicated_in_a_variety_of_human_tumors._{ECO:0000269|PubMed:3670300}.\x3b_DISEASE:_Bladder_cancer_(BLC)_[MIM:109800]:_A_malignancy_originating_in_tissues_of_the_urinary_bladder._It_often_presents_with_multiple_tumors_appearing_at_different_times_and_at_different_sites_in_the_bladder._Most_bladder_cancers_are_transitional_cell_carcinomas_that_begin_in_cells_that_normally_make_up_the_inner_lining_of_the_bladder._Other_types_of_bladder_cancer_include_squamous_cell_carcinoma_(cancer_that_begins_in_thin,_flat_cells)_and_adenocarcinoma_(cancer_that_begins_in_cells_that_make_and_release_mucus_and_other_fluids)._Bladder_cancer_is_a_complex_disorder_with_both_genetic_and_environmental_influences._{ECO:0000269|PubMed:6298635,_ECO:0000269|PubMed:6844927}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Schimmelpenning-Feuerstein-Mims_syndrome_(SFM)_[MIM:163200]:_A_disease_characterized_by_sebaceous_nevi,_often_on_the_face,_associated_with_variable_ipsilateral_abnormalities_of_the_central_nervous_system,_ocular_anomalies,_and_skeletal_defects._Many_oral_manifestations_have_been_reported,_not_only_including_hypoplastic_and_malformed_teeth,_and_mucosal_papillomatosis,_but_also_ankyloglossia,_hemihyperplastic_tongue,_intraoral_nevus,_giant_cell_granuloma,_ameloblastoma,_bone_cysts,_follicular_cysts,_oligodontia,_and_odontodysplasia._Sebaceous_nevi_follow_the_lines_of_Blaschko_and_these_can_continue_as_linear_intraoral_lesions,_as_in_mucosal_papillomatosis._{ECO:0000269|PubMed:22683711}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Widely_expressed._{ECO:0000269|PubMed:14500341}.\x3b_	ovary\x3bdevelopmental\x3bcolon\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3boptic_nerve\x3bwhole_body\x3boesophagus\x3bendometrium\x3bthyroid\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bhypothalamus\x3bblood\x3blens\x3bskeletal_muscle\x3blung\x3bplacenta\x3bvisual_apparatus\x3bhypopharynx\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bcerebellum\x3b	whole_brain\x3bmedulla_oblongata\x3btrigeminal_ganglion\x3b	0.99944	0.99980	-0.339715008	30.06605331	4.91473	0.18207	rs104894228	27645	Acute_myeloid_leukemia|Chronic_lymphocytic_leukemia|Pancreatic_adenocarcinoma|Squamous_cell_carcinoma_of_the_skin|Transitional_cell_carcinoma_of_the_bladder|Multiple_myeloma|Lung_adenocarcinoma|Squamous_cell_lung_carcinoma|Neoplasm_of_the_breast|Neoplasm_of_the_thyroid_gland|Squamous_cell_carcinoma_of_the_head_and_neck|Malignant_melanoma_of_skin|Uterine_cervical_neoplasms|Neoplasm|Colorectal_Neoplasms|Malignant_neoplasm_of_body_of_uterus|Adenocarcinoma_of_stomach|Costello_syndrome|Hepatocellular_carcinoma|Rasopathy|not_provided	Human_Phenotype_Ontology:HP:0004808,MeSH:D015470,MedGen:C0023467,OMIM:601626,Orphanet:ORPHA519,SNOMED_CT:17788007|Human_Phenotype_Ontology:HP:0005550,MeSH:D015451,MedGen:C0023434,OMIM:151400,SNOMED_CT:277473004,SNOMED_CT:51092000|Human_Phenotype_Ontology:HP:0006725,MedGen:C0281361|Human_Phenotype_Ontology:HP:0006739,MedGen:C0553723|Human_Phenotype_Ontology:HP:0006740,MedGen:C0279680|Human_Phenotype_Ontology:HP:0006775,MeSH:D009101,MedGen:C0026764,OMIM:254500,Orphanet:ORPHA29073,SNOMED_CT:109989006,SNOMED_CT:55921005|Human_Phenotype_Ontology:HP:0030078,MeSH:C538231,MedGen:C0152013|Human_Phenotype_Ontology:HP:0030359,MedGen:C0149782|Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|Human_Phenotype_Ontology:HP:0100031,MeSH:D013964,MedGen:C0040136,Orphanet:ORPHA100087|MeSH:C535575,MedGen:C1168401,OMIM:275355,Orphanet:ORPHA67037|MeSH:C562393,MedGen:C0151779,SNOMED_CT:93655004|MeSH:D002583,MedGen:CN236667|MeSH:D009369,MedGen:C0027651,SNOMED_CT:108369006|MeSH:D015179,MedGen:CN236642|MedGen:C0153574,Orphanet:ORPHA213569|MedGen:C0278701|MedGen:C0587248,OMIM:218040,Orphanet:ORPHA3071,SNOMED_CT:309776008|MedGen:C2239176,OMIM:114550,Orphanet:ORPHA88673,SNOMED_CT:187769009,SNOMED_CT:25370001|MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN517202	reviewed_by_expert_panel	Pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	D	2.49	0.728	M	-0.81	0.740	T	-7.68	0.957	D	0.434	0.896	D	0.484	0.803	T	0.429	0.940	D	0.961	0.996	0.994	0.955	D	c	0.280	0.156	1.000	0.747	0.767	0.994	0	3.0	0.336	6.086	0.708	0.852	0.362	1.000	0.715	0.574	0.284	14.152	0.648	P-loop_containing_nucleoside_triphosphate_hydrolase|Small_GTP-binding_protein_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,624	0	0	0	1	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
13	20763485	20763486	AG	A	exonic	GJB2	.	frameshift_deletion	GJB2:NM_004004:exon2:c.235delC:p.L79fs	1.02863295453376e-11	0.00164377442881105	0.998356225560903	gap_junction_protein_beta_2	FUNCTION:_One_gap_junction_consists_of_a_cluster_of_closely_packed_pairs_of_transmembrane_channels,_the_connexons,_through_which_materials_of_low_MW_diffuse_from_one_cell_to_a_neighboring_cell.\x3b_	DISEASE:_Deafness,_autosomal_recessive,_1A_(DFNB1A)_[MIM:220290]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10830906,_ECO:0000269|PubMed:11313763,_ECO:0000269|PubMed:11439000,_ECO:0000269|PubMed:12121355,_ECO:0000269|PubMed:12239718,_ECO:0000269|PubMed:12786758,_ECO:0000269|PubMed:14722929,_ECO:0000269|PubMed:15666300,_ECO:0000269|PubMed:15994881,_ECO:0000269|PubMed:17660464,_ECO:0000269|PubMed:17666888,_ECO:0000269|PubMed:19384972,_ECO:0000269|PubMed:23680645,_ECO:0000269|PubMed:9328482,_ECO:0000269|PubMed:9336442,_ECO:0000269|PubMed:9471561,_ECO:0000269|PubMed:9529365}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_dominant,_3A_(DFNA3A)_[MIM:601544]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10807696,_ECO:0000269|PubMed:11313763,_ECO:0000269|PubMed:11439000,_ECO:0000269|PubMed:12786758,_ECO:0000269|PubMed:19384972,_ECO:0000269|PubMed:9620796}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Vohwinkel_syndrome_(VS)_[MIM:124500]:_VS_is_an_autosomal_dominant_disease_characterized_by_hyperkeratosis,_constriction_on_fingers_and_toes_and_congenital_deafness._{ECO:0000269|PubMed:10369869,_ECO:0000269|PubMed:15954104,_ECO:0000269|PubMed:18688874}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Keratoderma,_palmoplantar,_with_deafness_(PPKDFN)_[MIM:148350]:_An_autosomal_dominant_disorder_characterized_by_the_association_of_palmoplantar_hyperkeratosis_with_progressive,_bilateral,_high-frequency,_sensorineural_deafness._{ECO:0000269|PubMed:10633135,_ECO:0000269|PubMed:10757647,_ECO:0000269|PubMed:12372058,_ECO:0000269|PubMed:15996214,_ECO:0000269|PubMed:17993581,_ECO:0000269|PubMed:9856479}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Keratitis-ichthyosis-deafness_syndrome_(KID_syndrome)_[MIM:148210]:_An_autosomal_dominant_form_of_ectodermal_dysplasia._Ectodermal_dysplasia_defines_a_heterogeneous_group_of_disorders_due_to_abnormal_development_of_two_or_more_ectodermal_structures._Keratitis-ichthyosis-deafness_syndrome_is_characterized_by_the_association_of_hyperkeratotic_skin_lesions_with_vascularizing_keratitis_and_profound_sensorineural_hearing_loss._Clinical_features_include_deafness,_ichthyosis,_photophobia,_absent_or_decreased_eyebrows,_sparse_or_absent_scalp_hair,_decreased_sweating_and_dysplastic_finger_and_toenails._{ECO:0000269|PubMed:11912510,_ECO:0000269|PubMed:12548749,_ECO:0000269|PubMed:12752120}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bart-Pumphrey_syndrome_(BPS)_[MIM:149200]:_An_autosomal_dominant_disorder_characterized_by_sensorineural_hearing_loss,_palmoplantar_keratoderma,_knuckle_pads,_and_leukonychia,_It_shows_considerable_phenotypic_variability._{ECO:0000269|PubMed:15482471,_ECO:0000269|PubMed:15952212}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ichthyosis_hystrix-like_with_deafness_syndrome_(HID_syndrome)_[MIM:602540]:_An_autosomal_dominant_keratinizing_disorder_characterized_by_sensorineural_deafness_and_spiky_hyperkeratosis_affecting_the_entire_skin._HID_syndrome_is_considered_to_differ_from_the_similar_KID_syndrome_in_the_extent_and_time_of_occurrence_of_skin_symptoms_and_the_severity_of_the_associated_keratitis._{ECO:0000269|PubMed:12072059}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	.	.	0.42941	0.50569	0.663285274	84.55414013	794.09383	5.55726	rs80338943	32053	Hearing_impairment|Deafness,_autosomal_recessive_1A|Deafness,_digenic,_GJB2/GJB3|Deafness,_autosomal_dominant_3a|Nonsyndromic_hearing_loss_and_deafness|not_specified|not_provided	Human_Phenotype_Ontology:HP:0000365,MedGen:C0018772|MedGen:C2673759,OMIM:220290|MedGen:C2673761|MedGen:C2675750,OMIM:601544|MedGen:CN043648,Orphanet:ORPHA87884|MedGen:CN169374|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0005	0	0	0	0.0092	0	0	0	0.0004	0	0	0	0.0061	0	1.791e-05	0.0002	3.249e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,868	1	0	0	0	0	0	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0.9492	Pathogenic
12	103245469	103245470	GA	G	exonic	PAH	.	frameshift_deletion	PAH:NM_000277:exon8:c.907delT:p.S303fs	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62642920	108624	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3.229e-05	0	0	0	0.0006	0	0	0	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,689	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103306581	103306582	CA	C	exonic	PAH	.	frameshift_deletion	PAH:NM_000277:exon2:c.155delT:p.L52fs	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs281865165	125904	Phenylketonuria	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006	no_assertion_provided	not_provided	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,835	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103306625	103306625	T	TC	exonic	PAH	.	frameshift_insertion	PAH:NM_000277:exon2:c.111dupG:p.I38fs	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475674	108267	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,841	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103260385	103260385	G	T	exonic	PAH	.	stopgain	PAH:NM_000277:exon5:c.C498A:p.Y166X	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475645	108438	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	.	.	.	0.000	0.843	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.916	0.536	D	c	0.624	0.442	0.000	0.070	0.554	0.246	0	2.98	0.334	1.459	0.346	1.048	0.713	1.000	0.715	0.998	0.697	8.165	0.302	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,785	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
21	36164712	36164712	G	T	exonic	RUNX1	.	stopgain	RUNX1:NM_001001890:exon6:c.C1082A:p.S361X,RUNX1:NM_001754:exon9:c.C1163A:p.S388X	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	.	.	.	.	.	.	.	.	.	0.004	0.337	N	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.899	0.503	D	c	0.811	0.680	1.000	0.747	0.660	0.495	0	5.22	0.722	8.951	0.929	1.029	0.652	1.000	0.715	0.985	0.512	18.382	0.904	Runx,_C-terminal__domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,949	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
21	36164461	36164461	G	GGC	exonic	RUNX1	.	frameshift_insertion	RUNX1:NM_001001890:exon6:c.1332_1333insGC:p.L445fs,RUNX1:NM_001754:exon9:c.1413_1414insGC:p.L472fs	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	.	533817	Familial_platelet_disorder_with_associated_myeloid_malignancy	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290	criteria_provided,_single_submitter	Uncertain_significance	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,944	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103306599	103306600	AC	A	exonic	PAH	.	frameshift_deletion	PAH:NM_000277:exon2:c.137delG:p.G46fs	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475591	108333	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,837	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
14	23889119	23889122	TCTC	T	exonic	MYH7	.	nonframeshift_deletion	MYH7:NM_000257:exon27:c.3658_3660del:p.1220_1220del	0.000145766291646031	0.999854233523213	1.85141250905742e-10	myosin,_heavy_chain_7,_cardiac_muscle,_beta	FUNCTION:_Muscle_contraction.\x3b_	DISEASE:_Cardiomyopathy,_familial_hypertrophic_1_(CMH1)_[MIM:192600]:_A_hereditary_heart_disorder_characterized_by_ventricular_hypertrophy,_which_is_usually_asymmetric_and_often_involves_the_interventricular_septum._The_symptoms_include_dyspnea,_syncope,_collapse,_palpitations,_and_chest_pain._They_can_be_readily_provoked_by_exercise._The_disorder_has_inter-_and_intrafamilial_variability_ranging_from_benign_to_malignant_forms_with_high_risk_of_cardiac_failure_and_sudden_cardiac_death._{ECO:0000269|PubMed:10065021,_ECO:0000269|PubMed:10329202,_ECO:0000269|PubMed:10521296,_ECO:0000269|PubMed:10563488,_ECO:0000269|PubMed:10679957,_ECO:0000269|PubMed:10862102,_ECO:0000269|PubMed:11113006,_ECO:0000269|PubMed:11133230,_ECO:0000269|PubMed:11214007,_ECO:0000269|PubMed:11424919,_ECO:0000269|PubMed:11733062,_ECO:0000269|PubMed:11861413,_ECO:0000269|PubMed:11968089,_ECO:0000269|PubMed:12081993,_ECO:0000269|PubMed:12566107,_ECO:0000269|PubMed:12590187,_ECO:0000269|PubMed:12707239,_ECO:0000269|PubMed:12818575,_ECO:0000269|PubMed:12820698,_ECO:0000269|PubMed:12951062,_ECO:0000269|PubMed:12974739,_ECO:0000269|PubMed:12975413,_ECO:0000269|PubMed:1417858,_ECO:0000269|PubMed:15358028,_ECO:0000269|PubMed:15483641,_ECO:0000269|PubMed:1552912,_ECO:0000269|PubMed:15563892,_ECO:0000269|PubMed:15856146,_ECO:0000269|PubMed:15858117,_ECO:0000269|PubMed:16199542,_ECO:0000269|PubMed:16267253,_ECO:0000269|PubMed:1638703,_ECO:0000269|PubMed:16650083,_ECO:0000269|PubMed:16938236,_ECO:0000269|PubMed:17372140,_ECO:0000269|PubMed:18175163,_ECO:0000269|PubMed:18403758,_ECO:0000269|PubMed:1975517,_ECO:0000269|PubMed:25182012,_ECO:0000269|PubMed:7581410,_ECO:0000269|PubMed:7731997,_ECO:0000269|PubMed:7848441,_ECO:0000269|PubMed:7874131,_ECO:0000269|PubMed:8250038,_ECO:0000269|PubMed:8254035,_ECO:0000269|PubMed:8268932,_ECO:0000269|PubMed:8282798,_ECO:0000269|PubMed:8343162,_ECO:0000269|PubMed:8435239,_ECO:0000269|PubMed:8483915,_ECO:0000269|PubMed:8655135,_ECO:0000269|PubMed:8899546,_ECO:0000269|PubMed:9544842,_ECO:0000269|PubMed:9822100,_ECO:0000269|PubMed:9829907}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Myopathy,_myosin_storage,_autosomal_dominant_(MSMA)_[MIM:608358]:_A_rare_congenital_myopathy_characterized_by_subsarcolemmal_hyalinized_bodies_in_type_1_muscle_fibers._{ECO:0000269|PubMed:14520662,_ECO:0000269|PubMed:15136674,_ECO:0000269|PubMed:16684601,_ECO:0000269|PubMed:17336526}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Scapuloperoneal_myopathy_MYH7-related_(SPMM)_[MIM:181430]:_Progressive_muscular_atrophia_beginning_in_the_lower_legs_and_affecting_the_shoulder_region_earlier_and_more_severely_than_distal_arm._{ECO:0000269|PubMed:17336526}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Cardiomyopathy,_dilated_1S_(CMD1S)_[MIM:613426]:_A_disorder_characterized_by_ventricular_dilation_and_impaired_systolic_function,_resulting_in_congestive_heart_failure_and_arrhythmia._Patients_are_at_risk_of_premature_death._{ECO:0000269|PubMed:11106718,_ECO:0000269|PubMed:12379228,_ECO:0000269|PubMed:15769782,_ECO:0000269|PubMed:18506004,_ECO:0000269|PubMed:21127202,_ECO:0000269|PubMed:21846512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Myopathy,_distal,_1_(MPD1)_[MIM:160500]:_A_muscular_disorder_characterized_by_early-onset_selective_weakness_of_the_great_toe_and_ankle_dorsiflexors,_followed_by_weakness_of_the_finger_extensors._Mild_proximal_weakness_occasionally_develops_years_later_after_the_onset_of_the_disease._{ECO:0000269|PubMed:15322983,_ECO:0000269|PubMed:17548557}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Myopathy,_myosin_storage,_autosomal_recessive_(MSMB)_[MIM:255160]:_An_autosomal_recessive_form_of_myosin_storage_myopathy,_a_muscle_disease_characterized_by_subsarcolemmal_accumulation_of_hyalinized_bodies_in_type_1_muscle_fibers._MSMB_clinical_features_include_muscle_weakness,_type_II_respiratory_failure_and_cardiac_failure,_due_to_hypertrophic_cardiomyopathy._{ECO:0000269|PubMed:25666907}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Both_wild_type_and_variant_Gln-403_are_detected_in_skeletal_muscle_(at_protein_level)._{ECO:0000269|PubMed:8514894}.\x3b_	unclassifiable_(Anatomical_System)\x3bgreater_omentum\x3bmyocardium\x3bprostate\x3blung\x3bheart\x3blarynx\x3bmuscle\x3btestis\x3bhead_and_neck\x3bskeletal_muscle\x3bperipheral_nerve\x3b	heart\x3btongue\x3bskeletal_muscle\x3b	0.43904	0.16764	-3.644803418	0.283085633	108.56923	2.26118	rs397516190	52138	Primary_dilated_cardiomyopathy|Ebstein's_anomaly_of_the_tricuspid_valve|Cardiovascular_phenotype	EFO:EFO_0000407,Human_Phenotype_Ontology:HP:0001644,MedGen:C0007193,Orphanet:ORPHA217604,SNOMED_CT:195021004|Human_Phenotype_Ontology:HP:0010316,MedGen:C0013481,OMIM:224700,Orphanet:ORPHA1880|MedGen:CN230736	reviewed_by_expert_panel	Likely_pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,875	0	0	0	1	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9878	Likely Pathogenic
14	23893244	23893247	TCTC	T	exonic	MYH7	.	nonframeshift_deletion	MYH7:NM_000257:exon23:c.2791_2793del:p.931_931del	0.000145766291646031	0.999854233523213	1.85141250905742e-10	myosin,_heavy_chain_7,_cardiac_muscle,_beta	FUNCTION:_Muscle_contraction.\x3b_	DISEASE:_Cardiomyopathy,_familial_hypertrophic_1_(CMH1)_[MIM:192600]:_A_hereditary_heart_disorder_characterized_by_ventricular_hypertrophy,_which_is_usually_asymmetric_and_often_involves_the_interventricular_septum._The_symptoms_include_dyspnea,_syncope,_collapse,_palpitations,_and_chest_pain._They_can_be_readily_provoked_by_exercise._The_disorder_has_inter-_and_intrafamilial_variability_ranging_from_benign_to_malignant_forms_with_high_risk_of_cardiac_failure_and_sudden_cardiac_death._{ECO:0000269|PubMed:10065021,_ECO:0000269|PubMed:10329202,_ECO:0000269|PubMed:10521296,_ECO:0000269|PubMed:10563488,_ECO:0000269|PubMed:10679957,_ECO:0000269|PubMed:10862102,_ECO:0000269|PubMed:11113006,_ECO:0000269|PubMed:11133230,_ECO:0000269|PubMed:11214007,_ECO:0000269|PubMed:11424919,_ECO:0000269|PubMed:11733062,_ECO:0000269|PubMed:11861413,_ECO:0000269|PubMed:11968089,_ECO:0000269|PubMed:12081993,_ECO:0000269|PubMed:12566107,_ECO:0000269|PubMed:12590187,_ECO:0000269|PubMed:12707239,_ECO:0000269|PubMed:12818575,_ECO:0000269|PubMed:12820698,_ECO:0000269|PubMed:12951062,_ECO:0000269|PubMed:12974739,_ECO:0000269|PubMed:12975413,_ECO:0000269|PubMed:1417858,_ECO:0000269|PubMed:15358028,_ECO:0000269|PubMed:15483641,_ECO:0000269|PubMed:1552912,_ECO:0000269|PubMed:15563892,_ECO:0000269|PubMed:15856146,_ECO:0000269|PubMed:15858117,_ECO:0000269|PubMed:16199542,_ECO:0000269|PubMed:16267253,_ECO:0000269|PubMed:1638703,_ECO:0000269|PubMed:16650083,_ECO:0000269|PubMed:16938236,_ECO:0000269|PubMed:17372140,_ECO:0000269|PubMed:18175163,_ECO:0000269|PubMed:18403758,_ECO:0000269|PubMed:1975517,_ECO:0000269|PubMed:25182012,_ECO:0000269|PubMed:7581410,_ECO:0000269|PubMed:7731997,_ECO:0000269|PubMed:7848441,_ECO:0000269|PubMed:7874131,_ECO:0000269|PubMed:8250038,_ECO:0000269|PubMed:8254035,_ECO:0000269|PubMed:8268932,_ECO:0000269|PubMed:8282798,_ECO:0000269|PubMed:8343162,_ECO:0000269|PubMed:8435239,_ECO:0000269|PubMed:8483915,_ECO:0000269|PubMed:8655135,_ECO:0000269|PubMed:8899546,_ECO:0000269|PubMed:9544842,_ECO:0000269|PubMed:9822100,_ECO:0000269|PubMed:9829907}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Myopathy,_myosin_storage,_autosomal_dominant_(MSMA)_[MIM:608358]:_A_rare_congenital_myopathy_characterized_by_subsarcolemmal_hyalinized_bodies_in_type_1_muscle_fibers._{ECO:0000269|PubMed:14520662,_ECO:0000269|PubMed:15136674,_ECO:0000269|PubMed:16684601,_ECO:0000269|PubMed:17336526}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Scapuloperoneal_myopathy_MYH7-related_(SPMM)_[MIM:181430]:_Progressive_muscular_atrophia_beginning_in_the_lower_legs_and_affecting_the_shoulder_region_earlier_and_more_severely_than_distal_arm._{ECO:0000269|PubMed:17336526}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Cardiomyopathy,_dilated_1S_(CMD1S)_[MIM:613426]:_A_disorder_characterized_by_ventricular_dilation_and_impaired_systolic_function,_resulting_in_congestive_heart_failure_and_arrhythmia._Patients_are_at_risk_of_premature_death._{ECO:0000269|PubMed:11106718,_ECO:0000269|PubMed:12379228,_ECO:0000269|PubMed:15769782,_ECO:0000269|PubMed:18506004,_ECO:0000269|PubMed:21127202,_ECO:0000269|PubMed:21846512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Myopathy,_distal,_1_(MPD1)_[MIM:160500]:_A_muscular_disorder_characterized_by_early-onset_selective_weakness_of_the_great_toe_and_ankle_dorsiflexors,_followed_by_weakness_of_the_finger_extensors._Mild_proximal_weakness_occasionally_develops_years_later_after_the_onset_of_the_disease._{ECO:0000269|PubMed:15322983,_ECO:0000269|PubMed:17548557}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Myopathy,_myosin_storage,_autosomal_recessive_(MSMB)_[MIM:255160]:_An_autosomal_recessive_form_of_myosin_storage_myopathy,_a_muscle_disease_characterized_by_subsarcolemmal_accumulation_of_hyalinized_bodies_in_type_1_muscle_fibers._MSMB_clinical_features_include_muscle_weakness,_type_II_respiratory_failure_and_cardiac_failure,_due_to_hypertrophic_cardiomyopathy._{ECO:0000269|PubMed:25666907}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Both_wild_type_and_variant_Gln-403_are_detected_in_skeletal_muscle_(at_protein_level)._{ECO:0000269|PubMed:8514894}.\x3b_	unclassifiable_(Anatomical_System)\x3bgreater_omentum\x3bmyocardium\x3bprostate\x3blung\x3bheart\x3blarynx\x3bmuscle\x3btestis\x3bhead_and_neck\x3bskeletal_muscle\x3bperipheral_nerve\x3b	heart\x3btongue\x3bskeletal_muscle\x3b	0.43904	0.16764	-3.644803418	0.283085633	108.56923	2.26118	rs397516172	52104	Primary_familial_hypertrophic_cardiomyopathy|not_provided	MedGen:C0949658,Orphanet:ORPHA155,SNOMED_CT:83978005|MedGen:CN517202	reviewed_by_expert_panel	Likely_pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,877	0	0	0	1	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9878	Likely Pathogenic
14	23894115	23894118	CCTT	C	exonic	MYH7	.	nonframeshift_deletion	MYH7:NM_000257:exon22:c.2539_2541del:p.847_847del	0.000145766291646031	0.999854233523213	1.85141250905742e-10	myosin,_heavy_chain_7,_cardiac_muscle,_beta	FUNCTION:_Muscle_contraction.\x3b_	DISEASE:_Cardiomyopathy,_familial_hypertrophic_1_(CMH1)_[MIM:192600]:_A_hereditary_heart_disorder_characterized_by_ventricular_hypertrophy,_which_is_usually_asymmetric_and_often_involves_the_interventricular_septum._The_symptoms_include_dyspnea,_syncope,_collapse,_palpitations,_and_chest_pain._They_can_be_readily_provoked_by_exercise._The_disorder_has_inter-_and_intrafamilial_variability_ranging_from_benign_to_malignant_forms_with_high_risk_of_cardiac_failure_and_sudden_cardiac_death._{ECO:0000269|PubMed:10065021,_ECO:0000269|PubMed:10329202,_ECO:0000269|PubMed:10521296,_ECO:0000269|PubMed:10563488,_ECO:0000269|PubMed:10679957,_ECO:0000269|PubMed:10862102,_ECO:0000269|PubMed:11113006,_ECO:0000269|PubMed:11133230,_ECO:0000269|PubMed:11214007,_ECO:0000269|PubMed:11424919,_ECO:0000269|PubMed:11733062,_ECO:0000269|PubMed:11861413,_ECO:0000269|PubMed:11968089,_ECO:0000269|PubMed:12081993,_ECO:0000269|PubMed:12566107,_ECO:0000269|PubMed:12590187,_ECO:0000269|PubMed:12707239,_ECO:0000269|PubMed:12818575,_ECO:0000269|PubMed:12820698,_ECO:0000269|PubMed:12951062,_ECO:0000269|PubMed:12974739,_ECO:0000269|PubMed:12975413,_ECO:0000269|PubMed:1417858,_ECO:0000269|PubMed:15358028,_ECO:0000269|PubMed:15483641,_ECO:0000269|PubMed:1552912,_ECO:0000269|PubMed:15563892,_ECO:0000269|PubMed:15856146,_ECO:0000269|PubMed:15858117,_ECO:0000269|PubMed:16199542,_ECO:0000269|PubMed:16267253,_ECO:0000269|PubMed:1638703,_ECO:0000269|PubMed:16650083,_ECO:0000269|PubMed:16938236,_ECO:0000269|PubMed:17372140,_ECO:0000269|PubMed:18175163,_ECO:0000269|PubMed:18403758,_ECO:0000269|PubMed:1975517,_ECO:0000269|PubMed:25182012,_ECO:0000269|PubMed:7581410,_ECO:0000269|PubMed:7731997,_ECO:0000269|PubMed:7848441,_ECO:0000269|PubMed:7874131,_ECO:0000269|PubMed:8250038,_ECO:0000269|PubMed:8254035,_ECO:0000269|PubMed:8268932,_ECO:0000269|PubMed:8282798,_ECO:0000269|PubMed:8343162,_ECO:0000269|PubMed:8435239,_ECO:0000269|PubMed:8483915,_ECO:0000269|PubMed:8655135,_ECO:0000269|PubMed:8899546,_ECO:0000269|PubMed:9544842,_ECO:0000269|PubMed:9822100,_ECO:0000269|PubMed:9829907}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Myopathy,_myosin_storage,_autosomal_dominant_(MSMA)_[MIM:608358]:_A_rare_congenital_myopathy_characterized_by_subsarcolemmal_hyalinized_bodies_in_type_1_muscle_fibers._{ECO:0000269|PubMed:14520662,_ECO:0000269|PubMed:15136674,_ECO:0000269|PubMed:16684601,_ECO:0000269|PubMed:17336526}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Scapuloperoneal_myopathy_MYH7-related_(SPMM)_[MIM:181430]:_Progressive_muscular_atrophia_beginning_in_the_lower_legs_and_affecting_the_shoulder_region_earlier_and_more_severely_than_distal_arm._{ECO:0000269|PubMed:17336526}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Cardiomyopathy,_dilated_1S_(CMD1S)_[MIM:613426]:_A_disorder_characterized_by_ventricular_dilation_and_impaired_systolic_function,_resulting_in_congestive_heart_failure_and_arrhythmia._Patients_are_at_risk_of_premature_death._{ECO:0000269|PubMed:11106718,_ECO:0000269|PubMed:12379228,_ECO:0000269|PubMed:15769782,_ECO:0000269|PubMed:18506004,_ECO:0000269|PubMed:21127202,_ECO:0000269|PubMed:21846512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Myopathy,_distal,_1_(MPD1)_[MIM:160500]:_A_muscular_disorder_characterized_by_early-onset_selective_weakness_of_the_great_toe_and_ankle_dorsiflexors,_followed_by_weakness_of_the_finger_extensors._Mild_proximal_weakness_occasionally_develops_years_later_after_the_onset_of_the_disease._{ECO:0000269|PubMed:15322983,_ECO:0000269|PubMed:17548557}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Myopathy,_myosin_storage,_autosomal_recessive_(MSMB)_[MIM:255160]:_An_autosomal_recessive_form_of_myosin_storage_myopathy,_a_muscle_disease_characterized_by_subsarcolemmal_accumulation_of_hyalinized_bodies_in_type_1_muscle_fibers._MSMB_clinical_features_include_muscle_weakness,_type_II_respiratory_failure_and_cardiac_failure,_due_to_hypertrophic_cardiomyopathy._{ECO:0000269|PubMed:25666907}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Both_wild_type_and_variant_Gln-403_are_detected_in_skeletal_muscle_(at_protein_level)._{ECO:0000269|PubMed:8514894}.\x3b_	unclassifiable_(Anatomical_System)\x3bgreater_omentum\x3bmyocardium\x3bprostate\x3blung\x3bheart\x3blarynx\x3bmuscle\x3btestis\x3bhead_and_neck\x3bskeletal_muscle\x3bperipheral_nerve\x3b	heart\x3btongue\x3bskeletal_muscle\x3b	0.43904	0.16764	-3.644803418	0.283085633	108.56923	2.26118	rs397516155	52083	Hypertrophic_cardiomyopathy|Primary_familial_hypertrophic_cardiomyopathy|Familial_hypertrophic_cardiomyopathy_1|not_specified|Cardiovascular_phenotype|not_provided	Human_Phenotype_Ontology:HP:0001639,MedGen:C0007194,Orphanet:ORPHA217569|MedGen:C0949658,Orphanet:ORPHA155,SNOMED_CT:83978005|MedGen:C3495498,OMIM:192600|MedGen:CN169374|MedGen:CN230736|MedGen:CN517202	reviewed_by_expert_panel	Likely_pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,878	0	0	0	1	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9878	Likely Pathogenic
15	66727442	66727442	T	C	exonic	MAP2K1	.	nonsynonymous_SNV	MAP2K1:NM_002755:exon2:c.T158C:p.F53S	0.994501270366062	0.00549805295620231	6.76677735529064e-07	mitogen-activated_protein_kinase_kinase_1	FUNCTION:_Dual_specificity_protein_kinase_which_acts_as_an_essential_component_of_the_MAP_kinase_signal_transduction_pathway._Binding_of_extracellular_ligands_such_as_growth_factors,_cytokines_and_hormones_to_their_cell-surface_receptors_activates_RAS_and_this_initiates_RAF1_activation._RAF1_then_further_activates_the_dual-specificity_protein_kinases_MAP2K1/MEK1_and_MAP2K2/MEK2._Both_MAP2K1/MEK1_and_MAP2K2/MEK2_function_specifically_in_the_MAPK/ERK_cascade,_and_catalyze_the_concomitant_phosphorylation_of_a_threonine_and_a_tyrosine_residue_in_a_Thr-Glu-Tyr_sequence_located_in_the_extracellular_signal-regulated_kinases_MAPK3/ERK1_and_MAPK1/ERK2,_leading_to_their_activation_and_further_transduction_of_the_signal_within_the_MAPK/ERK_cascade._Depending_on_the_cellular_context,_this_pathway_mediates_diverse_biological_functions_such_as_cell_growth,_adhesion,_survival_and_differentiation,_predominantly_through_the_regulation_of_transcription,_metabolism_and_cytoskeletal_rearrangements._One_target_of_the_MAPK/ERK_cascade_is_peroxisome_proliferator-_activated_receptor_gamma_(PPARG),_a_nuclear_receptor_that_promotes_differentiation_and_apoptosis._MAP2K1/MEK1_has_been_shown_to_export_PPARG_from_the_nucleus._The_MAPK/ERK_cascade_is_also_involved_in_the_regulation_of_endosomal_dynamics,_including_lysosome_processing_and_endosome_cycling_through_the_perinuclear_recycling_compartment_(PNRC),_as_well_as_in_the_fragmentation_of_the_Golgi_apparatus_during_mitosis._{ECO:0000269|PubMed:14737111,_ECO:0000269|PubMed:17101779}.\x3b_	DISEASE:_Cardiofaciocutaneous_syndrome_3_(CFC3)_[MIM:615279]:_A_form_of_cardiofaciocutaneous_syndrome,_a_multiple_congenital_anomaly_disorder_characterized_by_a_distinctive_facial_appearance,_heart_defects_and_mental_retardation._Heart_defects_include_pulmonic_stenosis,_atrial_septal_defects_and_hypertrophic_cardiomyopathy._Some_affected_individuals_present_with_ectodermal_abnormalities_such_as_sparse,_friable_hair,_hyperkeratotic_skin_lesions_and_a_generalized_ichthyosis-like_condition._Typical_facial_features_are_similar_to_Noonan_syndrome._They_include_high_forehead_with_bitemporal_constriction,_hypoplastic_supraorbital_ridges,_downslanting_palpebral_fissures,_a_depressed_nasal_bridge,_and_posteriorly_angulated_ears_with_prominent_helices._Distinctive_features_of_CFC3_include_macrostomia_and_horizontal_shape_of_palpebral_fissures._{ECO:0000269|PubMed:16439621,_ECO:0000269|PubMed:18042262}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Widely_expressed,_with_extremely_low_levels_in_brain._{ECO:0000269|PubMed:1281467}.\x3b_	ovary\x3bsympathetic_chain\x3bskin\x3bbone_marrow\x3bretina\x3bprostate\x3boptic_nerve\x3bendometrium\x3bthyroid\x3bgerminal_center\x3bbladder\x3bbrain\x3bheart\x3bcartilage\x3btongue\x3bpineal_body\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3btrabecular_meshwork\x3bvisual_apparatus\x3bmacula_lutea\x3bliver\x3bspleen\x3bmammary_gland\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bchoroid\x3bfovea_centralis\x3buterus\x3bwhole_body\x3bbone\x3btestis\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bislets_of_Langerhans\x3bhypothalamus\x3bpancreas\x3blung\x3bnasopharynx\x3bplacenta\x3bhippocampus\x3bhead_and_neck\x3bkidney\x3bstomach\x3baorta\x3bthymus\x3b	whole_brain\x3bamygdala\x3bthalamus\x3boccipital_lobe\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3bhypothalamus\x3btemporal_lobe\x3bcaudate_nucleus\x3bsubthalamic_nucleus\x3bprefrontal_cortex\x3bglobus_pallidus\x3bcingulate_cortex\x3bparietal_lobe\x3bcerebellum\x3b	0.94061	0.84890	-0.449946534	24.00330267	4.89315	0.18138	rs121908594	28389	Cardio-facio-cutaneous_syndrome|Cardiofaciocutaneous_syndrome_3|not_provided	MedGen:C1275081,Orphanet:ORPHA1340,SNOMED_CT:403770008|MedGen:C3809006,OMIM:615279|MedGen:CN517202	reviewed_by_expert_panel	Pathogenic	0.003	0.682	D	0.000	0.843	D	1	0.810	A	2.7	0.793	M	-3.23	0.934	D	-6.18	0.903	D	0.916	0.959	D	0.866	0.955	D	0.749	0.980	D	0.752	0.883	0.978	0.770	D	c	0.706	0.674	1.000	0.747	0.707	0.730	0	5.07	0.680	7.902	0.860	0.913	0.425	1.000	0.715	0.992	0.562	14.047	0.641	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,884	0	0	0	1	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9749	Likely Pathogenic
19	4117550	4117550	A	C	exonic	MAP2K2	.	nonsynonymous_SNV	MAP2K2:NM_030662:exon2:c.T170G:p.F57C	0.86326115931858	0.136320885012997	0.00041795566842237	mitogen-activated_protein_kinase_kinase_2	FUNCTION:_Catalyzes_the_concomitant_phosphorylation_of_a_threonine_and_a_tyrosine_residue_in_a_Thr-Glu-Tyr_sequence_located_in_MAP_kinases._Activates_the_ERK1_and_ERK2_MAP_kinases_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Cardiofaciocutaneous_syndrome_4_(CFC4)_[MIM:615280]:_A_form_of_cardiofaciocutaneous_syndrome,_a_multiple_congenital_anomaly_disorder_characterized_by_a_distinctive_facial_appearance,_heart_defects_and_mental_retardation._Heart_defects_include_pulmonic_stenosis,_atrial_septal_defects_and_hypertrophic_cardiomyopathy._Some_affected_individuals_present_with_ectodermal_abnormalities_such_as_sparse,_friable_hair,_hyperkeratotic_skin_lesions_and_a_generalized_ichthyosis-like_condition._Typical_facial_features_are_similar_to_Noonan_syndrome._They_include_high_forehead_with_bitemporal_constriction,_hypoplastic_supraorbital_ridges,_downslanting_palpebral_fissures,_a_depressed_nasal_bridge,_and_posteriorly_angulated_ears_with_prominent_helices._{ECO:0000269|PubMed:16439621,_ECO:0000269|PubMed:18042262,_ECO:0000269|PubMed:20358587}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	medulla_oblongata\x3bsmooth_muscle\x3bovary\x3bsalivary_gland\x3bsympathetic_chain\x3bcolon\x3bparathyroid\x3bskin\x3buterus\x3bprostate\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bmuscle\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbile_duct\x3bpancreas\x3blung\x3badrenal_gland\x3bplacenta\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	amygdala\x3bprefrontal_cortex\x3btestis\x3bpons\x3bcingulate_cortex\x3b	0.88489	0.51187	-0.800872469	12.33191791	40.94266	1.19949	rs121434497	23311	Cardio-facio-cutaneous_syndrome|Cardiofaciocutaneous_syndrome_4|not_provided	MedGen:C1275081,Orphanet:ORPHA1340,SNOMED_CT:403770008|MedGen:C3809007,OMIM:615280|MedGen:CN517202	reviewed_by_expert_panel	Pathogenic	0.001	0.784	D	0.000	0.843	D	1	0.810	A	2.39	0.691	M	-3.25	0.935	D	-6.22	0.904	D	1.033	0.978	D	0.873	0.958	D	0.891	0.992	D	0.814	0.929	0.992	0.933	D	c	0.726	0.653	1.000	0.747	0.672	0.522	0	4.14	0.477	9.113	0.936	1.088	0.866	1.000	0.715	0.998	0.697	12.153	0.532	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,939	0	0	0	1	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9749	Likely Pathogenic
19	4117551	4117551	A	C	exonic	MAP2K2	.	nonsynonymous_SNV	MAP2K2:NM_030662:exon2:c.T169G:p.F57V	0.86326115931858	0.136320885012997	0.00041795566842237	mitogen-activated_protein_kinase_kinase_2	FUNCTION:_Catalyzes_the_concomitant_phosphorylation_of_a_threonine_and_a_tyrosine_residue_in_a_Thr-Glu-Tyr_sequence_located_in_MAP_kinases._Activates_the_ERK1_and_ERK2_MAP_kinases_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Cardiofaciocutaneous_syndrome_4_(CFC4)_[MIM:615280]:_A_form_of_cardiofaciocutaneous_syndrome,_a_multiple_congenital_anomaly_disorder_characterized_by_a_distinctive_facial_appearance,_heart_defects_and_mental_retardation._Heart_defects_include_pulmonic_stenosis,_atrial_septal_defects_and_hypertrophic_cardiomyopathy._Some_affected_individuals_present_with_ectodermal_abnormalities_such_as_sparse,_friable_hair,_hyperkeratotic_skin_lesions_and_a_generalized_ichthyosis-like_condition._Typical_facial_features_are_similar_to_Noonan_syndrome._They_include_high_forehead_with_bitemporal_constriction,_hypoplastic_supraorbital_ridges,_downslanting_palpebral_fissures,_a_depressed_nasal_bridge,_and_posteriorly_angulated_ears_with_prominent_helices._{ECO:0000269|PubMed:16439621,_ECO:0000269|PubMed:18042262,_ECO:0000269|PubMed:20358587}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	medulla_oblongata\x3bsmooth_muscle\x3bovary\x3bsalivary_gland\x3bsympathetic_chain\x3bcolon\x3bparathyroid\x3bskin\x3buterus\x3bprostate\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bmuscle\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbile_duct\x3bpancreas\x3blung\x3badrenal_gland\x3bplacenta\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	amygdala\x3bprefrontal_cortex\x3btestis\x3bpons\x3bcingulate_cortex\x3b	0.88489	0.51187	-0.800872469	12.33191791	40.94266	1.19949	rs121434498	23312	Pancreatic_adenocarcinoma|Squamous_cell_carcinoma_of_the_head_and_neck|Malignant_melanoma_of_skin|Adenocarcinoma_of_stomach|Cardio-facio-cutaneous_syndrome|Cardiofaciocutaneous_syndrome_4	Human_Phenotype_Ontology:HP:0006725,MedGen:C0281361|MeSH:C535575,MedGen:C1168401,OMIM:275355,Orphanet:ORPHA67037|MeSH:C562393,MedGen:C0151779,SNOMED_CT:93655004|MedGen:C0278701|MedGen:C1275081,Orphanet:ORPHA1340,SNOMED_CT:403770008|MedGen:C3809007,OMIM:615280	reviewed_by_expert_panel	Pathogenic	0.006	0.614	D	0.000	0.843	D	1	0.810	A	2.39	0.691	M	-3.05	0.924	D	-5.65	0.870	D	0.985	0.969	D	0.850	0.950	D	0.834	0.987	D	0.851	0.953	0.992	0.933	D	c	0.722	0.649	1.000	0.747	0.672	0.522	0	4.14	0.477	9.113	0.936	1.088	0.866	1.000	0.715	0.997	0.653	12.153	0.532	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,940	0	0	0	1	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.9749	Likely Pathogenic
12	103249091	103249091	C	T	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon6:c.G529A:p.V177M	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475602	108462	Hyperphenylalaninemia,_non-pku|Phenylketonuria|not_provided	Human_Phenotype_Ontology:HP:0004923,MedGen:C0751435|MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	D	3.81	0.956	H	-6.57	0.997	D	-2.61	0.561	D	0.993	0.971	D	0.990	0.997	D	0.462	0.945	D	0.955	0.995	0.969	0.715	D	c	0.814	0.739	0.140	0.173	0.638	0.428	0	4.84	0.620	3.388	0.520	0.935	0.490	0.996	0.391	0.977	0.480	14.156	0.648	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	3.23e-05	0	0	0	0	0	6.668e-05	0	1.22e-05	0	2.98e-05	0	0	0	1.794e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,772	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103260383	103260383	T	A	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon5:c.A500T:p.N167I	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs77554925	98650	Phenylketonuria|not_specified|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN169374|MedGen:CN517202	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.007	0.599	D	0.000	0.513	D	1	0.810	D	3.455	0.924	M	-6.19	0.996	D	-6.23	0.905	D	1.094	0.994	D	0.978	0.993	D	0.827	0.987	D	0.836	0.944	0.803	0.397	D	c	-0.304	-0.467	0.001	0.075	0.554	0.246	0	-4.01	0.038	0.267	0.182	-0.221	0.097	0.999	0.424	0.990	0.544	7.660	0.274	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	6.459e-05	0.0001	0	0	0	0	6.665e-05	0	4.063e-05	0	5.963e-05	0	0	0	7.166e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,783	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103260393	103260393	T	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon5:c.A490G:p.I164V	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475647	108434	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_single_submitter	Pathogenic	0.18	0.258	T	0.000	0.843	D	1.000	0.588	D	2.77	0.812	M	-6.29	0.996	D	-0.83	0.227	N	1.097	0.995	D	0.974	0.992	D	0.197	0.866	D	0.883	0.970	0.961	0.674	D	c	0.492	0.548	0.895	0.259	0.638	0.428	0	6.08	0.990	5.310	0.653	1.061	0.807	1.000	0.715	0.992	0.562	14.385	0.664	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	1.625e-05	0	0	0	0	0	1.791e-05	0	6.497e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,788	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103260378	103260378	G	A	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon5:c.C505T:p.R169C	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs281865440	130974	Phenylketonuria	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006	no_assertion_criteria_provided	Likely_pathogenic	0.004	0.682	D	0.000	0.629	N	1.000	0.810	D	2.72	0.798	M	-6.26	0.996	D	-5.73	0.876	D	0.890	0.955	D	0.951	0.984	D	0.433	0.940	D	.	.	0.773	0.377	D	c	0.002	-0.016	0.000	0.050	0.554	0.246	0	-0.060	0.131	1.070	0.301	1.048	0.713	1.000	0.715	0.999	0.750	8.790	0.338	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	1.219e-05	0	0	0	0	0	1.791e-05	0	3.249e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,780	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103260410	103260410	C	T	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon5:c.G473A:p.R158Q	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs5030843	15626	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.475	0.989	H	-6.71	0.998	D	-3.87	0.726	D	0.923	0.960	D	0.994	0.999	D	0.811	0.985	D	.	.	0.956	0.650	D	c	0.933	0.834	0.085	0.160	0.638	0.428	0	5.17	0.707	5.240	0.650	0.935	0.490	1.000	0.715	0.992	0.562	14.650	0.683	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	0.0001	0	0	0	5.798e-05	0	0.0002	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,790	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103260375	103260375	G	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon5:c.C508G:p.H170D	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475655	98651	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	0.012	0.555	D	0.000	0.843	D	1	0.810	D	3.675	0.945	H	-6.16	0.996	D	-7.7	0.956	D	1.022	0.976	D	0.990	0.997	D	0.719	0.977	D	0.948	0.994	0.982	0.801	D	c	0.987	0.929	0.995	0.338	0.554	0.246	0	6.08	0.990	6.647	0.740	1.048	0.713	1.000	0.715	0.999	0.750	17.819	0.885	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	0.9920	0.844	.	.	.	.	.	.	.	.	2.032e-05	0	0.0001	0	0	0	0	0.0002	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,778	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103260411	103260411	G	A	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon5:c.C472T:p.R158W	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs75166491	108429	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.475	0.989	H	-6.77	0.998	D	-7.74	0.958	D	0.998	0.972	D	0.994	0.999	D	0.713	0.977	D	.	.	0.812	0.404	D	c	0.463	0.325	0.000	0.055	0.638	0.428	0	1.79	0.239	1.433	0.343	0.108	0.203	1.000	0.715	0.990	0.544	15.932	0.794	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	2.844e-05	0.0001	0	0.0001	0.0001	0	1.792e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,791	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103260419	103260419	C	T	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon5:c.G464A:p.R155H	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475663	108422	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_single_submitter	Pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.36	0.985	H	-6.74	0.998	D	-4.67	0.795	D	0.959	0.965	D	0.994	0.999	D	0.806	0.985	D	.	.	0.964	0.686	D	c	1.046	0.974	0.995	0.338	0.638	0.428	0	6.08	0.990	5.240	0.650	0.935	0.490	1.000	0.715	0.959	0.439	17.819	0.885	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	3.228e-05	0	0	0	0.0006	0	0	0	2.032e-05	0	2.981e-05	0	5.798e-05	0	1.792e-05	0	3.249e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,794	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103271241	103271241	G	A	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon4:c.C440T:p.P147L	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475694	108406	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_single_submitter	Pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	D	3.885	0.961	H	-7.12	0.998	D	-9.28	0.983	D	0.963	0.966	D	0.995	0.999	D	0.899	0.992	D	0.88	0.968	0.959	0.664	D	c	0.977	0.885	1.000	0.747	0.615	0.372	0	5.86	0.939	9.183	0.940	1.048	0.713	1.000	0.715	0.899	0.380	20.177	0.982	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	0.9930	0.916	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,798	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
1	41285565	41285565	G	A	exonic	KCNQ4	.	nonsynonymous_SNV	KCNQ4:NM_004700:exon6:c.G853A:p.G285S,KCNQ4:NM_172163:exon6:c.G853A:p.G285S	0.985178281898531	0.0148214036876789	3.14413790434247e-07	potassium_voltage-gated_channel_subfamily_Q_member_4	FUNCTION:_Probably_important_in_the_regulation_of_neuronal_excitability._May_underlie_a_potassium_current_involved_in_regulating_the_excitability_of_sensory_cells_of_the_cochlea._KCNQ4_channels_are_blocked_by_linopirdin,_XE991_and_bepridil,_whereas_clofilium_is_without_significant_effect._Muscarinic_agonist_oxotremorine-M_strongly_suppress_KCNQ4_current_in_CHO_cells_in_which_cloned_KCNQ4_channels_were_coexpressed_with_M1_muscarinic_receptors.\x3b_	DISEASE:_Deafness,_autosomal_dominant,_2A_(DFNA2A)_[MIM:600101]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10025409,_ECO:0000269|PubMed:10369879,_ECO:0000269|PubMed:10571947,_ECO:0000269|PubMed:10925378,_ECO:0000269|PubMed:21242547}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_the_outer,_but_not_the_inner,_sensory_hair_cells_of_the_cochlea._Slightly_expressed_in_heart,_brain_and_skeletal_muscle.\x3b_	lymphoreticular\x3bcartilage\x3bcolon\x3bfovea_centralis\x3bchoroid\x3blens\x3bretina\x3boptic_nerve\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3biris\x3bmammary_gland\x3bbrain\x3bstomach\x3b	superior_cervical_ganglion\x3bciliary_ganglion\x3batrioventricular_node\x3btrigeminal_ganglion\x3b	0.12943	0.14391	-0.66859065	15.76433121	646.02	5.10359	rs28937588	21280	DFNA_2_Nonsyndromic_Hearing_Loss|Nonsyndromic_hearing_loss_and_deafness	MedGen:C2677637,OMIM:600101|MedGen:CN043648,Orphanet:ORPHA87884	criteria_provided,_single_submitter	Likely_pathogenic	0.0	0.912	D	0.000	0.629	D	1	0.810	D	3.705	0.948	H	-7.52	0.999	D	-5.61	0.872	D	0.466	0.901	D	0.620	0.866	D	0.303	0.910	D	0.939	0.992	0.998	0.993	D	c	0.783	0.798	1.0	0.983	0.696	0.567	0	5.71	0.890	10.003	0.997	1.048	0.713	1.000	0.715	0.998	0.697	17.335	0.871	Ion_transport_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,442	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103249087	103249087	T	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon6:c.A533G:p.E178G	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs77958223	98653	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	0.019	0.501	D	0.001	0.426	D	0.998	0.444	D	3.195	0.893	M	-6.39	0.997	D	-4.47	0.778	D	1.036	0.978	D	0.983	0.995	D	0.718	0.977	D	0.876	0.966	0.953	0.639	D	c	0.558	0.576	0.165	0.177	0.638	0.428	0	5.73	0.897	5.253	0.650	1.061	0.807	1.000	0.715	0.998	0.697	11.507	0.495	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	0.0002	0.0001	0	0	0	0	0.0003	0	6.504e-05	0	5.96e-05	0	0	0	0.0001	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,771	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103271296	103271296	C	A	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon4:c.G385T:p.D129Y	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475606	108396	not_provided	MedGen:CN517202	criteria_provided,_single_submitter	Pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.35	0.985	H	-6.81	0.998	D	-8.68	0.980	D	0.914	0.959	D	0.995	0.999	D	0.815	0.986	D	0.979	0.998	0.979	0.775	D	c	0.937	0.834	1.000	0.416	0.615	0.372	0	4.97	0.653	7.279	0.778	0.935	0.490	1.000	0.715	0.997	0.653	14.717	0.688	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,801	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103249061	103249061	A	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon6:c.T559C:p.W187R	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62507272	108471	not_provided	MedGen:CN517202	criteria_provided,_single_submitter	Likely_pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.84	0.997	H	-8.49	0.999	D	-13.68	1.000	D	0.915	0.959	D	0.998	1.000	D	0.727	0.978	D	0.982	0.998	0.992	0.921	D	c	0.954	0.809	1.000	0.747	0.638	0.428	0	5.73	0.897	9.325	0.960	1.199	0.960	1.000	0.715	0.338	0.244	16.017	0.802	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,768	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103249052	103249052	C	T	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon6:c.G568A:p.V190M	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs281865441	125873	Phenylketonuria	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006	no_assertion_criteria_provided	Likely_pathogenic	0.018	0.524	D	0.000	0.843	D	1	0.810	D	2.78	0.814	M	-6.41	0.997	D	-2.52	0.547	D	0.969	0.967	D	0.991	0.998	D	0.555	0.959	D	0.763	0.891	0.977	0.764	D	c	0.610	0.480	0.999	0.395	0.638	0.428	0	4.82	0.615	6.170	0.716	0.935	0.490	1.000	0.715	0.358	0.247	16.541	0.842	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,766	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103249039	103249039	A	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon6:c.T581C:p.L194P	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs5030844	108478	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.42	0.987	H	-6.62	0.997	D	-6.8	0.929	D	0.984	0.969	D	0.992	0.998	D	0.611	0.966	D	0.969	0.997	0.989	0.882	D	c	0.653	0.510	0.904	0.261	0.638	0.428	0	4.73	0.593	9.325	0.960	1.199	0.960	1.000	0.715	0.975	0.474	11.814	0.513	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	2.032e-05	0	0	0	0	0	4.48e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,765	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103249029	103249029	C	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon6:c.G591C:p.L197F	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs281865442	125874	Phenylketonuria	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006	no_assertion_criteria_provided	Likely_pathogenic	0.001	0.784	D	0.000	0.629	D	1	0.810	D	3.365	0.914	M	-6.81	0.998	D	-3.76	0.712	D	1.045	0.980	D	0.989	0.997	D	0.753	0.980	D	0.906	0.980	0.892	0.493	D	c	0.472	0.325	0.004	0.104	0.638	0.428	0	2.96	0.332	0.367	0.200	0.935	0.490	0.990	0.367	1.000	0.888	8.082	0.297	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,764	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103248982	103248982	A	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon6:c.T638C:p.L213P	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62516109	98654	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.685	0.995	H	-6.85	0.998	D	-6.69	0.924	D	0.917	0.959	D	0.994	0.999	D	0.801	0.985	D	0.927	0.988	0.992	0.928	D	c	1.076	0.979	1.000	0.747	0.638	0.428	0	5.63	0.861	9.325	0.960	1.199	0.960	1.000	0.715	1.000	0.888	15.835	0.785	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,762	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103248932	103248932	C	T	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon6:c.G688A:p.V230I	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62516152	108520	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	0.238	0.181	T	0.000	0.629	D	1	0.810	D	0.185	0.091	N	-6.21	0.996	D	-0.16	0.095	N	1.062	0.984	D	0.920	0.974	D	0.242	0.888	D	.	.	0.883	0.479	D	c	-0.174	-0.012	0.850	0.250	0.638	0.428	0	5.47	0.803	1.651	0.367	0.935	0.490	0.834	0.299	0.908	0.386	14.538	0.674	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	0.0001	0	0	0	0	0.0006	0.0001	0	0.0006	0	0.0004	0.0027	0	0.0007	0.0002	0.0007	0.0016	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,760	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246714	103246714	G	A	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.C721T:p.R241C	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs76687508	108539	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	0.043	0.430	D	0.000	0.843	D	1	0.810	D	2.23	0.633	M	-6.17	0.996	D	-2.54	0.550	D	1.074	0.987	D	0.985	0.995	D	0.371	0.928	D	.	.	0.977	0.760	D	c	0.843	0.836	1.000	0.747	0.638	0.428	0	5.92	0.955	6.646	0.740	1.048	0.713	1.000	0.715	1.000	0.888	20.317	0.987	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	9.691e-05	0	0	0	0.0018	0	0	0	0.0001	0.0003	0	0	0.0013	0	4.493e-05	0	3.249e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,754	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246713	103246713	C	T	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.G722A:p.R241H	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62508730	108540	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	0.027	0.501	D	0.000	0.843	D	1	0.810	D	3.125	0.882	M	-6.15	0.995	D	-2.0	0.461	N	1.032	0.978	D	0.986	0.996	D	0.736	0.979	D	.	.	0.955	0.647	D	c	0.712	0.666	1.000	0.434	0.638	0.428	0	5.01	0.663	4.912	0.628	0.935	0.490	1.000	0.715	1.000	0.888	16.379	0.832	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	3.23e-05	0	0	0	0	0	6.666e-05	0	0.0002	0	0	0.0028	0	4.487e-05	5.389e-05	0.0009	3.249e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,753	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246701	103246701	A	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.T734C:p.V245A	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs76212747	15671	Hyperphenylalaninemia,_non-pku|Phenylketonuria|Hyperphenylalaninaemia|not_provided	Human_Phenotype_Ontology:HP:0004923,MedGen:C0751435|MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN221596|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	0.115	0.285	T	0.000	0.843	N	1	0.810	D	2.925	0.847	M	-6.69	0.998	D	-3.84	0.722	D	1.069	0.986	D	0.988	0.997	D	0.276	0.901	D	.	.	0.991	0.917	D	c	0.824	0.821	1.000	0.747	0.638	0.428	0	5.92	0.955	9.325	0.960	1.199	0.960	1.000	0.715	0.997	0.653	16.359	0.830	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	0.0003	0	0	0	0	0.0003	0.0005	0.0010	0.0005	6.534e-05	0.0003	0	0	4.485e-05	0.0010	0.0011	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,751	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246690	103246690	G	A	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.C745T:p.L249F	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs74503222	108557	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	0.001	0.784	D	0.000	0.843	D	1	0.810	D	4.06	0.972	H	-6.5	0.997	D	-3.84	0.722	D	0.944	0.963	D	0.993	0.998	D	0.703	0.976	D	0.9	0.978	0.986	0.843	D	c	0.962	0.867	1.000	0.747	0.638	0.428	0	5.03	0.669	8.154	0.895	1.048	0.713	1.000	0.715	0.998	0.697	14.970	0.707	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	4.065e-05	0	0	0	0	0.0001	6.278e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,746	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246680	103246680	C	T	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.G755A:p.R252Q	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62644503	108560	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	D	3.135	0.884	M	-6.71	0.998	D	-3.84	0.722	D	1.006	0.973	D	0.992	0.998	D	0.453	0.944	D	0.964	0.996	0.987	0.854	D	c	0.957	0.925	1.000	0.747	0.638	0.428	0	5.92	0.955	7.905	0.864	0.935	0.490	1.000	0.715	0.999	0.750	20.317	0.987	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	3.23e-05	0.0001	0	0	0	0	0	0	8.129e-06	0	0	0	5.8e-05	0	8.966e-06	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,743	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103271247	103271247	T	A	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon4:c.A434T:p.D145V	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs140175796	108403	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.305	0.983	H	-6.48	0.997	D	-8.38	0.971	D	0.954	0.965	D	0.992	0.998	D	0.866	0.990	D	.	.	0.940	0.595	D	c	0.903	0.797	1.000	0.747	0.615	0.372	0	5.86	0.939	7.382	0.788	1.061	0.807	1.000	0.715	0.977	0.480	16.244	0.822	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	3.234e-05	0	0	0	0	0	6.679e-05	0	6.497e-05	0	0.0001	0.0001	0	0	9.847e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,799	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103288671	103288671	A	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon3:c.T194C:p.I65T	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs75193786	15675	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.27	0.982	H	-5.67	0.993	D	-4.5	0.817	D	0.982	0.969	D	0.989	0.997	D	0.873	0.990	D	.	.	0.987	0.857	D	c	1.105	1.019	1.000	0.747	0.615	0.372	0	6.17	0.997	8.297	0.898	1.199	0.960	1.000	0.715	1.000	0.888	16.822	0.856	ACT_domain	.	.	.	.	0.0005	0.0005	0	0	0	0	0.0007	0	0.0003	6.537e-05	8.934e-05	0	0	0	0.0005	0.0002	3.249e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,819	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103271326	103271326	G	A	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon4:c.C355T:p.P119S	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs398123292	98648	Phenylketonuria	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006	criteria_provided,_single_submitter	Likely_pathogenic	0.018	0.912	D	0.000	0.843	D	1	0.810	D	3.285	0.905	M	-4.93	0.984	D	-6.71	0.952	D	1.097	0.995	D	0.969	0.990	D	0.660	0.972	D	.	.	0.988	0.870	D	c	1.002	0.972	1.000	0.747	0.615	0.372	0	5.86	0.939	9.183	0.940	1.048	0.713	1.000	0.715	1.000	0.888	20.177	0.982	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	0.0003	0	0	0	0	0	8.961e-06	0.0002	0.0022	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,804	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
16	68845762	68845762	G	T	exonic	CDH1	.	nonsynonymous_SNV	CDH1:NM_001317184:exon7:c.G1008T:p.E336D,CDH1:NM_004360:exon7:c.G1008T:p.E336D	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	rs267606712	33492	Hereditary_cancer-predisposing_syndrome|Hereditary_diffuse_gastric_cancer	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708349,OMIM:137215,Orphanet:ORPHA26106	criteria_provided,_single_submitter	Pathogenic	0.002	0.721	D	0.000	0.513	D	1	0.810	D	2.555	0.748	M	-0.65	0.722	T	-2.88	0.605	D	0.376	0.887	D	0.619	0.866	D	.	.	.	0.285	0.243	0.982	0.805	D	c	0.974	0.924	1.000	0.747	0.632	0.406	0	5.47	0.803	9.602	0.976	1.048	0.713	1.000	0.715	0.998	0.697	19.297	0.941	Cadherin|Cadherin-like	.	.	1.0000	0.996	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,901	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
21	36252995	36252995	C	G	exonic	RUNX1	.	nonsynonymous_SNV	RUNX1:NM_001001890:exon2:c.G286C:p.D96H,RUNX1:NM_001122607:exon2:c.G286C:p.D96H,RUNX1:NM_001754:exon5:c.G367C:p.D123H	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	rs373498347	422354	not_provided	MedGen:CN517202	criteria_provided,_single_submitter	Pathogenic	0.001	0.784	D	0.000	0.843	D	1	0.810	D	2.325	0.668	M	-6.1	0.995	D	-4.96	0.837	D	1.051	0.981	D	0.986	0.996	D	0.545	0.958	D	.	.	0.992	0.921	D	c	0.849	0.818	1.0	0.983	0.722	0.854	0	5.31	0.750	7.568	0.814	0.935	0.490	1.000	0.715	0.957	0.436	19.335	0.943	Runt_domain|p53-like_transcription_factor,_DNA-binding|p53/RUNT-type_transcription_factor,_DNA-binding_domain	.	.	.	.	.	.	.	.	.	.	.	.	1.219e-05	0	0	0	0	0	2.687e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,973	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
21	36252962	36252962	C	G	exonic	RUNX1	.	nonsynonymous_SNV	RUNX1:NM_001001890:exon2:c.G319C:p.A107P,RUNX1:NM_001122607:exon2:c.G319C:p.A107P,RUNX1:NM_001754:exon5:c.G400C:p.A134P	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	rs74315451	29507	Familial_platelet_disorder_with_associated_myeloid_malignancy	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290	no_assertion_criteria_provided	Pathogenic	0.001	0.784	D	0.000	0.843	D	1	0.810	A	2.88	0.837	M	-6.29	0.996	D	-4.28	0.790	D	1.014	0.974	D	0.989	0.997	D	0.820	0.986	D	0.804	0.922	0.992	0.921	D	c	0.944	0.880	1.0	0.983	0.722	0.854	0	5.31	0.750	7.568	0.814	0.935	0.490	1.000	0.715	0.987	0.523	19.335	0.943	Runt_domain|p53-like_transcription_factor,_DNA-binding|p53/RUNT-type_transcription_factor,_DNA-binding_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,971	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
21	36252895	36252895	G	T	exonic	RUNX1	.	nonsynonymous_SNV	RUNX1:NM_001001890:exon2:c.C386A:p.A129E,RUNX1:NM_001122607:exon2:c.C386A:p.A129E,RUNX1:NM_001754:exon5:c.C467A:p.A156E	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	rs267607026	29510	Familial_platelet_disorder_with_associated_myeloid_malignancy	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290	no_assertion_criteria_provided	Pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	D	2.91	0.844	M	-6.47	0.997	D	-4.45	0.789	D	0.994	0.971	D	0.991	0.998	D	0.718	0.977	D	0.776	0.902	0.994	0.960	D	c	0.840	0.718	1.0	0.983	0.722	0.854	0	5.31	0.750	9.602	0.976	1.045	0.669	1.000	0.715	0.855	0.357	19.335	0.943	Runt_domain|p53-like_transcription_factor,_DNA-binding|p53/RUNT-type_transcription_factor,_DNA-binding_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,968	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
21	36252865	36252865	C	T	exonic	RUNX1	.	nonsynonymous_SNV	RUNX1:NM_001001890:exon2:c.G416A:p.R139Q,RUNX1:NM_001122607:exon2:c.G416A:p.R139Q,RUNX1:NM_001754:exon5:c.G497A:p.R166Q	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	rs1060499616	404848	Familial_platelet_disorder_with_associated_myeloid_malignancy	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290	no_assertion_criteria_provided	Likely_pathogenic	0.001	0.784	D	0.000	0.843	D	1	0.810	D	2.89	0.840	M	-6.47	0.997	D	-3.72	0.717	D	0.996	0.971	D	0.991	0.998	D	0.607	0.966	D	.	.	0.988	0.864	D	c	0.940	0.878	1.0	0.983	0.722	0.854	0	5.31	0.750	7.568	0.814	0.932	0.445	1.000	0.715	0.998	0.697	19.335	0.943	Runt_domain|p53-like_transcription_factor,_DNA-binding|p53/RUNT-type_transcription_factor,_DNA-binding_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,967	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
21	36231827	36231827	A	T	exonic	RUNX1	.	nonsynonymous_SNV	RUNX1:NM_001001890:exon3:c.T476A:p.V159D,RUNX1:NM_001122607:exon3:c.T476A:p.V159D,RUNX1:NM_001754:exon6:c.T557A:p.V186D	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	rs797045927	208712	Familial_platelet_disorder_with_associated_myeloid_malignancy	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290	criteria_provided,_single_submitter	Likely_pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	D	2.36	0.681	M	-6.29	0.996	D	-6.29	0.922	D	1.039	0.979	D	0.985	0.995	D	0.889	0.992	D	0.857	0.956	0.953	0.638	D	c	0.725	0.705	1.000	0.747	0.707	0.730	0	5.11	0.691	9.318	0.954	1.199	0.960	1.000	0.715	0.990	0.544	12.877	0.572	Runt_domain|p53-like_transcription_factor,_DNA-binding|p53/RUNT-type_transcription_factor,_DNA-binding_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,963	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
21	36231782	36231782	C	T	exonic	RUNX1	.	nonsynonymous_SNV	RUNX1:NM_001001890:exon3:c.G521A:p.R174Q,RUNX1:NM_001122607:exon3:c.G521A:p.R174Q,RUNX1:NM_001754:exon6:c.G602A:p.R201Q	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	rs74315450	29503	Familial_platelet_disorder_with_associated_myeloid_malignancy	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290	criteria_provided,_single_submitter	Pathogenic	0.047	0.413	D	0.000	0.843	D	1	0.810	A	2.91	0.844	M	-6.47	0.997	D	-3.71	0.718	D	1.022	0.976	D	0.988	0.996	D	0.521	0.955	D	0.776	0.902	0.944	0.609	D	c	0.707	0.701	1.000	0.747	0.707	0.730	0	5.12	0.693	7.899	0.859	0.935	0.490	1.000	0.715	1.000	0.888	16.072	0.807	Runt_domain|p53-like_transcription_factor,_DNA-binding|p53/RUNT-type_transcription_factor,_DNA-binding_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,960	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
19	4101030	4101030	C	A	exonic	MAP2K2	.	nonsynonymous_SNV	MAP2K2:NM_030662:exon6:c.G692T:p.R231L	0.86326115931858	0.136320885012997	0.00041795566842237	mitogen-activated_protein_kinase_kinase_2	FUNCTION:_Catalyzes_the_concomitant_phosphorylation_of_a_threonine_and_a_tyrosine_residue_in_a_Thr-Glu-Tyr_sequence_located_in_MAP_kinases._Activates_the_ERK1_and_ERK2_MAP_kinases_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Cardiofaciocutaneous_syndrome_4_(CFC4)_[MIM:615280]:_A_form_of_cardiofaciocutaneous_syndrome,_a_multiple_congenital_anomaly_disorder_characterized_by_a_distinctive_facial_appearance,_heart_defects_and_mental_retardation._Heart_defects_include_pulmonic_stenosis,_atrial_septal_defects_and_hypertrophic_cardiomyopathy._Some_affected_individuals_present_with_ectodermal_abnormalities_such_as_sparse,_friable_hair,_hyperkeratotic_skin_lesions_and_a_generalized_ichthyosis-like_condition._Typical_facial_features_are_similar_to_Noonan_syndrome._They_include_high_forehead_with_bitemporal_constriction,_hypoplastic_supraorbital_ridges,_downslanting_palpebral_fissures,_a_depressed_nasal_bridge,_and_posteriorly_angulated_ears_with_prominent_helices._{ECO:0000269|PubMed:16439621,_ECO:0000269|PubMed:18042262,_ECO:0000269|PubMed:20358587}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	medulla_oblongata\x3bsmooth_muscle\x3bovary\x3bsalivary_gland\x3bsympathetic_chain\x3bcolon\x3bparathyroid\x3bskin\x3buterus\x3bprostate\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bmuscle\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbile_duct\x3bpancreas\x3blung\x3badrenal_gland\x3bplacenta\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	amygdala\x3bprefrontal_cortex\x3btestis\x3bpons\x3bcingulate_cortex\x3b	0.88489	0.51187	-0.800872469	12.33191791	40.94266	1.19949	rs730880511	49288	Rasopathy|not_provided	MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN517202	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.004	0.654	D	0.000	0.843	D	1	0.810	D	0.39	0.122	N	-2.94	0.919	D	-6.6	0.920	D	0.708	0.933	D	0.750	0.915	D	0.641	0.970	D	0.62	0.755	0.985	0.828	D	c	0.310	0.235	1.000	0.747	0.707	0.730	0	4.22	0.490	7.860	0.853	0.848	0.348	1.000	0.715	0.277	0.233	15.189	0.726	Protein_kinase_domain|Protein_kinase-like_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,930	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
16	68863674	68863674	G	A	exonic	CDH1	.	nonsynonymous_SNV	CDH1:NM_001317184:exon14:c.G2230A:p.D744N,CDH1:NM_001317186:exon14:c.G448A:p.D150N,CDH1:NM_001317185:exon15:c.G865A:p.D289N,CDH1:NM_004360:exon15:c.G2413A:p.D805N	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	rs200894246	133382	Hereditary_cancer-predisposing_syndrome|Hereditary_diffuse_gastric_cancer|not_specified	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708349,OMIM:137215,Orphanet:ORPHA26106|MedGen:CN169374	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.049	0.398	D	0.000	0.523	D	1	0.810	D	1.73	0.448	L	-1.04	0.766	T	-2.63	0.566	D	-0.236	0.768	T	0.543	0.832	D	0.533	0.956	D	.	.	0.989	0.885	D	c	0.702	0.751	1.000	0.747	0.672	0.522	0	6.05	0.981	5.804	0.686	1.038	0.658	1.000	0.715	0.999	0.750	20.198	0.982	Cadherin,_cytoplasmic_domain\x3bCadherin,_cytoplasmic_domain|Catenin_binding_domain	.	.	.	.	0.0002	0	0	0.0033	0	0	0.0003	0	0.0002	0	0.0004	0.0020	0	0	0.0002	0.0004	3.25e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,920	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
16	68862107	68862107	G	A	exonic	CDH1	.	nonsynonymous_SNV	CDH1:NM_001317184:exon13:c.G2012A:p.R671Q,CDH1:NM_001317186:exon13:c.G230A:p.R77Q,CDH1:NM_001317185:exon14:c.G647A:p.R216Q,CDH1:NM_004360:exon14:c.G2195A:p.R732Q	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	rs1060501244	402094	Hereditary_cancer-predisposing_syndrome|Hereditary_diffuse_gastric_cancer	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708349,OMIM:137215,Orphanet:ORPHA26106	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.006	0.654	D	0.000	0.441	D	1	0.810	D	1.965	0.534	M	0.31	0.588	T	-2.89	0.606	D	-0.364	0.732	T	0.404	0.755	T	0.028	0.511	D	0.807	0.925	0.707	0.344	D	c	0.712	0.704	1.000	0.747	0.672	0.522	0	6.07	0.987	3.102	0.497	1.048	0.713	1.000	0.715	0.998	0.697	20.254	0.984	Cadherin|Cadherin-like	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,916	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
16	68849506	68849506	C	T	exonic	CDH1	.	nonsynonymous_SNV	CDH1:NM_001317184:exon9:c.C1226T:p.T409I,CDH1:NM_004360:exon10:c.C1409T:p.T470I	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	rs370864592	133370	Hereditary_cancer-predisposing_syndrome|Hereditary_diffuse_gastric_cancer|not_specified|not_provided	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708349,OMIM:137215,Orphanet:ORPHA26106|MedGen:CN169374|MedGen:CN517202	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.0	0.912	D	0.000	0.504	D	1	0.810	D	2.98	0.858	M	0.46	0.582	T	-5.39	0.857	D	-0.146	0.790	T	0.411	0.760	T	0.103	0.778	D	.	.	0.991	0.909	D	c	0.865	0.819	1.000	0.747	0.707	0.730	0	5.7	0.886	7.482	0.800	0.932	0.445	1.000	0.715	0.518	0.274	19.433	0.947	Cadherin|Cadherin-like	.	.	.	.	9.681e-05	0.0002	0	0	0.0006	0	0	0	2.842e-05	6.534e-05	2.978e-05	0	0.0002	0	8.952e-06	0.0002	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,911	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
14	31346846	31346846	C	T	exonic	COCH	.	nonsynonymous_SNV	COCH:NM_001135058:exon3:c.C151T:p.P51S,COCH:NM_001347720:exon3:c.C346T:p.P116S,COCH:NM_004086:exon4:c.C151T:p.P51S	0.000262849456488043	0.983542807336405	0.0161943432071074	cochlin	FUNCTION:_Plays_a_role_in_the_control_of_cell_shape_and_motility_in_the_trabecular_meshwork._{ECO:0000269|PubMed:21886777}.\x3b_	DISEASE:_Deafness,_autosomal_dominant,_9_(DFNA9)_[MIM:601369]:_A_form_of_non-syndromic_hearing_loss_characterized_by_onset_in_the_fourth_or_fifth_decade_of_life_and_initially_involves_the_high_frequencies._Hearing_loss_is_progressive_and_usually_complete_by_the_sixth_decade._In_addition_to_cochlear_involvement,_DFNA9_patients_also_exhibit_a_spectrum_of_vestibular_dysfunctions._Penetrance_of_the_vestibular_symptoms_is_often_incomplete,_and_some_patients_are_minimally_affected,_whereas_others_suffer_from_severe_balance_disturbances_and_episodes_of_vertigo._Affected_individuals_have_mucopolysaccharide_depositions_in_the_channels_of_the_cochlear_and_vestibular_nerves._These_depositions_apparently_cause_strangulation_and_degeneration_of_dendritic_fibers._{ECO:0000269|PubMed:10400989,_ECO:0000269|PubMed:11295836,_ECO:0000269|PubMed:14512963,_ECO:0000269|PubMed:16835921,_ECO:0000269|PubMed:17561763,_ECO:0000269|PubMed:18312449,_ECO:0000269|PubMed:22610276,_ECO:0000269|PubMed:22931125,_ECO:0000269|PubMed:23993205,_ECO:0000269|PubMed:9806553,_ECO:0000269|PubMed:9931344}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_inner_ear_structures\x3b_the_cochlea_and_the_vestibule.\x3b_	unclassifiable_(Anatomical_System)\x3bcartilage\x3bovary\x3bhypothalamus\x3bcolon\x3bparathyroid\x3bretina\x3bprostate\x3blung\x3bcochlea\x3badrenal_gland\x3blarynx\x3btrabecular_meshwork\x3bplacenta\x3bvisual_apparatus\x3bliver\x3btestis\x3bhead_and_neck\x3bspleen\x3bkidney\x3bbrain\x3bstomach\x3b	pons\x3bcaudate_nucleus\x3b	0.53303	0.13199	0.286674996	71.49681529	2772.50763	9.93783	rs28938175	21650	Deafness,_autosomal_dominant_9|Nonsyndromic_hearing_loss_and_deafness	MedGen:C1832425,OMIM:601369|MedGen:CN043648,Orphanet:ORPHA87884	criteria_provided,_single_submitter	Pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	A	3.045	0.869	M	-3.69	0.953	D	-4.84	0.952	D	0.998	0.972	D	0.922	0.974	D	0.292	0.906	D	0.953	0.995	0.996	0.982	D	c	0.822	0.798	1.000	0.747	0.737	0.974	0	5.67	0.876	7.094	0.764	0.932	0.445	1.000	0.715	0.988	0.529	19.373	0.945	LCCL_domain	.	.	.	.	.	.	.	.	.	.	.	.	4.061e-06	0	0	0	0	0	8.951e-06	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,879	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103288515	103288515	G	A	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon3:c.C350T:p.T117I	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs281865439	125867	Phenylketonuria	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006	no_assertion_criteria_provided	Likely_pathogenic	0.112	0.721	T	0.000	0.843	D	1.000	0.588	D	2.52	0.738	M	-5.8	0.995	D	-2.8	0.629	D	1.077	0.988	D	0.957	0.986	D	0.584	0.963	D	0.367	0.376	0.989	0.881	D	c	0.439	0.579	1.000	0.747	0.615	0.372	0	6.17	0.997	8.899	0.921	1.048	0.713	1.000	0.715	0.988	0.529	20.879	0.999	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	0.9992	0.722	.	.	.	.	.	.	.	.	2.031e-05	0	8.934e-05	0	0	0	8.956e-06	0.0002	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,806	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
13	20763687	20763687	C	A	exonic	GJB2	.	nonsynonymous_SNV	GJB2:NM_004004:exon2:c.G34T:p.G12C	1.02863295453376e-11	0.00164377442881105	0.998356225560903	gap_junction_protein_beta_2	FUNCTION:_One_gap_junction_consists_of_a_cluster_of_closely_packed_pairs_of_transmembrane_channels,_the_connexons,_through_which_materials_of_low_MW_diffuse_from_one_cell_to_a_neighboring_cell.\x3b_	DISEASE:_Deafness,_autosomal_recessive,_1A_(DFNB1A)_[MIM:220290]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10830906,_ECO:0000269|PubMed:11313763,_ECO:0000269|PubMed:11439000,_ECO:0000269|PubMed:12121355,_ECO:0000269|PubMed:12239718,_ECO:0000269|PubMed:12786758,_ECO:0000269|PubMed:14722929,_ECO:0000269|PubMed:15666300,_ECO:0000269|PubMed:15994881,_ECO:0000269|PubMed:17660464,_ECO:0000269|PubMed:17666888,_ECO:0000269|PubMed:19384972,_ECO:0000269|PubMed:23680645,_ECO:0000269|PubMed:9328482,_ECO:0000269|PubMed:9336442,_ECO:0000269|PubMed:9471561,_ECO:0000269|PubMed:9529365}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_dominant,_3A_(DFNA3A)_[MIM:601544]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10807696,_ECO:0000269|PubMed:11313763,_ECO:0000269|PubMed:11439000,_ECO:0000269|PubMed:12786758,_ECO:0000269|PubMed:19384972,_ECO:0000269|PubMed:9620796}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Vohwinkel_syndrome_(VS)_[MIM:124500]:_VS_is_an_autosomal_dominant_disease_characterized_by_hyperkeratosis,_constriction_on_fingers_and_toes_and_congenital_deafness._{ECO:0000269|PubMed:10369869,_ECO:0000269|PubMed:15954104,_ECO:0000269|PubMed:18688874}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Keratoderma,_palmoplantar,_with_deafness_(PPKDFN)_[MIM:148350]:_An_autosomal_dominant_disorder_characterized_by_the_association_of_palmoplantar_hyperkeratosis_with_progressive,_bilateral,_high-frequency,_sensorineural_deafness._{ECO:0000269|PubMed:10633135,_ECO:0000269|PubMed:10757647,_ECO:0000269|PubMed:12372058,_ECO:0000269|PubMed:15996214,_ECO:0000269|PubMed:17993581,_ECO:0000269|PubMed:9856479}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Keratitis-ichthyosis-deafness_syndrome_(KID_syndrome)_[MIM:148210]:_An_autosomal_dominant_form_of_ectodermal_dysplasia._Ectodermal_dysplasia_defines_a_heterogeneous_group_of_disorders_due_to_abnormal_development_of_two_or_more_ectodermal_structures._Keratitis-ichthyosis-deafness_syndrome_is_characterized_by_the_association_of_hyperkeratotic_skin_lesions_with_vascularizing_keratitis_and_profound_sensorineural_hearing_loss._Clinical_features_include_deafness,_ichthyosis,_photophobia,_absent_or_decreased_eyebrows,_sparse_or_absent_scalp_hair,_decreased_sweating_and_dysplastic_finger_and_toenails._{ECO:0000269|PubMed:11912510,_ECO:0000269|PubMed:12548749,_ECO:0000269|PubMed:12752120}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bart-Pumphrey_syndrome_(BPS)_[MIM:149200]:_An_autosomal_dominant_disorder_characterized_by_sensorineural_hearing_loss,_palmoplantar_keratoderma,_knuckle_pads,_and_leukonychia,_It_shows_considerable_phenotypic_variability._{ECO:0000269|PubMed:15482471,_ECO:0000269|PubMed:15952212}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ichthyosis_hystrix-like_with_deafness_syndrome_(HID_syndrome)_[MIM:602540]:_An_autosomal_dominant_keratinizing_disorder_characterized_by_sensorineural_deafness_and_spiky_hyperkeratosis_affecting_the_entire_skin._HID_syndrome_is_considered_to_differ_from_the_similar_KID_syndrome_in_the_extent_and_time_of_occurrence_of_skin_symptoms_and_the_severity_of_the_associated_keratitis._{ECO:0000269|PubMed:12072059}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	.	.	0.42941	0.50569	0.663285274	84.55414013	794.09383	5.55726	rs104894408	53907	Hearing_impairment|Deafness,_autosomal_recessive_1A|Deafness,_autosomal_dominant_3a|Nonsyndromic_hearing_loss_and_deafness|not_specified|not_provided	Human_Phenotype_Ontology:HP:0000365,MedGen:C0018772|MedGen:C2673759,OMIM:220290|MedGen:C2675750,OMIM:601544|MedGen:CN043648,Orphanet:ORPHA87884|MedGen:CN169374|MedGen:CN517202	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.001	0.784	D	0.000	0.629	D	1	0.810	D	3.265	0.902	M	-5.47	0.991	D	-8.32	0.970	D	0.905	0.958	D	0.970	0.991	D	0.470	0.947	D	.	.	0.980	0.787	D	c	0.795	0.698	1.0	0.983	0.598	0.340	0	5.36	0.765	7.854	0.852	0.852	0.362	1.000	0.715	0.526	0.275	19.444	0.948	Connexin,_N-terminal	.	.	.	.	9.843e-05	0	0.0036	0	0	0	0	0	0.0005	0	0.0038	0	5.798e-05	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,873	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
13	20763614	20763614	A	G	exonic	GJB2	.	nonsynonymous_SNV	GJB2:NM_004004:exon2:c.T107C:p.L36P	1.02863295453376e-11	0.00164377442881105	0.998356225560903	gap_junction_protein_beta_2	FUNCTION:_One_gap_junction_consists_of_a_cluster_of_closely_packed_pairs_of_transmembrane_channels,_the_connexons,_through_which_materials_of_low_MW_diffuse_from_one_cell_to_a_neighboring_cell.\x3b_	DISEASE:_Deafness,_autosomal_recessive,_1A_(DFNB1A)_[MIM:220290]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10830906,_ECO:0000269|PubMed:11313763,_ECO:0000269|PubMed:11439000,_ECO:0000269|PubMed:12121355,_ECO:0000269|PubMed:12239718,_ECO:0000269|PubMed:12786758,_ECO:0000269|PubMed:14722929,_ECO:0000269|PubMed:15666300,_ECO:0000269|PubMed:15994881,_ECO:0000269|PubMed:17660464,_ECO:0000269|PubMed:17666888,_ECO:0000269|PubMed:19384972,_ECO:0000269|PubMed:23680645,_ECO:0000269|PubMed:9328482,_ECO:0000269|PubMed:9336442,_ECO:0000269|PubMed:9471561,_ECO:0000269|PubMed:9529365}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_dominant,_3A_(DFNA3A)_[MIM:601544]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10807696,_ECO:0000269|PubMed:11313763,_ECO:0000269|PubMed:11439000,_ECO:0000269|PubMed:12786758,_ECO:0000269|PubMed:19384972,_ECO:0000269|PubMed:9620796}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Vohwinkel_syndrome_(VS)_[MIM:124500]:_VS_is_an_autosomal_dominant_disease_characterized_by_hyperkeratosis,_constriction_on_fingers_and_toes_and_congenital_deafness._{ECO:0000269|PubMed:10369869,_ECO:0000269|PubMed:15954104,_ECO:0000269|PubMed:18688874}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Keratoderma,_palmoplantar,_with_deafness_(PPKDFN)_[MIM:148350]:_An_autosomal_dominant_disorder_characterized_by_the_association_of_palmoplantar_hyperkeratosis_with_progressive,_bilateral,_high-frequency,_sensorineural_deafness._{ECO:0000269|PubMed:10633135,_ECO:0000269|PubMed:10757647,_ECO:0000269|PubMed:12372058,_ECO:0000269|PubMed:15996214,_ECO:0000269|PubMed:17993581,_ECO:0000269|PubMed:9856479}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Keratitis-ichthyosis-deafness_syndrome_(KID_syndrome)_[MIM:148210]:_An_autosomal_dominant_form_of_ectodermal_dysplasia._Ectodermal_dysplasia_defines_a_heterogeneous_group_of_disorders_due_to_abnormal_development_of_two_or_more_ectodermal_structures._Keratitis-ichthyosis-deafness_syndrome_is_characterized_by_the_association_of_hyperkeratotic_skin_lesions_with_vascularizing_keratitis_and_profound_sensorineural_hearing_loss._Clinical_features_include_deafness,_ichthyosis,_photophobia,_absent_or_decreased_eyebrows,_sparse_or_absent_scalp_hair,_decreased_sweating_and_dysplastic_finger_and_toenails._{ECO:0000269|PubMed:11912510,_ECO:0000269|PubMed:12548749,_ECO:0000269|PubMed:12752120}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bart-Pumphrey_syndrome_(BPS)_[MIM:149200]:_An_autosomal_dominant_disorder_characterized_by_sensorineural_hearing_loss,_palmoplantar_keratoderma,_knuckle_pads,_and_leukonychia,_It_shows_considerable_phenotypic_variability._{ECO:0000269|PubMed:15482471,_ECO:0000269|PubMed:15952212}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ichthyosis_hystrix-like_with_deafness_syndrome_(HID_syndrome)_[MIM:602540]:_An_autosomal_dominant_keratinizing_disorder_characterized_by_sensorineural_deafness_and_spiky_hyperkeratosis_affecting_the_entire_skin._HID_syndrome_is_considered_to_differ_from_the_similar_KID_syndrome_in_the_extent_and_time_of_occurrence_of_skin_symptoms_and_the_severity_of_the_associated_keratitis._{ECO:0000269|PubMed:12072059}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	.	.	0.42941	0.50569	0.663285274	84.55414013	794.09383	5.55726	rs587783644	169014	Hearing_impairment|not_specified	Human_Phenotype_Ontology:HP:0000365,MedGen:C0018772|MedGen:CN169374	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.001	0.784	D	0.000	0.629	D	1	0.810	D	3.39	0.917	M	-5.67	0.993	D	-4.56	0.786	D	1.043	0.980	D	0.983	0.995	D	0.648	0.970	D	.	.	0.978	0.769	D	c	0.819	0.704	1.0	0.983	0.534	0.214	0	5.21	0.719	7.405	0.791	1.088	0.866	1.000	0.715	0.812	0.340	15.379	0.742	Connexin,_N-terminal	.	.	.	.	3.229e-05	0	0	0	0.0006	0	0	0	8.143e-06	6.534e-05	0	0	5.798e-05	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,869	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
13	20763150	20763150	A	G	exonic	GJB2	.	nonsynonymous_SNV	GJB2:NM_004004:exon2:c.T571C:p.F191L	1.02863295453376e-11	0.00164377442881105	0.998356225560903	gap_junction_protein_beta_2	FUNCTION:_One_gap_junction_consists_of_a_cluster_of_closely_packed_pairs_of_transmembrane_channels,_the_connexons,_through_which_materials_of_low_MW_diffuse_from_one_cell_to_a_neighboring_cell.\x3b_	DISEASE:_Deafness,_autosomal_recessive,_1A_(DFNB1A)_[MIM:220290]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10830906,_ECO:0000269|PubMed:11313763,_ECO:0000269|PubMed:11439000,_ECO:0000269|PubMed:12121355,_ECO:0000269|PubMed:12239718,_ECO:0000269|PubMed:12786758,_ECO:0000269|PubMed:14722929,_ECO:0000269|PubMed:15666300,_ECO:0000269|PubMed:15994881,_ECO:0000269|PubMed:17660464,_ECO:0000269|PubMed:17666888,_ECO:0000269|PubMed:19384972,_ECO:0000269|PubMed:23680645,_ECO:0000269|PubMed:9328482,_ECO:0000269|PubMed:9336442,_ECO:0000269|PubMed:9471561,_ECO:0000269|PubMed:9529365}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_dominant,_3A_(DFNA3A)_[MIM:601544]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10807696,_ECO:0000269|PubMed:11313763,_ECO:0000269|PubMed:11439000,_ECO:0000269|PubMed:12786758,_ECO:0000269|PubMed:19384972,_ECO:0000269|PubMed:9620796}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Vohwinkel_syndrome_(VS)_[MIM:124500]:_VS_is_an_autosomal_dominant_disease_characterized_by_hyperkeratosis,_constriction_on_fingers_and_toes_and_congenital_deafness._{ECO:0000269|PubMed:10369869,_ECO:0000269|PubMed:15954104,_ECO:0000269|PubMed:18688874}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Keratoderma,_palmoplantar,_with_deafness_(PPKDFN)_[MIM:148350]:_An_autosomal_dominant_disorder_characterized_by_the_association_of_palmoplantar_hyperkeratosis_with_progressive,_bilateral,_high-frequency,_sensorineural_deafness._{ECO:0000269|PubMed:10633135,_ECO:0000269|PubMed:10757647,_ECO:0000269|PubMed:12372058,_ECO:0000269|PubMed:15996214,_ECO:0000269|PubMed:17993581,_ECO:0000269|PubMed:9856479}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Keratitis-ichthyosis-deafness_syndrome_(KID_syndrome)_[MIM:148210]:_An_autosomal_dominant_form_of_ectodermal_dysplasia._Ectodermal_dysplasia_defines_a_heterogeneous_group_of_disorders_due_to_abnormal_development_of_two_or_more_ectodermal_structures._Keratitis-ichthyosis-deafness_syndrome_is_characterized_by_the_association_of_hyperkeratotic_skin_lesions_with_vascularizing_keratitis_and_profound_sensorineural_hearing_loss._Clinical_features_include_deafness,_ichthyosis,_photophobia,_absent_or_decreased_eyebrows,_sparse_or_absent_scalp_hair,_decreased_sweating_and_dysplastic_finger_and_toenails._{ECO:0000269|PubMed:11912510,_ECO:0000269|PubMed:12548749,_ECO:0000269|PubMed:12752120}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bart-Pumphrey_syndrome_(BPS)_[MIM:149200]:_An_autosomal_dominant_disorder_characterized_by_sensorineural_hearing_loss,_palmoplantar_keratoderma,_knuckle_pads,_and_leukonychia,_It_shows_considerable_phenotypic_variability._{ECO:0000269|PubMed:15482471,_ECO:0000269|PubMed:15952212}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ichthyosis_hystrix-like_with_deafness_syndrome_(HID_syndrome)_[MIM:602540]:_An_autosomal_dominant_keratinizing_disorder_characterized_by_sensorineural_deafness_and_spiky_hyperkeratosis_affecting_the_entire_skin._HID_syndrome_is_considered_to_differ_from_the_similar_KID_syndrome_in_the_extent_and_time_of_occurrence_of_skin_symptoms_and_the_severity_of_the_associated_keratitis._{ECO:0000269|PubMed:12072059}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	.	.	0.42941	0.50569	0.663285274	84.55414013	794.09383	5.55726	rs397516878	53927	not_specified	MedGen:CN169374	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.006	0.614	D	0.000	0.843	D	1	0.810	D	3.455	0.924	M	-4.07	0.966	D	-5.72	0.875	D	1.090	0.992	D	0.943	0.981	D	0.360	0.925	D	0.886	0.971	0.978	0.773	D	c	0.877	0.820	1.000	0.747	0.549	0.223	0	5.65	0.868	9.268	0.948	1.199	0.960	1.000	0.715	0.975	0.474	16.178	0.816	Connexin,_N-terminal|Gap_junction_protein,_cysteine-rich_domain	.	.	.	.	3.228e-05	0	0	0	0.0006	0	0	0	0.0001	0	0	0	0.0020	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,866	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103306627	103306627	A	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon2:c.T110C:p.L37P	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs869312996	227030	Phenylketonuria	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006	no_assertion_criteria_provided	Likely_pathogenic	0.001	0.912	D	0.000	0.504	D	1	0.810	D	3.965	0.966	H	-5.97	0.995	D	-4.7	0.825	D	1.020	0.975	D	0.987	0.996	D	0.867	0.990	D	0.814	0.929	0.930	0.569	D	c	0.857	0.760	1.000	0.747	0.638	0.428	0	5.46	0.799	5.968	0.699	1.199	0.960	1.000	0.715	1.000	0.888	13.057	0.582	ACT_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,842	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103306594	103306594	A	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon2:c.T143C:p.L48S	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs5030841	15647	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	0.0	0.912	D	0.000	0.629	D	1	0.810	A	4.36	0.985	H	-6.67	0.998	D	-5.47	0.890	D	0.926	0.961	D	0.995	0.999	D	0.823	0.986	D	.	.	0.929	0.565	D	c	0.957	0.835	1.000	0.747	0.638	0.428	0	5.46	0.799	5.968	0.699	1.199	0.960	0.998	0.411	0.997	0.653	13.057	0.582	ACT_domain	.	.	.	.	0.0002	0.0001	0	0	0	0	0.0003	0	0.0001	0	0.0003	0	0	0	0.0002	0.0004	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,836	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103306573	103306573	A	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon2:c.T164C:p.F55S	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs281865438	125860	Phenylketonuria	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006	no_assertion_criteria_provided	Likely_pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.58	0.992	H	-5.98	0.995	D	-6.91	0.962	D	0.980	0.969	D	0.990	0.997	D	0.801	0.985	D	0.827	0.938	0.950	0.628	D	c	0.950	0.835	1.000	0.747	0.638	0.428	0	5.46	0.799	5.968	0.699	1.199	0.960	1.000	0.715	0.999	0.750	13.073	0.583	ACT_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,833	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
1	216246634	216246634	C	T	exonic	USH2A	.	nonsynonymous_SNV	USH2A:NM_206933:exon28:c.G5581A:p.G1861S	3.68100336207458e-43	0.999989235571568	1.07644284322941e-05	Usher_syndrome_2A_(autosomal_recessive,_mild)	FUNCTION:_Involved_in_hearing_and_vision.\x3b_	DISEASE:_Usher_syndrome_2A_(USH2A)_[MIM:276901]:_USH_is_a_genetically_heterogeneous_condition_characterized_by_the_association_of_retinitis_pigmentosa_with_sensorineural_deafness._Age_at_onset_and_differences_in_auditory_and_vestibular_function_distinguish_Usher_syndrome_type_1_(USH1),_Usher_syndrome_type_2_(USH2)_and_Usher_syndrome_type_3_(USH3)._USH2_is_characterized_by_congenital_mild_hearing_impairment_with_normal_vestibular_responses._{ECO:0000269|PubMed:10729113,_ECO:0000269|PubMed:10738000,_ECO:0000269|PubMed:10909849,_ECO:0000269|PubMed:11311042,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:12525556,_ECO:0000269|PubMed:14970843,_ECO:0000269|PubMed:15015129,_ECO:0000269|PubMed:15025721,_ECO:0000269|PubMed:15241801,_ECO:0000269|PubMed:15325563,_ECO:0000269|PubMed:17085681,_ECO:0000269|PubMed:17405132,_ECO:0000269|PubMed:18273898,_ECO:0000269|PubMed:18452394,_ECO:0000269|PubMed:19683999,_ECO:0000269|PubMed:19737284,_ECO:0000269|PubMed:20309401,_ECO:0000269|PubMed:20440071,_ECO:0000269|PubMed:20507924,_ECO:0000269|PubMed:21593743,_ECO:0000269|PubMed:21686329,_ECO:0000269|PubMed:22004887,_ECO:0000269|PubMed:23737954,_ECO:0000269|PubMed:9624053}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Retinitis_pigmentosa_39_(RP39)_[MIM:613809]:_A_retinal_dystrophy_belonging_to_the_group_of_pigmentary_retinopathies._Retinitis_pigmentosa_is_characterized_by_retinal_pigment_deposits_visible_on_fundus_examination_and_primary_loss_of_rod_photoreceptor_cells_followed_by_secondary_loss_of_cone_photoreceptors._Patients_typically_have_night_vision_blindness_and_loss_of_midperipheral_visual_field._As_their_condition_progresses,_they_lose_their_far_peripheral_visual_field_and_eventually_central_vision_as_well._{ECO:0000269|PubMed:10775529,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:12427073,_ECO:0000269|PubMed:15325563,_ECO:0000269|PubMed:16098008,_ECO:0000269|PubMed:17296898,_ECO:0000269|PubMed:20507924,_ECO:0000269|PubMed:21686329,_ECO:0000269|PubMed:22334370,_ECO:0000269|PubMed:24227914}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Present_in_the_basement_membrane_of_many,_but_not_all_tissues._Expressed_in_retina,_cochlea,_small_and_large_intestine,_pancreas,_bladder,_prostate,_esophagus,_trachea,_thymus,_salivary_glands,_placenta,_ovary,_fallopian_tube,_uterus_and_testis._Absent_in_many_other_tissues_such_as_heart,_lung,_liver,_kidney_and_brain._In_the_retina,_it_is_present_in_the_basement_membranes_in_the_Bruch's_layer_choroid_capillary_basement_membranes,_where_it_localizes_just_beneath_the_retinal_pigment_epithelial_cells_(at_protein_level)._Weakly_expressed._Isoform_2_is_expressed_in_fetal_eye,_cochlea_and_heart,_and_at_very_low_level_in_brain,_CNS,_intestine,_skeleton,_tongue,_kidney_and_lung._Isoform_2_is_not_expressed_in_stomach_and_liver._In_adult_tissues,_isoform_2_is_expressed_in_neural_retina_and_testis,_and_at_low_level_in_brain,_heart,_kidney_and_liver._Isoform_1_displays_a_similar_pattern_of_expression_but_is_expressed_at_very_low_level_in_fetal_cochlea._{ECO:0000269|PubMed:11788194,_ECO:0000269|PubMed:12433396,_ECO:0000269|PubMed:15015129,_ECO:0000269|PubMed:9624053}.\x3b_	unclassifiable_(Anatomical_System)\x3bliver\x3btestis\x3bretina\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3badrenal_gland\x3btemporal_lobe\x3bciliary_ganglion\x3batrioventricular_node\x3btrigeminal_ganglion\x3bskin\x3bskeletal_muscle\x3bcerebellum\x3b	0.15836	.	4.179636958	99.70511913	6401.91635	16.71188	rs375668376	57697	Usher_syndrome,_type_2A	MedGen:C1848634,OMIM:276901	criteria_provided,_single_submitter	Likely_pathogenic	0.0	0.912	D	0.000	0.457	D	1	0.810	D	3.245	0.900	M	-4.98	0.985	D	-3.99	0.739	D	1.097	0.995	D	0.970	0.991	D	0.912	0.993	D	.	.	0.976	0.757	D	c	0.881	0.845	1.000	0.747	0.487	0.133	0	5.93	0.959	4.591	0.605	0.935	0.490	1.000	0.715	1.000	0.888	20.351	0.988	Concanavalin_A-like_lectin/glucanase_domain|Laminin_G_domain	.	.	.	.	.	.	.	.	.	.	.	.	1.225e-05	0	0	0	0.0002	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,453	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103288623	103288623	G	T	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon3:c.C242A:p.T81N	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs796064502	204456	Phenylketonuria	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006	no_assertion_criteria_provided	Likely_pathogenic	0.0	0.912	D	0.000	0.843	D	0.994	0.423	D	1.895	0.505	L	-4.91	0.984	D	-2.23	0.559	N	0.788	0.943	D	0.884	0.962	D	0.688	0.974	D	0.562	0.683	0.944	0.609	D	c	0.459	0.546	1.000	0.747	0.615	0.372	0	5.28	0.740	5.354	0.656	1.048	0.713	1.000	0.715	0.997	0.653	5.992	0.186	ACT_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,813	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103288572	103288572	A	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon3:c.T293C:p.L98S	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62517167	15666	Mild_non-PKU_hyperphenylalanemia|not_provided	MedGen:C2678416|MedGen:CN517202	no_assertion_criteria_provided	Pathogenic	0.047	0.912	D	0.000	0.843	D	1	0.810	A	3.735	0.950	H	-6.16	0.996	D	-1.65	0.508	N	1.092	0.993	D	0.987	0.996	D	0.651	0.971	D	0.89	0.973	0.987	0.857	D	c	0.889	0.858	1.000	0.747	0.615	0.372	0	6.17	0.997	8.297	0.898	1.199	0.960	1.000	0.715	0.849	0.354	16.822	0.856	ACT_domain	.	.	.	.	.	.	.	.	.	.	.	.	2.031e-05	0	0	0	0	0	0	0	0.0002	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,811	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103288554	103288554	G	T	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon3:c.C311A:p.A104D	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62642929	108386	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	0.65	0.408	T	0.000	0.629	D	1.000	0.490	D	1.385	0.346	L	-4.84	0.982	D	-1.12	0.314	N	0.634	0.923	D	0.843	0.948	D	0.200	0.867	D	.	.	0.904	0.513	D	c	-0.194	0.012	1.000	0.517	0.615	0.372	0	5.29	0.743	2.770	0.471	1.048	0.713	1.000	0.715	0.989	0.536	13.538	0.610	ACT_domain	.	.	.	.	.	.	.	.	.	.	.	.	5.28e-05	0	0	0	0	8.969e-05	8.955e-05	0.0002	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,809	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246654	103246654	G	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.C781G:p.R261G	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs5030850	137051	Phenylketonuria	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006	no_assertion_criteria_provided	Likely_pathogenic	0.002	0.912	D	0.000	0.843	D	1	0.810	D	3.39	0.917	M	-6.73	0.998	D	-6.59	0.920	D	0.979	0.968	D	0.990	0.997	D	0.718	0.977	D	0.912	0.983	0.952	0.637	D	c	0.649	0.573	0.982	0.302	0.638	0.428	0	3.79	0.426	2.806	0.474	1.048	0.713	1.000	0.715	1.000	0.888	14.330	0.660	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	4.063e-06	0	0	0	5.798e-05	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,740	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246653	103246653	C	T	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.G782A:p.R261Q	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs5030849	15621	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	D	3.98	0.967	H	-6.71	0.998	D	-3.75	0.711	D	0.960	0.965	D	0.994	0.999	D	0.448	0.943	D	.	.	0.984	0.825	D	c	1.024	0.955	1.000	0.747	0.638	0.428	0	5.72	0.893	7.905	0.864	0.935	0.490	1.000	0.715	1.000	0.888	19.876	0.969	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	0.0001	0	0.0012	0	0	0	0.0002	0	0.0002	6.534e-05	8.937e-05	0.0004	0.0001	4.485e-05	0.0004	0.0002	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,738	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246653	103246653	C	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.G782C:p.R261P	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs5030849	108568	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_single_submitter	Likely_pathogenic	0.013	0.564	D	0.000	0.843	D	1	0.810	D	4.67	0.994	H	-6.75	0.998	D	-6.44	0.913	D	0.940	0.962	D	0.995	0.999	D	0.616	0.967	D	0.959	0.996	0.989	0.877	D	c	1.069	0.982	1.000	0.747	0.638	0.428	0	5.72	0.893	7.905	0.864	0.935	0.490	1.000	0.715	1.000	0.888	19.876	0.969	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,737	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246650	103246650	A	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.T785G:p.V262G	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs281865445	125879	Phenylketonuria	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006	no_assertion_criteria_provided	Likely_pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.48	0.989	H	-6.6	0.997	D	-6.54	0.918	D	0.938	0.962	D	0.993	0.998	D	0.701	0.976	D	0.767	0.895	0.991	0.906	D	c	1.047	0.960	1.000	0.747	0.638	0.428	0	5.72	0.893	9.325	0.960	1.199	0.960	1.000	0.715	1.000	0.888	15.998	0.800	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,736	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
10	89711903	89711903	A	G	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon6:c.A521G:p.Y174C,PTEN:NM_001304717:exon7:c.A1040G:p.Y347C	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs864622341	222000	Hereditary_cancer-predisposing_syndrome|PTEN_hamartoma_tumor_syndrome|not_specified|not_provided	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498|MedGen:CN169374|MedGen:CN517202	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.0	0.912	D	0.000	0.629	D	1	0.810	D	3.975	0.967	H	-5.23	0.989	D	-8.24	0.969	D	1.042	0.979	D	0.982	0.994	D	0.873	0.990	D	0.884	0.970	0.964	0.685	D	c	0.983	0.907	1.000	0.747	0.722	0.854	0	5.74	0.900	8.820	0.916	1.140	0.893	1.000	0.715	1.000	0.888	16.045	0.804	Protein-tyrosine_phosphatase,_catalytic|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,564	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
10	89711902	89711902	T	A	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon6:c.T520A:p.Y174N,PTEN:NM_001304717:exon7:c.T1039A:p.Y347N	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs587782316	151934	Hereditary_cancer-predisposing_syndrome	MedGen:C0027672,SNOMED_CT:699346009	criteria_provided,_single_submitter	Likely_pathogenic	0.0	0.912	D	0.000	0.629	D	1	0.810	D	3.975	0.967	H	-5.23	0.989	D	-8.23	0.969	D	1.046	0.980	D	0.981	0.994	D	0.912	0.994	D	0.854	0.954	0.953	0.640	D	c	0.926	0.855	1.000	0.747	0.722	0.854	0	5.74	0.900	7.568	0.814	1.011	0.635	1.000	0.715	1.000	0.888	16.045	0.804	Protein-tyrosine_phosphatase,_catalytic|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,563	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
10	89711899	89711899	C	T	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon6:c.C517T:p.R173C,PTEN:NM_001304717:exon7:c.C1036T:p.R346C	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs121913293	187363	Neoplasm_of_brain|Hereditary_cancer-predisposing_syndrome|PTEN_hamartoma_tumor_syndrome|not_provided	Human_Phenotype_Ontology:HP:0030692,MeSH:D001932,MedGen:C0006118,SNOMED_CT:126952004|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.035	0.970	H	-5.24	0.989	D	-7.16	0.941	D	1.058	0.983	D	0.981	0.994	D	0.820	0.986	D	.	.	0.951	0.631	D	c	0.972	0.909	1.000	0.747	0.722	0.854	0	5.74	0.900	7.464	0.798	0.892	0.403	1.000	0.715	1.000	0.888	19.931	0.971	Protein-tyrosine_phosphatase,_catalytic|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,562	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
10	89711892	89711892	T	A	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon6:c.T510A:p.S170R,PTEN:NM_001304717:exon7:c.T1029A:p.S343R	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs121909221	22854	Bannayan-Riley-Ruvalcaba_syndrome	MedGen:C0265326,OMIM:153480,Orphanet:ORPHA109	no_assertion_criteria_provided	Pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	A	4.125	0.975	H	-5.21	0.989	D	-4.58	0.788	D	1.127	0.999	D	0.975	0.992	D	0.916	0.994	D	0.895	0.976	0.862	0.451	D	c	0.767	0.680	1.000	0.473	0.722	0.854	0	4.6	0.564	2.790	0.473	1.011	0.635	1.000	0.715	1.000	0.888	9.290	0.367	Protein-tyrosine_phosphatase,_catalytic|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,559	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
10	89711882	89711882	C	A	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon6:c.C500A:p.T167N,PTEN:NM_001304717:exon7:c.C1019A:p.T340N	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs397514559	48267	Macrocephaly/autism_syndrome	MedGen:C1854416,OMIM:605309,Orphanet:ORPHA210548	no_assertion_criteria_provided	Pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	D	2.83	0.826	M	-5.07	0.987	D	-4.58	0.788	D	1.095	0.994	D	0.972	0.991	D	0.842	0.988	D	0.378	0.394	0.958	0.662	D	c	0.861	0.838	1.000	0.747	0.722	0.854	0	5.74	0.900	7.464	0.798	0.892	0.403	1.000	0.715	1.000	0.888	19.931	0.971	Protein-tyrosine_phosphatase,_catalytic|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,557	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
10	89692993	89692993	G	T	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon5:c.G477T:p.R159S,PTEN:NM_001304717:exon6:c.G996T:p.R332S	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs1057519724	362838	Neoplasm_of_the_breast|Colorectal_Neoplasms	Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|MeSH:D015179,MedGen:CN236642	no_assertion_criteria_provided	Pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.15	0.976	H	-6.67	0.998	D	-5.79	0.880	D	0.921	0.960	D	0.994	0.999	D	0.885	0.991	D	0.843	0.948	0.991	0.918	D	c	0.992	0.899	1.000	0.747	0.722	0.854	0	5.09	0.685	9.525	0.971	0.953	0.551	1.000	0.715	1.000	0.888	18.493	0.908	Dual_specificity_phosphatase,_catalytic_domain|Protein-tyrosine_phosphatase,_catalytic|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain\x3bDual_specificity_phosphatase,_catalytic_domain|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,554	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
10	89692923	89692923	G	A	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon5:c.G407A:p.C136Y,PTEN:NM_001304717:exon6:c.G926A:p.C309Y	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs786204859	187355	Hereditary_cancer-predisposing_syndrome|PTEN_hamartoma_tumor_syndrome|not_provided	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	0.008	0.586	D	0.000	0.843	D	1	0.810	D	3.71	0.948	H	-5.11	0.987	D	-8.88	0.979	D	1.044	0.980	D	0.982	0.994	D	0.921	0.994	D	0.919	0.985	0.985	0.834	D	c	1.007	0.922	1.000	0.747	0.722	0.854	0	5.22	0.722	9.525	0.971	0.953	0.551	1.000	0.715	1.000	0.888	18.778	0.918	Dual_specificity_phosphatase,_catalytic_domain|Protein-tyrosine_phosphatase,_catalytic|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain\x3bDual_specificity_phosphatase,_catalytic_domain|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,551	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
10	89692911	89692911	G	A	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon5:c.G395A:p.G132D,PTEN:NM_001304717:exon6:c.G914A:p.G305D	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs121909241	98729	PTEN_hamartoma_tumor_syndrome|not_specified|not_provided	MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498|MedGen:CN169374|MedGen:CN517202	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.16	0.977	H	-6.17	0.996	D	-6.29	0.907	D	0.935	0.962	D	0.993	0.998	D	0.932	0.995	D	0.984	0.998	0.985	0.834	D	c	1.066	0.960	1.000	0.747	0.722	0.854	0	5.22	0.722	9.525	0.971	0.953	0.551	1.000	0.715	1.000	0.888	18.778	0.918	Dual_specificity_phosphatase,_catalytic_domain|Protein-tyrosine_phosphatase,_catalytic|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain\x3bDual_specificity_phosphatase,_catalytic_domain|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,550	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
10	89692908	89692908	C	T	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon5:c.C392T:p.T131I,PTEN:NM_001304717:exon6:c.C911T:p.T304I	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs397514560	48268	Macrocephaly/autism_syndrome	MedGen:C1854416,OMIM:605309,Orphanet:ORPHA210548	no_assertion_criteria_provided	Pathogenic	0.0	0.912	D	0.000	0.629	D	1	0.810	D	3.1	0.878	M	-5.89	0.994	D	-5.79	0.880	D	1.018	0.975	D	0.987	0.996	D	0.880	0.991	D	0.825	0.937	0.971	0.724	D	c	0.869	0.797	1.000	0.747	0.722	0.854	0	5.09	0.685	7.510	0.804	0.852	0.362	1.000	0.715	1.000	0.888	18.493	0.908	Dual_specificity_phosphatase,_catalytic_domain|Protein-tyrosine_phosphatase,_catalytic|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain\x3bDual_specificity_phosphatase,_catalytic_domain|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,549	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
10	89692905	89692905	G	A	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon5:c.G389A:p.R130Q,PTEN:NM_001304717:exon6:c.G908A:p.R303Q	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs121909229	22868	Small_cell_lung_cancer|Renal_cell_carcinoma,_papillary,_1|Squamous_cell_lung_carcinoma|Neoplasm_of_the_breast|Glioblastoma|Squamous_cell_carcinoma_of_the_head_and_neck|Malignant_melanoma_of_skin|Uterine_cervical_neoplasms|Neoplasm|Ovarian_Neoplasms|Colorectal_Neoplasms|Adenocarcinoma_of_prostate|Hereditary_cancer-predisposing_syndrome|Malignant_neoplasm_of_body_of_uterus|Adenocarcinoma_of_stomach|Uterine_Carcinosarcoma|PTEN_hamartoma_tumor_syndrome|Cowden_syndrome_1|not_provided	Gene:7864,Human_Phenotype_Ontology:HP:0030357,MeSH:D055752,MedGen:C0149925,OMIM:182280,Orphanet:ORPHA70573|Human_Phenotype_Ontology:HP:0005584,MeSH:D002292,MedGen:C0007134,OMIM:605074,Orphanet:ORPHA217071,SNOMED_CT:41607009|Human_Phenotype_Ontology:HP:0030359,MedGen:C0149782|Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|Human_Phenotype_Ontology:HP:0100843,MeSH:D005909,MedGen:C0017636,SNOMED_CT:63634009|MeSH:C535575,MedGen:C1168401,OMIM:275355,Orphanet:ORPHA67037|MeSH:C562393,MedGen:C0151779,SNOMED_CT:93655004|MeSH:D002583,MedGen:CN236667|MeSH:D009369,MedGen:C0027651,SNOMED_CT:108369006|MeSH:D010051,MedGen:CN236629|MeSH:D015179,MedGen:CN236642|MedGen:C0007112|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0153574,Orphanet:ORPHA213569|MedGen:C0278701|MedGen:C0280630|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498|MedGen:CN072330,OMIM:158350|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	A	3.615	0.940	H	-4.88	0.983	D	-3.86	0.724	D	1.062	0.984	D	0.978	0.993	D	0.849	0.988	D	0.98	0.998	0.985	0.834	D	c	1.012	0.926	1.000	0.747	0.722	0.854	0	5.22	0.722	9.525	0.971	0.953	0.551	1.000	0.715	1.000	0.888	18.778	0.918	Dual_specificity_phosphatase,_catalytic_domain|Protein-tyrosine_phosphatase,_catalytic|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain\x3bDual_specificity_phosphatase,_catalytic_domain|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,548	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
10	89692904	89692904	C	G	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon5:c.C388G:p.R130G,PTEN:NM_001304717:exon6:c.C907G:p.R303G	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs121909224	362837	Small_cell_lung_cancer|Renal_cell_carcinoma,_papillary,_1|Squamous_cell_lung_carcinoma|Neoplasm_of_the_breast|Glioblastoma|Squamous_cell_carcinoma_of_the_head_and_neck|Malignant_melanoma_of_skin|Uterine_cervical_neoplasms|Ovarian_Neoplasms|Colorectal_Neoplasms|Adenocarcinoma_of_prostate|Malignant_tumor_of_floor_of_mouth|Malignant_neoplasm_of_body_of_uterus|Adenocarcinoma_of_stomach|Uterine_Carcinosarcoma	Gene:7864,Human_Phenotype_Ontology:HP:0030357,MeSH:D055752,MedGen:C0149925,OMIM:182280,Orphanet:ORPHA70573|Human_Phenotype_Ontology:HP:0005584,MeSH:D002292,MedGen:C0007134,OMIM:605074,Orphanet:ORPHA217071,SNOMED_CT:41607009|Human_Phenotype_Ontology:HP:0030359,MedGen:C0149782|Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|Human_Phenotype_Ontology:HP:0100843,MeSH:D005909,MedGen:C0017636,SNOMED_CT:63634009|MeSH:C535575,MedGen:C1168401,OMIM:275355,Orphanet:ORPHA67037|MeSH:C562393,MedGen:C0151779,SNOMED_CT:93655004|MeSH:D002583,MedGen:CN236667|MeSH:D010051,MedGen:CN236629|MeSH:D015179,MedGen:CN236642|MedGen:C0007112|MedGen:C0153368|MedGen:C0153574,Orphanet:ORPHA213569|MedGen:C0278701|MedGen:C0280630	no_assertion_criteria_provided	Pathogenic/Likely_pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.165	0.977	H	-4.89	0.983	D	-6.75	0.927	D	1.026	0.976	D	0.982	0.995	D	0.898	0.992	D	0.965	0.997	0.960	0.669	D	c	0.960	0.848	1.000	0.747	0.722	0.854	0	5.22	0.722	5.574	0.669	0.852	0.362	1.000	0.715	1.000	0.888	18.778	0.918	Dual_specificity_phosphatase,_catalytic_domain|Protein-tyrosine_phosphatase,_catalytic|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain\x3bDual_specificity_phosphatase,_catalytic_domain|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,547	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
10	89692886	89692886	T	C	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon5:c.T370C:p.C124R,PTEN:NM_001304717:exon6:c.T889C:p.C297R	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs121909223	22856	Cowden_syndrome_1|not_provided	MedGen:CN072330,OMIM:158350|MedGen:CN517202	criteria_provided,_single_submitter	Pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	A	4.17	0.977	H	-7.6	0.999	D	-11.71	0.995	D	0.888	0.955	D	0.997	0.999	D	0.850	0.989	D	0.941	0.992	0.970	0.721	D	c	0.964	0.851	1.000	0.747	0.722	0.854	0	5.22	0.722	7.615	0.821	0.964	0.580	1.000	0.715	1.000	0.888	15.102	0.718	Dual_specificity_phosphatase,_catalytic_domain|Protein-tyrosine_phosphatase,_catalytic|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain\x3bDual_specificity_phosphatase,_catalytic_domain|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,546	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
10	89692884	89692884	A	G	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon5:c.A368G:p.H123R,PTEN:NM_001304717:exon6:c.A887G:p.H296R	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs121909222	22855	Cowden_syndrome_1|not_provided	MedGen:CN072330,OMIM:158350|MedGen:CN517202	criteria_provided,_single_submitter	Pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	A	4.18	0.978	H	-7.71	0.999	D	-7.8	0.959	D	0.890	0.955	D	0.998	0.999	D	0.830	0.987	D	0.955	0.995	0.981	0.792	D	c	0.997	0.886	1.000	0.747	0.722	0.854	0	5.22	0.722	8.875	0.919	1.088	0.866	1.000	0.715	1.000	0.888	15.102	0.718	Dual_specificity_phosphatase,_catalytic_domain|Protein-tyrosine_phosphatase,_catalytic|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain\x3bDual_specificity_phosphatase,_catalytic_domain|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,545	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
10	89692854	89692854	G	T	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon5:c.G338T:p.S113I,PTEN:NM_001304717:exon6:c.G857T:p.S286I	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs587781254	143197	PTEN_hamartoma_tumor_syndrome	MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498	no_assertion_criteria_provided	Pathogenic	0.029	0.457	D	0.000	0.843	D	1	0.810	D	1.655	0.426	L	-5.11	0.987	D	-4.09	0.748	D	1.090	0.992	D	0.958	0.986	D	0.751	0.980	D	0.369	0.379	0.987	0.852	D	c	0.785	0.777	1.000	0.747	0.722	0.854	0	5.22	0.722	9.525	0.971	0.953	0.551	1.000	0.715	1.000	0.888	18.778	0.918	Dual_specificity_phosphatase,_catalytic_domain|Protein-tyrosine_phosphatase,_catalytic|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain\x3bDual_specificity_phosphatase,_catalytic_domain|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,542	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
10	89692847	89692847	T	C	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon5:c.T331C:p.W111R,PTEN:NM_001304717:exon6:c.T850C:p.W284R	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs398123321	98727	not_provided	MedGen:CN517202	criteria_provided,_single_submitter	Likely_pathogenic	0.012	0.546	D	0.000	0.843	D	1	0.810	D	3.885	0.961	H	-5.04	0.986	D	-12.46	0.997	D	1.081	0.989	D	0.972	0.991	D	0.800	0.984	D	0.904	0.979	0.977	0.764	D	c	0.771	0.714	1.000	0.747	0.722	0.854	0	5.07	0.680	7.611	0.820	0.964	0.580	1.000	0.715	1.000	0.888	14.841	0.697	Dual_specificity_phosphatase,_catalytic_domain|Protein-tyrosine_phosphatase,_catalytic|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain\x3bDual_specificity_phosphatase,_catalytic_domain|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,541	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
10	89692836	89692836	A	T	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon5:c.A320T:p.D107V,PTEN:NM_001304717:exon6:c.A839T:p.D280V	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs786204858	359885	PTEN_hamartoma_tumor_syndrome|not_provided	MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	D	2.935	0.849	M	-2.08	0.860	D	-8.54	0.974	D	0.591	0.918	D	0.760	0.918	D	0.512	0.953	D	0.436	0.489	0.986	0.850	D	c	0.736	0.710	1.000	0.747	0.722	0.854	0	5.07	0.680	8.871	0.919	1.088	0.866	1.000	0.715	1.000	0.888	14.841	0.697	Dual_specificity_phosphatase,_catalytic_domain|Protein-tyrosine_phosphatase,_catalytic|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain\x3bDual_specificity_phosphatase,_catalytic_domain|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,540	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
10	89692800	89692800	C	T	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon5:c.C284T:p.P95L,PTEN:NM_001304717:exon6:c.C803T:p.P268L	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs786204856	187345	PTEN_hamartoma_tumor_syndrome	MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498	criteria_provided,_single_submitter	Pathogenic	0.001	0.784	D	0.000	0.843	D	1	0.810	D	3.345	0.912	M	-4.99	0.985	D	-7.78	0.959	D	1.100	0.996	D	0.965	0.989	D	0.784	0.983	D	0.543	0.656	0.979	0.776	D	c	0.809	0.763	1.000	0.747	0.732	0.924	0	5.07	0.680	7.506	0.804	0.852	0.362	1.000	0.715	0.999	0.750	18.458	0.906	Protein-tyrosine_phosphatase,_catalytic|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain\x3bProtein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,536	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
10	89685314	89685314	T	C	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon3:c.T209C:p.L70P,PTEN:NM_001304717:exon4:c.T728C:p.L243P	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs121909226	22865	Cowden_syndrome_1	MedGen:CN072330,OMIM:158350	no_assertion_criteria_provided	Pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	A	3.995	0.968	H	-5.28	0.990	D	-6.77	0.928	D	1.036	0.978	D	0.982	0.995	D	.	.	.	0.833	0.942	0.986	0.845	D	c	0.995	0.895	1.000	0.747	0.742	0.980	0	5.46	0.799	7.425	0.793	1.061	0.807	1.000	0.715	1.000	0.888	15.525	0.755	Protein-tyrosine_phosphatase,_catalytic|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain\x3bProtein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain	.	.	0.9701	0.918	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,529	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
10	89685286	89685286	C	G	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon3:c.C181G:p.H61D,PTEN:NM_001304717:exon4:c.C700G:p.H234D	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs121909236	22880	Vater_association_with_macrocephaly_and_ventriculomegaly	MedGen:C2749240	no_assertion_criteria_provided	Pathogenic	0.003	0.682	D	0.000	0.843	D	1	0.810	A	3.79	0.954	H	-5.02	0.986	D	-8.28	0.969	D	1.049	0.981	D	0.980	0.994	D	0.786	0.983	D	0.803	0.922	0.990	0.900	D	c	0.998	0.909	1.000	0.747	0.707	0.730	0	5.46	0.799	7.323	0.782	0.935	0.490	1.000	0.715	1.000	0.888	19.299	0.941	Protein-tyrosine_phosphatase,_catalytic|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain\x3bProtein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,527	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
10	89653806	89653806	T	G	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon2:c.T104G:p.M35R,PTEN:NM_001304717:exon3:c.T623G:p.M208R	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs121909225	22864	Cowden_syndrome_1	MedGen:CN072330,OMIM:158350	no_assertion_criteria_provided	Pathogenic	0.001	0.784	D	0.000	0.843	D	1	0.810	A	3.825	0.957	H	-5.06	0.986	D	-5.84	0.884	D	1.065	0.985	D	0.978	0.993	D	0.880	0.991	D	0.969	0.997	0.968	0.707	D	c	0.873	0.787	1.000	0.747	0.732	0.924	0	5.19	0.713	7.532	0.807	1.061	0.807	1.000	0.715	1.000	0.888	14.014	0.639	Protein-tyrosine_phosphatase,_catalytic|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain\x3bProtein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,523	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
10	89653805	89653805	A	G	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon2:c.A103G:p.M35V,PTEN:NM_001304717:exon3:c.A622G:p.M208V	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs876659443	233842	Inborn_genetic_diseases|PTEN_hamartoma_tumor_syndrome|not_provided	MeSH:D030342,MedGen:C0950123|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498|MedGen:CN517202	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.002	0.721	D	0.000	0.843	D	1	0.810	D	2.26	0.646	M	-5.03	0.986	D	-3.88	0.727	D	1.086	0.991	D	0.959	0.987	D	0.750	0.980	D	0.915	0.984	0.976	0.755	D	c	0.716	0.699	1.000	0.747	0.732	0.924	0	5.19	0.713	8.777	0.914	1.199	0.960	1.000	0.715	1.000	0.888	14.014	0.639	Protein-tyrosine_phosphatase,_catalytic|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain\x3bProtein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,522	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
10	89624270	89624270	G	A	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon1:c.G44A:p.R15K,PTEN:NM_001304717:exon2:c.G563A:p.R188K	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs398123324	397912	PTEN_hamartoma_tumor_syndrome|not_provided	MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498|MedGen:CN517202	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.0	0.912	D	0.000	0.629	D	1	0.810	D	3.44	0.923	M	-3.81	0.957	D	-2.48	0.540	N	0.744	0.937	D	0.865	0.955	D	0.916	0.994	D	0.502	0.595	0.947	0.618	D	c	0.297	0.409	1.0	0.983	0.733	0.969	0	5.05	0.674	8.949	0.929	0.956	0.564	1.000	0.715	1.000	0.888	17.161	0.866	Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,514	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
10	73464800	73464800	G	A	exonic	CDH23	.	nonsynonymous_SNV	CDH23:NM_001171930:exon24:c.G2866A:p.E956K,CDH23:NM_001171931:exon24:c.G2866A:p.E956K,CDH23:NM_022124:exon24:c.G2866A:p.E956K	0.0506929591139338	0.949268622794338	3.84180917276542e-05	cadherin-related_23	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells._CDH23_is_required_for_establishing_and/or_maintaining_the_proper_organization_of_the_stereocilia_bundle_of_hair_cells_in_the_cochlea_and_the_vestibule_during_late_embryonic/early_postnatal_development._It_is_part_of_the_functional_network_formed_by_USH1C,_USH1G,_CDH23_and_MYO7A_that_mediates_mechanotransduction_in_cochlear_hair_cells._Required_for_normal_hearing.\x3b_	DISEASE:_Usher_syndrome_1D_(USH1D)_[MIM:601067]:_USH_is_a_genetically_heterogeneous_condition_characterized_by_the_association_of_retinitis_pigmentosa_with_sensorineural_deafness._Age_at_onset_and_differences_in_auditory_and_vestibular_function_distinguish_Usher_syndrome_type_1_(USH1),_Usher_syndrome_type_2_(USH2)_and_Usher_syndrome_type_3_(USH3)._USH1_is_characterized_by_profound_congenital_sensorineural_deafness,_absent_vestibular_function_and_prepubertal_onset_of_progressive_retinitis_pigmentosa_leading_to_blindness._{ECO:0000269|PubMed:11138009,_ECO:0000269|PubMed:12075507,_ECO:0000269|PubMed:15660226,_ECO:0000269|PubMed:16679490,_ECO:0000269|PubMed:18429043}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Usher_syndrome_1D/F_(USH1DF)_[MIM:601067]:_USH1DF_patients_are_heterozygous_for_mutations_in_CDH23_and_PCDH15,_indicating_a_digenic_inheritance_pattern._{ECO:0000269|PubMed:15537665}._Note\x3dThe_disease_is_caused_by_mutations_affecting_distinct_genetic_loci,_including_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_recessive,_12_(DFNB12)_[MIM:601386]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:11090341,_ECO:0000269|PubMed:12075507,_ECO:0000269|PubMed:12522556,_ECO:0000269|PubMed:15829536,_ECO:0000269|PubMed:16679490,_ECO:0000269|PubMed:17850630,_ECO:0000269|PubMed:22899989,_ECO:0000269|PubMed:24767429}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Particularly_strong_expression_in_the_retina._Found_also_in_the_cochlea.\x3b_	medulla_oblongata\x3bovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bfovea_centralis\x3bchoroid\x3bskin\x3bbone_marrow\x3bretina\x3bprostate\x3boptic_nerve\x3bbone\x3btestis\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bpharynx\x3bblood\x3blens\x3bbreast\x3bpancreas\x3blung\x3bmacula_lutea\x3bvisual_apparatus\x3bliver\x3bspleen\x3bkidney\x3bstomach\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bsubthalamic_nucleus\x3btestis_-_interstitial\x3bglobus_pallidus\x3bciliary_ganglion\x3bpons\x3batrioventricular_node\x3btrigeminal_ganglion\x3bcerebellum\x3b	0.32126	0.20307	-1.837761842	2.05826846	23222.44281	31.45196	rs756147087	437859	Deafness,_autosomal_recessive_12|not_provided	MedGen:C1832394,OMIM:601386|MedGen:CN517202	criteria_provided,_single_submitter	Pathogenic	.	.	.	0.000	0.629	D	1	0.810	D	4.075	0.972	H	.	.	.	.	.	.	0.196	0.858	D	0.558	0.839	D	0.543	0.958	D	.	.	0.992	0.923	D	c	0.962	0.918	1.0	0.983	0.554	0.283	0	5.5	0.813	9.964	0.990	1.048	0.713	1.000	0.715	0.980	0.490	19.374	0.945	Cadherin|Cadherin-like	.	.	.	.	6.476e-05	0.0002	0	0	0	0	0	0	3.284e-05	0.0003	2.982e-05	0	5.831e-05	0	0	0	6.505e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,497	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
7	140501333	140501333	A	G	exonic	BRAF	.	nonsynonymous_SNV	BRAF:NM_004333:exon6:c.T739C:p.F247L	0.999978196041997	2.18039579639691e-05	3.88216441101404e-14	B-Raf_proto-oncogene,_serine/threonine_kinase	FUNCTION:_Protein_kinase_involved_in_the_transduction_of_mitogenic_signals_from_the_cell_membrane_to_the_nucleus._May_play_a_role_in_the_postsynaptic_responses_of_hippocampal_neuron._Phosphorylates_MAP2K1,_and_thereby_contributes_to_the_MAP_kinase_signal_transduction_pathway._{ECO:0000269|PubMed:21441910}.\x3b_	DISEASE:_Note\x3dDefects_in_BRAF_are_found_in_a_wide_range_of_cancers._{ECO:0000269|PubMed:18974108}.\x3b_DISEASE:_Colorectal_cancer_(CRC)_[MIM:114500]:_A_complex_disease_characterized_by_malignant_lesions_arising_from_the_inner_wall_of_the_large_intestine_(the_colon)_and_the_rectum._Genetic_alterations_are_often_associated_with_progression_from_premalignant_lesion_(adenoma)_to_invasive_adenocarcinoma._Risk_factors_for_cancer_of_the_colon_and_rectum_include_colon_polyps,_long-standing_ulcerative_colitis,_and_genetic_family_history._{ECO:0000269|PubMed:12198537,_ECO:0000269|PubMed:23263490,_ECO:0000269|PubMed:24455489}._Note\x3dThe_disease_may_be_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lung_cancer_(LNCR)_[MIM:211980]:_A_common_malignancy_affecting_tissues_of_the_lung._The_most_common_form_of_lung_cancer_is_non-small_cell_lung_cancer_(NSCLC)_that_can_be_divided_into_3_major_histologic_subtypes:_squamous_cell_carcinoma,_adenocarcinoma,_and_large_cell_lung_cancer._NSCLC_is_often_diagnosed_at_an_advanced_stage_and_has_a_poor_prognosis._{ECO:0000269|PubMed:12460919}._Note\x3dThe_gene_represented_in_this_entry_is_involved_in_disease_pathogenesis.\x3b_DISEASE:_Familial_non-Hodgkin_lymphoma_(NHL)_[MIM:605027]:_Cancer_that_starts_in_cells_of_the_lymph_system,_which_is_part_of_the_body's_immune_system._NHLs_can_occur_at_any_age_and_are_often_marked_by_enlarged_lymph_nodes,_fever_and_weight_loss._{ECO:0000269|PubMed:14612909}._Note\x3dThe_gene_represented_in_this_entry_is_involved_in_disease_pathogenesis.\x3b_DISEASE:_Cardiofaciocutaneous_syndrome_1_(CFC1)_[MIM:115150]:_A_multiple_congenital_anomaly_disorder_characterized_by_a_distinctive_facial_appearance,_heart_defects_and_mental_retardation._Heart_defects_include_pulmonic_stenosis,_atrial_septal_defects_and_hypertrophic_cardiomyopathy._Some_affected_individuals_present_with_ectodermal_abnormalities_such_as_sparse,_friable_hair,_hyperkeratotic_skin_lesions_and_a_generalized_ichthyosis-like_condition._Typical_facial_features_are_similar_to_Noonan_syndrome._They_include_high_forehead_with_bitemporal_constriction,_hypoplastic_supraorbital_ridges,_downslanting_palpebral_fissures,_a_depressed_nasal_bridge,_and_posteriorly_angulated_ears_with_prominent_helices._{ECO:0000269|PubMed:16439621,_ECO:0000269|PubMed:16474404,_ECO:0000269|PubMed:18042262,_ECO:0000269|PubMed:19206169}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Noonan_syndrome_7_(NS7)_[MIM:613706]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._{ECO:0000269|PubMed:19206169}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_LEOPARD_syndrome_3_(LPRD3)_[MIM:613707]:_A_disorder_characterized_by_lentigines,_electrocardiographic_conduction_abnormalities,_ocular_hypertelorism,_pulmonic_stenosis,_abnormalities_of_genitalia,_retardation_of_growth,_and_sensorineural_deafness._{ECO:0000269|PubMed:19206169}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_BRAF_is_found_in_pilocytic_astrocytomas._A_tandem_duplication_of_2_Mb_at_7q34_leads_to_the_expression_of_a_KIAA1549-BRAF_fusion_protein_with_a_constitutive_kinase_activity_and_inducing_cell_transformation._{ECO:0000269|PubMed:18974108}.\x3b_	TISSUE_SPECIFICITY:_Brain_and_testis.\x3b_	unclassifiable_(Anatomical_System)\x3bamygdala\x3bislets_of_Langerhans\x3bwhole_body\x3blung\x3bfrontal_lobe\x3bplacenta\x3bthyroid\x3bliver\x3btestis\x3bhead_and_neck\x3bspleen\x3bgerminal_center\x3bbrain\x3bstomach\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3btestis\x3bciliary_ganglion\x3batrioventricular_node\x3bpons\x3btrigeminal_ganglion\x3b	0.95401	.	-0.60427181	17.74593064	63.2093	1.62731	rs397516903	179102	not_provided	MedGen:CN517202	criteria_provided,_single_submitter	Pathogenic	0.002	0.721	D	0.000	0.843	D	1	0.810	D	3.36	0.914	M	-3.26	0.936	D	-4.06	0.745	D	0.856	0.951	D	0.831	0.943	D	0.332	0.918	D	0.695	0.832	0.991	0.913	D	c	0.675	0.691	1.000	0.747	0.651	0.465	0	5.43	0.789	9.270	0.949	1.194	0.916	1.000	0.715	1.000	0.888	15.498	0.753	Protein_kinase_C-like,_phorbol_ester/diacylglycerol-binding_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,495	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
7	140501331	140501331	A	C	exonic	BRAF	.	nonsynonymous_SNV	BRAF:NM_004333:exon6:c.T741G:p.F247L	0.999978196041997	2.18039579639691e-05	3.88216441101404e-14	B-Raf_proto-oncogene,_serine/threonine_kinase	FUNCTION:_Protein_kinase_involved_in_the_transduction_of_mitogenic_signals_from_the_cell_membrane_to_the_nucleus._May_play_a_role_in_the_postsynaptic_responses_of_hippocampal_neuron._Phosphorylates_MAP2K1,_and_thereby_contributes_to_the_MAP_kinase_signal_transduction_pathway._{ECO:0000269|PubMed:21441910}.\x3b_	DISEASE:_Note\x3dDefects_in_BRAF_are_found_in_a_wide_range_of_cancers._{ECO:0000269|PubMed:18974108}.\x3b_DISEASE:_Colorectal_cancer_(CRC)_[MIM:114500]:_A_complex_disease_characterized_by_malignant_lesions_arising_from_the_inner_wall_of_the_large_intestine_(the_colon)_and_the_rectum._Genetic_alterations_are_often_associated_with_progression_from_premalignant_lesion_(adenoma)_to_invasive_adenocarcinoma._Risk_factors_for_cancer_of_the_colon_and_rectum_include_colon_polyps,_long-standing_ulcerative_colitis,_and_genetic_family_history._{ECO:0000269|PubMed:12198537,_ECO:0000269|PubMed:23263490,_ECO:0000269|PubMed:24455489}._Note\x3dThe_disease_may_be_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lung_cancer_(LNCR)_[MIM:211980]:_A_common_malignancy_affecting_tissues_of_the_lung._The_most_common_form_of_lung_cancer_is_non-small_cell_lung_cancer_(NSCLC)_that_can_be_divided_into_3_major_histologic_subtypes:_squamous_cell_carcinoma,_adenocarcinoma,_and_large_cell_lung_cancer._NSCLC_is_often_diagnosed_at_an_advanced_stage_and_has_a_poor_prognosis._{ECO:0000269|PubMed:12460919}._Note\x3dThe_gene_represented_in_this_entry_is_involved_in_disease_pathogenesis.\x3b_DISEASE:_Familial_non-Hodgkin_lymphoma_(NHL)_[MIM:605027]:_Cancer_that_starts_in_cells_of_the_lymph_system,_which_is_part_of_the_body's_immune_system._NHLs_can_occur_at_any_age_and_are_often_marked_by_enlarged_lymph_nodes,_fever_and_weight_loss._{ECO:0000269|PubMed:14612909}._Note\x3dThe_gene_represented_in_this_entry_is_involved_in_disease_pathogenesis.\x3b_DISEASE:_Cardiofaciocutaneous_syndrome_1_(CFC1)_[MIM:115150]:_A_multiple_congenital_anomaly_disorder_characterized_by_a_distinctive_facial_appearance,_heart_defects_and_mental_retardation._Heart_defects_include_pulmonic_stenosis,_atrial_septal_defects_and_hypertrophic_cardiomyopathy._Some_affected_individuals_present_with_ectodermal_abnormalities_such_as_sparse,_friable_hair,_hyperkeratotic_skin_lesions_and_a_generalized_ichthyosis-like_condition._Typical_facial_features_are_similar_to_Noonan_syndrome._They_include_high_forehead_with_bitemporal_constriction,_hypoplastic_supraorbital_ridges,_downslanting_palpebral_fissures,_a_depressed_nasal_bridge,_and_posteriorly_angulated_ears_with_prominent_helices._{ECO:0000269|PubMed:16439621,_ECO:0000269|PubMed:16474404,_ECO:0000269|PubMed:18042262,_ECO:0000269|PubMed:19206169}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Noonan_syndrome_7_(NS7)_[MIM:613706]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._{ECO:0000269|PubMed:19206169}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_LEOPARD_syndrome_3_(LPRD3)_[MIM:613707]:_A_disorder_characterized_by_lentigines,_electrocardiographic_conduction_abnormalities,_ocular_hypertelorism,_pulmonic_stenosis,_abnormalities_of_genitalia,_retardation_of_growth,_and_sensorineural_deafness._{ECO:0000269|PubMed:19206169}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_BRAF_is_found_in_pilocytic_astrocytomas._A_tandem_duplication_of_2_Mb_at_7q34_leads_to_the_expression_of_a_KIAA1549-BRAF_fusion_protein_with_a_constitutive_kinase_activity_and_inducing_cell_transformation._{ECO:0000269|PubMed:18974108}.\x3b_	TISSUE_SPECIFICITY:_Brain_and_testis.\x3b_	unclassifiable_(Anatomical_System)\x3bamygdala\x3bislets_of_Langerhans\x3bwhole_body\x3blung\x3bfrontal_lobe\x3bplacenta\x3bthyroid\x3bliver\x3btestis\x3bhead_and_neck\x3bspleen\x3bgerminal_center\x3bbrain\x3bstomach\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3btestis\x3bciliary_ganglion\x3batrioventricular_node\x3bpons\x3btrigeminal_ganglion\x3b	0.95401	.	-0.60427181	17.74593064	63.2093	1.62731	rs397509343	70449	not_provided	MedGen:CN517202	criteria_provided,_single_submitter	Pathogenic	0.002	0.721	D	0.000	0.843	D	1.000	0.588	D	3.36	0.914	M	-3.26	0.936	D	-4.06	0.745	D	0.504	0.906	D	0.777	0.924	D	0.344	0.921	D	0.695	0.832	0.934	0.578	D	c	0.362	0.339	0.138	0.172	0.651	0.465	0	3.08	0.344	3.428	0.523	1.194	0.916	1.000	0.715	1.000	0.888	4.597	0.116	Protein_kinase_C-like,_phorbol_ester/diacylglycerol-binding_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,494	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
6	76558195	76558195	C	T	exonic	MYO6	.	nonsynonymous_SNV	MYO6:NM_001300899:exon11:c.C1025T:p.A342V,MYO6:NM_004999:exon11:c.C1025T:p.A342V	0.0177883990936548	0.982211600378647	5.27698444208756e-10	myosin_VI	FUNCTION:_Myosins_are_actin-based_motor_molecules_with_ATPase_activity._Unconventional_myosins_serve_in_intracellular_movements._Myosin_6_is_a_reverse-direction_motor_protein_that_moves_towards_the_minus-end_of_actin_filaments._Has_slow_rate_of_actin-activated_ADP_release_due_to_weak_ATP_binding._Functions_in_a_variety_of_intracellular_processes_such_as_vesicular_membrane_trafficking_and_cell_migration._Required_for_the_structural_integrity_of_the_Golgi_apparatus_via_the_p53-dependent_pro-survival_pathway._Appears_to_be_involved_in_a_very_early_step_of_clathrin-mediated_endocytosis_in_polarized_epithelial_cells._May_act_as_a_regulator_of_F-actin_dynamics._May_play_a_role_in_transporting_DAB2_from_the_plasma_membrane_to_specific_cellular_targets._Required_for_structural_integrity_of_inner_ear_hair_cells_(By_similarity)._{ECO:0000250,_ECO:0000269|PubMed:10519557,_ECO:0000269|PubMed:11447109,_ECO:0000269|PubMed:16507995,_ECO:0000269|PubMed:16949370}.\x3b_	DISEASE:_Deafness,_autosomal_dominant,_22_(DFNA22)_[MIM:606346]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._DFNA22_is_progressive_and_postlingual,_with_onset_during_childhood._By_the_age_of_approximately_50_years,_affected_individuals_invariably_have_profound_sensorineural_deafness._{ECO:0000269|PubMed:11468689}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_recessive,_37_(DFNB37)_[MIM:607821]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:12687499}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_sensorineural,_with_hypertrophic_cardiomyopathy_(DFNHCM)_[MIM:606346]:_An_autosomal_dominant_sensorineural_deafness_associated_with_hypertrophic_cardiomyopathy._{ECO:0000269|PubMed:15060111}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_most_tissues_examined_including_heart,_brain,_placenta,_pancreas,_spleen,_thymus,_prostate,_testis,_ovary,_small_intestine_and_colon._Highest_levels_in_brain,_pancreas,_testis_and_small_intestine._Also_expressed_in_fetal_brain_and_cochlea._Isoform_1_and_isoform_2,_containing_the_small_insert,_and_isoform_4,_containing_neither_insert,_are_expressed_in_unpolarized_epithelial_cells._{ECO:0000269|PubMed:9259267}.\x3b_	.	.	0.26137	0.31948	-0.369255208	28.25548478	419.15519	4.27823	rs145564837	54298	not_specified|Nonsyndromic_Hearing_Loss,_Dominant|Nonsyndromic_Hearing_Loss,_Recessive|not_provided	MedGen:CN169374|MedGen:CN239435|MedGen:CN239439|MedGen:CN517202	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.001	0.784	D	0.000	0.843	D	1	0.810	D	3.54	0.933	H	-3.19	0.932	D	-3.8	0.717	D	1.064	0.984	D	0.924	0.975	D	0.332	0.918	D	.	.	0.978	0.772	D	c	0.824	0.780	1.000	0.747	0.644	0.439	0	5.37	0.769	7.545	0.809	0.935	0.490	1.000	0.715	0.995	0.604	19.119	0.933	Myosin_head,_motor_domain|P-loop_containing_nucleoside_triphosphate_hydrolase	.	.	.	.	0.0013	0.0002	0	0	0	0.0014	0.0021	0.0020	0.0013	0.0003	0.0002	0.0004	0	0.0017	0.0024	0.0013	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,487	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
1	216498754	216498754	T	G	exonic	USH2A	.	nonsynonymous_SNV	USH2A:NM_007123:exon6:c.A1036C:p.N346H,USH2A:NM_206933:exon6:c.A1036C:p.N346H	3.68100336207458e-43	0.999989235571568	1.07644284322941e-05	Usher_syndrome_2A_(autosomal_recessive,_mild)	FUNCTION:_Involved_in_hearing_and_vision.\x3b_	DISEASE:_Usher_syndrome_2A_(USH2A)_[MIM:276901]:_USH_is_a_genetically_heterogeneous_condition_characterized_by_the_association_of_retinitis_pigmentosa_with_sensorineural_deafness._Age_at_onset_and_differences_in_auditory_and_vestibular_function_distinguish_Usher_syndrome_type_1_(USH1),_Usher_syndrome_type_2_(USH2)_and_Usher_syndrome_type_3_(USH3)._USH2_is_characterized_by_congenital_mild_hearing_impairment_with_normal_vestibular_responses._{ECO:0000269|PubMed:10729113,_ECO:0000269|PubMed:10738000,_ECO:0000269|PubMed:10909849,_ECO:0000269|PubMed:11311042,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:12525556,_ECO:0000269|PubMed:14970843,_ECO:0000269|PubMed:15015129,_ECO:0000269|PubMed:15025721,_ECO:0000269|PubMed:15241801,_ECO:0000269|PubMed:15325563,_ECO:0000269|PubMed:17085681,_ECO:0000269|PubMed:17405132,_ECO:0000269|PubMed:18273898,_ECO:0000269|PubMed:18452394,_ECO:0000269|PubMed:19683999,_ECO:0000269|PubMed:19737284,_ECO:0000269|PubMed:20309401,_ECO:0000269|PubMed:20440071,_ECO:0000269|PubMed:20507924,_ECO:0000269|PubMed:21593743,_ECO:0000269|PubMed:21686329,_ECO:0000269|PubMed:22004887,_ECO:0000269|PubMed:23737954,_ECO:0000269|PubMed:9624053}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Retinitis_pigmentosa_39_(RP39)_[MIM:613809]:_A_retinal_dystrophy_belonging_to_the_group_of_pigmentary_retinopathies._Retinitis_pigmentosa_is_characterized_by_retinal_pigment_deposits_visible_on_fundus_examination_and_primary_loss_of_rod_photoreceptor_cells_followed_by_secondary_loss_of_cone_photoreceptors._Patients_typically_have_night_vision_blindness_and_loss_of_midperipheral_visual_field._As_their_condition_progresses,_they_lose_their_far_peripheral_visual_field_and_eventually_central_vision_as_well._{ECO:0000269|PubMed:10775529,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:12427073,_ECO:0000269|PubMed:15325563,_ECO:0000269|PubMed:16098008,_ECO:0000269|PubMed:17296898,_ECO:0000269|PubMed:20507924,_ECO:0000269|PubMed:21686329,_ECO:0000269|PubMed:22334370,_ECO:0000269|PubMed:24227914}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Present_in_the_basement_membrane_of_many,_but_not_all_tissues._Expressed_in_retina,_cochlea,_small_and_large_intestine,_pancreas,_bladder,_prostate,_esophagus,_trachea,_thymus,_salivary_glands,_placenta,_ovary,_fallopian_tube,_uterus_and_testis._Absent_in_many_other_tissues_such_as_heart,_lung,_liver,_kidney_and_brain._In_the_retina,_it_is_present_in_the_basement_membranes_in_the_Bruch's_layer_choroid_capillary_basement_membranes,_where_it_localizes_just_beneath_the_retinal_pigment_epithelial_cells_(at_protein_level)._Weakly_expressed._Isoform_2_is_expressed_in_fetal_eye,_cochlea_and_heart,_and_at_very_low_level_in_brain,_CNS,_intestine,_skeleton,_tongue,_kidney_and_lung._Isoform_2_is_not_expressed_in_stomach_and_liver._In_adult_tissues,_isoform_2_is_expressed_in_neural_retina_and_testis,_and_at_low_level_in_brain,_heart,_kidney_and_liver._Isoform_1_displays_a_similar_pattern_of_expression_but_is_expressed_at_very_low_level_in_fetal_cochlea._{ECO:0000269|PubMed:11788194,_ECO:0000269|PubMed:12433396,_ECO:0000269|PubMed:15015129,_ECO:0000269|PubMed:9624053}.\x3b_	unclassifiable_(Anatomical_System)\x3bliver\x3btestis\x3bretina\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3badrenal_gland\x3btemporal_lobe\x3bciliary_ganglion\x3batrioventricular_node\x3btrigeminal_ganglion\x3bskin\x3bskeletal_muscle\x3bcerebellum\x3b	0.15836	.	4.179636958	99.70511913	6401.91635	16.71188	rs369522997	57509	Usher_syndrome,_type_2A|Retinitis_pigmentosa_39	MedGen:C1848634,OMIM:276901|MedGen:C3151138,OMIM:613809	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	0.0	0.912	D	0.000	0.466	D	1	0.810	D	3.2	0.893	M	-1.37	0.802	T	-2.98	0.672	D	0.490	0.904	D	0.682	0.890	D	0.365	0.926	D	.	.	0.987	0.860	D	c	0.779	0.740	1.000	0.747	0.487	0.133	0	5.36	0.765	7.674	0.830	1.061	0.807	1.000	0.715	0.997	0.653	15.361	0.741	Galactose-binding_domain-like|Laminin,_N-terminal	.	.	.	.	6.46e-05	0	0	0	0	0	0.0001	0	7.325e-05	0	0	0	0	0	0.0002	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,458	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
10	89711927	89711927	T	C	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon6:c.T545C:p.L182S,PTEN:NM_001304717:exon7:c.T1064C:p.L355S	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs794729664	185731	Macrocephaly/autism_syndrome	MedGen:C1854416,OMIM:605309,Orphanet:ORPHA210548	no_assertion_criteria_provided	Pathogenic	0.002	0.721	D	0.000	0.843	D	1	0.810	D	3.03	0.867	M	-5.31	0.990	D	-4.0	0.740	D	1.089	0.992	D	0.971	0.991	D	0.828	0.987	D	0.725	0.860	0.960	0.670	D	c	0.765	0.749	1.000	0.747	0.722	0.854	0	5.73	0.897	7.568	0.814	1.011	0.635	1.000	0.715	0.999	0.750	16.029	0.803	Protein-tyrosine_phosphatase,_catalytic|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,566	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
10	89717715	89717715	T	C	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon7:c.T740C:p.L247S,PTEN:NM_001304718:exon7:c.T149C:p.L50S,PTEN:NM_001304717:exon8:c.T1259C:p.L420S	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs1057519368	224868	Macrocephaly/autism_syndrome	MedGen:C1854416,OMIM:605309,Orphanet:ORPHA210548	no_assertion_criteria_provided	Pathogenic	0.002	0.721	D	0.000	0.843	D	1	0.810	D	2.945	0.851	M	-2.17	0.866	D	-4.12	0.750	D	0.692	0.931	D	0.785	0.927	D	0.569	0.961	D	0.742	0.874	0.973	0.740	D	c	0.727	0.686	1.000	0.747	0.719	0.830	0	5.15	0.702	7.615	0.821	0.913	0.425	1.000	0.715	0.991	0.552	14.966	0.707	C2_domain|Tensin_phosphatase,_C2_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,577	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
10	89717730	89717730	A	G	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon7:c.A755G:p.D252G,PTEN:NM_001304718:exon7:c.A164G:p.D55G,PTEN:NM_001304717:exon8:c.A1274G:p.D425G	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs121909239	22888	Macrocephaly/autism_syndrome	MedGen:C1854416,OMIM:605309,Orphanet:ORPHA210548	no_assertion_criteria_provided	Pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	A	3.265	0.902	M	-5.57	0.992	D	-6.49	0.915	D	1.079	0.989	D	0.975	0.992	D	0.904	0.993	D	0.849	0.952	0.983	0.813	D	c	0.754	0.719	1.000	0.747	0.706	0.609	0	5.15	0.702	8.875	0.919	1.028	0.649	1.000	0.715	0.994	0.587	14.966	0.707	C2_domain|Tensin_phosphatase,_C2_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,578	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103237484	103237484	G	A	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon11:c.C1139T:p.T380M	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62642937	15667	Hyperphenylalaninemia,_non-pku|Phenylketonuria|not_provided	Human_Phenotype_Ontology:HP:0004923,MedGen:C0751435|MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	0.001	0.784	D	0.000	0.843	D	1	0.810	A	4.35	0.985	H	-6.25	0.996	D	-5.78	0.880	D	0.961	0.966	D	0.992	0.998	D	0.886	0.991	D	.	.	0.979	0.777	D	c	0.843	0.690	0.997	0.355	0.638	0.428	0	5.34	0.759	7.984	0.877	0.998	0.613	1.000	0.715	0.661	0.301	19.048	0.930	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	0.0002	0.0003	0.0012	0.0033	0	0	6.67e-05	0	0.0004	0	0.0003	0.0047	5.8e-05	0	0.0004	0.0004	0.0001	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,664	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246639	103246639	T	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.A796C:p.T266P	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62508752	125880	Phenylketonuria	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006	no_assertion_criteria_provided	Likely_pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.6	0.993	H	-6.59	0.997	D	-5.75	0.877	D	0.932	0.961	D	0.993	0.998	D	0.616	0.967	D	.	.	0.986	0.845	D	c	1.026	0.933	1.000	0.747	0.638	0.428	0	5.73	0.897	8.017	0.886	1.061	0.807	1.000	0.715	1.000	0.888	16.014	0.801	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,733	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246635	103246635	T	A	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.A800T:p.Q267L	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs778154939	227028	Phenylketonuria	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006	no_assertion_criteria_provided	Likely_pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	D	3.925	0.964	H	-6.52	0.997	D	-6.71	0.925	D	0.973	0.968	D	0.991	0.998	D	0.641	0.969	D	0.879	0.968	0.985	0.835	D	c	0.941	0.879	1.000	0.747	0.638	0.428	0	5.73	0.897	8.017	0.886	1.061	0.807	1.000	0.715	1.000	0.888	16.014	0.801	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	4.063e-06	0	0	0	5.798e-05	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,730	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246630	103246630	T	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.A805C:p.I269L	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62508692	108578	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_single_submitter	Pathogenic	0.039	0.424	D	0.000	0.843	D	1	0.810	D	2.24	0.636	M	-6.33	0.997	D	-1.65	0.395	N	0.988	0.970	D	0.985	0.995	D	0.490	0.950	D	.	.	0.974	0.742	D	c	0.435	0.514	1.000	0.500	0.638	0.428	0	5.73	0.897	6.271	0.724	1.061	0.807	1.000	0.715	0.999	0.750	16.014	0.801	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	6.459e-05	0	0	0	0	0	0.0001	0	9.345e-05	0	0.0002	0	0	0	0.0001	0.0005	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,726	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246623	103246623	T	A	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.A812T:p.H271L	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475692	125881	Phenylketonuria	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006	no_assertion_criteria_provided	Likely_pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.45	0.988	H	-6.59	0.997	D	-10.54	0.991	D	0.939	0.962	D	0.993	0.998	D	0.629	0.968	D	0.873	0.965	0.985	0.835	D	c	1.007	0.917	1.000	0.747	0.638	0.428	0	5.73	0.897	8.017	0.886	1.061	0.807	1.000	0.715	0.997	0.653	16.014	0.801	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,722	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246617	103246617	G	A	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.C818T:p.S273F	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62514953	15637	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	no_assertion_criteria_provided	Pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	A	3.94	0.965	H	-6.23	0.996	D	-5.57	0.863	D	1.000	0.972	D	0.991	0.998	D	0.615	0.967	D	0.87	0.963	0.986	0.842	D	c	1.000	0.933	1.000	0.747	0.638	0.428	0	5.73	0.897	8.129	0.894	1.048	0.713	1.000	0.715	0.999	0.750	19.896	0.969	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	4.063e-06	0	0	0	0	0	8.963e-06	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,718	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246606	103246606	A	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.T829G:p.Y277D	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs78655458	15642	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	0.005	0.632	D	0.000	0.629	D	1	0.810	A	4.785	0.996	H	-6.94	0.998	D	-9.58	0.985	D	0.947	0.964	D	0.995	0.999	D	0.725	0.978	D	.	.	0.983	0.815	D	c	0.830	0.684	1.000	0.441	0.638	0.428	0	4.58	0.559	7.517	0.805	1.199	0.960	1.000	0.715	0.944	0.418	11.516	0.496	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	3.228e-05	0	0	0	0	0	6.661e-05	0	1.625e-05	0	2.978e-05	0	0	0	2.689e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,711	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246593	103246593	G	A	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.C842T:p.P281L	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs5030851	15628	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	A	4.86	0.997	H	-7.9	0.999	D	-9.59	0.985	D	0.910	0.958	D	0.998	0.999	D	0.773	0.982	D	.	.	0.992	0.920	D	c	1.098	0.978	1.000	0.747	0.638	0.428	0	5.73	0.897	10.003	0.997	1.048	0.713	1.000	0.715	0.980	0.490	19.896	0.969	Aromatic_amino_acid_hydroxylase,_C-terminal|Aromatic_amino_acid_hydroxylase,_iron/copper_binding_site	.	.	0.9929	0.856	9.687e-05	0.0001	0	0	0	0	0.0001	0	0.0001	0	0	0	0	8.969e-05	0.0002	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,708	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103245490	103245490	T	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon8:c.A887G:p.D296G	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs281865446	125885	Phenylketonuria	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006	no_assertion_criteria_provided	Likely_pathogenic	0.001	0.784	D	0.000	0.843	N	1	0.810	D	4.04	0.971	H	-6.47	0.997	D	-6.04	0.897	D	0.946	0.963	D	0.993	0.998	D	0.856	0.989	D	0.734	0.867	0.969	0.716	D	c	1.005	0.912	1.000	0.747	0.638	0.428	0	5.51	0.817	7.674	0.830	1.061	0.807	1.000	0.715	0.999	0.750	15.919	0.792	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,696	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103245487	103245487	C	T	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon8:c.G890A:p.R297H	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62642939	98657	Hyperphenylalaninemia,_non-pku|Phenylketonuria|not_provided	Human_Phenotype_Ontology:HP:0004923,MedGen:C0751435|MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	0.011	0.599	D	0.000	0.460	D	0.968	0.386	D	1.585	0.400	L	-6.14	0.995	D	-0.51	0.160	N	1.091	0.993	D	0.960	0.987	D	0.390	0.932	D	0.9	0.978	0.840	0.428	D	c	0.484	0.534	0.999	0.373	0.638	0.428	0	5.51	0.817	3.046	0.493	0.935	0.490	0.999	0.424	0.997	0.653	14.301	0.658	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	8.137e-06	0	0	0	5.801e-05	0	8.981e-06	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,694	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103245482	103245482	A	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon8:c.T895C:p.F299L	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs796064504	204454	Phenylketonuria	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006	no_assertion_criteria_provided	Likely_pathogenic	0.001	0.784	D	0.000	0.843	D	1	0.810	D	3.755	0.952	H	-6.9	0.998	D	-5.83	0.883	D	0.941	0.963	D	0.994	0.999	D	0.789	0.984	D	0.939	0.992	0.980	0.783	D	c	0.981	0.909	1.000	0.747	0.638	0.428	0	5.51	0.817	8.947	0.927	1.199	0.960	1.000	0.715	1.000	0.888	15.919	0.792	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,693	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103240726	103240726	T	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon9:c.A916G:p.I306V	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62642934	15657	Hyperphenylalaninemia,_non-pku|Phenylketonuria|not_provided	Human_Phenotype_Ontology:HP:0004923,MedGen:C0751435|MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	0.022	0.486	D	0.000	0.843	D	1	0.810	A	2.705	0.794	M	-6.43	0.997	D	-0.94	0.251	N	1.063	0.984	D	0.983	0.995	D	0.742	0.979	D	.	.	0.995	0.963	D	c	0.644	0.593	1.000	0.747	0.638	0.428	0	5.38	0.772	7.671	0.828	0.960	0.565	1.000	0.715	0.974	0.471	15.398	0.744	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	1.22e-05	0	0	0	0	0	2.69e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,686	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103240716	103240716	G	A	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon9:c.C926T:p.A309V	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62642935	98660	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	0.015	0.546	D	0.000	0.843	D	1	0.810	D	2.85	0.831	M	-6.66	0.998	D	-3.42	0.672	D	0.994	0.971	D	0.991	0.998	D	0.750	0.980	D	.	.	0.997	0.985	D	c	0.899	0.831	1.000	0.747	0.638	0.428	0	5.38	0.772	9.598	0.974	0.948	0.535	1.000	0.715	0.980	0.490	19.136	0.934	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	1.626e-05	0	0	0	0	0	2.69e-05	0	3.249e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,685	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
21	36259163	36259163	T	C	exonic	RUNX1	.	nonsynonymous_SNV	RUNX1:NM_001001890:exon1:c.A247G:p.K83E,RUNX1:NM_001122607:exon1:c.A247G:p.K83E,RUNX1:NM_001754:exon4:c.A328G:p.K110E	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	rs121912498	29504	Familial_platelet_disorder_with_associated_myeloid_malignancy	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290	no_assertion_criteria_provided	Pathogenic	0.005	0.632	D	0.000	0.843	D	1	0.810	A	2.82	0.824	M	-6.57	0.997	D	-3.01	0.704	D	0.986	0.970	D	0.990	0.997	D	0.924	0.994	D	0.752	0.883	0.953	0.639	D	c	0.823	0.741	1.0	0.983	0.405	0.054	1	4.72	0.591	5.758	0.682	0.964	0.580	1.000	0.715	1.000	0.888	14.361	0.662	Runt_domain|p53-like_transcription_factor,_DNA-binding|p53/RUNT-type_transcription_factor,_DNA-binding_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,979	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103237461	103237461	C	T	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon11:c.G1162A:p.V388M	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62516101	15658	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	0.007	0.614	D	0.000	0.629	D	1	0.810	D	3.685	0.946	H	-6.68	0.998	D	-1.91	0.444	N	0.977	0.968	D	0.992	0.998	D	0.772	0.982	D	.	.	0.964	0.685	D	c	0.759	0.634	0.999	0.383	0.638	0.428	0	5.34	0.759	5.037	0.637	0.892	0.403	1.000	0.715	0.484	0.268	12.403	0.546	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	9.698e-05	0.0001	0.0024	0	0	0	0	0	8.129e-05	0	0.0004	0	0	0	4.481e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,662	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103234270	103234270	C	T	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon12:c.G1223A:p.R408Q	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs5030859	15651	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	0.001	0.784	D	0.000	0.629	D	1.000	0.588	A	3.8	0.955	H	-6.71	0.998	D	-3.14	0.640	D	0.952	0.964	D	0.993	0.998	D	0.736	0.979	D	0.953	0.995	0.850	0.438	D	c	0.664	0.520	0.165	0.176	0.638	0.428	0	4.74	0.596	3.769	0.548	0.935	0.490	0.998	0.411	0.993	0.574	13.236	0.592	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	6.465e-05	0	0	0	0	0	0.0001	0	4.468e-05	0	0	0	0.0003	0	5.372e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,652	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
11	121008285	121008285	C	T	exonic	TECTA	.	nonsynonymous_SNV	TECTA:NM_005422:exon10:c.C3097T:p.R1033W	1.06498565113514e-12	0.999989745526101	1.02544728344311e-05	tectorin_alpha	FUNCTION:_One_of_the_major_non-collagenous_components_of_the_tectorial_membrane_(By_similarity)._The_tectorial_membrane_is_an_extracellular_matrix_of_the_inner_ear_that_covers_the_neuroepithelium_of_the_cochlea_and_contacts_the_stereocilia_bundles_of_specialized_sensory_hair_cells._Sound_induces_movement_of_these_hair_cells_relative_to_the_tectorial_membrane,_deflects_the_stereocilia_and_leads_to_fluctuations_in_hair-cell_membrane_potential,_transducing_sound_into_electrical_signals._{ECO:0000250}.\x3b_	DISEASE:_Deafness,_autosomal_dominant,_12_(DFNA12)_[MIM:601543]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10196713,_ECO:0000269|PubMed:10987647,_ECO:0000269|PubMed:12162770,_ECO:0000269|PubMed:15319541,_ECO:0000269|PubMed:16718611,_ECO:0000269|PubMed:17661817,_ECO:0000269|PubMed:20947814,_ECO:0000269|PubMed:21520338,_ECO:0000269|PubMed:9590290}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_recessive,_21_(DFNB21)_[MIM:603629]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:12746400,_ECO:0000269|PubMed:9949200}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	liver\x3btestis\x3bspleen\x3bblood\x3bbrain\x3b	superior_cervical_ganglion\x3batrioventricular_node\x3bskeletal_muscle\x3b	0.64735	0.20702	-2.430013277	1.032083038	4846.67098	14.13953	rs142486386	175360	not_specified	MedGen:CN169374	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.027	0.465	D	0.000	0.629	D	0.839	0.350	D	2.175	0.612	M	-1.32	0.798	T	-2.09	0.476	N	0.412	0.893	D	0.605	0.860	D	0.122	0.803	D	.	.	0.929	0.566	D	c	0.449	0.391	0.091	0.161	0.554	0.246	0	4.29	0.502	1.508	0.352	0.935	0.490	0.778	0.292	0.869	0.363	12.553	0.554	Trypsin_Inhibitor-like,_cysteine_rich_domain	.	.	.	.	0.0010	0.0031	0.0012	0	0.0006	0	0	0.0010	0.0003	0.0035	0.0002	0	0.0003	0	8.068e-05	0.0007	3.249e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,636	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103234250	103234250	C	T	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon12:c.G1243A:p.D415N	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62644499	15656	Hyperphenylalaninemia,_non-pku|Phenylketonuria|not_provided	Human_Phenotype_Ontology:HP:0004923,MedGen:C0751435|MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	1.0	0.010	T	0.000	0.843	D	0.999	0.456	A	-0.81	0.015	N	-6.06	0.995	D	3.26	0.001	N	0.572	0.915	D	0.797	0.931	D	0.297	0.908	D	0.899	0.977	0.595	0.307	D	c	-0.580	-0.296	0.025	0.136	0.638	0.428	0	4.74	0.596	3.759	0.547	0.935	0.490	1.000	0.715	0.960	0.441	7.614	0.272	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	0.0001	0	0.0004	0	0	0	0.0001	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,647	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103234252	103234252	T	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon12:c.A1241G:p.Y414C	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs5030860	15632	Hyperphenylalaninemia,_non-pku|Phenylketonuria|not_provided	Human_Phenotype_Ontology:HP:0004923,MedGen:C0751435|MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	0.001	0.784	D	0.000	0.843	D	1	0.810	A	4.28	0.982	H	-6.56	0.997	D	-8.12	0.967	D	0.956	0.965	D	0.992	0.998	D	0.823	0.986	D	.	.	0.962	0.679	D	c	0.927	0.826	1.000	0.428	0.638	0.428	0	5.63	0.861	7.628	0.822	1.061	0.807	1.000	0.715	0.914	0.390	14.816	0.695	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	0.0003	0	0	0	0	0.0003	0.0004	0.0010	0.0004	0	0.0001	0	0	8.969e-05	0.0007	0.0004	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,649	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103234253	103234253	A	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon12:c.T1240C:p.Y414H	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs281865437	125859	Phenylketonuria	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006	no_assertion_criteria_provided	Likely_pathogenic	0.017	0.524	D	0.000	0.843	D	1	0.810	D	3.59	0.938	H	-6.52	0.997	D	-4.54	0.784	D	0.978	0.968	D	0.991	0.998	D	0.676	0.973	D	0.944	0.993	0.973	0.739	D	c	0.905	0.818	1.000	0.428	0.638	0.428	0	5.63	0.861	8.892	0.921	1.199	0.960	1.000	0.715	0.885	0.372	14.816	0.695	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	4.061e-06	0	0	0	0	0	8.952e-06	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,650	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103234255	103234255	C	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon12:c.G1238C:p.R413P	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs79931499	15631	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	0.003	0.721	D	0.000	0.629	D	1	0.810	A	4.095	0.974	H	-6.36	0.997	D	-5.67	0.871	D	1.142	0.999	D	0.988	0.996	D	0.807	0.985	D	0.955	0.995	0.856	0.445	D	c	-0.131	-0.316	0.000	0.056	0.638	0.428	0	-1.62	0.079	0.933	0.283	-0.341	0.072	0.945	0.326	0.814	0.341	11.161	0.476	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	4.061e-06	0	0	0	5.798e-05	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,651	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103234271	103234271	G	A	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon12:c.C1222T:p.R408W	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs5030858	15616	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	0.0	0.912	D	0.000	0.629	D	1.000	0.588	A	4.15	0.976	H	-6.77	0.998	D	-6.83	0.930	D	1.028	0.977	D	0.993	0.998	D	0.641	0.970	D	.	.	0.826	0.415	D	c	0.468	0.267	0.000	0.057	0.638	0.428	0	1.44	0.215	4.590	0.605	1.048	0.713	1.000	0.715	0.990	0.544	14.510	0.672	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	0.0019	0.0003	0	0	0	0.0006	0.0035	0.0031	0.0008	0.0003	0	0.0003	0	0.0005	0.0015	0.0009	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,653	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103237454	103237454	T	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon11:c.A1169G:p.E390G	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs5030856	15664	Hyperphenylalaninemia,_non-pku|Phenylketonuria|not_provided	Human_Phenotype_Ontology:HP:0004923,MedGen:C0751435|MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	0.011	0.586	D	0.000	0.843	D	1	0.810	A	3.1	0.878	M	-6.46	0.997	D	-4.98	0.821	D	1.009	0.973	D	0.988	0.996	D	0.817	0.986	D	.	.	0.985	0.837	D	c	0.739	0.652	1.000	0.517	0.638	0.428	0	5.34	0.759	8.015	0.882	1.011	0.635	1.000	0.715	0.835	0.348	15.322	0.737	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	3.233e-05	0	0	0	0	0	6.671e-05	0	0.0001	0	0.0001	0	0	0	0.0002	0.0002	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,660	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103237460	103237460	A	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon11:c.T1163C:p.V388A	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs281865435	125854	Phenylketonuria	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006	no_assertion_criteria_provided	Likely_pathogenic	0.008	0.599	D	0.000	0.629	D	1	0.810	D	2.37	0.685	M	-6.64	0.998	D	-3.11	0.636	D	0.994	0.971	D	0.986	0.996	D	0.784	0.983	D	0.864	0.960	0.992	0.921	D	c	0.575	0.539	1.000	0.517	0.638	0.428	0	5.34	0.759	9.322	0.955	1.140	0.893	1.000	0.715	0.499	0.271	15.322	0.737	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,661	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
11	76869378	76869378	G	A	exonic	MYO7A	.	nonsynonymous_SNV	MYO7A:NM_000260:exon9:c.G905A:p.R302H,MYO7A:NM_001127179:exon9:c.G905A:p.R302H,MYO7A:NM_001127180:exon9:c.G905A:p.R302H	5.37673856270135e-25	0.207164598627406	0.792835401372594	myosin_VIIA	FUNCTION:_Myosins_are_actin-based_motor_molecules_with_ATPase_activity._Unconventional_myosins_serve_in_intracellular_movements._Their_highly_divergent_tails_bind_to_membranous_compartments,_which_are_then_moved_relative_to_actin_filaments._In_the_retina,_plays_an_important_role_in_the_renewal_of_the_outer_photoreceptor_disks._Plays_an_important_role_in_the_distribution_and_migration_of_retinal_pigment_epithelial_(RPE)_melanosomes_and_phagosomes,_and_in_the_regulation_of_opsin_transport_in_retinal_photoreceptors._In_the_inner_ear,_plays_an_important_role_in_differentiation,_morphogenesis_and_organization_of_cochlear_hair_cell_bundles._Involved_in_hair-cell_vesicle_trafficking_of_aminoglycosides,_which_are_known_to_induce_ototoxicity_(By_similarity)._Motor_protein_that_is_a_part_of_the_functional_network_formed_by_USH1C,_USH1G,_CDH23_and_MYO7A_that_mediates_mechanotransduction_in_cochlear_hair_cells._Required_for_normal_hearing._{ECO:0000250,_ECO:0000269|PubMed:19643958,_ECO:0000269|PubMed:21493626,_ECO:0000269|PubMed:21687988,_ECO:0000269|PubMed:21709241}.\x3b_	DISEASE:_Usher_syndrome_1B_(USH1B)_[MIM:276900]:_USH_is_a_genetically_heterogeneous_condition_characterized_by_the_association_of_retinitis_pigmentosa_with_sensorineural_deafness._Age_at_onset_and_differences_in_auditory_and_vestibular_function_distinguish_Usher_syndrome_type_1_(USH1),_Usher_syndrome_type_2_(USH2)_and_Usher_syndrome_type_3_(USH3)._USH1_is_characterized_by_profound_congenital_sensorineural_deafness,_absent_vestibular_function_and_prepubertal_onset_of_progressive_retinitis_pigmentosa_leading_to_blindness._{ECO:0000269|PubMed:10094549,_ECO:0000269|PubMed:10364543,_ECO:0000269|PubMed:10447383,_ECO:0000269|PubMed:10930322,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:15660226,_ECO:0000269|PubMed:16679490,_ECO:0000269|PubMed:23559863,_ECO:0000269|PubMed:24831256,_ECO:0000269|PubMed:25798947,_ECO:0000269|PubMed:7870171,_ECO:0000269|PubMed:8900236,_ECO:0000269|PubMed:9002678,_ECO:0000269|PubMed:9382091,_ECO:0000269|PubMed:9718356}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_recessive,_2_(DFNB2)_[MIM:600060]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:9171832,_ECO:0000269|PubMed:9171833}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_dominant,_11_(DFNA11)_[MIM:601317]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._DFNA11_is_characterized_by_onset_after_complete_speech_acquisition_and_subsequent_gradual_progression._{ECO:0000269|PubMed:15121790,_ECO:0000269|PubMed:15221449,_ECO:0000269|PubMed:15300860,_ECO:0000269|PubMed:9354784}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dDefects_in_MYO7A_may_be_a_cause_of_Leber_congenital_amaurosis_(LCA),_a_severe_dystrophy_of_the_retina,_typically_becoming_evident_in_the_first_years_of_life._Visual_function_is_usually_poor_and_often_accompanied_by_nystagmus,_sluggish_or_near-_absent_pupillary_responses,_photophobia,_high_hyperopia_and_keratoconus.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_the_pigment_epithelium_and_the_photoreceptor_cells_of_the_retina._Also_found_in_kidney,_liver,_testis,_cochlea,_lymphocytes._Not_expressed_in_brain._{ECO:0000269|PubMed:19643958,_ECO:0000269|PubMed:21493626,_ECO:0000269|PubMed:21709241}.\x3b_	unclassifiable_(Anatomical_System)\x3bmedulla_oblongata\x3bovary\x3bcolon\x3bparathyroid\x3bchoroid\x3bretina\x3bbreast\x3buterus\x3bprostate\x3boptic_nerve\x3blung\x3bendometrium\x3badrenal_gland\x3bthyroid\x3bplacenta\x3bvisual_apparatus\x3bliver\x3btestis\x3bspleen\x3bgerminal_center\x3bkidney\x3bbrain\x3bpineal_gland\x3bperipheral_nerve\x3b	superior_cervical_ganglion\x3bsubthalamic_nucleus\x3btestis_-_seminiferous_tubule\x3badrenal_gland\x3badrenal_cortex\x3btestis\x3bciliary_ganglion\x3bpons\x3batrioventricular_node\x3btrigeminal_ganglion\x3bskeletal_muscle\x3b	0.12096	0.33881	-2.513092117	0.925925926	4945.67513	14.33992	rs41298135	26891	Usher_syndrome,_type_1B|Retinitis_pigmentosa-deafness_syndrome|not_specified|Nonsyndromic_Hearing_Loss,_Dominant|Nonsyndromic_Hearing_Loss,_Recessive	MedGen:C1848638|MedGen:CN033130,OMIM:500004,SNOMED_CT:57838006|MedGen:CN169374|MedGen:CN239435|MedGen:CN239439	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.002	0.721	D	0.000	0.629	D	1.000	0.588	A	2.58	0.756	M	-2.36	0.882	D	-4.28	0.782	D	0.806	0.945	D	0.831	0.943	D	0.197	0.865	D	.	.	0.906	0.516	D	c	0.746	0.714	1.000	0.747	0.497	0.185	0	5.72	0.893	3.173	0.503	0.953	0.551	1.000	0.715	0.993	0.574	19.895	0.969	Myosin_head,_motor_domain|P-loop_containing_nucleoside_triphosphate_hydrolase	.	.	.	.	0.0027	0.0010	0.0024	0.0066	0	0.0032	0.0038	0.0031	0.0026	0.0007	0.0004	0.0005	0	0.0029	0.0048	0.0033	3.261e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,628	0	0	0	0	0	1	1	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0.3246	Likely Pathogenic
12	103234285	103234285	G	A	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon12:c.C1208T:p.A403V	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs5030857	98638	Inborn_genetic_diseases|Phenylketonuria|not_provided	MeSH:D030342,MedGen:C0950123|MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	0.123	0.275	T	0.000	0.843	D	1	0.810	D	2.69	0.790	M	-6.21	0.996	D	-3.22	0.649	D	1.096	0.995	D	0.984	0.995	D	0.353	0.924	D	.	.	0.945	0.611	D	c	0.813	0.795	0.987	0.312	0.638	0.428	0	5.63	0.861	7.702	0.834	1.048	0.713	1.000	0.715	1.000	0.888	18.445	0.906	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	0.0004	0.0002	0	0.0066	0	0	0.0006	0	0.0006	6.535e-05	0.0002	0.0050	0	0	0.0008	0.0009	3.249e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,657	0	0	0	0	0	1	1	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0.3246	Likely Pathogenic
12	103245479	103245479	C	A	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon8:c.G898T:p.A300S	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs5030853	98658	Hyperphenylalaninemia,_non-pku|Phenylketonuria|not_provided	Human_Phenotype_Ontology:HP:0004923,MedGen:C0751435|MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	0.0	0.912	D	0.000	0.843	D	1	0.810	D	3.545	0.934	H	-7.0	0.998	D	-2.92	0.611	D	0.955	0.965	D	0.994	0.999	D	0.688	0.974	D	.	.	0.976	0.755	D	c	1.002	0.934	1.000	0.747	0.638	0.428	0	5.51	0.817	7.568	0.814	0.935	0.490	1.000	0.715	1.000	0.888	19.779	0.964	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	0.0002	0	0	0.0066	0	0	0.0003	0	0.0006	0	8.942e-05	0.0066	0	0	0.0005	0.0009	0.0005	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,691	0	0	0	0	0	1	1	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0.3246	Likely Pathogenic
11	121039471	121039471	T	C	exonic	TECTA	.	nonsynonymous_SNV	TECTA:NM_005422:exon19:c.T5836C:p.Y1946H	1.06498565113514e-12	0.999989745526101	1.02544728344311e-05	tectorin_alpha	FUNCTION:_One_of_the_major_non-collagenous_components_of_the_tectorial_membrane_(By_similarity)._The_tectorial_membrane_is_an_extracellular_matrix_of_the_inner_ear_that_covers_the_neuroepithelium_of_the_cochlea_and_contacts_the_stereocilia_bundles_of_specialized_sensory_hair_cells._Sound_induces_movement_of_these_hair_cells_relative_to_the_tectorial_membrane,_deflects_the_stereocilia_and_leads_to_fluctuations_in_hair-cell_membrane_potential,_transducing_sound_into_electrical_signals._{ECO:0000250}.\x3b_	DISEASE:_Deafness,_autosomal_dominant,_12_(DFNA12)_[MIM:601543]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10196713,_ECO:0000269|PubMed:10987647,_ECO:0000269|PubMed:12162770,_ECO:0000269|PubMed:15319541,_ECO:0000269|PubMed:16718611,_ECO:0000269|PubMed:17661817,_ECO:0000269|PubMed:20947814,_ECO:0000269|PubMed:21520338,_ECO:0000269|PubMed:9590290}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_recessive,_21_(DFNB21)_[MIM:603629]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:12746400,_ECO:0000269|PubMed:9949200}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	liver\x3btestis\x3bspleen\x3bblood\x3bbrain\x3b	superior_cervical_ganglion\x3batrioventricular_node\x3bskeletal_muscle\x3b	0.64735	0.20702	-2.430013277	1.032083038	4846.67098	14.13953	rs144343770	175091	not_specified|Nonsyndromic_Hearing_Loss,_Dominant|Nonsyndromic_Hearing_Loss,_Recessive	MedGen:CN169374|MedGen:CN239435|MedGen:CN239439	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.0	0.912	D	0.000	0.843	D	1.000	0.537	D	2.43	0.707	M	-1.72	0.833	D	-1.07	0.279	N	0.680	0.929	D	0.753	0.916	D	0.153	0.835	D	.	.	0.978	0.768	D	c	0.868	0.829	1.000	0.747	0.554	0.246	0	5.81	0.924	7.645	0.824	1.061	0.807	1.000	0.715	0.983	0.502	16.166	0.815	Zona_pellucida_domain	.	.	.	.	9.683e-05	0	0	0	0	0	0.0002	0	0.0005	0.0002	0.0005	0.0063	0	0	0.0003	0.0015	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,638	0	0	0	0	0	1	1	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0.3246	Likely Pathogenic
7	107329565	107329565	G	A	exonic	SLC26A4	.	nonsynonymous_SNV	SLC26A4:NM_000441:exon9:c.G1069A:p.A357T	6.36692519367205e-13	0.204987783815785	0.795012216183578	solute_carrier_family_26_member_4	FUNCTION:_Sodium-independent_transporter_of_chloride_and_iodide._{ECO:0000269|PubMed:10192399}.\x3b_	DISEASE:_Deafness,_autosomal_recessive,_4_(DFNB4)_[MIM:600791]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._DFNB4_is_associated_with_an_enlarged_vestibular_aqueduct._{ECO:0000269|PubMed:10190331,_ECO:0000269|PubMed:10700480,_ECO:0000269|PubMed:11748854,_ECO:0000269|PubMed:12676893,_ECO:0000269|PubMed:14508505,_ECO:0000269|PubMed:14679580,_ECO:0000269|PubMed:19204907,_ECO:0000269|PubMed:20108392,_ECO:0000269|PubMed:20597900,_ECO:0000269|PubMed:9500541}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_High_expression_in_adult_thyroid,_lower_expression_in_adult_and_fetal_kidney_and_fetal_brain._Not_expressed_in_other_tissues.\x3b_	unclassifiable_(Anatomical_System)\x3bheart\x3bhypothalamus\x3badrenal_cortex\x3bparathyroid\x3bskeletal_muscle\x3bskin\x3buterus\x3blung\x3badrenal_gland\x3bthyroid\x3bhead_and_neck\x3bkidney\x3bbrain\x3bpineal_gland\x3b	superior_cervical_ganglion\x3bthyroid\x3batrioventricular_node\x3btrigeminal_ganglion\x3bskeletal_muscle\x3b	0.51161	0.43881	1.139030387	92.34489266	1009.39813	6.11806	rs145467740	52661	Pendred's_syndrome|not_specified|Nonsyndromic_Hearing_Loss,_Recessive	MedGen:C0271829,OMIM:274600,Orphanet:ORPHA705,SNOMED_CT:70348004|MedGen:CN169374|MedGen:CN239439	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.001	0.784	D	0.000	0.481	D	0.999	0.455	D	1.78	0.463	L	-3.53	0.948	D	-3.57	0.690	D	0.733	0.936	D	0.813	0.937	D	0.229	0.882	D	.	.	0.976	0.758	D	c	0.579	0.561	1.000	0.489	0.487	0.133	0	4.73	0.593	7.127	0.766	1.048	0.713	1.000	0.715	0.938	0.411	15.908	0.791	SLC26A/SulP_transporter_domain	.	.	.	.	0.0017	0.0058	0.0012	0	0	0	6.662e-05	0	0.0004	0.0052	0.0003	0	0.0001	0	7.178e-05	0.0007	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,491	0	0	0	0	0	1	1	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0.3246	Likely Pathogenic
12	103306579	103306579	C	T	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon2:c.G158A:p.R53H	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs118092776	108337	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.007	0.632	D	0.000	0.629	D	1.000	0.588	D	2.22	0.631	M	-5.54	0.992	D	-2.24	0.592	N	0.739	0.937	D	0.902	0.967	D	.	.	.	.	.	0.902	0.509	D	c	0.510	0.540	1.000	0.747	0.638	0.428	0	5.46	0.799	3.511	0.529	0.069	0.176	1.000	0.715	0.962	0.444	16.241	0.822	ACT_domain	.	.	.	.	0.0011	0.0002	0	0	0.0130	0.0003	0.0006	0.0010	0.0017	6.534e-05	0.0009	0.0002	0.0141	8.979e-05	0.0007	0.0015	0.0015	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,834	0	0	0	0	0	1	1	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0.3246	Likely Pathogenic
12	103260377	103260377	C	T	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon5:c.G506A:p.R169H	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475679	108442	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.011	0.564	D	0.000	0.629	D	1.000	0.588	D	2.925	0.847	M	-6.23	0.996	D	-3.52	0.684	D	1.027	0.977	D	0.949	0.983	D	0.561	0.960	D	0.907	0.981	0.902	0.509	D	c	0.289	0.344	0.104	0.165	0.554	0.246	0	5.19	0.713	2.062	0.408	0.935	0.490	1.000	0.715	0.999	0.750	12.835	0.570	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	0.0002	0	0	0.0132	0	0	0.0001	0	0.0003	0	0	0.0064	0	0	8.183e-05	0.0004	3.25e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,779	0	0	0	0	0	1	1	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0.3246	Likely Pathogenic
10	89624275	89624277	CAA	C	exonic	PTEN	.	frameshift_deletion	PTEN:NM_000314:exon1:c.50_51del:p.Q17fs,PTEN:NM_001304717:exon2:c.569_570del:p.Q190fs	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs587781912	151368	Hereditary_cancer-predisposing_syndrome|not_provided	MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	4.061e-06	0	0	0	0	0	8.951e-06	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,515	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.9878	VUS
12	103246611	103246611	G	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.C824G:p.P275R	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62508715	108590	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.46	0.989	H	-6.91	0.998	D	-8.62	0.975	D	0.926	0.960	D	0.996	0.999	D	0.512	0.953	D	0.923	0.987	0.993	0.945	D	c	1.089	0.992	1.000	0.747	0.638	0.428	0	5.73	0.897	10.003	0.997	1.048	0.713	1.000	0.715	0.992	0.562	19.896	0.969	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,715	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103260419	103260419	C	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon5:c.G464C:p.R155P	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475663	108423	not_specified|not_provided	MedGen:CN169374|MedGen:CN517202	criteria_provided,_single_submitter	Uncertain_significance	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.36	0.985	H	-6.75	0.998	D	-6.53	0.917	D	0.962	0.966	D	0.994	0.999	D	0.848	0.988	D	0.958	0.996	0.973	0.735	D	c	1.045	0.972	0.995	0.338	0.638	0.428	0	6.08	0.990	5.240	0.650	0.935	0.490	1.000	0.715	0.959	0.439	17.819	0.885	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,793	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103237523	103237523	A	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon11:c.T1100G:p.L367R	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	.	.	.	.	.	.	0.0	0.912	D	0.000	0.629	D	1.000	0.530	D	2.795	0.818	M	-6.33	0.997	D	-3.22	0.649	D	1.034	0.978	D	0.984	0.995	D	0.893	0.992	D	0.96	0.996	0.994	0.951	D	c	0.710	0.620	1.000	0.500	0.693	0.558	0	5.24	0.728	9.322	0.955	1.140	0.893	1.000	0.715	0.560	0.281	15.140	0.722	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,666	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103237523	103237523	A	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon11:c.T1100C:p.L367P	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62508574	108261	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.0	0.912	D	0.000	0.629	D	1	0.810	D	2.795	0.818	M	-6.34	0.997	D	-4.12	0.750	D	1.030	0.977	D	0.985	0.996	D	0.932	0.995	D	0.955	0.995	0.993	0.945	D	c	0.726	0.631	1.000	0.500	0.693	0.558	0	5.24	0.728	9.322	0.955	1.140	0.893	1.000	0.715	0.560	0.281	15.140	0.722	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,667	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103237524	103237524	G	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon11:c.C1099G:p.L367V	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	.	.	.	.	.	.	0.001	0.912	D	0.000	0.629	D	0.990	0.442	D	2.45	0.713	M	-6.24	0.996	D	-1.18	0.301	N	1.076	0.988	D	0.968	0.990	D	0.580	0.963	D	0.962	0.996	0.968	0.710	D	c	0.202	0.243	0.929	0.269	0.693	0.558	0	5.24	0.728	5.332	0.655	0.100	0.199	1.000	0.715	0.395	0.253	12.217	0.535	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,668	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103237528	103237531	GAGA	G	exonic	PAH	.	nonframeshift_deletion	PAH:NM_000277:exon11:c.1092_1094del:p.364_365del	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62516096	15636	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	no_assertion_criteria_provided	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,669	0	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103238146	103238146	C	T	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon10:c.G1033A:p.A345T	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62516062	108219	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_single_submitter	Uncertain_significance	0.001	0.784	D	0.000	0.843	D	1	0.810	D	4.73	0.995	H	-7.01	0.998	D	-3.79	0.716	D	0.918	0.959	D	0.996	0.999	D	0.792	0.984	D	0.977	0.998	0.990	0.891	D	c	1.115	1.023	1.000	0.747	0.638	0.428	0	5.81	0.924	7.905	0.864	0.935	0.490	1.000	0.715	1.000	0.888	20.078	0.977	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,677	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103238196	103238196	G	A	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon10:c.C983T:p.T328I	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs886042096	265310	not_specified	MedGen:CN169374	criteria_provided,_single_submitter	Uncertain_significance	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.27	0.982	H	-7.12	0.998	D	-5.81	0.882	D	0.936	0.962	D	0.996	0.999	D	0.784	0.983	D	0.899	0.977	0.994	0.949	D	c	1.142	1.062	1.000	0.747	0.638	0.428	0	5.81	0.924	10.003	0.997	1.045	0.669	1.000	0.715	1.000	0.888	20.078	0.977	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,679	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103240702	103240702	G	A	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon9:c.C940T:p.P314S	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475650	108641	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	1.0	0.010	T	0.000	0.843	D	1	0.810	D	0.075	0.083	N	-5.88	0.994	D	-4.43	0.775	D	0.996	0.971	D	0.911	0.970	D	0.474	0.948	D	0.834	0.942	0.982	0.807	D	c	0.024	0.116	1.000	0.413	0.638	0.428	0	5.38	0.772	5.493	0.664	0.948	0.535	1.000	0.715	0.943	0.417	19.136	0.934	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,682	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103271313	103271313	C	A	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon4:c.G368T:p.R123I	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475681	108394	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.001	0.784	D	0.000	0.559	D	1	0.810	D	3.605	0.939	H	-6.39	0.997	D	-6.23	0.910	D	1.011	0.974	D	0.991	0.997	D	0.844	0.988	D	0.643	0.780	0.905	0.515	D	c	0.498	0.395	0.207	0.182	0.615	0.372	0	4.04	0.461	1.515	0.352	0.065	0.171	0.993	0.376	0.951	0.427	12.356	0.543	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,802	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103240708	103240708	C	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon9:c.G934C:p.G312R	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	.	.	.	.	.	.	0.0	0.912	D	0.000	0.843	D	1	0.810	D	2.45	0.713	M	-7.03	0.998	D	-7.77	0.958	D	0.987	0.970	D	0.991	0.998	D	0.822	0.986	D	0.797	0.917	0.996	0.974	D	c	0.753	0.696	1.000	0.747	0.638	0.428	0	5.38	0.772	7.565	0.812	0.847	0.346	1.000	0.715	0.943	0.417	19.136	0.934	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,683	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103260413	103260413	C	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon5:c.G470C:p.R157T	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	.	.	.	.	.	.	0.0	0.912	D	0.000	0.843	D	1.000	0.588	D	4.44	0.988	H	-6.72	0.998	D	-5.8	0.881	D	0.944	0.963	D	0.994	0.999	D	0.841	0.988	D	0.874	0.965	0.967	0.702	D	c	0.934	0.837	0.099	0.163	0.638	0.428	0	5.19	0.713	5.240	0.650	0.935	0.490	1.000	0.715	0.983	0.502	12.540	0.553	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,792	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103245470	103245470	A	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon8:c.T907C:p.S303P	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475608	108625	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.001	0.784	D	0.000	0.843	D	1	0.810	D	4.02	0.969	H	-6.64	0.998	D	-4.83	0.809	D	0.947	0.964	D	0.993	0.998	D	0.774	0.982	D	0.931	0.989	0.980	0.783	D	c	1.001	0.922	1.000	0.747	0.638	0.428	0	5.51	0.817	8.947	0.927	1.199	0.960	1.000	0.715	1.000	0.888	15.919	0.792	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,690	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103245488	103245488	G	A	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon8:c.C889T:p.R297C	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62642945	108621	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.001	0.784	D	0.000	0.460	D	1.000	0.499	D	1.935	0.520	L	-6.16	0.996	D	-1.44	0.354	N	1.086	0.991	D	0.970	0.991	D	0.716	0.977	D	0.938	0.991	0.908	0.521	D	c	0.507	0.514	0.966	0.288	0.638	0.428	0	4.61	0.566	3.220	0.507	0.079	0.188	1.000	0.715	0.997	0.653	16.249	0.822	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	2.848e-05	0	0	0	0	0.0002	2.695e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,695	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103245512	103245512	C	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon8:c.G865C:p.G289R	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475693	108618	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.855	0.997	H	-7.98	0.999	D	-7.8	0.959	D	0.919	0.959	D	0.998	0.999	D	0.869	0.990	D	0.966	0.997	0.977	0.762	D	c	1.072	0.979	1.000	0.747	0.638	0.428	0	5.51	0.817	7.568	0.814	0.935	0.490	1.000	0.715	0.999	0.750	19.779	0.964	Aromatic_amino_acid_hydroxylase,_C-terminal|Aromatic_amino_acid_hydroxylase,_iron/copper_binding_site	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,698	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103245513	103245513	C	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon8:c.G864C:p.L288F	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62507327	108617	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.001	0.784	D	0.000	0.559	D	1	0.810	D	1.705	0.444	L	-6.66	0.998	D	-3.57	0.690	D	0.992	0.971	D	0.978	0.993	D	0.553	0.959	D	0.892	0.974	0.836	0.425	D	c	0.547	0.528	0.450	0.205	0.638	0.428	0	3.56	0.397	0.533	0.226	0.935	0.490	0.998	0.411	0.998	0.697	3.651	0.077	Aromatic_amino_acid_hydroxylase,_C-terminal|Aromatic_amino_acid_hydroxylase,_iron/copper_binding_site	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,699	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103271295	103271295	T	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon4:c.A386G:p.D129G	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475623	108397	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.001	0.912	D	0.000	0.843	D	1	0.810	D	4.35	0.985	H	-6.77	0.998	D	-6.75	0.935	D	0.938	0.962	D	0.994	0.999	D	0.784	0.983	D	0.972	0.997	0.977	0.763	D	c	0.935	0.879	1.000	0.747	0.615	0.372	0	5.86	0.939	7.382	0.788	1.061	0.807	1.000	0.715	0.999	0.750	16.244	0.822	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	4.061e-06	0	0	0	0	0	8.955e-06	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,800	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103234277	103234277	T	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon12:c.A1216G:p.I406V	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs749613899	.	.	.	.	.	0.03	0.453	D	0.000	0.843	D	1	0.810	D	3.21	0.895	M	-6.28	0.996	D	-0.86	0.234	N	1.015	0.974	D	0.986	0.996	D	0.669	0.972	D	0.762	0.891	0.962	0.679	D	c	0.803	0.763	1.000	0.428	0.638	0.428	0	5.63	0.861	7.628	0.822	1.061	0.807	1.000	0.715	0.985	0.512	14.816	0.695	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	3.232e-05	0	0	0	0.0006	0	0	0	8.123e-06	0	0	0	0.0001	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,656	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103306612	103306612	T	A	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon2:c.A125T:p.K42I	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62635346	108317	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.002	0.784	D	0.000	0.843	D	1.000	0.588	D	2.645	0.776	M	-5.46	0.991	D	-4.21	0.895	D	1.087	0.991	D	0.972	0.991	D	0.643	0.970	D	0.831	0.941	0.908	0.520	D	c	0.411	0.467	1.000	0.747	0.638	0.428	0	5.46	0.799	5.101	0.642	1.061	0.807	1.000	0.715	1.000	0.888	13.057	0.582	ACT_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,840	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103234276	103234276	A	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon12:c.T1217C:p.I406T	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62644469	108303	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.003	0.682	D	0.000	0.843	D	1	0.810	D	3.76	0.952	H	-6.47	0.997	D	-4.31	0.765	D	0.998	0.972	D	0.990	0.997	D	0.725	0.978	D	0.919	0.985	0.973	0.739	D	c	0.889	0.835	1.000	0.428	0.638	0.428	0	5.63	0.861	8.892	0.921	1.199	0.960	1.000	0.715	0.989	0.536	14.816	0.695	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,655	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103288696	103288696	C	T	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon3:c.G169A:p.E57K	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs140945592	98644	not_specified	MedGen:CN169374	criteria_provided,_single_submitter	Uncertain_significance	0.321	0.182	T	0.000	0.629	D	1	0.810	D	1.43	0.360	L	-5.53	0.992	D	-1.51	0.537	N	0.939	0.962	D	0.913	0.971	D	.	.	.	.	.	0.972	0.731	D	c	0.019	0.207	1.000	0.747	0.615	0.372	0	6.17	0.997	5.274	0.652	0.935	0.490	1.000	0.715	0.944	0.418	20.879	0.999	ACT_domain	.	.	0.9996	0.844	3.23e-05	0	0	0	0	0	6.662e-05	0	1.224e-05	0	0	0	0	0	1.799e-05	0	3.249e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,826	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103249099	103249099	A	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon6:c.T521C:p.I174T	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs138809906	108457	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.165	0.977	H	-6.5	0.997	D	-4.4	0.773	D	0.984	0.969	D	0.990	0.997	D	0.808	0.985	D	0.937	0.991	0.998	0.995	D	c	0.951	0.896	1.000	0.747	0.554	0.246	0	5.73	0.897	9.325	0.960	1.199	0.960	1.000	0.715	0.976	0.476	16.017	0.802	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,775	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103288689	103288689	T	A	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon3:c.A176T:p.D59V	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	.	.	.	.	.	.	0.07	0.506	T	0.000	0.491	D	1	0.810	D	3.09	0.877	M	-5.46	0.991	D	-2.87	0.603	D	0.890	0.955	D	0.935	0.979	D	0.667	0.972	D	0.608	0.741	0.870	0.461	D	c	-0.005	0.058	0.999	0.392	0.615	0.372	0	3.8	0.427	1.266	0.324	1.061	0.807	0.995	0.385	0.997	0.653	5.595	0.165	ACT_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,824	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103288681	103288681	G	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon3:c.C184G:p.L62V	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	.	.	.	.	.	.	0.347	0.682	T	0.000	0.843	D	1	0.810	D	2.9	0.842	M	-5.1	0.987	D	-2.41	0.571	N	1.003	0.972	D	0.929	0.977	D	0.513	0.953	D	0.509	0.606	0.954	0.644	D	c	0.218	0.294	1.000	0.747	0.615	0.372	0	5.28	0.740	2.380	0.437	1.048	0.713	1.000	0.715	1.000	0.888	10.857	0.458	ACT_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,823	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103288678	103288678	T	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon3:c.A187C:p.T63P	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475568	108355	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.219	0.632	T	0.000	0.843	D	1	0.810	D	4.455	0.989	H	-5.52	0.992	D	-3.26	0.662	D	1.116	0.999	D	0.984	0.995	D	0.444	0.942	D	0.48	0.560	0.982	0.807	D	c	0.956	0.896	1.000	0.747	0.615	0.372	0	6.17	0.997	7.131	0.767	1.061	0.807	1.000	0.715	1.000	0.888	16.822	0.856	ACT_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,822	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103288675	103288675	G	T	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon3:c.C190A:p.H64N	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475569	108356	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.001	0.784	D	0.000	0.843	D	1	0.810	D	2.3	0.659	M	-4.95	0.984	D	-5.74	0.923	D	1.096	0.995	D	0.960	0.987	D	0.843	0.988	D	0.693	0.831	0.986	0.843	D	c	0.876	0.885	1.000	0.747	0.615	0.372	0	6.17	0.997	7.060	0.762	1.048	0.713	1.000	0.715	1.000	0.888	20.879	0.999	ACT_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,821	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103288671	103288671	A	T	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon3:c.T194A:p.I65N	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs75193786	108359	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.615	0.993	H	-5.68	0.993	D	-6.32	0.934	D	0.982	0.969	D	0.989	0.997	D	0.904	0.993	D	0.961	0.996	0.987	0.858	D	c	1.105	1.019	1.000	0.747	0.615	0.372	0	6.17	0.997	8.297	0.898	1.199	0.960	1.000	0.715	1.000	0.888	16.822	0.856	ACT_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,820	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103288654	103288657	GAGA	G	exonic	PAH	.	nonframeshift_deletion	PAH:NM_000277:exon3:c.208_210del:p.70_70del	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62642094	108368	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	8.127e-06	0	5.956e-05	0	0	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,817	0	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103288653	103288653	C	CGAGAAG	exonic	PAH	.	nonframeshift_insertion	PAH:NM_000277:exon3:c.211_212insCTTCTC:p.R71delinsPSR	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs281865431	125865	Phenylketonuria	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006	no_assertion_criteria_provided	Likely_pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,816	0	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103288641	103288641	T	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon3:c.A224G:p.D75G	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	.	.	.	.	.	.	0.396	0.277	T	0.000	0.629	D	1.000	0.588	D	-0.52	0.025	N	-4.71	0.980	D	-0.12	0.375	N	0.370	0.886	D	0.764	0.920	D	0.073	0.717	D	0.46	0.528	0.954	0.644	D	c	-0.173	0.105	1.000	0.747	0.615	0.372	0	6.17	0.997	7.131	0.767	1.061	0.807	1.000	0.715	0.998	0.697	16.822	0.856	ACT_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,815	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103288641	103288641	T	A	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon3:c.A224T:p.D75V	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	.	.	.	.	.	.	0.21	0.599	T	0.000	0.629	D	1	0.810	D	2.67	0.784	M	-4.78	0.981	D	-3.05	0.733	D	1.070	0.986	D	0.943	0.981	D	0.347	0.922	D	0.579	0.705	0.965	0.692	D	c	0.441	0.519	1.000	0.747	0.615	0.372	0	6.17	0.997	7.131	0.767	1.061	0.807	1.000	0.715	0.998	0.697	16.822	0.856	ACT_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,814	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
11	76883813	76883813	G	A	exonic	MYO7A	.	nonsynonymous_SNV	MYO7A:NM_000260:exon16:c.G1817A:p.R606H,MYO7A:NM_001127179:exon16:c.G1817A:p.R606H,MYO7A:NM_001127180:exon16:c.G1817A:p.R606H	5.37673856270135e-25	0.207164598627406	0.792835401372594	myosin_VIIA	FUNCTION:_Myosins_are_actin-based_motor_molecules_with_ATPase_activity._Unconventional_myosins_serve_in_intracellular_movements._Their_highly_divergent_tails_bind_to_membranous_compartments,_which_are_then_moved_relative_to_actin_filaments._In_the_retina,_plays_an_important_role_in_the_renewal_of_the_outer_photoreceptor_disks._Plays_an_important_role_in_the_distribution_and_migration_of_retinal_pigment_epithelial_(RPE)_melanosomes_and_phagosomes,_and_in_the_regulation_of_opsin_transport_in_retinal_photoreceptors._In_the_inner_ear,_plays_an_important_role_in_differentiation,_morphogenesis_and_organization_of_cochlear_hair_cell_bundles._Involved_in_hair-cell_vesicle_trafficking_of_aminoglycosides,_which_are_known_to_induce_ototoxicity_(By_similarity)._Motor_protein_that_is_a_part_of_the_functional_network_formed_by_USH1C,_USH1G,_CDH23_and_MYO7A_that_mediates_mechanotransduction_in_cochlear_hair_cells._Required_for_normal_hearing._{ECO:0000250,_ECO:0000269|PubMed:19643958,_ECO:0000269|PubMed:21493626,_ECO:0000269|PubMed:21687988,_ECO:0000269|PubMed:21709241}.\x3b_	DISEASE:_Usher_syndrome_1B_(USH1B)_[MIM:276900]:_USH_is_a_genetically_heterogeneous_condition_characterized_by_the_association_of_retinitis_pigmentosa_with_sensorineural_deafness._Age_at_onset_and_differences_in_auditory_and_vestibular_function_distinguish_Usher_syndrome_type_1_(USH1),_Usher_syndrome_type_2_(USH2)_and_Usher_syndrome_type_3_(USH3)._USH1_is_characterized_by_profound_congenital_sensorineural_deafness,_absent_vestibular_function_and_prepubertal_onset_of_progressive_retinitis_pigmentosa_leading_to_blindness._{ECO:0000269|PubMed:10094549,_ECO:0000269|PubMed:10364543,_ECO:0000269|PubMed:10447383,_ECO:0000269|PubMed:10930322,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:15660226,_ECO:0000269|PubMed:16679490,_ECO:0000269|PubMed:23559863,_ECO:0000269|PubMed:24831256,_ECO:0000269|PubMed:25798947,_ECO:0000269|PubMed:7870171,_ECO:0000269|PubMed:8900236,_ECO:0000269|PubMed:9002678,_ECO:0000269|PubMed:9382091,_ECO:0000269|PubMed:9718356}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_recessive,_2_(DFNB2)_[MIM:600060]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:9171832,_ECO:0000269|PubMed:9171833}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_dominant,_11_(DFNA11)_[MIM:601317]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._DFNA11_is_characterized_by_onset_after_complete_speech_acquisition_and_subsequent_gradual_progression._{ECO:0000269|PubMed:15121790,_ECO:0000269|PubMed:15221449,_ECO:0000269|PubMed:15300860,_ECO:0000269|PubMed:9354784}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dDefects_in_MYO7A_may_be_a_cause_of_Leber_congenital_amaurosis_(LCA),_a_severe_dystrophy_of_the_retina,_typically_becoming_evident_in_the_first_years_of_life._Visual_function_is_usually_poor_and_often_accompanied_by_nystagmus,_sluggish_or_near-_absent_pupillary_responses,_photophobia,_high_hyperopia_and_keratoconus.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_the_pigment_epithelium_and_the_photoreceptor_cells_of_the_retina._Also_found_in_kidney,_liver,_testis,_cochlea,_lymphocytes._Not_expressed_in_brain._{ECO:0000269|PubMed:19643958,_ECO:0000269|PubMed:21493626,_ECO:0000269|PubMed:21709241}.\x3b_	unclassifiable_(Anatomical_System)\x3bmedulla_oblongata\x3bovary\x3bcolon\x3bparathyroid\x3bchoroid\x3bretina\x3bbreast\x3buterus\x3bprostate\x3boptic_nerve\x3blung\x3bendometrium\x3badrenal_gland\x3bthyroid\x3bplacenta\x3bvisual_apparatus\x3bliver\x3btestis\x3bspleen\x3bgerminal_center\x3bkidney\x3bbrain\x3bpineal_gland\x3bperipheral_nerve\x3b	superior_cervical_ganglion\x3bsubthalamic_nucleus\x3btestis_-_seminiferous_tubule\x3badrenal_gland\x3badrenal_cortex\x3btestis\x3bciliary_ganglion\x3bpons\x3batrioventricular_node\x3btrigeminal_ganglion\x3bskeletal_muscle\x3b	0.12096	0.33881	-2.513092117	0.925925926	4945.67513	14.33992	rs782311929	508743	not_specified	MedGen:CN169374	criteria_provided,_single_submitter	Uncertain_significance	0.003	0.721	D	0.000	0.843	D	1	0.810	D	2.155	0.604	M	-2.29	0.876	D	-4.03	0.759	D	0.755	0.939	D	0.790	0.929	D	0.397	0.933	D	.	.	0.970	0.716	D	c	0.791	0.740	1.000	0.747	0.609	0.351	0	4.77	0.603	7.657	0.826	1.036	0.656	1.000	0.715	0.998	0.697	18.157	0.896	Myosin_head,_motor_domain|P-loop_containing_nucleoside_triphosphate_hydrolase	.	.	.	.	9.692e-05	0	0	0	0.0006	0	0.0001	0	8.727e-05	0	0	0	0	0	9.299e-05	0	0.0003	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,630	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103234208	103234208	G	T	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon12:c.C1285A:p.Q429K	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs764974157	.	.	.	.	.	1.0	0.010	T	0.000	0.843	D	1	0.810	D	0.68	0.165	N	-6.02	0.995	D	-1.56	0.377	N	1.091	0.993	D	0.913	0.971	D	0.288	0.905	D	0.529	0.636	0.942	0.602	D	c	0.034	0.217	1.000	0.747	0.638	0.428	0	5.33	0.756	7.500	0.803	1.048	0.713	1.000	0.715	0.997	0.653	18.147	0.895	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	8.123e-06	0	0	0	0	0	1.791e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,644	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103234222	103234222	A	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon12:c.T1271C:p.L424S	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475670	108320	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.0	0.912	D	0.000	0.843	D	1	0.810	D	3.375	0.916	M	-6.83	0.998	D	-5.03	0.825	D	0.987	0.970	D	0.990	0.997	D	0.753	0.980	D	0.949	0.994	0.959	0.665	D	c	0.872	0.817	1.000	0.402	0.638	0.428	0	5.33	0.756	8.813	0.915	1.199	0.960	1.000	0.715	0.996	0.625	14.569	0.676	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,646	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103271319	103271319	A	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon4:c.T362C:p.F121S	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	.	.	.	.	.	.	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.28	0.982	H	-5.41	0.991	D	-7.7	0.964	D	1.023	0.976	D	0.985	0.995	D	0.754	0.980	D	0.929	0.989	0.986	0.844	D	c	1.049	0.968	1.000	0.747	0.615	0.372	0	5.86	0.939	8.567	0.905	1.199	0.960	1.000	0.715	0.994	0.587	16.244	0.822	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,803	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103245518	103245518	G	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon8:c.C859G:p.L287V	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs781096854	.	.	.	.	.	0.027	0.465	D	0.000	0.843	D	1	0.810	D	1.57	0.397	L	-6.73	0.998	D	-2.31	0.513	N	1.077	0.988	D	0.981	0.994	D	0.402	0.934	D	0.902	0.979	0.975	0.749	D	c	0.665	0.696	1.000	0.747	0.638	0.428	0	5.51	0.817	6.553	0.736	1.048	0.713	1.000	0.715	0.986	0.517	19.779	0.964	Aromatic_amino_acid_hydroxylase,_C-terminal|Aromatic_amino_acid_hydroxylase,_iron/copper_binding_site	.	.	.	.	.	.	.	.	.	.	.	.	8.139e-06	0	0	0	0	0	1.797e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,700	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103245521	103245521	C	T	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon8:c.G856A:p.E286K	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62508739	108616	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.001	0.912	D	0.000	0.843	D	1	0.810	D	4.705	0.995	H	-6.7	0.998	D	-3.9	0.729	D	0.924	0.960	D	0.995	0.999	D	0.783	0.983	D	0.964	0.996	0.972	0.729	D	c	1.095	0.993	1.000	0.747	0.638	0.428	0	5.51	0.817	7.568	0.814	0.935	0.490	1.000	0.715	0.997	0.653	19.779	0.964	Aromatic_amino_acid_hydroxylase,_C-terminal|Aromatic_amino_acid_hydroxylase,_iron/copper_binding_site	.	.	.	.	.	.	.	.	.	.	.	.	8.14e-06	0	0	0	0.0001	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,701	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103245529	103245529	A	T	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon8:c.T848A:p.I283N	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62508693	108613	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.001	0.784	D	0.000	0.629	D	1.000	0.588	D	3.62	0.941	H	-6.3	0.996	D	-5.44	0.854	D	1.009	0.973	D	0.988	0.997	D	0.874	0.990	D	0.903	0.979	0.911	0.525	D	c	0.809	0.744	1.000	0.404	0.638	0.428	0	5.51	0.817	4.006	0.566	1.199	0.960	1.000	0.715	1.000	0.888	15.919	0.792	Aromatic_amino_acid_hydroxylase,_C-terminal|Aromatic_amino_acid_hydroxylase,_iron/copper_binding_site	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,702	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103260410	103260410	C	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon5:c.G473C:p.R158P	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs5030843	108430	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.475	0.989	H	-6.75	0.998	D	-6.78	0.928	D	0.923	0.960	D	0.994	0.999	D	0.815	0.986	D	0.986	0.999	0.965	0.694	D	c	0.933	0.834	0.085	0.160	0.638	0.428	0	5.17	0.707	5.240	0.650	0.935	0.490	1.000	0.715	0.992	0.562	14.650	0.683	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	8.126e-06	0	0	0	0	0	1.792e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,789	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103246662	103246662	A	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.T773C:p.L258P	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	.	.	.	.	.	.	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.76	0.996	H	-6.9	0.998	D	-6.58	0.919	D	0.902	0.957	D	0.996	0.999	D	0.751	0.980	D	0.973	0.997	0.990	0.892	D	c	1.084	0.986	1.000	0.747	0.638	0.428	0	5.72	0.893	9.325	0.960	1.199	0.960	1.000	0.715	0.999	0.750	15.998	0.800	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,741	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103260390	103260390	C	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon5:c.G493C:p.A165P	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475626	108437	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.001	0.784	D	0.000	0.843	D	1	0.810	D	4.09	0.973	H	-6.71	0.998	D	-4.86	0.812	D	0.976	0.968	D	0.994	0.999	D	0.747	0.980	D	0.989	0.999	0.973	0.735	D	c	0.976	0.900	0.995	0.338	0.638	0.428	0	6.08	0.990	5.240	0.650	0.935	0.490	0.999	0.424	0.992	0.562	17.819	0.885	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	4.063e-06	0	0	0	0	0	8.958e-06	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,786	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103246681	103246681	G	A	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.C754T:p.R252W	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs5030847	.	.	.	.	.	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.49	0.990	H	-6.77	0.998	D	-7.66	0.955	D	0.927	0.961	D	0.993	0.998	D	0.780	0.983	D	.	.	0.943	0.605	D	c	0.765	0.664	0.867	0.253	0.638	0.428	0	3.88	0.438	3.291	0.512	1.048	0.713	1.000	0.715	1.000	0.888	16.585	0.845	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	2.439e-05	0	0	0	5.8e-05	0	4.482e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,744	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103246681	103246681	G	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.C754G:p.R252G	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs5030847	108559	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.001	0.784	D	0.000	0.843	D	1	0.810	D	3.17	0.889	M	-6.73	0.998	D	-6.71	0.925	D	0.966	0.966	D	0.991	0.997	D	0.803	0.985	D	0.962	0.996	0.952	0.635	D	c	0.665	0.600	0.867	0.253	0.638	0.428	0	3.88	0.438	3.291	0.512	1.048	0.713	1.000	0.715	1.000	0.888	16.585	0.845	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,745	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103246695	103246695	C	T	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.G740A:p.G247D	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475579	108553	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.395	0.987	H	-7.02	0.998	D	-6.71	0.925	D	0.939	0.962	D	0.996	0.999	D	0.656	0.971	D	0.994	0.999	0.987	0.854	D	c	1.073	0.999	1.000	0.747	0.638	0.428	0	5.92	0.955	7.905	0.864	0.935	0.490	1.000	0.715	0.999	0.750	20.317	0.987	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	4.065e-06	0	0	0	0	0	0	0	3.249e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,747	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103246696	103246696	C	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.G739C:p.G247R	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62508731	108552	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.74	0.996	H	-7.03	0.998	D	-7.67	0.955	D	0.922	0.960	D	0.996	0.999	D	0.769	0.982	D	0.975	0.998	0.990	0.901	D	c	1.110	1.023	1.000	0.747	0.638	0.428	0	5.92	0.955	7.905	0.864	0.935	0.490	1.000	0.715	0.998	0.697	20.317	0.987	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,748	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103246696	103246696	C	T	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.G739A:p.G247S	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62508731	108551	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.19	0.978	H	-6.99	0.998	D	-5.76	0.878	D	0.922	0.960	D	0.996	0.999	D	0.677	0.973	D	0.981	0.998	0.987	0.854	D	c	1.110	1.023	1.000	0.747	0.638	0.428	0	5.92	0.955	7.905	0.864	0.935	0.490	1.000	0.715	0.998	0.697	20.317	0.987	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,749	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103246723	103246723	T	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.A712G:p.T238A	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	.	.	.	.	.	.	0.009	0.586	D	0.000	0.843	D	1	0.810	D	4.215	0.979	H	-7.0	0.998	D	-4.42	0.774	D	0.916	0.959	D	0.995	0.999	D	0.650	0.971	D	0.933	0.990	0.964	0.685	D	c	0.924	0.843	1.000	0.489	0.638	0.428	0	5.92	0.955	4.910	0.628	1.061	0.807	1.000	0.715	0.999	0.750	16.359	0.830	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,755	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103249109	103249109	C	T	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon6:c.G511A:p.G171R	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475613	108452	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_single_submitter	Uncertain_significance	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.09	0.973	H	-7.03	0.998	D	-7.78	0.959	D	0.926	0.960	D	0.996	0.999	D	0.698	0.975	D	0.924	0.987	0.997	0.989	D	c	1.055	0.967	1.000	0.747	0.554	0.246	0	5.73	0.897	7.905	0.864	0.935	0.490	1.000	0.715	0.985	0.512	19.899	0.970	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	0.9911	0.828	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,777	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103249100	103249100	T	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon6:c.A520G:p.I174V	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475632	108456	not_specified|not_provided	MedGen:CN169374|MedGen:CN517202	criteria_provided,_single_submitter	Uncertain_significance	0.001	0.784	D	0.000	0.843	D	1	0.810	D	2.43	0.707	M	-6.3	0.996	D	-0.91	0.245	N	1.058	0.983	D	0.983	0.995	D	0.444	0.942	D	0.916	0.984	0.991	0.912	D	c	0.735	0.717	1.000	0.747	0.554	0.246	0	5.73	0.897	6.223	0.720	1.061	0.807	1.000	0.715	0.987	0.523	16.017	0.802	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,776	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103248923	103248923	A	T	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon6:c.T697A:p.F233I	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	.	.	.	.	.	.	0.0	0.912	D	0.000	0.843	D	1	0.810	D	2.605	0.765	M	-6.66	0.998	D	-5.63	0.868	D	0.989	0.970	D	0.989	0.997	D	0.826	0.987	D	0.84	0.946	0.992	0.928	D	c	0.744	0.663	1.000	0.500	0.638	0.428	0	5.17	0.707	9.325	0.960	1.199	0.960	1.000	0.715	0.959	0.439	15.309	0.736	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,758	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103248926	103248926	G	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon6:c.C694G:p.Q232E	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	.	.	.	.	.	.	0.968	0.067	T	0.000	0.452	D	0.830	0.349	D	0.255	0.098	N	-5.87	0.994	D	-0.44	0.146	N	0.814	0.946	D	0.861	0.954	D	0.177	0.853	D	0.419	0.461	0.952	0.635	D	c	-0.349	-0.109	0.385	0.200	0.638	0.428	0	5.17	0.707	4.135	0.575	1.048	0.713	1.000	0.715	0.965	0.450	12.266	0.538	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,759	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103248970	103248970	C	T	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon6:c.G650A:p.C217Y	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62508617	108508	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.24	0.980	H	-6.29	0.996	D	-10.64	0.991	D	0.979	0.968	D	0.992	0.998	D	0.792	0.984	D	0.93	0.989	0.988	0.868	D	c	1.048	0.968	1.000	0.747	0.638	0.428	0	5.63	0.861	7.905	0.864	0.935	0.490	1.000	0.715	0.996	0.625	19.674	0.959	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,761	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103249072	103249073	TC	AA	exonic	PAH	.	nonframeshift_substitution	PAH:NM_000277:exon6:c.547_548TT	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs281865433	125872	Phenylketonuria	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006	no_assertion_criteria_provided	Likely_pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,769	0	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103249085	103249085	A	T	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon6:c.T535A:p.Y179N	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475671	108465	not_specified|not_provided	MedGen:CN169374|MedGen:CN517202	criteria_provided,_single_submitter	Uncertain_significance	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.795	0.996	H	-7.23	0.999	D	-8.57	0.974	D	0.893	0.956	D	0.997	0.999	D	0.861	0.989	D	0.831	0.941	0.992	0.922	D	c	1.060	0.953	1.000	0.747	0.638	0.428	0	5.73	0.897	9.325	0.960	1.199	0.960	1.000	0.715	0.998	0.697	16.017	0.802	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,770	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103246647	103246647	A	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.T788C:p.F263S	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	.	.	.	.	.	.	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.79	0.996	H	-7.21	0.999	D	-7.47	0.949	D	0.892	0.956	D	0.997	0.999	D	0.871	0.990	D	0.948	0.994	0.990	0.892	D	c	1.083	0.983	1.000	0.747	0.638	0.428	0	5.72	0.893	9.325	0.960	1.199	0.960	1.000	0.715	1.000	0.888	15.998	0.800	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,735	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103246646	103246646	G	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.C789G:p.F263L	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62642944	108569	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.006	0.632	D	0.000	0.843	D	1	0.810	D	2.655	0.780	M	-7.0	0.998	D	-5.42	0.852	D	1.051	0.981	D	0.991	0.998	D	0.717	0.977	D	0.97	0.997	0.930	0.569	D	c	0.519	0.427	0.250	0.187	0.638	0.428	0	2.95	0.331	1.924	0.395	0.143	0.228	1.000	0.715	1.000	0.888	10.218	0.422	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	1.219e-05	0	0	0	0	0	2.688e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,734	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103246636	103246636	G	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.C799G:p.Q267E	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475676	108575	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.13	0.975	H	-6.48	0.997	D	-2.88	0.605	D	0.949	0.964	D	0.994	0.999	D	0.586	0.963	D	0.94	0.992	0.993	0.945	D	c	1.127	1.044	1.000	0.747	0.638	0.428	0	5.73	0.897	10.003	0.997	1.048	0.713	1.000	0.715	0.999	0.750	19.896	0.969	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,732	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103246612	103246612	G	A	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.C823T:p.P275S	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62508691	108589	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.46	0.989	H	-6.87	0.998	D	-7.67	0.955	D	0.936	0.962	D	0.995	0.999	D	0.651	0.971	D	.	.	0.992	0.920	D	c	1.095	1.000	1.000	0.747	0.638	0.428	0	5.73	0.897	10.003	0.997	1.048	0.713	1.000	0.715	0.994	0.587	19.896	0.969	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,716	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103260390	103260390	C	T	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon5:c.G493A:p.A165T	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475626	108436	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.008	0.599	D	0.000	0.843	D	1	0.810	D	4.09	0.973	H	-6.65	0.998	D	-3.89	0.728	D	0.962	0.966	D	0.994	0.999	D	0.779	0.983	D	0.971	0.997	0.964	0.686	D	c	1.003	0.917	0.995	0.338	0.638	0.428	0	6.08	0.990	5.240	0.650	0.935	0.490	0.999	0.424	0.992	0.562	17.819	0.885	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	4.063e-06	0	0	0	0	0	8.958e-06	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,787	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103246594	103246594	G	A	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.C841T:p.P281S	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475654	98656	not_specified|not_provided	MedGen:CN169374|MedGen:CN517202	criteria_provided,_single_submitter	Uncertain_significance	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.86	0.997	H	-7.88	0.999	D	-7.68	0.956	D	0.915	0.959	D	0.998	0.999	D	0.713	0.977	D	0.975	0.998	0.992	0.920	D	c	1.058	0.950	1.000	0.747	0.638	0.428	0	5.73	0.897	10.003	0.997	1.048	0.713	1.000	0.715	0.975	0.474	19.896	0.969	Aromatic_amino_acid_hydroxylase,_C-terminal|Aromatic_amino_acid_hydroxylase,_iron/copper_binding_site	.	.	0.9859	0.878	.	.	.	.	.	.	.	.	4.064e-06	0	0	0	0	0	8.969e-06	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,709	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103246608	103246608	A	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.T827G:p.M276R	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62508722	108594	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.01	0.564	D	0.000	0.843	D	1	0.810	D	2.87	0.836	M	-6.22	0.996	D	-3.83	0.721	D	1.106	0.998	D	0.968	0.990	D	0.548	0.958	D	0.87	0.963	0.974	0.740	D	c	0.374	0.441	1.000	0.480	0.638	0.428	0	5.73	0.897	7.445	0.795	1.199	0.960	1.000	0.715	0.983	0.502	16.014	0.801	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,712	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103246608	103246608	A	T	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.T827A:p.M276K	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62508722	108593	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.081	0.339	T	0.000	0.843	D	1	0.810	D	1.83	0.482	L	-6.21	0.996	D	-3.73	0.709	D	1.030	0.977	D	0.956	0.986	D	0.511	0.953	D	0.884	0.970	0.969	0.712	D	c	0.086	0.245	1.000	0.480	0.638	0.428	0	5.73	0.897	7.445	0.795	1.199	0.960	1.000	0.715	0.983	0.502	16.014	0.801	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,713	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103246609	103246609	T	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.A826G:p.M276V	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62516149	108592	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.015	0.524	D	0.000	0.843	D	1.000	0.588	D	3.215	0.895	M	-6.13	0.995	D	-1.83	0.429	N	1.097	0.995	D	0.969	0.990	D	0.470	0.947	D	0.876	0.966	0.959	0.665	D	c	0.235	0.323	1.000	0.462	0.638	0.428	0	5.73	0.897	4.983	0.633	1.061	0.807	1.000	0.715	0.986	0.517	16.014	0.801	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,714	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
1	41285135	41285135	G	C	exonic	KCNQ4	.	nonsynonymous_SNV	KCNQ4:NM_004700:exon5:c.G825C:p.W275C,KCNQ4:NM_172163:exon5:c.G825C:p.W275C	0.985178281898531	0.0148214036876789	3.14413790434247e-07	potassium_voltage-gated_channel_subfamily_Q_member_4	FUNCTION:_Probably_important_in_the_regulation_of_neuronal_excitability._May_underlie_a_potassium_current_involved_in_regulating_the_excitability_of_sensory_cells_of_the_cochlea._KCNQ4_channels_are_blocked_by_linopirdin,_XE991_and_bepridil,_whereas_clofilium_is_without_significant_effect._Muscarinic_agonist_oxotremorine-M_strongly_suppress_KCNQ4_current_in_CHO_cells_in_which_cloned_KCNQ4_channels_were_coexpressed_with_M1_muscarinic_receptors.\x3b_	DISEASE:_Deafness,_autosomal_dominant,_2A_(DFNA2A)_[MIM:600101]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10025409,_ECO:0000269|PubMed:10369879,_ECO:0000269|PubMed:10571947,_ECO:0000269|PubMed:10925378,_ECO:0000269|PubMed:21242547}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_the_outer,_but_not_the_inner,_sensory_hair_cells_of_the_cochlea._Slightly_expressed_in_heart,_brain_and_skeletal_muscle.\x3b_	lymphoreticular\x3bcartilage\x3bcolon\x3bfovea_centralis\x3bchoroid\x3blens\x3bretina\x3boptic_nerve\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3biris\x3bmammary_gland\x3bbrain\x3bstomach\x3b	superior_cervical_ganglion\x3bciliary_ganglion\x3batrioventricular_node\x3btrigeminal_ganglion\x3b	0.12943	0.14391	-0.66859065	15.76433121	646.02	5.10359	rs956666801	496205	not_specified	MedGen:CN169374	criteria_provided,_single_submitter	Uncertain_significance	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.28	0.982	H	-4.66	0.980	D	-12.14	0.997	D	1.077	0.988	D	0.973	0.991	D	0.686	0.974	D	0.773	0.899	0.990	0.899	D	c	1.056	0.955	1.000	0.747	0.767	0.994	0	5.08	0.682	10.003	0.997	1.048	0.713	1.000	0.715	1.000	0.888	15.967	0.797	Ion_transport_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,441	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103246618	103246618	A	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.T817C:p.S273P	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	.	.	.	.	.	.	0.001	0.784	D	0.000	0.843	D	1	0.810	D	4.285	0.982	H	-6.2	0.996	D	-4.6	0.789	D	0.973	0.967	D	0.991	0.998	D	0.724	0.978	D	0.894	0.975	0.981	0.793	D	c	0.956	0.874	1.000	0.747	0.638	0.428	0	5.73	0.897	7.358	0.786	1.199	0.960	1.000	0.715	0.999	0.750	16.014	0.801	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,719	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103246635	103246635	T	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.A800G:p.Q267R	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	.	.	.	.	.	.	0.0	0.912	D	0.000	0.843	D	1	0.810	D	3.375	0.916	M	-6.49	0.997	D	-3.83	0.721	D	0.973	0.968	D	0.991	0.998	D	0.530	0.956	D	0.886	0.971	0.983	0.814	D	c	0.941	0.879	1.000	0.747	0.638	0.428	0	5.73	0.897	8.017	0.886	1.061	0.807	1.000	0.715	1.000	0.888	16.014	0.801	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,731	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103246622	103246622	A	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.T813G:p.H271Q	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	.	.	.	.	.	.	0.0	0.912	D	0.000	0.843	D	1	0.810	D	2.805	0.820	M	-6.6	0.997	D	-7.67	0.955	D	1.098	0.996	D	0.986	0.996	D	0.751	0.980	D	0.947	0.993	0.511	0.286	D	c	-0.043	-0.219	0.161	0.176	0.638	0.428	0	-2.18	0.066	0.750	0.258	-0.128	0.111	0.256	0.247	0.995	0.604	13.763	0.623	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,721	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103246623	103246623	T	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.A812G:p.H271R	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475692	108586	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.0	0.912	D	0.000	0.843	D	1	0.810	D	2.55	0.747	M	-6.58	0.997	D	-7.67	0.955	D	1.021	0.976	D	0.987	0.996	D	0.520	0.955	D	0.852	0.953	0.983	0.814	D	c	0.829	0.804	1.000	0.747	0.638	0.428	0	5.73	0.897	8.017	0.886	1.061	0.807	1.000	0.715	0.997	0.653	16.014	0.801	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	4.063e-06	0	0	0	0	0	0	0	3.249e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,723	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103246624	103246624	G	A	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.C811T:p.H271Y	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62517164	108585	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.105	0.974	H	-6.6	0.997	D	-5.75	0.877	D	0.970	0.967	D	0.993	0.998	D	0.614	0.967	D	.	.	0.992	0.920	D	c	1.084	1.014	1.000	0.747	0.638	0.428	0	5.73	0.897	10.003	0.997	1.048	0.713	1.000	0.715	0.996	0.625	19.896	0.969	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,724	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103246632	103246632	T	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.A803G:p.Y268C	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	.	.	.	.	.	.	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.465	0.989	H	-6.78	0.998	D	-8.62	0.975	D	0.923	0.960	D	0.994	0.999	D	0.704	0.976	D	0.896	0.976	0.983	0.814	D	c	1.015	0.926	1.000	0.747	0.638	0.428	0	5.73	0.897	8.017	0.886	1.061	0.807	1.000	0.715	1.000	0.888	16.014	0.801	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,727	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103246633	103246633	A	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.T802C:p.Y268H	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62507263	108577	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.465	0.989	H	-6.75	0.998	D	-4.79	0.806	D	0.923	0.960	D	0.994	0.999	D	0.651	0.971	D	0.943	0.993	0.990	0.893	D	c	1.052	0.965	1.000	0.747	0.638	0.428	0	5.73	0.897	9.325	0.960	1.199	0.960	1.000	0.715	1.000	0.888	16.014	0.801	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	4.063e-06	0	0	0	0	4.484e-05	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,728	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103246634	103246634	C	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.G801C:p.Q267H	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475675	108576	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.13	0.975	H	-6.55	0.997	D	-4.79	0.806	D	1.040	0.979	D	0.991	0.998	D	0.719	0.977	D	0.93	0.989	0.950	0.630	D	c	0.662	0.522	0.853	0.250	0.638	0.428	0	2.95	0.331	2.247	0.426	0.935	0.490	1.000	0.715	1.000	0.888	9.744	0.394	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,729	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103306601	103306601	C	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon2:c.G136C:p.G46R	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	.	.	.	.	.	.	0.002	0.912	D	0.000	0.843	D	1	0.810	D	4.675	0.994	H	-8.26	0.999	D	-7.23	0.962	D	0.934	0.962	D	0.998	1.000	D	0.707	0.976	D	0.817	0.931	0.924	0.555	D	c	1.006	0.893	1.000	0.747	0.638	0.428	0	5.46	0.799	5.034	0.637	0.935	0.490	1.000	0.715	1.000	0.888	16.222	0.820	ACT_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,838	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103249097	103249097	G	A	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon6:c.C523T:p.P175S	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	.	.	.	.	.	.	0.001	0.912	D	0.000	0.843	D	1	0.810	D	4.45	0.988	H	-6.87	0.998	D	-7.78	0.959	D	0.955	0.965	D	0.994	0.999	D	0.565	0.961	D	0.92	0.986	0.998	0.997	D	c	1.082	1.009	1.000	0.747	0.554	0.246	0	5.73	0.897	10.003	0.997	1.048	0.713	1.000	0.715	0.955	0.433	19.899	0.970	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,774	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
1	216061814	216061814	C	T	exonic	USH2A	.	nonsynonymous_SNV	USH2A:NM_206933:exon41:c.G8177A:p.G2726E	3.68100336207458e-43	0.999989235571568	1.07644284322941e-05	Usher_syndrome_2A_(autosomal_recessive,_mild)	FUNCTION:_Involved_in_hearing_and_vision.\x3b_	DISEASE:_Usher_syndrome_2A_(USH2A)_[MIM:276901]:_USH_is_a_genetically_heterogeneous_condition_characterized_by_the_association_of_retinitis_pigmentosa_with_sensorineural_deafness._Age_at_onset_and_differences_in_auditory_and_vestibular_function_distinguish_Usher_syndrome_type_1_(USH1),_Usher_syndrome_type_2_(USH2)_and_Usher_syndrome_type_3_(USH3)._USH2_is_characterized_by_congenital_mild_hearing_impairment_with_normal_vestibular_responses._{ECO:0000269|PubMed:10729113,_ECO:0000269|PubMed:10738000,_ECO:0000269|PubMed:10909849,_ECO:0000269|PubMed:11311042,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:12525556,_ECO:0000269|PubMed:14970843,_ECO:0000269|PubMed:15015129,_ECO:0000269|PubMed:15025721,_ECO:0000269|PubMed:15241801,_ECO:0000269|PubMed:15325563,_ECO:0000269|PubMed:17085681,_ECO:0000269|PubMed:17405132,_ECO:0000269|PubMed:18273898,_ECO:0000269|PubMed:18452394,_ECO:0000269|PubMed:19683999,_ECO:0000269|PubMed:19737284,_ECO:0000269|PubMed:20309401,_ECO:0000269|PubMed:20440071,_ECO:0000269|PubMed:20507924,_ECO:0000269|PubMed:21593743,_ECO:0000269|PubMed:21686329,_ECO:0000269|PubMed:22004887,_ECO:0000269|PubMed:23737954,_ECO:0000269|PubMed:9624053}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Retinitis_pigmentosa_39_(RP39)_[MIM:613809]:_A_retinal_dystrophy_belonging_to_the_group_of_pigmentary_retinopathies._Retinitis_pigmentosa_is_characterized_by_retinal_pigment_deposits_visible_on_fundus_examination_and_primary_loss_of_rod_photoreceptor_cells_followed_by_secondary_loss_of_cone_photoreceptors._Patients_typically_have_night_vision_blindness_and_loss_of_midperipheral_visual_field._As_their_condition_progresses,_they_lose_their_far_peripheral_visual_field_and_eventually_central_vision_as_well._{ECO:0000269|PubMed:10775529,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:12427073,_ECO:0000269|PubMed:15325563,_ECO:0000269|PubMed:16098008,_ECO:0000269|PubMed:17296898,_ECO:0000269|PubMed:20507924,_ECO:0000269|PubMed:21686329,_ECO:0000269|PubMed:22334370,_ECO:0000269|PubMed:24227914}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Present_in_the_basement_membrane_of_many,_but_not_all_tissues._Expressed_in_retina,_cochlea,_small_and_large_intestine,_pancreas,_bladder,_prostate,_esophagus,_trachea,_thymus,_salivary_glands,_placenta,_ovary,_fallopian_tube,_uterus_and_testis._Absent_in_many_other_tissues_such_as_heart,_lung,_liver,_kidney_and_brain._In_the_retina,_it_is_present_in_the_basement_membranes_in_the_Bruch's_layer_choroid_capillary_basement_membranes,_where_it_localizes_just_beneath_the_retinal_pigment_epithelial_cells_(at_protein_level)._Weakly_expressed._Isoform_2_is_expressed_in_fetal_eye,_cochlea_and_heart,_and_at_very_low_level_in_brain,_CNS,_intestine,_skeleton,_tongue,_kidney_and_lung._Isoform_2_is_not_expressed_in_stomach_and_liver._In_adult_tissues,_isoform_2_is_expressed_in_neural_retina_and_testis,_and_at_low_level_in_brain,_heart,_kidney_and_liver._Isoform_1_displays_a_similar_pattern_of_expression_but_is_expressed_at_very_low_level_in_fetal_cochlea._{ECO:0000269|PubMed:11788194,_ECO:0000269|PubMed:12433396,_ECO:0000269|PubMed:15015129,_ECO:0000269|PubMed:9624053}.\x3b_	unclassifiable_(Anatomical_System)\x3bliver\x3btestis\x3bretina\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3badrenal_gland\x3btemporal_lobe\x3bciliary_ganglion\x3batrioventricular_node\x3btrigeminal_ganglion\x3bskin\x3bskeletal_muscle\x3bcerebellum\x3b	0.15836	.	4.179636958	99.70511913	6401.91635	16.71188	rs549796389	172902	not_specified	MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	0.005	0.632	D	0.001	0.434	D	1.000	0.537	D	2.16	0.606	M	0.61	0.535	T	-4.89	0.814	D	-0.618	0.641	T	0.249	0.618	T	0.422	0.938	D	0.761	0.890	0.853	0.442	D	c	0.280	0.162	0.903	0.261	0.526	0.212	0	3.82	0.430	2.799	0.473	0.852	0.362	0.981	0.351	0.137	0.201	12.461	0.549	Fibronectin_type_III|Immunoglobulin-like_fold	.	.	.	.	.	.	.	.	.	.	.	.	1.221e-05	0	0	0	0	0	2.696e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,452	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
1	215848748	215848748	T	C	exonic	USH2A	.	nonsynonymous_SNV	USH2A:NM_206933:exon63:c.A12505G:p.T4169A	3.68100336207458e-43	0.999989235571568	1.07644284322941e-05	Usher_syndrome_2A_(autosomal_recessive,_mild)	FUNCTION:_Involved_in_hearing_and_vision.\x3b_	DISEASE:_Usher_syndrome_2A_(USH2A)_[MIM:276901]:_USH_is_a_genetically_heterogeneous_condition_characterized_by_the_association_of_retinitis_pigmentosa_with_sensorineural_deafness._Age_at_onset_and_differences_in_auditory_and_vestibular_function_distinguish_Usher_syndrome_type_1_(USH1),_Usher_syndrome_type_2_(USH2)_and_Usher_syndrome_type_3_(USH3)._USH2_is_characterized_by_congenital_mild_hearing_impairment_with_normal_vestibular_responses._{ECO:0000269|PubMed:10729113,_ECO:0000269|PubMed:10738000,_ECO:0000269|PubMed:10909849,_ECO:0000269|PubMed:11311042,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:12525556,_ECO:0000269|PubMed:14970843,_ECO:0000269|PubMed:15015129,_ECO:0000269|PubMed:15025721,_ECO:0000269|PubMed:15241801,_ECO:0000269|PubMed:15325563,_ECO:0000269|PubMed:17085681,_ECO:0000269|PubMed:17405132,_ECO:0000269|PubMed:18273898,_ECO:0000269|PubMed:18452394,_ECO:0000269|PubMed:19683999,_ECO:0000269|PubMed:19737284,_ECO:0000269|PubMed:20309401,_ECO:0000269|PubMed:20440071,_ECO:0000269|PubMed:20507924,_ECO:0000269|PubMed:21593743,_ECO:0000269|PubMed:21686329,_ECO:0000269|PubMed:22004887,_ECO:0000269|PubMed:23737954,_ECO:0000269|PubMed:9624053}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Retinitis_pigmentosa_39_(RP39)_[MIM:613809]:_A_retinal_dystrophy_belonging_to_the_group_of_pigmentary_retinopathies._Retinitis_pigmentosa_is_characterized_by_retinal_pigment_deposits_visible_on_fundus_examination_and_primary_loss_of_rod_photoreceptor_cells_followed_by_secondary_loss_of_cone_photoreceptors._Patients_typically_have_night_vision_blindness_and_loss_of_midperipheral_visual_field._As_their_condition_progresses,_they_lose_their_far_peripheral_visual_field_and_eventually_central_vision_as_well._{ECO:0000269|PubMed:10775529,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:12427073,_ECO:0000269|PubMed:15325563,_ECO:0000269|PubMed:16098008,_ECO:0000269|PubMed:17296898,_ECO:0000269|PubMed:20507924,_ECO:0000269|PubMed:21686329,_ECO:0000269|PubMed:22334370,_ECO:0000269|PubMed:24227914}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Present_in_the_basement_membrane_of_many,_but_not_all_tissues._Expressed_in_retina,_cochlea,_small_and_large_intestine,_pancreas,_bladder,_prostate,_esophagus,_trachea,_thymus,_salivary_glands,_placenta,_ovary,_fallopian_tube,_uterus_and_testis._Absent_in_many_other_tissues_such_as_heart,_lung,_liver,_kidney_and_brain._In_the_retina,_it_is_present_in_the_basement_membranes_in_the_Bruch's_layer_choroid_capillary_basement_membranes,_where_it_localizes_just_beneath_the_retinal_pigment_epithelial_cells_(at_protein_level)._Weakly_expressed._Isoform_2_is_expressed_in_fetal_eye,_cochlea_and_heart,_and_at_very_low_level_in_brain,_CNS,_intestine,_skeleton,_tongue,_kidney_and_lung._Isoform_2_is_not_expressed_in_stomach_and_liver._In_adult_tissues,_isoform_2_is_expressed_in_neural_retina_and_testis,_and_at_low_level_in_brain,_heart,_kidney_and_liver._Isoform_1_displays_a_similar_pattern_of_expression_but_is_expressed_at_very_low_level_in_fetal_cochlea._{ECO:0000269|PubMed:11788194,_ECO:0000269|PubMed:12433396,_ECO:0000269|PubMed:15015129,_ECO:0000269|PubMed:9624053}.\x3b_	unclassifiable_(Anatomical_System)\x3bliver\x3btestis\x3bretina\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3badrenal_gland\x3btemporal_lobe\x3bciliary_ganglion\x3batrioventricular_node\x3btrigeminal_ganglion\x3bskin\x3bskeletal_muscle\x3bcerebellum\x3b	0.15836	.	4.179636958	99.70511913	6401.91635	16.71188	rs113107803	172743	Retinitis_pigmentosa|not_specified	Human_Phenotype_Ontology:HP:0000547,MeSH:D012174,MedGen:C0035334,OMIM:268000,Orphanet:ORPHA791,SNOMED_CT:28835009|MedGen:CN169374	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.043	0.413	D	0.056	0.226	N	0.996	0.232	N	2.255	0.644	M	0.09	0.615	T	-2.69	0.574	D	-0.879	0.499	T	0.170	0.512	T	0.222	0.879	D	.	.	0.751	0.365	D	c	-0.208	-0.155	0.000	0.071	0.487	0.133	0	4.1	0.470	2.036	0.405	0.141	0.225	1.000	0.715	0.008	0.104	10.281	0.425	Fibronectin_type_III|Immunoglobulin-like_fold	.	.	.	.	0.0010	0.0035	0	0	0	0	0	0	0.0002	0.0032	0.0001	0	0	0	0	0	3.25e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,449	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.8121	VUS
10	89692820	89692820	A	C	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon5:c.A304C:p.K102Q,PTEN:NM_001304717:exon6:c.A823C:p.K275Q	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs786202944	183022	Hereditary_cancer-predisposing_syndrome|not_specified	MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	0.572	0.061	T	0.000	0.843	D	1	0.810	D	0.295	0.102	N	-2.1	0.862	D	-1.59	0.383	N	0.053	0.833	D	0.562	0.841	D	0.054	0.658	D	0.433	0.484	0.988	0.863	D	c	0.495	0.551	1.000	0.747	0.722	0.854	0	5.07	0.680	8.871	0.919	1.088	0.866	1.000	0.715	1.000	0.888	14.841	0.697	Dual_specificity_phosphatase,_catalytic_domain|Protein-tyrosine_phosphatase,_catalytic|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain\x3bDual_specificity_phosphatase,_catalytic_domain|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,538	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
10	89692794	89692794	A	G	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon5:c.A278G:p.H93R,PTEN:NM_001304717:exon6:c.A797G:p.H266R	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs121909238	22887	Macrocephaly/autism_syndrome|PTEN_hamartoma_tumor_syndrome	MedGen:C1854416,OMIM:605309,Orphanet:ORPHA210548|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498	criteria_provided,_single_submitter	Uncertain_significance	0.0	0.912	D	0.000	0.843	D	1	0.810	A	3.41	0.920	M	-5.14	0.988	D	-7.53	0.951	D	1.091	0.993	D	0.972	0.991	D	0.854	0.989	D	0.879	0.968	0.986	0.846	D	c	0.831	0.770	1.000	0.747	0.732	0.924	0	5.07	0.680	8.871	0.919	1.088	0.866	1.000	0.715	1.000	0.888	14.841	0.697	Protein-tyrosine_phosphatase,_catalytic|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain\x3bProtein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,535	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
21	36259160	36259160	T	C	exonic	RUNX1	.	nonsynonymous_SNV	RUNX1:NM_001001890:exon1:c.A250G:p.T84A,RUNX1:NM_001122607:exon1:c.A250G:p.T84A,RUNX1:NM_001754:exon4:c.A331G:p.T111A	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	.	533856	Familial_platelet_disorder_with_associated_myeloid_malignancy	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290	criteria_provided,_single_submitter	Uncertain_significance	0.008	0.632	D	0.000	0.843	D	1	0.810	D	2.14	0.601	M	-6.31	0.997	D	-3.68	0.797	D	1.045	0.980	D	0.983	0.995	D	0.887	0.992	D	0.622	0.757	0.953	0.639	D	c	0.622	0.605	1.0	0.983	0.405	0.054	1	4.72	0.591	7.530	0.807	0.964	0.580	1.000	0.715	1.000	0.888	14.361	0.662	Runt_domain|p53-like_transcription_factor,_DNA-binding|p53/RUNT-type_transcription_factor,_DNA-binding_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,978	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
21	36252971	36252971	T	C	exonic	RUNX1	.	nonsynonymous_SNV	RUNX1:NM_001001890:exon2:c.A310G:p.T104A,RUNX1:NM_001122607:exon2:c.A310G:p.T104A,RUNX1:NM_001754:exon5:c.A391G:p.T131A	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	.	471189	Familial_platelet_disorder_with_associated_myeloid_malignancy	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290	criteria_provided,_single_submitter	Uncertain_significance	0.002	0.784	D	0.000	0.843	D	1.000	0.588	D	2.715	0.797	M	-6.06	0.995	D	-4.46	0.788	D	1.042	0.979	D	0.984	0.995	D	0.632	0.969	D	0.526	0.632	0.984	0.823	D	c	0.746	0.725	1.000	0.747	0.722	0.854	0	5.31	0.750	7.674	0.830	1.061	0.807	1.000	0.715	0.998	0.697	15.556	0.758	Runt_domain|p53-like_transcription_factor,_DNA-binding|p53/RUNT-type_transcription_factor,_DNA-binding_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,972	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
10	89685275	89685275	T	G	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon3:c.T170G:p.L57W,PTEN:NM_001304717:exon4:c.T689G:p.L230W	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs786202398	183018	Hereditary_cancer-predisposing_syndrome|not_specified	MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	0.001	0.784	D	0.000	0.629	D	1	0.810	D	3.995	0.968	H	-5.21	0.989	D	-4.41	0.774	D	1.044	0.980	D	0.981	0.994	D	0.917	0.994	D	0.785	0.909	0.991	0.908	D	c	0.931	0.842	1.000	0.747	0.707	0.730	0	5.45	0.796	7.425	0.793	1.061	0.807	1.000	0.715	1.000	0.888	15.508	0.754	Protein-tyrosine_phosphatase,_catalytic|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain\x3bProtein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,526	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
13	20763685	20763686	AC	A	exonic	GJB2	.	frameshift_deletion	GJB2:NM_004004:exon2:c.35delG:p.G12fs	1.02863295453376e-11	0.00164377442881105	0.998356225560903	gap_junction_protein_beta_2	FUNCTION:_One_gap_junction_consists_of_a_cluster_of_closely_packed_pairs_of_transmembrane_channels,_the_connexons,_through_which_materials_of_low_MW_diffuse_from_one_cell_to_a_neighboring_cell.\x3b_	DISEASE:_Deafness,_autosomal_recessive,_1A_(DFNB1A)_[MIM:220290]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10830906,_ECO:0000269|PubMed:11313763,_ECO:0000269|PubMed:11439000,_ECO:0000269|PubMed:12121355,_ECO:0000269|PubMed:12239718,_ECO:0000269|PubMed:12786758,_ECO:0000269|PubMed:14722929,_ECO:0000269|PubMed:15666300,_ECO:0000269|PubMed:15994881,_ECO:0000269|PubMed:17660464,_ECO:0000269|PubMed:17666888,_ECO:0000269|PubMed:19384972,_ECO:0000269|PubMed:23680645,_ECO:0000269|PubMed:9328482,_ECO:0000269|PubMed:9336442,_ECO:0000269|PubMed:9471561,_ECO:0000269|PubMed:9529365}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_dominant,_3A_(DFNA3A)_[MIM:601544]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10807696,_ECO:0000269|PubMed:11313763,_ECO:0000269|PubMed:11439000,_ECO:0000269|PubMed:12786758,_ECO:0000269|PubMed:19384972,_ECO:0000269|PubMed:9620796}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Vohwinkel_syndrome_(VS)_[MIM:124500]:_VS_is_an_autosomal_dominant_disease_characterized_by_hyperkeratosis,_constriction_on_fingers_and_toes_and_congenital_deafness._{ECO:0000269|PubMed:10369869,_ECO:0000269|PubMed:15954104,_ECO:0000269|PubMed:18688874}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Keratoderma,_palmoplantar,_with_deafness_(PPKDFN)_[MIM:148350]:_An_autosomal_dominant_disorder_characterized_by_the_association_of_palmoplantar_hyperkeratosis_with_progressive,_bilateral,_high-frequency,_sensorineural_deafness._{ECO:0000269|PubMed:10633135,_ECO:0000269|PubMed:10757647,_ECO:0000269|PubMed:12372058,_ECO:0000269|PubMed:15996214,_ECO:0000269|PubMed:17993581,_ECO:0000269|PubMed:9856479}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Keratitis-ichthyosis-deafness_syndrome_(KID_syndrome)_[MIM:148210]:_An_autosomal_dominant_form_of_ectodermal_dysplasia._Ectodermal_dysplasia_defines_a_heterogeneous_group_of_disorders_due_to_abnormal_development_of_two_or_more_ectodermal_structures._Keratitis-ichthyosis-deafness_syndrome_is_characterized_by_the_association_of_hyperkeratotic_skin_lesions_with_vascularizing_keratitis_and_profound_sensorineural_hearing_loss._Clinical_features_include_deafness,_ichthyosis,_photophobia,_absent_or_decreased_eyebrows,_sparse_or_absent_scalp_hair,_decreased_sweating_and_dysplastic_finger_and_toenails._{ECO:0000269|PubMed:11912510,_ECO:0000269|PubMed:12548749,_ECO:0000269|PubMed:12752120}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bart-Pumphrey_syndrome_(BPS)_[MIM:149200]:_An_autosomal_dominant_disorder_characterized_by_sensorineural_hearing_loss,_palmoplantar_keratoderma,_knuckle_pads,_and_leukonychia,_It_shows_considerable_phenotypic_variability._{ECO:0000269|PubMed:15482471,_ECO:0000269|PubMed:15952212}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ichthyosis_hystrix-like_with_deafness_syndrome_(HID_syndrome)_[MIM:602540]:_An_autosomal_dominant_keratinizing_disorder_characterized_by_sensorineural_deafness_and_spiky_hyperkeratosis_affecting_the_entire_skin._HID_syndrome_is_considered_to_differ_from_the_similar_KID_syndrome_in_the_extent_and_time_of_occurrence_of_skin_symptoms_and_the_severity_of_the_associated_keratitis._{ECO:0000269|PubMed:12072059}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	.	.	0.42941	0.50569	0.663285274	84.55414013	794.09383	5.55726	rs80338939	32043	Hearing_impairment|Bilateral_conductive_hearing_impairment|Bilateral_sensorineural_hearing_impairment|Severe_sensorineural_hearing_impairment|Inborn_genetic_diseases|Deafness|Mutilating_keratoderma|Knuckle_pads,_deafness_AND_leukonychia_syndrome|Keratoderma_palmoplantar_deafness|Keratitis-ichthyosis-deafness_syndrome,_autosomal_dominant|Hystrix-like_ichthyosis_with_deafness|Deafness,_autosomal_recessive_1A|Deafness,_digenic,_GJB2/GJB6|Deafness,_autosomal_dominant_3a|Nonsyndromic_hearing_loss_and_deafness|not_specified|Nonsyndromic_Hearing_Loss,_Recessive|not_provided	Human_Phenotype_Ontology:HP:0000365,MedGen:C0018772|Human_Phenotype_Ontology:HP:0008513,MedGen:C0452136|Human_Phenotype_Ontology:HP:0008619,MedGen:C0452138|Human_Phenotype_Ontology:HP:0008625,MedGen:C4021533|MeSH:D030342,MedGen:C0950123|MedGen:C0011053|MedGen:C0265964,OMIM:124500,Orphanet:ORPHA494,SNOMED_CT:24559001|MedGen:C0266004,OMIM:149200,Orphanet:ORPHA2698,SNOMED_CT:1271009|MedGen:C1835672,OMIM:148350,Orphanet:ORPHA2202|MedGen:C1835678,OMIM:148210|MedGen:C1865234,OMIM:602540|MedGen:C2673759,OMIM:220290|MedGen:C2673760|MedGen:C2675750,OMIM:601544|MedGen:CN043648,Orphanet:ORPHA87884|MedGen:CN169374|MedGen:CN239439|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0079	0.0009	0.0036	0.0099	0	0.0089	0.0124	0.0133	0.0061	0.0013	0.0047	0.0035	0	0.0081	0.0093	0.0071	0.0007	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,872	1	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0.8121	VUS
10	89653795	89653798	CATT	C	exonic	PTEN	.	nonframeshift_deletion	PTEN:NM_000314:exon2:c.94_96del:p.32_32del,PTEN:NM_001304717:exon3:c.613_615del:p.205_205del	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	.	444672	Hereditary_cancer-predisposing_syndrome|not_provided	MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,521	0	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0.8121	VUS
14	31348132	31348132	G	A	exonic	COCH	.	nonsynonymous_SNV	COCH:NM_001135058:exon4:c.G355A:p.A119T,COCH:NM_001347720:exon4:c.G550A:p.A184T,COCH:NM_004086:exon5:c.G355A:p.A119T	0.000262849456488043	0.983542807336405	0.0161943432071074	cochlin	FUNCTION:_Plays_a_role_in_the_control_of_cell_shape_and_motility_in_the_trabecular_meshwork._{ECO:0000269|PubMed:21886777}.\x3b_	DISEASE:_Deafness,_autosomal_dominant,_9_(DFNA9)_[MIM:601369]:_A_form_of_non-syndromic_hearing_loss_characterized_by_onset_in_the_fourth_or_fifth_decade_of_life_and_initially_involves_the_high_frequencies._Hearing_loss_is_progressive_and_usually_complete_by_the_sixth_decade._In_addition_to_cochlear_involvement,_DFNA9_patients_also_exhibit_a_spectrum_of_vestibular_dysfunctions._Penetrance_of_the_vestibular_symptoms_is_often_incomplete,_and_some_patients_are_minimally_affected,_whereas_others_suffer_from_severe_balance_disturbances_and_episodes_of_vertigo._Affected_individuals_have_mucopolysaccharide_depositions_in_the_channels_of_the_cochlear_and_vestibular_nerves._These_depositions_apparently_cause_strangulation_and_degeneration_of_dendritic_fibers._{ECO:0000269|PubMed:10400989,_ECO:0000269|PubMed:11295836,_ECO:0000269|PubMed:14512963,_ECO:0000269|PubMed:16835921,_ECO:0000269|PubMed:17561763,_ECO:0000269|PubMed:18312449,_ECO:0000269|PubMed:22610276,_ECO:0000269|PubMed:22931125,_ECO:0000269|PubMed:23993205,_ECO:0000269|PubMed:9806553,_ECO:0000269|PubMed:9931344}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_inner_ear_structures\x3b_the_cochlea_and_the_vestibule.\x3b_	unclassifiable_(Anatomical_System)\x3bcartilage\x3bovary\x3bhypothalamus\x3bcolon\x3bparathyroid\x3bretina\x3bprostate\x3blung\x3bcochlea\x3badrenal_gland\x3blarynx\x3btrabecular_meshwork\x3bplacenta\x3bvisual_apparatus\x3bliver\x3btestis\x3bhead_and_neck\x3bspleen\x3bkidney\x3bbrain\x3bstomach\x3b	pons\x3bcaudate_nucleus\x3b	0.53303	0.13199	0.286674996	71.49681529	2772.50763	9.93783	rs121908931	21652	Deafness,_autosomal_dominant_9	MedGen:C1832425,OMIM:601369	no_assertion_criteria_provided	Pathogenic	0.129	0.564	T	0.000	0.629	D	0.999	0.451	A	0.55	0.145	N	-2.49	0.892	D	-0.63	0.251	N	-0.573	0.659	T	0.391	0.745	T	0.025	0.485	D	0.732	0.866	0.863	0.453	D	c	-0.322	-0.110	0.999	0.383	0.706	0.609	0	3.9	0.441	0.954	0.286	1.045	0.669	0.980	0.350	1.000	0.888	6.554	0.215	LCCL_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,880	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.8121	VUS
21	36252860	36252860	C	T	exonic	RUNX1	.	nonsynonymous_SNV	RUNX1:NM_001001890:exon2:c.G421A:p.G141R,RUNX1:NM_001122607:exon2:c.G421A:p.G141R,RUNX1:NM_001754:exon5:c.G502A:p.G168R	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	.	.	.	.	.	.	0.001	0.784	D	0.000	0.843	N	1	0.810	D	2.91	0.844	M	-6.78	0.998	D	-7.4	0.952	D	0.969	0.967	D	0.992	0.998	D	0.752	0.980	D	0.691	0.829	0.988	0.876	D	c	0.920	0.852	1.0	0.983	0.722	0.854	0	5.18	0.710	7.568	0.814	0.932	0.445	1.000	0.715	1.000	0.888	19.051	0.930	Runt_domain|p53-like_transcription_factor,_DNA-binding|p53/RUNT-type_transcription_factor,_DNA-binding_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,966	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
21	36231852	36231852	T	G	exonic	RUNX1	.	nonsynonymous_SNV	RUNX1:NM_001001890:exon3:c.A451C:p.T151P,RUNX1:NM_001122607:exon3:c.A451C:p.T151P,RUNX1:NM_001754:exon6:c.A532C:p.T178P	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	.	.	.	.	.	.	0.001	0.912	D	0.000	0.843	D	1	0.810	D	2.64	0.775	M	-5.99	0.995	D	-5.61	0.876	D	1.055	0.982	D	0.982	0.995	D	0.799	0.984	D	0.727	0.861	0.941	0.599	D	c	0.826	0.767	1.000	0.747	0.707	0.730	0	5.11	0.691	8.011	0.881	1.061	0.807	1.000	0.715	0.999	0.750	12.877	0.572	Runt_domain|p53-like_transcription_factor,_DNA-binding|p53/RUNT-type_transcription_factor,_DNA-binding_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,964	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
16	68842599	68842599	A	G	exonic	CDH1	.	nonsynonymous_SNV	CDH1:NM_001317184:exon5:c.A535G:p.K179E,CDH1:NM_004360:exon5:c.A535G:p.K179E	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	.	487892	not_provided	MedGen:CN517202	criteria_provided,_single_submitter	Uncertain_significance	0.003	0.682	D	0.000	0.537	D	1	0.810	D	2.55	0.747	M	-0.4	0.693	T	-3.0	0.627	D	-0.054	0.811	T	0.476	0.799	T	0.085	0.746	D	0.542	0.655	0.910	0.524	D	c	0.725	0.715	1.000	0.747	0.719	0.830	0	5.78	0.914	5.526	0.666	1.199	0.960	1.000	0.715	0.999	0.750	16.059	0.805	Cadherin|Cadherin-like	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,894	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
16	68842699	68842699	G	T	exonic	CDH1	.	nonsynonymous_SNV	CDH1:NM_001317184:exon5:c.G635T:p.G212V,CDH1:NM_004360:exon5:c.G635T:p.G212V	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	.	477773	Hereditary_cancer-predisposing_syndrome	MedGen:C0027672,SNOMED_CT:699346009	criteria_provided,_single_submitter	Uncertain_significance	0.0	0.912	D	0.000	0.497	D	1	0.810	D	4.65	0.994	H	0.09	0.615	T	-8.57	0.974	D	0.442	0.897	D	0.586	0.852	D	0.173	0.850	D	0.929	0.989	0.967	0.703	D	c	1.089	1.005	1.000	0.747	0.719	0.830	0	5.78	0.914	7.649	0.825	1.048	0.713	1.000	0.715	0.994	0.587	19.962	0.972	Cadherin|Cadherin-like	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,896	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
21	36231821	36231821	G	C	exonic	RUNX1	.	nonsynonymous_SNV	RUNX1:NM_001001890:exon3:c.C482G:p.T161S,RUNX1:NM_001122607:exon3:c.C482G:p.T161S,RUNX1:NM_001754:exon6:c.C563G:p.T188S	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	.	533850	Familial_platelet_disorder_with_associated_myeloid_malignancy	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290	criteria_provided,_single_submitter	Uncertain_significance	0.055	0.395	T	0.000	0.843	D	1	0.810	D	2.415	0.700	M	-5.93	0.995	D	-3.6	0.716	D	1.069	0.986	D	0.980	0.994	D	0.440	0.942	D	0.734	0.867	0.964	0.688	D	c	0.638	0.670	1.000	0.747	0.707	0.730	0	5.11	0.691	9.994	0.993	1.048	0.713	1.000	0.715	0.995	0.604	16.052	0.805	Runt_domain|p53-like_transcription_factor,_DNA-binding|p53/RUNT-type_transcription_factor,_DNA-binding_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,962	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
16	68846147	68846147	C	T	exonic	CDH1	.	nonsynonymous_SNV	CDH1:NM_001317184:exon8:c.C1118T:p.P373L,CDH1:NM_004360:exon8:c.C1118T:p.P373L	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	rs587782359	151999	Hereditary_cancer-predisposing_syndrome|Hereditary_diffuse_gastric_cancer|not_specified	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708349,OMIM:137215,Orphanet:ORPHA26106|MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	0.001	0.784	D	0.000	0.504	D	1	0.810	D	4.315	0.984	H	-1.5	0.813	D	-9.53	0.985	D	0.951	0.964	D	0.831	0.943	D	0.518	0.954	D	0.789	0.912	0.975	0.749	D	c	0.951	0.797	1.000	0.747	0.672	0.522	0	5.72	0.893	7.448	0.795	0.935	0.490	1.000	0.715	0.028	0.145	19.481	0.950	Cadherin|Cadherin_conserved_site|Cadherin-like	.	.	.	.	3.228e-05	0	0	0	0	0	6.663e-05	0	2.436e-05	0	0	0	0.0002	0	1.79e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,904	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
16	68847303	68847303	T	C	exonic	CDH1	.	nonsynonymous_SNV	CDH1:NM_004360:exon9:c.T1225C:p.W409R	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	rs587778176	137594	Hereditary_cancer-predisposing_syndrome|Hereditary_diffuse_gastric_cancer|not_specified|not_provided	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708349,OMIM:137215,Orphanet:ORPHA26106|MedGen:CN169374|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	0.0	0.912	D	0.000	0.477	D	1	0.810	D	3.755	0.952	H	1.21	0.372	T	-13.0	0.999	D	-0.581	0.656	T	0.247	0.616	T	0.141	0.824	D	0.838	0.945	0.985	0.832	D	c	0.558	0.466	0.991	0.324	0.672	0.522	0	6.04	0.980	5.079	0.640	1.058	0.762	1.000	0.715	0.092	0.186	16.238	0.821	Cadherin|Cadherin-like	.	.	.	.	.	.	.	.	.	.	.	.	2.03e-05	0	0	0	0	0	4.476e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,908	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
10	73572580	73572580	G	A	exonic	CDH23	.	nonsynonymous_SNV	CDH23:NM_001171935:exon3:c.G257A:p.R86Q,CDH23:NM_001171936:exon3:c.G257A:p.R86Q,CDH23:NM_001171933:exon21:c.G2846A:p.R949Q,CDH23:NM_001171934:exon21:c.G2846A:p.R949Q,CDH23:NM_022124:exon66:c.G9566A:p.R3189Q	0.0506929591139338	0.949268622794338	3.84180917276542e-05	cadherin-related_23	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells._CDH23_is_required_for_establishing_and/or_maintaining_the_proper_organization_of_the_stereocilia_bundle_of_hair_cells_in_the_cochlea_and_the_vestibule_during_late_embryonic/early_postnatal_development._It_is_part_of_the_functional_network_formed_by_USH1C,_USH1G,_CDH23_and_MYO7A_that_mediates_mechanotransduction_in_cochlear_hair_cells._Required_for_normal_hearing.\x3b_	DISEASE:_Usher_syndrome_1D_(USH1D)_[MIM:601067]:_USH_is_a_genetically_heterogeneous_condition_characterized_by_the_association_of_retinitis_pigmentosa_with_sensorineural_deafness._Age_at_onset_and_differences_in_auditory_and_vestibular_function_distinguish_Usher_syndrome_type_1_(USH1),_Usher_syndrome_type_2_(USH2)_and_Usher_syndrome_type_3_(USH3)._USH1_is_characterized_by_profound_congenital_sensorineural_deafness,_absent_vestibular_function_and_prepubertal_onset_of_progressive_retinitis_pigmentosa_leading_to_blindness._{ECO:0000269|PubMed:11138009,_ECO:0000269|PubMed:12075507,_ECO:0000269|PubMed:15660226,_ECO:0000269|PubMed:16679490,_ECO:0000269|PubMed:18429043}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Usher_syndrome_1D/F_(USH1DF)_[MIM:601067]:_USH1DF_patients_are_heterozygous_for_mutations_in_CDH23_and_PCDH15,_indicating_a_digenic_inheritance_pattern._{ECO:0000269|PubMed:15537665}._Note\x3dThe_disease_is_caused_by_mutations_affecting_distinct_genetic_loci,_including_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_recessive,_12_(DFNB12)_[MIM:601386]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:11090341,_ECO:0000269|PubMed:12075507,_ECO:0000269|PubMed:12522556,_ECO:0000269|PubMed:15829536,_ECO:0000269|PubMed:16679490,_ECO:0000269|PubMed:17850630,_ECO:0000269|PubMed:22899989,_ECO:0000269|PubMed:24767429}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Particularly_strong_expression_in_the_retina._Found_also_in_the_cochlea.\x3b_	medulla_oblongata\x3bovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bfovea_centralis\x3bchoroid\x3bskin\x3bbone_marrow\x3bretina\x3bprostate\x3boptic_nerve\x3bbone\x3btestis\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bpharynx\x3bblood\x3blens\x3bbreast\x3bpancreas\x3blung\x3bmacula_lutea\x3bvisual_apparatus\x3bliver\x3bspleen\x3bkidney\x3bstomach\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bsubthalamic_nucleus\x3btestis_-_interstitial\x3bglobus_pallidus\x3bciliary_ganglion\x3bpons\x3batrioventricular_node\x3btrigeminal_ganglion\x3bcerebellum\x3b	0.32126	0.20307	-1.837761842	2.05826846	23222.44281	31.45196	rs727502936	175286	not_specified	MedGen:CN169374	criteria_provided,_single_submitter	Uncertain_significance	0.0	0.912	D	0.000	0.843	D	1	0.810	D	1.04	0.263	L	-1.65	0.826	D	-0.81	0.223	N	0.404	0.892	D	0.687	0.892	D	0.195	0.864	D	0.606	0.739	0.957	0.658	D	c	0.863	0.876	1.0	0.983	0.701	0.575	0	5.84	0.934	9.933	0.988	1.048	0.713	1.000	0.715	0.992	0.562	20.128	0.980	Cadherin|Cadherin-like	.	.	.	.	3.231e-05	0	0	0	0	0	6.674e-05	0	4.081e-05	0	2.99e-05	0	0	0	1.799e-05	0	0.0002	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,500	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
10	73572579	73572579	C	T	exonic	CDH23	.	nonsynonymous_SNV	CDH23:NM_001171935:exon3:c.C256T:p.R86W,CDH23:NM_001171936:exon3:c.C256T:p.R86W,CDH23:NM_001171933:exon21:c.C2845T:p.R949W,CDH23:NM_001171934:exon21:c.C2845T:p.R949W,CDH23:NM_022124:exon66:c.C9565T:p.R3189W	0.0506929591139338	0.949268622794338	3.84180917276542e-05	cadherin-related_23	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells._CDH23_is_required_for_establishing_and/or_maintaining_the_proper_organization_of_the_stereocilia_bundle_of_hair_cells_in_the_cochlea_and_the_vestibule_during_late_embryonic/early_postnatal_development._It_is_part_of_the_functional_network_formed_by_USH1C,_USH1G,_CDH23_and_MYO7A_that_mediates_mechanotransduction_in_cochlear_hair_cells._Required_for_normal_hearing.\x3b_	DISEASE:_Usher_syndrome_1D_(USH1D)_[MIM:601067]:_USH_is_a_genetically_heterogeneous_condition_characterized_by_the_association_of_retinitis_pigmentosa_with_sensorineural_deafness._Age_at_onset_and_differences_in_auditory_and_vestibular_function_distinguish_Usher_syndrome_type_1_(USH1),_Usher_syndrome_type_2_(USH2)_and_Usher_syndrome_type_3_(USH3)._USH1_is_characterized_by_profound_congenital_sensorineural_deafness,_absent_vestibular_function_and_prepubertal_onset_of_progressive_retinitis_pigmentosa_leading_to_blindness._{ECO:0000269|PubMed:11138009,_ECO:0000269|PubMed:12075507,_ECO:0000269|PubMed:15660226,_ECO:0000269|PubMed:16679490,_ECO:0000269|PubMed:18429043}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Usher_syndrome_1D/F_(USH1DF)_[MIM:601067]:_USH1DF_patients_are_heterozygous_for_mutations_in_CDH23_and_PCDH15,_indicating_a_digenic_inheritance_pattern._{ECO:0000269|PubMed:15537665}._Note\x3dThe_disease_is_caused_by_mutations_affecting_distinct_genetic_loci,_including_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_recessive,_12_(DFNB12)_[MIM:601386]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:11090341,_ECO:0000269|PubMed:12075507,_ECO:0000269|PubMed:12522556,_ECO:0000269|PubMed:15829536,_ECO:0000269|PubMed:16679490,_ECO:0000269|PubMed:17850630,_ECO:0000269|PubMed:22899989,_ECO:0000269|PubMed:24767429}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Particularly_strong_expression_in_the_retina._Found_also_in_the_cochlea.\x3b_	medulla_oblongata\x3bovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bfovea_centralis\x3bchoroid\x3bskin\x3bbone_marrow\x3bretina\x3bprostate\x3boptic_nerve\x3bbone\x3btestis\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bpharynx\x3bblood\x3blens\x3bbreast\x3bpancreas\x3blung\x3bmacula_lutea\x3bvisual_apparatus\x3bliver\x3bspleen\x3bkidney\x3bstomach\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bsubthalamic_nucleus\x3btestis_-_interstitial\x3bglobus_pallidus\x3bciliary_ganglion\x3bpons\x3batrioventricular_node\x3btrigeminal_ganglion\x3bcerebellum\x3b	0.32126	0.20307	-1.837761842	2.05826846	23222.44281	31.45196	rs121908353	19965	Usher_syndrome,_type_1|USHER_SYNDROME,_TYPE_ID/F,_DIGENIC|not_specified	MedGen:C1568247,OMIM:276900,Orphanet:ORPHA231169|MedGen:C3276419|MedGen:CN169374	criteria_provided,_single_submitter	Uncertain_significance	0.0	0.912	D	0.000	0.843	D	1	0.810	A	1.04	0.263	L	-1.71	0.832	D	-2.19	0.493	N	0.386	0.889	D	0.650	0.878	D	0.348	0.922	D	0.883	0.970	0.806	0.399	D	c	0.386	0.381	1.000	0.747	0.701	0.575	0	4.93	0.643	3.118	0.499	0.044	0.157	1.000	0.715	0.994	0.587	13.982	0.637	Cadherin|Cadherin-like	.	.	.	.	6.462e-05	0.0002	0	0	0	0	0	0	1.633e-05	0	0	0.0004	0	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,499	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
16	68847376	68847376	A	G	exonic	CDH1	.	nonsynonymous_SNV	CDH1:NM_004360:exon9:c.A1298G:p.D433G	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	rs376097289	151524	Hereditary_cancer-predisposing_syndrome|Hereditary_diffuse_gastric_cancer|not_specified|not_provided	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708349,OMIM:137215,Orphanet:ORPHA26106|MedGen:CN169374|MedGen:CN517202	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.019	0.501	D	0.408	0.130	N	1.000	0.511	D	1.85	0.492	L	1.15	0.382	T	-3.85	0.723	D	-0.775	0.566	T	0.194	0.548	T	0.067	0.701	D	0.704	0.841	0.981	0.791	D	c	0.500	0.442	0.991	0.322	0.672	0.522	0	5.82	0.927	5.995	0.701	1.194	0.916	1.000	0.715	0.746	0.321	10.274	0.425	Cadherin|Cadherin-like	.	.	.	.	.	.	.	.	.	.	.	.	4.467e-05	0	0	0	0.0005	0	8.952e-06	0.0002	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,910	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.8121	VUS
16	68853296	68853296	C	G	exonic	CDH1	.	nonsynonymous_SNV	CDH1:NM_001317184:exon10:c.C1496G:p.T499R,CDH1:NM_001317185:exon11:c.C131G:p.T44R,CDH1:NM_004360:exon11:c.C1679G:p.T560R	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	rs746481984	231976	Hereditary_cancer-predisposing_syndrome|not_specified	MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN169374	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.039	0.440	D	0.000	0.523	D	0.997	0.439	D	1.53	0.389	L	0.71	0.512	T	-2.92	0.617	D	-0.654	0.625	T	0.242	0.610	T	0.169	0.847	D	0.504	0.598	0.479	0.279	N	c	0.169	0.100	0.641	0.220	0.706	0.609	0	4.57	0.557	1.206	0.317	0.872	0.381	0.619	0.277	0.650	0.298	16.143	0.813	Cadherin|Cadherin-like	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,912	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.8121	VUS
16	68862157	68862157	C	T	exonic	CDH1	.	nonsynonymous_SNV	CDH1:NM_001317184:exon13:c.C2062T:p.R688W,CDH1:NM_001317186:exon13:c.C280T:p.R94W,CDH1:NM_001317185:exon14:c.C697T:p.R233W,CDH1:NM_004360:exon14:c.C2245T:p.R749W	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	rs776975632	409709	not_specified	MedGen:CN169374	criteria_provided,_single_submitter	Uncertain_significance	0.0	0.912	D	0.000	0.454	D	1	0.810	D	4.005	0.969	H	-1.87	0.844	D	-7.51	0.951	D	0.890	0.955	D	0.834	0.944	D	0.213	0.875	D	0.86	0.958	0.703	0.343	D	c	0.726	0.612	0.953	0.280	0.672	0.522	0	5.1	0.688	1.285	0.326	0.935	0.490	0.951	0.329	1.000	0.888	16.499	0.840	Cadherin,_cytoplasmic_domain\x3bCadherin-like	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,917	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
16	68863657	68863657	C	G	exonic	CDH1	.	nonsynonymous_SNV	CDH1:NM_001317184:exon14:c.C2213G:p.P738R,CDH1:NM_001317186:exon14:c.C431G:p.P144R,CDH1:NM_001317185:exon15:c.C848G:p.P283R,CDH1:NM_004360:exon15:c.C2396G:p.P799R	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	rs587781335	150585	Hereditary_cancer-predisposing_syndrome|Hereditary_diffuse_gastric_cancer	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708349,OMIM:137215,Orphanet:ORPHA26106	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	0.02	0.496	D	0.000	0.504	D	1	0.810	D	2.13	0.595	M	-1.11	0.775	T	-6.06	0.898	D	-0.030	0.816	T	0.617	0.865	D	0.154	0.836	D	0.832	0.941	0.986	0.847	D	c	0.747	0.753	1.000	0.747	0.672	0.522	0	6.05	0.981	6.021	0.703	0.927	0.437	1.000	0.715	0.993	0.574	20.198	0.982	Cadherin,_cytoplasmic_domain\x3bCadherin,_cytoplasmic_domain|Catenin_binding_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,919	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
10	89692830	89692830	G	A	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon5:c.G314A:p.C105Y,PTEN:NM_001304717:exon6:c.G833A:p.C278Y	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs587782343	151975	Hereditary_cancer-predisposing_syndrome|PTEN_hamartoma_tumor_syndrome|not_specified	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498|MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	0.0	0.912	D	0.000	0.843	D	1	0.810	D	3.26	0.901	M	-1.98	0.853	D	-10.73	0.992	D	0.801	0.944	D	0.804	0.934	D	0.542	0.958	D	0.837	0.944	0.988	0.873	D	c	0.911	0.851	1.000	0.747	0.722	0.854	0	5.07	0.680	9.520	0.971	0.953	0.551	1.000	0.715	1.000	0.888	18.458	0.906	Dual_specificity_phosphatase,_catalytic_domain|Protein-tyrosine_phosphatase,_catalytic|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain\x3bDual_specificity_phosphatase,_catalytic_domain|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,539	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
3	12633207	12633207	C	A	exonic	RAF1	.	nonsynonymous_SNV	RAF1:NM_002880:exon11:c.G1193T:p.R398L	0.999776866110749	0.000223133833869176	5.53819998824154e-11	Raf-1_proto-oncogene,_serine/threonine_kinase	FUNCTION:_Serine/threonine-protein_kinase_that_acts_as_a_regulatory_link_between_the_membrane-associated_Ras_GTPases_and_the_MAPK/ERK_cascade,_and_this_critical_regulatory_link_functions_as_a_switch_determining_cell_fate_decisions_including_proliferation,_differentiation,_apoptosis,_survival_and_oncogenic_transformation._RAF1_activation_initiates_a_mitogen-activated_protein_kinase_(MAPK)_cascade_that_comprises_a_sequential_phosphorylation_of_the_dual-specific_MAPK_kinases_(MAP2K1/MEK1_and_MAP2K2/MEK2)_and_the_extracellular_signal-regulated_kinases_(MAPK3/ERK1_and_MAPK1/ERK2)._The_phosphorylated_form_of_RAF1_(on_residues_Ser-338_and_Ser-339,_by_PAK1)_phosphorylates_BAD/Bcl2-_antagonist_of_cell_death_at_'Ser-75'._Phosphorylates_adenylyl_cyclases:_ADCY2,_ADCY5_and_ADCY6,_resulting_in_their_activation._Phosphorylates_PPP1R12A_resulting_in_inhibition_of_the_phosphatase_activity._Phosphorylates_TNNT2/cardiac_muscle_troponin_T._Can_promote_NF-kB_activation_and_inhibit_signal_transducers_involved_in_motility_(ROCK2),_apoptosis_(MAP3K5/ASK1_and_STK3/MST2),_proliferation_and_angiogenesis_(RB1)._Can_protect_cells_from_apoptosis_also_by_translocating_to_the_mitochondria_where_it_binds_BCL2_and_displaces_BAD/Bcl2-antagonist_of_cell_death._Regulates_Rho_signaling_and_migration,_and_is_required_for_normal_wound_healing._Plays_a_role_in_the_oncogenic_transformation_of_epithelial_cells_via_repression_of_the_TJ_protein,_occludin_(OCLN)_by_inducing_the_up-regulation_of_a_transcriptional_repressor_SNAI2/SLUG,_which_induces_down-regulation_of_OCLN._Restricts_caspase_activation_in_response_to_selected_stimuli,_notably_Fas_stimulation,_pathogen-mediated_macrophage_apoptosis,_and_erythroid_differentiation._{ECO:0000269|PubMed:11427728,_ECO:0000269|PubMed:11719507,_ECO:0000269|PubMed:15385642,_ECO:0000269|PubMed:15618521,_ECO:0000269|PubMed:15849194,_ECO:0000269|PubMed:16892053,_ECO:0000269|PubMed:16924233,_ECO:0000269|PubMed:9360956}.\x3b_	DISEASE:_Noonan_syndrome_5_(NS5)_[MIM:611553]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._{ECO:0000269|PubMed:17603482,_ECO:0000269|PubMed:17603483,_ECO:0000269|PubMed:20683980}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_LEOPARD_syndrome_2_(LPRD2)_[MIM:611554]:_A_disorder_characterized_by_lentigines,_electrocardiographic_conduction_abnormalities,_ocular_hypertelorism,_pulmonic_stenosis,_abnormalities_of_genitalia,_retardation_of_growth,_and_sensorineural_deafness._{ECO:0000269|PubMed:17603483}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Cardiomyopathy,_dilated_1NN_(CMD1NN)_[MIM:615916]:_A_disorder_characterized_by_ventricular_dilation_and_impaired_systolic_function,_resulting_in_congestive_heart_failure_and_arrhythmia._Patients_are_at_risk_of_premature_death._{ECO:0000269|PubMed:24777450}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_In_skeletal_muscle,_isoform_1_is_more_abundant_than_isoform_2._{ECO:0000269|PubMed:1886707}.\x3b_	ovary\x3bumbilical_cord\x3bsympathetic_chain\x3bskin\x3bretina\x3bbone_marrow\x3bprostate\x3boptic_nerve\x3bfrontal_lobe\x3bcochlea\x3bendometrium\x3bgerminal_center\x3bbladder\x3bbrain\x3bheart\x3bcartilage\x3bspinal_cord\x3badrenal_cortex\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bmacula_lutea\x3bvisual_apparatus\x3bliver\x3balveolus\x3bspleen\x3bcervix\x3bmammary_gland\x3bperipheral_nerve\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3buterus\x3bwhole_body\x3boesophagus\x3bbone\x3btestis\x3bspinal_ganglion\x3bpineal_gland\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bislets_of_Langerhans\x3bhypothalamus\x3bmuscle\x3bpancreas\x3blung\x3btrachea\x3bplacenta\x3bamnion\x3bkidney\x3bstomach\x3baorta\x3bthymus\x3b	superior_cervical_ganglion\x3bciliary_ganglion\x3bwhole_blood\x3bskeletal_muscle\x3b	0.99869	0.93060	-0.646543901	16.44255721	87.82499	2.00185	rs730880382	49084	Rasopathy|not_specified|not_provided	MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374|MedGen:CN517202	reviewed_by_expert_panel	Uncertain_significance	0.001	0.784	D	0.000	0.843	D	1	0.810	D	0.855	0.214	L	-1.68	0.829	D	-6.44	0.918	D	0.155	0.851	D	0.634	0.872	D	0.292	0.906	D	0.735	0.868	0.999	0.999	D	c	0.752	0.757	1.000	0.747	0.707	0.730	0	5.15	0.702	7.900	0.859	0.935	0.490	1.000	0.715	0.937	0.410	19.178	0.936	Protein_kinase_domain|Protein_kinase-like_domain|Serine-threonine/tyrosine-protein_kinase,_catalytic_domain	.	.	1.0000	0.97	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,477	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
10	89717676	89717676	G	A	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon7:c.G701A:p.R234Q,PTEN:NM_001304718:exon7:c.G110A:p.R37Q,PTEN:NM_001304717:exon8:c.G1220A:p.R407Q	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs121909235	22879	Meningioma|Hereditary_cancer-predisposing_syndrome|PTEN_hamartoma_tumor_syndrome|Glioma_susceptibility_2	Human_Phenotype_Ontology:HP:0002858,MedGen:C0025286,Orphanet:ORPHA2495|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498|MedGen:C2751642,OMIM:613028	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	0.094	0.313	T	0.000	0.843	D	1	0.810	D	2.785	0.815	M	-1.98	0.853	D	-1.66	0.397	N	0.267	0.870	D	0.630	0.870	D	0.238	0.886	D	0.441	0.497	0.987	0.851	D	c	0.679	0.696	1.000	0.747	0.719	0.830	0	5.15	0.702	9.525	0.971	0.902	0.416	1.000	0.715	0.999	0.750	18.616	0.912	C2_domain|Tensin_phosphatase,_C2_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,574	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
1	215822033	215822033	C	T	exonic	USH2A	.	nonsynonymous_SNV	USH2A:NM_206933:exon66:c.G14419A:p.A4807T	3.68100336207458e-43	0.999989235571568	1.07644284322941e-05	Usher_syndrome_2A_(autosomal_recessive,_mild)	FUNCTION:_Involved_in_hearing_and_vision.\x3b_	DISEASE:_Usher_syndrome_2A_(USH2A)_[MIM:276901]:_USH_is_a_genetically_heterogeneous_condition_characterized_by_the_association_of_retinitis_pigmentosa_with_sensorineural_deafness._Age_at_onset_and_differences_in_auditory_and_vestibular_function_distinguish_Usher_syndrome_type_1_(USH1),_Usher_syndrome_type_2_(USH2)_and_Usher_syndrome_type_3_(USH3)._USH2_is_characterized_by_congenital_mild_hearing_impairment_with_normal_vestibular_responses._{ECO:0000269|PubMed:10729113,_ECO:0000269|PubMed:10738000,_ECO:0000269|PubMed:10909849,_ECO:0000269|PubMed:11311042,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:12525556,_ECO:0000269|PubMed:14970843,_ECO:0000269|PubMed:15015129,_ECO:0000269|PubMed:15025721,_ECO:0000269|PubMed:15241801,_ECO:0000269|PubMed:15325563,_ECO:0000269|PubMed:17085681,_ECO:0000269|PubMed:17405132,_ECO:0000269|PubMed:18273898,_ECO:0000269|PubMed:18452394,_ECO:0000269|PubMed:19683999,_ECO:0000269|PubMed:19737284,_ECO:0000269|PubMed:20309401,_ECO:0000269|PubMed:20440071,_ECO:0000269|PubMed:20507924,_ECO:0000269|PubMed:21593743,_ECO:0000269|PubMed:21686329,_ECO:0000269|PubMed:22004887,_ECO:0000269|PubMed:23737954,_ECO:0000269|PubMed:9624053}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Retinitis_pigmentosa_39_(RP39)_[MIM:613809]:_A_retinal_dystrophy_belonging_to_the_group_of_pigmentary_retinopathies._Retinitis_pigmentosa_is_characterized_by_retinal_pigment_deposits_visible_on_fundus_examination_and_primary_loss_of_rod_photoreceptor_cells_followed_by_secondary_loss_of_cone_photoreceptors._Patients_typically_have_night_vision_blindness_and_loss_of_midperipheral_visual_field._As_their_condition_progresses,_they_lose_their_far_peripheral_visual_field_and_eventually_central_vision_as_well._{ECO:0000269|PubMed:10775529,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:12427073,_ECO:0000269|PubMed:15325563,_ECO:0000269|PubMed:16098008,_ECO:0000269|PubMed:17296898,_ECO:0000269|PubMed:20507924,_ECO:0000269|PubMed:21686329,_ECO:0000269|PubMed:22334370,_ECO:0000269|PubMed:24227914}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Present_in_the_basement_membrane_of_many,_but_not_all_tissues._Expressed_in_retina,_cochlea,_small_and_large_intestine,_pancreas,_bladder,_prostate,_esophagus,_trachea,_thymus,_salivary_glands,_placenta,_ovary,_fallopian_tube,_uterus_and_testis._Absent_in_many_other_tissues_such_as_heart,_lung,_liver,_kidney_and_brain._In_the_retina,_it_is_present_in_the_basement_membranes_in_the_Bruch's_layer_choroid_capillary_basement_membranes,_where_it_localizes_just_beneath_the_retinal_pigment_epithelial_cells_(at_protein_level)._Weakly_expressed._Isoform_2_is_expressed_in_fetal_eye,_cochlea_and_heart,_and_at_very_low_level_in_brain,_CNS,_intestine,_skeleton,_tongue,_kidney_and_lung._Isoform_2_is_not_expressed_in_stomach_and_liver._In_adult_tissues,_isoform_2_is_expressed_in_neural_retina_and_testis,_and_at_low_level_in_brain,_heart,_kidney_and_liver._Isoform_1_displays_a_similar_pattern_of_expression_but_is_expressed_at_very_low_level_in_fetal_cochlea._{ECO:0000269|PubMed:11788194,_ECO:0000269|PubMed:12433396,_ECO:0000269|PubMed:15015129,_ECO:0000269|PubMed:9624053}.\x3b_	unclassifiable_(Anatomical_System)\x3bliver\x3btestis\x3bretina\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3badrenal_gland\x3btemporal_lobe\x3bciliary_ganglion\x3batrioventricular_node\x3btrigeminal_ganglion\x3bskin\x3bskeletal_muscle\x3bcerebellum\x3b	0.15836	.	4.179636958	99.70511913	6401.91635	16.71188	rs534656527	195527	not_specified	MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	0.035	0.437	D	0.001	0.432	D	1.000	0.537	D	3.46	0.925	M	-0.1	0.643	T	-1.51	0.368	N	0.039	0.830	D	0.449	0.784	T	0.393	0.932	D	.	.	0.991	0.917	D	c	0.874	0.849	1.000	0.747	0.487	0.133	0	5.63	0.861	7.705	0.835	0.935	0.490	1.000	0.715	0.993	0.574	19.710	0.961	Fibronectin_type_III|Immunoglobulin-like_fold	.	.	.	.	.	.	.	.	.	.	.	.	6.5e-05	0	0	0	0	0	9.856e-05	0	0.0002	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,447	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
10	89711916	89711917	TA	AT	exonic	PTEN	.	nonframeshift_substitution	PTEN:NM_000314:exon6:c.534_535AT,PTEN:NM_001304717:exon7:c.1053_1054AT	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs397515374	22863	Bannayan-Riley-Ruvalcaba_syndrome	MedGen:C0265326,OMIM:153480,Orphanet:ORPHA109	no_assertion_criteria_provided	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,565	0	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0.8121	VUS
10	89717697	89717697	T	C	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon7:c.T722C:p.F241S,PTEN:NM_001304718:exon7:c.T131C:p.F44S,PTEN:NM_001304717:exon8:c.T1241C:p.F414S	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs121909240	22889	Macrocephaly/autism_syndrome|PTEN_hamartoma_tumor_syndrome	MedGen:C1854416,OMIM:605309,Orphanet:ORPHA210548|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498	criteria_provided,_single_submitter	Uncertain_significance	0.14	0.256	T	0.000	0.843	D	1	0.810	A	2.84	0.828	M	-2.07	0.860	D	-3.21	0.648	D	0.007	0.824	D	0.535	0.828	D	0.312	0.912	D	0.722	0.857	0.973	0.740	D	c	0.140	0.280	1.000	0.747	0.719	0.830	0	5.15	0.702	7.615	0.821	0.913	0.425	1.000	0.715	1.000	0.888	14.966	0.707	C2_domain|Tensin_phosphatase,_C2_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,576	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
21	36259175	36259175	A	T	exonic	RUNX1	.	nonsynonymous_SNV	RUNX1:NM_001001890:exon1:c.T235A:p.W79R,RUNX1:NM_001122607:exon1:c.T235A:p.W79R,RUNX1:NM_001754:exon4:c.T316A:p.W106R	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	.	430422	not_specified	MedGen:CN169374	criteria_provided,_single_submitter	Uncertain_significance	0.0	0.912	D	0.000	0.629	D	1	0.810	D	2.82	0.824	M	-7.5	0.999	D	-10.22	0.998	D	0.898	0.956	D	0.995	0.999	D	0.943	0.996	D	0.934	0.990	0.967	0.704	D	c	0.860	0.779	1.0	0.983	0.405	0.054	1	4.72	0.591	8.773	0.913	1.088	0.866	1.000	0.715	1.000	0.888	14.361	0.662	Runt_domain|p53-like_transcription_factor,_DNA-binding|p53/RUNT-type_transcription_factor,_DNA-binding_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,980	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
21	36259336	36259336	A	T	exonic	RUNX1	.	nonsynonymous_SNV	RUNX1:NM_001001890:exon1:c.T74A:p.M25K,RUNX1:NM_001122607:exon1:c.T74A:p.M25K,RUNX1:NM_001754:exon4:c.T155A:p.M52K	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	rs200431130	243618	Familial_platelet_disorder_with_associated_myeloid_malignancy|not_specified	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290|MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	0.001	0.784	D	0.000	0.843	D	1.000	0.588	D	2.405	0.698	M	-4.31	0.994	D	-3.9	0.788	D	1.087	0.991	D	0.975	0.992	D	0.898	0.992	D	.	.	0.936	0.583	D	c	0.617	0.586	1.0	0.983	0.628	0.401	0	5.04	0.672	6.863	0.751	1.088	0.866	1.000	0.715	1.000	0.888	14.769	0.691	Runt_domain|p53-like_transcription_factor,_DNA-binding|p53/RUNT-type_transcription_factor,_DNA-binding_domain	.	.	.	.	0.0002	0	0	0	0	0	0.0003	0	0.0002	0	3.002e-05	0	0	0	0.0005	0.0006	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,986	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
10	89717675	89717675	C	T	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon7:c.C700T:p.R234W,PTEN:NM_001304718:exon7:c.C109T:p.R37W,PTEN:NM_001304717:exon8:c.C1219T:p.R407W	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs786201730	183040	Neoplasm|Hereditary_cancer-predisposing_syndrome|not_specified	MeSH:D009369,MedGen:C0027651,SNOMED_CT:108369006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	0.081	0.334	T	0.000	0.843	D	1	0.810	D	1.69	0.435	L	-2.03	0.856	D	-4.9	0.815	D	0.478	0.902	D	0.727	0.906	D	0.326	0.916	D	0.475	0.552	0.945	0.611	D	c	0.648	0.627	1.000	0.747	0.719	0.830	0	5.15	0.702	4.498	0.599	0.807	0.329	1.000	0.715	0.999	0.750	18.616	0.912	C2_domain|Tensin_phosphatase,_C2_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,573	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
21	36259177	36259177	T	G	exonic	RUNX1	.	nonsynonymous_SNV	RUNX1:NM_001001890:exon1:c.A233C:p.H78P,RUNX1:NM_001122607:exon1:c.A233C:p.H78P,RUNX1:NM_001754:exon4:c.A314C:p.H105P	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	.	.	.	.	.	.	0.001	0.784	D	0.000	0.843	D	1	0.810	D	2.82	0.824	M	-7.14	0.998	D	-7.63	0.982	D	0.940	0.962	D	0.993	0.998	D	0.961	0.997	D	0.861	0.958	0.959	0.663	D	c	0.789	0.717	1.0	0.983	0.405	0.054	1	4.72	0.591	5.758	0.682	0.964	0.580	1.000	0.715	1.000	0.888	14.361	0.662	Runt_domain|p53-like_transcription_factor,_DNA-binding|p53/RUNT-type_transcription_factor,_DNA-binding_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,981	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
10	89720763	89720763	G	A	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon8:c.G914A:p.S305N,PTEN:NM_001304718:exon8:c.G323A:p.S108N,PTEN:NM_001304717:exon9:c.G1433A:p.S478N	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs587780007	133153	Hereditary_cancer-predisposing_syndrome|PTEN_hamartoma_tumor_syndrome|not_specified|not_provided	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498|MedGen:CN169374|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	0.231	0.182	T	0.001	0.392	N	1.000	0.478	D	2.215	0.627	M	-3.46	0.945	D	-0.16	0.095	N	0.296	0.875	D	0.746	0.913	D	0.112	0.790	D	0.354	0.355	0.987	0.856	D	c	0.073	0.246	1.000	0.747	0.732	0.924	0	5.13	0.696	5.663	0.675	0.998	0.613	1.000	0.715	1.000	0.888	18.563	0.910	C2_domain|Tensin_phosphatase,_C2_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,587	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
21	36259238	36259238	G	T	exonic	RUNX1	.	nonsynonymous_SNV	RUNX1:NM_001001890:exon1:c.C172A:p.H58N,RUNX1:NM_001122607:exon1:c.C172A:p.H58N,RUNX1:NM_001754:exon4:c.C253A:p.H85N	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	rs121912500	29508	Familial_platelet_disorder_with_associated_myeloid_malignancy|Leukemia,_acute_myeloid,_m0_subtype|Transient_myeloproliferative_disorder_of_Down_syndrome	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290|MedGen:C1835434|MedGen:C1860788	criteria_provided,_single_submitter	Uncertain_significance	0.0	0.912	D	0.000	0.843	D	1	0.810	A	2.525	0.740	M	-5.94	0.995	D	-5.3	0.908	D	1.081	0.989	D	0.980	0.994	D	0.911	0.993	D	0.659	0.797	0.993	0.944	D	c	0.766	0.769	1.0	0.983	0.405	0.054	1	5.25	0.731	9.415	0.966	0.953	0.551	1.000	0.715	1.000	0.888	18.832	0.921	Runt_domain|p53-like_transcription_factor,_DNA-binding|p53/RUNT-type_transcription_factor,_DNA-binding_domain	.	.	.	.	3.231e-05	0	0	0	0.0006	0	0	0	3.294e-05	0	0	0	0.0004	0	9.151e-06	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,983	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
10	89720690	89720690	C	G	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon8:c.C841G:p.P281A,PTEN:NM_001304718:exon8:c.C250G:p.P84A,PTEN:NM_001304717:exon9:c.C1360G:p.P454A	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs750705904	183047	Hereditary_cancer-predisposing_syndrome|PTEN_hamartoma_tumor_syndrome|not_specified	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498|MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	0.574	0.061	T	0.000	0.843	D	1	0.810	D	2.295	0.656	M	-1.94	0.849	D	-1.07	0.279	N	0.108	0.843	D	0.590	0.853	D	0.118	0.799	D	0.512	0.611	0.994	0.959	D	c	0.549	0.583	1.000	0.747	0.707	0.730	0	5.13	0.696	6.545	0.736	0.892	0.403	1.000	0.715	1.000	0.888	17.335	0.871	C2_domain|Tensin_phosphatase,_C2_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,584	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	112888151	112888151	T	C	exonic	PTPN11	.	nonsynonymous_SNV	PTPN11:NM_001330437:exon3:c.T167C:p.I56T,PTPN11:NM_002834:exon3:c.T167C:p.I56T,PTPN11:NM_080601:exon3:c.T167C:p.I56T	0.999877230878678	0.000122769057470549	6.38519788034449e-11	protein_tyrosine_phosphatase,_non-receptor_type_11	FUNCTION:_Acts_downstream_of_various_receptor_and_cytoplasmic_protein_tyrosine_kinases_to_participate_in_the_signal_transduction_from_the_cell_surface_to_the_nucleus._Dephosphorylates_ROCK2_at_Tyr-722_resulting_in_stimulatation_of_its_RhoA_binding_activity._{ECO:0000269|PubMed:10655584,_ECO:0000269|PubMed:18559669,_ECO:0000269|PubMed:18829466}.\x3b_	DISEASE:_LEOPARD_syndrome_1_(LPRD1)_[MIM:151100]:_A_disorder_characterized_by_lentigines,_electrocardiographic_conduction_abnormalities,_ocular_hypertelorism,_pulmonic_stenosis,_abnormalities_of_genitalia,_retardation_of_growth,_and_sensorineural_deafness._{ECO:0000269|PubMed:12058348,_ECO:0000269|PubMed:14961557,_ECO:0000269|PubMed:15121796,_ECO:0000269|PubMed:15389709,_ECO:0000269|PubMed:15520399,_ECO:0000269|PubMed:15690106,_ECO:0000269|PubMed:16679933,_ECO:0000269|PubMed:24891296}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Noonan_syndrome_1_(NS1)_[MIM:163950]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._Some_patients_with_NS1_develop_multiple_giant_cell_lesions_of_the_jaw_or_other_bony_or_soft_tissues,_which_are_classified_as_pigmented_villonodular_synovitis_(PVNS)_when_occurring_in_the_jaw_or_joints._{ECO:0000269|PubMed:11704759,_ECO:0000269|PubMed:11992261,_ECO:0000269|PubMed:12161469,_ECO:0000269|PubMed:12325025,_ECO:0000269|PubMed:12529711,_ECO:0000269|PubMed:12634870,_ECO:0000269|PubMed:12717436,_ECO:0000269|PubMed:12739139,_ECO:0000269|PubMed:12960218,_ECO:0000269|PubMed:15384080,_ECO:0000269|PubMed:15948193,_ECO:0000269|PubMed:19020799,_ECO:0000269|PubMed:24891296}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry._Mutations_in_PTPN11_account_for_more_than_50%_of_the_cases.\x3b_DISEASE:_Leukemia,_juvenile_myelomonocytic_(JMML)_[MIM:607785]:_An_aggressive_pediatric_myelodysplastic_syndrome/myeloproliferative_disorder_characterized_by_malignant_transformation_in_the_hematopoietic_stem_cell_compartment_with_proliferation_of_differentiated_progeny._Patients_have_splenomegaly,_enlarged_lymph_nodes,_rashes,_and_hemorrhages._{ECO:0000269|PubMed:12717436}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Metachondromatosis_(MC)_[MIM:156250]:_A_skeletal_disorder_with_radiologic_features_of_both_multiple_exostoses_and_Ollier_disease,_characterized_by_the_presence_of_exostoses,_commonly_of_the_bones_of_the_hands_and_feet,_and_enchondromas_of_the_metaphyses_of_long_bones_and_iliac_crest._{ECO:0000269|PubMed:20577567}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Widely_expressed,_with_highest_levels_in_heart,_brain,_and_skeletal_muscle._{ECO:0000269|PubMed:1280823,_ECO:0000269|PubMed:7681589,_ECO:0000269|PubMed:8216283}.\x3b_	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3bfrontal_lobe\x3bendometrium\x3boesophagus\x3blarynx\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bpineal_gland\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bpineal_body\x3burinary\x3badrenal_cortex\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3blung\x3bcornea\x3badrenal_gland\x3bplacenta\x3bvisual_apparatus\x3bhippocampus\x3bhypopharynx\x3bliver\x3bhead_and_neck\x3bcervix\x3bkidney\x3bmammary_gland\x3baorta\x3bstomach\x3b	amygdala\x3btestis_-_interstitial\x3bthalamus\x3bmedulla_oblongata\x3bsuperior_cervical_ganglion\x3boccipital_lobe\x3bhypothalamus\x3bspinal_cord\x3bcaudate_nucleus\x3bpons\x3bskeletal_muscle\x3bsubthalamic_nucleus\x3bprefrontal_cortex\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bparietal_lobe\x3b	0.26245	0.72890	-0.427900189	25.14744043	19.44641	0.66817	rs1052382672	462420	Rasopathy	MedGen:CN166718,Orphanet:ORPHA98733	criteria_provided,_single_submitter	Uncertain_significance	0.0	0.912	D	0.000	0.843	D	1	0.810	D	3.93	0.964	H	-4.95	0.984	D	-4.48	0.779	D	1.020	0.975	D	0.982	0.995	D	0.706	0.976	D	0.878	0.967	0.990	0.892	D	c	1.075	0.962	1.000	0.747	0.722	0.854	0	5.63	0.861	8.008	0.880	1.057	0.759	1.000	0.715	0.997	0.653	15.855	0.787	SH2_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,854	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
16	68847240	68847240	G	A	exonic	CDH1	.	nonsynonymous_SNV	CDH1:NM_004360:exon9:c.G1162A:p.E388K	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	rs372838203	133363	Hereditary_cancer-predisposing_syndrome|Hereditary_diffuse_gastric_cancer|not_specified	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708349,OMIM:137215,Orphanet:ORPHA26106|MedGen:CN169374	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.414	0.100	T	0.878	0.088	N	1	0.090	N	0.93	0.236	L	0.66	0.524	T	-0.49	0.156	N	-1.004	0.286	T	0.061	0.253	T	0.015	0.361	T	.	.	0.137	0.178	N	c	-1.333	-1.311	0.005	0.110	0.672	0.522	0	-1.35	0.086	-0.197	0.094	-0.826	0.030	0.001	0.137	0.003	0.074	8.235	0.306	Cadherin-like\x3bCadherin|Cadherin-like	.	.	.	.	6.457e-05	0	0	0	0.0006	0	6.661e-05	0	2.843e-05	0	0.0001	0	5.798e-05	0	1.791e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,907	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0.6752	VUS
16	68846047	68846047	A	G	exonic	CDH1	.	nonsynonymous_SNV	CDH1:NM_001317184:exon8:c.A1018G:p.T340A,CDH1:NM_004360:exon8:c.A1018G:p.T340A	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	rs116093741	27284	Hereditary_cancer-predisposing_syndrome|Hereditary_diffuse_gastric_cancer|not_specified	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708349,OMIM:137215,Orphanet:ORPHA26106|MedGen:CN169374	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.046	0.405	D	0.689	0.061	N	1	0.090	N	0.825	0.210	L	0.68	0.520	T	-0.68	0.195	N	-0.977	0.357	T	0.066	0.273	T	0.013	0.322	T	.	.	0.130	0.174	N	c	-1.267	-1.290	1.000	0.462	0.672	0.522	0	-3.7	0.041	-0.366	0.076	0.234	0.260	0.000	0.063	0.001	0.043	7.090	0.243	Cadherin|Cadherin-like	.	.	.	.	0.0002	0	0	0	0.0043	0	0	0	0.0002	0	0	0	0.0035	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,902	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0.6752	VUS
21	36164771	36164771	C	CATGCCG	exonic	RUNX1	.	nonframeshift_insertion	RUNX1:NM_001001890:exon6:c.1022_1023insCGGCAT:p.M341delinsIGM,RUNX1:NM_001754:exon9:c.1103_1104insCGGCAT:p.M368delinsIGM	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	rs750495319	243603	Familial_platelet_disorder_with_associated_myeloid_malignancy	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290	criteria_provided,_single_submitter	Uncertain_significance	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	6.483e-05	0	0	0	0.0006	0	6.696e-05	0	7.711e-05	0	0	0	0	0	0.0001	0.0004	0.0002	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,951	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
12	103234275	103234275	T	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon12:c.A1218G:p.I406M	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs773526027	.	.	.	.	.	0.085	0.327	T	0.000	0.843	D	1	0.810	D	1.42	0.358	L	-6.4	0.997	D	-2.21	0.496	N	1.022	0.976	D	0.970	0.990	D	0.838	0.988	D	0.813	0.929	0.649	0.323	D	c	-0.074	-0.152	0.000	0.055	0.638	0.428	0	-1.78	0.075	-0.030	0.122	0.128	0.215	0.816	0.297	0.989	0.536	6.608	0.218	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	3.232e-05	0	0	0	0	0	6.664e-05	0	8.123e-06	0	0	0	0	0	1.791e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,654	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
12	103310907	103310907	A	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon1:c.T2C:p.M1T	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62508575	200225	not_provided	MedGen:CN517202	criteria_provided,_single_submitter	Pathogenic	0.004	0.912	D	0.765	0.096	N	1	0.810	D	.	.	.	-5.72	0.993	D	-0.48	0.183	N	1.024	0.976	D	0.975	0.992	D	0.972	0.998	D	.	.	0.894	0.496	D	c	0.366	0.338	1.000	0.747	0.405	0.054	1	5.2	0.716	3.852	0.554	1.199	0.960	1.000	0.715	0.275	0.232	11.636	0.503	.	.	.	.	.	3.229e-05	0.0001	0	0	0	0	0	0	8.122e-06	0.0001	0	0	0	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,850	0	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.6752	VUS
10	89717690	89717690	A	G	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon7:c.A715G:p.M239V,PTEN:NM_001304718:exon7:c.A124G:p.M42V,PTEN:NM_001304717:exon8:c.A1234G:p.M412V	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs786201758	183042	Hereditary_cancer-predisposing_syndrome|not_specified	MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	0.844	0.028	T	0.000	0.843	D	1	0.810	D	0.98	0.250	L	-1.88	0.845	D	-0.23	0.107	N	-0.553	0.667	T	0.360	0.722	T	0.091	0.757	D	0.47	0.544	0.983	0.813	D	c	-0.045	0.175	1.000	0.747	0.719	0.830	0	5.15	0.702	8.875	0.919	1.028	0.649	1.000	0.715	1.000	0.888	14.966	0.707	C2_domain|Tensin_phosphatase,_C2_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,575	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
10	89725066	89725069	CAGT	C	exonic	PTEN	.	nonframeshift_deletion	PTEN:NM_000314:exon9:c.1050_1052del:p.350_351del,PTEN:NM_001304718:exon9:c.459_461del:p.153_154del,PTEN:NM_001304717:exon10:c.1569_1571del:p.523_524del	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs587780003	133144	Hereditary_cancer-predisposing_syndrome|not_specified	MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,593	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
10	112724635	112724635	G	A	exonic	SHOC2	.	nonsynonymous_SNV	SHOC2:NM_001269039:exon2:c.G519A:p.M173I,SHOC2:NM_001324336:exon2:c.G519A:p.M173I,SHOC2:NM_007373:exon2:c.G519A:p.M173I,SHOC2:NM_001324337:exon3:c.G519A:p.M173I	0.991705191552454	0.00829295945769003	1.84898985615785e-06	SHOC2_leucine-rich_repeat_scaffold_protein	FUNCTION:_Regulatory_subunit_of_protein_phosphatase_1_(PP1c)_that_acts_as_a_M-Ras/MRAS_effector_and_participates_in_MAPK_pathway_activation._Upon_M-Ras/MRAS_activation,_targets_PP1c_to_specifically_dephosphorylate_the_'Ser-259'_inhibitory_site_of_RAF1_kinase_and_stimulate_RAF1_activity_at_specialized_signaling_complexes._{ECO:0000269|PubMed:10783161,_ECO:0000269|PubMed:16630891,_ECO:0000269|PubMed:25137548}.\x3b_	DISEASE:_Noonan_syndrome-like_disorder_with_loose_anagen_hair_(NSLH)_[MIM:607721]:_A_syndrome_characterized_by_Noonan_dysmorphic_features_such_as_macrocephaly,_high_forehead,_hypertelorism,_palpebral_ptosis,_low-set_and_posteriorly_rotated_ears,_short_and_webbed_neck,_pectus_anomalies,_in_association_with_pluckable,_sparse,_thin_and_slow-growing_hair._{ECO:0000269|PubMed:19684605,_ECO:0000269|PubMed:25137548}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bpineal_body\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bcornea\x3bnasopharynx\x3bplacenta\x3bmacula_lutea\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bcervix\x3bkidney\x3bmammary_gland\x3bstomach\x3b	superior_cervical_ganglion\x3btestis_-_seminiferous_tubule\x3bprefrontal_cortex\x3btestis\x3btrigeminal_ganglion\x3b	0.46401	0.24608	-0.183570861	39.95046001	30.58108	0.97282	rs730881020	179142	Noonan_syndrome-like_disorder_with_loose_anagen_hair_1|Rasopathy|not_specified|not_provided	MedGen:C1843181,OMIM:607721|MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374|MedGen:CN517202	reviewed_by_expert_panel	Uncertain_significance	0.075	0.344	T	0.000	0.843	D	1	0.810	D	-0.12	0.045	N	0.44	0.566	T	0.27	0.052	N	-1.061	0.115	T	0.065	0.268	T	0.803	0.985	D	0.317	0.295	0.989	0.887	D	c	-0.421	-0.184	1.000	0.747	0.707	0.730	0	4.89	0.632	10.003	0.997	0.949	0.536	1.000	0.715	1.000	0.888	14.823	0.696	Leucine-rich_repeat_domain,_L_domain-like	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,603	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
16	68867265	68867265	A	G	exonic	CDH1	.	nonsynonymous_SNV	CDH1:NM_001317184:exon15:c.A2329G:p.S777G,CDH1:NM_001317186:exon15:c.A547G:p.S183G,CDH1:NM_001317185:exon16:c.A964G:p.S322G,CDH1:NM_004360:exon16:c.A2512G:p.S838G	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	rs121964872	27272	Neoplasm_of_ovary|Hereditary_cancer-predisposing_syndrome|Hereditary_diffuse_gastric_cancer|not_specified|not_provided	Gene:6765,Human_Phenotype_Ontology:HP:0100615,MedGen:C0919267,OMIM:167000,SNOMED_CT:123843001|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708349,OMIM:137215,Orphanet:ORPHA26106|MedGen:CN169374|MedGen:CN517202	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.138	0.272	T	0.000	0.629	D	0.818	0.349	D	0.225	0.096	N	-1.02	0.763	T	-1.47	0.360	N	-0.622	0.639	T	0.242	0.610	T	0.027	0.497	D	.	.	0.880	0.475	D	c	-0.124	0.111	0.026	0.137	0.632	0.406	0	6.04	0.980	4.411	0.593	1.199	0.960	0.996	0.391	0.978	0.483	11.589	0.500	Cadherin,_cytoplasmic_domain\x3bCadherin,_cytoplasmic_domain|Catenin_binding_domain	.	.	.	.	0.0002	0	0	0	0	0	0.0003	0	4.061e-05	0	0	0	0	0	8.951e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,923	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0.6752	VUS
21	36164715	36164715	C	G	exonic	RUNX1	.	nonsynonymous_SNV	RUNX1:NM_001001890:exon6:c.G1079C:p.G360A,RUNX1:NM_001754:exon9:c.G1160C:p.G387A	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	.	533838	Familial_platelet_disorder_with_associated_myeloid_malignancy	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290	criteria_provided,_single_submitter	Uncertain_significance	0.064	0.614	T	0.006	0.321	N	0.999	0.470	D	2.08	0.576	M	1.54	0.301	T	-3.76	0.745	D	-0.991	0.324	T	0.136	0.451	T	0.263	0.896	D	0.668	0.806	0.871	0.463	D	c	0.217	0.316	1.000	0.747	0.660	0.495	0	5.22	0.722	5.484	0.663	0.918	0.429	1.000	0.715	0.997	0.653	18.382	0.904	Runx,_C-terminal__domain	.	.	.	.	.	.	.	.	.	.	.	.	5.873e-06	0	0	0	0	0	1.434e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,950	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
16	68847375	68847375	G	A	exonic	CDH1	.	nonsynonymous_SNV	CDH1:NM_004360:exon9:c.G1297A:p.D433N	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	rs199886166	133367	Hereditary_cancer-predisposing_syndrome|Hereditary_diffuse_gastric_cancer|not_specified|not_provided	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708349,OMIM:137215,Orphanet:ORPHA26106|MedGen:CN169374|MedGen:CN517202	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.089	0.321	T	0.408	0.130	N	1	0.225	N	0.925	0.236	L	1.2	0.374	T	-1.61	0.387	N	-1.034	0.192	T	0.055	0.233	T	0.014	0.347	T	.	.	0.861	0.451	D	c	-0.433	-0.342	0.073	0.156	0.672	0.522	0	2.84	0.321	3.888	0.557	0.141	0.225	1.000	0.715	0.492	0.269	7.808	0.282	Cadherin|Cadherin-like	.	.	.	.	.	.	.	.	.	.	.	.	4.873e-05	0	0	0.0008	0.0001	0	1.79e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,909	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0.6752	VUS
16	68835597	68835597	G	A	exonic	CDH1	.	nonsynonymous_SNV	CDH1:NM_001317184:exon3:c.G188A:p.R63Q,CDH1:NM_004360:exon3:c.G188A:p.R63Q	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	rs587780117	133376	Hereditary_cancer-predisposing_syndrome|Hereditary_diffuse_gastric_cancer|not_specified	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708349,OMIM:137215,Orphanet:ORPHA26106|MedGen:CN169374	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.34	0.158	T	0.085	0.207	N	1.000	0.182	N	1.8	0.476	L	0.13	0.610	T	-1.29	0.336	N	-0.988	0.332	T	0.143	0.465	T	0.044	0.616	D	.	.	0.065	0.124	N	c	-0.722	-0.745	1.000	0.473	0.707	0.730	0	2.18	0.267	0.326	0.192	-0.307	0.079	0.000	0.063	0.043	0.159	5.762	0.174	Cadherin_prodomain|Cadherin-like	.	.	.	.	.	.	.	.	.	.	.	.	6.905e-05	6.534e-05	0	0	0	0	2.687e-05	0.0011	0.0002	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,890	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0.6752	VUS
2	39262409	39262409	G	A	exonic	SOS1	.	nonsynonymous_SNV	SOS1:NM_005633:exon8:c.C1018T:p.P340S	0.99999989519361	1.04806389809942e-07	1.77231495230296e-20	SOS_Ras/Rac_guanine_nucleotide_exchange_factor_1	FUNCTION:_Promotes_the_exchange_of_Ras-bound_GDP_by_GTP._Catalytic_component_of_a_trimeric_complex_that_participates_in_transduction_of_signals_from_Ras_to_Rac_by_promoting_the_Rac-specific_guanine_nucleotide_exchange_factor_(GEF)_activity_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Noonan_syndrome_4_(NS4)_[MIM:610733]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._Some_patients_with_NS4_have_polyarticular_villonodular_synovitis._{ECO:0000269|PubMed:17143282,_ECO:0000269|PubMed:17143285,_ECO:0000269|PubMed:19020799,_ECO:0000269|PubMed:19438935,_ECO:0000269|PubMed:19953625,_ECO:0000269|PubMed:20673819,_ECO:0000269|PubMed:20683980,_ECO:0000269|PubMed:21387466}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_gingival_tissues._{ECO:0000269|PubMed:11868160}.\x3b_	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3blarynx\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bbile_duct\x3blung\x3bplacenta\x3bmacula_lutea\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3btestis\x3bciliary_ganglion\x3bpons\x3batrioventricular_node\x3bskeletal_muscle\x3b	0.72054	0.38414	-0.995664936	8.539749941	106.78667	2.24216	rs190222208	49134	Rasopathy|not_specified|not_provided	MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374|MedGen:CN517202	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.0	0.912	D	0.000	0.629	D	1	0.810	D	2.89	0.840	M	0.05	0.619	T	-7.14	0.941	D	0.001	0.823	D	0.503	0.813	D	0.190	0.862	D	.	.	0.991	0.907	D	c	0.996	0.975	1.000	0.747	0.706	0.609	0	6.01	0.974	9.460	0.968	1.048	0.713	1.000	0.715	0.996	0.625	20.521	0.992	Dbl_homology_(DH)_domain	.	.	.	.	6.477e-05	0.0001	0	0	0.0006	0	0	0	8.533e-05	0.0003	0	0	0.0005	0	0	0.0002	0.0003	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,468	0	0	0	0	0	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.6752	VUS
16	68835695	68835695	A	G	exonic	CDH1	.	nonsynonymous_SNV	CDH1:NM_001317184:exon3:c.A286G:p.I96V,CDH1:NM_004360:exon3:c.A286G:p.I96V	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	rs749306433	222499	Hereditary_cancer-predisposing_syndrome|Hereditary_diffuse_gastric_cancer|not_specified	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708349,OMIM:137215,Orphanet:ORPHA26106|MedGen:CN169374	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.65	0.065	T	0.969	0.082	N	1	0.090	N	1.175	0.300	L	0.18	0.604	T	0.03	0.078	N	-0.834	0.531	T	0.175	0.519	T	0.027	0.503	D	0.562	0.683	0.165	0.192	N	c	-0.842	-0.863	1.000	0.420	0.707	0.730	0	1.83	0.242	1.677	0.370	0.242	0.267	0.093	0.224	0.009	0.108	7.722	0.277	Cadherin_prodomain|Cadherin-like	.	.	.	.	.	.	.	.	.	.	.	.	0.0002	0	0.0012	0	0	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,892	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0.6752	VUS
12	103288546	103288555	GGACAGTGGC	G	exonic	PAH	.	nonframeshift_deletion	PAH:NM_000277:exon3:c.310_318del:p.104_106del	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs398123291	98647	not_specified	MedGen:CN169374	criteria_provided,_single_submitter	Uncertain_significance	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	4.061e-06	6.534e-05	0	0	0	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,808	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
10	89692819	89692819	C	CAAA	exonic	PTEN	.	nonframeshift_insertion	PTEN:NM_000314:exon5:c.303_304insAAA:p.I101delinsIK,PTEN:NM_001304717:exon6:c.822_823insAAA:p.I274delinsIK	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs587782641	152395	Hereditary_cancer-predisposing_syndrome|not_specified	MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,537	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
12	103288566	103288566	T	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon3:c.A299G:p.H100R	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs148393887	315838	Phenylketonuria	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006	criteria_provided,_single_submitter	Uncertain_significance	0.44	0.106	T	0.038	0.243	N	1	0.090	N	0.09	0.084	N	-4.73	0.981	D	0.23	0.046	N	0.043	0.831	D	0.810	0.936	D	0.078	0.729	D	.	.	0.512	0.286	D	c	-0.395	-0.234	0.999	0.398	0.615	0.372	0	5.03	0.669	1.730	0.375	1.061	0.807	0.781	0.292	0.143	0.203	10.907	0.461	ACT_domain	.	.	.	.	0.0001	0	0	0	0	0	0.0003	0	0.0003	6.534e-05	0.0004	0	0	4.485e-05	0.0005	0.0009	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,810	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
21	36164453	36164453	C	A	exonic	RUNX1	.	nonsynonymous_SNV	RUNX1:NM_001001890:exon6:c.G1341T:p.E447D,RUNX1:NM_001754:exon9:c.G1422T:p.E474D	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	rs886057047	350633	Familial_platelet_disorder_with_associated_myeloid_malignancy	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	0.0	0.912	D	.	.	.	0.815	0.375	D	2.24	0.636	M	0.84	0.475	T	-2.08	0.511	N	-0.742	0.584	T	0.241	0.609	T	0.339	0.920	D	0.681	0.819	0.879	0.473	D	c	0.362	0.263	1.000	0.489	0.581	0.326	0	1.48	0.218	1.074	0.301	0.764	0.310	1.000	0.715	1.000	0.888	5.556	0.163	Runx,_C-terminal__domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,943	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
12	103288576	103288576	T	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon3:c.A289C:p.I97L	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs142516271	363815	not_provided	MedGen:CN517202	criteria_provided,_single_submitter	Uncertain_significance	0.345	0.149	T	0.003	0.356	N	0.999	0.215	N	0.42	0.125	N	-4.8	0.982	D	0.22	0.047	N	-0.191	0.779	T	0.765	0.920	D	0.094	0.763	D	.	.	0.875	0.468	D	c	-0.380	-0.104	1.000	0.462	0.615	0.372	0	6.17	0.997	1.235	0.321	1.061	0.807	1.000	0.715	0.971	0.463	10.892	0.460	ACT_domain	.	.	.	.	0.0004	0.0015	0	0	0	0	0	0	0.0001	0.0021	0.0001	0	0	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,812	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
13	20763382	20763382	A	C	exonic	GJB2	.	nonsynonymous_SNV	GJB2:NM_004004:exon2:c.T339G:p.S113R	1.02863295453376e-11	0.00164377442881105	0.998356225560903	gap_junction_protein_beta_2	FUNCTION:_One_gap_junction_consists_of_a_cluster_of_closely_packed_pairs_of_transmembrane_channels,_the_connexons,_through_which_materials_of_low_MW_diffuse_from_one_cell_to_a_neighboring_cell.\x3b_	DISEASE:_Deafness,_autosomal_recessive,_1A_(DFNB1A)_[MIM:220290]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10830906,_ECO:0000269|PubMed:11313763,_ECO:0000269|PubMed:11439000,_ECO:0000269|PubMed:12121355,_ECO:0000269|PubMed:12239718,_ECO:0000269|PubMed:12786758,_ECO:0000269|PubMed:14722929,_ECO:0000269|PubMed:15666300,_ECO:0000269|PubMed:15994881,_ECO:0000269|PubMed:17660464,_ECO:0000269|PubMed:17666888,_ECO:0000269|PubMed:19384972,_ECO:0000269|PubMed:23680645,_ECO:0000269|PubMed:9328482,_ECO:0000269|PubMed:9336442,_ECO:0000269|PubMed:9471561,_ECO:0000269|PubMed:9529365}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_dominant,_3A_(DFNA3A)_[MIM:601544]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10807696,_ECO:0000269|PubMed:11313763,_ECO:0000269|PubMed:11439000,_ECO:0000269|PubMed:12786758,_ECO:0000269|PubMed:19384972,_ECO:0000269|PubMed:9620796}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Vohwinkel_syndrome_(VS)_[MIM:124500]:_VS_is_an_autosomal_dominant_disease_characterized_by_hyperkeratosis,_constriction_on_fingers_and_toes_and_congenital_deafness._{ECO:0000269|PubMed:10369869,_ECO:0000269|PubMed:15954104,_ECO:0000269|PubMed:18688874}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Keratoderma,_palmoplantar,_with_deafness_(PPKDFN)_[MIM:148350]:_An_autosomal_dominant_disorder_characterized_by_the_association_of_palmoplantar_hyperkeratosis_with_progressive,_bilateral,_high-frequency,_sensorineural_deafness._{ECO:0000269|PubMed:10633135,_ECO:0000269|PubMed:10757647,_ECO:0000269|PubMed:12372058,_ECO:0000269|PubMed:15996214,_ECO:0000269|PubMed:17993581,_ECO:0000269|PubMed:9856479}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Keratitis-ichthyosis-deafness_syndrome_(KID_syndrome)_[MIM:148210]:_An_autosomal_dominant_form_of_ectodermal_dysplasia._Ectodermal_dysplasia_defines_a_heterogeneous_group_of_disorders_due_to_abnormal_development_of_two_or_more_ectodermal_structures._Keratitis-ichthyosis-deafness_syndrome_is_characterized_by_the_association_of_hyperkeratotic_skin_lesions_with_vascularizing_keratitis_and_profound_sensorineural_hearing_loss._Clinical_features_include_deafness,_ichthyosis,_photophobia,_absent_or_decreased_eyebrows,_sparse_or_absent_scalp_hair,_decreased_sweating_and_dysplastic_finger_and_toenails._{ECO:0000269|PubMed:11912510,_ECO:0000269|PubMed:12548749,_ECO:0000269|PubMed:12752120}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bart-Pumphrey_syndrome_(BPS)_[MIM:149200]:_An_autosomal_dominant_disorder_characterized_by_sensorineural_hearing_loss,_palmoplantar_keratoderma,_knuckle_pads,_and_leukonychia,_It_shows_considerable_phenotypic_variability._{ECO:0000269|PubMed:15482471,_ECO:0000269|PubMed:15952212}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ichthyosis_hystrix-like_with_deafness_syndrome_(HID_syndrome)_[MIM:602540]:_An_autosomal_dominant_keratinizing_disorder_characterized_by_sensorineural_deafness_and_spiky_hyperkeratosis_affecting_the_entire_skin._HID_syndrome_is_considered_to_differ_from_the_similar_KID_syndrome_in_the_extent_and_time_of_occurrence_of_skin_symptoms_and_the_severity_of_the_associated_keratitis._{ECO:0000269|PubMed:12072059}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	.	.	0.42941	0.50569	0.663285274	84.55414013	794.09383	5.55726	rs80338946	34237	Keratitis-Ichthyosis-Deafness_Syndrome|Mutilating_keratoderma|Hystrix-like_ichthyosis_with_deafness|Deafness,_autosomal_recessive_1A|Nonsyndromic_Hearing_Loss,_Dominant|Nonsyndromic_Hearing_Loss,_Recessive	MedGen:C0265336|MedGen:C0265964,OMIM:124500,Orphanet:ORPHA494,SNOMED_CT:24559001|MedGen:C1865234,OMIM:602540|MedGen:C2673759,OMIM:220290|MedGen:CN239435|MedGen:CN239439	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.321	0.135	T	0.991	0.080	N	0.000	0.090	A	1.04	0.263	L	-4.41	0.974	D	-0.88	0.238	N	-0.099	0.801	T	0.705	0.899	D	0.025	0.479	T	0.783	0.907	0.203	0.208	N	c	-1.445	-1.479	1.000	0.747	0.765	0.991	0	-4.09	0.037	-0.688	0.052	-0.214	0.099	0.000	0.063	0.652	0.299	10.222	0.422	Connexin,_N-terminal	.	.	.	.	.	.	.	.	.	.	.	.	1.224e-05	0	0	0.0003	0	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,867	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0.6752	VUS
11	120998747	120998747	C	G	exonic	TECTA	.	nonsynonymous_SNV	TECTA:NM_005422:exon8:c.C2061G:p.N687K	1.06498565113514e-12	0.999989745526101	1.02544728344311e-05	tectorin_alpha	FUNCTION:_One_of_the_major_non-collagenous_components_of_the_tectorial_membrane_(By_similarity)._The_tectorial_membrane_is_an_extracellular_matrix_of_the_inner_ear_that_covers_the_neuroepithelium_of_the_cochlea_and_contacts_the_stereocilia_bundles_of_specialized_sensory_hair_cells._Sound_induces_movement_of_these_hair_cells_relative_to_the_tectorial_membrane,_deflects_the_stereocilia_and_leads_to_fluctuations_in_hair-cell_membrane_potential,_transducing_sound_into_electrical_signals._{ECO:0000250}.\x3b_	DISEASE:_Deafness,_autosomal_dominant,_12_(DFNA12)_[MIM:601543]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10196713,_ECO:0000269|PubMed:10987647,_ECO:0000269|PubMed:12162770,_ECO:0000269|PubMed:15319541,_ECO:0000269|PubMed:16718611,_ECO:0000269|PubMed:17661817,_ECO:0000269|PubMed:20947814,_ECO:0000269|PubMed:21520338,_ECO:0000269|PubMed:9590290}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_recessive,_21_(DFNB21)_[MIM:603629]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:12746400,_ECO:0000269|PubMed:9949200}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	liver\x3btestis\x3bspleen\x3bblood\x3bbrain\x3b	superior_cervical_ganglion\x3batrioventricular_node\x3bskeletal_muscle\x3b	0.64735	0.20702	-2.430013277	1.032083038	4846.67098	14.13953	rs139165033	54484	not_specified|Nonsyndromic_Hearing_Loss,_Dominant|Nonsyndromic_Hearing_Loss,_Recessive	MedGen:CN169374|MedGen:CN239435|MedGen:CN239439	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.524	0.071	T	0.000	0.629	D	0.560	0.312	N	0.9	0.233	L	3.56	0.047	T	-0.89	0.240	N	-1.134	0.016	T	0.035	0.149	T	0.008	0.221	T	.	.	0.839	0.427	D	c	0.525	0.523	0.008	0.116	0.487	0.133	0	4.57	0.557	0.168	0.163	0.934	0.450	0.968	0.339	1.000	0.888	13.279	0.595	TILa_domain|VWFC_domain	.	.	.	.	0.0019	0.0003	0	0	0	0.0006	0.0035	0.0010	0.0017	0.0003	0.0012	0.0008	0	0.0007	0.0031	0.0011	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,635	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0.6752	VUS
11	120984338	120984338	A	G	exonic	TECTA	.	nonsynonymous_SNV	TECTA:NM_005422:exon5:c.A701G:p.Q234R	1.06498565113514e-12	0.999989745526101	1.02544728344311e-05	tectorin_alpha	FUNCTION:_One_of_the_major_non-collagenous_components_of_the_tectorial_membrane_(By_similarity)._The_tectorial_membrane_is_an_extracellular_matrix_of_the_inner_ear_that_covers_the_neuroepithelium_of_the_cochlea_and_contacts_the_stereocilia_bundles_of_specialized_sensory_hair_cells._Sound_induces_movement_of_these_hair_cells_relative_to_the_tectorial_membrane,_deflects_the_stereocilia_and_leads_to_fluctuations_in_hair-cell_membrane_potential,_transducing_sound_into_electrical_signals._{ECO:0000250}.\x3b_	DISEASE:_Deafness,_autosomal_dominant,_12_(DFNA12)_[MIM:601543]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10196713,_ECO:0000269|PubMed:10987647,_ECO:0000269|PubMed:12162770,_ECO:0000269|PubMed:15319541,_ECO:0000269|PubMed:16718611,_ECO:0000269|PubMed:17661817,_ECO:0000269|PubMed:20947814,_ECO:0000269|PubMed:21520338,_ECO:0000269|PubMed:9590290}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_recessive,_21_(DFNB21)_[MIM:603629]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:12746400,_ECO:0000269|PubMed:9949200}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	liver\x3btestis\x3bspleen\x3bblood\x3bbrain\x3b	superior_cervical_ganglion\x3batrioventricular_node\x3bskeletal_muscle\x3b	0.64735	0.20702	-2.430013277	1.032083038	4846.67098	14.13953	rs144682235	175072	not_specified|Nonsyndromic_Hearing_Loss,_Dominant|Nonsyndromic_Hearing_Loss,_Recessive	MedGen:CN169374|MedGen:CN239435|MedGen:CN239439	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.445	0.091	T	0.000	0.629	D	0.966	0.385	D	0	0.065	N	-0.61	0.718	T	-0.68	0.195	N	-0.804	0.549	T	0.200	0.556	T	0.020	0.430	T	.	.	0.988	0.870	D	c	0.035	0.227	1.000	0.747	0.516	0.203	0	4.92	0.640	9.289	0.950	1.086	0.855	1.000	0.715	0.999	0.750	14.760	0.691	NIDO_domain	.	.	.	.	0.0015	0.0048	0.0024	0.0033	0	0	0	0.0010	0.0004	0.0041	0.0005	0.0015	0	0	5.375e-05	0.0011	3.249e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,632	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0.6752	VUS
11	76870496	76870496	G	A	exonic	MYO7A	.	nonsynonymous_SNV	MYO7A:NM_000260:exon10:c.G1007A:p.R336H,MYO7A:NM_001127179:exon10:c.G1007A:p.R336H,MYO7A:NM_001127180:exon10:c.G1007A:p.R336H	5.37673856270135e-25	0.207164598627406	0.792835401372594	myosin_VIIA	FUNCTION:_Myosins_are_actin-based_motor_molecules_with_ATPase_activity._Unconventional_myosins_serve_in_intracellular_movements._Their_highly_divergent_tails_bind_to_membranous_compartments,_which_are_then_moved_relative_to_actin_filaments._In_the_retina,_plays_an_important_role_in_the_renewal_of_the_outer_photoreceptor_disks._Plays_an_important_role_in_the_distribution_and_migration_of_retinal_pigment_epithelial_(RPE)_melanosomes_and_phagosomes,_and_in_the_regulation_of_opsin_transport_in_retinal_photoreceptors._In_the_inner_ear,_plays_an_important_role_in_differentiation,_morphogenesis_and_organization_of_cochlear_hair_cell_bundles._Involved_in_hair-cell_vesicle_trafficking_of_aminoglycosides,_which_are_known_to_induce_ototoxicity_(By_similarity)._Motor_protein_that_is_a_part_of_the_functional_network_formed_by_USH1C,_USH1G,_CDH23_and_MYO7A_that_mediates_mechanotransduction_in_cochlear_hair_cells._Required_for_normal_hearing._{ECO:0000250,_ECO:0000269|PubMed:19643958,_ECO:0000269|PubMed:21493626,_ECO:0000269|PubMed:21687988,_ECO:0000269|PubMed:21709241}.\x3b_	DISEASE:_Usher_syndrome_1B_(USH1B)_[MIM:276900]:_USH_is_a_genetically_heterogeneous_condition_characterized_by_the_association_of_retinitis_pigmentosa_with_sensorineural_deafness._Age_at_onset_and_differences_in_auditory_and_vestibular_function_distinguish_Usher_syndrome_type_1_(USH1),_Usher_syndrome_type_2_(USH2)_and_Usher_syndrome_type_3_(USH3)._USH1_is_characterized_by_profound_congenital_sensorineural_deafness,_absent_vestibular_function_and_prepubertal_onset_of_progressive_retinitis_pigmentosa_leading_to_blindness._{ECO:0000269|PubMed:10094549,_ECO:0000269|PubMed:10364543,_ECO:0000269|PubMed:10447383,_ECO:0000269|PubMed:10930322,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:15660226,_ECO:0000269|PubMed:16679490,_ECO:0000269|PubMed:23559863,_ECO:0000269|PubMed:24831256,_ECO:0000269|PubMed:25798947,_ECO:0000269|PubMed:7870171,_ECO:0000269|PubMed:8900236,_ECO:0000269|PubMed:9002678,_ECO:0000269|PubMed:9382091,_ECO:0000269|PubMed:9718356}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_recessive,_2_(DFNB2)_[MIM:600060]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:9171832,_ECO:0000269|PubMed:9171833}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_dominant,_11_(DFNA11)_[MIM:601317]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._DFNA11_is_characterized_by_onset_after_complete_speech_acquisition_and_subsequent_gradual_progression._{ECO:0000269|PubMed:15121790,_ECO:0000269|PubMed:15221449,_ECO:0000269|PubMed:15300860,_ECO:0000269|PubMed:9354784}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dDefects_in_MYO7A_may_be_a_cause_of_Leber_congenital_amaurosis_(LCA),_a_severe_dystrophy_of_the_retina,_typically_becoming_evident_in_the_first_years_of_life._Visual_function_is_usually_poor_and_often_accompanied_by_nystagmus,_sluggish_or_near-_absent_pupillary_responses,_photophobia,_high_hyperopia_and_keratoconus.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_the_pigment_epithelium_and_the_photoreceptor_cells_of_the_retina._Also_found_in_kidney,_liver,_testis,_cochlea,_lymphocytes._Not_expressed_in_brain._{ECO:0000269|PubMed:19643958,_ECO:0000269|PubMed:21493626,_ECO:0000269|PubMed:21709241}.\x3b_	unclassifiable_(Anatomical_System)\x3bmedulla_oblongata\x3bovary\x3bcolon\x3bparathyroid\x3bchoroid\x3bretina\x3bbreast\x3buterus\x3bprostate\x3boptic_nerve\x3blung\x3bendometrium\x3badrenal_gland\x3bthyroid\x3bplacenta\x3bvisual_apparatus\x3bliver\x3btestis\x3bspleen\x3bgerminal_center\x3bkidney\x3bbrain\x3bpineal_gland\x3bperipheral_nerve\x3b	superior_cervical_ganglion\x3bsubthalamic_nucleus\x3btestis_-_seminiferous_tubule\x3badrenal_gland\x3badrenal_cortex\x3btestis\x3bciliary_ganglion\x3bpons\x3batrioventricular_node\x3btrigeminal_ganglion\x3bskeletal_muscle\x3b	0.12096	0.33881	-2.513092117	0.925925926	4945.67513	14.33992	rs45629132	52304	not_specified	MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Likely_benign	0.069	0.419	T	0.000	0.477	D	1	0.810	D	0.975	0.246	L	-2.29	0.876	D	-2.31	0.524	N	0.335	0.881	D	0.631	0.871	D	0.139	0.822	D	.	.	0.992	0.934	D	c	0.426	0.429	1.000	0.747	0.497	0.185	0	4.87	0.627	7.725	0.836	0.902	0.416	1.000	0.715	0.945	0.419	18.196	0.897	Myosin_head,_motor_domain|P-loop_containing_nucleoside_triphosphate_hydrolase	.	.	.	.	0.0015	0.0012	0	0	0.0006	0.0003	0.0022	0.0011	0.0011	0.0006	0.0006	0.0001	0	0	0.0022	0.0007	3.252e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,629	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0.6752	VUS
12	103310908	103310908	T	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon1:c.A1G:p.M1V	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62514891	15625	Hyperphenylalaninemia,_non-pku|Phenylketonuria|not_provided	Human_Phenotype_Ontology:HP:0004923,MedGen:C0751435|MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	0.02	0.912	D	0.765	0.096	N	1	0.810	D	.	.	.	-5.64	0.993	D	-0.48	0.187	N	1.099	0.996	D	0.973	0.992	D	.	.	.	0.996	1.000	0.858	0.447	D	c	0.230	0.237	1.000	0.747	0.405	0.054	1	5.2	0.716	3.296	0.513	1.061	0.807	1.000	0.715	0.287	0.235	11.636	0.503	.	.	.	.	.	.	.	.	.	.	.	.	.	8.122e-06	0	0	0	0	0	1.791e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,852	0	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.6752	VUS
12	103245479	103245482	CAAA	C	exonic	PAH	.	nonframeshift_deletion	PAH:NM_000277:exon8:c.895_897del:p.299_299del	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62507267	108622	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,692	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
10	89692880	89692880	A	G	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon5:c.A364G:p.I122V,PTEN:NM_001304717:exon6:c.A883G:p.I295V	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs786202740	183026	Hereditary_cancer-predisposing_syndrome|PTEN_hamartoma_tumor_syndrome|not_specified	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498|MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	0.918	0.023	T	0.000	0.843	D	1	0.810	D	-0.235	0.039	N	-1.12	0.776	T	-0.31	0.121	N	-0.703	0.603	T	0.238	0.605	T	0.039	0.584	D	0.678	0.816	0.981	0.792	D	c	0.083	0.277	1.000	0.747	0.722	0.854	0	5.22	0.722	8.875	0.919	1.088	0.866	1.000	0.715	1.000	0.888	15.102	0.718	Dual_specificity_phosphatase,_catalytic_domain|Protein-tyrosine_phosphatase,_catalytic|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain\x3bDual_specificity_phosphatase,_catalytic_domain|Protein-tyrosine_phosphatase-like|Tensin-type_phosphatase_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,544	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
12	103288689	103288689	T	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon3:c.A176G:p.D59G	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475672	108352	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.933	0.034	T	0.000	0.491	N	0.999	0.472	D	-0.955	0.012	N	-4.68	0.980	D	0.63	0.038	N	-0.184	0.781	T	0.614	0.864	D	0.067	0.702	D	0.448	0.509	0.705	0.343	D	c	-0.677	-0.414	0.999	0.392	0.615	0.372	0	3.8	0.427	1.266	0.324	1.061	0.807	0.995	0.385	0.997	0.653	5.595	0.165	ACT_domain	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,825	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
21	36252918	36252918	G	A	exonic	RUNX1	.	synonymous_SNV	RUNX1:NM_001001890:exon2:c.C363T:p.T121T,RUNX1:NM_001122607:exon2:c.C363T:p.T121T,RUNX1:NM_001754:exon5:c.C444T:p.T148T	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	rs773689002	346405	Familial_platelet_disorder_with_associated_myeloid_malignancy	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3.229e-05	0.0001	0	0	0	0	0	0	6.093e-05	6.535e-05	0	0	0	0	0.0001	0	6.498e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,970	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.4999	VUS
21	36252850	36252851	GT	G	intronic	RUNX1	.	.	.	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	rs587776810	29505	Familial_platelet_disorder_with_associated_myeloid_malignancy	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290	criteria_provided,_single_submitter	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,965	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.4999	VUS
12	103310849	103310849	C	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon1:c.G60C:p.Q20H	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475688	108493	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.034	0.465	D	0.044	0.237	N	0.995	0.810	D	0.55	0.145	N	-5.79	0.994	D	-0.22	0.146	N	0.823	0.947	D	0.839	0.946	D	0.509	0.953	D	0.796	0.917	0.886	0.483	D	c	-0.003	0.151	1.000	0.747	0.493	0.174	0	5.2	0.716	3.236	0.508	0.935	0.490	1.000	0.715	0.382	0.251	14.428	0.667	.	.	.	1.0000	0.994	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,843	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.4999	VUS
19	4101030	4101030	C	T	exonic	MAP2K2	.	nonsynonymous_SNV	MAP2K2:NM_030662:exon6:c.G692A:p.R231H	0.86326115931858	0.136320885012997	0.00041795566842237	mitogen-activated_protein_kinase_kinase_2	FUNCTION:_Catalyzes_the_concomitant_phosphorylation_of_a_threonine_and_a_tyrosine_residue_in_a_Thr-Glu-Tyr_sequence_located_in_MAP_kinases._Activates_the_ERK1_and_ERK2_MAP_kinases_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Cardiofaciocutaneous_syndrome_4_(CFC4)_[MIM:615280]:_A_form_of_cardiofaciocutaneous_syndrome,_a_multiple_congenital_anomaly_disorder_characterized_by_a_distinctive_facial_appearance,_heart_defects_and_mental_retardation._Heart_defects_include_pulmonic_stenosis,_atrial_septal_defects_and_hypertrophic_cardiomyopathy._Some_affected_individuals_present_with_ectodermal_abnormalities_such_as_sparse,_friable_hair,_hyperkeratotic_skin_lesions_and_a_generalized_ichthyosis-like_condition._Typical_facial_features_are_similar_to_Noonan_syndrome._They_include_high_forehead_with_bitemporal_constriction,_hypoplastic_supraorbital_ridges,_downslanting_palpebral_fissures,_a_depressed_nasal_bridge,_and_posteriorly_angulated_ears_with_prominent_helices._{ECO:0000269|PubMed:16439621,_ECO:0000269|PubMed:18042262,_ECO:0000269|PubMed:20358587}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	medulla_oblongata\x3bsmooth_muscle\x3bovary\x3bsalivary_gland\x3bsympathetic_chain\x3bcolon\x3bparathyroid\x3bskin\x3buterus\x3bprostate\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bmuscle\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbile_duct\x3bpancreas\x3blung\x3badrenal_gland\x3bplacenta\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	amygdala\x3bprefrontal_cortex\x3btestis\x3bpons\x3bcingulate_cortex\x3b	0.88489	0.51187	-0.800872469	12.33191791	40.94266	1.19949	rs730880511	533045	Rasopathy	MedGen:CN166718,Orphanet:ORPHA98733	criteria_provided,_single_submitter	Uncertain_significance	0.002	0.721	D	0.000	0.843	D	1	0.810	D	1.73	0.448	L	-3.1	0.927	D	-4.72	0.800	D	0.869	0.953	D	0.838	0.946	D	0.589	0.964	D	0.57	0.693	0.980	0.786	D	c	0.466	0.335	1.000	0.747	0.707	0.730	0	4.22	0.490	7.860	0.853	0.848	0.348	1.000	0.715	0.277	0.233	15.189	0.726	Protein_kinase_domain|Protein_kinase-like_domain	.	.	.	.	.	.	.	.	.	.	.	.	2.406e-05	0	7.953e-05	0	8.786e-05	0	0	0.0002	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,931	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.4999	VUS
16	68846166	68846166	G	A	exonic	CDH1	.	synonymous_SNV	CDH1:NM_001317184:exon8:c.G1137A:p.T379T,CDH1:NM_004360:exon8:c.G1137A:p.T379T	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	rs587783050	166264	Hereditary_cancer-predisposing_syndrome|Hereditary_diffuse_gastric_cancer|not_provided	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708349,OMIM:137215,Orphanet:ORPHA26106|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.9998	0.984	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,905	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.4999	VUS
12	103310906	103310906	C	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon1:c.G3C:p.M1I	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	.	.	.	.	.	.	0.036	0.912	D	0.765	0.096	N	1	0.810	D	.	.	.	-5.65	0.993	D	-0.58	0.199	N	1.023	0.976	D	0.975	0.992	D	0.970	0.998	D	0.997	1.000	0.884	0.480	D	c	0.334	0.329	1.000	0.747	0.405	0.054	1	5.2	0.716	3.256	0.509	0.935	0.490	1.000	0.715	0.229	0.223	14.428	0.667	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,848	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.4999	VUS
12	103310907	103310907	A	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon1:c.T2G:p.M1R	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62508575	108383	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.003	0.912	D	0.765	0.096	N	1	0.810	D	.	.	.	-5.73	0.993	D	-0.3	0.142	N	1.031	0.977	D	0.977	0.993	D	0.973	0.998	D	0.996	1.000	0.899	0.503	D	c	0.399	0.362	1.000	0.747	0.405	0.054	1	5.2	0.716	3.852	0.554	1.199	0.960	1.000	0.715	0.275	0.232	11.636	0.503	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,849	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.4999	VUS
12	103310908	103310908	T	A	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon1:c.A1T:p.M1L	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62514891	108362	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.597	0.912	T	0.765	0.096	N	1	0.810	D	.	.	.	-5.59	0.992	D	-0.47	0.172	N	0.903	0.957	D	0.959	0.987	D	.	.	.	0.998	1.000	0.870	0.461	D	c	0.040	0.086	1.000	0.747	0.405	0.054	1	5.2	0.716	3.296	0.513	1.061	0.807	1.000	0.715	0.287	0.235	11.636	0.503	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,851	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.4999	VUS
12	112888228	112888228	A	G	exonic	PTPN11	.	nonsynonymous_SNV	PTPN11:NM_001330437:exon3:c.A244G:p.M82V,PTPN11:NM_002834:exon3:c.A244G:p.M82V,PTPN11:NM_080601:exon3:c.A244G:p.M82V	0.999877230878678	0.000122769057470549	6.38519788034449e-11	protein_tyrosine_phosphatase,_non-receptor_type_11	FUNCTION:_Acts_downstream_of_various_receptor_and_cytoplasmic_protein_tyrosine_kinases_to_participate_in_the_signal_transduction_from_the_cell_surface_to_the_nucleus._Dephosphorylates_ROCK2_at_Tyr-722_resulting_in_stimulatation_of_its_RhoA_binding_activity._{ECO:0000269|PubMed:10655584,_ECO:0000269|PubMed:18559669,_ECO:0000269|PubMed:18829466}.\x3b_	DISEASE:_LEOPARD_syndrome_1_(LPRD1)_[MIM:151100]:_A_disorder_characterized_by_lentigines,_electrocardiographic_conduction_abnormalities,_ocular_hypertelorism,_pulmonic_stenosis,_abnormalities_of_genitalia,_retardation_of_growth,_and_sensorineural_deafness._{ECO:0000269|PubMed:12058348,_ECO:0000269|PubMed:14961557,_ECO:0000269|PubMed:15121796,_ECO:0000269|PubMed:15389709,_ECO:0000269|PubMed:15520399,_ECO:0000269|PubMed:15690106,_ECO:0000269|PubMed:16679933,_ECO:0000269|PubMed:24891296}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Noonan_syndrome_1_(NS1)_[MIM:163950]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._Some_patients_with_NS1_develop_multiple_giant_cell_lesions_of_the_jaw_or_other_bony_or_soft_tissues,_which_are_classified_as_pigmented_villonodular_synovitis_(PVNS)_when_occurring_in_the_jaw_or_joints._{ECO:0000269|PubMed:11704759,_ECO:0000269|PubMed:11992261,_ECO:0000269|PubMed:12161469,_ECO:0000269|PubMed:12325025,_ECO:0000269|PubMed:12529711,_ECO:0000269|PubMed:12634870,_ECO:0000269|PubMed:12717436,_ECO:0000269|PubMed:12739139,_ECO:0000269|PubMed:12960218,_ECO:0000269|PubMed:15384080,_ECO:0000269|PubMed:15948193,_ECO:0000269|PubMed:19020799,_ECO:0000269|PubMed:24891296}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry._Mutations_in_PTPN11_account_for_more_than_50%_of_the_cases.\x3b_DISEASE:_Leukemia,_juvenile_myelomonocytic_(JMML)_[MIM:607785]:_An_aggressive_pediatric_myelodysplastic_syndrome/myeloproliferative_disorder_characterized_by_malignant_transformation_in_the_hematopoietic_stem_cell_compartment_with_proliferation_of_differentiated_progeny._Patients_have_splenomegaly,_enlarged_lymph_nodes,_rashes,_and_hemorrhages._{ECO:0000269|PubMed:12717436}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Metachondromatosis_(MC)_[MIM:156250]:_A_skeletal_disorder_with_radiologic_features_of_both_multiple_exostoses_and_Ollier_disease,_characterized_by_the_presence_of_exostoses,_commonly_of_the_bones_of_the_hands_and_feet,_and_enchondromas_of_the_metaphyses_of_long_bones_and_iliac_crest._{ECO:0000269|PubMed:20577567}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Widely_expressed,_with_highest_levels_in_heart,_brain,_and_skeletal_muscle._{ECO:0000269|PubMed:1280823,_ECO:0000269|PubMed:7681589,_ECO:0000269|PubMed:8216283}.\x3b_	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3bfrontal_lobe\x3bendometrium\x3boesophagus\x3blarynx\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bpineal_gland\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bpineal_body\x3burinary\x3badrenal_cortex\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3blung\x3bcornea\x3badrenal_gland\x3bplacenta\x3bvisual_apparatus\x3bhippocampus\x3bhypopharynx\x3bliver\x3bhead_and_neck\x3bcervix\x3bkidney\x3bmammary_gland\x3baorta\x3bstomach\x3b	amygdala\x3btestis_-_interstitial\x3bthalamus\x3bmedulla_oblongata\x3bsuperior_cervical_ganglion\x3boccipital_lobe\x3bhypothalamus\x3bspinal_cord\x3bcaudate_nucleus\x3bpons\x3bskeletal_muscle\x3bsubthalamic_nucleus\x3bprefrontal_cortex\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bparietal_lobe\x3b	0.26245	0.72890	-0.427900189	25.14744043	19.44641	0.66817	rs397507515	48974	Rasopathy|not_specified	MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374	reviewed_by_expert_panel	Uncertain_significance	0.287	0.157	T	0.000	0.843	D	1	0.810	D	0.935	0.237	L	-3.92	0.961	D	-1.13	0.291	N	0.241	0.866	D	0.716	0.903	D	0.047	0.630	D	0.622	0.757	0.991	0.907	D	c	0.064	0.296	1.000	0.747	0.722	0.854	0	5.9	0.949	9.314	0.953	1.193	0.911	1.000	0.715	1.000	0.888	16.329	0.828	SH2_domain	.	.	.	.	.	.	.	.	.	.	.	.	4.067e-06	0	0	0	0	0	8.983e-06	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,855	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.4999	VUS
13	20763044	20763044	A	C	exonic	GJB2	.	nonsynonymous_SNV	GJB2:NM_004004:exon2:c.T677G:p.V226G	1.02863295453376e-11	0.00164377442881105	0.998356225560903	gap_junction_protein_beta_2	FUNCTION:_One_gap_junction_consists_of_a_cluster_of_closely_packed_pairs_of_transmembrane_channels,_the_connexons,_through_which_materials_of_low_MW_diffuse_from_one_cell_to_a_neighboring_cell.\x3b_	DISEASE:_Deafness,_autosomal_recessive,_1A_(DFNB1A)_[MIM:220290]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10830906,_ECO:0000269|PubMed:11313763,_ECO:0000269|PubMed:11439000,_ECO:0000269|PubMed:12121355,_ECO:0000269|PubMed:12239718,_ECO:0000269|PubMed:12786758,_ECO:0000269|PubMed:14722929,_ECO:0000269|PubMed:15666300,_ECO:0000269|PubMed:15994881,_ECO:0000269|PubMed:17660464,_ECO:0000269|PubMed:17666888,_ECO:0000269|PubMed:19384972,_ECO:0000269|PubMed:23680645,_ECO:0000269|PubMed:9328482,_ECO:0000269|PubMed:9336442,_ECO:0000269|PubMed:9471561,_ECO:0000269|PubMed:9529365}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_dominant,_3A_(DFNA3A)_[MIM:601544]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10807696,_ECO:0000269|PubMed:11313763,_ECO:0000269|PubMed:11439000,_ECO:0000269|PubMed:12786758,_ECO:0000269|PubMed:19384972,_ECO:0000269|PubMed:9620796}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Vohwinkel_syndrome_(VS)_[MIM:124500]:_VS_is_an_autosomal_dominant_disease_characterized_by_hyperkeratosis,_constriction_on_fingers_and_toes_and_congenital_deafness._{ECO:0000269|PubMed:10369869,_ECO:0000269|PubMed:15954104,_ECO:0000269|PubMed:18688874}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Keratoderma,_palmoplantar,_with_deafness_(PPKDFN)_[MIM:148350]:_An_autosomal_dominant_disorder_characterized_by_the_association_of_palmoplantar_hyperkeratosis_with_progressive,_bilateral,_high-frequency,_sensorineural_deafness._{ECO:0000269|PubMed:10633135,_ECO:0000269|PubMed:10757647,_ECO:0000269|PubMed:12372058,_ECO:0000269|PubMed:15996214,_ECO:0000269|PubMed:17993581,_ECO:0000269|PubMed:9856479}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Keratitis-ichthyosis-deafness_syndrome_(KID_syndrome)_[MIM:148210]:_An_autosomal_dominant_form_of_ectodermal_dysplasia._Ectodermal_dysplasia_defines_a_heterogeneous_group_of_disorders_due_to_abnormal_development_of_two_or_more_ectodermal_structures._Keratitis-ichthyosis-deafness_syndrome_is_characterized_by_the_association_of_hyperkeratotic_skin_lesions_with_vascularizing_keratitis_and_profound_sensorineural_hearing_loss._Clinical_features_include_deafness,_ichthyosis,_photophobia,_absent_or_decreased_eyebrows,_sparse_or_absent_scalp_hair,_decreased_sweating_and_dysplastic_finger_and_toenails._{ECO:0000269|PubMed:11912510,_ECO:0000269|PubMed:12548749,_ECO:0000269|PubMed:12752120}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bart-Pumphrey_syndrome_(BPS)_[MIM:149200]:_An_autosomal_dominant_disorder_characterized_by_sensorineural_hearing_loss,_palmoplantar_keratoderma,_knuckle_pads,_and_leukonychia,_It_shows_considerable_phenotypic_variability._{ECO:0000269|PubMed:15482471,_ECO:0000269|PubMed:15952212}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ichthyosis_hystrix-like_with_deafness_syndrome_(HID_syndrome)_[MIM:602540]:_An_autosomal_dominant_keratinizing_disorder_characterized_by_sensorineural_deafness_and_spiky_hyperkeratosis_affecting_the_entire_skin._HID_syndrome_is_considered_to_differ_from_the_similar_KID_syndrome_in_the_extent_and_time_of_occurrence_of_skin_symptoms_and_the_severity_of_the_associated_keratitis._{ECO:0000269|PubMed:12072059}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	.	.	0.42941	0.50569	0.663285274	84.55414013	794.09383	5.55726	rs773846324	441576	not_specified	MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	0.001	0.784	D	0.063	0.220	N	1.000	0.506	D	-0.345	0.033	N	-4.5	0.977	D	0.53	0.028	N	0.359	0.885	D	0.731	0.908	D	0.222	0.879	D	0.835	0.943	0.877	0.470	D	c	-0.277	-0.146	1.000	0.747	0.554	0.246	0	4.77	0.603	2.043	0.406	1.199	0.960	0.966	0.337	0.479	0.267	7.494	0.265	.	.	.	.	.	3.227e-05	0	0	0	0	0	6.66e-05	0	8.255e-06	0	2.983e-05	0	0	0	9.181e-06	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,862	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.4999	VUS
13	20763044	20763044	A	T	exonic	GJB2	.	nonsynonymous_SNV	GJB2:NM_004004:exon2:c.T677A:p.V226D	1.02863295453376e-11	0.00164377442881105	0.998356225560903	gap_junction_protein_beta_2	FUNCTION:_One_gap_junction_consists_of_a_cluster_of_closely_packed_pairs_of_transmembrane_channels,_the_connexons,_through_which_materials_of_low_MW_diffuse_from_one_cell_to_a_neighboring_cell.\x3b_	DISEASE:_Deafness,_autosomal_recessive,_1A_(DFNB1A)_[MIM:220290]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10830906,_ECO:0000269|PubMed:11313763,_ECO:0000269|PubMed:11439000,_ECO:0000269|PubMed:12121355,_ECO:0000269|PubMed:12239718,_ECO:0000269|PubMed:12786758,_ECO:0000269|PubMed:14722929,_ECO:0000269|PubMed:15666300,_ECO:0000269|PubMed:15994881,_ECO:0000269|PubMed:17660464,_ECO:0000269|PubMed:17666888,_ECO:0000269|PubMed:19384972,_ECO:0000269|PubMed:23680645,_ECO:0000269|PubMed:9328482,_ECO:0000269|PubMed:9336442,_ECO:0000269|PubMed:9471561,_ECO:0000269|PubMed:9529365}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_dominant,_3A_(DFNA3A)_[MIM:601544]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10807696,_ECO:0000269|PubMed:11313763,_ECO:0000269|PubMed:11439000,_ECO:0000269|PubMed:12786758,_ECO:0000269|PubMed:19384972,_ECO:0000269|PubMed:9620796}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Vohwinkel_syndrome_(VS)_[MIM:124500]:_VS_is_an_autosomal_dominant_disease_characterized_by_hyperkeratosis,_constriction_on_fingers_and_toes_and_congenital_deafness._{ECO:0000269|PubMed:10369869,_ECO:0000269|PubMed:15954104,_ECO:0000269|PubMed:18688874}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Keratoderma,_palmoplantar,_with_deafness_(PPKDFN)_[MIM:148350]:_An_autosomal_dominant_disorder_characterized_by_the_association_of_palmoplantar_hyperkeratosis_with_progressive,_bilateral,_high-frequency,_sensorineural_deafness._{ECO:0000269|PubMed:10633135,_ECO:0000269|PubMed:10757647,_ECO:0000269|PubMed:12372058,_ECO:0000269|PubMed:15996214,_ECO:0000269|PubMed:17993581,_ECO:0000269|PubMed:9856479}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Keratitis-ichthyosis-deafness_syndrome_(KID_syndrome)_[MIM:148210]:_An_autosomal_dominant_form_of_ectodermal_dysplasia._Ectodermal_dysplasia_defines_a_heterogeneous_group_of_disorders_due_to_abnormal_development_of_two_or_more_ectodermal_structures._Keratitis-ichthyosis-deafness_syndrome_is_characterized_by_the_association_of_hyperkeratotic_skin_lesions_with_vascularizing_keratitis_and_profound_sensorineural_hearing_loss._Clinical_features_include_deafness,_ichthyosis,_photophobia,_absent_or_decreased_eyebrows,_sparse_or_absent_scalp_hair,_decreased_sweating_and_dysplastic_finger_and_toenails._{ECO:0000269|PubMed:11912510,_ECO:0000269|PubMed:12548749,_ECO:0000269|PubMed:12752120}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bart-Pumphrey_syndrome_(BPS)_[MIM:149200]:_An_autosomal_dominant_disorder_characterized_by_sensorineural_hearing_loss,_palmoplantar_keratoderma,_knuckle_pads,_and_leukonychia,_It_shows_considerable_phenotypic_variability._{ECO:0000269|PubMed:15482471,_ECO:0000269|PubMed:15952212}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ichthyosis_hystrix-like_with_deafness_syndrome_(HID_syndrome)_[MIM:602540]:_An_autosomal_dominant_keratinizing_disorder_characterized_by_sensorineural_deafness_and_spiky_hyperkeratosis_affecting_the_entire_skin._HID_syndrome_is_considered_to_differ_from_the_similar_KID_syndrome_in_the_extent_and_time_of_occurrence_of_skin_symptoms_and_the_severity_of_the_associated_keratitis._{ECO:0000269|PubMed:12072059}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	.	.	0.42941	0.50569	0.663285274	84.55414013	794.09383	5.55726	.	.	.	.	.	.	0.001	0.784	D	0.063	0.220	N	1.000	0.497	D	0	0.065	N	-4.51	0.977	D	0.6	0.025	N	0.404	0.892	D	0.718	0.903	D	0.242	0.888	D	0.818	0.932	0.881	0.476	D	c	-0.099	-0.021	1.000	0.747	0.554	0.246	0	4.77	0.603	2.043	0.406	1.199	0.960	0.966	0.337	0.479	0.267	7.494	0.265	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,863	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.4999	VUS
13	20763047	20763047	G	A	exonic	GJB2	.	nonsynonymous_SNV	GJB2:NM_004004:exon2:c.C674T:p.P225L	1.02863295453376e-11	0.00164377442881105	0.998356225560903	gap_junction_protein_beta_2	FUNCTION:_One_gap_junction_consists_of_a_cluster_of_closely_packed_pairs_of_transmembrane_channels,_the_connexons,_through_which_materials_of_low_MW_diffuse_from_one_cell_to_a_neighboring_cell.\x3b_	DISEASE:_Deafness,_autosomal_recessive,_1A_(DFNB1A)_[MIM:220290]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10830906,_ECO:0000269|PubMed:11313763,_ECO:0000269|PubMed:11439000,_ECO:0000269|PubMed:12121355,_ECO:0000269|PubMed:12239718,_ECO:0000269|PubMed:12786758,_ECO:0000269|PubMed:14722929,_ECO:0000269|PubMed:15666300,_ECO:0000269|PubMed:15994881,_ECO:0000269|PubMed:17660464,_ECO:0000269|PubMed:17666888,_ECO:0000269|PubMed:19384972,_ECO:0000269|PubMed:23680645,_ECO:0000269|PubMed:9328482,_ECO:0000269|PubMed:9336442,_ECO:0000269|PubMed:9471561,_ECO:0000269|PubMed:9529365}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_dominant,_3A_(DFNA3A)_[MIM:601544]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10807696,_ECO:0000269|PubMed:11313763,_ECO:0000269|PubMed:11439000,_ECO:0000269|PubMed:12786758,_ECO:0000269|PubMed:19384972,_ECO:0000269|PubMed:9620796}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Vohwinkel_syndrome_(VS)_[MIM:124500]:_VS_is_an_autosomal_dominant_disease_characterized_by_hyperkeratosis,_constriction_on_fingers_and_toes_and_congenital_deafness._{ECO:0000269|PubMed:10369869,_ECO:0000269|PubMed:15954104,_ECO:0000269|PubMed:18688874}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Keratoderma,_palmoplantar,_with_deafness_(PPKDFN)_[MIM:148350]:_An_autosomal_dominant_disorder_characterized_by_the_association_of_palmoplantar_hyperkeratosis_with_progressive,_bilateral,_high-frequency,_sensorineural_deafness._{ECO:0000269|PubMed:10633135,_ECO:0000269|PubMed:10757647,_ECO:0000269|PubMed:12372058,_ECO:0000269|PubMed:15996214,_ECO:0000269|PubMed:17993581,_ECO:0000269|PubMed:9856479}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Keratitis-ichthyosis-deafness_syndrome_(KID_syndrome)_[MIM:148210]:_An_autosomal_dominant_form_of_ectodermal_dysplasia._Ectodermal_dysplasia_defines_a_heterogeneous_group_of_disorders_due_to_abnormal_development_of_two_or_more_ectodermal_structures._Keratitis-ichthyosis-deafness_syndrome_is_characterized_by_the_association_of_hyperkeratotic_skin_lesions_with_vascularizing_keratitis_and_profound_sensorineural_hearing_loss._Clinical_features_include_deafness,_ichthyosis,_photophobia,_absent_or_decreased_eyebrows,_sparse_or_absent_scalp_hair,_decreased_sweating_and_dysplastic_finger_and_toenails._{ECO:0000269|PubMed:11912510,_ECO:0000269|PubMed:12548749,_ECO:0000269|PubMed:12752120}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bart-Pumphrey_syndrome_(BPS)_[MIM:149200]:_An_autosomal_dominant_disorder_characterized_by_sensorineural_hearing_loss,_palmoplantar_keratoderma,_knuckle_pads,_and_leukonychia,_It_shows_considerable_phenotypic_variability._{ECO:0000269|PubMed:15482471,_ECO:0000269|PubMed:15952212}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ichthyosis_hystrix-like_with_deafness_syndrome_(HID_syndrome)_[MIM:602540]:_An_autosomal_dominant_keratinizing_disorder_characterized_by_sensorineural_deafness_and_spiky_hyperkeratosis_affecting_the_entire_skin._HID_syndrome_is_considered_to_differ_from_the_similar_KID_syndrome_in_the_extent_and_time_of_occurrence_of_skin_symptoms_and_the_severity_of_the_associated_keratitis._{ECO:0000269|PubMed:12072059}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	.	.	0.42941	0.50569	0.663285274	84.55414013	794.09383	5.55726	.	.	.	.	.	.	0.002	0.721	D	0.005	0.334	N	1.000	0.498	D	0.505	0.135	N	-4.52	0.977	D	-1.16	0.297	N	0.647	0.925	D	0.827	0.942	D	0.301	0.909	D	0.342	0.335	0.932	0.574	D	c	-0.023	0.101	1.000	0.747	0.554	0.246	0	5.65	0.868	5.501	0.664	1.048	0.713	1.000	0.715	0.636	0.296	13.984	0.637	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,864	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.4999	VUS
13	20763068	20763068	C	T	exonic	GJB2	.	nonsynonymous_SNV	GJB2:NM_004004:exon2:c.G653A:p.C218Y	1.02863295453376e-11	0.00164377442881105	0.998356225560903	gap_junction_protein_beta_2	FUNCTION:_One_gap_junction_consists_of_a_cluster_of_closely_packed_pairs_of_transmembrane_channels,_the_connexons,_through_which_materials_of_low_MW_diffuse_from_one_cell_to_a_neighboring_cell.\x3b_	DISEASE:_Deafness,_autosomal_recessive,_1A_(DFNB1A)_[MIM:220290]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10830906,_ECO:0000269|PubMed:11313763,_ECO:0000269|PubMed:11439000,_ECO:0000269|PubMed:12121355,_ECO:0000269|PubMed:12239718,_ECO:0000269|PubMed:12786758,_ECO:0000269|PubMed:14722929,_ECO:0000269|PubMed:15666300,_ECO:0000269|PubMed:15994881,_ECO:0000269|PubMed:17660464,_ECO:0000269|PubMed:17666888,_ECO:0000269|PubMed:19384972,_ECO:0000269|PubMed:23680645,_ECO:0000269|PubMed:9328482,_ECO:0000269|PubMed:9336442,_ECO:0000269|PubMed:9471561,_ECO:0000269|PubMed:9529365}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_dominant,_3A_(DFNA3A)_[MIM:601544]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10807696,_ECO:0000269|PubMed:11313763,_ECO:0000269|PubMed:11439000,_ECO:0000269|PubMed:12786758,_ECO:0000269|PubMed:19384972,_ECO:0000269|PubMed:9620796}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Vohwinkel_syndrome_(VS)_[MIM:124500]:_VS_is_an_autosomal_dominant_disease_characterized_by_hyperkeratosis,_constriction_on_fingers_and_toes_and_congenital_deafness._{ECO:0000269|PubMed:10369869,_ECO:0000269|PubMed:15954104,_ECO:0000269|PubMed:18688874}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Keratoderma,_palmoplantar,_with_deafness_(PPKDFN)_[MIM:148350]:_An_autosomal_dominant_disorder_characterized_by_the_association_of_palmoplantar_hyperkeratosis_with_progressive,_bilateral,_high-frequency,_sensorineural_deafness._{ECO:0000269|PubMed:10633135,_ECO:0000269|PubMed:10757647,_ECO:0000269|PubMed:12372058,_ECO:0000269|PubMed:15996214,_ECO:0000269|PubMed:17993581,_ECO:0000269|PubMed:9856479}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Keratitis-ichthyosis-deafness_syndrome_(KID_syndrome)_[MIM:148210]:_An_autosomal_dominant_form_of_ectodermal_dysplasia._Ectodermal_dysplasia_defines_a_heterogeneous_group_of_disorders_due_to_abnormal_development_of_two_or_more_ectodermal_structures._Keratitis-ichthyosis-deafness_syndrome_is_characterized_by_the_association_of_hyperkeratotic_skin_lesions_with_vascularizing_keratitis_and_profound_sensorineural_hearing_loss._Clinical_features_include_deafness,_ichthyosis,_photophobia,_absent_or_decreased_eyebrows,_sparse_or_absent_scalp_hair,_decreased_sweating_and_dysplastic_finger_and_toenails._{ECO:0000269|PubMed:11912510,_ECO:0000269|PubMed:12548749,_ECO:0000269|PubMed:12752120}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bart-Pumphrey_syndrome_(BPS)_[MIM:149200]:_An_autosomal_dominant_disorder_characterized_by_sensorineural_hearing_loss,_palmoplantar_keratoderma,_knuckle_pads,_and_leukonychia,_It_shows_considerable_phenotypic_variability._{ECO:0000269|PubMed:15482471,_ECO:0000269|PubMed:15952212}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ichthyosis_hystrix-like_with_deafness_syndrome_(HID_syndrome)_[MIM:602540]:_An_autosomal_dominant_keratinizing_disorder_characterized_by_sensorineural_deafness_and_spiky_hyperkeratosis_affecting_the_entire_skin._HID_syndrome_is_considered_to_differ_from_the_similar_KID_syndrome_in_the_extent_and_time_of_occurrence_of_skin_symptoms_and_the_severity_of_the_associated_keratitis._{ECO:0000269|PubMed:12072059}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	.	.	0.42941	0.50569	0.663285274	84.55414013	794.09383	5.55726	rs752812448	.	.	.	.	.	0.012	0.546	D	0.000	0.486	D	1.000	0.488	D	2.68	0.787	M	-4.46	0.976	D	-4.71	0.799	D	0.844	0.950	D	0.874	0.958	D	0.421	0.938	D	0.804	0.922	0.938	0.588	D	c	0.057	0.123	1.000	0.747	0.554	0.246	0	4.79	0.608	2.470	0.445	0.935	0.490	0.921	0.317	0.974	0.471	11.655	0.504	.	.	.	.	.	.	.	.	.	.	.	.	.	8.207e-06	0	0	0	0	0	1.819e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,865	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.4999	VUS
12	103271235	103271235	C	A	intronic	PAH	.	.	.	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62507321	98649	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1.0000	0.976	3.23e-05	0	0	0	0	0	6.665e-05	0	2.843e-05	0	0.0001	0	0	0	2.686e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,797	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.4999	VUS
12	103271234	103271234	A	T	intronic	PAH	.	.	.	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475698	125869	Phenylketonuria	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006	no_assertion_criteria_provided	Likely_pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.9813	0.616	.	.	.	.	.	.	.	.	4.061e-06	0	0	0	0	0	8.952e-06	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,796	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.4999	VUS
14	31348684	31348684	A	G	exonic	COCH	.	synonymous_SNV	COCH:NM_001135058:exon5:c.A429G:p.P143P,COCH:NM_001347720:exon5:c.A624G:p.P208P,COCH:NM_004086:exon6:c.A429G:p.P143P	0.000262849456488043	0.983542807336405	0.0161943432071074	cochlin	FUNCTION:_Plays_a_role_in_the_control_of_cell_shape_and_motility_in_the_trabecular_meshwork._{ECO:0000269|PubMed:21886777}.\x3b_	DISEASE:_Deafness,_autosomal_dominant,_9_(DFNA9)_[MIM:601369]:_A_form_of_non-syndromic_hearing_loss_characterized_by_onset_in_the_fourth_or_fifth_decade_of_life_and_initially_involves_the_high_frequencies._Hearing_loss_is_progressive_and_usually_complete_by_the_sixth_decade._In_addition_to_cochlear_involvement,_DFNA9_patients_also_exhibit_a_spectrum_of_vestibular_dysfunctions._Penetrance_of_the_vestibular_symptoms_is_often_incomplete,_and_some_patients_are_minimally_affected,_whereas_others_suffer_from_severe_balance_disturbances_and_episodes_of_vertigo._Affected_individuals_have_mucopolysaccharide_depositions_in_the_channels_of_the_cochlear_and_vestibular_nerves._These_depositions_apparently_cause_strangulation_and_degeneration_of_dendritic_fibers._{ECO:0000269|PubMed:10400989,_ECO:0000269|PubMed:11295836,_ECO:0000269|PubMed:14512963,_ECO:0000269|PubMed:16835921,_ECO:0000269|PubMed:17561763,_ECO:0000269|PubMed:18312449,_ECO:0000269|PubMed:22610276,_ECO:0000269|PubMed:22931125,_ECO:0000269|PubMed:23993205,_ECO:0000269|PubMed:9806553,_ECO:0000269|PubMed:9931344}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_inner_ear_structures\x3b_the_cochlea_and_the_vestibule.\x3b_	unclassifiable_(Anatomical_System)\x3bcartilage\x3bovary\x3bhypothalamus\x3bcolon\x3bparathyroid\x3bretina\x3bprostate\x3blung\x3bcochlea\x3badrenal_gland\x3blarynx\x3btrabecular_meshwork\x3bplacenta\x3bvisual_apparatus\x3bliver\x3btestis\x3bhead_and_neck\x3bspleen\x3bkidney\x3bbrain\x3bstomach\x3b	pons\x3bcaudate_nucleus\x3b	0.53303	0.13199	0.286674996	71.49681529	2772.50763	9.93783	rs147841606	230518	not_specified|Nonsyndromic_Hearing_Loss,_Dominant	MedGen:CN169374|MedGen:CN239435	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0007	0.0024	0	0	0	0	0	0.0010	0.0001	0.0015	0.0003	0	0	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,881	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.4999	VUS
12	103310850	103310850	T	A	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon1:c.A59T:p.Q20L	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475662	108485	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.188	0.253	T	0.044	0.237	N	0.947	0.810	D	0.55	0.145	N	-5.76	0.993	D	-1.18	0.332	N	0.388	0.889	D	0.839	0.946	D	0.324	0.916	D	0.808	0.925	0.779	0.381	D	c	-0.530	-0.364	1.000	0.747	0.493	0.174	0	2.81	0.318	1.903	0.393	1.061	0.807	1.000	0.715	0.373	0.250	4.624	0.118	.	.	.	0.5648	0.572	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,844	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.4999	VUS
16	68771321	68771321	G	A	exonic	CDH1	.	nonsynonymous_SNV	CDH1:NM_001317184:exon1:c.G3A:p.M1I,CDH1:NM_004360:exon1:c.G3A:p.M1I	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	rs878854691	242448	Hereditary_cancer-predisposing_syndrome|Hereditary_diffuse_gastric_cancer	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708349,OMIM:137215,Orphanet:ORPHA26106	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	0.0	0.912	D	0.000	0.441	D	1	0.810	D	.	.	.	0.68	0.527	T	-1.39	0.366	N	-0.952	0.407	T	0.119	0.417	T	0.957	0.997	D	0.997	1.000	0.469	0.276	N	c	-0.001	0.122	1.000	0.747	0.598	0.340	0	5.01	0.663	2.000	0.402	0.954	0.563	1.000	0.715	0.345	0.245	13.679	0.618	.	.	.	.	.	.	.	.	.	.	.	.	.	0	0	0	0	0	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,888	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.4999	VUS
16	68842668	68842668	G	A	exonic	CDH1	.	nonsynonymous_SNV	CDH1:NM_001317184:exon5:c.G604A:p.V202I,CDH1:NM_004360:exon5:c.G604A:p.V202I	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	rs546716073	137592	Hereditary_cancer-predisposing_syndrome|Hereditary_diffuse_gastric_cancer|not_specified|not_provided	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708349,OMIM:137215,Orphanet:ORPHA26106|MedGen:CN169374|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Benign/Likely_benign	0.155	0.276	T	0.801	0.068	N	1	0.090	N	1.47	0.371	L	0.71	0.512	T	-0.81	0.223	N	-0.971	0.371	T	0.112	0.401	T	.	.	.	0.427	0.474	0.231	0.217	N	c	-0.703	-0.649	0.994	0.332	0.719	0.830	0	1.44	0.215	1.621	0.364	0.112	0.206	0.011	0.184	0.478	0.267	11.847	0.515	Cadherin|Cadherin-like	.	.	.	.	3.228e-05	0	0	0	0.0006	0	0	0	0.0005	0	2.979e-05	0	0.0008	0	0	0.0002	0.0035	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,895	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0.4999	VUS
16	68845762	68845762	G	A	exonic	CDH1	.	synonymous_SNV	CDH1:NM_001317184:exon7:c.G1008A:p.E336E,CDH1:NM_004360:exon7:c.G1008A:p.E336E	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	rs267606712	235390	Hereditary_cancer-predisposing_syndrome|Hereditary_diffuse_gastric_cancer	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708349,OMIM:137215,Orphanet:ORPHA26106	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1.0000	0.994	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,900	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.4999	VUS
14	31349945	31349945	C	T	ncRNA_intronic	LOC100506071	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs202109231	266218	not_specified|Nonsyndromic_Hearing_Loss,_Dominant	MedGen:CN169374|MedGen:CN239435	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0003	0.01	0.0008	0.0001	0.0012	0.0033	0	0.0003	0.0013	0.0010	0.0009	6.548e-05	0.0009	0.0019	0	9.013e-05	0.0013	0.0004	0.0009	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,882	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.4999	VUS
21	36421179	36421179	T	C	exonic	RUNX1	.	nonsynonymous_SNV	RUNX1:NM_001754:exon2:c.A18G:p.I6M	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	rs199929612	469611	Familial_platelet_disorder_with_associated_myeloid_malignancy	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290	criteria_provided,_single_submitter	Benign	0.036	0.433	D	0.089	0.204	N	1	0.810	D	.	.	.	-4.26	0.979	D	-0.32	0.605	N	0.032	0.829	D	0.782	0.926	D	0.117	0.797	D	.	.	0.651	0.324	D	c	-0.395	-0.319	1.000	0.747	0.394	0.051	0	-1.77	0.075	0.345	0.196	0.086	0.193	0.999	0.424	1.000	0.888	1.616	0.025	.	.	.	.	.	3.236e-05	0	0	0	0	0	6.676e-05	0	0.0002	0	0	0.0037	0	0	1.79e-05	0.0004	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,989	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.4999	VUS
10	89623428	89623428	G	C	UTR5	PTEN	NM_001304718:c.-88546G>C\x3bNM_001304717:c.-279G>C\x3bNM_000314:c.-799G>C	.	.	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs587779992	133131	Hereditary_cancer-predisposing_syndrome|PTEN_hamartoma_tumor_syndrome|not_specified	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498|MedGen:CN169374	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,508	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.4999	VUS
10	89720649	89720650	AG	A	splicing	PTEN	NM_001304718:exon8:c.211-1G>-\x3bNM_001304717:exon9:c.1321-1G>-\x3bNM_000314:exon8:c.802-1G>-	.	.	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs587776672	22878	Cowden_syndrome_1	MedGen:CN072330,OMIM:158350	no_assertion_criteria_provided	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,583	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.4999	VUS
11	533779	533779	T	C	exonic	HRAS	.	nonsynonymous_SNV	HRAS:NM_001130442:exon3:c.A277G:p.I93V,HRAS:NM_005343:exon3:c.A277G:p.I93V,HRAS:NM_176795:exon3:c.A277G:p.I93V	0.00794104930284198	0.785285637637198	0.20677331305996	Harvey_rat_sarcoma_viral_oncogene_homolog	FUNCTION:_Ras_proteins_bind_GDP/GTP_and_possess_intrinsic_GTPase_activity._{ECO:0000269|PubMed:12740440,_ECO:0000269|PubMed:14500341,_ECO:0000269|PubMed:9020151}.\x3b_	DISEASE:_Costello_syndrome_(CSTLO)_[MIM:218040]:_A_rare_condition_characterized_by_prenatally_increased_growth,_postnatal_growth_deficiency,_mental_retardation,_distinctive_facial_appearance,_cardiovascular_abnormalities_(typically_pulmonic_stenosis,_hypertrophic_cardiomyopathy_and/or_atrial_tachycardia),_tumor_predisposition,_skin_and_musculoskeletal_abnormalities._{ECO:0000269|PubMed:16170316,_ECO:0000269|PubMed:16329078,_ECO:0000269|PubMed:16443854,_ECO:0000269|PubMed:17054105,_ECO:0000269|PubMed:18039947,_ECO:0000269|PubMed:18247425,_ECO:0000269|PubMed:19995790}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Congenital_myopathy_with_excess_of_muscle_spindles_(CMEMS)_[MIM:218040]:_Variant_of_Costello_syndrome._{ECO:0000269|PubMed:17412879}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hurthle_cell_thyroid_carcinoma_(HCTC)_[MIM:607464]:_A_rare_type_of_thyroid_cancer_accounting_for_only_about_3-10%_of_all_differentiated_thyroid_cancers._These_neoplasms_are_considered_a_variant_of_follicular_carcinoma_of_the_thyroid_and_are_referred_to_as_follicular_carcinoma,_oxyphilic_type._{ECO:0000269|PubMed:12727991}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dMutations_which_change_positions_12,_13_or_61_activate_the_potential_of_HRAS_to_transform_cultured_cells_and_are_implicated_in_a_variety_of_human_tumors._{ECO:0000269|PubMed:3670300}.\x3b_DISEASE:_Bladder_cancer_(BLC)_[MIM:109800]:_A_malignancy_originating_in_tissues_of_the_urinary_bladder._It_often_presents_with_multiple_tumors_appearing_at_different_times_and_at_different_sites_in_the_bladder._Most_bladder_cancers_are_transitional_cell_carcinomas_that_begin_in_cells_that_normally_make_up_the_inner_lining_of_the_bladder._Other_types_of_bladder_cancer_include_squamous_cell_carcinoma_(cancer_that_begins_in_thin,_flat_cells)_and_adenocarcinoma_(cancer_that_begins_in_cells_that_make_and_release_mucus_and_other_fluids)._Bladder_cancer_is_a_complex_disorder_with_both_genetic_and_environmental_influences._{ECO:0000269|PubMed:6298635,_ECO:0000269|PubMed:6844927}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Schimmelpenning-Feuerstein-Mims_syndrome_(SFM)_[MIM:163200]:_A_disease_characterized_by_sebaceous_nevi,_often_on_the_face,_associated_with_variable_ipsilateral_abnormalities_of_the_central_nervous_system,_ocular_anomalies,_and_skeletal_defects._Many_oral_manifestations_have_been_reported,_not_only_including_hypoplastic_and_malformed_teeth,_and_mucosal_papillomatosis,_but_also_ankyloglossia,_hemihyperplastic_tongue,_intraoral_nevus,_giant_cell_granuloma,_ameloblastoma,_bone_cysts,_follicular_cysts,_oligodontia,_and_odontodysplasia._Sebaceous_nevi_follow_the_lines_of_Blaschko_and_these_can_continue_as_linear_intraoral_lesions,_as_in_mucosal_papillomatosis._{ECO:0000269|PubMed:22683711}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Widely_expressed._{ECO:0000269|PubMed:14500341}.\x3b_	ovary\x3bdevelopmental\x3bcolon\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3boptic_nerve\x3bwhole_body\x3boesophagus\x3bendometrium\x3bthyroid\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bhypothalamus\x3bblood\x3blens\x3bskeletal_muscle\x3blung\x3bplacenta\x3bvisual_apparatus\x3bhypopharynx\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bcerebellum\x3b	whole_brain\x3bmedulla_oblongata\x3btrigeminal_ganglion\x3b	0.99944	0.99980	-0.339715008	30.06605331	4.91473	0.18207	rs587782949	48909	Pulmonic_stenosis|Supravalvar_aortic_stenosis|Costello_syndrome|not_specified	Human_Phenotype_Ontology:HP:0001642,MedGen:C1956257,OMIM:265500|Human_Phenotype_Ontology:HP:0004381,MedGen:C0003499,OMIM:185500,Orphanet:ORPHA3193,SNOMED_CT:268185002|MedGen:C0587248,OMIM:218040,Orphanet:ORPHA3071,SNOMED_CT:309776008|MedGen:CN169374	reviewed_by_expert_panel	Uncertain_significance	0.163	0.234	T	0.000	0.843	N	1.000	0.588	D	-0.275	0.037	N	-0.88	0.747	T	-0.66	0.191	N	-0.990	0.325	T	0.162	0.498	T	0.019	0.414	T	0.359	0.363	0.947	0.617	D	c	-0.494	-0.352	1.000	0.747	0.722	0.854	0	2.33	0.279	3.967	0.563	0.964	0.580	1.000	0.715	0.999	0.750	7.699	0.276	P-loop_containing_nucleoside_triphosphate_hydrolase|Small_GTP-binding_protein_domain	.	.	.	.	3.237e-05	0	0	0	0	0	0	0.0010	4.063e-06	0	0	0	0	4.484e-05	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,619	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0.4999	VUS
10	89685314	89685318	TGTAA	T	splicing	PTEN	.	.	.	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs398123318	98723	Hereditary_cancer-predisposing_syndrome|PTEN_hamartoma_tumor_syndrome|Cowden_syndrome_1	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498|MedGen:CN072330,OMIM:158350	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,530	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.4999	VUS
11	121008680	121008680	C	T	exonic	TECTA	.	synonymous_SNV	TECTA:NM_005422:exon10:c.C3492T:p.T1164T	1.06498565113514e-12	0.999989745526101	1.02544728344311e-05	tectorin_alpha	FUNCTION:_One_of_the_major_non-collagenous_components_of_the_tectorial_membrane_(By_similarity)._The_tectorial_membrane_is_an_extracellular_matrix_of_the_inner_ear_that_covers_the_neuroepithelium_of_the_cochlea_and_contacts_the_stereocilia_bundles_of_specialized_sensory_hair_cells._Sound_induces_movement_of_these_hair_cells_relative_to_the_tectorial_membrane,_deflects_the_stereocilia_and_leads_to_fluctuations_in_hair-cell_membrane_potential,_transducing_sound_into_electrical_signals._{ECO:0000250}.\x3b_	DISEASE:_Deafness,_autosomal_dominant,_12_(DFNA12)_[MIM:601543]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10196713,_ECO:0000269|PubMed:10987647,_ECO:0000269|PubMed:12162770,_ECO:0000269|PubMed:15319541,_ECO:0000269|PubMed:16718611,_ECO:0000269|PubMed:17661817,_ECO:0000269|PubMed:20947814,_ECO:0000269|PubMed:21520338,_ECO:0000269|PubMed:9590290}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_recessive,_21_(DFNB21)_[MIM:603629]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:12746400,_ECO:0000269|PubMed:9949200}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	liver\x3btestis\x3bspleen\x3bblood\x3bbrain\x3b	superior_cervical_ganglion\x3batrioventricular_node\x3bskeletal_muscle\x3b	0.64735	0.20702	-2.430013277	1.032083038	4846.67098	14.13953	rs144012985	175361	not_specified|Nonsyndromic_Hearing_Loss,_Dominant|Nonsyndromic_Hearing_Loss,_Recessive	MedGen:CN169374|MedGen:CN239435|MedGen:CN239439	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0015	0.0050	0	0	0	0	6.667e-05	0	0.0004	0.0045	0.0003	0	0	0	0.0001	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,637	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.4999	VUS
10	89717673	89717673	G	A	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon7:c.G698A:p.R233Q,PTEN:NM_001304718:exon7:c.G107A:p.R36Q,PTEN:NM_001304717:exon8:c.G1217A:p.R406Q	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs770025422	363389	Transitional_cell_carcinoma_of_the_bladder|Glioblastoma|Uterine_cervical_neoplasms|Colorectal_Neoplasms|Adenocarcinoma_of_prostate|Hereditary_cancer-predisposing_syndrome|Malignant_neoplasm_of_body_of_uterus|Adenocarcinoma_of_stomach|Uterine_Carcinosarcoma|PTEN_hamartoma_tumor_syndrome	Human_Phenotype_Ontology:HP:0006740,MedGen:C0279680|Human_Phenotype_Ontology:HP:0100843,MeSH:D005909,MedGen:C0017636,SNOMED_CT:63634009|MeSH:D002583,MedGen:CN236667|MeSH:D015179,MedGen:CN236642|MedGen:C0007112|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0153574,Orphanet:ORPHA213569|MedGen:C0278701|MedGen:C0280630|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	0.101	0.303	T	0.000	0.629	D	1.000	0.588	D	2.02	0.555	M	-1.91	0.847	D	-1.81	0.425	N	-0.158	0.787	T	0.472	0.797	T	0.115	0.794	D	0.495	0.584	0.971	0.725	D	c	0.356	0.453	1.000	0.747	0.719	0.830	0	5.15	0.702	7.734	0.837	0.902	0.416	1.000	0.715	0.999	0.750	12.040	0.526	C2_domain|Tensin_phosphatase,_C2_domain	.	.	.	.	.	.	.	.	.	.	.	.	4.061e-06	0	0	0	0	0	8.953e-06	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,572	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.4999	VUS
10	89623365	89623365	G	T	UTR5	PTEN	NM_001304718:c.-88609G>T\x3bNM_001304717:c.-342G>T\x3bNM_000314:c.-862G>T	.	.	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs587776675	22884	Cowden_syndrome_1	MedGen:CN072330,OMIM:158350	no_assertion_criteria_provided	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,507	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.4999	VUS
12	103237426	103237426	T	A	exonic	PAH	.	synonymous_SNV	PAH:NM_000277:exon11:c.A1197T:p.V399V	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475584	15640	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0494	0.71	.	.	.	.	.	.	.	.	4.064e-06	0	0	0	5.799e-05	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,659	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.4999	VUS
12	103237568	103237568	C	T	intronic	PAH	.	.	.	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs5030855	15646	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.9998	0.976	0.0002	0.0001	0	0	0	0	0.0004	0	0.0002	0	0.0001	0.0001	0	4.536e-05	0.0004	0.0009	9.748e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,674	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.4999	VUS
10	89623026	89623038	TGCAAAAGCCGCA	T	UTR5	KLLN	NM_001126049:c.-783_-794delTGCGGCTTTTGC	.	.	.	.	.	killin,_p53-regulated_DNA_replication_inhibitor	FUNCTION:_DNA-binding_protein_involved_in_S_phase_checkpoint_control-coupled_apoptosis_by_mediating_p53/TP53-induced_apoptosis._Has_the_ability_to_inhibit_DNA_synthesis_and_S_phase_arrest_coupled_to_apoptosis._Has_affinity_to_both_double-_and_single-_stranded_DNA._{ECO:0000269|PubMed:18385383}.\x3b_	DISEASE:_Cowden_syndrome_4_(CWS4)_[MIM:615107]:_A_form_of_Cowden_syndrome,_a_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:21177507}._Note\x3dThe_gene_represented_in_this_entry_is_involved_in_disease_pathogenesis._Germline_KLLN_methylation_is_common_among_patients_with_Cowden_syndrome_or_Cowden-like_syndrome_and_is_associated_with_increased_risks_of_breast_and_renal_cancer_over_PTEN_mutation-positive_individuals_(PubMed:21177507)._{ECO:0000269|PubMed:21177507}.\x3b_	.	.	.	.	.	1.012423333	90.829205	121.24747	2.39863	rs587781340	187281	Hereditary_cancer-predisposing_syndrome|not_specified|not_provided	MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN169374|MedGen:CN517202	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0001	0	0.0012	0	0	0	0.0002	0	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,502	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.4999	VUS
6	76599951	76599951	C	T	exonic	MYO6	.	nonsynonymous_SNV	MYO6:NM_001300899:exon26:c.C2836T:p.R946C,MYO6:NM_004999:exon26:c.C2836T:p.R946C	0.0177883990936548	0.982211600378647	5.27698444208756e-10	myosin_VI	FUNCTION:_Myosins_are_actin-based_motor_molecules_with_ATPase_activity._Unconventional_myosins_serve_in_intracellular_movements._Myosin_6_is_a_reverse-direction_motor_protein_that_moves_towards_the_minus-end_of_actin_filaments._Has_slow_rate_of_actin-activated_ADP_release_due_to_weak_ATP_binding._Functions_in_a_variety_of_intracellular_processes_such_as_vesicular_membrane_trafficking_and_cell_migration._Required_for_the_structural_integrity_of_the_Golgi_apparatus_via_the_p53-dependent_pro-survival_pathway._Appears_to_be_involved_in_a_very_early_step_of_clathrin-mediated_endocytosis_in_polarized_epithelial_cells._May_act_as_a_regulator_of_F-actin_dynamics._May_play_a_role_in_transporting_DAB2_from_the_plasma_membrane_to_specific_cellular_targets._Required_for_structural_integrity_of_inner_ear_hair_cells_(By_similarity)._{ECO:0000250,_ECO:0000269|PubMed:10519557,_ECO:0000269|PubMed:11447109,_ECO:0000269|PubMed:16507995,_ECO:0000269|PubMed:16949370}.\x3b_	DISEASE:_Deafness,_autosomal_dominant,_22_(DFNA22)_[MIM:606346]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._DFNA22_is_progressive_and_postlingual,_with_onset_during_childhood._By_the_age_of_approximately_50_years,_affected_individuals_invariably_have_profound_sensorineural_deafness._{ECO:0000269|PubMed:11468689}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_recessive,_37_(DFNB37)_[MIM:607821]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:12687499}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_sensorineural,_with_hypertrophic_cardiomyopathy_(DFNHCM)_[MIM:606346]:_An_autosomal_dominant_sensorineural_deafness_associated_with_hypertrophic_cardiomyopathy._{ECO:0000269|PubMed:15060111}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_most_tissues_examined_including_heart,_brain,_placenta,_pancreas,_spleen,_thymus,_prostate,_testis,_ovary,_small_intestine_and_colon._Highest_levels_in_brain,_pancreas,_testis_and_small_intestine._Also_expressed_in_fetal_brain_and_cochlea._Isoform_1_and_isoform_2,_containing_the_small_insert,_and_isoform_4,_containing_neither_insert,_are_expressed_in_unpolarized_epithelial_cells._{ECO:0000269|PubMed:9259267}.\x3b_	.	.	0.26137	0.31948	-0.369255208	28.25548478	419.15519	4.27823	rs141845119	174149	not_specified|not_provided	MedGen:CN169374|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	0.001	0.784	D	0.001	0.428	D	0.994	0.421	D	2.56	0.750	M	2.19	0.231	T	-4.45	0.783	D	-1.088	0.058	T	0.057	0.238	T	0.022	0.450	T	.	.	0.873	0.465	D	c	0.346	0.314	0.565	0.214	0.672	0.522	0	5.98	0.971	3.133	0.500	0.888	0.391	0.946	0.326	0.103	0.190	15.906	0.791	.	.	.	.	.	0.0006	0.0002	0	0	0	0.0011	0.0009	0	0.0007	6.546e-05	0.0001	0.0003	0	0.0011	0.0010	0.0009	0.0013	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,488	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.4999	VUS
10	89720733	89720749	TATGTGATCAAGAAATC	G	exonic	PTEN	.	frameshift_substitution	PTEN:NM_000314:exon8:c.884_900G,PTEN:NM_001304718:exon8:c.293_309G,PTEN:NM_001304717:exon9:c.1403_1419G	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	.	419759	Hereditary_cancer-predisposing_syndrome	MedGen:C0027672,SNOMED_CT:699346009	criteria_provided,_single_submitter	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,585	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.4999	VUS
1	216258168	216258168	T	C	exonic	USH2A	.	nonsynonymous_SNV	USH2A:NM_206933:exon25:c.A5039G:p.K1680R	3.68100336207458e-43	0.999989235571568	1.07644284322941e-05	Usher_syndrome_2A_(autosomal_recessive,_mild)	FUNCTION:_Involved_in_hearing_and_vision.\x3b_	DISEASE:_Usher_syndrome_2A_(USH2A)_[MIM:276901]:_USH_is_a_genetically_heterogeneous_condition_characterized_by_the_association_of_retinitis_pigmentosa_with_sensorineural_deafness._Age_at_onset_and_differences_in_auditory_and_vestibular_function_distinguish_Usher_syndrome_type_1_(USH1),_Usher_syndrome_type_2_(USH2)_and_Usher_syndrome_type_3_(USH3)._USH2_is_characterized_by_congenital_mild_hearing_impairment_with_normal_vestibular_responses._{ECO:0000269|PubMed:10729113,_ECO:0000269|PubMed:10738000,_ECO:0000269|PubMed:10909849,_ECO:0000269|PubMed:11311042,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:12525556,_ECO:0000269|PubMed:14970843,_ECO:0000269|PubMed:15015129,_ECO:0000269|PubMed:15025721,_ECO:0000269|PubMed:15241801,_ECO:0000269|PubMed:15325563,_ECO:0000269|PubMed:17085681,_ECO:0000269|PubMed:17405132,_ECO:0000269|PubMed:18273898,_ECO:0000269|PubMed:18452394,_ECO:0000269|PubMed:19683999,_ECO:0000269|PubMed:19737284,_ECO:0000269|PubMed:20309401,_ECO:0000269|PubMed:20440071,_ECO:0000269|PubMed:20507924,_ECO:0000269|PubMed:21593743,_ECO:0000269|PubMed:21686329,_ECO:0000269|PubMed:22004887,_ECO:0000269|PubMed:23737954,_ECO:0000269|PubMed:9624053}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Retinitis_pigmentosa_39_(RP39)_[MIM:613809]:_A_retinal_dystrophy_belonging_to_the_group_of_pigmentary_retinopathies._Retinitis_pigmentosa_is_characterized_by_retinal_pigment_deposits_visible_on_fundus_examination_and_primary_loss_of_rod_photoreceptor_cells_followed_by_secondary_loss_of_cone_photoreceptors._Patients_typically_have_night_vision_blindness_and_loss_of_midperipheral_visual_field._As_their_condition_progresses,_they_lose_their_far_peripheral_visual_field_and_eventually_central_vision_as_well._{ECO:0000269|PubMed:10775529,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:12427073,_ECO:0000269|PubMed:15325563,_ECO:0000269|PubMed:16098008,_ECO:0000269|PubMed:17296898,_ECO:0000269|PubMed:20507924,_ECO:0000269|PubMed:21686329,_ECO:0000269|PubMed:22334370,_ECO:0000269|PubMed:24227914}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Present_in_the_basement_membrane_of_many,_but_not_all_tissues._Expressed_in_retina,_cochlea,_small_and_large_intestine,_pancreas,_bladder,_prostate,_esophagus,_trachea,_thymus,_salivary_glands,_placenta,_ovary,_fallopian_tube,_uterus_and_testis._Absent_in_many_other_tissues_such_as_heart,_lung,_liver,_kidney_and_brain._In_the_retina,_it_is_present_in_the_basement_membranes_in_the_Bruch's_layer_choroid_capillary_basement_membranes,_where_it_localizes_just_beneath_the_retinal_pigment_epithelial_cells_(at_protein_level)._Weakly_expressed._Isoform_2_is_expressed_in_fetal_eye,_cochlea_and_heart,_and_at_very_low_level_in_brain,_CNS,_intestine,_skeleton,_tongue,_kidney_and_lung._Isoform_2_is_not_expressed_in_stomach_and_liver._In_adult_tissues,_isoform_2_is_expressed_in_neural_retina_and_testis,_and_at_low_level_in_brain,_heart,_kidney_and_liver._Isoform_1_displays_a_similar_pattern_of_expression_but_is_expressed_at_very_low_level_in_fetal_cochlea._{ECO:0000269|PubMed:11788194,_ECO:0000269|PubMed:12433396,_ECO:0000269|PubMed:15015129,_ECO:0000269|PubMed:9624053}.\x3b_	unclassifiable_(Anatomical_System)\x3bliver\x3btestis\x3bretina\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3badrenal_gland\x3btemporal_lobe\x3bciliary_ganglion\x3batrioventricular_node\x3btrigeminal_ganglion\x3bskin\x3bskeletal_muscle\x3bcerebellum\x3b	0.15836	.	4.179636958	99.70511913	6401.91635	16.71188	rs150982499	172526	not_specified	MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	0.276	0.157	T	0.000	0.469	D	0.718	0.299	N	1.7	0.440	L	-1.22	0.788	T	-0.8	0.221	N	-0.664	0.621	T	0.253	0.624	T	0.222	0.879	D	.	.	0.842	0.430	D	c	0.015	0.130	0.000	0.066	0.487	0.133	0	4.93	0.643	2.193	0.420	1.061	0.807	1.000	0.715	0.623	0.293	6.188	0.196	Concanavalin_A-like_lectin/glucanase_domain|Laminin_G_domain	.	.	.	.	6.463e-05	0	0.0012	0	0	0	6.667e-05	0	0.0001	0	0.0006	0	0	0	0.0001	0.0002	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,454	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0.4999	VUS
12	103246590	103246590	C	G	intronic	PAH	.	.	.	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62507324	108607	Phenylketonuria|not_specified|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN169374|MedGen:CN517202	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.9213	0.748	.	.	.	.	.	.	.	.	1.219e-05	0	5.957e-05	0	0	0	8.969e-06	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,705	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.4999	VUS
1	216040521	216040521	T	C	intronic	USH2A	.	.	.	3.68100336207458e-43	0.999989235571568	1.07644284322941e-05	Usher_syndrome_2A_(autosomal_recessive,_mild)	FUNCTION:_Involved_in_hearing_and_vision.\x3b_	DISEASE:_Usher_syndrome_2A_(USH2A)_[MIM:276901]:_USH_is_a_genetically_heterogeneous_condition_characterized_by_the_association_of_retinitis_pigmentosa_with_sensorineural_deafness._Age_at_onset_and_differences_in_auditory_and_vestibular_function_distinguish_Usher_syndrome_type_1_(USH1),_Usher_syndrome_type_2_(USH2)_and_Usher_syndrome_type_3_(USH3)._USH2_is_characterized_by_congenital_mild_hearing_impairment_with_normal_vestibular_responses._{ECO:0000269|PubMed:10729113,_ECO:0000269|PubMed:10738000,_ECO:0000269|PubMed:10909849,_ECO:0000269|PubMed:11311042,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:12525556,_ECO:0000269|PubMed:14970843,_ECO:0000269|PubMed:15015129,_ECO:0000269|PubMed:15025721,_ECO:0000269|PubMed:15241801,_ECO:0000269|PubMed:15325563,_ECO:0000269|PubMed:17085681,_ECO:0000269|PubMed:17405132,_ECO:0000269|PubMed:18273898,_ECO:0000269|PubMed:18452394,_ECO:0000269|PubMed:19683999,_ECO:0000269|PubMed:19737284,_ECO:0000269|PubMed:20309401,_ECO:0000269|PubMed:20440071,_ECO:0000269|PubMed:20507924,_ECO:0000269|PubMed:21593743,_ECO:0000269|PubMed:21686329,_ECO:0000269|PubMed:22004887,_ECO:0000269|PubMed:23737954,_ECO:0000269|PubMed:9624053}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Retinitis_pigmentosa_39_(RP39)_[MIM:613809]:_A_retinal_dystrophy_belonging_to_the_group_of_pigmentary_retinopathies._Retinitis_pigmentosa_is_characterized_by_retinal_pigment_deposits_visible_on_fundus_examination_and_primary_loss_of_rod_photoreceptor_cells_followed_by_secondary_loss_of_cone_photoreceptors._Patients_typically_have_night_vision_blindness_and_loss_of_midperipheral_visual_field._As_their_condition_progresses,_they_lose_their_far_peripheral_visual_field_and_eventually_central_vision_as_well._{ECO:0000269|PubMed:10775529,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:12427073,_ECO:0000269|PubMed:15325563,_ECO:0000269|PubMed:16098008,_ECO:0000269|PubMed:17296898,_ECO:0000269|PubMed:20507924,_ECO:0000269|PubMed:21686329,_ECO:0000269|PubMed:22334370,_ECO:0000269|PubMed:24227914}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Present_in_the_basement_membrane_of_many,_but_not_all_tissues._Expressed_in_retina,_cochlea,_small_and_large_intestine,_pancreas,_bladder,_prostate,_esophagus,_trachea,_thymus,_salivary_glands,_placenta,_ovary,_fallopian_tube,_uterus_and_testis._Absent_in_many_other_tissues_such_as_heart,_lung,_liver,_kidney_and_brain._In_the_retina,_it_is_present_in_the_basement_membranes_in_the_Bruch's_layer_choroid_capillary_basement_membranes,_where_it_localizes_just_beneath_the_retinal_pigment_epithelial_cells_(at_protein_level)._Weakly_expressed._Isoform_2_is_expressed_in_fetal_eye,_cochlea_and_heart,_and_at_very_low_level_in_brain,_CNS,_intestine,_skeleton,_tongue,_kidney_and_lung._Isoform_2_is_not_expressed_in_stomach_and_liver._In_adult_tissues,_isoform_2_is_expressed_in_neural_retina_and_testis,_and_at_low_level_in_brain,_heart,_kidney_and_liver._Isoform_1_displays_a_similar_pattern_of_expression_but_is_expressed_at_very_low_level_in_fetal_cochlea._{ECO:0000269|PubMed:11788194,_ECO:0000269|PubMed:12433396,_ECO:0000269|PubMed:15015129,_ECO:0000269|PubMed:9624053}.\x3b_	unclassifiable_(Anatomical_System)\x3bliver\x3btestis\x3bretina\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3badrenal_gland\x3btemporal_lobe\x3bciliary_ganglion\x3batrioventricular_node\x3btrigeminal_ganglion\x3bskin\x3bskeletal_muscle\x3bcerebellum\x3b	0.15836	.	4.179636958	99.70511913	6401.91635	16.71188	rs372347027	194671	Usher_syndrome,_type_2A|Retinitis_pigmentosa_39|not_provided	MedGen:C1848634,OMIM:276901|MedGen:C3151138,OMIM:613809|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.9982	0.984	3.234e-05	0	0	0	0	0	6.676e-05	0	7.352e-05	0	0	0.0005	0	0	0.0001	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,451	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.4999	VUS
10	89692957	89692958	GG	A	exonic	PTEN	.	frameshift_substitution	PTEN:NM_000314:exon5:c.441_442A,PTEN:NM_001304717:exon6:c.960_961A	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	.	419731	Hereditary_cancer-predisposing_syndrome	MedGen:C0027672,SNOMED_CT:699346009	criteria_provided,_single_submitter	Pathogenic	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,552	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.4999	VUS
10	89712021	89712021	G	C	intronic	PTEN	.	.	.	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	.	416984	Cowden_syndrome_1|not_specified	MedGen:CN072330,OMIM:158350|MedGen:CN169374	criteria_provided,_single_submitter	Uncertain_significance	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1.0000	0.966	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,569	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
10	89717626	89717626	C	T	exonic	PTEN	.	synonymous_SNV	PTEN:NM_000314:exon7:c.C651T:p.V217V,PTEN:NM_001304718:exon7:c.C60T:p.V20V,PTEN:NM_001304717:exon8:c.C1170T:p.V390V	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs886038278	253902	not_specified	MedGen:CN169374	criteria_provided,_single_submitter	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,570	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
12	103310863	103310863	A	G	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon1:c.T46C:p.S16P	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62642946	108425	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	0.097	0.413	T	0.016	0.280	N	1	0.277	N	0.55	0.145	N	-5.84	0.994	D	-0.66	0.191	N	0.668	0.928	D	0.877	0.959	D	0.290	0.906	D	0.774	0.900	0.609	0.311	D	c	-0.671	-0.571	1.000	0.747	0.628	0.401	0	4.05	0.462	2.438	0.443	1.199	0.960	0.991	0.370	0.061	0.171	8.137	0.300	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,847	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
12	103248897	103248897	C	A	intronic	PAH	.	.	.	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62508592	108528	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0006	0.0019	0.0012	0	0	0	6.663e-05	0	0.0002	0.0025	0.0003	0	0	0	8.968e-06	0.0002	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,757	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
10	89623492	89623492	G	A	UTR5	PTEN	NM_001304718:c.-88482G>A\x3bNM_001304717:c.-215G>A\x3bNM_000314:c.-735G>A	.	.	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs886047384	133129	PTEN_hamartoma_tumor_syndrome|not_specified	MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498|MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,510	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
12	103306564	103306564	C	A	intronic	PAH	.	.	.	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62507288	108343	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.9923	0.836	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,829	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
16	68847213	68847213	C	T	intronic	CDH1	.	.	.	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	rs36103202	184375	Hereditary_cancer-predisposing_syndrome|Hereditary_diffuse_gastric_cancer|not_specified	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708349,OMIM:137215,Orphanet:ORPHA26106|MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Benign/Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0121	0.068	0.0003	0.0009	0	0	0	0	0	0	0.0001	0.0014	0.0002	0	0	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,906	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
21	36164618	36164618	C	T	exonic	RUNX1	.	synonymous_SNV	RUNX1:NM_001001890:exon6:c.G1176A:p.V392V,RUNX1:NM_001754:exon9:c.G1257A:p.V419V	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	.	430417	Familial_platelet_disorder_with_associated_myeloid_malignancy|not_specified	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290|MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2.683e-05	0	0.0002	0	0	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,948	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
21	36265218	36265218	A	C	intronic	RUNX1	.	.	.	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	rs754042987	350638	Familial_platelet_disorder_with_associated_myeloid_malignancy	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0001	0.002	6.46e-05	0	0	0	0	0	0.0001	0	2.871e-05	6.56e-05	0	0	0	0	5.412e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,987	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
12	103306564	103306564	C	T	intronic	PAH	.	.	.	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62507288	108341	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.9989	0.916	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,830	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
10	89685317	89685317	A	T	intronic	PTEN	.	.	.	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs786202612	183020	Hereditary_cancer-predisposing_syndrome|not_specified	MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.9997	1.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,531	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
12	103245465	103245465	C	T	exonic	PAH	.	synonymous_SNV	PAH:NM_000277:exon8:c.G912A:p.Q304Q	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs199475583	108628	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.9999	0.998	.	.	.	.	.	.	.	.	4.069e-06	0	2.981e-05	0	0	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,688	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
12	103238111	103238111	T	C	intronic	PAH	.	.	.	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62508689	15672	Hyperphenylalaninemia,_non-pku|not_specified|not_provided	Human_Phenotype_Ontology:HP:0004923,MedGen:C0751435|MedGen:CN169374|MedGen:CN517202	criteria_provided,_single_submitter	Uncertain_significance	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.9987	0.88	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,675	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
12	103237522	103237522	C	T	exonic	PAH	.	synonymous_SNV	PAH:NM_000277:exon11:c.G1101A:p.L367L	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62508648	108262	not_provided	MedGen:CN517202	no_assertion_provided	not_provided	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,665	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
12	103246589	103246589	T	C	intronic	PAH	.	.	.	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	.	432709	not_specified	MedGen:CN169374	criteria_provided,_single_submitter	Uncertain_significance	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.9968	0.93	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,704	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
1	215802181	215802181	G	C	exonic	USH2A	.	nonsynonymous_SNV	USH2A:NM_206933:exon71:c.C15494G:p.A5165G	3.68100336207458e-43	0.999989235571568	1.07644284322941e-05	Usher_syndrome_2A_(autosomal_recessive,_mild)	FUNCTION:_Involved_in_hearing_and_vision.\x3b_	DISEASE:_Usher_syndrome_2A_(USH2A)_[MIM:276901]:_USH_is_a_genetically_heterogeneous_condition_characterized_by_the_association_of_retinitis_pigmentosa_with_sensorineural_deafness._Age_at_onset_and_differences_in_auditory_and_vestibular_function_distinguish_Usher_syndrome_type_1_(USH1),_Usher_syndrome_type_2_(USH2)_and_Usher_syndrome_type_3_(USH3)._USH2_is_characterized_by_congenital_mild_hearing_impairment_with_normal_vestibular_responses._{ECO:0000269|PubMed:10729113,_ECO:0000269|PubMed:10738000,_ECO:0000269|PubMed:10909849,_ECO:0000269|PubMed:11311042,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:12525556,_ECO:0000269|PubMed:14970843,_ECO:0000269|PubMed:15015129,_ECO:0000269|PubMed:15025721,_ECO:0000269|PubMed:15241801,_ECO:0000269|PubMed:15325563,_ECO:0000269|PubMed:17085681,_ECO:0000269|PubMed:17405132,_ECO:0000269|PubMed:18273898,_ECO:0000269|PubMed:18452394,_ECO:0000269|PubMed:19683999,_ECO:0000269|PubMed:19737284,_ECO:0000269|PubMed:20309401,_ECO:0000269|PubMed:20440071,_ECO:0000269|PubMed:20507924,_ECO:0000269|PubMed:21593743,_ECO:0000269|PubMed:21686329,_ECO:0000269|PubMed:22004887,_ECO:0000269|PubMed:23737954,_ECO:0000269|PubMed:9624053}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Retinitis_pigmentosa_39_(RP39)_[MIM:613809]:_A_retinal_dystrophy_belonging_to_the_group_of_pigmentary_retinopathies._Retinitis_pigmentosa_is_characterized_by_retinal_pigment_deposits_visible_on_fundus_examination_and_primary_loss_of_rod_photoreceptor_cells_followed_by_secondary_loss_of_cone_photoreceptors._Patients_typically_have_night_vision_blindness_and_loss_of_midperipheral_visual_field._As_their_condition_progresses,_they_lose_their_far_peripheral_visual_field_and_eventually_central_vision_as_well._{ECO:0000269|PubMed:10775529,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:12427073,_ECO:0000269|PubMed:15325563,_ECO:0000269|PubMed:16098008,_ECO:0000269|PubMed:17296898,_ECO:0000269|PubMed:20507924,_ECO:0000269|PubMed:21686329,_ECO:0000269|PubMed:22334370,_ECO:0000269|PubMed:24227914}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Present_in_the_basement_membrane_of_many,_but_not_all_tissues._Expressed_in_retina,_cochlea,_small_and_large_intestine,_pancreas,_bladder,_prostate,_esophagus,_trachea,_thymus,_salivary_glands,_placenta,_ovary,_fallopian_tube,_uterus_and_testis._Absent_in_many_other_tissues_such_as_heart,_lung,_liver,_kidney_and_brain._In_the_retina,_it_is_present_in_the_basement_membranes_in_the_Bruch's_layer_choroid_capillary_basement_membranes,_where_it_localizes_just_beneath_the_retinal_pigment_epithelial_cells_(at_protein_level)._Weakly_expressed._Isoform_2_is_expressed_in_fetal_eye,_cochlea_and_heart,_and_at_very_low_level_in_brain,_CNS,_intestine,_skeleton,_tongue,_kidney_and_lung._Isoform_2_is_not_expressed_in_stomach_and_liver._In_adult_tissues,_isoform_2_is_expressed_in_neural_retina_and_testis,_and_at_low_level_in_brain,_heart,_kidney_and_liver._Isoform_1_displays_a_similar_pattern_of_expression_but_is_expressed_at_very_low_level_in_fetal_cochlea._{ECO:0000269|PubMed:11788194,_ECO:0000269|PubMed:12433396,_ECO:0000269|PubMed:15015129,_ECO:0000269|PubMed:9624053}.\x3b_	unclassifiable_(Anatomical_System)\x3bliver\x3btestis\x3bretina\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3badrenal_gland\x3btemporal_lobe\x3bciliary_ganglion\x3batrioventricular_node\x3btrigeminal_ganglion\x3bskin\x3bskeletal_muscle\x3bcerebellum\x3b	0.15836	.	4.179636958	99.70511913	6401.91635	16.71188	rs146892520	266381	not_specified	MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	0.133	0.264	T	0.019	0.273	U	1.000	0.208	N	0.55	0.145	N	0.9	0.453	T	-0.6	0.178	N	-1.040	0.174	T	0.055	0.233	T	0.027	0.500	D	.	.	0.937	0.586	D	c	-0.138	0.096	0.102	0.164	0.487	0.133	0	5.67	0.876	4.723	0.614	0.998	0.613	1.000	0.715	0.976	0.476	15.272	0.733	.	.	.	.	.	0.0008	0.0024	0	0	0	0	0.0002	0	0.0002	0.0027	0.0002	0	0	0	0	0.0002	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,444	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0.1877	VUS
6	76542642	76542642	G	A	exonic	MYO6	.	nonsynonymous_SNV	MYO6:NM_001300899:exon6:c.G475A:p.E159K,MYO6:NM_004999:exon6:c.G475A:p.E159K	0.0177883990936548	0.982211600378647	5.27698444208756e-10	myosin_VI	FUNCTION:_Myosins_are_actin-based_motor_molecules_with_ATPase_activity._Unconventional_myosins_serve_in_intracellular_movements._Myosin_6_is_a_reverse-direction_motor_protein_that_moves_towards_the_minus-end_of_actin_filaments._Has_slow_rate_of_actin-activated_ADP_release_due_to_weak_ATP_binding._Functions_in_a_variety_of_intracellular_processes_such_as_vesicular_membrane_trafficking_and_cell_migration._Required_for_the_structural_integrity_of_the_Golgi_apparatus_via_the_p53-dependent_pro-survival_pathway._Appears_to_be_involved_in_a_very_early_step_of_clathrin-mediated_endocytosis_in_polarized_epithelial_cells._May_act_as_a_regulator_of_F-actin_dynamics._May_play_a_role_in_transporting_DAB2_from_the_plasma_membrane_to_specific_cellular_targets._Required_for_structural_integrity_of_inner_ear_hair_cells_(By_similarity)._{ECO:0000250,_ECO:0000269|PubMed:10519557,_ECO:0000269|PubMed:11447109,_ECO:0000269|PubMed:16507995,_ECO:0000269|PubMed:16949370}.\x3b_	DISEASE:_Deafness,_autosomal_dominant,_22_(DFNA22)_[MIM:606346]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._DFNA22_is_progressive_and_postlingual,_with_onset_during_childhood._By_the_age_of_approximately_50_years,_affected_individuals_invariably_have_profound_sensorineural_deafness._{ECO:0000269|PubMed:11468689}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_recessive,_37_(DFNB37)_[MIM:607821]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:12687499}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_sensorineural,_with_hypertrophic_cardiomyopathy_(DFNHCM)_[MIM:606346]:_An_autosomal_dominant_sensorineural_deafness_associated_with_hypertrophic_cardiomyopathy._{ECO:0000269|PubMed:15060111}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_most_tissues_examined_including_heart,_brain,_placenta,_pancreas,_spleen,_thymus,_prostate,_testis,_ovary,_small_intestine_and_colon._Highest_levels_in_brain,_pancreas,_testis_and_small_intestine._Also_expressed_in_fetal_brain_and_cochlea._Isoform_1_and_isoform_2,_containing_the_small_insert,_and_isoform_4,_containing_neither_insert,_are_expressed_in_unpolarized_epithelial_cells._{ECO:0000269|PubMed:9259267}.\x3b_	.	.	0.26137	0.31948	-0.369255208	28.25548478	419.15519	4.27823	rs201507590	54330	not_specified|Nonsyndromic_Hearing_Loss,_Dominant|Nonsyndromic_Hearing_Loss,_Recessive	MedGen:CN169374|MedGen:CN239435|MedGen:CN239439	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	0.0	0.912	D	0.000	0.843	D	1	0.810	D	4.22	0.980	H	-2.47	0.890	D	-3.87	0.726	D	1.028	0.977	D	0.899	0.967	D	0.292	0.906	D	.	.	0.998	0.994	D	c	1.113	1.021	1.000	0.747	0.706	0.609	0	5.45	0.796	9.602	0.976	1.048	0.713	1.000	0.715	1.000	0.888	19.655	0.958	Myosin_head,_motor_domain|P-loop_containing_nucleoside_triphosphate_hydrolase	.	.	.	.	9.687e-05	0	0	0.0066	0	0	6.663e-05	0	0.0005	0	2.98e-05	0.0090	0	0	0.0001	0.0005	0.0002	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,486	0	0	0	0	0	1	1	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0.1877	VUS
16	68856080	68856080	C	G	exonic	CDH1	.	nonsynonymous_SNV	CDH1:NM_001317184:exon11:c.C1705G:p.L569V,CDH1:NM_001317185:exon12:c.C340G:p.L114V,CDH1:NM_004360:exon12:c.C1888G:p.L630V	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	rs2276331	137585	Hereditary_cancer-predisposing_syndrome|Hereditary_diffuse_gastric_cancer|not_specified	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708349,OMIM:137215,Orphanet:ORPHA26106|MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Benign/Likely_benign	0.002	0.784	D	0.001	0.392	N	1.000	0.530	D	3.61	0.940	H	-0.11	0.645	T	-2.73	0.580	D	0.065	0.835	D	0.408	0.757	T	0.186	0.859	D	.	.	0.967	0.704	D	c	0.606	0.500	1.000	0.747	0.707	0.730	0	3.39	0.378	1.203	0.317	0.927	0.437	0.332	0.254	0.971	0.463	13.283	0.595	Cadherin|Cadherin-like	.	.	.	.	0.0002	0	0	0	0.0043	0	0	0	0.0004	0	0	0	0.0053	0	0	0.0005	3.249e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,915	0	0	0	0	0	1	1	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0.1877	VUS
10	89624244	89624244	A	G	exonic	PTEN	.	synonymous_SNV	PTEN:NM_000314:exon1:c.A18G:p.K6K,PTEN:NM_001304717:exon2:c.A537G:p.K179K	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs876660391	233839	Hereditary_cancer-predisposing_syndrome	MedGen:C0027672,SNOMED_CT:699346009	criteria_provided,_single_submitter	Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,512	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.1877	VUS
10	89624301	89624301	G	A	exonic	PTEN	.	synonymous_SNV	PTEN:NM_000314:exon1:c.G75A:p.L25L,PTEN:NM_001304717:exon2:c.G594A:p.L198L	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs786201506	183008	Hereditary_cancer-predisposing_syndrome|PTEN_hamartoma_tumor_syndrome	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498	criteria_provided,_multiple_submitters,_no_conflicts	Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,516	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.1877	VUS
14	31354707	31354707	G	A	exonic	COCH	.	nonsynonymous_SNV	COCH:NM_001135058:exon9:c.G841A:p.D281N,COCH:NM_001347720:exon9:c.G1036A:p.D346N,COCH:NM_004086:exon10:c.G841A:p.D281N	0.000262849456488043	0.983542807336405	0.0161943432071074	cochlin	FUNCTION:_Plays_a_role_in_the_control_of_cell_shape_and_motility_in_the_trabecular_meshwork._{ECO:0000269|PubMed:21886777}.\x3b_	DISEASE:_Deafness,_autosomal_dominant,_9_(DFNA9)_[MIM:601369]:_A_form_of_non-syndromic_hearing_loss_characterized_by_onset_in_the_fourth_or_fifth_decade_of_life_and_initially_involves_the_high_frequencies._Hearing_loss_is_progressive_and_usually_complete_by_the_sixth_decade._In_addition_to_cochlear_involvement,_DFNA9_patients_also_exhibit_a_spectrum_of_vestibular_dysfunctions._Penetrance_of_the_vestibular_symptoms_is_often_incomplete,_and_some_patients_are_minimally_affected,_whereas_others_suffer_from_severe_balance_disturbances_and_episodes_of_vertigo._Affected_individuals_have_mucopolysaccharide_depositions_in_the_channels_of_the_cochlear_and_vestibular_nerves._These_depositions_apparently_cause_strangulation_and_degeneration_of_dendritic_fibers._{ECO:0000269|PubMed:10400989,_ECO:0000269|PubMed:11295836,_ECO:0000269|PubMed:14512963,_ECO:0000269|PubMed:16835921,_ECO:0000269|PubMed:17561763,_ECO:0000269|PubMed:18312449,_ECO:0000269|PubMed:22610276,_ECO:0000269|PubMed:22931125,_ECO:0000269|PubMed:23993205,_ECO:0000269|PubMed:9806553,_ECO:0000269|PubMed:9931344}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_inner_ear_structures\x3b_the_cochlea_and_the_vestibule.\x3b_	unclassifiable_(Anatomical_System)\x3bcartilage\x3bovary\x3bhypothalamus\x3bcolon\x3bparathyroid\x3bretina\x3bprostate\x3blung\x3bcochlea\x3badrenal_gland\x3blarynx\x3btrabecular_meshwork\x3bplacenta\x3bvisual_apparatus\x3bliver\x3btestis\x3bhead_and_neck\x3bspleen\x3bkidney\x3bbrain\x3bstomach\x3b	pons\x3bcaudate_nucleus\x3b	0.53303	0.13199	0.286674996	71.49681529	2772.50763	9.93783	rs28362775	230519	not_specified|Nonsyndromic_Hearing_Loss,_Dominant	MedGen:CN169374|MedGen:CN239435	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.218	0.272	T	0.000	0.523	D	0.993	0.417	D	1.025	0.256	L	-1.8	0.839	D	0.5	0.293	N	-1.055	0.131	T	0.070	0.285	T	0.015	0.356	T	.	.	0.811	0.403	D	c	0.082	0.198	1.000	0.747	0.706	0.609	0	4.62	0.568	3.093	0.497	1.048	0.713	1.000	0.715	1.000	0.888	8.942	0.347	von_Willebrand_factor,_type_A	.	.	.	.	0.0016	0.0055	0	0	0	0	6.666e-05	0	0.0004	0.0063	0.0003	0	0	0	8.952e-06	0.0002	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,883	0	0	0	0	0	1	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0.1877	VUS
10	89624312	89624312	A	G	intronic	PTEN	.	.	.	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs374331677	133149	Hereditary_cancer-predisposing_syndrome|PTEN_hamartoma_tumor_syndrome|Cowden_syndrome_1|not_specified	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498|MedGen:CN072330,OMIM:158350|MedGen:CN169374	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0522	0	.	.	.	.	.	.	.	.	1.218e-05	0	2.978e-05	0	0	0	1.79e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,517	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.1877	VUS
10	89624325	89624325	C	G	intronic	PTEN	.	.	.	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs587781291	150521	Hereditary_cancer-predisposing_syndrome	MedGen:C0027672,SNOMED_CT:699346009	criteria_provided,_single_submitter	Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,518	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.1877	VUS
11	533799	533799	T	G	exonic	HRAS	.	nonsynonymous_SNV	HRAS:NM_001130442:exon3:c.A257C:p.N86T,HRAS:NM_005343:exon3:c.A257C:p.N86T,HRAS:NM_176795:exon3:c.A257C:p.N86T	0.00794104930284198	0.785285637637198	0.20677331305996	Harvey_rat_sarcoma_viral_oncogene_homolog	FUNCTION:_Ras_proteins_bind_GDP/GTP_and_possess_intrinsic_GTPase_activity._{ECO:0000269|PubMed:12740440,_ECO:0000269|PubMed:14500341,_ECO:0000269|PubMed:9020151}.\x3b_	DISEASE:_Costello_syndrome_(CSTLO)_[MIM:218040]:_A_rare_condition_characterized_by_prenatally_increased_growth,_postnatal_growth_deficiency,_mental_retardation,_distinctive_facial_appearance,_cardiovascular_abnormalities_(typically_pulmonic_stenosis,_hypertrophic_cardiomyopathy_and/or_atrial_tachycardia),_tumor_predisposition,_skin_and_musculoskeletal_abnormalities._{ECO:0000269|PubMed:16170316,_ECO:0000269|PubMed:16329078,_ECO:0000269|PubMed:16443854,_ECO:0000269|PubMed:17054105,_ECO:0000269|PubMed:18039947,_ECO:0000269|PubMed:18247425,_ECO:0000269|PubMed:19995790}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Congenital_myopathy_with_excess_of_muscle_spindles_(CMEMS)_[MIM:218040]:_Variant_of_Costello_syndrome._{ECO:0000269|PubMed:17412879}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hurthle_cell_thyroid_carcinoma_(HCTC)_[MIM:607464]:_A_rare_type_of_thyroid_cancer_accounting_for_only_about_3-10%_of_all_differentiated_thyroid_cancers._These_neoplasms_are_considered_a_variant_of_follicular_carcinoma_of_the_thyroid_and_are_referred_to_as_follicular_carcinoma,_oxyphilic_type._{ECO:0000269|PubMed:12727991}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dMutations_which_change_positions_12,_13_or_61_activate_the_potential_of_HRAS_to_transform_cultured_cells_and_are_implicated_in_a_variety_of_human_tumors._{ECO:0000269|PubMed:3670300}.\x3b_DISEASE:_Bladder_cancer_(BLC)_[MIM:109800]:_A_malignancy_originating_in_tissues_of_the_urinary_bladder._It_often_presents_with_multiple_tumors_appearing_at_different_times_and_at_different_sites_in_the_bladder._Most_bladder_cancers_are_transitional_cell_carcinomas_that_begin_in_cells_that_normally_make_up_the_inner_lining_of_the_bladder._Other_types_of_bladder_cancer_include_squamous_cell_carcinoma_(cancer_that_begins_in_thin,_flat_cells)_and_adenocarcinoma_(cancer_that_begins_in_cells_that_make_and_release_mucus_and_other_fluids)._Bladder_cancer_is_a_complex_disorder_with_both_genetic_and_environmental_influences._{ECO:0000269|PubMed:6298635,_ECO:0000269|PubMed:6844927}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Schimmelpenning-Feuerstein-Mims_syndrome_(SFM)_[MIM:163200]:_A_disease_characterized_by_sebaceous_nevi,_often_on_the_face,_associated_with_variable_ipsilateral_abnormalities_of_the_central_nervous_system,_ocular_anomalies,_and_skeletal_defects._Many_oral_manifestations_have_been_reported,_not_only_including_hypoplastic_and_malformed_teeth,_and_mucosal_papillomatosis,_but_also_ankyloglossia,_hemihyperplastic_tongue,_intraoral_nevus,_giant_cell_granuloma,_ameloblastoma,_bone_cysts,_follicular_cysts,_oligodontia,_and_odontodysplasia._Sebaceous_nevi_follow_the_lines_of_Blaschko_and_these_can_continue_as_linear_intraoral_lesions,_as_in_mucosal_papillomatosis._{ECO:0000269|PubMed:22683711}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Widely_expressed._{ECO:0000269|PubMed:14500341}.\x3b_	ovary\x3bdevelopmental\x3bcolon\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3boptic_nerve\x3bwhole_body\x3boesophagus\x3bendometrium\x3bthyroid\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bhypothalamus\x3bblood\x3blens\x3bskeletal_muscle\x3blung\x3bplacenta\x3bvisual_apparatus\x3bhypopharynx\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bcerebellum\x3b	whole_brain\x3bmedulla_oblongata\x3btrigeminal_ganglion\x3b	0.99944	0.99980	-0.339715008	30.06605331	4.91473	0.18207	rs138272051	48907	Costello_syndrome|Rasopathy|not_specified	MedGen:C0587248,OMIM:218040,Orphanet:ORPHA3071,SNOMED_CT:309776008|MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374	reviewed_by_expert_panel	Benign	0.007	0.599	D	0.000	0.843	D	1	0.810	D	2.04	0.558	M	-0.59	0.716	T	-3.14	0.640	D	-0.340	0.739	T	0.341	0.707	T	0.079	0.732	D	.	.	0.969	0.712	D	c	0.076	0.094	1.000	0.747	0.722	0.854	0	3.64	0.407	4.096	0.572	0.964	0.580	1.000	0.715	1.000	0.888	11.887	0.517	P-loop_containing_nucleoside_triphosphate_hydrolase|Small_GTP-binding_protein_domain	.	.	.	.	0.0002	0.0006	0	0	0	0	6.687e-05	0	0.0002	0.0009	5.956e-05	0	5.798e-05	0	0.0002	0	0.0001	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,620	0	0	0	0	0	1	1	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0.1877	VUS
21	36259232	36259232	C	A	exonic	RUNX1	.	nonsynonymous_SNV	RUNX1:NM_001001890:exon1:c.G178T:p.G60C,RUNX1:NM_001122607:exon1:c.G178T:p.G60C,RUNX1:NM_001754:exon4:c.G259T:p.G87C	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	rs561166961	430423	Familial_platelet_disorder_with_associated_myeloid_malignancy|not_specified	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290|MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	0.0	0.912	D	0.000	0.629	D	1	0.810	D	2.54	0.743	M	-6.21	0.996	D	-4.42	0.898	D	1.016	0.975	D	0.987	0.996	D	0.920	0.994	D	0.774	0.900	0.962	0.677	D	c	0.846	0.774	1.0	0.983	0.405	0.054	1	4.72	0.591	7.376	0.788	0.852	0.362	1.000	0.715	0.998	0.697	17.867	0.887	Runt_domain|p53-like_transcription_factor,_DNA-binding|p53/RUNT-type_transcription_factor,_DNA-binding_domain	.	.	.	.	.	.	.	.	.	.	.	.	4.107e-06	0	2.983e-05	0	0	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,982	0	0	0	0	0	1	1	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0.1877	VUS
10	89690790	89690795	ACTTTT	A	intronic	PTEN	.	.	.	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs587780544	152111	Hereditary_cancer-predisposing_syndrome|PTEN_hamartoma_tumor_syndrome|Cowden_syndrome_1|not_specified|not_provided	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498|MedGen:CN072330,OMIM:158350|MedGen:CN169374|MedGen:CN517202	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0002	0.0002	0	0	0	0	0.0003	0	0.0003	0.0003	0.0003	0.0016	0.0002	0	0.0003	0.0007	3.262e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,532	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.1877	VUS
1	41285030	41285030	C	G	exonic	KCNQ4	.	synonymous_SNV	KCNQ4:NM_004700:exon5:c.C720G:p.T240T,KCNQ4:NM_172163:exon5:c.C720G:p.T240T	0.985178281898531	0.0148214036876789	3.14413790434247e-07	potassium_voltage-gated_channel_subfamily_Q_member_4	FUNCTION:_Probably_important_in_the_regulation_of_neuronal_excitability._May_underlie_a_potassium_current_involved_in_regulating_the_excitability_of_sensory_cells_of_the_cochlea._KCNQ4_channels_are_blocked_by_linopirdin,_XE991_and_bepridil,_whereas_clofilium_is_without_significant_effect._Muscarinic_agonist_oxotremorine-M_strongly_suppress_KCNQ4_current_in_CHO_cells_in_which_cloned_KCNQ4_channels_were_coexpressed_with_M1_muscarinic_receptors.\x3b_	DISEASE:_Deafness,_autosomal_dominant,_2A_(DFNA2A)_[MIM:600101]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10025409,_ECO:0000269|PubMed:10369879,_ECO:0000269|PubMed:10571947,_ECO:0000269|PubMed:10925378,_ECO:0000269|PubMed:21242547}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_the_outer,_but_not_the_inner,_sensory_hair_cells_of_the_cochlea._Slightly_expressed_in_heart,_brain_and_skeletal_muscle.\x3b_	lymphoreticular\x3bcartilage\x3bcolon\x3bfovea_centralis\x3bchoroid\x3blens\x3bretina\x3boptic_nerve\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3biris\x3bmammary_gland\x3bbrain\x3bstomach\x3b	superior_cervical_ganglion\x3bciliary_ganglion\x3batrioventricular_node\x3btrigeminal_ganglion\x3b	0.12943	0.14391	-0.66859065	15.76433121	646.02	5.10359	rs752131356	228470	not_specified	MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,440	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.1877	VUS
10	89725078	89725078	C	T	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon9:c.C1061T:p.P354L,PTEN:NM_001304718:exon9:c.C470T:p.P157L,PTEN:NM_001304717:exon10:c.C1580T:p.P527L	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs375709098	151926	Hereditary_cancer-predisposing_syndrome|PTEN_hamartoma_tumor_syndrome|not_specified	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498|MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	0.028	0.461	D	0.000	0.537	D	1	0.810	D	0.55	0.145	N	-3.4	0.943	D	-2.94	0.614	D	-0.036	0.815	T	0.551	0.836	D	0.151	0.833	D	.	.	0.975	0.752	D	c	0.021	0.228	1.000	0.747	0.732	0.924	0	5.35	0.762	5.590	0.670	0.807	0.329	1.000	0.715	1.000	0.888	19.431	0.947	.	.	.	.	.	.	.	.	.	.	.	.	.	8.338e-06	0	0	0	0	0	1.854e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,594	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.1877	VUS
10	89725230	89725231	AT	A	UTR3	PTEN	NM_001304718:c.*2delT\x3bNM_001304717:c.*2delT\x3bNM_000314:c.*2delT	.	.	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs786204876	187390	Hereditary_cancer-predisposing_syndrome|Cowden_syndrome_1	MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN072330,OMIM:158350	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2.133e-05	0	0	0	0	0	3.773e-05	0	3.452e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,598	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.1877	VUS
10	89725188	89725188	C	T	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon9:c.C1171T:p.P391S,PTEN:NM_001304718:exon9:c.C580T:p.P194S,PTEN:NM_001304717:exon10:c.C1690T:p.P564S	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs786203911	183064	Hereditary_cancer-predisposing_syndrome|PTEN_hamartoma_tumor_syndrome|not_specified|not_provided	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498|MedGen:CN169374|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	0.192	0.210	T	0.000	0.843	D	1.000	0.588	D	0	0.065	N	-3.44	0.944	D	-0.84	0.229	N	0.008	0.824	D	0.623	0.867	D	0.082	0.740	D	0.204	0.120	0.960	0.667	D	c	-0.059	0.168	1.000	0.747	0.732	0.924	0	5.26	0.734	5.709	0.678	0.807	0.329	1.000	0.715	1.000	0.888	19.215	0.937	.	.	.	.	.	.	.	.	.	.	.	.	.	8.335e-06	0	0	0	0	0	9.239e-06	0.0002	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,597	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.1877	VUS
21	36265254	36265254	A	T	exonic	RUNX1	.	nonsynonymous_SNV	RUNX1:NM_001754:exon3:c.T65A:p.I22K	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	rs749430925	469605	Familial_platelet_disorder_with_associated_myeloid_malignancy	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290	criteria_provided,_single_submitter	Likely_benign	0.027	0.465	D	0.479	0.050	N	1.000	0.230	N	.	.	.	-4.17	0.969	D	-0.11	0.491	N	-0.028	0.817	T	0.701	0.897	D	0.132	0.815	D	0.4	0.430	0.539	0.292	D	c	-0.600	-0.485	1.000	0.448	0.624	0.395	0	2.95	0.331	1.480	0.348	1.199	0.960	0.777	0.292	0.985	0.512	7.136	0.246	.	.	.	.	.	3.232e-05	0	0.0012	0	0	0	0	0	0.0002	0	0.0015	0	0	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,988	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.1877	VUS
10	89725110	89725110	G	A	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_000314:exon9:c.G1093A:p.V365I,PTEN:NM_001304718:exon9:c.G502A:p.V168I,PTEN:NM_001304717:exon10:c.G1612A:p.V538I	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs758542021	240889	Hereditary_cancer-predisposing_syndrome|PTEN_hamartoma_tumor_syndrome|not_specified	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498|MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	0.378	0.112	T	0.000	0.843	D	1.000	0.588	D	0.695	0.181	N	-3.45	0.945	D	-0.37	0.132	N	0.044	0.831	D	0.619	0.866	D	0.084	0.744	D	0.119	0.027	0.986	0.843	D	c	0.086	0.307	1.000	0.747	0.732	0.924	0	5.26	0.734	9.556	0.972	0.902	0.416	1.000	0.715	0.999	0.750	19.215	0.937	.	.	.	.	.	.	.	.	.	.	.	.	.	8.528e-06	0	0	0	0	0	1.917e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,595	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.1877	VUS
10	89623462	89623462	G	A	UTR5	PTEN	NM_001304718:c.-88512G>A\x3bNM_001304717:c.-245G>A\x3bNM_000314:c.-765G>A	.	.	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs587776674	22883	PTEN_hamartoma_tumor_syndrome|Cowden_syndrome_1|not_specified	MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498|MedGen:CN072330,OMIM:158350|MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3.248e-05	0.0001	0	0	0	0	0	0	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,509	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	VUS
12	103260383	103260383	T	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon5:c.A500G:p.N167S	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs77554925	108439	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_single_submitter	Uncertain_significance	0.171	0.235	T	0.000	0.513	N	1.000	0.588	D	1.985	0.540	M	-6.13	0.995	D	-2.94	0.614	D	0.317	0.878	D	0.884	0.962	D	.	.	.	.	.	0.737	0.358	D	c	-0.825	-0.835	0.001	0.075	0.554	0.246	0	-4.01	0.038	0.267	0.182	-0.221	0.097	0.999	0.424	0.990	0.544	7.660	0.274	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	0.0041	0.0143	0.0012	0	0	0	0	0	0.0010	0.0148	0.0005	0	0	0	1.792e-05	0.0004	3.249e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,784	0	0	0	0	0	1	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.1	VUS
3	12660127	12660127	T	C	exonic	RAF1	.	nonsynonymous_SNV	RAF1:NM_002880:exon2:c.A94G:p.I32V	0.999776866110749	0.000223133833869176	5.53819998824154e-11	Raf-1_proto-oncogene,_serine/threonine_kinase	FUNCTION:_Serine/threonine-protein_kinase_that_acts_as_a_regulatory_link_between_the_membrane-associated_Ras_GTPases_and_the_MAPK/ERK_cascade,_and_this_critical_regulatory_link_functions_as_a_switch_determining_cell_fate_decisions_including_proliferation,_differentiation,_apoptosis,_survival_and_oncogenic_transformation._RAF1_activation_initiates_a_mitogen-activated_protein_kinase_(MAPK)_cascade_that_comprises_a_sequential_phosphorylation_of_the_dual-specific_MAPK_kinases_(MAP2K1/MEK1_and_MAP2K2/MEK2)_and_the_extracellular_signal-regulated_kinases_(MAPK3/ERK1_and_MAPK1/ERK2)._The_phosphorylated_form_of_RAF1_(on_residues_Ser-338_and_Ser-339,_by_PAK1)_phosphorylates_BAD/Bcl2-_antagonist_of_cell_death_at_'Ser-75'._Phosphorylates_adenylyl_cyclases:_ADCY2,_ADCY5_and_ADCY6,_resulting_in_their_activation._Phosphorylates_PPP1R12A_resulting_in_inhibition_of_the_phosphatase_activity._Phosphorylates_TNNT2/cardiac_muscle_troponin_T._Can_promote_NF-kB_activation_and_inhibit_signal_transducers_involved_in_motility_(ROCK2),_apoptosis_(MAP3K5/ASK1_and_STK3/MST2),_proliferation_and_angiogenesis_(RB1)._Can_protect_cells_from_apoptosis_also_by_translocating_to_the_mitochondria_where_it_binds_BCL2_and_displaces_BAD/Bcl2-antagonist_of_cell_death._Regulates_Rho_signaling_and_migration,_and_is_required_for_normal_wound_healing._Plays_a_role_in_the_oncogenic_transformation_of_epithelial_cells_via_repression_of_the_TJ_protein,_occludin_(OCLN)_by_inducing_the_up-regulation_of_a_transcriptional_repressor_SNAI2/SLUG,_which_induces_down-regulation_of_OCLN._Restricts_caspase_activation_in_response_to_selected_stimuli,_notably_Fas_stimulation,_pathogen-mediated_macrophage_apoptosis,_and_erythroid_differentiation._{ECO:0000269|PubMed:11427728,_ECO:0000269|PubMed:11719507,_ECO:0000269|PubMed:15385642,_ECO:0000269|PubMed:15618521,_ECO:0000269|PubMed:15849194,_ECO:0000269|PubMed:16892053,_ECO:0000269|PubMed:16924233,_ECO:0000269|PubMed:9360956}.\x3b_	DISEASE:_Noonan_syndrome_5_(NS5)_[MIM:611553]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._{ECO:0000269|PubMed:17603482,_ECO:0000269|PubMed:17603483,_ECO:0000269|PubMed:20683980}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_LEOPARD_syndrome_2_(LPRD2)_[MIM:611554]:_A_disorder_characterized_by_lentigines,_electrocardiographic_conduction_abnormalities,_ocular_hypertelorism,_pulmonic_stenosis,_abnormalities_of_genitalia,_retardation_of_growth,_and_sensorineural_deafness._{ECO:0000269|PubMed:17603483}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Cardiomyopathy,_dilated_1NN_(CMD1NN)_[MIM:615916]:_A_disorder_characterized_by_ventricular_dilation_and_impaired_systolic_function,_resulting_in_congestive_heart_failure_and_arrhythmia._Patients_are_at_risk_of_premature_death._{ECO:0000269|PubMed:24777450}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_In_skeletal_muscle,_isoform_1_is_more_abundant_than_isoform_2._{ECO:0000269|PubMed:1886707}.\x3b_	ovary\x3bumbilical_cord\x3bsympathetic_chain\x3bskin\x3bretina\x3bbone_marrow\x3bprostate\x3boptic_nerve\x3bfrontal_lobe\x3bcochlea\x3bendometrium\x3bgerminal_center\x3bbladder\x3bbrain\x3bheart\x3bcartilage\x3bspinal_cord\x3badrenal_cortex\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bmacula_lutea\x3bvisual_apparatus\x3bliver\x3balveolus\x3bspleen\x3bcervix\x3bmammary_gland\x3bperipheral_nerve\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3buterus\x3bwhole_body\x3boesophagus\x3bbone\x3btestis\x3bspinal_ganglion\x3bpineal_gland\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bislets_of_Langerhans\x3bhypothalamus\x3bmuscle\x3bpancreas\x3blung\x3btrachea\x3bplacenta\x3bamnion\x3bkidney\x3bstomach\x3baorta\x3bthymus\x3b	superior_cervical_ganglion\x3bciliary_ganglion\x3bwhole_blood\x3bskeletal_muscle\x3b	0.99869	0.93060	-0.646543901	16.44255721	87.82499	2.00185	rs372738063	49054	Rasopathy|not_specified	MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.198	0.236	T	0.000	0.523	D	0.999	0.810	D	1.525	0.387	L	-0.84	0.744	T	0.09	0.066	N	-0.903	0.477	T	0.210	0.570	T	0.020	0.422	T	.	.	0.914	0.531	D	c	-0.357	-0.196	1.000	0.480	0.707	0.730	0	2.05	0.257	1.544	0.355	-0.216	0.099	0.998	0.411	0.995	0.604	9.701	0.392	.	.	.	.	.	0.0003	0.0002	0	0	0	0	0.0004	0	8.527e-05	0.0003	2.978e-05	0	0	0	0.0001	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,484	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0.1	VUS
10	89692876	89692876	A	C	exonic	PTEN	.	synonymous_SNV	PTEN:NM_000314:exon5:c.A360C:p.A120A,PTEN:NM_001304717:exon6:c.A879C:p.A293A	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs759485888	187351	Hereditary_cancer-predisposing_syndrome|PTEN_hamartoma_tumor_syndrome|not_specified	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498|MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Benign/Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	4.065e-06	0	0	0	0	0	8.971e-06	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,543	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	VUS
13	20763620	20763620	A	G	exonic	GJB2	.	nonsynonymous_SNV	GJB2:NM_004004:exon2:c.T101C:p.M34T	1.02863295453376e-11	0.00164377442881105	0.998356225560903	gap_junction_protein_beta_2	FUNCTION:_One_gap_junction_consists_of_a_cluster_of_closely_packed_pairs_of_transmembrane_channels,_the_connexons,_through_which_materials_of_low_MW_diffuse_from_one_cell_to_a_neighboring_cell.\x3b_	DISEASE:_Deafness,_autosomal_recessive,_1A_(DFNB1A)_[MIM:220290]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10830906,_ECO:0000269|PubMed:11313763,_ECO:0000269|PubMed:11439000,_ECO:0000269|PubMed:12121355,_ECO:0000269|PubMed:12239718,_ECO:0000269|PubMed:12786758,_ECO:0000269|PubMed:14722929,_ECO:0000269|PubMed:15666300,_ECO:0000269|PubMed:15994881,_ECO:0000269|PubMed:17660464,_ECO:0000269|PubMed:17666888,_ECO:0000269|PubMed:19384972,_ECO:0000269|PubMed:23680645,_ECO:0000269|PubMed:9328482,_ECO:0000269|PubMed:9336442,_ECO:0000269|PubMed:9471561,_ECO:0000269|PubMed:9529365}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_dominant,_3A_(DFNA3A)_[MIM:601544]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10807696,_ECO:0000269|PubMed:11313763,_ECO:0000269|PubMed:11439000,_ECO:0000269|PubMed:12786758,_ECO:0000269|PubMed:19384972,_ECO:0000269|PubMed:9620796}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Vohwinkel_syndrome_(VS)_[MIM:124500]:_VS_is_an_autosomal_dominant_disease_characterized_by_hyperkeratosis,_constriction_on_fingers_and_toes_and_congenital_deafness._{ECO:0000269|PubMed:10369869,_ECO:0000269|PubMed:15954104,_ECO:0000269|PubMed:18688874}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Keratoderma,_palmoplantar,_with_deafness_(PPKDFN)_[MIM:148350]:_An_autosomal_dominant_disorder_characterized_by_the_association_of_palmoplantar_hyperkeratosis_with_progressive,_bilateral,_high-frequency,_sensorineural_deafness._{ECO:0000269|PubMed:10633135,_ECO:0000269|PubMed:10757647,_ECO:0000269|PubMed:12372058,_ECO:0000269|PubMed:15996214,_ECO:0000269|PubMed:17993581,_ECO:0000269|PubMed:9856479}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Keratitis-ichthyosis-deafness_syndrome_(KID_syndrome)_[MIM:148210]:_An_autosomal_dominant_form_of_ectodermal_dysplasia._Ectodermal_dysplasia_defines_a_heterogeneous_group_of_disorders_due_to_abnormal_development_of_two_or_more_ectodermal_structures._Keratitis-ichthyosis-deafness_syndrome_is_characterized_by_the_association_of_hyperkeratotic_skin_lesions_with_vascularizing_keratitis_and_profound_sensorineural_hearing_loss._Clinical_features_include_deafness,_ichthyosis,_photophobia,_absent_or_decreased_eyebrows,_sparse_or_absent_scalp_hair,_decreased_sweating_and_dysplastic_finger_and_toenails._{ECO:0000269|PubMed:11912510,_ECO:0000269|PubMed:12548749,_ECO:0000269|PubMed:12752120}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bart-Pumphrey_syndrome_(BPS)_[MIM:149200]:_An_autosomal_dominant_disorder_characterized_by_sensorineural_hearing_loss,_palmoplantar_keratoderma,_knuckle_pads,_and_leukonychia,_It_shows_considerable_phenotypic_variability._{ECO:0000269|PubMed:15482471,_ECO:0000269|PubMed:15952212}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ichthyosis_hystrix-like_with_deafness_syndrome_(HID_syndrome)_[MIM:602540]:_An_autosomal_dominant_keratinizing_disorder_characterized_by_sensorineural_deafness_and_spiky_hyperkeratosis_affecting_the_entire_skin._HID_syndrome_is_considered_to_differ_from_the_similar_KID_syndrome_in_the_extent_and_time_of_occurrence_of_skin_symptoms_and_the_severity_of_the_associated_keratitis._{ECO:0000269|PubMed:12072059}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	.	.	0.42941	0.50569	0.663285274	84.55414013	794.09383	5.55726	rs35887622	32039	Keratitis-Ichthyosis-Deafness_Syndrome|Mutilating_keratoderma|Hystrix-like_ichthyosis_with_deafness|Deafness,_autosomal_recessive_1A|Deafness,_autosomal_dominant_3a|Nonsyndromic_hearing_loss_and_deafness|not_specified|Nonsyndromic_Hearing_Loss,_Dominant|Nonsyndromic_Hearing_Loss,_Recessive|not_provided	MedGen:C0265336|MedGen:C0265964,OMIM:124500,Orphanet:ORPHA494,SNOMED_CT:24559001|MedGen:C1865234,OMIM:602540|MedGen:C2673759,OMIM:220290|MedGen:C2675750,OMIM:601544|MedGen:CN043648,Orphanet:ORPHA87884|MedGen:CN169374|MedGen:CN239435|MedGen:CN239439|MedGen:CN517202	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.027	0.465	D	0.000	0.629	D	1.000	0.548	D	2.315	0.665	M	-5.41	0.991	D	-3.8	0.717	D	0.765	0.940	D	0.843	0.948	D	.	.	.	.	.	0.923	0.550	D	c	-0.071	0.060	1.000	0.747	0.534	0.214	0	5.21	0.719	5.061	0.639	1.088	0.866	1.000	0.715	0.960	0.441	15.379	0.742	Connexin,_N-terminal	.	.	.	.	0.0114	0.0026	0.0119	0.0066	0	0.0186	0.0161	0.0112	0.0087	0.0022	0.0043	0.0078	0	0.0203	0.0124	0.0095	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,870	0	0	0	0	0	1	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0.1	VUS
2	39213367	39213367	G	C	exonic	SOS1	.	nonsynonymous_SNV	SOS1:NM_005633:exon23:c.C3600G:p.D1200E	0.99999989519361	1.04806389809942e-07	1.77231495230296e-20	SOS_Ras/Rac_guanine_nucleotide_exchange_factor_1	FUNCTION:_Promotes_the_exchange_of_Ras-bound_GDP_by_GTP._Catalytic_component_of_a_trimeric_complex_that_participates_in_transduction_of_signals_from_Ras_to_Rac_by_promoting_the_Rac-specific_guanine_nucleotide_exchange_factor_(GEF)_activity_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Noonan_syndrome_4_(NS4)_[MIM:610733]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._Some_patients_with_NS4_have_polyarticular_villonodular_synovitis._{ECO:0000269|PubMed:17143282,_ECO:0000269|PubMed:17143285,_ECO:0000269|PubMed:19020799,_ECO:0000269|PubMed:19438935,_ECO:0000269|PubMed:19953625,_ECO:0000269|PubMed:20673819,_ECO:0000269|PubMed:20683980,_ECO:0000269|PubMed:21387466}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_gingival_tissues._{ECO:0000269|PubMed:11868160}.\x3b_	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3blarynx\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bbile_duct\x3blung\x3bplacenta\x3bmacula_lutea\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3btestis\x3bciliary_ganglion\x3bpons\x3batrioventricular_node\x3bskeletal_muscle\x3b	0.72054	0.38414	-0.995664936	8.539749941	106.78667	2.24216	rs141594736	49203	Rasopathy|not_specified	MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.212	0.195	T	0.034	0.248	N	0.853	0.352	D	0	0.065	N	-0.9	0.758	T	-0.68	0.195	N	-0.971	0.370	T	0.086	0.333	T	0.006	0.152	T	.	.	0.475	0.277	N	c	-1.027	-0.867	0.076	0.157	0.707	0.730	0	-0.526	0.113	-0.043	0.119	0.154	0.240	0.837	0.300	0.999	0.750	0.610	0.007	.	.	.	.	.	0.0001	0	0	0	0	0	0.0003	0	0.0002	0	0	0	0	0	0.0003	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,460	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0.1	VUS
12	25362762	25362765	TTTC	T	exonic	KRAS	.	nonframeshift_deletion	KRAS:NM_004985:exon5:c.531_533del:p.177_178del	0.00106119304255182	0.603148256118395	0.395790550839053	Kirsten_rat_sarcoma_viral_oncogene_homolog	FUNCTION:_Ras_proteins_bind_GDP/GTP_and_possess_intrinsic_GTPase_activity._Plays_an_important_role_in_the_regulation_of_cell_proliferation_(PubMed:23698361,_PubMed:22711838)._{ECO:0000269|PubMed:22711838,_ECO:0000269|PubMed:23698361,_ECO:0000305}.\x3b_	DISEASE:_Leukemia,_acute_myelogenous_(AML)_[MIM:601626]:_A_subtype_of_acute_leukemia,_a_cancer_of_the_white_blood_cells._AML_is_a_malignant_disease_of_bone_marrow_characterized_by_maturational_arrest_of_hematopoietic_precursors_at_an_early_stage_of_development._Clonal_expansion_of_myeloid_blasts_occurs_in_bone_marrow,_blood,_and_other_tissue._Myelogenous_leukemias_develop_from_changes_in_cells_that_normally_produce_neutrophils,_basophils,_eosinophils_and_monocytes._{ECO:0000269|PubMed:8955068}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Leukemia,_juvenile_myelomonocytic_(JMML)_[MIM:607785]:_An_aggressive_pediatric_myelodysplastic_syndrome/myeloproliferative_disorder_characterized_by_malignant_transformation_in_the_hematopoietic_stem_cell_compartment_with_proliferation_of_differentiated_progeny._Patients_have_splenomegaly,_enlarged_lymph_nodes,_rashes,_and_hemorrhages._{ECO:0000269|PubMed:17332249}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Noonan_syndrome_3_(NS3)_[MIM:609942]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._{ECO:0000269|PubMed:16474405,_ECO:0000269|PubMed:16773572,_ECO:0000269|PubMed:17056636,_ECO:0000269|PubMed:17468812,_ECO:0000269|PubMed:19396835}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Gastric_cancer_(GASC)_[MIM:613659]:_A_malignant_disease_which_starts_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._The_term_gastric_cancer_or_gastric_carcinoma_refers_to_adenocarcinoma_of_the_stomach_that_accounts_for_most_of_all_gastric_malignant_tumors._Two_main_histologic_types_are_recognized,_diffuse_type_and_intestinal_type_carcinomas._Diffuse_tumors_are_poorly_differentiated_infiltrating_lesions,_resulting_in_thickening_of_the_stomach._In_contrast,_intestinal_tumors_are_usually_exophytic,_often_ulcerating,_and_associated_with_intestinal_metaplasia_of_the_stomach,_most_often_observed_in_sporadic_disease._{ECO:0000269|PubMed:14534542,_ECO:0000269|PubMed:3034404,_ECO:0000269|PubMed:7773929}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dDefects_in_KRAS_are_a_cause_of_pylocytic_astrocytoma_(PA)._Pylocytic_astrocytomas_are_neoplasms_of_the_brain_and_spinal_cord_derived_from_glial_cells_which_vary_from_histologically_benign_forms_to_highly_anaplastic_and_malignant_tumors._{ECO:0000269|PubMed:16247081}.\x3b_DISEASE:_Cardiofaciocutaneous_syndrome_2_(CFC2)_[MIM:615278]:_A_form_of_cardiofaciocutaneous_syndrome,_a_multiple_congenital_anomaly_disorder_characterized_by_a_distinctive_facial_appearance,_heart_defects_and_mental_retardation._Heart_defects_include_pulmonic_stenosis,_atrial_septal_defects_and_hypertrophic_cardiomyopathy._Some_affected_individuals_present_with_ectodermal_abnormalities_such_as_sparse,_friable_hair,_hyperkeratotic_skin_lesions_and_a_generalized_ichthyosis-like_condition._Typical_facial_features_are_similar_to_Noonan_syndrome._They_include_high_forehead_with_bitemporal_constriction,_hypoplastic_supraorbital_ridges,_downslanting_palpebral_fissures,_a_depressed_nasal_bridge,_and_posteriorly_angulated_ears_with_prominent_helices._CFC2_patients_often_do_not_have_the_skin_abnormalities,_such_as_ichthyosis,_hyperkeratosis,_and_hemangioma_observed_in_CFC1._{ECO:0000269|PubMed:16474404,_ECO:0000269|PubMed:16474405,_ECO:0000269|PubMed:17056636,_ECO:0000269|PubMed:21797849}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dKRAS_mutations_are_involved_in_cancer_development._{ECO:0000269|PubMed:14534542,_ECO:0000269|PubMed:1553789,_ECO:0000269|PubMed:16533793,_ECO:0000269|PubMed:3034404,_ECO:0000269|PubMed:3627975,_ECO:0000269|PubMed:6092920,_ECO:0000269|PubMed:6695174,_ECO:0000269|PubMed:7773929}.\x3b_	.	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bfrontal_lobe\x3bcochlea\x3bendometrium\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bspinal_ganglion\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bspinal_cord\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bbile_duct\x3bpancreas\x3blung\x3bcornea\x3bplacenta\x3bvisual_apparatus\x3bliver\x3bcervix\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bperipheral_nerve\x3b	dorsal_root_ganglion\x3bwhole_brain\x3bamygdala\x3boccipital_lobe\x3bsuperior_cervical_ganglion\x3batrioventricular_node\x3bpons\x3bsubthalamic_nucleus\x3bprefrontal_cortex\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3bcerebellum\x3b	0.99997	0.53296	-0.141298762	42.87567823	3.46519	0.12617	rs397517043	54296	Rasopathy|not_specified|not_provided	MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374|MedGen:CN517202	reviewed_by_expert_panel	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0007	0.0006	0	0	0.0006	0	0.0009	0.0020	0.0005	0.0005	0.0002	0	0.0002	8.998e-05	0.0010	0.0004	6.557e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,639	0	0	0	0	0	0	1	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0.1	VUS
19	4099195	4099195	G	A	intronic	MAP2K2	.	.	.	0.86326115931858	0.136320885012997	0.00041795566842237	mitogen-activated_protein_kinase_kinase_2	FUNCTION:_Catalyzes_the_concomitant_phosphorylation_of_a_threonine_and_a_tyrosine_residue_in_a_Thr-Glu-Tyr_sequence_located_in_MAP_kinases._Activates_the_ERK1_and_ERK2_MAP_kinases_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Cardiofaciocutaneous_syndrome_4_(CFC4)_[MIM:615280]:_A_form_of_cardiofaciocutaneous_syndrome,_a_multiple_congenital_anomaly_disorder_characterized_by_a_distinctive_facial_appearance,_heart_defects_and_mental_retardation._Heart_defects_include_pulmonic_stenosis,_atrial_septal_defects_and_hypertrophic_cardiomyopathy._Some_affected_individuals_present_with_ectodermal_abnormalities_such_as_sparse,_friable_hair,_hyperkeratotic_skin_lesions_and_a_generalized_ichthyosis-like_condition._Typical_facial_features_are_similar_to_Noonan_syndrome._They_include_high_forehead_with_bitemporal_constriction,_hypoplastic_supraorbital_ridges,_downslanting_palpebral_fissures,_a_depressed_nasal_bridge,_and_posteriorly_angulated_ears_with_prominent_helices._{ECO:0000269|PubMed:16439621,_ECO:0000269|PubMed:18042262,_ECO:0000269|PubMed:20358587}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	medulla_oblongata\x3bsmooth_muscle\x3bovary\x3bsalivary_gland\x3bsympathetic_chain\x3bcolon\x3bparathyroid\x3bskin\x3buterus\x3bprostate\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bmuscle\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbile_duct\x3bpancreas\x3blung\x3badrenal_gland\x3bplacenta\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	amygdala\x3bprefrontal_cortex\x3btestis\x3bpons\x3bcingulate_cortex\x3b	0.88489	0.51187	-0.800872469	12.33191791	40.94266	1.19949	rs763424788	49304	not_specified|not_provided	MedGen:CN169374|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0002	0.024	6.469e-05	0.0001	0	0	0	0	6.676e-05	0	4.216e-05	8.321e-05	0	0	0	0	7.398e-05	0	3.508e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,925	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.0507	VUS
7	107301201	107301201	T	C	ncRNA_intronic	SLC26A4-AS1	.	.	.	.	.	.	SLC26A4_antisense_RNA_1	.	.	.	.	.	.	.	.	.	.	.	rs60284988	19877	Enlarged_vestibular_aqueduct|Pendred's_syndrome|not_specified|SLC26A4-Related_Disorders|not_provided	Human_Phenotype_Ontology:HP:0011387,MedGen:C1863752,OMIM:600791|MedGen:C0271829,OMIM:274600,Orphanet:ORPHA705,SNOMED_CT:70348004|MedGen:CN169374|MedGen:CN239421|MedGen:CN517202	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0021	0.0003	0	0.0033	0	0.0011	0.0035	0.0051	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,489	0	0	0	0	0	0	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0.0507	VUS
12	112915779	112915779	G	A	exonic	PTPN11	.	nonsynonymous_SNV	PTPN11:NM_001330437:exon9:c.G1052A:p.R351Q,PTPN11:NM_002834:exon9:c.G1052A:p.R351Q,PTPN11:NM_080601:exon9:c.G1052A:p.R351Q	0.999877230878678	0.000122769057470549	6.38519788034449e-11	protein_tyrosine_phosphatase,_non-receptor_type_11	FUNCTION:_Acts_downstream_of_various_receptor_and_cytoplasmic_protein_tyrosine_kinases_to_participate_in_the_signal_transduction_from_the_cell_surface_to_the_nucleus._Dephosphorylates_ROCK2_at_Tyr-722_resulting_in_stimulatation_of_its_RhoA_binding_activity._{ECO:0000269|PubMed:10655584,_ECO:0000269|PubMed:18559669,_ECO:0000269|PubMed:18829466}.\x3b_	DISEASE:_LEOPARD_syndrome_1_(LPRD1)_[MIM:151100]:_A_disorder_characterized_by_lentigines,_electrocardiographic_conduction_abnormalities,_ocular_hypertelorism,_pulmonic_stenosis,_abnormalities_of_genitalia,_retardation_of_growth,_and_sensorineural_deafness._{ECO:0000269|PubMed:12058348,_ECO:0000269|PubMed:14961557,_ECO:0000269|PubMed:15121796,_ECO:0000269|PubMed:15389709,_ECO:0000269|PubMed:15520399,_ECO:0000269|PubMed:15690106,_ECO:0000269|PubMed:16679933,_ECO:0000269|PubMed:24891296}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Noonan_syndrome_1_(NS1)_[MIM:163950]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._Some_patients_with_NS1_develop_multiple_giant_cell_lesions_of_the_jaw_or_other_bony_or_soft_tissues,_which_are_classified_as_pigmented_villonodular_synovitis_(PVNS)_when_occurring_in_the_jaw_or_joints._{ECO:0000269|PubMed:11704759,_ECO:0000269|PubMed:11992261,_ECO:0000269|PubMed:12161469,_ECO:0000269|PubMed:12325025,_ECO:0000269|PubMed:12529711,_ECO:0000269|PubMed:12634870,_ECO:0000269|PubMed:12717436,_ECO:0000269|PubMed:12739139,_ECO:0000269|PubMed:12960218,_ECO:0000269|PubMed:15384080,_ECO:0000269|PubMed:15948193,_ECO:0000269|PubMed:19020799,_ECO:0000269|PubMed:24891296}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry._Mutations_in_PTPN11_account_for_more_than_50%_of_the_cases.\x3b_DISEASE:_Leukemia,_juvenile_myelomonocytic_(JMML)_[MIM:607785]:_An_aggressive_pediatric_myelodysplastic_syndrome/myeloproliferative_disorder_characterized_by_malignant_transformation_in_the_hematopoietic_stem_cell_compartment_with_proliferation_of_differentiated_progeny._Patients_have_splenomegaly,_enlarged_lymph_nodes,_rashes,_and_hemorrhages._{ECO:0000269|PubMed:12717436}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Metachondromatosis_(MC)_[MIM:156250]:_A_skeletal_disorder_with_radiologic_features_of_both_multiple_exostoses_and_Ollier_disease,_characterized_by_the_presence_of_exostoses,_commonly_of_the_bones_of_the_hands_and_feet,_and_enchondromas_of_the_metaphyses_of_long_bones_and_iliac_crest._{ECO:0000269|PubMed:20577567}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Widely_expressed,_with_highest_levels_in_heart,_brain,_and_skeletal_muscle._{ECO:0000269|PubMed:1280823,_ECO:0000269|PubMed:7681589,_ECO:0000269|PubMed:8216283}.\x3b_	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3bfrontal_lobe\x3bendometrium\x3boesophagus\x3blarynx\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bpineal_gland\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bpineal_body\x3burinary\x3badrenal_cortex\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3blung\x3bcornea\x3badrenal_gland\x3bplacenta\x3bvisual_apparatus\x3bhippocampus\x3bhypopharynx\x3bliver\x3bhead_and_neck\x3bcervix\x3bkidney\x3bmammary_gland\x3baorta\x3bstomach\x3b	amygdala\x3btestis_-_interstitial\x3bthalamus\x3bmedulla_oblongata\x3bsuperior_cervical_ganglion\x3boccipital_lobe\x3bhypothalamus\x3bspinal_cord\x3bcaudate_nucleus\x3bpons\x3bskeletal_muscle\x3bsubthalamic_nucleus\x3bprefrontal_cortex\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bparietal_lobe\x3b	0.26245	0.72890	-0.427900189	25.14744043	19.44641	0.66817	rs397507534	49011	Rasopathy|not_specified	MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374	reviewed_by_expert_panel	Benign	0.062	0.384	T	0.000	0.843	D	1	0.810	D	1.435	0.361	L	-5.65	0.993	D	-2.16	0.488	N	1.015	0.974	D	0.933	0.978	D	0.130	0.813	D	0.586	0.714	0.978	0.768	D	c	0.337	0.490	1.000	0.480	0.722	0.854	0	6.03	0.978	5.431	0.660	1.026	0.645	1.000	0.715	1.000	0.888	20.624	0.995	PTP_type_protein_phosphatase|Protein-tyrosine_phosphatase-like	.	.	.	.	.	.	.	.	.	.	.	.	0.0004	0	0	0	5.798e-05	0	8.953e-06	0	0.0035	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,858	0	0	0	0	0	1	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0.0507	VUS
12	112915755	112915755	G	A	exonic	PTPN11	.	nonsynonymous_SNV	PTPN11:NM_001330437:exon9:c.G1028A:p.R343Q,PTPN11:NM_002834:exon9:c.G1028A:p.R343Q,PTPN11:NM_080601:exon9:c.G1028A:p.R343Q	0.999877230878678	0.000122769057470549	6.38519788034449e-11	protein_tyrosine_phosphatase,_non-receptor_type_11	FUNCTION:_Acts_downstream_of_various_receptor_and_cytoplasmic_protein_tyrosine_kinases_to_participate_in_the_signal_transduction_from_the_cell_surface_to_the_nucleus._Dephosphorylates_ROCK2_at_Tyr-722_resulting_in_stimulatation_of_its_RhoA_binding_activity._{ECO:0000269|PubMed:10655584,_ECO:0000269|PubMed:18559669,_ECO:0000269|PubMed:18829466}.\x3b_	DISEASE:_LEOPARD_syndrome_1_(LPRD1)_[MIM:151100]:_A_disorder_characterized_by_lentigines,_electrocardiographic_conduction_abnormalities,_ocular_hypertelorism,_pulmonic_stenosis,_abnormalities_of_genitalia,_retardation_of_growth,_and_sensorineural_deafness._{ECO:0000269|PubMed:12058348,_ECO:0000269|PubMed:14961557,_ECO:0000269|PubMed:15121796,_ECO:0000269|PubMed:15389709,_ECO:0000269|PubMed:15520399,_ECO:0000269|PubMed:15690106,_ECO:0000269|PubMed:16679933,_ECO:0000269|PubMed:24891296}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Noonan_syndrome_1_(NS1)_[MIM:163950]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._Some_patients_with_NS1_develop_multiple_giant_cell_lesions_of_the_jaw_or_other_bony_or_soft_tissues,_which_are_classified_as_pigmented_villonodular_synovitis_(PVNS)_when_occurring_in_the_jaw_or_joints._{ECO:0000269|PubMed:11704759,_ECO:0000269|PubMed:11992261,_ECO:0000269|PubMed:12161469,_ECO:0000269|PubMed:12325025,_ECO:0000269|PubMed:12529711,_ECO:0000269|PubMed:12634870,_ECO:0000269|PubMed:12717436,_ECO:0000269|PubMed:12739139,_ECO:0000269|PubMed:12960218,_ECO:0000269|PubMed:15384080,_ECO:0000269|PubMed:15948193,_ECO:0000269|PubMed:19020799,_ECO:0000269|PubMed:24891296}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry._Mutations_in_PTPN11_account_for_more_than_50%_of_the_cases.\x3b_DISEASE:_Leukemia,_juvenile_myelomonocytic_(JMML)_[MIM:607785]:_An_aggressive_pediatric_myelodysplastic_syndrome/myeloproliferative_disorder_characterized_by_malignant_transformation_in_the_hematopoietic_stem_cell_compartment_with_proliferation_of_differentiated_progeny._Patients_have_splenomegaly,_enlarged_lymph_nodes,_rashes,_and_hemorrhages._{ECO:0000269|PubMed:12717436}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Metachondromatosis_(MC)_[MIM:156250]:_A_skeletal_disorder_with_radiologic_features_of_both_multiple_exostoses_and_Ollier_disease,_characterized_by_the_presence_of_exostoses,_commonly_of_the_bones_of_the_hands_and_feet,_and_enchondromas_of_the_metaphyses_of_long_bones_and_iliac_crest._{ECO:0000269|PubMed:20577567}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Widely_expressed,_with_highest_levels_in_heart,_brain,_and_skeletal_muscle._{ECO:0000269|PubMed:1280823,_ECO:0000269|PubMed:7681589,_ECO:0000269|PubMed:8216283}.\x3b_	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3bfrontal_lobe\x3bendometrium\x3boesophagus\x3blarynx\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bpineal_gland\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bpineal_body\x3burinary\x3badrenal_cortex\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3blung\x3bcornea\x3badrenal_gland\x3bplacenta\x3bvisual_apparatus\x3bhippocampus\x3bhypopharynx\x3bliver\x3bhead_and_neck\x3bcervix\x3bkidney\x3bmammary_gland\x3baorta\x3bstomach\x3b	amygdala\x3btestis_-_interstitial\x3bthalamus\x3bmedulla_oblongata\x3bsuperior_cervical_ganglion\x3boccipital_lobe\x3bhypothalamus\x3bspinal_cord\x3bcaudate_nucleus\x3bpons\x3bskeletal_muscle\x3bsubthalamic_nucleus\x3bprefrontal_cortex\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bparietal_lobe\x3b	0.26245	0.72890	-0.427900189	25.14744043	19.44641	0.66817	rs535800148	179454	Rasopathy|not_specified	MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374	reviewed_by_expert_panel	Benign	1.0	0.010	T	0.000	0.843	D	1.000	0.588	D	0.355	0.120	N	-5.7	0.993	D	0.13	0.055	N	0.795	0.943	D	0.861	0.954	D	0.171	0.849	D	0.721	0.856	0.971	0.726	D	c	-0.236	0.024	0.931	0.270	0.722	0.854	0	5.12	0.693	5.421	0.660	1.026	0.645	1.000	0.715	1.000	0.888	16.618	0.847	PTP_type_protein_phosphatase|Protein-tyrosine_phosphatase-like	.	.	.	.	.	.	.	.	.	.	.	.	0.0002	0	0	0	0	0	8.954e-06	0	0.0015	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,857	0	0	0	0	0	1	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0.0507	VUS
1	215802242	215802242	C	T	exonic	USH2A	.	nonsynonymous_SNV	USH2A:NM_206933:exon71:c.G15433A:p.V5145I	3.68100336207458e-43	0.999989235571568	1.07644284322941e-05	Usher_syndrome_2A_(autosomal_recessive,_mild)	FUNCTION:_Involved_in_hearing_and_vision.\x3b_	DISEASE:_Usher_syndrome_2A_(USH2A)_[MIM:276901]:_USH_is_a_genetically_heterogeneous_condition_characterized_by_the_association_of_retinitis_pigmentosa_with_sensorineural_deafness._Age_at_onset_and_differences_in_auditory_and_vestibular_function_distinguish_Usher_syndrome_type_1_(USH1),_Usher_syndrome_type_2_(USH2)_and_Usher_syndrome_type_3_(USH3)._USH2_is_characterized_by_congenital_mild_hearing_impairment_with_normal_vestibular_responses._{ECO:0000269|PubMed:10729113,_ECO:0000269|PubMed:10738000,_ECO:0000269|PubMed:10909849,_ECO:0000269|PubMed:11311042,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:12525556,_ECO:0000269|PubMed:14970843,_ECO:0000269|PubMed:15015129,_ECO:0000269|PubMed:15025721,_ECO:0000269|PubMed:15241801,_ECO:0000269|PubMed:15325563,_ECO:0000269|PubMed:17085681,_ECO:0000269|PubMed:17405132,_ECO:0000269|PubMed:18273898,_ECO:0000269|PubMed:18452394,_ECO:0000269|PubMed:19683999,_ECO:0000269|PubMed:19737284,_ECO:0000269|PubMed:20309401,_ECO:0000269|PubMed:20440071,_ECO:0000269|PubMed:20507924,_ECO:0000269|PubMed:21593743,_ECO:0000269|PubMed:21686329,_ECO:0000269|PubMed:22004887,_ECO:0000269|PubMed:23737954,_ECO:0000269|PubMed:9624053}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Retinitis_pigmentosa_39_(RP39)_[MIM:613809]:_A_retinal_dystrophy_belonging_to_the_group_of_pigmentary_retinopathies._Retinitis_pigmentosa_is_characterized_by_retinal_pigment_deposits_visible_on_fundus_examination_and_primary_loss_of_rod_photoreceptor_cells_followed_by_secondary_loss_of_cone_photoreceptors._Patients_typically_have_night_vision_blindness_and_loss_of_midperipheral_visual_field._As_their_condition_progresses,_they_lose_their_far_peripheral_visual_field_and_eventually_central_vision_as_well._{ECO:0000269|PubMed:10775529,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:12427073,_ECO:0000269|PubMed:15325563,_ECO:0000269|PubMed:16098008,_ECO:0000269|PubMed:17296898,_ECO:0000269|PubMed:20507924,_ECO:0000269|PubMed:21686329,_ECO:0000269|PubMed:22334370,_ECO:0000269|PubMed:24227914}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Present_in_the_basement_membrane_of_many,_but_not_all_tissues._Expressed_in_retina,_cochlea,_small_and_large_intestine,_pancreas,_bladder,_prostate,_esophagus,_trachea,_thymus,_salivary_glands,_placenta,_ovary,_fallopian_tube,_uterus_and_testis._Absent_in_many_other_tissues_such_as_heart,_lung,_liver,_kidney_and_brain._In_the_retina,_it_is_present_in_the_basement_membranes_in_the_Bruch's_layer_choroid_capillary_basement_membranes,_where_it_localizes_just_beneath_the_retinal_pigment_epithelial_cells_(at_protein_level)._Weakly_expressed._Isoform_2_is_expressed_in_fetal_eye,_cochlea_and_heart,_and_at_very_low_level_in_brain,_CNS,_intestine,_skeleton,_tongue,_kidney_and_lung._Isoform_2_is_not_expressed_in_stomach_and_liver._In_adult_tissues,_isoform_2_is_expressed_in_neural_retina_and_testis,_and_at_low_level_in_brain,_heart,_kidney_and_liver._Isoform_1_displays_a_similar_pattern_of_expression_but_is_expressed_at_very_low_level_in_fetal_cochlea._{ECO:0000269|PubMed:11788194,_ECO:0000269|PubMed:12433396,_ECO:0000269|PubMed:15015129,_ECO:0000269|PubMed:9624053}.\x3b_	unclassifiable_(Anatomical_System)\x3bliver\x3btestis\x3bretina\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3badrenal_gland\x3btemporal_lobe\x3bciliary_ganglion\x3batrioventricular_node\x3btrigeminal_ganglion\x3bskin\x3bskeletal_muscle\x3bcerebellum\x3b	0.15836	.	4.179636958	99.70511913	6401.91635	16.71188	rs111033269	57626	Retinitis_pigmentosa|not_specified|not_provided	Human_Phenotype_Ontology:HP:0000547,MeSH:D012174,MedGen:C0035334,OMIM:268000,Orphanet:ORPHA791,SNOMED_CT:28835009|MedGen:CN169374|MedGen:CN517202	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.03	0.453	D	0.002	0.364	U	0.840	0.350	D	2.325	0.668	M	0.4	0.573	T	-0.55	0.168	N	-0.816	0.542	T	0.104	0.383	T	0.340	0.920	D	.	.	0.922	0.549	D	c	-0.032	-0.002	0.180	0.179	0.487	0.133	0	3.75	0.421	2.729	0.468	0.892	0.403	0.990	0.367	0.994	0.587	12.027	0.525	.	.	.	.	.	0.0046	0.0006	0	0	0	0.0103	0.0066	0.0031	0.0031	0.0007	0.0006	0	0	0.0073	0.0050	0.0018	0.0001	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,445	0	0	0	0	0	0	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0.0507	VUS
10	89717799	89717799	G	A	intronic	PTEN	.	.	.	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs116160352	98736	Cowden_syndrome_1	MedGen:CN072330,OMIM:158350	criteria_provided,_single_submitter	Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0006	0.0019	0	0	0	0	0.0001	0	0.0003	0.0027	2.982e-05	0.0025	0	0	7.173e-05	0.0004	3.251e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,581	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.0507	VUS
10	89624340	89624340	C	T	intronic	PTEN	.	.	.	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs190707033	98734	Hereditary_cancer-predisposing_syndrome	MedGen:C0027672,SNOMED_CT:699346009	criteria_provided,_single_submitter	Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0011	0.0006	0.0012	0	0	0.0006	0.0017	0	0.0019	0.0005	0.0021	0.0007	5.798e-05	0.0013	0.0019	0.0038	0.0034	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,519	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.0507	VUS
11	533525	533525	T	C	exonic	HRAS	.	nonsynonymous_SNV	HRAS:NM_001318054:exon4:c.A59G:p.N20S	0.00794104930284198	0.785285637637198	0.20677331305996	Harvey_rat_sarcoma_viral_oncogene_homolog	FUNCTION:_Ras_proteins_bind_GDP/GTP_and_possess_intrinsic_GTPase_activity._{ECO:0000269|PubMed:12740440,_ECO:0000269|PubMed:14500341,_ECO:0000269|PubMed:9020151}.\x3b_	DISEASE:_Costello_syndrome_(CSTLO)_[MIM:218040]:_A_rare_condition_characterized_by_prenatally_increased_growth,_postnatal_growth_deficiency,_mental_retardation,_distinctive_facial_appearance,_cardiovascular_abnormalities_(typically_pulmonic_stenosis,_hypertrophic_cardiomyopathy_and/or_atrial_tachycardia),_tumor_predisposition,_skin_and_musculoskeletal_abnormalities._{ECO:0000269|PubMed:16170316,_ECO:0000269|PubMed:16329078,_ECO:0000269|PubMed:16443854,_ECO:0000269|PubMed:17054105,_ECO:0000269|PubMed:18039947,_ECO:0000269|PubMed:18247425,_ECO:0000269|PubMed:19995790}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Congenital_myopathy_with_excess_of_muscle_spindles_(CMEMS)_[MIM:218040]:_Variant_of_Costello_syndrome._{ECO:0000269|PubMed:17412879}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hurthle_cell_thyroid_carcinoma_(HCTC)_[MIM:607464]:_A_rare_type_of_thyroid_cancer_accounting_for_only_about_3-10%_of_all_differentiated_thyroid_cancers._These_neoplasms_are_considered_a_variant_of_follicular_carcinoma_of_the_thyroid_and_are_referred_to_as_follicular_carcinoma,_oxyphilic_type._{ECO:0000269|PubMed:12727991}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dMutations_which_change_positions_12,_13_or_61_activate_the_potential_of_HRAS_to_transform_cultured_cells_and_are_implicated_in_a_variety_of_human_tumors._{ECO:0000269|PubMed:3670300}.\x3b_DISEASE:_Bladder_cancer_(BLC)_[MIM:109800]:_A_malignancy_originating_in_tissues_of_the_urinary_bladder._It_often_presents_with_multiple_tumors_appearing_at_different_times_and_at_different_sites_in_the_bladder._Most_bladder_cancers_are_transitional_cell_carcinomas_that_begin_in_cells_that_normally_make_up_the_inner_lining_of_the_bladder._Other_types_of_bladder_cancer_include_squamous_cell_carcinoma_(cancer_that_begins_in_thin,_flat_cells)_and_adenocarcinoma_(cancer_that_begins_in_cells_that_make_and_release_mucus_and_other_fluids)._Bladder_cancer_is_a_complex_disorder_with_both_genetic_and_environmental_influences._{ECO:0000269|PubMed:6298635,_ECO:0000269|PubMed:6844927}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Schimmelpenning-Feuerstein-Mims_syndrome_(SFM)_[MIM:163200]:_A_disease_characterized_by_sebaceous_nevi,_often_on_the_face,_associated_with_variable_ipsilateral_abnormalities_of_the_central_nervous_system,_ocular_anomalies,_and_skeletal_defects._Many_oral_manifestations_have_been_reported,_not_only_including_hypoplastic_and_malformed_teeth,_and_mucosal_papillomatosis,_but_also_ankyloglossia,_hemihyperplastic_tongue,_intraoral_nevus,_giant_cell_granuloma,_ameloblastoma,_bone_cysts,_follicular_cysts,_oligodontia,_and_odontodysplasia._Sebaceous_nevi_follow_the_lines_of_Blaschko_and_these_can_continue_as_linear_intraoral_lesions,_as_in_mucosal_papillomatosis._{ECO:0000269|PubMed:22683711}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Widely_expressed._{ECO:0000269|PubMed:14500341}.\x3b_	ovary\x3bdevelopmental\x3bcolon\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3boptic_nerve\x3bwhole_body\x3boesophagus\x3bendometrium\x3bthyroid\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bhypothalamus\x3bblood\x3blens\x3bskeletal_muscle\x3blung\x3bplacenta\x3bvisual_apparatus\x3bhypopharynx\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bcerebellum\x3b	whole_brain\x3bmedulla_oblongata\x3btrigeminal_ganglion\x3b	0.99944	0.99980	-0.339715008	30.06605331	4.91473	0.18207	rs397517140	48912	Costello_syndrome|Rasopathy|not_specified|not_provided	MedGen:C0587248,OMIM:218040,Orphanet:ORPHA3071,SNOMED_CT:309776008|MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374|MedGen:CN517202	reviewed_by_expert_panel	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0002	0	0	0	0	0	8.956e-06	0	0.0014	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,613	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.025	VUS
1	215807798	215807798	T	C	intronic	USH2A	.	.	.	3.68100336207458e-43	0.999989235571568	1.07644284322941e-05	Usher_syndrome_2A_(autosomal_recessive,_mild)	FUNCTION:_Involved_in_hearing_and_vision.\x3b_	DISEASE:_Usher_syndrome_2A_(USH2A)_[MIM:276901]:_USH_is_a_genetically_heterogeneous_condition_characterized_by_the_association_of_retinitis_pigmentosa_with_sensorineural_deafness._Age_at_onset_and_differences_in_auditory_and_vestibular_function_distinguish_Usher_syndrome_type_1_(USH1),_Usher_syndrome_type_2_(USH2)_and_Usher_syndrome_type_3_(USH3)._USH2_is_characterized_by_congenital_mild_hearing_impairment_with_normal_vestibular_responses._{ECO:0000269|PubMed:10729113,_ECO:0000269|PubMed:10738000,_ECO:0000269|PubMed:10909849,_ECO:0000269|PubMed:11311042,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:12525556,_ECO:0000269|PubMed:14970843,_ECO:0000269|PubMed:15015129,_ECO:0000269|PubMed:15025721,_ECO:0000269|PubMed:15241801,_ECO:0000269|PubMed:15325563,_ECO:0000269|PubMed:17085681,_ECO:0000269|PubMed:17405132,_ECO:0000269|PubMed:18273898,_ECO:0000269|PubMed:18452394,_ECO:0000269|PubMed:19683999,_ECO:0000269|PubMed:19737284,_ECO:0000269|PubMed:20309401,_ECO:0000269|PubMed:20440071,_ECO:0000269|PubMed:20507924,_ECO:0000269|PubMed:21593743,_ECO:0000269|PubMed:21686329,_ECO:0000269|PubMed:22004887,_ECO:0000269|PubMed:23737954,_ECO:0000269|PubMed:9624053}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Retinitis_pigmentosa_39_(RP39)_[MIM:613809]:_A_retinal_dystrophy_belonging_to_the_group_of_pigmentary_retinopathies._Retinitis_pigmentosa_is_characterized_by_retinal_pigment_deposits_visible_on_fundus_examination_and_primary_loss_of_rod_photoreceptor_cells_followed_by_secondary_loss_of_cone_photoreceptors._Patients_typically_have_night_vision_blindness_and_loss_of_midperipheral_visual_field._As_their_condition_progresses,_they_lose_their_far_peripheral_visual_field_and_eventually_central_vision_as_well._{ECO:0000269|PubMed:10775529,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:12427073,_ECO:0000269|PubMed:15325563,_ECO:0000269|PubMed:16098008,_ECO:0000269|PubMed:17296898,_ECO:0000269|PubMed:20507924,_ECO:0000269|PubMed:21686329,_ECO:0000269|PubMed:22334370,_ECO:0000269|PubMed:24227914}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Present_in_the_basement_membrane_of_many,_but_not_all_tissues._Expressed_in_retina,_cochlea,_small_and_large_intestine,_pancreas,_bladder,_prostate,_esophagus,_trachea,_thymus,_salivary_glands,_placenta,_ovary,_fallopian_tube,_uterus_and_testis._Absent_in_many_other_tissues_such_as_heart,_lung,_liver,_kidney_and_brain._In_the_retina,_it_is_present_in_the_basement_membranes_in_the_Bruch's_layer_choroid_capillary_basement_membranes,_where_it_localizes_just_beneath_the_retinal_pigment_epithelial_cells_(at_protein_level)._Weakly_expressed._Isoform_2_is_expressed_in_fetal_eye,_cochlea_and_heart,_and_at_very_low_level_in_brain,_CNS,_intestine,_skeleton,_tongue,_kidney_and_lung._Isoform_2_is_not_expressed_in_stomach_and_liver._In_adult_tissues,_isoform_2_is_expressed_in_neural_retina_and_testis,_and_at_low_level_in_brain,_heart,_kidney_and_liver._Isoform_1_displays_a_similar_pattern_of_expression_but_is_expressed_at_very_low_level_in_fetal_cochlea._{ECO:0000269|PubMed:11788194,_ECO:0000269|PubMed:12433396,_ECO:0000269|PubMed:15015129,_ECO:0000269|PubMed:9624053}.\x3b_	unclassifiable_(Anatomical_System)\x3bliver\x3btestis\x3bretina\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3badrenal_gland\x3btemporal_lobe\x3bciliary_ganglion\x3batrioventricular_node\x3btrigeminal_ganglion\x3bskin\x3bskeletal_muscle\x3bcerebellum\x3b	0.15836	.	4.179636958	99.70511913	6401.91635	16.71188	rs57754754	57621	not_specified	MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.9676	0.754	0.0027	0.0095	0	0	0	0	0	0.0010	0.0008	0.0119	0.0006	0	0	0	1.791e-05	0.0004	6.498e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,446	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.025	VUS
1	215799170	215799170	T	C	exonic	USH2A	.	nonsynonymous_SNV	USH2A:NM_206933:exon72:c.A15562G:p.S5188G	3.68100336207458e-43	0.999989235571568	1.07644284322941e-05	Usher_syndrome_2A_(autosomal_recessive,_mild)	FUNCTION:_Involved_in_hearing_and_vision.\x3b_	DISEASE:_Usher_syndrome_2A_(USH2A)_[MIM:276901]:_USH_is_a_genetically_heterogeneous_condition_characterized_by_the_association_of_retinitis_pigmentosa_with_sensorineural_deafness._Age_at_onset_and_differences_in_auditory_and_vestibular_function_distinguish_Usher_syndrome_type_1_(USH1),_Usher_syndrome_type_2_(USH2)_and_Usher_syndrome_type_3_(USH3)._USH2_is_characterized_by_congenital_mild_hearing_impairment_with_normal_vestibular_responses._{ECO:0000269|PubMed:10729113,_ECO:0000269|PubMed:10738000,_ECO:0000269|PubMed:10909849,_ECO:0000269|PubMed:11311042,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:12525556,_ECO:0000269|PubMed:14970843,_ECO:0000269|PubMed:15015129,_ECO:0000269|PubMed:15025721,_ECO:0000269|PubMed:15241801,_ECO:0000269|PubMed:15325563,_ECO:0000269|PubMed:17085681,_ECO:0000269|PubMed:17405132,_ECO:0000269|PubMed:18273898,_ECO:0000269|PubMed:18452394,_ECO:0000269|PubMed:19683999,_ECO:0000269|PubMed:19737284,_ECO:0000269|PubMed:20309401,_ECO:0000269|PubMed:20440071,_ECO:0000269|PubMed:20507924,_ECO:0000269|PubMed:21593743,_ECO:0000269|PubMed:21686329,_ECO:0000269|PubMed:22004887,_ECO:0000269|PubMed:23737954,_ECO:0000269|PubMed:9624053}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Retinitis_pigmentosa_39_(RP39)_[MIM:613809]:_A_retinal_dystrophy_belonging_to_the_group_of_pigmentary_retinopathies._Retinitis_pigmentosa_is_characterized_by_retinal_pigment_deposits_visible_on_fundus_examination_and_primary_loss_of_rod_photoreceptor_cells_followed_by_secondary_loss_of_cone_photoreceptors._Patients_typically_have_night_vision_blindness_and_loss_of_midperipheral_visual_field._As_their_condition_progresses,_they_lose_their_far_peripheral_visual_field_and_eventually_central_vision_as_well._{ECO:0000269|PubMed:10775529,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:12427073,_ECO:0000269|PubMed:15325563,_ECO:0000269|PubMed:16098008,_ECO:0000269|PubMed:17296898,_ECO:0000269|PubMed:20507924,_ECO:0000269|PubMed:21686329,_ECO:0000269|PubMed:22334370,_ECO:0000269|PubMed:24227914}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Present_in_the_basement_membrane_of_many,_but_not_all_tissues._Expressed_in_retina,_cochlea,_small_and_large_intestine,_pancreas,_bladder,_prostate,_esophagus,_trachea,_thymus,_salivary_glands,_placenta,_ovary,_fallopian_tube,_uterus_and_testis._Absent_in_many_other_tissues_such_as_heart,_lung,_liver,_kidney_and_brain._In_the_retina,_it_is_present_in_the_basement_membranes_in_the_Bruch's_layer_choroid_capillary_basement_membranes,_where_it_localizes_just_beneath_the_retinal_pigment_epithelial_cells_(at_protein_level)._Weakly_expressed._Isoform_2_is_expressed_in_fetal_eye,_cochlea_and_heart,_and_at_very_low_level_in_brain,_CNS,_intestine,_skeleton,_tongue,_kidney_and_lung._Isoform_2_is_not_expressed_in_stomach_and_liver._In_adult_tissues,_isoform_2_is_expressed_in_neural_retina_and_testis,_and_at_low_level_in_brain,_heart,_kidney_and_liver._Isoform_1_displays_a_similar_pattern_of_expression_but_is_expressed_at_very_low_level_in_fetal_cochlea._{ECO:0000269|PubMed:11788194,_ECO:0000269|PubMed:12433396,_ECO:0000269|PubMed:15015129,_ECO:0000269|PubMed:9624053}.\x3b_	unclassifiable_(Anatomical_System)\x3bliver\x3btestis\x3bretina\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3badrenal_gland\x3btemporal_lobe\x3bciliary_ganglion\x3batrioventricular_node\x3btrigeminal_ganglion\x3bskin\x3bskeletal_muscle\x3bcerebellum\x3b	0.15836	.	4.179636958	99.70511913	6401.91635	16.71188	rs58257972	57630	not_specified	MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Benign	0.065	0.363	T	0.000	0.504	U	1.000	0.506	D	2.595	0.761	M	0.93	0.441	T	-1.7	0.404	N	-1.134	0.016	T	0.018	0.074	T	.	.	.	.	.	0.970	0.717	D	c	0.378	0.481	0.905	0.262	0.487	0.133	0	5.93	0.959	5.553	0.668	1.011	0.635	1.000	0.715	0.998	0.697	16.374	0.831	.	.	.	.	.	0.0033	0.0010	0.0012	0.0033	0.0160	0.0031	0.0030	0.0081	0.0127	0.0009	0.0018	0.0001	0.0187	0.0029	0.0038	0.0078	0.0715	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,443	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.025	VUS
11	533618	533618	A	C	intronic	HRAS	.	.	.	0.00794104930284198	0.785285637637198	0.20677331305996	Harvey_rat_sarcoma_viral_oncogene_homolog	FUNCTION:_Ras_proteins_bind_GDP/GTP_and_possess_intrinsic_GTPase_activity._{ECO:0000269|PubMed:12740440,_ECO:0000269|PubMed:14500341,_ECO:0000269|PubMed:9020151}.\x3b_	DISEASE:_Costello_syndrome_(CSTLO)_[MIM:218040]:_A_rare_condition_characterized_by_prenatally_increased_growth,_postnatal_growth_deficiency,_mental_retardation,_distinctive_facial_appearance,_cardiovascular_abnormalities_(typically_pulmonic_stenosis,_hypertrophic_cardiomyopathy_and/or_atrial_tachycardia),_tumor_predisposition,_skin_and_musculoskeletal_abnormalities._{ECO:0000269|PubMed:16170316,_ECO:0000269|PubMed:16329078,_ECO:0000269|PubMed:16443854,_ECO:0000269|PubMed:17054105,_ECO:0000269|PubMed:18039947,_ECO:0000269|PubMed:18247425,_ECO:0000269|PubMed:19995790}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Congenital_myopathy_with_excess_of_muscle_spindles_(CMEMS)_[MIM:218040]:_Variant_of_Costello_syndrome._{ECO:0000269|PubMed:17412879}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hurthle_cell_thyroid_carcinoma_(HCTC)_[MIM:607464]:_A_rare_type_of_thyroid_cancer_accounting_for_only_about_3-10%_of_all_differentiated_thyroid_cancers._These_neoplasms_are_considered_a_variant_of_follicular_carcinoma_of_the_thyroid_and_are_referred_to_as_follicular_carcinoma,_oxyphilic_type._{ECO:0000269|PubMed:12727991}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dMutations_which_change_positions_12,_13_or_61_activate_the_potential_of_HRAS_to_transform_cultured_cells_and_are_implicated_in_a_variety_of_human_tumors._{ECO:0000269|PubMed:3670300}.\x3b_DISEASE:_Bladder_cancer_(BLC)_[MIM:109800]:_A_malignancy_originating_in_tissues_of_the_urinary_bladder._It_often_presents_with_multiple_tumors_appearing_at_different_times_and_at_different_sites_in_the_bladder._Most_bladder_cancers_are_transitional_cell_carcinomas_that_begin_in_cells_that_normally_make_up_the_inner_lining_of_the_bladder._Other_types_of_bladder_cancer_include_squamous_cell_carcinoma_(cancer_that_begins_in_thin,_flat_cells)_and_adenocarcinoma_(cancer_that_begins_in_cells_that_make_and_release_mucus_and_other_fluids)._Bladder_cancer_is_a_complex_disorder_with_both_genetic_and_environmental_influences._{ECO:0000269|PubMed:6298635,_ECO:0000269|PubMed:6844927}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Schimmelpenning-Feuerstein-Mims_syndrome_(SFM)_[MIM:163200]:_A_disease_characterized_by_sebaceous_nevi,_often_on_the_face,_associated_with_variable_ipsilateral_abnormalities_of_the_central_nervous_system,_ocular_anomalies,_and_skeletal_defects._Many_oral_manifestations_have_been_reported,_not_only_including_hypoplastic_and_malformed_teeth,_and_mucosal_papillomatosis,_but_also_ankyloglossia,_hemihyperplastic_tongue,_intraoral_nevus,_giant_cell_granuloma,_ameloblastoma,_bone_cysts,_follicular_cysts,_oligodontia,_and_odontodysplasia._Sebaceous_nevi_follow_the_lines_of_Blaschko_and_these_can_continue_as_linear_intraoral_lesions,_as_in_mucosal_papillomatosis._{ECO:0000269|PubMed:22683711}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Widely_expressed._{ECO:0000269|PubMed:14500341}.\x3b_	ovary\x3bdevelopmental\x3bcolon\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3boptic_nerve\x3bwhole_body\x3boesophagus\x3bendometrium\x3bthyroid\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bhypothalamus\x3bblood\x3blens\x3bskeletal_muscle\x3blung\x3bplacenta\x3bvisual_apparatus\x3bhypopharynx\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bcerebellum\x3b	whole_brain\x3bmedulla_oblongata\x3btrigeminal_ganglion\x3b	0.99944	0.99980	-0.339715008	30.06605331	4.91473	0.18207	rs766909143	442535	Rasopathy	MedGen:CN166718,Orphanet:ORPHA98733	reviewed_by_expert_panel	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0024	0.154	.	.	.	.	.	.	.	.	0.0001	0	0	0	0	0	0	0.0002	0.0010	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,618	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.025	VUS
11	533594	533594	C	T	exonic	HRAS	.	synonymous_SNV	HRAS:NM_001130442:exon4:c.G309A:p.V103V,HRAS:NM_005343:exon4:c.G309A:p.V103V,HRAS:NM_176795:exon4:c.G309A:p.V103V	0.00794104930284198	0.785285637637198	0.20677331305996	Harvey_rat_sarcoma_viral_oncogene_homolog	FUNCTION:_Ras_proteins_bind_GDP/GTP_and_possess_intrinsic_GTPase_activity._{ECO:0000269|PubMed:12740440,_ECO:0000269|PubMed:14500341,_ECO:0000269|PubMed:9020151}.\x3b_	DISEASE:_Costello_syndrome_(CSTLO)_[MIM:218040]:_A_rare_condition_characterized_by_prenatally_increased_growth,_postnatal_growth_deficiency,_mental_retardation,_distinctive_facial_appearance,_cardiovascular_abnormalities_(typically_pulmonic_stenosis,_hypertrophic_cardiomyopathy_and/or_atrial_tachycardia),_tumor_predisposition,_skin_and_musculoskeletal_abnormalities._{ECO:0000269|PubMed:16170316,_ECO:0000269|PubMed:16329078,_ECO:0000269|PubMed:16443854,_ECO:0000269|PubMed:17054105,_ECO:0000269|PubMed:18039947,_ECO:0000269|PubMed:18247425,_ECO:0000269|PubMed:19995790}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Congenital_myopathy_with_excess_of_muscle_spindles_(CMEMS)_[MIM:218040]:_Variant_of_Costello_syndrome._{ECO:0000269|PubMed:17412879}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hurthle_cell_thyroid_carcinoma_(HCTC)_[MIM:607464]:_A_rare_type_of_thyroid_cancer_accounting_for_only_about_3-10%_of_all_differentiated_thyroid_cancers._These_neoplasms_are_considered_a_variant_of_follicular_carcinoma_of_the_thyroid_and_are_referred_to_as_follicular_carcinoma,_oxyphilic_type._{ECO:0000269|PubMed:12727991}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dMutations_which_change_positions_12,_13_or_61_activate_the_potential_of_HRAS_to_transform_cultured_cells_and_are_implicated_in_a_variety_of_human_tumors._{ECO:0000269|PubMed:3670300}.\x3b_DISEASE:_Bladder_cancer_(BLC)_[MIM:109800]:_A_malignancy_originating_in_tissues_of_the_urinary_bladder._It_often_presents_with_multiple_tumors_appearing_at_different_times_and_at_different_sites_in_the_bladder._Most_bladder_cancers_are_transitional_cell_carcinomas_that_begin_in_cells_that_normally_make_up_the_inner_lining_of_the_bladder._Other_types_of_bladder_cancer_include_squamous_cell_carcinoma_(cancer_that_begins_in_thin,_flat_cells)_and_adenocarcinoma_(cancer_that_begins_in_cells_that_make_and_release_mucus_and_other_fluids)._Bladder_cancer_is_a_complex_disorder_with_both_genetic_and_environmental_influences._{ECO:0000269|PubMed:6298635,_ECO:0000269|PubMed:6844927}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Schimmelpenning-Feuerstein-Mims_syndrome_(SFM)_[MIM:163200]:_A_disease_characterized_by_sebaceous_nevi,_often_on_the_face,_associated_with_variable_ipsilateral_abnormalities_of_the_central_nervous_system,_ocular_anomalies,_and_skeletal_defects._Many_oral_manifestations_have_been_reported,_not_only_including_hypoplastic_and_malformed_teeth,_and_mucosal_papillomatosis,_but_also_ankyloglossia,_hemihyperplastic_tongue,_intraoral_nevus,_giant_cell_granuloma,_ameloblastoma,_bone_cysts,_follicular_cysts,_oligodontia,_and_odontodysplasia._Sebaceous_nevi_follow_the_lines_of_Blaschko_and_these_can_continue_as_linear_intraoral_lesions,_as_in_mucosal_papillomatosis._{ECO:0000269|PubMed:22683711}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Widely_expressed._{ECO:0000269|PubMed:14500341}.\x3b_	ovary\x3bdevelopmental\x3bcolon\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3boptic_nerve\x3bwhole_body\x3boesophagus\x3bendometrium\x3bthyroid\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bhypothalamus\x3bblood\x3blens\x3bskeletal_muscle\x3blung\x3bplacenta\x3bvisual_apparatus\x3bhypopharynx\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bcerebellum\x3b	whole_brain\x3bmedulla_oblongata\x3btrigeminal_ganglion\x3b	0.99944	0.99980	-0.339715008	30.06605331	4.91473	0.18207	rs575789207	48910	Costello_syndrome|Rasopathy	MedGen:C0587248,OMIM:218040,Orphanet:ORPHA3071,SNOMED_CT:309776008|MedGen:CN166718,Orphanet:ORPHA98733	reviewed_by_expert_panel	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	6.465e-05	0	0	0	0.0012	0	0	0	6.904e-05	0	0	0	0.0010	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,617	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.025	VUS
11	533546	533546	G	A	exonic	HRAS	.	nonsynonymous_SNV	HRAS:NM_001318054:exon4:c.C38T:p.T13I	0.00794104930284198	0.785285637637198	0.20677331305996	Harvey_rat_sarcoma_viral_oncogene_homolog	FUNCTION:_Ras_proteins_bind_GDP/GTP_and_possess_intrinsic_GTPase_activity._{ECO:0000269|PubMed:12740440,_ECO:0000269|PubMed:14500341,_ECO:0000269|PubMed:9020151}.\x3b_	DISEASE:_Costello_syndrome_(CSTLO)_[MIM:218040]:_A_rare_condition_characterized_by_prenatally_increased_growth,_postnatal_growth_deficiency,_mental_retardation,_distinctive_facial_appearance,_cardiovascular_abnormalities_(typically_pulmonic_stenosis,_hypertrophic_cardiomyopathy_and/or_atrial_tachycardia),_tumor_predisposition,_skin_and_musculoskeletal_abnormalities._{ECO:0000269|PubMed:16170316,_ECO:0000269|PubMed:16329078,_ECO:0000269|PubMed:16443854,_ECO:0000269|PubMed:17054105,_ECO:0000269|PubMed:18039947,_ECO:0000269|PubMed:18247425,_ECO:0000269|PubMed:19995790}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Congenital_myopathy_with_excess_of_muscle_spindles_(CMEMS)_[MIM:218040]:_Variant_of_Costello_syndrome._{ECO:0000269|PubMed:17412879}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hurthle_cell_thyroid_carcinoma_(HCTC)_[MIM:607464]:_A_rare_type_of_thyroid_cancer_accounting_for_only_about_3-10%_of_all_differentiated_thyroid_cancers._These_neoplasms_are_considered_a_variant_of_follicular_carcinoma_of_the_thyroid_and_are_referred_to_as_follicular_carcinoma,_oxyphilic_type._{ECO:0000269|PubMed:12727991}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dMutations_which_change_positions_12,_13_or_61_activate_the_potential_of_HRAS_to_transform_cultured_cells_and_are_implicated_in_a_variety_of_human_tumors._{ECO:0000269|PubMed:3670300}.\x3b_DISEASE:_Bladder_cancer_(BLC)_[MIM:109800]:_A_malignancy_originating_in_tissues_of_the_urinary_bladder._It_often_presents_with_multiple_tumors_appearing_at_different_times_and_at_different_sites_in_the_bladder._Most_bladder_cancers_are_transitional_cell_carcinomas_that_begin_in_cells_that_normally_make_up_the_inner_lining_of_the_bladder._Other_types_of_bladder_cancer_include_squamous_cell_carcinoma_(cancer_that_begins_in_thin,_flat_cells)_and_adenocarcinoma_(cancer_that_begins_in_cells_that_make_and_release_mucus_and_other_fluids)._Bladder_cancer_is_a_complex_disorder_with_both_genetic_and_environmental_influences._{ECO:0000269|PubMed:6298635,_ECO:0000269|PubMed:6844927}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Schimmelpenning-Feuerstein-Mims_syndrome_(SFM)_[MIM:163200]:_A_disease_characterized_by_sebaceous_nevi,_often_on_the_face,_associated_with_variable_ipsilateral_abnormalities_of_the_central_nervous_system,_ocular_anomalies,_and_skeletal_defects._Many_oral_manifestations_have_been_reported,_not_only_including_hypoplastic_and_malformed_teeth,_and_mucosal_papillomatosis,_but_also_ankyloglossia,_hemihyperplastic_tongue,_intraoral_nevus,_giant_cell_granuloma,_ameloblastoma,_bone_cysts,_follicular_cysts,_oligodontia,_and_odontodysplasia._Sebaceous_nevi_follow_the_lines_of_Blaschko_and_these_can_continue_as_linear_intraoral_lesions,_as_in_mucosal_papillomatosis._{ECO:0000269|PubMed:22683711}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Widely_expressed._{ECO:0000269|PubMed:14500341}.\x3b_	ovary\x3bdevelopmental\x3bcolon\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3boptic_nerve\x3bwhole_body\x3boesophagus\x3bendometrium\x3bthyroid\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bhypothalamus\x3bblood\x3blens\x3bskeletal_muscle\x3blung\x3bplacenta\x3bvisual_apparatus\x3bhypopharynx\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bcerebellum\x3b	whole_brain\x3bmedulla_oblongata\x3btrigeminal_ganglion\x3b	0.99944	0.99980	-0.339715008	30.06605331	4.91473	0.18207	rs111352454	48911	Costello_syndrome|Rasopathy|not_specified	MedGen:C0587248,OMIM:218040,Orphanet:ORPHA3071,SNOMED_CT:309776008|MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374	reviewed_by_expert_panel	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0009	0.0007	0	0	0	0	0.0015	0.0010	0.0010	0.0005	0.0007	0.0012	0	0	0.0018	0.0011	9.746e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,615	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.025	VUS
12	112884118	112884118	A	G	exonic	PTPN11	.	nonsynonymous_SNV	PTPN11:NM_001330437:exon2:c.A53G:p.N18S,PTPN11:NM_002834:exon2:c.A53G:p.N18S,PTPN11:NM_080601:exon2:c.A53G:p.N18S	0.999877230878678	0.000122769057470549	6.38519788034449e-11	protein_tyrosine_phosphatase,_non-receptor_type_11	FUNCTION:_Acts_downstream_of_various_receptor_and_cytoplasmic_protein_tyrosine_kinases_to_participate_in_the_signal_transduction_from_the_cell_surface_to_the_nucleus._Dephosphorylates_ROCK2_at_Tyr-722_resulting_in_stimulatation_of_its_RhoA_binding_activity._{ECO:0000269|PubMed:10655584,_ECO:0000269|PubMed:18559669,_ECO:0000269|PubMed:18829466}.\x3b_	DISEASE:_LEOPARD_syndrome_1_(LPRD1)_[MIM:151100]:_A_disorder_characterized_by_lentigines,_electrocardiographic_conduction_abnormalities,_ocular_hypertelorism,_pulmonic_stenosis,_abnormalities_of_genitalia,_retardation_of_growth,_and_sensorineural_deafness._{ECO:0000269|PubMed:12058348,_ECO:0000269|PubMed:14961557,_ECO:0000269|PubMed:15121796,_ECO:0000269|PubMed:15389709,_ECO:0000269|PubMed:15520399,_ECO:0000269|PubMed:15690106,_ECO:0000269|PubMed:16679933,_ECO:0000269|PubMed:24891296}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Noonan_syndrome_1_(NS1)_[MIM:163950]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._Some_patients_with_NS1_develop_multiple_giant_cell_lesions_of_the_jaw_or_other_bony_or_soft_tissues,_which_are_classified_as_pigmented_villonodular_synovitis_(PVNS)_when_occurring_in_the_jaw_or_joints._{ECO:0000269|PubMed:11704759,_ECO:0000269|PubMed:11992261,_ECO:0000269|PubMed:12161469,_ECO:0000269|PubMed:12325025,_ECO:0000269|PubMed:12529711,_ECO:0000269|PubMed:12634870,_ECO:0000269|PubMed:12717436,_ECO:0000269|PubMed:12739139,_ECO:0000269|PubMed:12960218,_ECO:0000269|PubMed:15384080,_ECO:0000269|PubMed:15948193,_ECO:0000269|PubMed:19020799,_ECO:0000269|PubMed:24891296}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry._Mutations_in_PTPN11_account_for_more_than_50%_of_the_cases.\x3b_DISEASE:_Leukemia,_juvenile_myelomonocytic_(JMML)_[MIM:607785]:_An_aggressive_pediatric_myelodysplastic_syndrome/myeloproliferative_disorder_characterized_by_malignant_transformation_in_the_hematopoietic_stem_cell_compartment_with_proliferation_of_differentiated_progeny._Patients_have_splenomegaly,_enlarged_lymph_nodes,_rashes,_and_hemorrhages._{ECO:0000269|PubMed:12717436}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Metachondromatosis_(MC)_[MIM:156250]:_A_skeletal_disorder_with_radiologic_features_of_both_multiple_exostoses_and_Ollier_disease,_characterized_by_the_presence_of_exostoses,_commonly_of_the_bones_of_the_hands_and_feet,_and_enchondromas_of_the_metaphyses_of_long_bones_and_iliac_crest._{ECO:0000269|PubMed:20577567}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Widely_expressed,_with_highest_levels_in_heart,_brain,_and_skeletal_muscle._{ECO:0000269|PubMed:1280823,_ECO:0000269|PubMed:7681589,_ECO:0000269|PubMed:8216283}.\x3b_	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3bfrontal_lobe\x3bendometrium\x3boesophagus\x3blarynx\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bpineal_gland\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bpineal_body\x3burinary\x3badrenal_cortex\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3blung\x3bcornea\x3badrenal_gland\x3bplacenta\x3bvisual_apparatus\x3bhippocampus\x3bhypopharynx\x3bliver\x3bhead_and_neck\x3bcervix\x3bkidney\x3bmammary_gland\x3baorta\x3bstomach\x3b	amygdala\x3btestis_-_interstitial\x3bthalamus\x3bmedulla_oblongata\x3bsuperior_cervical_ganglion\x3boccipital_lobe\x3bhypothalamus\x3bspinal_cord\x3bcaudate_nucleus\x3bpons\x3bskeletal_muscle\x3bsubthalamic_nucleus\x3bprefrontal_cortex\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bparietal_lobe\x3b	0.26245	0.72890	-0.427900189	25.14744043	19.44641	0.66817	rs587778635	138851	Noonan_syndrome|Noonan_syndrome_with_multiple_lentigines|Metachondromatosis|Rasopathy|not_specified	MeSH:D009634,MedGen:C0028326,Orphanet:ORPHA648,SNOMED_CT:205824006|MedGen:C0175704,Orphanet:ORPHA500|MedGen:C0410530,OMIM:156250,Orphanet:ORPHA2499,SNOMED_CT:205481009|MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374	reviewed_by_expert_panel	Benign	0.195	0.208	T	0.000	0.843	D	1	0.810	D	-0.065	0.048	N	-2.33	0.879	D	-0.06	0.079	N	-0.510	0.683	T	0.354	0.718	T	0.016	0.373	T	0.437	0.491	0.991	0.905	D	c	-0.115	0.167	1.000	0.747	0.732	0.924	0	5.93	0.959	9.226	0.943	1.199	0.960	1.000	0.715	1.000	0.888	16.380	0.832	SH2_domain	.	.	.	.	.	.	.	.	.	.	.	.	9.341e-05	0	0	0	0	0	0	0.0002	0.0007	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,853	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.025	VUS
12	103246663	103246663	G	A	exonic	PAH	.	synonymous_SNV	PAH:NM_000277:exon7:c.C772T:p.L258L	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs75065106	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0027	0.0095	0.0012	0	0	0	6.662e-05	0	0.0006	0.0091	0.0004	0	0	0	0	0.0002	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,742	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.025	VUS
11	532729	532729	C	T	exonic	HRAS	.	synonymous_SNV	HRAS:NM_001130442:exon5:c.G477A:p.L159L,HRAS:NM_005343:exon5:c.G477A:p.L159L,HRAS:NM_001318054:exon6:c.G240A:p.L80L	0.00794104930284198	0.785285637637198	0.20677331305996	Harvey_rat_sarcoma_viral_oncogene_homolog	FUNCTION:_Ras_proteins_bind_GDP/GTP_and_possess_intrinsic_GTPase_activity._{ECO:0000269|PubMed:12740440,_ECO:0000269|PubMed:14500341,_ECO:0000269|PubMed:9020151}.\x3b_	DISEASE:_Costello_syndrome_(CSTLO)_[MIM:218040]:_A_rare_condition_characterized_by_prenatally_increased_growth,_postnatal_growth_deficiency,_mental_retardation,_distinctive_facial_appearance,_cardiovascular_abnormalities_(typically_pulmonic_stenosis,_hypertrophic_cardiomyopathy_and/or_atrial_tachycardia),_tumor_predisposition,_skin_and_musculoskeletal_abnormalities._{ECO:0000269|PubMed:16170316,_ECO:0000269|PubMed:16329078,_ECO:0000269|PubMed:16443854,_ECO:0000269|PubMed:17054105,_ECO:0000269|PubMed:18039947,_ECO:0000269|PubMed:18247425,_ECO:0000269|PubMed:19995790}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Congenital_myopathy_with_excess_of_muscle_spindles_(CMEMS)_[MIM:218040]:_Variant_of_Costello_syndrome._{ECO:0000269|PubMed:17412879}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hurthle_cell_thyroid_carcinoma_(HCTC)_[MIM:607464]:_A_rare_type_of_thyroid_cancer_accounting_for_only_about_3-10%_of_all_differentiated_thyroid_cancers._These_neoplasms_are_considered_a_variant_of_follicular_carcinoma_of_the_thyroid_and_are_referred_to_as_follicular_carcinoma,_oxyphilic_type._{ECO:0000269|PubMed:12727991}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dMutations_which_change_positions_12,_13_or_61_activate_the_potential_of_HRAS_to_transform_cultured_cells_and_are_implicated_in_a_variety_of_human_tumors._{ECO:0000269|PubMed:3670300}.\x3b_DISEASE:_Bladder_cancer_(BLC)_[MIM:109800]:_A_malignancy_originating_in_tissues_of_the_urinary_bladder._It_often_presents_with_multiple_tumors_appearing_at_different_times_and_at_different_sites_in_the_bladder._Most_bladder_cancers_are_transitional_cell_carcinomas_that_begin_in_cells_that_normally_make_up_the_inner_lining_of_the_bladder._Other_types_of_bladder_cancer_include_squamous_cell_carcinoma_(cancer_that_begins_in_thin,_flat_cells)_and_adenocarcinoma_(cancer_that_begins_in_cells_that_make_and_release_mucus_and_other_fluids)._Bladder_cancer_is_a_complex_disorder_with_both_genetic_and_environmental_influences._{ECO:0000269|PubMed:6298635,_ECO:0000269|PubMed:6844927}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Schimmelpenning-Feuerstein-Mims_syndrome_(SFM)_[MIM:163200]:_A_disease_characterized_by_sebaceous_nevi,_often_on_the_face,_associated_with_variable_ipsilateral_abnormalities_of_the_central_nervous_system,_ocular_anomalies,_and_skeletal_defects._Many_oral_manifestations_have_been_reported,_not_only_including_hypoplastic_and_malformed_teeth,_and_mucosal_papillomatosis,_but_also_ankyloglossia,_hemihyperplastic_tongue,_intraoral_nevus,_giant_cell_granuloma,_ameloblastoma,_bone_cysts,_follicular_cysts,_oligodontia,_and_odontodysplasia._Sebaceous_nevi_follow_the_lines_of_Blaschko_and_these_can_continue_as_linear_intraoral_lesions,_as_in_mucosal_papillomatosis._{ECO:0000269|PubMed:22683711}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Widely_expressed._{ECO:0000269|PubMed:14500341}.\x3b_	ovary\x3bdevelopmental\x3bcolon\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3boptic_nerve\x3bwhole_body\x3boesophagus\x3bendometrium\x3bthyroid\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bhypothalamus\x3bblood\x3blens\x3bskeletal_muscle\x3blung\x3bplacenta\x3bvisual_apparatus\x3bhypopharynx\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bcerebellum\x3b	whole_brain\x3bmedulla_oblongata\x3btrigeminal_ganglion\x3b	0.99944	0.99980	-0.339715008	30.06605331	4.91473	0.18207	rs140060409	48916	Costello_syndrome|Rasopathy|not_specified	MedGen:C0587248,OMIM:218040,Orphanet:ORPHA3071,SNOMED_CT:309776008|MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374	reviewed_by_expert_panel	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0018	0.0014	0	0.0033	0	0	0.0029	0	0.0015	0.0007	0.0021	0	0	0	0.0026	0.0020	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,612	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.025	VUS
10	89623167	89623167	C	G	UTR5	KLLN	NM_001126049:c.-923G>C	.	.	.	.	.	killin,_p53-regulated_DNA_replication_inhibitor	FUNCTION:_DNA-binding_protein_involved_in_S_phase_checkpoint_control-coupled_apoptosis_by_mediating_p53/TP53-induced_apoptosis._Has_the_ability_to_inhibit_DNA_synthesis_and_S_phase_arrest_coupled_to_apoptosis._Has_affinity_to_both_double-_and_single-_stranded_DNA._{ECO:0000269|PubMed:18385383}.\x3b_	DISEASE:_Cowden_syndrome_4_(CWS4)_[MIM:615107]:_A_form_of_Cowden_syndrome,_a_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:21177507}._Note\x3dThe_gene_represented_in_this_entry_is_involved_in_disease_pathogenesis._Germline_KLLN_methylation_is_common_among_patients_with_Cowden_syndrome_or_Cowden-like_syndrome_and_is_associated_with_increased_risks_of_breast_and_renal_cancer_over_PTEN_mutation-positive_individuals_(PubMed:21177507)._{ECO:0000269|PubMed:21177507}.\x3b_	.	.	.	.	.	1.012423333	90.829205	121.24747	2.39863	rs144620057	172162	not_specified|not_provided	MedGen:CN169374|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Benign/Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0040	0.0138	0	0	0	0	0.0002	0	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,503	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.025	VUS
11	533534	533534	G	A	exonic	HRAS	.	nonsynonymous_SNV	HRAS:NM_001318054:exon4:c.C50T:p.A17V	0.00794104930284198	0.785285637637198	0.20677331305996	Harvey_rat_sarcoma_viral_oncogene_homolog	FUNCTION:_Ras_proteins_bind_GDP/GTP_and_possess_intrinsic_GTPase_activity._{ECO:0000269|PubMed:12740440,_ECO:0000269|PubMed:14500341,_ECO:0000269|PubMed:9020151}.\x3b_	DISEASE:_Costello_syndrome_(CSTLO)_[MIM:218040]:_A_rare_condition_characterized_by_prenatally_increased_growth,_postnatal_growth_deficiency,_mental_retardation,_distinctive_facial_appearance,_cardiovascular_abnormalities_(typically_pulmonic_stenosis,_hypertrophic_cardiomyopathy_and/or_atrial_tachycardia),_tumor_predisposition,_skin_and_musculoskeletal_abnormalities._{ECO:0000269|PubMed:16170316,_ECO:0000269|PubMed:16329078,_ECO:0000269|PubMed:16443854,_ECO:0000269|PubMed:17054105,_ECO:0000269|PubMed:18039947,_ECO:0000269|PubMed:18247425,_ECO:0000269|PubMed:19995790}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Congenital_myopathy_with_excess_of_muscle_spindles_(CMEMS)_[MIM:218040]:_Variant_of_Costello_syndrome._{ECO:0000269|PubMed:17412879}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hurthle_cell_thyroid_carcinoma_(HCTC)_[MIM:607464]:_A_rare_type_of_thyroid_cancer_accounting_for_only_about_3-10%_of_all_differentiated_thyroid_cancers._These_neoplasms_are_considered_a_variant_of_follicular_carcinoma_of_the_thyroid_and_are_referred_to_as_follicular_carcinoma,_oxyphilic_type._{ECO:0000269|PubMed:12727991}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dMutations_which_change_positions_12,_13_or_61_activate_the_potential_of_HRAS_to_transform_cultured_cells_and_are_implicated_in_a_variety_of_human_tumors._{ECO:0000269|PubMed:3670300}.\x3b_DISEASE:_Bladder_cancer_(BLC)_[MIM:109800]:_A_malignancy_originating_in_tissues_of_the_urinary_bladder._It_often_presents_with_multiple_tumors_appearing_at_different_times_and_at_different_sites_in_the_bladder._Most_bladder_cancers_are_transitional_cell_carcinomas_that_begin_in_cells_that_normally_make_up_the_inner_lining_of_the_bladder._Other_types_of_bladder_cancer_include_squamous_cell_carcinoma_(cancer_that_begins_in_thin,_flat_cells)_and_adenocarcinoma_(cancer_that_begins_in_cells_that_make_and_release_mucus_and_other_fluids)._Bladder_cancer_is_a_complex_disorder_with_both_genetic_and_environmental_influences._{ECO:0000269|PubMed:6298635,_ECO:0000269|PubMed:6844927}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Schimmelpenning-Feuerstein-Mims_syndrome_(SFM)_[MIM:163200]:_A_disease_characterized_by_sebaceous_nevi,_often_on_the_face,_associated_with_variable_ipsilateral_abnormalities_of_the_central_nervous_system,_ocular_anomalies,_and_skeletal_defects._Many_oral_manifestations_have_been_reported,_not_only_including_hypoplastic_and_malformed_teeth,_and_mucosal_papillomatosis,_but_also_ankyloglossia,_hemihyperplastic_tongue,_intraoral_nevus,_giant_cell_granuloma,_ameloblastoma,_bone_cysts,_follicular_cysts,_oligodontia,_and_odontodysplasia._Sebaceous_nevi_follow_the_lines_of_Blaschko_and_these_can_continue_as_linear_intraoral_lesions,_as_in_mucosal_papillomatosis._{ECO:0000269|PubMed:22683711}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Widely_expressed._{ECO:0000269|PubMed:14500341}.\x3b_	ovary\x3bdevelopmental\x3bcolon\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3boptic_nerve\x3bwhole_body\x3boesophagus\x3bendometrium\x3bthyroid\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bhypothalamus\x3bblood\x3blens\x3bskeletal_muscle\x3blung\x3bplacenta\x3bvisual_apparatus\x3bhypopharynx\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bcerebellum\x3b	whole_brain\x3bmedulla_oblongata\x3btrigeminal_ganglion\x3b	0.99944	0.99980	-0.339715008	30.06605331	4.91473	0.18207	rs200945755	254209	Costello_syndrome|Rasopathy|not_specified|not_provided	MedGen:C0587248,OMIM:218040,Orphanet:ORPHA3071,SNOMED_CT:309776008|MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374|MedGen:CN517202	reviewed_by_expert_panel	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0002	0	0	0	0.0031	0	0	0	0.0001	0	0	0	0.0020	0	0	0	3.249e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,614	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.025	VUS
11	532686	532686	G	A	exonic	HRAS	.	nonsynonymous_SNV	HRAS:NM_001130442:exon5:c.C520T:p.P174S,HRAS:NM_005343:exon5:c.C520T:p.P174S,HRAS:NM_001318054:exon6:c.C283T:p.P95S	0.00794104930284198	0.785285637637198	0.20677331305996	Harvey_rat_sarcoma_viral_oncogene_homolog	FUNCTION:_Ras_proteins_bind_GDP/GTP_and_possess_intrinsic_GTPase_activity._{ECO:0000269|PubMed:12740440,_ECO:0000269|PubMed:14500341,_ECO:0000269|PubMed:9020151}.\x3b_	DISEASE:_Costello_syndrome_(CSTLO)_[MIM:218040]:_A_rare_condition_characterized_by_prenatally_increased_growth,_postnatal_growth_deficiency,_mental_retardation,_distinctive_facial_appearance,_cardiovascular_abnormalities_(typically_pulmonic_stenosis,_hypertrophic_cardiomyopathy_and/or_atrial_tachycardia),_tumor_predisposition,_skin_and_musculoskeletal_abnormalities._{ECO:0000269|PubMed:16170316,_ECO:0000269|PubMed:16329078,_ECO:0000269|PubMed:16443854,_ECO:0000269|PubMed:17054105,_ECO:0000269|PubMed:18039947,_ECO:0000269|PubMed:18247425,_ECO:0000269|PubMed:19995790}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Congenital_myopathy_with_excess_of_muscle_spindles_(CMEMS)_[MIM:218040]:_Variant_of_Costello_syndrome._{ECO:0000269|PubMed:17412879}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hurthle_cell_thyroid_carcinoma_(HCTC)_[MIM:607464]:_A_rare_type_of_thyroid_cancer_accounting_for_only_about_3-10%_of_all_differentiated_thyroid_cancers._These_neoplasms_are_considered_a_variant_of_follicular_carcinoma_of_the_thyroid_and_are_referred_to_as_follicular_carcinoma,_oxyphilic_type._{ECO:0000269|PubMed:12727991}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dMutations_which_change_positions_12,_13_or_61_activate_the_potential_of_HRAS_to_transform_cultured_cells_and_are_implicated_in_a_variety_of_human_tumors._{ECO:0000269|PubMed:3670300}.\x3b_DISEASE:_Bladder_cancer_(BLC)_[MIM:109800]:_A_malignancy_originating_in_tissues_of_the_urinary_bladder._It_often_presents_with_multiple_tumors_appearing_at_different_times_and_at_different_sites_in_the_bladder._Most_bladder_cancers_are_transitional_cell_carcinomas_that_begin_in_cells_that_normally_make_up_the_inner_lining_of_the_bladder._Other_types_of_bladder_cancer_include_squamous_cell_carcinoma_(cancer_that_begins_in_thin,_flat_cells)_and_adenocarcinoma_(cancer_that_begins_in_cells_that_make_and_release_mucus_and_other_fluids)._Bladder_cancer_is_a_complex_disorder_with_both_genetic_and_environmental_influences._{ECO:0000269|PubMed:6298635,_ECO:0000269|PubMed:6844927}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Schimmelpenning-Feuerstein-Mims_syndrome_(SFM)_[MIM:163200]:_A_disease_characterized_by_sebaceous_nevi,_often_on_the_face,_associated_with_variable_ipsilateral_abnormalities_of_the_central_nervous_system,_ocular_anomalies,_and_skeletal_defects._Many_oral_manifestations_have_been_reported,_not_only_including_hypoplastic_and_malformed_teeth,_and_mucosal_papillomatosis,_but_also_ankyloglossia,_hemihyperplastic_tongue,_intraoral_nevus,_giant_cell_granuloma,_ameloblastoma,_bone_cysts,_follicular_cysts,_oligodontia,_and_odontodysplasia._Sebaceous_nevi_follow_the_lines_of_Blaschko_and_these_can_continue_as_linear_intraoral_lesions,_as_in_mucosal_papillomatosis._{ECO:0000269|PubMed:22683711}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Widely_expressed._{ECO:0000269|PubMed:14500341}.\x3b_	ovary\x3bdevelopmental\x3bcolon\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3boptic_nerve\x3bwhole_body\x3boesophagus\x3bendometrium\x3bthyroid\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bhypothalamus\x3bblood\x3blens\x3bskeletal_muscle\x3blung\x3bplacenta\x3bvisual_apparatus\x3bhypopharynx\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bcerebellum\x3b	whole_brain\x3bmedulla_oblongata\x3btrigeminal_ganglion\x3b	0.99944	0.99980	-0.339715008	30.06605331	4.91473	0.18207	rs397517144	48918	Costello_syndrome|Rasopathy|not_specified	MedGen:C0587248,OMIM:218040,Orphanet:ORPHA3071,SNOMED_CT:309776008|MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374	reviewed_by_expert_panel	Benign	0.506	0.076	T	0.000	0.629	D	1.000	0.810	D	-0.315	0.036	N	-0.21	0.663	T	0.63	0.024	N	-1.017	0.248	T	0.132	0.445	T	0.051	0.646	D	0.25	0.188	0.980	0.789	D	c	-0.602	-0.506	1.000	0.747	0.722	0.854	0	2.98	0.334	4.658	0.610	1.045	0.669	1.000	0.715	0.521	0.274	11.928	0.519	.	.	.	.	.	3.233e-05	0	0.0012	0	0	0	0	0	0.0003	0	0.0018	0	0	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,609	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.025	VUS
10	89623251	89623251	G	C	UTR5	PTEN	NM_001304718:c.-88723G>C\x3bNM_001304717:c.-456G>C\x3bNM_000314:c.-976G>C	.	.	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs587780001	133142	Hereditary_cancer-predisposing_syndrome|not_specified|not_provided	MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN169374|MedGen:CN517202	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0018	0	0	0	0	0.0061	0.0020	0.0041	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,505	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0.0122	VUS
2	39224072	39224072	G	A	exonic	SOS1	.	synonymous_SNV	SOS1:NM_005633:exon19:c.C3072T:p.L1024L	0.99999989519361	1.04806389809942e-07	1.77231495230296e-20	SOS_Ras/Rac_guanine_nucleotide_exchange_factor_1	FUNCTION:_Promotes_the_exchange_of_Ras-bound_GDP_by_GTP._Catalytic_component_of_a_trimeric_complex_that_participates_in_transduction_of_signals_from_Ras_to_Rac_by_promoting_the_Rac-specific_guanine_nucleotide_exchange_factor_(GEF)_activity_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Noonan_syndrome_4_(NS4)_[MIM:610733]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._Some_patients_with_NS4_have_polyarticular_villonodular_synovitis._{ECO:0000269|PubMed:17143282,_ECO:0000269|PubMed:17143285,_ECO:0000269|PubMed:19020799,_ECO:0000269|PubMed:19438935,_ECO:0000269|PubMed:19953625,_ECO:0000269|PubMed:20673819,_ECO:0000269|PubMed:20683980,_ECO:0000269|PubMed:21387466}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_gingival_tissues._{ECO:0000269|PubMed:11868160}.\x3b_	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3blarynx\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bbile_duct\x3blung\x3bplacenta\x3bmacula_lutea\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3btestis\x3bciliary_ganglion\x3bpons\x3batrioventricular_node\x3bskeletal_muscle\x3b	0.72054	0.38414	-0.995664936	8.539749941	106.78667	2.24216	rs558386297	442514	Rasopathy|not_specified	MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374	reviewed_by_expert_panel	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0001	0	0	0	0	0	0	0	0.0011	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,463	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.0059	VUS
3	12626702	12626702	C	T	exonic	RAF1	.	synonymous_SNV	RAF1:NM_002880:exon15:c.G1587A:p.S529S	0.999776866110749	0.000223133833869176	5.53819998824154e-11	Raf-1_proto-oncogene,_serine/threonine_kinase	FUNCTION:_Serine/threonine-protein_kinase_that_acts_as_a_regulatory_link_between_the_membrane-associated_Ras_GTPases_and_the_MAPK/ERK_cascade,_and_this_critical_regulatory_link_functions_as_a_switch_determining_cell_fate_decisions_including_proliferation,_differentiation,_apoptosis,_survival_and_oncogenic_transformation._RAF1_activation_initiates_a_mitogen-activated_protein_kinase_(MAPK)_cascade_that_comprises_a_sequential_phosphorylation_of_the_dual-specific_MAPK_kinases_(MAP2K1/MEK1_and_MAP2K2/MEK2)_and_the_extracellular_signal-regulated_kinases_(MAPK3/ERK1_and_MAPK1/ERK2)._The_phosphorylated_form_of_RAF1_(on_residues_Ser-338_and_Ser-339,_by_PAK1)_phosphorylates_BAD/Bcl2-_antagonist_of_cell_death_at_'Ser-75'._Phosphorylates_adenylyl_cyclases:_ADCY2,_ADCY5_and_ADCY6,_resulting_in_their_activation._Phosphorylates_PPP1R12A_resulting_in_inhibition_of_the_phosphatase_activity._Phosphorylates_TNNT2/cardiac_muscle_troponin_T._Can_promote_NF-kB_activation_and_inhibit_signal_transducers_involved_in_motility_(ROCK2),_apoptosis_(MAP3K5/ASK1_and_STK3/MST2),_proliferation_and_angiogenesis_(RB1)._Can_protect_cells_from_apoptosis_also_by_translocating_to_the_mitochondria_where_it_binds_BCL2_and_displaces_BAD/Bcl2-antagonist_of_cell_death._Regulates_Rho_signaling_and_migration,_and_is_required_for_normal_wound_healing._Plays_a_role_in_the_oncogenic_transformation_of_epithelial_cells_via_repression_of_the_TJ_protein,_occludin_(OCLN)_by_inducing_the_up-regulation_of_a_transcriptional_repressor_SNAI2/SLUG,_which_induces_down-regulation_of_OCLN._Restricts_caspase_activation_in_response_to_selected_stimuli,_notably_Fas_stimulation,_pathogen-mediated_macrophage_apoptosis,_and_erythroid_differentiation._{ECO:0000269|PubMed:11427728,_ECO:0000269|PubMed:11719507,_ECO:0000269|PubMed:15385642,_ECO:0000269|PubMed:15618521,_ECO:0000269|PubMed:15849194,_ECO:0000269|PubMed:16892053,_ECO:0000269|PubMed:16924233,_ECO:0000269|PubMed:9360956}.\x3b_	DISEASE:_Noonan_syndrome_5_(NS5)_[MIM:611553]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._{ECO:0000269|PubMed:17603482,_ECO:0000269|PubMed:17603483,_ECO:0000269|PubMed:20683980}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_LEOPARD_syndrome_2_(LPRD2)_[MIM:611554]:_A_disorder_characterized_by_lentigines,_electrocardiographic_conduction_abnormalities,_ocular_hypertelorism,_pulmonic_stenosis,_abnormalities_of_genitalia,_retardation_of_growth,_and_sensorineural_deafness._{ECO:0000269|PubMed:17603483}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Cardiomyopathy,_dilated_1NN_(CMD1NN)_[MIM:615916]:_A_disorder_characterized_by_ventricular_dilation_and_impaired_systolic_function,_resulting_in_congestive_heart_failure_and_arrhythmia._Patients_are_at_risk_of_premature_death._{ECO:0000269|PubMed:24777450}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_In_skeletal_muscle,_isoform_1_is_more_abundant_than_isoform_2._{ECO:0000269|PubMed:1886707}.\x3b_	ovary\x3bumbilical_cord\x3bsympathetic_chain\x3bskin\x3bretina\x3bbone_marrow\x3bprostate\x3boptic_nerve\x3bfrontal_lobe\x3bcochlea\x3bendometrium\x3bgerminal_center\x3bbladder\x3bbrain\x3bheart\x3bcartilage\x3bspinal_cord\x3badrenal_cortex\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bmacula_lutea\x3bvisual_apparatus\x3bliver\x3balveolus\x3bspleen\x3bcervix\x3bmammary_gland\x3bperipheral_nerve\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3buterus\x3bwhole_body\x3boesophagus\x3bbone\x3btestis\x3bspinal_ganglion\x3bpineal_gland\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bislets_of_Langerhans\x3bhypothalamus\x3bmuscle\x3bpancreas\x3blung\x3btrachea\x3bplacenta\x3bamnion\x3bkidney\x3bstomach\x3baorta\x3bthymus\x3b	superior_cervical_ganglion\x3bciliary_ganglion\x3bwhole_blood\x3bskeletal_muscle\x3b	0.99869	0.93060	-0.646543901	16.44255721	87.82499	2.00185	rs114687276	49090	Rasopathy	MedGen:CN166718,Orphanet:ORPHA98733	reviewed_by_expert_panel	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0002	0.0006	0	0	0	0	0	0	7.311e-05	0.0008	0	0	5.798e-05	0	0	0	0.0001	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,476	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.0059	VUS
2	39213415	39213415	A	C	exonic	SOS1	.	synonymous_SNV	SOS1:NM_005633:exon23:c.T3552G:p.P1184P	0.99999989519361	1.04806389809942e-07	1.77231495230296e-20	SOS_Ras/Rac_guanine_nucleotide_exchange_factor_1	FUNCTION:_Promotes_the_exchange_of_Ras-bound_GDP_by_GTP._Catalytic_component_of_a_trimeric_complex_that_participates_in_transduction_of_signals_from_Ras_to_Rac_by_promoting_the_Rac-specific_guanine_nucleotide_exchange_factor_(GEF)_activity_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Noonan_syndrome_4_(NS4)_[MIM:610733]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._Some_patients_with_NS4_have_polyarticular_villonodular_synovitis._{ECO:0000269|PubMed:17143282,_ECO:0000269|PubMed:17143285,_ECO:0000269|PubMed:19020799,_ECO:0000269|PubMed:19438935,_ECO:0000269|PubMed:19953625,_ECO:0000269|PubMed:20673819,_ECO:0000269|PubMed:20683980,_ECO:0000269|PubMed:21387466}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_gingival_tissues._{ECO:0000269|PubMed:11868160}.\x3b_	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3blarynx\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bbile_duct\x3blung\x3bplacenta\x3bmacula_lutea\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3btestis\x3bciliary_ganglion\x3bpons\x3batrioventricular_node\x3bskeletal_muscle\x3b	0.72054	0.38414	-0.995664936	8.539749941	106.78667	2.24216	rs200485215	442512	Rasopathy	MedGen:CN166718,Orphanet:ORPHA98733	reviewed_by_expert_panel	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3.234e-05	0	0	0	0.0006	0	0	0	0.0001	0	2.984e-05	0	0.0016	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,461	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.0059	VUS
2	39294841	39294841	A	G	exonic	SOS1	.	synonymous_SNV	SOS1:NM_005633:exon2:c.T141C:p.Y47Y	0.99999989519361	1.04806389809942e-07	1.77231495230296e-20	SOS_Ras/Rac_guanine_nucleotide_exchange_factor_1	FUNCTION:_Promotes_the_exchange_of_Ras-bound_GDP_by_GTP._Catalytic_component_of_a_trimeric_complex_that_participates_in_transduction_of_signals_from_Ras_to_Rac_by_promoting_the_Rac-specific_guanine_nucleotide_exchange_factor_(GEF)_activity_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Noonan_syndrome_4_(NS4)_[MIM:610733]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._Some_patients_with_NS4_have_polyarticular_villonodular_synovitis._{ECO:0000269|PubMed:17143282,_ECO:0000269|PubMed:17143285,_ECO:0000269|PubMed:19020799,_ECO:0000269|PubMed:19438935,_ECO:0000269|PubMed:19953625,_ECO:0000269|PubMed:20673819,_ECO:0000269|PubMed:20683980,_ECO:0000269|PubMed:21387466}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_gingival_tissues._{ECO:0000269|PubMed:11868160}.\x3b_	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3blarynx\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bbile_duct\x3blung\x3bplacenta\x3bmacula_lutea\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3btestis\x3bciliary_ganglion\x3bpons\x3batrioventricular_node\x3bskeletal_muscle\x3b	0.72054	0.38414	-0.995664936	8.539749941	106.78667	2.24216	rs201649682	442520	Rasopathy	MedGen:CN166718,Orphanet:ORPHA98733	reviewed_by_expert_panel	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9.683e-05	0	0	0	0.0018	0	0	0	0.0001	0	0	0	0.0017	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,473	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.0059	VUS
3	12626660	12626660	C	G	exonic	RAF1	.	synonymous_SNV	RAF1:NM_002880:exon15:c.G1629C:p.T543T	0.999776866110749	0.000223133833869176	5.53819998824154e-11	Raf-1_proto-oncogene,_serine/threonine_kinase	FUNCTION:_Serine/threonine-protein_kinase_that_acts_as_a_regulatory_link_between_the_membrane-associated_Ras_GTPases_and_the_MAPK/ERK_cascade,_and_this_critical_regulatory_link_functions_as_a_switch_determining_cell_fate_decisions_including_proliferation,_differentiation,_apoptosis,_survival_and_oncogenic_transformation._RAF1_activation_initiates_a_mitogen-activated_protein_kinase_(MAPK)_cascade_that_comprises_a_sequential_phosphorylation_of_the_dual-specific_MAPK_kinases_(MAP2K1/MEK1_and_MAP2K2/MEK2)_and_the_extracellular_signal-regulated_kinases_(MAPK3/ERK1_and_MAPK1/ERK2)._The_phosphorylated_form_of_RAF1_(on_residues_Ser-338_and_Ser-339,_by_PAK1)_phosphorylates_BAD/Bcl2-_antagonist_of_cell_death_at_'Ser-75'._Phosphorylates_adenylyl_cyclases:_ADCY2,_ADCY5_and_ADCY6,_resulting_in_their_activation._Phosphorylates_PPP1R12A_resulting_in_inhibition_of_the_phosphatase_activity._Phosphorylates_TNNT2/cardiac_muscle_troponin_T._Can_promote_NF-kB_activation_and_inhibit_signal_transducers_involved_in_motility_(ROCK2),_apoptosis_(MAP3K5/ASK1_and_STK3/MST2),_proliferation_and_angiogenesis_(RB1)._Can_protect_cells_from_apoptosis_also_by_translocating_to_the_mitochondria_where_it_binds_BCL2_and_displaces_BAD/Bcl2-antagonist_of_cell_death._Regulates_Rho_signaling_and_migration,_and_is_required_for_normal_wound_healing._Plays_a_role_in_the_oncogenic_transformation_of_epithelial_cells_via_repression_of_the_TJ_protein,_occludin_(OCLN)_by_inducing_the_up-regulation_of_a_transcriptional_repressor_SNAI2/SLUG,_which_induces_down-regulation_of_OCLN._Restricts_caspase_activation_in_response_to_selected_stimuli,_notably_Fas_stimulation,_pathogen-mediated_macrophage_apoptosis,_and_erythroid_differentiation._{ECO:0000269|PubMed:11427728,_ECO:0000269|PubMed:11719507,_ECO:0000269|PubMed:15385642,_ECO:0000269|PubMed:15618521,_ECO:0000269|PubMed:15849194,_ECO:0000269|PubMed:16892053,_ECO:0000269|PubMed:16924233,_ECO:0000269|PubMed:9360956}.\x3b_	DISEASE:_Noonan_syndrome_5_(NS5)_[MIM:611553]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._{ECO:0000269|PubMed:17603482,_ECO:0000269|PubMed:17603483,_ECO:0000269|PubMed:20683980}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_LEOPARD_syndrome_2_(LPRD2)_[MIM:611554]:_A_disorder_characterized_by_lentigines,_electrocardiographic_conduction_abnormalities,_ocular_hypertelorism,_pulmonic_stenosis,_abnormalities_of_genitalia,_retardation_of_growth,_and_sensorineural_deafness._{ECO:0000269|PubMed:17603483}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Cardiomyopathy,_dilated_1NN_(CMD1NN)_[MIM:615916]:_A_disorder_characterized_by_ventricular_dilation_and_impaired_systolic_function,_resulting_in_congestive_heart_failure_and_arrhythmia._Patients_are_at_risk_of_premature_death._{ECO:0000269|PubMed:24777450}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_In_skeletal_muscle,_isoform_1_is_more_abundant_than_isoform_2._{ECO:0000269|PubMed:1886707}.\x3b_	ovary\x3bumbilical_cord\x3bsympathetic_chain\x3bskin\x3bretina\x3bbone_marrow\x3bprostate\x3boptic_nerve\x3bfrontal_lobe\x3bcochlea\x3bendometrium\x3bgerminal_center\x3bbladder\x3bbrain\x3bheart\x3bcartilage\x3bspinal_cord\x3badrenal_cortex\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bmacula_lutea\x3bvisual_apparatus\x3bliver\x3balveolus\x3bspleen\x3bcervix\x3bmammary_gland\x3bperipheral_nerve\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3buterus\x3bwhole_body\x3boesophagus\x3bbone\x3btestis\x3bspinal_ganglion\x3bpineal_gland\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bislets_of_Langerhans\x3bhypothalamus\x3bmuscle\x3bpancreas\x3blung\x3btrachea\x3bplacenta\x3bamnion\x3bkidney\x3bstomach\x3baorta\x3bthymus\x3b	superior_cervical_ganglion\x3bciliary_ganglion\x3bwhole_blood\x3bskeletal_muscle\x3b	0.99869	0.93060	-0.646543901	16.44255721	87.82499	2.00185	rs5746244	49091	Rasopathy|not_provided	MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN517202	reviewed_by_expert_panel	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	8.938e-05	0	2.978e-05	0	0.0009	0	8.961e-06	0.0002	0.0001	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,474	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.0059	VUS
3	12626660	12626660	C	T	exonic	RAF1	.	synonymous_SNV	RAF1:NM_002880:exon15:c.G1629A:p.T543T	0.999776866110749	0.000223133833869176	5.53819998824154e-11	Raf-1_proto-oncogene,_serine/threonine_kinase	FUNCTION:_Serine/threonine-protein_kinase_that_acts_as_a_regulatory_link_between_the_membrane-associated_Ras_GTPases_and_the_MAPK/ERK_cascade,_and_this_critical_regulatory_link_functions_as_a_switch_determining_cell_fate_decisions_including_proliferation,_differentiation,_apoptosis,_survival_and_oncogenic_transformation._RAF1_activation_initiates_a_mitogen-activated_protein_kinase_(MAPK)_cascade_that_comprises_a_sequential_phosphorylation_of_the_dual-specific_MAPK_kinases_(MAP2K1/MEK1_and_MAP2K2/MEK2)_and_the_extracellular_signal-regulated_kinases_(MAPK3/ERK1_and_MAPK1/ERK2)._The_phosphorylated_form_of_RAF1_(on_residues_Ser-338_and_Ser-339,_by_PAK1)_phosphorylates_BAD/Bcl2-_antagonist_of_cell_death_at_'Ser-75'._Phosphorylates_adenylyl_cyclases:_ADCY2,_ADCY5_and_ADCY6,_resulting_in_their_activation._Phosphorylates_PPP1R12A_resulting_in_inhibition_of_the_phosphatase_activity._Phosphorylates_TNNT2/cardiac_muscle_troponin_T._Can_promote_NF-kB_activation_and_inhibit_signal_transducers_involved_in_motility_(ROCK2),_apoptosis_(MAP3K5/ASK1_and_STK3/MST2),_proliferation_and_angiogenesis_(RB1)._Can_protect_cells_from_apoptosis_also_by_translocating_to_the_mitochondria_where_it_binds_BCL2_and_displaces_BAD/Bcl2-antagonist_of_cell_death._Regulates_Rho_signaling_and_migration,_and_is_required_for_normal_wound_healing._Plays_a_role_in_the_oncogenic_transformation_of_epithelial_cells_via_repression_of_the_TJ_protein,_occludin_(OCLN)_by_inducing_the_up-regulation_of_a_transcriptional_repressor_SNAI2/SLUG,_which_induces_down-regulation_of_OCLN._Restricts_caspase_activation_in_response_to_selected_stimuli,_notably_Fas_stimulation,_pathogen-mediated_macrophage_apoptosis,_and_erythroid_differentiation._{ECO:0000269|PubMed:11427728,_ECO:0000269|PubMed:11719507,_ECO:0000269|PubMed:15385642,_ECO:0000269|PubMed:15618521,_ECO:0000269|PubMed:15849194,_ECO:0000269|PubMed:16892053,_ECO:0000269|PubMed:16924233,_ECO:0000269|PubMed:9360956}.\x3b_	DISEASE:_Noonan_syndrome_5_(NS5)_[MIM:611553]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._{ECO:0000269|PubMed:17603482,_ECO:0000269|PubMed:17603483,_ECO:0000269|PubMed:20683980}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_LEOPARD_syndrome_2_(LPRD2)_[MIM:611554]:_A_disorder_characterized_by_lentigines,_electrocardiographic_conduction_abnormalities,_ocular_hypertelorism,_pulmonic_stenosis,_abnormalities_of_genitalia,_retardation_of_growth,_and_sensorineural_deafness._{ECO:0000269|PubMed:17603483}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Cardiomyopathy,_dilated_1NN_(CMD1NN)_[MIM:615916]:_A_disorder_characterized_by_ventricular_dilation_and_impaired_systolic_function,_resulting_in_congestive_heart_failure_and_arrhythmia._Patients_are_at_risk_of_premature_death._{ECO:0000269|PubMed:24777450}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_In_skeletal_muscle,_isoform_1_is_more_abundant_than_isoform_2._{ECO:0000269|PubMed:1886707}.\x3b_	ovary\x3bumbilical_cord\x3bsympathetic_chain\x3bskin\x3bretina\x3bbone_marrow\x3bprostate\x3boptic_nerve\x3bfrontal_lobe\x3bcochlea\x3bendometrium\x3bgerminal_center\x3bbladder\x3bbrain\x3bheart\x3bcartilage\x3bspinal_cord\x3badrenal_cortex\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bmacula_lutea\x3bvisual_apparatus\x3bliver\x3balveolus\x3bspleen\x3bcervix\x3bmammary_gland\x3bperipheral_nerve\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3buterus\x3bwhole_body\x3boesophagus\x3bbone\x3btestis\x3bspinal_ganglion\x3bpineal_gland\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bislets_of_Langerhans\x3bhypothalamus\x3bmuscle\x3bpancreas\x3blung\x3btrachea\x3bplacenta\x3bamnion\x3bkidney\x3bstomach\x3baorta\x3bthymus\x3b	superior_cervical_ganglion\x3bciliary_ganglion\x3bwhole_blood\x3bskeletal_muscle\x3b	0.99869	0.93060	-0.646543901	16.44255721	87.82499	2.00185	rs5746244	442521	Rasopathy	MedGen:CN166718,Orphanet:ORPHA98733	reviewed_by_expert_panel	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0002	0	0	0	0	0	0	0	0.0012	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,475	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.0059	VUS
2	39249799	39249799	C	T	exonic	SOS1	.	synonymous_SNV	SOS1:NM_005633:exon10:c.G1770A:p.E590E	0.99999989519361	1.04806389809942e-07	1.77231495230296e-20	SOS_Ras/Rac_guanine_nucleotide_exchange_factor_1	FUNCTION:_Promotes_the_exchange_of_Ras-bound_GDP_by_GTP._Catalytic_component_of_a_trimeric_complex_that_participates_in_transduction_of_signals_from_Ras_to_Rac_by_promoting_the_Rac-specific_guanine_nucleotide_exchange_factor_(GEF)_activity_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Noonan_syndrome_4_(NS4)_[MIM:610733]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._Some_patients_with_NS4_have_polyarticular_villonodular_synovitis._{ECO:0000269|PubMed:17143282,_ECO:0000269|PubMed:17143285,_ECO:0000269|PubMed:19020799,_ECO:0000269|PubMed:19438935,_ECO:0000269|PubMed:19953625,_ECO:0000269|PubMed:20673819,_ECO:0000269|PubMed:20683980,_ECO:0000269|PubMed:21387466}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_gingival_tissues._{ECO:0000269|PubMed:11868160}.\x3b_	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3blarynx\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bbile_duct\x3blung\x3bplacenta\x3bmacula_lutea\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3btestis\x3bciliary_ganglion\x3bpons\x3batrioventricular_node\x3bskeletal_muscle\x3b	0.72054	0.38414	-0.995664936	8.539749941	106.78667	2.24216	rs553331572	49157	Rasopathy|not_provided	MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN517202	reviewed_by_expert_panel	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0002	0	0	0	0.0043	0	0	0	0.0003	0	0	0	0.0038	0	0	0.0002	9.75e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,466	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.0059	VUS
10	112760217	112760217	C	T	exonic	SHOC2	.	synonymous_SNV	SHOC2:NM_001269039:exon3:c.C748T:p.L250L,SHOC2:NM_001324336:exon4:c.C886T:p.L296L,SHOC2:NM_007373:exon4:c.C886T:p.L296L,SHOC2:NM_001324337:exon5:c.C886T:p.L296L	0.991705191552454	0.00829295945769003	1.84898985615785e-06	SHOC2_leucine-rich_repeat_scaffold_protein	FUNCTION:_Regulatory_subunit_of_protein_phosphatase_1_(PP1c)_that_acts_as_a_M-Ras/MRAS_effector_and_participates_in_MAPK_pathway_activation._Upon_M-Ras/MRAS_activation,_targets_PP1c_to_specifically_dephosphorylate_the_'Ser-259'_inhibitory_site_of_RAF1_kinase_and_stimulate_RAF1_activity_at_specialized_signaling_complexes._{ECO:0000269|PubMed:10783161,_ECO:0000269|PubMed:16630891,_ECO:0000269|PubMed:25137548}.\x3b_	DISEASE:_Noonan_syndrome-like_disorder_with_loose_anagen_hair_(NSLH)_[MIM:607721]:_A_syndrome_characterized_by_Noonan_dysmorphic_features_such_as_macrocephaly,_high_forehead,_hypertelorism,_palpebral_ptosis,_low-set_and_posteriorly_rotated_ears,_short_and_webbed_neck,_pectus_anomalies,_in_association_with_pluckable,_sparse,_thin_and_slow-growing_hair._{ECO:0000269|PubMed:19684605,_ECO:0000269|PubMed:25137548}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bpineal_body\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bcornea\x3bnasopharynx\x3bplacenta\x3bmacula_lutea\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bcervix\x3bkidney\x3bmammary_gland\x3bstomach\x3b	superior_cervical_ganglion\x3btestis_-_seminiferous_tubule\x3bprefrontal_cortex\x3btestis\x3btrigeminal_ganglion\x3b	0.46401	0.24608	-0.183570861	39.95046001	30.58108	0.97282	rs199723694	442531	Rasopathy	MedGen:CN166718,Orphanet:ORPHA98733	reviewed_by_expert_panel	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0001	0	0.0008	0	0	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,605	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.0059	VUS
19	4101032	4101032	C	T	exonic	MAP2K2	.	synonymous_SNV	MAP2K2:NM_030662:exon6:c.G690A:p.T230T	0.86326115931858	0.136320885012997	0.00041795566842237	mitogen-activated_protein_kinase_kinase_2	FUNCTION:_Catalyzes_the_concomitant_phosphorylation_of_a_threonine_and_a_tyrosine_residue_in_a_Thr-Glu-Tyr_sequence_located_in_MAP_kinases._Activates_the_ERK1_and_ERK2_MAP_kinases_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Cardiofaciocutaneous_syndrome_4_(CFC4)_[MIM:615280]:_A_form_of_cardiofaciocutaneous_syndrome,_a_multiple_congenital_anomaly_disorder_characterized_by_a_distinctive_facial_appearance,_heart_defects_and_mental_retardation._Heart_defects_include_pulmonic_stenosis,_atrial_septal_defects_and_hypertrophic_cardiomyopathy._Some_affected_individuals_present_with_ectodermal_abnormalities_such_as_sparse,_friable_hair,_hyperkeratotic_skin_lesions_and_a_generalized_ichthyosis-like_condition._Typical_facial_features_are_similar_to_Noonan_syndrome._They_include_high_forehead_with_bitemporal_constriction,_hypoplastic_supraorbital_ridges,_downslanting_palpebral_fissures,_a_depressed_nasal_bridge,_and_posteriorly_angulated_ears_with_prominent_helices._{ECO:0000269|PubMed:16439621,_ECO:0000269|PubMed:18042262,_ECO:0000269|PubMed:20358587}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	medulla_oblongata\x3bsmooth_muscle\x3bovary\x3bsalivary_gland\x3bsympathetic_chain\x3bcolon\x3bparathyroid\x3bskin\x3buterus\x3bprostate\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bmuscle\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbile_duct\x3bpancreas\x3blung\x3badrenal_gland\x3bplacenta\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	amygdala\x3bprefrontal_cortex\x3btestis\x3bpons\x3bcingulate_cortex\x3b	0.88489	0.51187	-0.800872469	12.33191791	40.94266	1.19949	rs201287884	141862	Rasopathy|not_specified|not_provided	MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3.241e-05	0	0	0	0	0	6.691e-05	0	0.0003	0.0001	0.0018	0	8.55e-05	0	8.527e-05	0	8.269e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,932	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0.0059	VUS
3	12641168	12641181	AAAGGGAGGGCCCC	A	intronic	RAF1	.	.	.	0.999776866110749	0.000223133833869176	5.53819998824154e-11	Raf-1_proto-oncogene,_serine/threonine_kinase	FUNCTION:_Serine/threonine-protein_kinase_that_acts_as_a_regulatory_link_between_the_membrane-associated_Ras_GTPases_and_the_MAPK/ERK_cascade,_and_this_critical_regulatory_link_functions_as_a_switch_determining_cell_fate_decisions_including_proliferation,_differentiation,_apoptosis,_survival_and_oncogenic_transformation._RAF1_activation_initiates_a_mitogen-activated_protein_kinase_(MAPK)_cascade_that_comprises_a_sequential_phosphorylation_of_the_dual-specific_MAPK_kinases_(MAP2K1/MEK1_and_MAP2K2/MEK2)_and_the_extracellular_signal-regulated_kinases_(MAPK3/ERK1_and_MAPK1/ERK2)._The_phosphorylated_form_of_RAF1_(on_residues_Ser-338_and_Ser-339,_by_PAK1)_phosphorylates_BAD/Bcl2-_antagonist_of_cell_death_at_'Ser-75'._Phosphorylates_adenylyl_cyclases:_ADCY2,_ADCY5_and_ADCY6,_resulting_in_their_activation._Phosphorylates_PPP1R12A_resulting_in_inhibition_of_the_phosphatase_activity._Phosphorylates_TNNT2/cardiac_muscle_troponin_T._Can_promote_NF-kB_activation_and_inhibit_signal_transducers_involved_in_motility_(ROCK2),_apoptosis_(MAP3K5/ASK1_and_STK3/MST2),_proliferation_and_angiogenesis_(RB1)._Can_protect_cells_from_apoptosis_also_by_translocating_to_the_mitochondria_where_it_binds_BCL2_and_displaces_BAD/Bcl2-antagonist_of_cell_death._Regulates_Rho_signaling_and_migration,_and_is_required_for_normal_wound_healing._Plays_a_role_in_the_oncogenic_transformation_of_epithelial_cells_via_repression_of_the_TJ_protein,_occludin_(OCLN)_by_inducing_the_up-regulation_of_a_transcriptional_repressor_SNAI2/SLUG,_which_induces_down-regulation_of_OCLN._Restricts_caspase_activation_in_response_to_selected_stimuli,_notably_Fas_stimulation,_pathogen-mediated_macrophage_apoptosis,_and_erythroid_differentiation._{ECO:0000269|PubMed:11427728,_ECO:0000269|PubMed:11719507,_ECO:0000269|PubMed:15385642,_ECO:0000269|PubMed:15618521,_ECO:0000269|PubMed:15849194,_ECO:0000269|PubMed:16892053,_ECO:0000269|PubMed:16924233,_ECO:0000269|PubMed:9360956}.\x3b_	DISEASE:_Noonan_syndrome_5_(NS5)_[MIM:611553]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._{ECO:0000269|PubMed:17603482,_ECO:0000269|PubMed:17603483,_ECO:0000269|PubMed:20683980}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_LEOPARD_syndrome_2_(LPRD2)_[MIM:611554]:_A_disorder_characterized_by_lentigines,_electrocardiographic_conduction_abnormalities,_ocular_hypertelorism,_pulmonic_stenosis,_abnormalities_of_genitalia,_retardation_of_growth,_and_sensorineural_deafness._{ECO:0000269|PubMed:17603483}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Cardiomyopathy,_dilated_1NN_(CMD1NN)_[MIM:615916]:_A_disorder_characterized_by_ventricular_dilation_and_impaired_systolic_function,_resulting_in_congestive_heart_failure_and_arrhythmia._Patients_are_at_risk_of_premature_death._{ECO:0000269|PubMed:24777450}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_In_skeletal_muscle,_isoform_1_is_more_abundant_than_isoform_2._{ECO:0000269|PubMed:1886707}.\x3b_	ovary\x3bumbilical_cord\x3bsympathetic_chain\x3bskin\x3bretina\x3bbone_marrow\x3bprostate\x3boptic_nerve\x3bfrontal_lobe\x3bcochlea\x3bendometrium\x3bgerminal_center\x3bbladder\x3bbrain\x3bheart\x3bcartilage\x3bspinal_cord\x3badrenal_cortex\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bmacula_lutea\x3bvisual_apparatus\x3bliver\x3balveolus\x3bspleen\x3bcervix\x3bmammary_gland\x3bperipheral_nerve\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3buterus\x3bwhole_body\x3boesophagus\x3bbone\x3btestis\x3bspinal_ganglion\x3bpineal_gland\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bislets_of_Langerhans\x3bhypothalamus\x3bmuscle\x3bpancreas\x3blung\x3btrachea\x3bplacenta\x3bamnion\x3bkidney\x3bstomach\x3baorta\x3bthymus\x3b	superior_cervical_ganglion\x3bciliary_ganglion\x3bwhole_blood\x3bskeletal_muscle\x3b	0.99869	0.93060	-0.646543901	16.44255721	87.82499	2.00185	rs727504451	173884	Rasopathy|not_specified|not_provided	MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374|MedGen:CN517202	reviewed_by_expert_panel	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0003	0.0001	0.0012	0	0	0	0.0005	0	0.0004	0.0002	8.934e-05	0	0	0	0.0007	0.0002	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,479	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.0059	VUS
10	89725121	89725121	T	C	exonic	PTEN	.	synonymous_SNV	PTEN:NM_000314:exon9:c.T1104C:p.D368D,PTEN:NM_001304718:exon9:c.T513C:p.D171D,PTEN:NM_001304717:exon10:c.T1623C:p.D541D	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs35979531	142538	Hereditary_cancer-predisposing_syndrome|PTEN_hamartoma_tumor_syndrome|not_specified	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498|MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Benign/Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0015	0.0054	0	0	0	0	0	0	0.0004	0.0058	0.0004	0	0	0	1.916e-05	0.0004	0.0002	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,596	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.0059	VUS
12	112915678	112915678	G	A	exonic	PTPN11	.	synonymous_SNV	PTPN11:NM_001330437:exon9:c.G951A:p.K317K,PTPN11:NM_002834:exon9:c.G951A:p.K317K,PTPN11:NM_080601:exon9:c.G951A:p.K317K	0.999877230878678	0.000122769057470549	6.38519788034449e-11	protein_tyrosine_phosphatase,_non-receptor_type_11	FUNCTION:_Acts_downstream_of_various_receptor_and_cytoplasmic_protein_tyrosine_kinases_to_participate_in_the_signal_transduction_from_the_cell_surface_to_the_nucleus._Dephosphorylates_ROCK2_at_Tyr-722_resulting_in_stimulatation_of_its_RhoA_binding_activity._{ECO:0000269|PubMed:10655584,_ECO:0000269|PubMed:18559669,_ECO:0000269|PubMed:18829466}.\x3b_	DISEASE:_LEOPARD_syndrome_1_(LPRD1)_[MIM:151100]:_A_disorder_characterized_by_lentigines,_electrocardiographic_conduction_abnormalities,_ocular_hypertelorism,_pulmonic_stenosis,_abnormalities_of_genitalia,_retardation_of_growth,_and_sensorineural_deafness._{ECO:0000269|PubMed:12058348,_ECO:0000269|PubMed:14961557,_ECO:0000269|PubMed:15121796,_ECO:0000269|PubMed:15389709,_ECO:0000269|PubMed:15520399,_ECO:0000269|PubMed:15690106,_ECO:0000269|PubMed:16679933,_ECO:0000269|PubMed:24891296}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Noonan_syndrome_1_(NS1)_[MIM:163950]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._Some_patients_with_NS1_develop_multiple_giant_cell_lesions_of_the_jaw_or_other_bony_or_soft_tissues,_which_are_classified_as_pigmented_villonodular_synovitis_(PVNS)_when_occurring_in_the_jaw_or_joints._{ECO:0000269|PubMed:11704759,_ECO:0000269|PubMed:11992261,_ECO:0000269|PubMed:12161469,_ECO:0000269|PubMed:12325025,_ECO:0000269|PubMed:12529711,_ECO:0000269|PubMed:12634870,_ECO:0000269|PubMed:12717436,_ECO:0000269|PubMed:12739139,_ECO:0000269|PubMed:12960218,_ECO:0000269|PubMed:15384080,_ECO:0000269|PubMed:15948193,_ECO:0000269|PubMed:19020799,_ECO:0000269|PubMed:24891296}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry._Mutations_in_PTPN11_account_for_more_than_50%_of_the_cases.\x3b_DISEASE:_Leukemia,_juvenile_myelomonocytic_(JMML)_[MIM:607785]:_An_aggressive_pediatric_myelodysplastic_syndrome/myeloproliferative_disorder_characterized_by_malignant_transformation_in_the_hematopoietic_stem_cell_compartment_with_proliferation_of_differentiated_progeny._Patients_have_splenomegaly,_enlarged_lymph_nodes,_rashes,_and_hemorrhages._{ECO:0000269|PubMed:12717436}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Metachondromatosis_(MC)_[MIM:156250]:_A_skeletal_disorder_with_radiologic_features_of_both_multiple_exostoses_and_Ollier_disease,_characterized_by_the_presence_of_exostoses,_commonly_of_the_bones_of_the_hands_and_feet,_and_enchondromas_of_the_metaphyses_of_long_bones_and_iliac_crest._{ECO:0000269|PubMed:20577567}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Widely_expressed,_with_highest_levels_in_heart,_brain,_and_skeletal_muscle._{ECO:0000269|PubMed:1280823,_ECO:0000269|PubMed:7681589,_ECO:0000269|PubMed:8216283}.\x3b_	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3bfrontal_lobe\x3bendometrium\x3boesophagus\x3blarynx\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bpineal_gland\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bpineal_body\x3burinary\x3badrenal_cortex\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3blung\x3bcornea\x3badrenal_gland\x3bplacenta\x3bvisual_apparatus\x3bhippocampus\x3bhypopharynx\x3bliver\x3bhead_and_neck\x3bcervix\x3bkidney\x3bmammary_gland\x3baorta\x3bstomach\x3b	amygdala\x3btestis_-_interstitial\x3bthalamus\x3bmedulla_oblongata\x3bsuperior_cervical_ganglion\x3boccipital_lobe\x3bhypothalamus\x3bspinal_cord\x3bcaudate_nucleus\x3bpons\x3bskeletal_muscle\x3bsubthalamic_nucleus\x3bprefrontal_cortex\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bparietal_lobe\x3b	0.26245	0.72890	-0.427900189	25.14744043	19.44641	0.66817	rs576405446	330590	Noonan_syndrome|Noonan_syndrome_with_multiple_lentigines|Metachondromatosis|Rasopathy	MeSH:D009634,MedGen:C0028326,Orphanet:ORPHA648,SNOMED_CT:205824006|MedGen:C0175704,Orphanet:ORPHA500|MedGen:C0410530,OMIM:156250,Orphanet:ORPHA2499,SNOMED_CT:205481009|MedGen:CN166718,Orphanet:ORPHA98733	reviewed_by_expert_panel	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0003	0	0	0	0	0	8.959e-06	0	0.0026	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,856	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.0059	VUS
12	112920006	112920006	A	G	exonic	PTPN11	.	synonymous_SNV	PTPN11:NM_001330437:exon10:c.A1221G:p.G407G,PTPN11:NM_002834:exon10:c.A1221G:p.G407G,PTPN11:NM_080601:exon10:c.A1221G:p.G407G	0.999877230878678	0.000122769057470549	6.38519788034449e-11	protein_tyrosine_phosphatase,_non-receptor_type_11	FUNCTION:_Acts_downstream_of_various_receptor_and_cytoplasmic_protein_tyrosine_kinases_to_participate_in_the_signal_transduction_from_the_cell_surface_to_the_nucleus._Dephosphorylates_ROCK2_at_Tyr-722_resulting_in_stimulatation_of_its_RhoA_binding_activity._{ECO:0000269|PubMed:10655584,_ECO:0000269|PubMed:18559669,_ECO:0000269|PubMed:18829466}.\x3b_	DISEASE:_LEOPARD_syndrome_1_(LPRD1)_[MIM:151100]:_A_disorder_characterized_by_lentigines,_electrocardiographic_conduction_abnormalities,_ocular_hypertelorism,_pulmonic_stenosis,_abnormalities_of_genitalia,_retardation_of_growth,_and_sensorineural_deafness._{ECO:0000269|PubMed:12058348,_ECO:0000269|PubMed:14961557,_ECO:0000269|PubMed:15121796,_ECO:0000269|PubMed:15389709,_ECO:0000269|PubMed:15520399,_ECO:0000269|PubMed:15690106,_ECO:0000269|PubMed:16679933,_ECO:0000269|PubMed:24891296}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Noonan_syndrome_1_(NS1)_[MIM:163950]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._Some_patients_with_NS1_develop_multiple_giant_cell_lesions_of_the_jaw_or_other_bony_or_soft_tissues,_which_are_classified_as_pigmented_villonodular_synovitis_(PVNS)_when_occurring_in_the_jaw_or_joints._{ECO:0000269|PubMed:11704759,_ECO:0000269|PubMed:11992261,_ECO:0000269|PubMed:12161469,_ECO:0000269|PubMed:12325025,_ECO:0000269|PubMed:12529711,_ECO:0000269|PubMed:12634870,_ECO:0000269|PubMed:12717436,_ECO:0000269|PubMed:12739139,_ECO:0000269|PubMed:12960218,_ECO:0000269|PubMed:15384080,_ECO:0000269|PubMed:15948193,_ECO:0000269|PubMed:19020799,_ECO:0000269|PubMed:24891296}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry._Mutations_in_PTPN11_account_for_more_than_50%_of_the_cases.\x3b_DISEASE:_Leukemia,_juvenile_myelomonocytic_(JMML)_[MIM:607785]:_An_aggressive_pediatric_myelodysplastic_syndrome/myeloproliferative_disorder_characterized_by_malignant_transformation_in_the_hematopoietic_stem_cell_compartment_with_proliferation_of_differentiated_progeny._Patients_have_splenomegaly,_enlarged_lymph_nodes,_rashes,_and_hemorrhages._{ECO:0000269|PubMed:12717436}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Metachondromatosis_(MC)_[MIM:156250]:_A_skeletal_disorder_with_radiologic_features_of_both_multiple_exostoses_and_Ollier_disease,_characterized_by_the_presence_of_exostoses,_commonly_of_the_bones_of_the_hands_and_feet,_and_enchondromas_of_the_metaphyses_of_long_bones_and_iliac_crest._{ECO:0000269|PubMed:20577567}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Widely_expressed,_with_highest_levels_in_heart,_brain,_and_skeletal_muscle._{ECO:0000269|PubMed:1280823,_ECO:0000269|PubMed:7681589,_ECO:0000269|PubMed:8216283}.\x3b_	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3bfrontal_lobe\x3bendometrium\x3boesophagus\x3blarynx\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bpineal_gland\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bpineal_body\x3burinary\x3badrenal_cortex\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3blung\x3bcornea\x3badrenal_gland\x3bplacenta\x3bvisual_apparatus\x3bhippocampus\x3bhypopharynx\x3bliver\x3bhead_and_neck\x3bcervix\x3bkidney\x3bmammary_gland\x3baorta\x3bstomach\x3b	amygdala\x3btestis_-_interstitial\x3bthalamus\x3bmedulla_oblongata\x3bsuperior_cervical_ganglion\x3boccipital_lobe\x3bhypothalamus\x3bspinal_cord\x3bcaudate_nucleus\x3bpons\x3bskeletal_muscle\x3bsubthalamic_nucleus\x3bprefrontal_cortex\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bparietal_lobe\x3b	0.26245	0.72890	-0.427900189	25.14744043	19.44641	0.66817	rs532529560	429364	Rasopathy|not_specified	MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374	reviewed_by_expert_panel	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0002	0	2.978e-05	0	0	0	0	0	0.0015	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,859	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.0059	VUS
12	112939998	112939998	G	A	exonic	PTPN11	.	synonymous_SNV	PTPN11:NM_001330437:exon14:c.G1662A:p.A554A,PTPN11:NM_002834:exon14:c.G1650A:p.A550A	0.999877230878678	0.000122769057470549	6.38519788034449e-11	protein_tyrosine_phosphatase,_non-receptor_type_11	FUNCTION:_Acts_downstream_of_various_receptor_and_cytoplasmic_protein_tyrosine_kinases_to_participate_in_the_signal_transduction_from_the_cell_surface_to_the_nucleus._Dephosphorylates_ROCK2_at_Tyr-722_resulting_in_stimulatation_of_its_RhoA_binding_activity._{ECO:0000269|PubMed:10655584,_ECO:0000269|PubMed:18559669,_ECO:0000269|PubMed:18829466}.\x3b_	DISEASE:_LEOPARD_syndrome_1_(LPRD1)_[MIM:151100]:_A_disorder_characterized_by_lentigines,_electrocardiographic_conduction_abnormalities,_ocular_hypertelorism,_pulmonic_stenosis,_abnormalities_of_genitalia,_retardation_of_growth,_and_sensorineural_deafness._{ECO:0000269|PubMed:12058348,_ECO:0000269|PubMed:14961557,_ECO:0000269|PubMed:15121796,_ECO:0000269|PubMed:15389709,_ECO:0000269|PubMed:15520399,_ECO:0000269|PubMed:15690106,_ECO:0000269|PubMed:16679933,_ECO:0000269|PubMed:24891296}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Noonan_syndrome_1_(NS1)_[MIM:163950]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._Some_patients_with_NS1_develop_multiple_giant_cell_lesions_of_the_jaw_or_other_bony_or_soft_tissues,_which_are_classified_as_pigmented_villonodular_synovitis_(PVNS)_when_occurring_in_the_jaw_or_joints._{ECO:0000269|PubMed:11704759,_ECO:0000269|PubMed:11992261,_ECO:0000269|PubMed:12161469,_ECO:0000269|PubMed:12325025,_ECO:0000269|PubMed:12529711,_ECO:0000269|PubMed:12634870,_ECO:0000269|PubMed:12717436,_ECO:0000269|PubMed:12739139,_ECO:0000269|PubMed:12960218,_ECO:0000269|PubMed:15384080,_ECO:0000269|PubMed:15948193,_ECO:0000269|PubMed:19020799,_ECO:0000269|PubMed:24891296}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry._Mutations_in_PTPN11_account_for_more_than_50%_of_the_cases.\x3b_DISEASE:_Leukemia,_juvenile_myelomonocytic_(JMML)_[MIM:607785]:_An_aggressive_pediatric_myelodysplastic_syndrome/myeloproliferative_disorder_characterized_by_malignant_transformation_in_the_hematopoietic_stem_cell_compartment_with_proliferation_of_differentiated_progeny._Patients_have_splenomegaly,_enlarged_lymph_nodes,_rashes,_and_hemorrhages._{ECO:0000269|PubMed:12717436}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Metachondromatosis_(MC)_[MIM:156250]:_A_skeletal_disorder_with_radiologic_features_of_both_multiple_exostoses_and_Ollier_disease,_characterized_by_the_presence_of_exostoses,_commonly_of_the_bones_of_the_hands_and_feet,_and_enchondromas_of_the_metaphyses_of_long_bones_and_iliac_crest._{ECO:0000269|PubMed:20577567}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Widely_expressed,_with_highest_levels_in_heart,_brain,_and_skeletal_muscle._{ECO:0000269|PubMed:1280823,_ECO:0000269|PubMed:7681589,_ECO:0000269|PubMed:8216283}.\x3b_	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3bfrontal_lobe\x3bendometrium\x3boesophagus\x3blarynx\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bpineal_gland\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bpineal_body\x3burinary\x3badrenal_cortex\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3blung\x3bcornea\x3badrenal_gland\x3bplacenta\x3bvisual_apparatus\x3bhippocampus\x3bhypopharynx\x3bliver\x3bhead_and_neck\x3bcervix\x3bkidney\x3bmammary_gland\x3baorta\x3bstomach\x3b	amygdala\x3btestis_-_interstitial\x3bthalamus\x3bmedulla_oblongata\x3bsuperior_cervical_ganglion\x3boccipital_lobe\x3bhypothalamus\x3bspinal_cord\x3bcaudate_nucleus\x3bpons\x3bskeletal_muscle\x3bsubthalamic_nucleus\x3bprefrontal_cortex\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bparietal_lobe\x3b	0.26245	0.72890	-0.427900189	25.14744043	19.44641	0.66817	rs374896287	142546	Noonan_syndrome|Noonan_syndrome_with_multiple_lentigines|Metachondromatosis|Rasopathy|not_specified|Cardiovascular_phenotype	MeSH:D009634,MedGen:C0028326,Orphanet:ORPHA648,SNOMED_CT:205824006|MedGen:C0175704,Orphanet:ORPHA500|MedGen:C0410530,OMIM:156250,Orphanet:ORPHA2499,SNOMED_CT:205481009|MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374|MedGen:CN230736	reviewed_by_expert_panel	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0001	0	0.0009	0	0.0001	0	1.797e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,861	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.0059	VUS
12	103246735	103246735	T	A	intronic	PAH	.	.	.	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs62508624	108531	Phenylketonuria|not_specified|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN169374|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Benign/Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0	0	0.0261	0.0907	0.0084	0.0166	0	0	0.0003	0.0020	0.0069	0.0896	0.0050	0.0095	5.823e-05	0	0.0003	0.0048	9.756e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,756	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.0059	VUS
10	89653834	89653834	C	T	exonic	PTEN	.	synonymous_SNV	PTEN:NM_000314:exon2:c.C132T:p.G44G,PTEN:NM_001304717:exon3:c.C651T:p.G217G	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs150651961	98720	Hereditary_cancer-predisposing_syndrome|PTEN_hamartoma_tumor_syndrome|not_specified|not_provided	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498|MedGen:CN169374|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Benign/Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0030	0.0002	0	0.0066	0	0.0037	0.0047	0.0051	0.0015	6.536e-05	0.0001	0.0032	0.0002	0.0032	0.0022	0.0020	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,524	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.0059	VUS
10	89624218	89624218	C	G	exonic	PTEN	.	nonsynonymous_SNV	PTEN:NM_001304717:exon2:c.C511G:p.L171V	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs11202592	98715	Hereditary_cancer-predisposing_syndrome|PTEN_hamartoma_tumor_syndrome|Cowden_syndrome_1|not_specified	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498|MedGen:CN072330,OMIM:158350|MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Benign/Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0035	0.0001	0	0	0.0635	0	0.0002	0.0020	0.0036	0	2.978e-05	0	0.0464	0	0.0001	0.0016	0.0022	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,511	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.0059	VUS
12	103234215	103234215	A	G	exonic	PAH	.	synonymous_SNV	PAH:NM_000277:exon12:c.T1278C:p.N426N	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs59326968	98639	Phenylketonuria|not_specified|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN169374|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Benign/Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0406	0.1420	0.0048	0	0	0	0.0006	0.0071	0.0106	0.1468	0.0076	0.0004	5.798e-05	4.484e-05	0.0005	0.0067	0.0003	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,645	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.0059	VUS
10	112760225	112760225	A	C	exonic	SHOC2	.	synonymous_SNV	SHOC2:NM_001269039:exon3:c.A756C:p.A252A,SHOC2:NM_001324336:exon4:c.A894C:p.A298A,SHOC2:NM_007373:exon4:c.A894C:p.A298A,SHOC2:NM_001324337:exon5:c.A894C:p.A298A	0.991705191552454	0.00829295945769003	1.84898985615785e-06	SHOC2_leucine-rich_repeat_scaffold_protein	FUNCTION:_Regulatory_subunit_of_protein_phosphatase_1_(PP1c)_that_acts_as_a_M-Ras/MRAS_effector_and_participates_in_MAPK_pathway_activation._Upon_M-Ras/MRAS_activation,_targets_PP1c_to_specifically_dephosphorylate_the_'Ser-259'_inhibitory_site_of_RAF1_kinase_and_stimulate_RAF1_activity_at_specialized_signaling_complexes._{ECO:0000269|PubMed:10783161,_ECO:0000269|PubMed:16630891,_ECO:0000269|PubMed:25137548}.\x3b_	DISEASE:_Noonan_syndrome-like_disorder_with_loose_anagen_hair_(NSLH)_[MIM:607721]:_A_syndrome_characterized_by_Noonan_dysmorphic_features_such_as_macrocephaly,_high_forehead,_hypertelorism,_palpebral_ptosis,_low-set_and_posteriorly_rotated_ears,_short_and_webbed_neck,_pectus_anomalies,_in_association_with_pluckable,_sparse,_thin_and_slow-growing_hair._{ECO:0000269|PubMed:19684605,_ECO:0000269|PubMed:25137548}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bpineal_body\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bcornea\x3bnasopharynx\x3bplacenta\x3bmacula_lutea\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bcervix\x3bkidney\x3bmammary_gland\x3bstomach\x3b	superior_cervical_ganglion\x3btestis_-_seminiferous_tubule\x3bprefrontal_cortex\x3btestis\x3btrigeminal_ganglion\x3b	0.46401	0.24608	-0.183570861	39.95046001	30.58108	0.97282	rs767912952	442532	Rasopathy	MedGen:CN166718,Orphanet:ORPHA98733	reviewed_by_expert_panel	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	6.457e-05	0	0	0	0.0012	0	0	0	6.5e-05	0	0	0	0.0009	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,606	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.0059	VUS
10	89623323	89623323	G	A	UTR5	PTEN	NM_001304718:c.-88651G>A\x3bNM_001304717:c.-384G>A\x3bNM_000314:c.-904G>A	.	.	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs1044322	142540	not_specified	MedGen:CN169374	criteria_provided,_single_submitter	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0111	0.0059	0.0122	0.0232	0.0018	0.0102	0.0149	0.0143	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,506	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.0059	VUS
10	89623200	89623200	C	A	UTR5	PTEN	NM_001304718:c.-88774C>A\x3bNM_001304717:c.-507C>A\x3bNM_000314:c.-1027C>A	.	.	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs34149102	142539	not_specified	MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Benign/Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0056	0.0018	0.0036	0.01	0	0.0055	0.0084	0.0061	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,504	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.0059	VUS
7	140624468	140624468	C	T	exonic	BRAF	.	synonymous_SNV	BRAF:NM_004333:exon1:c.G36A:p.A12A	0.999978196041997	2.18039579639691e-05	3.88216441101404e-14	B-Raf_proto-oncogene,_serine/threonine_kinase	FUNCTION:_Protein_kinase_involved_in_the_transduction_of_mitogenic_signals_from_the_cell_membrane_to_the_nucleus._May_play_a_role_in_the_postsynaptic_responses_of_hippocampal_neuron._Phosphorylates_MAP2K1,_and_thereby_contributes_to_the_MAP_kinase_signal_transduction_pathway._{ECO:0000269|PubMed:21441910}.\x3b_	DISEASE:_Note\x3dDefects_in_BRAF_are_found_in_a_wide_range_of_cancers._{ECO:0000269|PubMed:18974108}.\x3b_DISEASE:_Colorectal_cancer_(CRC)_[MIM:114500]:_A_complex_disease_characterized_by_malignant_lesions_arising_from_the_inner_wall_of_the_large_intestine_(the_colon)_and_the_rectum._Genetic_alterations_are_often_associated_with_progression_from_premalignant_lesion_(adenoma)_to_invasive_adenocarcinoma._Risk_factors_for_cancer_of_the_colon_and_rectum_include_colon_polyps,_long-standing_ulcerative_colitis,_and_genetic_family_history._{ECO:0000269|PubMed:12198537,_ECO:0000269|PubMed:23263490,_ECO:0000269|PubMed:24455489}._Note\x3dThe_disease_may_be_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lung_cancer_(LNCR)_[MIM:211980]:_A_common_malignancy_affecting_tissues_of_the_lung._The_most_common_form_of_lung_cancer_is_non-small_cell_lung_cancer_(NSCLC)_that_can_be_divided_into_3_major_histologic_subtypes:_squamous_cell_carcinoma,_adenocarcinoma,_and_large_cell_lung_cancer._NSCLC_is_often_diagnosed_at_an_advanced_stage_and_has_a_poor_prognosis._{ECO:0000269|PubMed:12460919}._Note\x3dThe_gene_represented_in_this_entry_is_involved_in_disease_pathogenesis.\x3b_DISEASE:_Familial_non-Hodgkin_lymphoma_(NHL)_[MIM:605027]:_Cancer_that_starts_in_cells_of_the_lymph_system,_which_is_part_of_the_body's_immune_system._NHLs_can_occur_at_any_age_and_are_often_marked_by_enlarged_lymph_nodes,_fever_and_weight_loss._{ECO:0000269|PubMed:14612909}._Note\x3dThe_gene_represented_in_this_entry_is_involved_in_disease_pathogenesis.\x3b_DISEASE:_Cardiofaciocutaneous_syndrome_1_(CFC1)_[MIM:115150]:_A_multiple_congenital_anomaly_disorder_characterized_by_a_distinctive_facial_appearance,_heart_defects_and_mental_retardation._Heart_defects_include_pulmonic_stenosis,_atrial_septal_defects_and_hypertrophic_cardiomyopathy._Some_affected_individuals_present_with_ectodermal_abnormalities_such_as_sparse,_friable_hair,_hyperkeratotic_skin_lesions_and_a_generalized_ichthyosis-like_condition._Typical_facial_features_are_similar_to_Noonan_syndrome._They_include_high_forehead_with_bitemporal_constriction,_hypoplastic_supraorbital_ridges,_downslanting_palpebral_fissures,_a_depressed_nasal_bridge,_and_posteriorly_angulated_ears_with_prominent_helices._{ECO:0000269|PubMed:16439621,_ECO:0000269|PubMed:16474404,_ECO:0000269|PubMed:18042262,_ECO:0000269|PubMed:19206169}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Noonan_syndrome_7_(NS7)_[MIM:613706]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._{ECO:0000269|PubMed:19206169}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_LEOPARD_syndrome_3_(LPRD3)_[MIM:613707]:_A_disorder_characterized_by_lentigines,_electrocardiographic_conduction_abnormalities,_ocular_hypertelorism,_pulmonic_stenosis,_abnormalities_of_genitalia,_retardation_of_growth,_and_sensorineural_deafness._{ECO:0000269|PubMed:19206169}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_BRAF_is_found_in_pilocytic_astrocytomas._A_tandem_duplication_of_2_Mb_at_7q34_leads_to_the_expression_of_a_KIAA1549-BRAF_fusion_protein_with_a_constitutive_kinase_activity_and_inducing_cell_transformation._{ECO:0000269|PubMed:18974108}.\x3b_	TISSUE_SPECIFICITY:_Brain_and_testis.\x3b_	unclassifiable_(Anatomical_System)\x3bamygdala\x3bislets_of_Langerhans\x3bwhole_body\x3blung\x3bfrontal_lobe\x3bplacenta\x3bthyroid\x3bliver\x3btestis\x3bhead_and_neck\x3bspleen\x3bgerminal_center\x3bbrain\x3bstomach\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3btestis\x3bciliary_ganglion\x3batrioventricular_node\x3bpons\x3btrigeminal_ganglion\x3b	0.95401	.	-0.60427181	17.74593064	63.2093	1.62731	rs397507454	48803	Noonan_syndrome|Noonan_syndrome_with_multiple_lentigines|Cardio-facio-cutaneous_syndrome|Rasopathy|not_provided	MeSH:D009634,MedGen:C0028326,Orphanet:ORPHA648,SNOMED_CT:205824006|MedGen:C0175704,Orphanet:ORPHA500|MedGen:C1275081,Orphanet:ORPHA1340,SNOMED_CT:403770008|MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN517202	reviewed_by_expert_panel	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0002	0	0.0025	0	0	0	0.0003	0	0.0007	0	0.0002	0	0	0.0002	0.0002	0.0003	0.0030	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,496	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.0059	VUS
7	140487375	140487375	T	C	exonic	BRAF	.	nonsynonymous_SNV	BRAF:NM_004333:exon9:c.A1150G:p.R384G	0.999978196041997	2.18039579639691e-05	3.88216441101404e-14	B-Raf_proto-oncogene,_serine/threonine_kinase	FUNCTION:_Protein_kinase_involved_in_the_transduction_of_mitogenic_signals_from_the_cell_membrane_to_the_nucleus._May_play_a_role_in_the_postsynaptic_responses_of_hippocampal_neuron._Phosphorylates_MAP2K1,_and_thereby_contributes_to_the_MAP_kinase_signal_transduction_pathway._{ECO:0000269|PubMed:21441910}.\x3b_	DISEASE:_Note\x3dDefects_in_BRAF_are_found_in_a_wide_range_of_cancers._{ECO:0000269|PubMed:18974108}.\x3b_DISEASE:_Colorectal_cancer_(CRC)_[MIM:114500]:_A_complex_disease_characterized_by_malignant_lesions_arising_from_the_inner_wall_of_the_large_intestine_(the_colon)_and_the_rectum._Genetic_alterations_are_often_associated_with_progression_from_premalignant_lesion_(adenoma)_to_invasive_adenocarcinoma._Risk_factors_for_cancer_of_the_colon_and_rectum_include_colon_polyps,_long-standing_ulcerative_colitis,_and_genetic_family_history._{ECO:0000269|PubMed:12198537,_ECO:0000269|PubMed:23263490,_ECO:0000269|PubMed:24455489}._Note\x3dThe_disease_may_be_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lung_cancer_(LNCR)_[MIM:211980]:_A_common_malignancy_affecting_tissues_of_the_lung._The_most_common_form_of_lung_cancer_is_non-small_cell_lung_cancer_(NSCLC)_that_can_be_divided_into_3_major_histologic_subtypes:_squamous_cell_carcinoma,_adenocarcinoma,_and_large_cell_lung_cancer._NSCLC_is_often_diagnosed_at_an_advanced_stage_and_has_a_poor_prognosis._{ECO:0000269|PubMed:12460919}._Note\x3dThe_gene_represented_in_this_entry_is_involved_in_disease_pathogenesis.\x3b_DISEASE:_Familial_non-Hodgkin_lymphoma_(NHL)_[MIM:605027]:_Cancer_that_starts_in_cells_of_the_lymph_system,_which_is_part_of_the_body's_immune_system._NHLs_can_occur_at_any_age_and_are_often_marked_by_enlarged_lymph_nodes,_fever_and_weight_loss._{ECO:0000269|PubMed:14612909}._Note\x3dThe_gene_represented_in_this_entry_is_involved_in_disease_pathogenesis.\x3b_DISEASE:_Cardiofaciocutaneous_syndrome_1_(CFC1)_[MIM:115150]:_A_multiple_congenital_anomaly_disorder_characterized_by_a_distinctive_facial_appearance,_heart_defects_and_mental_retardation._Heart_defects_include_pulmonic_stenosis,_atrial_septal_defects_and_hypertrophic_cardiomyopathy._Some_affected_individuals_present_with_ectodermal_abnormalities_such_as_sparse,_friable_hair,_hyperkeratotic_skin_lesions_and_a_generalized_ichthyosis-like_condition._Typical_facial_features_are_similar_to_Noonan_syndrome._They_include_high_forehead_with_bitemporal_constriction,_hypoplastic_supraorbital_ridges,_downslanting_palpebral_fissures,_a_depressed_nasal_bridge,_and_posteriorly_angulated_ears_with_prominent_helices._{ECO:0000269|PubMed:16439621,_ECO:0000269|PubMed:16474404,_ECO:0000269|PubMed:18042262,_ECO:0000269|PubMed:19206169}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Noonan_syndrome_7_(NS7)_[MIM:613706]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._{ECO:0000269|PubMed:19206169}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_LEOPARD_syndrome_3_(LPRD3)_[MIM:613707]:_A_disorder_characterized_by_lentigines,_electrocardiographic_conduction_abnormalities,_ocular_hypertelorism,_pulmonic_stenosis,_abnormalities_of_genitalia,_retardation_of_growth,_and_sensorineural_deafness._{ECO:0000269|PubMed:19206169}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_BRAF_is_found_in_pilocytic_astrocytomas._A_tandem_duplication_of_2_Mb_at_7q34_leads_to_the_expression_of_a_KIAA1549-BRAF_fusion_protein_with_a_constitutive_kinase_activity_and_inducing_cell_transformation._{ECO:0000269|PubMed:18974108}.\x3b_	TISSUE_SPECIFICITY:_Brain_and_testis.\x3b_	unclassifiable_(Anatomical_System)\x3bamygdala\x3bislets_of_Langerhans\x3bwhole_body\x3blung\x3bfrontal_lobe\x3bplacenta\x3bthyroid\x3bliver\x3btestis\x3bhead_and_neck\x3bspleen\x3bgerminal_center\x3bbrain\x3bstomach\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3btestis\x3bciliary_ganglion\x3batrioventricular_node\x3bpons\x3btrigeminal_ganglion\x3b	0.95401	.	-0.60427181	17.74593064	63.2093	1.62731	rs545495379	442525	Rasopathy	MedGen:CN166718,Orphanet:ORPHA98733	reviewed_by_expert_panel	Benign	0.064	0.365	T	0.000	0.843	D	1.000	0.588	D	0.9	0.233	L	-1.43	0.807	T	-2.19	0.493	N	-0.551	0.668	T	0.345	0.710	T	0.045	0.617	D	0.452	0.515	0.872	0.464	D	c	-0.032	0.139	0.656	0.222	0.732	0.924	0	5.65	0.868	2.527	0.450	1.058	0.762	1.000	0.715	1.000	0.888	11.823	0.513	.	.	.	.	.	0.0001	0	0	0	0.0025	0	0	0	0.0002	0	0	0	0.0026	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,492	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.0059	VUS
12	103240679	103240679	G	A	exonic	PAH	.	synonymous_SNV	PAH:NM_000277:exon9:c.C963T:p.L321L	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs61747292	108647	not_specified|not_provided	MedGen:CN169374|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0149	0.0518	0.0060	0	0	0	6.67e-05	0.0020	0.0038	0.0532	0.0026	0	0	0	7.174e-05	0.0018	0.0001	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,681	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.0059	VUS
19	4099293	4099293	C	T	exonic	MAP2K2	.	synonymous_SNV	MAP2K2:NM_030662:exon7:c.G825A:p.L275L	0.86326115931858	0.136320885012997	0.00041795566842237	mitogen-activated_protein_kinase_kinase_2	FUNCTION:_Catalyzes_the_concomitant_phosphorylation_of_a_threonine_and_a_tyrosine_residue_in_a_Thr-Glu-Tyr_sequence_located_in_MAP_kinases._Activates_the_ERK1_and_ERK2_MAP_kinases_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Cardiofaciocutaneous_syndrome_4_(CFC4)_[MIM:615280]:_A_form_of_cardiofaciocutaneous_syndrome,_a_multiple_congenital_anomaly_disorder_characterized_by_a_distinctive_facial_appearance,_heart_defects_and_mental_retardation._Heart_defects_include_pulmonic_stenosis,_atrial_septal_defects_and_hypertrophic_cardiomyopathy._Some_affected_individuals_present_with_ectodermal_abnormalities_such_as_sparse,_friable_hair,_hyperkeratotic_skin_lesions_and_a_generalized_ichthyosis-like_condition._Typical_facial_features_are_similar_to_Noonan_syndrome._They_include_high_forehead_with_bitemporal_constriction,_hypoplastic_supraorbital_ridges,_downslanting_palpebral_fissures,_a_depressed_nasal_bridge,_and_posteriorly_angulated_ears_with_prominent_helices._{ECO:0000269|PubMed:16439621,_ECO:0000269|PubMed:18042262,_ECO:0000269|PubMed:20358587}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	medulla_oblongata\x3bsmooth_muscle\x3bovary\x3bsalivary_gland\x3bsympathetic_chain\x3bcolon\x3bparathyroid\x3bskin\x3buterus\x3bprostate\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bmuscle\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbile_duct\x3bpancreas\x3blung\x3badrenal_gland\x3bplacenta\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	amygdala\x3bprefrontal_cortex\x3btestis\x3bpons\x3bcingulate_cortex\x3b	0.88489	0.51187	-0.800872469	12.33191791	40.94266	1.19949	rs587781027	141864	Rasopathy|not_specified|not_provided	MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374|MedGen:CN517202	reviewed_by_expert_panel	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0002	0	0	0	0.0037	0	0	0	0.0001	0	0	0	0.0017	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,927	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.0059	VUS
12	103234251	103234251	G	A	exonic	PAH	.	synonymous_SNV	PAH:NM_000277:exon12:c.C1242T:p.Y414Y	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs1801152	108313	Phenylketonuria|not_specified|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN169374|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Benign/Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0064	0.0025	0.0060	0	0	0.0011	0.0109	0.0041	0.0075	0.0025	0.0033	0.0003	5.798e-05	0.0021	0.0140	0.0069	0.0014	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,648	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.0059	VUS
1	215824001	215824001	C	T	exonic	USH2A	.	nonsynonymous_SNV	USH2A:NM_206933:exon65:c.G14276A:p.G4759E	3.68100336207458e-43	0.999989235571568	1.07644284322941e-05	Usher_syndrome_2A_(autosomal_recessive,_mild)	FUNCTION:_Involved_in_hearing_and_vision.\x3b_	DISEASE:_Usher_syndrome_2A_(USH2A)_[MIM:276901]:_USH_is_a_genetically_heterogeneous_condition_characterized_by_the_association_of_retinitis_pigmentosa_with_sensorineural_deafness._Age_at_onset_and_differences_in_auditory_and_vestibular_function_distinguish_Usher_syndrome_type_1_(USH1),_Usher_syndrome_type_2_(USH2)_and_Usher_syndrome_type_3_(USH3)._USH2_is_characterized_by_congenital_mild_hearing_impairment_with_normal_vestibular_responses._{ECO:0000269|PubMed:10729113,_ECO:0000269|PubMed:10738000,_ECO:0000269|PubMed:10909849,_ECO:0000269|PubMed:11311042,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:12525556,_ECO:0000269|PubMed:14970843,_ECO:0000269|PubMed:15015129,_ECO:0000269|PubMed:15025721,_ECO:0000269|PubMed:15241801,_ECO:0000269|PubMed:15325563,_ECO:0000269|PubMed:17085681,_ECO:0000269|PubMed:17405132,_ECO:0000269|PubMed:18273898,_ECO:0000269|PubMed:18452394,_ECO:0000269|PubMed:19683999,_ECO:0000269|PubMed:19737284,_ECO:0000269|PubMed:20309401,_ECO:0000269|PubMed:20440071,_ECO:0000269|PubMed:20507924,_ECO:0000269|PubMed:21593743,_ECO:0000269|PubMed:21686329,_ECO:0000269|PubMed:22004887,_ECO:0000269|PubMed:23737954,_ECO:0000269|PubMed:9624053}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Retinitis_pigmentosa_39_(RP39)_[MIM:613809]:_A_retinal_dystrophy_belonging_to_the_group_of_pigmentary_retinopathies._Retinitis_pigmentosa_is_characterized_by_retinal_pigment_deposits_visible_on_fundus_examination_and_primary_loss_of_rod_photoreceptor_cells_followed_by_secondary_loss_of_cone_photoreceptors._Patients_typically_have_night_vision_blindness_and_loss_of_midperipheral_visual_field._As_their_condition_progresses,_they_lose_their_far_peripheral_visual_field_and_eventually_central_vision_as_well._{ECO:0000269|PubMed:10775529,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:12427073,_ECO:0000269|PubMed:15325563,_ECO:0000269|PubMed:16098008,_ECO:0000269|PubMed:17296898,_ECO:0000269|PubMed:20507924,_ECO:0000269|PubMed:21686329,_ECO:0000269|PubMed:22334370,_ECO:0000269|PubMed:24227914}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Present_in_the_basement_membrane_of_many,_but_not_all_tissues._Expressed_in_retina,_cochlea,_small_and_large_intestine,_pancreas,_bladder,_prostate,_esophagus,_trachea,_thymus,_salivary_glands,_placenta,_ovary,_fallopian_tube,_uterus_and_testis._Absent_in_many_other_tissues_such_as_heart,_lung,_liver,_kidney_and_brain._In_the_retina,_it_is_present_in_the_basement_membranes_in_the_Bruch's_layer_choroid_capillary_basement_membranes,_where_it_localizes_just_beneath_the_retinal_pigment_epithelial_cells_(at_protein_level)._Weakly_expressed._Isoform_2_is_expressed_in_fetal_eye,_cochlea_and_heart,_and_at_very_low_level_in_brain,_CNS,_intestine,_skeleton,_tongue,_kidney_and_lung._Isoform_2_is_not_expressed_in_stomach_and_liver._In_adult_tissues,_isoform_2_is_expressed_in_neural_retina_and_testis,_and_at_low_level_in_brain,_heart,_kidney_and_liver._Isoform_1_displays_a_similar_pattern_of_expression_but_is_expressed_at_very_low_level_in_fetal_cochlea._{ECO:0000269|PubMed:11788194,_ECO:0000269|PubMed:12433396,_ECO:0000269|PubMed:15015129,_ECO:0000269|PubMed:9624053}.\x3b_	unclassifiable_(Anatomical_System)\x3bliver\x3btestis\x3bretina\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3badrenal_gland\x3btemporal_lobe\x3bciliary_ganglion\x3batrioventricular_node\x3btrigeminal_ganglion\x3bskin\x3bskeletal_muscle\x3bcerebellum\x3b	0.15836	.	4.179636958	99.70511913	6401.91635	16.71188	rs112459877	172375	Retinitis_pigmentosa|not_specified	Human_Phenotype_Ontology:HP:0000547,MeSH:D012174,MedGen:C0035334,OMIM:268000,Orphanet:ORPHA791,SNOMED_CT:28835009|MedGen:CN169374	criteria_provided,_single_submitter	Likely_benign	1.0	0.010	T	0.002	0.008	N	1	0.090	N	-0.705	0.018	N	0.72	0.510	T	0.7	0.022	N	-0.994	0.316	T	0.026	0.110	T	0.003	0.074	T	.	.	0.045	0.100	N	c	-2.801	-2.822	1.000	0.747	0.487	0.133	0	-11.5	0.001	-0.656	0.054	-3.043	0.001	0.000	0.063	0.001	0.043	0.471	0.005	Fibronectin_type_III|Immunoglobulin-like_fold	.	.	.	.	0.0013	0.0045	0.0012	0	0	0	0	0	0.0003	0.0041	0.0001	0	0	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,448	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0.3246	Likely Benign
21	36164520	36164520	A	C	exonic	RUNX1	.	nonsynonymous_SNV	RUNX1:NM_001001890:exon6:c.T1274G:p.V425G,RUNX1:NM_001754:exon9:c.T1355G:p.V452G	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	rs751710767	336744	Familial_platelet_disorder_with_associated_myeloid_malignancy	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290	criteria_provided,_multiple_submitters,_no_conflicts	Likely_benign	1.0	0.010	T	0.001	0.392	N	1.000	0.588	D	0.17	0.090	N	1.77	0.258	T	2.15	0.003	N	-0.943	0.421	T	0.015	0.058	T	0.157	0.838	D	0.351	0.350	0.537	0.292	D	c	-0.970	-0.807	1.000	0.517	0.660	0.495	0	-3.7	0.041	0.227	0.174	1.085	0.854	0.639	0.278	1.000	0.888	6.211	0.197	Runx,_C-terminal__domain	.	.	.	.	0.0002	0	0	0	0.0031	0	0	0	0.0001	0	0	0	0.0016	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,946	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0.3246	Likely Benign
16	68842734	68842734	C	T	exonic	CDH1	.	nonsynonymous_SNV	CDH1:NM_001317184:exon5:c.C670T:p.R224C,CDH1:NM_004360:exon5:c.C670T:p.R224C	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	rs200310662	133389	Hereditary_cancer-predisposing_syndrome|Hereditary_diffuse_gastric_cancer|not_specified|Anophthalmia_-_microphthalmia|not_provided	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708349,OMIM:137215,Orphanet:ORPHA26106|MedGen:CN169374|MedGen:CN235161|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Likely_benign	0.01	0.564	D	0.003	0.010	N	1	0.090	N	1.415	0.357	L	0.64	0.529	T	-3.34	0.663	D	-0.704	0.603	T	0.132	0.443	T	0.048	0.635	D	.	.	0.160	0.190	N	c	-1.855	-2.061	1.000	0.747	0.719	0.830	0	-11.6	0.000	-3.576	0.005	-2.101	0.004	0.000	0.063	0.017	0.128	17.484	0.875	Cadherin|Cadherin-like	.	.	.	.	0.0002	0	0	0	0	0	0.0003	0	0.0002	0.0001	2.979e-05	0	0	4.492e-05	0.0003	0	0.0003	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,897	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0.3246	Likely Benign
21	36164870	36164870	C	A	exonic	RUNX1	.	nonsynonymous_SNV	RUNX1:NM_001001890:exon6:c.G924T:p.Q308H,RUNX1:NM_001754:exon9:c.G1005T:p.Q335H	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	rs80314254	243604	Familial_platelet_disorder_with_associated_myeloid_malignancy	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290	criteria_provided,_multiple_submitters,_no_conflicts	Likely_benign	0.084	0.375	T	0.257	0.154	N	0.586	0.324	D	2.07	0.570	M	-2.52	0.894	D	-2.56	0.656	D	0.133	0.848	D	0.621	0.866	D	0.208	0.872	D	.	.	0.834	0.422	D	c	0.226	0.234	1.000	0.443	0.707	0.730	0	3.06	0.342	0.779	0.262	0.920	0.431	1.000	0.715	1.000	0.888	4.433	0.109	Runx,_central_domain	.	.	.	.	0.0003	0.0001	0	0	0.0037	0	0	0.0010	0.0001	0	0.0001	0	0.0014	0	0	0.0006	6.969e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,952	0	0	0	0	0	1	1	0	0	0	1	0	0	1	0	0	0	0	1	0	0	0.1	Likely Benign
12	103246615	103246615	T	C	exonic	PAH	.	nonsynonymous_SNV	PAH:NM_000277:exon7:c.A820G:p.K274E	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs142934616	108587	Phenylketonuria|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN517202	criteria_provided,_single_submitter	Likely_benign	0.196	0.207	T	0.000	0.843	D	1.000	0.588	D	0.665	0.163	N	-5.98	0.995	D	-1.42	0.350	N	0.683	0.930	D	0.836	0.945	D	.	.	.	.	.	0.932	0.573	D	c	0.052	0.207	1.000	0.500	0.638	0.428	0	5.73	0.897	3.492	0.528	1.061	0.807	1.000	0.715	0.997	0.653	16.014	0.801	Aromatic_amino_acid_hydroxylase,_C-terminal	.	.	.	.	0.0039	0.0134	0.0024	0	0	0	0	0.0010	0.0012	0.0165	0.0010	0	0	0	2.689e-05	0.0007	6.497e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,717	0	0	0	0	0	1	1	0	0	0	1	0	1	0	0	0	0	0	1	0	0	0.1	Likely Benign
10	112724493	112724493	C	T	exonic	SHOC2	.	nonsynonymous_SNV	SHOC2:NM_001269039:exon2:c.C377T:p.T126I,SHOC2:NM_001324336:exon2:c.C377T:p.T126I,SHOC2:NM_007373:exon2:c.C377T:p.T126I,SHOC2:NM_001324337:exon3:c.C377T:p.T126I	0.991705191552454	0.00829295945769003	1.84898985615785e-06	SHOC2_leucine-rich_repeat_scaffold_protein	FUNCTION:_Regulatory_subunit_of_protein_phosphatase_1_(PP1c)_that_acts_as_a_M-Ras/MRAS_effector_and_participates_in_MAPK_pathway_activation._Upon_M-Ras/MRAS_activation,_targets_PP1c_to_specifically_dephosphorylate_the_'Ser-259'_inhibitory_site_of_RAF1_kinase_and_stimulate_RAF1_activity_at_specialized_signaling_complexes._{ECO:0000269|PubMed:10783161,_ECO:0000269|PubMed:16630891,_ECO:0000269|PubMed:25137548}.\x3b_	DISEASE:_Noonan_syndrome-like_disorder_with_loose_anagen_hair_(NSLH)_[MIM:607721]:_A_syndrome_characterized_by_Noonan_dysmorphic_features_such_as_macrocephaly,_high_forehead,_hypertelorism,_palpebral_ptosis,_low-set_and_posteriorly_rotated_ears,_short_and_webbed_neck,_pectus_anomalies,_in_association_with_pluckable,_sparse,_thin_and_slow-growing_hair._{ECO:0000269|PubMed:19684605,_ECO:0000269|PubMed:25137548}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bpineal_body\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bcornea\x3bnasopharynx\x3bplacenta\x3bmacula_lutea\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bcervix\x3bkidney\x3bmammary_gland\x3bstomach\x3b	superior_cervical_ganglion\x3btestis_-_seminiferous_tubule\x3bprefrontal_cortex\x3btestis\x3btrigeminal_ganglion\x3b	0.46401	0.24608	-0.183570861	39.95046001	30.58108	0.97282	rs138375593	442529	Rasopathy	MedGen:CN166718,Orphanet:ORPHA98733	reviewed_by_expert_panel	Likely_benign	0.09	0.319	T	0.000	0.843	D	1	0.810	D	1.445	0.365	L	-2.7	0.905	D	-1.36	0.383	N	0.182	0.856	D	0.684	0.891	D	0.060	0.678	D	.	.	0.979	0.778	D	c	0.173	0.331	1.0	0.983	0.737	0.974	0	5.99	0.973	6.109	0.710	0.848	0.348	1.000	0.715	1.000	0.888	20.478	0.992	Leucine-rich_repeat_domain,_L_domain-like	.	.	.	.	0.0003	0.0010	0	0	0	0	0	0	4.884e-05	0.0007	2.982e-05	0	0	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,601	0	0	0	0	0	1	0	0	0	0	1	0	0	0	1	0	0	0	1	0	0	0.025	Likely Benign
19	4101272	4101272	G	A	exonic	MAP2K2	.	nonsynonymous_SNV	MAP2K2:NM_030662:exon5:c.C535T:p.R179W	0.86326115931858	0.136320885012997	0.00041795566842237	mitogen-activated_protein_kinase_kinase_2	FUNCTION:_Catalyzes_the_concomitant_phosphorylation_of_a_threonine_and_a_tyrosine_residue_in_a_Thr-Glu-Tyr_sequence_located_in_MAP_kinases._Activates_the_ERK1_and_ERK2_MAP_kinases_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Cardiofaciocutaneous_syndrome_4_(CFC4)_[MIM:615280]:_A_form_of_cardiofaciocutaneous_syndrome,_a_multiple_congenital_anomaly_disorder_characterized_by_a_distinctive_facial_appearance,_heart_defects_and_mental_retardation._Heart_defects_include_pulmonic_stenosis,_atrial_septal_defects_and_hypertrophic_cardiomyopathy._Some_affected_individuals_present_with_ectodermal_abnormalities_such_as_sparse,_friable_hair,_hyperkeratotic_skin_lesions_and_a_generalized_ichthyosis-like_condition._Typical_facial_features_are_similar_to_Noonan_syndrome._They_include_high_forehead_with_bitemporal_constriction,_hypoplastic_supraorbital_ridges,_downslanting_palpebral_fissures,_a_depressed_nasal_bridge,_and_posteriorly_angulated_ears_with_prominent_helices._{ECO:0000269|PubMed:16439621,_ECO:0000269|PubMed:18042262,_ECO:0000269|PubMed:20358587}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	medulla_oblongata\x3bsmooth_muscle\x3bovary\x3bsalivary_gland\x3bsympathetic_chain\x3bcolon\x3bparathyroid\x3bskin\x3buterus\x3bprostate\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bmuscle\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbile_duct\x3bpancreas\x3blung\x3badrenal_gland\x3bplacenta\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	amygdala\x3bprefrontal_cortex\x3btestis\x3bpons\x3bcingulate_cortex\x3b	0.88489	0.51187	-0.800872469	12.33191791	40.94266	1.19949	rs370799450	179825	Rasopathy|not_specified	MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374	reviewed_by_expert_panel	Likely_benign	0.002	0.721	D	0.000	0.843	D	1	0.810	D	1.99	0.540	M	-0.3	0.679	T	-4.71	0.799	D	-0.271	0.758	T	0.372	0.731	T	0.176	0.853	D	.	.	0.961	0.674	D	c	0.485	0.436	0.999	0.380	0.707	0.730	0	4.25	0.495	2.223	0.423	0.953	0.551	1.000	0.715	0.903	0.383	10.641	0.446	Protein_kinase_domain|Protein_kinase-like_domain	.	.	.	.	3.24e-05	0	0	0	0	0	6.684e-05	0	0.0001	9.355e-05	3.656e-05	0	0.0002	0	6.005e-05	0	0.0005	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,934	0	0	0	0	0	1	0	0	0	0	1	0	0	0	1	0	0	0	1	0	0	0.025	Likely Benign
11	120996243	120996243	C	T	exonic	TECTA	.	nonsynonymous_SNV	TECTA:NM_005422:exon7:c.C1436T:p.P479L	1.06498565113514e-12	0.999989745526101	1.02544728344311e-05	tectorin_alpha	FUNCTION:_One_of_the_major_non-collagenous_components_of_the_tectorial_membrane_(By_similarity)._The_tectorial_membrane_is_an_extracellular_matrix_of_the_inner_ear_that_covers_the_neuroepithelium_of_the_cochlea_and_contacts_the_stereocilia_bundles_of_specialized_sensory_hair_cells._Sound_induces_movement_of_these_hair_cells_relative_to_the_tectorial_membrane,_deflects_the_stereocilia_and_leads_to_fluctuations_in_hair-cell_membrane_potential,_transducing_sound_into_electrical_signals._{ECO:0000250}.\x3b_	DISEASE:_Deafness,_autosomal_dominant,_12_(DFNA12)_[MIM:601543]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10196713,_ECO:0000269|PubMed:10987647,_ECO:0000269|PubMed:12162770,_ECO:0000269|PubMed:15319541,_ECO:0000269|PubMed:16718611,_ECO:0000269|PubMed:17661817,_ECO:0000269|PubMed:20947814,_ECO:0000269|PubMed:21520338,_ECO:0000269|PubMed:9590290}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_recessive,_21_(DFNB21)_[MIM:603629]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:12746400,_ECO:0000269|PubMed:9949200}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	liver\x3btestis\x3bspleen\x3bblood\x3bbrain\x3b	superior_cervical_ganglion\x3batrioventricular_node\x3bskeletal_muscle\x3b	0.64735	0.20702	-2.430013277	1.032083038	4846.67098	14.13953	rs35107075	175075	not_specified|Nonsyndromic_Hearing_Loss,_Dominant|Nonsyndromic_Hearing_Loss,_Recessive	MedGen:CN169374|MedGen:CN239435|MedGen:CN239439	criteria_provided,_multiple_submitters,_no_conflicts	Likely_benign	0.406	0.103	T	0.000	0.452	D	0.985	0.402	D	-0.14	0.045	N	1.44	0.327	T	0.95	0.015	N	-1.050	0.144	T	0.021	0.087	T	0.004	0.110	T	.	.	0.644	0.321	D	c	-0.427	-0.168	0.559	0.214	0.554	0.246	0	5.02	0.666	1.957	0.398	0.934	0.450	0.934	0.322	0.998	0.697	10.059	0.412	von_Willebrand_factor,_type_D_domain	.	.	.	.	0.0018	0.0058	0	0	0.0006	0	0.0003	0	0.0014	0.0061	0.0005	0	5.798e-05	0	0.0002	0.0004	0.0071	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,634	0	0	0	0	0	1	1	0	0	0	0	0	1	0	0	0	0	1	1	0	0	0.025	Likely Benign
21	36206814	36206814	C	T	exonic	RUNX1	.	nonsynonymous_SNV	RUNX1:NM_001001890:exon4:c.G617A:p.R206H,RUNX1:NM_001122607:exon4:c.G617A:p.R206H,RUNX1:NM_001754:exon7:c.G698A:p.R233H	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	rs150042294	404272	Familial_platelet_disorder_with_associated_myeloid_malignancy	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290	criteria_provided,_single_submitter	Likely_benign	0.465	0.096	T	0.000	0.843	D	0.988	0.810	D	1.2	0.304	L	-4.17	0.993	D	-0.32	0.208	N	1.105	0.998	D	0.961	0.987	D	0.461	0.945	D	.	.	0.895	0.498	D	c	0.320	0.379	1.000	0.747	0.732	0.924	0	4.86	0.625	4.499	0.599	0.935	0.490	1.000	0.715	0.999	0.750	17.989	0.890	.	.	.	.	.	0.0005	0.0016	0	0	0	0	6.697e-05	0.0010	0.0001	0.0013	2.978e-05	0	0	0.0003	1.794e-05	0.0002	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,955	0	0	0	0	0	0	1	0	0	0	1	0	0	1	0	0	0	0	1	0	0	0.025	Likely Benign
2	39281777	39281777	T	C	exonic	SOS1	.	nonsynonymous_SNV	SOS1:NM_005633:exon5:c.A698G:p.N233S	0.99999989519361	1.04806389809942e-07	1.77231495230296e-20	SOS_Ras/Rac_guanine_nucleotide_exchange_factor_1	FUNCTION:_Promotes_the_exchange_of_Ras-bound_GDP_by_GTP._Catalytic_component_of_a_trimeric_complex_that_participates_in_transduction_of_signals_from_Ras_to_Rac_by_promoting_the_Rac-specific_guanine_nucleotide_exchange_factor_(GEF)_activity_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Noonan_syndrome_4_(NS4)_[MIM:610733]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._Some_patients_with_NS4_have_polyarticular_villonodular_synovitis._{ECO:0000269|PubMed:17143282,_ECO:0000269|PubMed:17143285,_ECO:0000269|PubMed:19020799,_ECO:0000269|PubMed:19438935,_ECO:0000269|PubMed:19953625,_ECO:0000269|PubMed:20673819,_ECO:0000269|PubMed:20683980,_ECO:0000269|PubMed:21387466}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_gingival_tissues._{ECO:0000269|PubMed:11868160}.\x3b_	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3blarynx\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bbile_duct\x3blung\x3bplacenta\x3bmacula_lutea\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3btestis\x3bciliary_ganglion\x3bpons\x3batrioventricular_node\x3bskeletal_muscle\x3b	0.72054	0.38414	-0.995664936	8.539749941	106.78667	2.24216	rs144934321	194939	Rasopathy|not_specified	MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374	reviewed_by_expert_panel	Likely_benign	0.827	0.029	T	0.000	0.486	D	0.908	0.363	D	1.115	0.288	L	-2.99	0.921	D	-0.26	0.112	N	-0.198	0.777	T	0.541	0.831	D	0.028	0.510	D	.	.	0.897	0.501	D	c	-0.228	-0.001	0.985	0.308	0.651	0.465	0	5.55	0.832	2.113	0.413	1.061	0.807	1.000	0.715	1.000	0.888	10.374	0.431	Dbl_homology_(DH)_domain	.	.	.	.	0.0004	0.0013	0	0	0	0	0	0	4.88e-05	0.0007	2.978e-05	0	0	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,469	0	0	0	0	0	1	0	0	0	0	1	0	0	0	1	0	0	0	1	0	0	0.025	Likely Benign
2	39285879	39285879	T	C	exonic	SOS1	.	nonsynonymous_SNV	SOS1:NM_005633:exon3:c.A280G:p.I94V	0.99999989519361	1.04806389809942e-07	1.77231495230296e-20	SOS_Ras/Rac_guanine_nucleotide_exchange_factor_1	FUNCTION:_Promotes_the_exchange_of_Ras-bound_GDP_by_GTP._Catalytic_component_of_a_trimeric_complex_that_participates_in_transduction_of_signals_from_Ras_to_Rac_by_promoting_the_Rac-specific_guanine_nucleotide_exchange_factor_(GEF)_activity_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Noonan_syndrome_4_(NS4)_[MIM:610733]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._Some_patients_with_NS4_have_polyarticular_villonodular_synovitis._{ECO:0000269|PubMed:17143282,_ECO:0000269|PubMed:17143285,_ECO:0000269|PubMed:19020799,_ECO:0000269|PubMed:19438935,_ECO:0000269|PubMed:19953625,_ECO:0000269|PubMed:20673819,_ECO:0000269|PubMed:20683980,_ECO:0000269|PubMed:21387466}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_gingival_tissues._{ECO:0000269|PubMed:11868160}.\x3b_	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3blarynx\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bbile_duct\x3blung\x3bplacenta\x3bmacula_lutea\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3btestis\x3bciliary_ganglion\x3bpons\x3batrioventricular_node\x3bskeletal_muscle\x3b	0.72054	0.38414	-0.995664936	8.539749941	106.78667	2.24216	rs144757941	442518	Rasopathy	MedGen:CN166718,Orphanet:ORPHA98733	reviewed_by_expert_panel	Likely_benign	0.013	0.538	D	0.000	0.629	D	1.000	0.537	D	2.62	0.769	M	-1.87	0.844	D	-0.78	0.249	N	-0.029	0.817	T	0.576	0.847	D	0.037	0.577	D	.	.	0.980	0.786	D	c	0.117	0.231	1.000	0.517	0.706	0.609	0	4.56	0.555	6.148	0.714	1.061	0.807	1.000	0.715	0.998	0.697	12.865	0.571	Histone_H2A/H2B/H3|Histone-fold	.	.	.	.	0.0002	0.0006	0	0	0	0	0	0	3.254e-05	0.0005	0	0	0	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,471	0	0	0	0	0	1	0	0	0	0	1	0	0	0	1	0	0	0	1	0	0	0.025	Likely Benign
11	534287	534287	G	A	exonic	HRAS	.	synonymous_SNV	HRAS:NM_001130442:exon2:c.C36T:p.G12G,HRAS:NM_005343:exon2:c.C36T:p.G12G,HRAS:NM_176795:exon2:c.C36T:p.G12G	0.00794104930284198	0.785285637637198	0.20677331305996	Harvey_rat_sarcoma_viral_oncogene_homolog	FUNCTION:_Ras_proteins_bind_GDP/GTP_and_possess_intrinsic_GTPase_activity._{ECO:0000269|PubMed:12740440,_ECO:0000269|PubMed:14500341,_ECO:0000269|PubMed:9020151}.\x3b_	DISEASE:_Costello_syndrome_(CSTLO)_[MIM:218040]:_A_rare_condition_characterized_by_prenatally_increased_growth,_postnatal_growth_deficiency,_mental_retardation,_distinctive_facial_appearance,_cardiovascular_abnormalities_(typically_pulmonic_stenosis,_hypertrophic_cardiomyopathy_and/or_atrial_tachycardia),_tumor_predisposition,_skin_and_musculoskeletal_abnormalities._{ECO:0000269|PubMed:16170316,_ECO:0000269|PubMed:16329078,_ECO:0000269|PubMed:16443854,_ECO:0000269|PubMed:17054105,_ECO:0000269|PubMed:18039947,_ECO:0000269|PubMed:18247425,_ECO:0000269|PubMed:19995790}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Congenital_myopathy_with_excess_of_muscle_spindles_(CMEMS)_[MIM:218040]:_Variant_of_Costello_syndrome._{ECO:0000269|PubMed:17412879}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hurthle_cell_thyroid_carcinoma_(HCTC)_[MIM:607464]:_A_rare_type_of_thyroid_cancer_accounting_for_only_about_3-10%_of_all_differentiated_thyroid_cancers._These_neoplasms_are_considered_a_variant_of_follicular_carcinoma_of_the_thyroid_and_are_referred_to_as_follicular_carcinoma,_oxyphilic_type._{ECO:0000269|PubMed:12727991}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dMutations_which_change_positions_12,_13_or_61_activate_the_potential_of_HRAS_to_transform_cultured_cells_and_are_implicated_in_a_variety_of_human_tumors._{ECO:0000269|PubMed:3670300}.\x3b_DISEASE:_Bladder_cancer_(BLC)_[MIM:109800]:_A_malignancy_originating_in_tissues_of_the_urinary_bladder._It_often_presents_with_multiple_tumors_appearing_at_different_times_and_at_different_sites_in_the_bladder._Most_bladder_cancers_are_transitional_cell_carcinomas_that_begin_in_cells_that_normally_make_up_the_inner_lining_of_the_bladder._Other_types_of_bladder_cancer_include_squamous_cell_carcinoma_(cancer_that_begins_in_thin,_flat_cells)_and_adenocarcinoma_(cancer_that_begins_in_cells_that_make_and_release_mucus_and_other_fluids)._Bladder_cancer_is_a_complex_disorder_with_both_genetic_and_environmental_influences._{ECO:0000269|PubMed:6298635,_ECO:0000269|PubMed:6844927}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Schimmelpenning-Feuerstein-Mims_syndrome_(SFM)_[MIM:163200]:_A_disease_characterized_by_sebaceous_nevi,_often_on_the_face,_associated_with_variable_ipsilateral_abnormalities_of_the_central_nervous_system,_ocular_anomalies,_and_skeletal_defects._Many_oral_manifestations_have_been_reported,_not_only_including_hypoplastic_and_malformed_teeth,_and_mucosal_papillomatosis,_but_also_ankyloglossia,_hemihyperplastic_tongue,_intraoral_nevus,_giant_cell_granuloma,_ameloblastoma,_bone_cysts,_follicular_cysts,_oligodontia,_and_odontodysplasia._Sebaceous_nevi_follow_the_lines_of_Blaschko_and_these_can_continue_as_linear_intraoral_lesions,_as_in_mucosal_papillomatosis._{ECO:0000269|PubMed:22683711}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Widely_expressed._{ECO:0000269|PubMed:14500341}.\x3b_	ovary\x3bdevelopmental\x3bcolon\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3boptic_nerve\x3bwhole_body\x3boesophagus\x3bendometrium\x3bthyroid\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bhypothalamus\x3bblood\x3blens\x3bskeletal_muscle\x3blung\x3bplacenta\x3bvisual_apparatus\x3bhypopharynx\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bcerebellum\x3b	whole_brain\x3bmedulla_oblongata\x3btrigeminal_ganglion\x3b	0.99944	0.99980	-0.339715008	30.06605331	4.91473	0.18207	rs727504424	223774	Costello_syndrome|Rasopathy|not_provided	MedGen:C0587248,OMIM:218040,Orphanet:ORPHA3071,SNOMED_CT:309776008|MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN517202	reviewed_by_expert_panel	Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0002	0	0	0	0.0037	0	0	0	8.55e-05	0	0	0	0.0012	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,625	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0.0122	Likely Benign
21	36171741	36171741	G	A	exonic	RUNX1	.	nonsynonymous_SNV	RUNX1:NM_001001890:exon5:c.C743T:p.P248L,RUNX1:NM_001754:exon8:c.C824T:p.P275L	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	rs201164283	471187	Familial_platelet_disorder_with_associated_myeloid_malignancy	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290	criteria_provided,_single_submitter	Likely_benign	0.002	0.721	D	0.000	0.441	D	1.000	0.524	D	1.5	0.380	L	-0.0	0.626	T	-2.8	0.629	D	-0.712	0.599	T	0.223	0.588	T	0.019	0.420	T	.	.	0.990	0.895	D	c	0.347	0.507	1.000	0.747	0.707	0.730	0	5.78	0.914	9.166	0.939	1.048	0.713	1.000	0.715	1.000	0.888	19.607	0.956	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0002	0	0.0015	0	0	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,954	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0.0122	Likely Benign
10	89622915	89622915	T	C	UTR5	KLLN	NM_001126049:c.-671A>G	.	.	.	.	.	killin,_p53-regulated_DNA_replication_inhibitor	FUNCTION:_DNA-binding_protein_involved_in_S_phase_checkpoint_control-coupled_apoptosis_by_mediating_p53/TP53-induced_apoptosis._Has_the_ability_to_inhibit_DNA_synthesis_and_S_phase_arrest_coupled_to_apoptosis._Has_affinity_to_both_double-_and_single-_stranded_DNA._{ECO:0000269|PubMed:18385383}.\x3b_	DISEASE:_Cowden_syndrome_4_(CWS4)_[MIM:615107]:_A_form_of_Cowden_syndrome,_a_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:21177507}._Note\x3dThe_gene_represented_in_this_entry_is_involved_in_disease_pathogenesis._Germline_KLLN_methylation_is_common_among_patients_with_Cowden_syndrome_or_Cowden-like_syndrome_and_is_associated_with_increased_risks_of_breast_and_renal_cancer_over_PTEN_mutation-positive_individuals_(PubMed:21177507)._{ECO:0000269|PubMed:21177507}.\x3b_	.	.	.	.	.	1.012423333	90.829205	121.24747	2.39863	rs70937047	133124	not_specified	MedGen:CN169374	criteria_provided,_single_submitter	Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0007	0	0	0	0.0142	0	0	0	.	.	.	.	.	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,501	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0.0122	Likely Benign
2	39241061	39241061	C	G	exonic	SOS1	.	nonsynonymous_SNV	SOS1:NM_005633:exon12:c.G2010C:p.L670F	0.99999989519361	1.04806389809942e-07	1.77231495230296e-20	SOS_Ras/Rac_guanine_nucleotide_exchange_factor_1	FUNCTION:_Promotes_the_exchange_of_Ras-bound_GDP_by_GTP._Catalytic_component_of_a_trimeric_complex_that_participates_in_transduction_of_signals_from_Ras_to_Rac_by_promoting_the_Rac-specific_guanine_nucleotide_exchange_factor_(GEF)_activity_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Noonan_syndrome_4_(NS4)_[MIM:610733]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._Some_patients_with_NS4_have_polyarticular_villonodular_synovitis._{ECO:0000269|PubMed:17143282,_ECO:0000269|PubMed:17143285,_ECO:0000269|PubMed:19020799,_ECO:0000269|PubMed:19438935,_ECO:0000269|PubMed:19953625,_ECO:0000269|PubMed:20673819,_ECO:0000269|PubMed:20683980,_ECO:0000269|PubMed:21387466}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_gingival_tissues._{ECO:0000269|PubMed:11868160}.\x3b_	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3blarynx\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bbile_duct\x3blung\x3bplacenta\x3bmacula_lutea\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3btestis\x3bciliary_ganglion\x3bpons\x3batrioventricular_node\x3bskeletal_muscle\x3b	0.72054	0.38414	-0.995664936	8.539749941	106.78667	2.24216	rs200712930	442515	Rasopathy	MedGen:CN166718,Orphanet:ORPHA98733	reviewed_by_expert_panel	Benign	0.083	0.330	T	0.000	0.497	N	1.000	0.548	D	1.825	0.480	L	1.47	0.320	T	-1.46	0.358	N	-1.095	0.048	T	0.082	0.322	T	0.010	0.271	T	.	.	0.245	0.222	N	c	-0.356	-0.303	0.143	0.173	0.706	0.609	0	2.68	0.307	-0.141	0.102	0.935	0.490	0.584	0.274	0.998	0.697	11.291	0.483	Ras_guanine_nucleotide_exchange_factor_domain|Ras-like_guanine_nucleotide_exchange_factor,_N-terminal	.	.	.	.	.	.	.	.	.	.	.	.	6.527e-05	0	0	0	0.0009	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,465	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0.0122	Likely Benign
10	112724729	112724729	A	G	exonic	SHOC2	.	nonsynonymous_SNV	SHOC2:NM_001269039:exon2:c.A613G:p.T205A,SHOC2:NM_001324336:exon2:c.A613G:p.T205A,SHOC2:NM_007373:exon2:c.A613G:p.T205A,SHOC2:NM_001324337:exon3:c.A613G:p.T205A	0.991705191552454	0.00829295945769003	1.84898985615785e-06	SHOC2_leucine-rich_repeat_scaffold_protein	FUNCTION:_Regulatory_subunit_of_protein_phosphatase_1_(PP1c)_that_acts_as_a_M-Ras/MRAS_effector_and_participates_in_MAPK_pathway_activation._Upon_M-Ras/MRAS_activation,_targets_PP1c_to_specifically_dephosphorylate_the_'Ser-259'_inhibitory_site_of_RAF1_kinase_and_stimulate_RAF1_activity_at_specialized_signaling_complexes._{ECO:0000269|PubMed:10783161,_ECO:0000269|PubMed:16630891,_ECO:0000269|PubMed:25137548}.\x3b_	DISEASE:_Noonan_syndrome-like_disorder_with_loose_anagen_hair_(NSLH)_[MIM:607721]:_A_syndrome_characterized_by_Noonan_dysmorphic_features_such_as_macrocephaly,_high_forehead,_hypertelorism,_palpebral_ptosis,_low-set_and_posteriorly_rotated_ears,_short_and_webbed_neck,_pectus_anomalies,_in_association_with_pluckable,_sparse,_thin_and_slow-growing_hair._{ECO:0000269|PubMed:19684605,_ECO:0000269|PubMed:25137548}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bpineal_body\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bcornea\x3bnasopharynx\x3bplacenta\x3bmacula_lutea\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bcervix\x3bkidney\x3bmammary_gland\x3bstomach\x3b	superior_cervical_ganglion\x3btestis_-_seminiferous_tubule\x3bprefrontal_cortex\x3btestis\x3btrigeminal_ganglion\x3b	0.46401	0.24608	-0.183570861	39.95046001	30.58108	0.97282	rs768411950	442530	Rasopathy	MedGen:CN166718,Orphanet:ORPHA98733	reviewed_by_expert_panel	Likely_benign	0.077	0.341	T	0.000	0.843	D	1	0.810	D	2.615	0.767	M	1.66	0.275	T	-1.58	0.437	N	-0.919	0.457	T	0.172	0.515	T	0.017	0.389	T	0.293	0.256	0.989	0.882	D	c	0.574	0.633	1.000	0.747	0.706	0.609	0	5.66	0.872	9.325	0.960	1.083	0.853	1.000	0.715	1.000	0.888	15.887	0.789	Leucine-rich_repeat_domain,_L_domain-like	.	.	.	.	.	.	.	.	.	.	.	.	5.698e-05	0	0	0	0	0	8.966e-06	0	0.0004	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,604	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0.0122	Likely Benign
11	532696	532696	C	T	exonic	HRAS	.	synonymous_SNV	HRAS:NM_001130442:exon5:c.G510A:p.K170K,HRAS:NM_005343:exon5:c.G510A:p.K170K,HRAS:NM_001318054:exon6:c.G273A:p.K91K	0.00794104930284198	0.785285637637198	0.20677331305996	Harvey_rat_sarcoma_viral_oncogene_homolog	FUNCTION:_Ras_proteins_bind_GDP/GTP_and_possess_intrinsic_GTPase_activity._{ECO:0000269|PubMed:12740440,_ECO:0000269|PubMed:14500341,_ECO:0000269|PubMed:9020151}.\x3b_	DISEASE:_Costello_syndrome_(CSTLO)_[MIM:218040]:_A_rare_condition_characterized_by_prenatally_increased_growth,_postnatal_growth_deficiency,_mental_retardation,_distinctive_facial_appearance,_cardiovascular_abnormalities_(typically_pulmonic_stenosis,_hypertrophic_cardiomyopathy_and/or_atrial_tachycardia),_tumor_predisposition,_skin_and_musculoskeletal_abnormalities._{ECO:0000269|PubMed:16170316,_ECO:0000269|PubMed:16329078,_ECO:0000269|PubMed:16443854,_ECO:0000269|PubMed:17054105,_ECO:0000269|PubMed:18039947,_ECO:0000269|PubMed:18247425,_ECO:0000269|PubMed:19995790}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Congenital_myopathy_with_excess_of_muscle_spindles_(CMEMS)_[MIM:218040]:_Variant_of_Costello_syndrome._{ECO:0000269|PubMed:17412879}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hurthle_cell_thyroid_carcinoma_(HCTC)_[MIM:607464]:_A_rare_type_of_thyroid_cancer_accounting_for_only_about_3-10%_of_all_differentiated_thyroid_cancers._These_neoplasms_are_considered_a_variant_of_follicular_carcinoma_of_the_thyroid_and_are_referred_to_as_follicular_carcinoma,_oxyphilic_type._{ECO:0000269|PubMed:12727991}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dMutations_which_change_positions_12,_13_or_61_activate_the_potential_of_HRAS_to_transform_cultured_cells_and_are_implicated_in_a_variety_of_human_tumors._{ECO:0000269|PubMed:3670300}.\x3b_DISEASE:_Bladder_cancer_(BLC)_[MIM:109800]:_A_malignancy_originating_in_tissues_of_the_urinary_bladder._It_often_presents_with_multiple_tumors_appearing_at_different_times_and_at_different_sites_in_the_bladder._Most_bladder_cancers_are_transitional_cell_carcinomas_that_begin_in_cells_that_normally_make_up_the_inner_lining_of_the_bladder._Other_types_of_bladder_cancer_include_squamous_cell_carcinoma_(cancer_that_begins_in_thin,_flat_cells)_and_adenocarcinoma_(cancer_that_begins_in_cells_that_make_and_release_mucus_and_other_fluids)._Bladder_cancer_is_a_complex_disorder_with_both_genetic_and_environmental_influences._{ECO:0000269|PubMed:6298635,_ECO:0000269|PubMed:6844927}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Schimmelpenning-Feuerstein-Mims_syndrome_(SFM)_[MIM:163200]:_A_disease_characterized_by_sebaceous_nevi,_often_on_the_face,_associated_with_variable_ipsilateral_abnormalities_of_the_central_nervous_system,_ocular_anomalies,_and_skeletal_defects._Many_oral_manifestations_have_been_reported,_not_only_including_hypoplastic_and_malformed_teeth,_and_mucosal_papillomatosis,_but_also_ankyloglossia,_hemihyperplastic_tongue,_intraoral_nevus,_giant_cell_granuloma,_ameloblastoma,_bone_cysts,_follicular_cysts,_oligodontia,_and_odontodysplasia._Sebaceous_nevi_follow_the_lines_of_Blaschko_and_these_can_continue_as_linear_intraoral_lesions,_as_in_mucosal_papillomatosis._{ECO:0000269|PubMed:22683711}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Widely_expressed._{ECO:0000269|PubMed:14500341}.\x3b_	ovary\x3bdevelopmental\x3bcolon\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3boptic_nerve\x3bwhole_body\x3boesophagus\x3bendometrium\x3bthyroid\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bhypothalamus\x3bblood\x3blens\x3bskeletal_muscle\x3blung\x3bplacenta\x3bvisual_apparatus\x3bhypopharynx\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bcerebellum\x3b	whole_brain\x3bmedulla_oblongata\x3btrigeminal_ganglion\x3b	0.99944	0.99980	-0.339715008	30.06605331	4.91473	0.18207	rs397517143	54472	Costello_syndrome|Rasopathy|not_specified	MedGen:C0587248,OMIM:218040,Orphanet:ORPHA3071,SNOMED_CT:309776008|MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374	reviewed_by_expert_panel	Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	4.499e-05	0	0	0	0.0006	0	0	0	3.249e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,610	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0.0122	Likely Benign
3	12633259	12633259	C	T	exonic	RAF1	.	nonsynonymous_SNV	RAF1:NM_002880:exon11:c.G1141A:p.D381N	0.999776866110749	0.000223133833869176	5.53819998824154e-11	Raf-1_proto-oncogene,_serine/threonine_kinase	FUNCTION:_Serine/threonine-protein_kinase_that_acts_as_a_regulatory_link_between_the_membrane-associated_Ras_GTPases_and_the_MAPK/ERK_cascade,_and_this_critical_regulatory_link_functions_as_a_switch_determining_cell_fate_decisions_including_proliferation,_differentiation,_apoptosis,_survival_and_oncogenic_transformation._RAF1_activation_initiates_a_mitogen-activated_protein_kinase_(MAPK)_cascade_that_comprises_a_sequential_phosphorylation_of_the_dual-specific_MAPK_kinases_(MAP2K1/MEK1_and_MAP2K2/MEK2)_and_the_extracellular_signal-regulated_kinases_(MAPK3/ERK1_and_MAPK1/ERK2)._The_phosphorylated_form_of_RAF1_(on_residues_Ser-338_and_Ser-339,_by_PAK1)_phosphorylates_BAD/Bcl2-_antagonist_of_cell_death_at_'Ser-75'._Phosphorylates_adenylyl_cyclases:_ADCY2,_ADCY5_and_ADCY6,_resulting_in_their_activation._Phosphorylates_PPP1R12A_resulting_in_inhibition_of_the_phosphatase_activity._Phosphorylates_TNNT2/cardiac_muscle_troponin_T._Can_promote_NF-kB_activation_and_inhibit_signal_transducers_involved_in_motility_(ROCK2),_apoptosis_(MAP3K5/ASK1_and_STK3/MST2),_proliferation_and_angiogenesis_(RB1)._Can_protect_cells_from_apoptosis_also_by_translocating_to_the_mitochondria_where_it_binds_BCL2_and_displaces_BAD/Bcl2-antagonist_of_cell_death._Regulates_Rho_signaling_and_migration,_and_is_required_for_normal_wound_healing._Plays_a_role_in_the_oncogenic_transformation_of_epithelial_cells_via_repression_of_the_TJ_protein,_occludin_(OCLN)_by_inducing_the_up-regulation_of_a_transcriptional_repressor_SNAI2/SLUG,_which_induces_down-regulation_of_OCLN._Restricts_caspase_activation_in_response_to_selected_stimuli,_notably_Fas_stimulation,_pathogen-mediated_macrophage_apoptosis,_and_erythroid_differentiation._{ECO:0000269|PubMed:11427728,_ECO:0000269|PubMed:11719507,_ECO:0000269|PubMed:15385642,_ECO:0000269|PubMed:15618521,_ECO:0000269|PubMed:15849194,_ECO:0000269|PubMed:16892053,_ECO:0000269|PubMed:16924233,_ECO:0000269|PubMed:9360956}.\x3b_	DISEASE:_Noonan_syndrome_5_(NS5)_[MIM:611553]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._{ECO:0000269|PubMed:17603482,_ECO:0000269|PubMed:17603483,_ECO:0000269|PubMed:20683980}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_LEOPARD_syndrome_2_(LPRD2)_[MIM:611554]:_A_disorder_characterized_by_lentigines,_electrocardiographic_conduction_abnormalities,_ocular_hypertelorism,_pulmonic_stenosis,_abnormalities_of_genitalia,_retardation_of_growth,_and_sensorineural_deafness._{ECO:0000269|PubMed:17603483}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Cardiomyopathy,_dilated_1NN_(CMD1NN)_[MIM:615916]:_A_disorder_characterized_by_ventricular_dilation_and_impaired_systolic_function,_resulting_in_congestive_heart_failure_and_arrhythmia._Patients_are_at_risk_of_premature_death._{ECO:0000269|PubMed:24777450}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_In_skeletal_muscle,_isoform_1_is_more_abundant_than_isoform_2._{ECO:0000269|PubMed:1886707}.\x3b_	ovary\x3bumbilical_cord\x3bsympathetic_chain\x3bskin\x3bretina\x3bbone_marrow\x3bprostate\x3boptic_nerve\x3bfrontal_lobe\x3bcochlea\x3bendometrium\x3bgerminal_center\x3bbladder\x3bbrain\x3bheart\x3bcartilage\x3bspinal_cord\x3badrenal_cortex\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bmacula_lutea\x3bvisual_apparatus\x3bliver\x3balveolus\x3bspleen\x3bcervix\x3bmammary_gland\x3bperipheral_nerve\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3buterus\x3bwhole_body\x3boesophagus\x3bbone\x3btestis\x3bspinal_ganglion\x3bpineal_gland\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bislets_of_Langerhans\x3bhypothalamus\x3bmuscle\x3bpancreas\x3blung\x3btrachea\x3bplacenta\x3bamnion\x3bkidney\x3bstomach\x3baorta\x3bthymus\x3b	superior_cervical_ganglion\x3bciliary_ganglion\x3bwhole_blood\x3bskeletal_muscle\x3b	0.99869	0.93060	-0.646543901	16.44255721	87.82499	2.00185	rs559632360	179051	Rasopathy|not_specified	MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374	reviewed_by_expert_panel	Benign	0.741	0.054	T	0.000	0.523	N	0.801	0.291	N	0.725	0.188	N	-1.61	0.823	D	-1.58	0.420	N	-0.808	0.547	T	0.262	0.633	T	.	.	.	0.348	0.345	0.910	0.524	D	c	-0.798	-0.629	0.999	0.385	0.707	0.730	0	2.44	0.287	2.247	0.426	-2.474	0.003	0.959	0.333	0.030	0.147	8.808	0.339	Protein_kinase_domain|Protein_kinase-like_domain|Serine-threonine/tyrosine-protein_kinase,_catalytic_domain	.	.	.	.	3.23e-05	0	0	0	0	0	0	0.0010	0.0003	0	0	0	0	0	8.961e-06	0	0.0022	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,478	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0.0122	Likely Benign
12	25398229	25398229	G	A	exonic	KRAS	.	synonymous_SNV	KRAS:NM_004985:exon2:c.C90T:p.D30D,KRAS:NM_033360:exon2:c.C90T:p.D30D	0.00106119304255182	0.603148256118395	0.395790550839053	Kirsten_rat_sarcoma_viral_oncogene_homolog	FUNCTION:_Ras_proteins_bind_GDP/GTP_and_possess_intrinsic_GTPase_activity._Plays_an_important_role_in_the_regulation_of_cell_proliferation_(PubMed:23698361,_PubMed:22711838)._{ECO:0000269|PubMed:22711838,_ECO:0000269|PubMed:23698361,_ECO:0000305}.\x3b_	DISEASE:_Leukemia,_acute_myelogenous_(AML)_[MIM:601626]:_A_subtype_of_acute_leukemia,_a_cancer_of_the_white_blood_cells._AML_is_a_malignant_disease_of_bone_marrow_characterized_by_maturational_arrest_of_hematopoietic_precursors_at_an_early_stage_of_development._Clonal_expansion_of_myeloid_blasts_occurs_in_bone_marrow,_blood,_and_other_tissue._Myelogenous_leukemias_develop_from_changes_in_cells_that_normally_produce_neutrophils,_basophils,_eosinophils_and_monocytes._{ECO:0000269|PubMed:8955068}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Leukemia,_juvenile_myelomonocytic_(JMML)_[MIM:607785]:_An_aggressive_pediatric_myelodysplastic_syndrome/myeloproliferative_disorder_characterized_by_malignant_transformation_in_the_hematopoietic_stem_cell_compartment_with_proliferation_of_differentiated_progeny._Patients_have_splenomegaly,_enlarged_lymph_nodes,_rashes,_and_hemorrhages._{ECO:0000269|PubMed:17332249}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Noonan_syndrome_3_(NS3)_[MIM:609942]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._{ECO:0000269|PubMed:16474405,_ECO:0000269|PubMed:16773572,_ECO:0000269|PubMed:17056636,_ECO:0000269|PubMed:17468812,_ECO:0000269|PubMed:19396835}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Gastric_cancer_(GASC)_[MIM:613659]:_A_malignant_disease_which_starts_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._The_term_gastric_cancer_or_gastric_carcinoma_refers_to_adenocarcinoma_of_the_stomach_that_accounts_for_most_of_all_gastric_malignant_tumors._Two_main_histologic_types_are_recognized,_diffuse_type_and_intestinal_type_carcinomas._Diffuse_tumors_are_poorly_differentiated_infiltrating_lesions,_resulting_in_thickening_of_the_stomach._In_contrast,_intestinal_tumors_are_usually_exophytic,_often_ulcerating,_and_associated_with_intestinal_metaplasia_of_the_stomach,_most_often_observed_in_sporadic_disease._{ECO:0000269|PubMed:14534542,_ECO:0000269|PubMed:3034404,_ECO:0000269|PubMed:7773929}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dDefects_in_KRAS_are_a_cause_of_pylocytic_astrocytoma_(PA)._Pylocytic_astrocytomas_are_neoplasms_of_the_brain_and_spinal_cord_derived_from_glial_cells_which_vary_from_histologically_benign_forms_to_highly_anaplastic_and_malignant_tumors._{ECO:0000269|PubMed:16247081}.\x3b_DISEASE:_Cardiofaciocutaneous_syndrome_2_(CFC2)_[MIM:615278]:_A_form_of_cardiofaciocutaneous_syndrome,_a_multiple_congenital_anomaly_disorder_characterized_by_a_distinctive_facial_appearance,_heart_defects_and_mental_retardation._Heart_defects_include_pulmonic_stenosis,_atrial_septal_defects_and_hypertrophic_cardiomyopathy._Some_affected_individuals_present_with_ectodermal_abnormalities_such_as_sparse,_friable_hair,_hyperkeratotic_skin_lesions_and_a_generalized_ichthyosis-like_condition._Typical_facial_features_are_similar_to_Noonan_syndrome._They_include_high_forehead_with_bitemporal_constriction,_hypoplastic_supraorbital_ridges,_downslanting_palpebral_fissures,_a_depressed_nasal_bridge,_and_posteriorly_angulated_ears_with_prominent_helices._CFC2_patients_often_do_not_have_the_skin_abnormalities,_such_as_ichthyosis,_hyperkeratosis,_and_hemangioma_observed_in_CFC1._{ECO:0000269|PubMed:16474404,_ECO:0000269|PubMed:16474405,_ECO:0000269|PubMed:17056636,_ECO:0000269|PubMed:21797849}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dKRAS_mutations_are_involved_in_cancer_development._{ECO:0000269|PubMed:14534542,_ECO:0000269|PubMed:1553789,_ECO:0000269|PubMed:16533793,_ECO:0000269|PubMed:3034404,_ECO:0000269|PubMed:3627975,_ECO:0000269|PubMed:6092920,_ECO:0000269|PubMed:6695174,_ECO:0000269|PubMed:7773929}.\x3b_	.	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bfrontal_lobe\x3bcochlea\x3bendometrium\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bspinal_ganglion\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bspinal_cord\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bbile_duct\x3bpancreas\x3blung\x3bcornea\x3bplacenta\x3bvisual_apparatus\x3bliver\x3bcervix\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bperipheral_nerve\x3b	dorsal_root_ganglion\x3bwhole_brain\x3bamygdala\x3boccipital_lobe\x3bsuperior_cervical_ganglion\x3batrioventricular_node\x3bpons\x3bsubthalamic_nucleus\x3bprefrontal_cortex\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3bcerebellum\x3b	0.99997	0.53296	-0.141298762	42.87567823	3.46519	0.12617	rs113623140	141764	Rasopathy|not_specified	MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374	reviewed_by_expert_panel	Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	6.46e-05	0	0	0.0033	0	0	6.668e-05	0	0.0002	0.0002	0.0003	0.0012	0.0005	4.515e-05	0.0001	0.0004	6.657e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,640	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0.0122	Likely Benign
2	39240612	39240612	C	G	exonic	SOS1	.	nonsynonymous_SNV	SOS1:NM_005633:exon13:c.G2156C:p.G719A	0.99999989519361	1.04806389809942e-07	1.77231495230296e-20	SOS_Ras/Rac_guanine_nucleotide_exchange_factor_1	FUNCTION:_Promotes_the_exchange_of_Ras-bound_GDP_by_GTP._Catalytic_component_of_a_trimeric_complex_that_participates_in_transduction_of_signals_from_Ras_to_Rac_by_promoting_the_Rac-specific_guanine_nucleotide_exchange_factor_(GEF)_activity_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Noonan_syndrome_4_(NS4)_[MIM:610733]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._Some_patients_with_NS4_have_polyarticular_villonodular_synovitis._{ECO:0000269|PubMed:17143282,_ECO:0000269|PubMed:17143285,_ECO:0000269|PubMed:19020799,_ECO:0000269|PubMed:19438935,_ECO:0000269|PubMed:19953625,_ECO:0000269|PubMed:20673819,_ECO:0000269|PubMed:20683980,_ECO:0000269|PubMed:21387466}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_gingival_tissues._{ECO:0000269|PubMed:11868160}.\x3b_	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3blarynx\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bbile_duct\x3blung\x3bplacenta\x3bmacula_lutea\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3btestis\x3bciliary_ganglion\x3bpons\x3batrioventricular_node\x3bskeletal_muscle\x3b	0.72054	0.38414	-0.995664936	8.539749941	106.78667	2.24216	rs200794965	49168	Rasopathy|not_specified	MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374	reviewed_by_expert_panel	Likely_benign	0.357	0.120	T	0.000	0.559	D	1.000	0.516	D	-0.29	0.037	N	1.55	0.299	T	-0.18	0.103	N	-1.062	0.113	T	0.046	0.196	T	0.005	0.140	T	0.344	0.339	0.895	0.496	D	c	-0.174	0.091	1.000	0.747	0.707	0.730	0	5.92	0.955	3.282	0.512	0.935	0.490	1.000	0.715	1.000	0.888	20.327	0.987	Ras_guanine_nucleotide_exchange_factor_domain|Ras-like_guanine_nucleotide_exchange_factor,_N-terminal	.	.	.	.	9.787e-05	0	0	0	0	0.0003	0.0001	0	0.0002	0	5.959e-05	0	0	8.972e-05	0.0004	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,464	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	1	1	0	0	0.0059	Likely Benign
2	39222280	39222280	C	G	exonic	SOS1	.	synonymous_SNV	SOS1:NM_005633:exon20:c.G3330C:p.S1110S	0.99999989519361	1.04806389809942e-07	1.77231495230296e-20	SOS_Ras/Rac_guanine_nucleotide_exchange_factor_1	FUNCTION:_Promotes_the_exchange_of_Ras-bound_GDP_by_GTP._Catalytic_component_of_a_trimeric_complex_that_participates_in_transduction_of_signals_from_Ras_to_Rac_by_promoting_the_Rac-specific_guanine_nucleotide_exchange_factor_(GEF)_activity_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Noonan_syndrome_4_(NS4)_[MIM:610733]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._Some_patients_with_NS4_have_polyarticular_villonodular_synovitis._{ECO:0000269|PubMed:17143282,_ECO:0000269|PubMed:17143285,_ECO:0000269|PubMed:19020799,_ECO:0000269|PubMed:19438935,_ECO:0000269|PubMed:19953625,_ECO:0000269|PubMed:20673819,_ECO:0000269|PubMed:20683980,_ECO:0000269|PubMed:21387466}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_gingival_tissues._{ECO:0000269|PubMed:11868160}.\x3b_	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3blarynx\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bbile_duct\x3blung\x3bplacenta\x3bmacula_lutea\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3btestis\x3bciliary_ganglion\x3bpons\x3batrioventricular_node\x3bskeletal_muscle\x3b	0.72054	0.38414	-0.995664936	8.539749941	106.78667	2.24216	rs146383828	442513	Rasopathy|not_specified	MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374	reviewed_by_expert_panel	Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0002	0.0006	0	0	0	0	0	0	5.705e-05	0.0007	0.0001	0	0	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,462	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0.0028	Likely Benign
19	4123828	4123828	G	A	exonic	MAP2K2	.	synonymous_SNV	MAP2K2:NM_030662:exon1:c.C45T:p.N15N	0.86326115931858	0.136320885012997	0.00041795566842237	mitogen-activated_protein_kinase_kinase_2	FUNCTION:_Catalyzes_the_concomitant_phosphorylation_of_a_threonine_and_a_tyrosine_residue_in_a_Thr-Glu-Tyr_sequence_located_in_MAP_kinases._Activates_the_ERK1_and_ERK2_MAP_kinases_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Cardiofaciocutaneous_syndrome_4_(CFC4)_[MIM:615280]:_A_form_of_cardiofaciocutaneous_syndrome,_a_multiple_congenital_anomaly_disorder_characterized_by_a_distinctive_facial_appearance,_heart_defects_and_mental_retardation._Heart_defects_include_pulmonic_stenosis,_atrial_septal_defects_and_hypertrophic_cardiomyopathy._Some_affected_individuals_present_with_ectodermal_abnormalities_such_as_sparse,_friable_hair,_hyperkeratotic_skin_lesions_and_a_generalized_ichthyosis-like_condition._Typical_facial_features_are_similar_to_Noonan_syndrome._They_include_high_forehead_with_bitemporal_constriction,_hypoplastic_supraorbital_ridges,_downslanting_palpebral_fissures,_a_depressed_nasal_bridge,_and_posteriorly_angulated_ears_with_prominent_helices._{ECO:0000269|PubMed:16439621,_ECO:0000269|PubMed:18042262,_ECO:0000269|PubMed:20358587}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	medulla_oblongata\x3bsmooth_muscle\x3bovary\x3bsalivary_gland\x3bsympathetic_chain\x3bcolon\x3bparathyroid\x3bskin\x3buterus\x3bprostate\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bmuscle\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbile_duct\x3bpancreas\x3blung\x3badrenal_gland\x3bplacenta\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	amygdala\x3bprefrontal_cortex\x3btestis\x3bpons\x3bcingulate_cortex\x3b	0.88489	0.51187	-0.800872469	12.33191791	40.94266	1.19949	rs767770776	442542	Rasopathy	MedGen:CN166718,Orphanet:ORPHA98733	reviewed_by_expert_panel	Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	6.382e-05	0	0	0	0	0	0	0	0.0005	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,942	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0.0028	Likely Benign
19	4099305	4099305	G	A	exonic	MAP2K2	.	synonymous_SNV	MAP2K2:NM_030662:exon7:c.C813T:p.D271D	0.86326115931858	0.136320885012997	0.00041795566842237	mitogen-activated_protein_kinase_kinase_2	FUNCTION:_Catalyzes_the_concomitant_phosphorylation_of_a_threonine_and_a_tyrosine_residue_in_a_Thr-Glu-Tyr_sequence_located_in_MAP_kinases._Activates_the_ERK1_and_ERK2_MAP_kinases_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Cardiofaciocutaneous_syndrome_4_(CFC4)_[MIM:615280]:_A_form_of_cardiofaciocutaneous_syndrome,_a_multiple_congenital_anomaly_disorder_characterized_by_a_distinctive_facial_appearance,_heart_defects_and_mental_retardation._Heart_defects_include_pulmonic_stenosis,_atrial_septal_defects_and_hypertrophic_cardiomyopathy._Some_affected_individuals_present_with_ectodermal_abnormalities_such_as_sparse,_friable_hair,_hyperkeratotic_skin_lesions_and_a_generalized_ichthyosis-like_condition._Typical_facial_features_are_similar_to_Noonan_syndrome._They_include_high_forehead_with_bitemporal_constriction,_hypoplastic_supraorbital_ridges,_downslanting_palpebral_fissures,_a_depressed_nasal_bridge,_and_posteriorly_angulated_ears_with_prominent_helices._{ECO:0000269|PubMed:16439621,_ECO:0000269|PubMed:18042262,_ECO:0000269|PubMed:20358587}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	medulla_oblongata\x3bsmooth_muscle\x3bovary\x3bsalivary_gland\x3bsympathetic_chain\x3bcolon\x3bparathyroid\x3bskin\x3buterus\x3bprostate\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bmuscle\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbile_duct\x3bpancreas\x3blung\x3badrenal_gland\x3bplacenta\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	amygdala\x3bprefrontal_cortex\x3btestis\x3bpons\x3bcingulate_cortex\x3b	0.88489	0.51187	-0.800872469	12.33191791	40.94266	1.19949	rs201726622	377687	Rasopathy|not_specified	MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374	reviewed_by_expert_panel	Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	6.065e-05	0	3.098e-05	0	6.081e-05	4.762e-05	9.661e-05	0	3.395e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,929	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0.0028	Likely Benign
2	39249922	39249922	T	C	exonic	SOS1	.	synonymous_SNV	SOS1:NM_005633:exon10:c.A1647G:p.T549T	0.99999989519361	1.04806389809942e-07	1.77231495230296e-20	SOS_Ras/Rac_guanine_nucleotide_exchange_factor_1	FUNCTION:_Promotes_the_exchange_of_Ras-bound_GDP_by_GTP._Catalytic_component_of_a_trimeric_complex_that_participates_in_transduction_of_signals_from_Ras_to_Rac_by_promoting_the_Rac-specific_guanine_nucleotide_exchange_factor_(GEF)_activity_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Noonan_syndrome_4_(NS4)_[MIM:610733]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._Some_patients_with_NS4_have_polyarticular_villonodular_synovitis._{ECO:0000269|PubMed:17143282,_ECO:0000269|PubMed:17143285,_ECO:0000269|PubMed:19020799,_ECO:0000269|PubMed:19438935,_ECO:0000269|PubMed:19953625,_ECO:0000269|PubMed:20673819,_ECO:0000269|PubMed:20683980,_ECO:0000269|PubMed:21387466}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_gingival_tissues._{ECO:0000269|PubMed:11868160}.\x3b_	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3blarynx\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bbile_duct\x3blung\x3bplacenta\x3bmacula_lutea\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3btestis\x3bciliary_ganglion\x3bpons\x3batrioventricular_node\x3bskeletal_muscle\x3b	0.72054	0.38414	-0.995664936	8.539749941	106.78667	2.24216	rs139683425	142939	Rasopathy|not_specified	MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374	reviewed_by_expert_panel	Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9.697e-05	0.0003	0	0	0	0	0	0	3.664e-05	0.0005	5.96e-05	0	0	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,467	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0.0028	Likely Benign
15	66782869	66782869	T	C	exonic	MAP2K1	.	synonymous_SNV	MAP2K1:NM_002755:exon11:c.T1098C:p.A366A	0.994501270366062	0.00549805295620231	6.76677735529064e-07	mitogen-activated_protein_kinase_kinase_1	FUNCTION:_Dual_specificity_protein_kinase_which_acts_as_an_essential_component_of_the_MAP_kinase_signal_transduction_pathway._Binding_of_extracellular_ligands_such_as_growth_factors,_cytokines_and_hormones_to_their_cell-surface_receptors_activates_RAS_and_this_initiates_RAF1_activation._RAF1_then_further_activates_the_dual-specificity_protein_kinases_MAP2K1/MEK1_and_MAP2K2/MEK2._Both_MAP2K1/MEK1_and_MAP2K2/MEK2_function_specifically_in_the_MAPK/ERK_cascade,_and_catalyze_the_concomitant_phosphorylation_of_a_threonine_and_a_tyrosine_residue_in_a_Thr-Glu-Tyr_sequence_located_in_the_extracellular_signal-regulated_kinases_MAPK3/ERK1_and_MAPK1/ERK2,_leading_to_their_activation_and_further_transduction_of_the_signal_within_the_MAPK/ERK_cascade._Depending_on_the_cellular_context,_this_pathway_mediates_diverse_biological_functions_such_as_cell_growth,_adhesion,_survival_and_differentiation,_predominantly_through_the_regulation_of_transcription,_metabolism_and_cytoskeletal_rearrangements._One_target_of_the_MAPK/ERK_cascade_is_peroxisome_proliferator-_activated_receptor_gamma_(PPARG),_a_nuclear_receptor_that_promotes_differentiation_and_apoptosis._MAP2K1/MEK1_has_been_shown_to_export_PPARG_from_the_nucleus._The_MAPK/ERK_cascade_is_also_involved_in_the_regulation_of_endosomal_dynamics,_including_lysosome_processing_and_endosome_cycling_through_the_perinuclear_recycling_compartment_(PNRC),_as_well_as_in_the_fragmentation_of_the_Golgi_apparatus_during_mitosis._{ECO:0000269|PubMed:14737111,_ECO:0000269|PubMed:17101779}.\x3b_	DISEASE:_Cardiofaciocutaneous_syndrome_3_(CFC3)_[MIM:615279]:_A_form_of_cardiofaciocutaneous_syndrome,_a_multiple_congenital_anomaly_disorder_characterized_by_a_distinctive_facial_appearance,_heart_defects_and_mental_retardation._Heart_defects_include_pulmonic_stenosis,_atrial_septal_defects_and_hypertrophic_cardiomyopathy._Some_affected_individuals_present_with_ectodermal_abnormalities_such_as_sparse,_friable_hair,_hyperkeratotic_skin_lesions_and_a_generalized_ichthyosis-like_condition._Typical_facial_features_are_similar_to_Noonan_syndrome._They_include_high_forehead_with_bitemporal_constriction,_hypoplastic_supraorbital_ridges,_downslanting_palpebral_fissures,_a_depressed_nasal_bridge,_and_posteriorly_angulated_ears_with_prominent_helices._Distinctive_features_of_CFC3_include_macrostomia_and_horizontal_shape_of_palpebral_fissures._{ECO:0000269|PubMed:16439621,_ECO:0000269|PubMed:18042262}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Widely_expressed,_with_extremely_low_levels_in_brain._{ECO:0000269|PubMed:1281467}.\x3b_	ovary\x3bsympathetic_chain\x3bskin\x3bbone_marrow\x3bretina\x3bprostate\x3boptic_nerve\x3bendometrium\x3bthyroid\x3bgerminal_center\x3bbladder\x3bbrain\x3bheart\x3bcartilage\x3btongue\x3bpineal_body\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3btrabecular_meshwork\x3bvisual_apparatus\x3bmacula_lutea\x3bliver\x3bspleen\x3bmammary_gland\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bchoroid\x3bfovea_centralis\x3buterus\x3bwhole_body\x3bbone\x3btestis\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bislets_of_Langerhans\x3bhypothalamus\x3bpancreas\x3blung\x3bnasopharynx\x3bplacenta\x3bhippocampus\x3bhead_and_neck\x3bkidney\x3bstomach\x3baorta\x3bthymus\x3b	whole_brain\x3bamygdala\x3bthalamus\x3boccipital_lobe\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3bhypothalamus\x3btemporal_lobe\x3bcaudate_nucleus\x3bsubthalamic_nucleus\x3bprefrontal_cortex\x3bglobus_pallidus\x3bcingulate_cortex\x3bparietal_lobe\x3bcerebellum\x3b	0.94061	0.84890	-0.449946534	24.00330267	4.89315	0.18138	rs200293968	442538	Rasopathy	MedGen:CN166718,Orphanet:ORPHA98733	reviewed_by_expert_panel	Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3.228e-05	0	0	0	0.0006	0	0	0	8.528e-05	0	0	0	0.0012	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,887	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0.0028	Likely Benign
2	39285934	39285934	T	C	exonic	SOS1	.	synonymous_SNV	SOS1:NM_005633:exon3:c.A225G:p.Q75Q	0.99999989519361	1.04806389809942e-07	1.77231495230296e-20	SOS_Ras/Rac_guanine_nucleotide_exchange_factor_1	FUNCTION:_Promotes_the_exchange_of_Ras-bound_GDP_by_GTP._Catalytic_component_of_a_trimeric_complex_that_participates_in_transduction_of_signals_from_Ras_to_Rac_by_promoting_the_Rac-specific_guanine_nucleotide_exchange_factor_(GEF)_activity_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Noonan_syndrome_4_(NS4)_[MIM:610733]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._Some_patients_with_NS4_have_polyarticular_villonodular_synovitis._{ECO:0000269|PubMed:17143282,_ECO:0000269|PubMed:17143285,_ECO:0000269|PubMed:19020799,_ECO:0000269|PubMed:19438935,_ECO:0000269|PubMed:19953625,_ECO:0000269|PubMed:20673819,_ECO:0000269|PubMed:20683980,_ECO:0000269|PubMed:21387466}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_gingival_tissues._{ECO:0000269|PubMed:11868160}.\x3b_	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3blarynx\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bbile_duct\x3blung\x3bplacenta\x3bmacula_lutea\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3btestis\x3bciliary_ganglion\x3bpons\x3batrioventricular_node\x3bskeletal_muscle\x3b	0.72054	0.38414	-0.995664936	8.539749941	106.78667	2.24216	rs560037748	442519	Rasopathy	MedGen:CN166718,Orphanet:ORPHA98733	reviewed_by_expert_panel	Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0001	0	0	0	0	0	4.488e-05	0	0.0008	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,472	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0.0028	Likely Benign
2	39285865	39285865	C	T	exonic	SOS1	.	synonymous_SNV	SOS1:NM_005633:exon3:c.G294A:p.K98K	0.99999989519361	1.04806389809942e-07	1.77231495230296e-20	SOS_Ras/Rac_guanine_nucleotide_exchange_factor_1	FUNCTION:_Promotes_the_exchange_of_Ras-bound_GDP_by_GTP._Catalytic_component_of_a_trimeric_complex_that_participates_in_transduction_of_signals_from_Ras_to_Rac_by_promoting_the_Rac-specific_guanine_nucleotide_exchange_factor_(GEF)_activity_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Noonan_syndrome_4_(NS4)_[MIM:610733]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._Some_patients_with_NS4_have_polyarticular_villonodular_synovitis._{ECO:0000269|PubMed:17143282,_ECO:0000269|PubMed:17143285,_ECO:0000269|PubMed:19020799,_ECO:0000269|PubMed:19438935,_ECO:0000269|PubMed:19953625,_ECO:0000269|PubMed:20673819,_ECO:0000269|PubMed:20683980,_ECO:0000269|PubMed:21387466}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_gingival_tissues._{ECO:0000269|PubMed:11868160}.\x3b_	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3blarynx\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bbile_duct\x3blung\x3bplacenta\x3bmacula_lutea\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3btestis\x3bciliary_ganglion\x3bpons\x3batrioventricular_node\x3bskeletal_muscle\x3b	0.72054	0.38414	-0.995664936	8.539749941	106.78667	2.24216	rs748478952	442517	Rasopathy	MedGen:CN166718,Orphanet:ORPHA98733	reviewed_by_expert_panel	Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	7.727e-05	0	0	0	0	0	0	0	0.0006	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,470	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0.0028	Likely Benign
10	112724479	112724479	G	A	exonic	SHOC2	.	synonymous_SNV	SHOC2:NM_001269039:exon2:c.G363A:p.E121E,SHOC2:NM_001324336:exon2:c.G363A:p.E121E,SHOC2:NM_007373:exon2:c.G363A:p.E121E,SHOC2:NM_001324337:exon3:c.G363A:p.E121E	0.991705191552454	0.00829295945769003	1.84898985615785e-06	SHOC2_leucine-rich_repeat_scaffold_protein	FUNCTION:_Regulatory_subunit_of_protein_phosphatase_1_(PP1c)_that_acts_as_a_M-Ras/MRAS_effector_and_participates_in_MAPK_pathway_activation._Upon_M-Ras/MRAS_activation,_targets_PP1c_to_specifically_dephosphorylate_the_'Ser-259'_inhibitory_site_of_RAF1_kinase_and_stimulate_RAF1_activity_at_specialized_signaling_complexes._{ECO:0000269|PubMed:10783161,_ECO:0000269|PubMed:16630891,_ECO:0000269|PubMed:25137548}.\x3b_	DISEASE:_Noonan_syndrome-like_disorder_with_loose_anagen_hair_(NSLH)_[MIM:607721]:_A_syndrome_characterized_by_Noonan_dysmorphic_features_such_as_macrocephaly,_high_forehead,_hypertelorism,_palpebral_ptosis,_low-set_and_posteriorly_rotated_ears,_short_and_webbed_neck,_pectus_anomalies,_in_association_with_pluckable,_sparse,_thin_and_slow-growing_hair._{ECO:0000269|PubMed:19684605,_ECO:0000269|PubMed:25137548}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bpineal_body\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bcornea\x3bnasopharynx\x3bplacenta\x3bmacula_lutea\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bcervix\x3bkidney\x3bmammary_gland\x3bstomach\x3b	superior_cervical_ganglion\x3btestis_-_seminiferous_tubule\x3bprefrontal_cortex\x3btestis\x3btrigeminal_ganglion\x3b	0.46401	0.24608	-0.183570861	39.95046001	30.58108	0.97282	rs115713408	442528	Rasopathy	MedGen:CN166718,Orphanet:ORPHA98733	reviewed_by_expert_panel	Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	6.459e-05	0.0002	0	0	0	0	0	0	3.255e-05	0.0005	0	0	0	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,600	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0.0028	Likely Benign
2	39213309	39213309	C	T	exonic	SOS1	.	nonsynonymous_SNV	SOS1:NM_005633:exon23:c.G3658A:p.V1220M	0.99999989519361	1.04806389809942e-07	1.77231495230296e-20	SOS_Ras/Rac_guanine_nucleotide_exchange_factor_1	FUNCTION:_Promotes_the_exchange_of_Ras-bound_GDP_by_GTP._Catalytic_component_of_a_trimeric_complex_that_participates_in_transduction_of_signals_from_Ras_to_Rac_by_promoting_the_Rac-specific_guanine_nucleotide_exchange_factor_(GEF)_activity_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Noonan_syndrome_4_(NS4)_[MIM:610733]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._Some_patients_with_NS4_have_polyarticular_villonodular_synovitis._{ECO:0000269|PubMed:17143282,_ECO:0000269|PubMed:17143285,_ECO:0000269|PubMed:19020799,_ECO:0000269|PubMed:19438935,_ECO:0000269|PubMed:19953625,_ECO:0000269|PubMed:20673819,_ECO:0000269|PubMed:20683980,_ECO:0000269|PubMed:21387466}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_gingival_tissues._{ECO:0000269|PubMed:11868160}.\x3b_	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3blarynx\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bbile_duct\x3blung\x3bplacenta\x3bmacula_lutea\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3btestis\x3bciliary_ganglion\x3bpons\x3batrioventricular_node\x3bskeletal_muscle\x3b	0.72054	0.38414	-0.995664936	8.539749941	106.78667	2.24216	rs776814547	442511	Rasopathy	MedGen:CN166718,Orphanet:ORPHA98733	reviewed_by_expert_panel	Likely_benign	0.07	0.353	T	0.000	0.497	D	1.000	0.548	D	1.5	0.380	L	-0.94	0.773	T	0.04	0.065	N	-0.128	0.795	T	0.526	0.824	D	0.085	0.746	D	0.087	0.009	0.928	0.562	D	c	0.586	0.622	1.000	0.747	0.707	0.730	0	5.8	0.921	4.111	0.573	0.935	0.490	1.000	0.715	1.000	0.888	20.059	0.977	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0001	0	2.98e-05	0	0	0	0	0	0.0008	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,459	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0.0028	Likely Benign
10	89692731	89692731	G	T	intronic	PTEN	.	.	.	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs35034871	98725	Hereditary_cancer-predisposing_syndrome	MedGen:C0027672,SNOMED_CT:699346009	criteria_provided,_single_submitter	Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0002	0	0	0	0.0037	0.0003	0	0	0.0005	0	0	0	0.0067	0	0	0	3.505e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,533	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0.0028	Likely Benign
7	140500166	140500166	T	C	exonic	BRAF	.	nonsynonymous_SNV	BRAF:NM_004333:exon7:c.A976G:p.I326V	0.999978196041997	2.18039579639691e-05	3.88216441101404e-14	B-Raf_proto-oncogene,_serine/threonine_kinase	FUNCTION:_Protein_kinase_involved_in_the_transduction_of_mitogenic_signals_from_the_cell_membrane_to_the_nucleus._May_play_a_role_in_the_postsynaptic_responses_of_hippocampal_neuron._Phosphorylates_MAP2K1,_and_thereby_contributes_to_the_MAP_kinase_signal_transduction_pathway._{ECO:0000269|PubMed:21441910}.\x3b_	DISEASE:_Note\x3dDefects_in_BRAF_are_found_in_a_wide_range_of_cancers._{ECO:0000269|PubMed:18974108}.\x3b_DISEASE:_Colorectal_cancer_(CRC)_[MIM:114500]:_A_complex_disease_characterized_by_malignant_lesions_arising_from_the_inner_wall_of_the_large_intestine_(the_colon)_and_the_rectum._Genetic_alterations_are_often_associated_with_progression_from_premalignant_lesion_(adenoma)_to_invasive_adenocarcinoma._Risk_factors_for_cancer_of_the_colon_and_rectum_include_colon_polyps,_long-standing_ulcerative_colitis,_and_genetic_family_history._{ECO:0000269|PubMed:12198537,_ECO:0000269|PubMed:23263490,_ECO:0000269|PubMed:24455489}._Note\x3dThe_disease_may_be_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lung_cancer_(LNCR)_[MIM:211980]:_A_common_malignancy_affecting_tissues_of_the_lung._The_most_common_form_of_lung_cancer_is_non-small_cell_lung_cancer_(NSCLC)_that_can_be_divided_into_3_major_histologic_subtypes:_squamous_cell_carcinoma,_adenocarcinoma,_and_large_cell_lung_cancer._NSCLC_is_often_diagnosed_at_an_advanced_stage_and_has_a_poor_prognosis._{ECO:0000269|PubMed:12460919}._Note\x3dThe_gene_represented_in_this_entry_is_involved_in_disease_pathogenesis.\x3b_DISEASE:_Familial_non-Hodgkin_lymphoma_(NHL)_[MIM:605027]:_Cancer_that_starts_in_cells_of_the_lymph_system,_which_is_part_of_the_body's_immune_system._NHLs_can_occur_at_any_age_and_are_often_marked_by_enlarged_lymph_nodes,_fever_and_weight_loss._{ECO:0000269|PubMed:14612909}._Note\x3dThe_gene_represented_in_this_entry_is_involved_in_disease_pathogenesis.\x3b_DISEASE:_Cardiofaciocutaneous_syndrome_1_(CFC1)_[MIM:115150]:_A_multiple_congenital_anomaly_disorder_characterized_by_a_distinctive_facial_appearance,_heart_defects_and_mental_retardation._Heart_defects_include_pulmonic_stenosis,_atrial_septal_defects_and_hypertrophic_cardiomyopathy._Some_affected_individuals_present_with_ectodermal_abnormalities_such_as_sparse,_friable_hair,_hyperkeratotic_skin_lesions_and_a_generalized_ichthyosis-like_condition._Typical_facial_features_are_similar_to_Noonan_syndrome._They_include_high_forehead_with_bitemporal_constriction,_hypoplastic_supraorbital_ridges,_downslanting_palpebral_fissures,_a_depressed_nasal_bridge,_and_posteriorly_angulated_ears_with_prominent_helices._{ECO:0000269|PubMed:16439621,_ECO:0000269|PubMed:16474404,_ECO:0000269|PubMed:18042262,_ECO:0000269|PubMed:19206169}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Noonan_syndrome_7_(NS7)_[MIM:613706]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._{ECO:0000269|PubMed:19206169}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_LEOPARD_syndrome_3_(LPRD3)_[MIM:613707]:_A_disorder_characterized_by_lentigines,_electrocardiographic_conduction_abnormalities,_ocular_hypertelorism,_pulmonic_stenosis,_abnormalities_of_genitalia,_retardation_of_growth,_and_sensorineural_deafness._{ECO:0000269|PubMed:19206169}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_BRAF_is_found_in_pilocytic_astrocytomas._A_tandem_duplication_of_2_Mb_at_7q34_leads_to_the_expression_of_a_KIAA1549-BRAF_fusion_protein_with_a_constitutive_kinase_activity_and_inducing_cell_transformation._{ECO:0000269|PubMed:18974108}.\x3b_	TISSUE_SPECIFICITY:_Brain_and_testis.\x3b_	unclassifiable_(Anatomical_System)\x3bamygdala\x3bislets_of_Langerhans\x3bwhole_body\x3blung\x3bfrontal_lobe\x3bplacenta\x3bthyroid\x3bliver\x3btestis\x3bhead_and_neck\x3bspleen\x3bgerminal_center\x3bbrain\x3bstomach\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3btestis\x3bciliary_ganglion\x3batrioventricular_node\x3bpons\x3btrigeminal_ganglion\x3b	0.95401	.	-0.60427181	17.74593064	63.2093	1.62731	rs775040765	395821	Rasopathy|not_provided	MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN517202	reviewed_by_expert_panel	Benign	0.693	0.043	T	0.776	0.066	N	1	0.090	N	0	0.065	N	-1.01	0.762	T	0.15	0.053	N	-0.971	0.370	T	0.180	0.528	T	0.017	0.386	T	0.14	0.044	0.151	0.186	N	c	-1.803	-1.813	0.081	0.159	0.707	0.730	0	-5.32	0.025	-0.005	0.127	-1.565	0.009	0.000	0.063	0.750	0.322	7.739	0.278	.	.	.	.	.	3.23e-05	0	0	0	0	0.0003	0	0	8.123e-05	6.534e-05	2.978e-05	0	0.0008	0	0	0.0002	9.746e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,493	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0.0028	Likely Benign
3	12660096	12660096	G	A	exonic	RAF1	.	nonsynonymous_SNV	RAF1:NM_002880:exon2:c.C125T:p.A42V	0.999776866110749	0.000223133833869176	5.53819998824154e-11	Raf-1_proto-oncogene,_serine/threonine_kinase	FUNCTION:_Serine/threonine-protein_kinase_that_acts_as_a_regulatory_link_between_the_membrane-associated_Ras_GTPases_and_the_MAPK/ERK_cascade,_and_this_critical_regulatory_link_functions_as_a_switch_determining_cell_fate_decisions_including_proliferation,_differentiation,_apoptosis,_survival_and_oncogenic_transformation._RAF1_activation_initiates_a_mitogen-activated_protein_kinase_(MAPK)_cascade_that_comprises_a_sequential_phosphorylation_of_the_dual-specific_MAPK_kinases_(MAP2K1/MEK1_and_MAP2K2/MEK2)_and_the_extracellular_signal-regulated_kinases_(MAPK3/ERK1_and_MAPK1/ERK2)._The_phosphorylated_form_of_RAF1_(on_residues_Ser-338_and_Ser-339,_by_PAK1)_phosphorylates_BAD/Bcl2-_antagonist_of_cell_death_at_'Ser-75'._Phosphorylates_adenylyl_cyclases:_ADCY2,_ADCY5_and_ADCY6,_resulting_in_their_activation._Phosphorylates_PPP1R12A_resulting_in_inhibition_of_the_phosphatase_activity._Phosphorylates_TNNT2/cardiac_muscle_troponin_T._Can_promote_NF-kB_activation_and_inhibit_signal_transducers_involved_in_motility_(ROCK2),_apoptosis_(MAP3K5/ASK1_and_STK3/MST2),_proliferation_and_angiogenesis_(RB1)._Can_protect_cells_from_apoptosis_also_by_translocating_to_the_mitochondria_where_it_binds_BCL2_and_displaces_BAD/Bcl2-antagonist_of_cell_death._Regulates_Rho_signaling_and_migration,_and_is_required_for_normal_wound_healing._Plays_a_role_in_the_oncogenic_transformation_of_epithelial_cells_via_repression_of_the_TJ_protein,_occludin_(OCLN)_by_inducing_the_up-regulation_of_a_transcriptional_repressor_SNAI2/SLUG,_which_induces_down-regulation_of_OCLN._Restricts_caspase_activation_in_response_to_selected_stimuli,_notably_Fas_stimulation,_pathogen-mediated_macrophage_apoptosis,_and_erythroid_differentiation._{ECO:0000269|PubMed:11427728,_ECO:0000269|PubMed:11719507,_ECO:0000269|PubMed:15385642,_ECO:0000269|PubMed:15618521,_ECO:0000269|PubMed:15849194,_ECO:0000269|PubMed:16892053,_ECO:0000269|PubMed:16924233,_ECO:0000269|PubMed:9360956}.\x3b_	DISEASE:_Noonan_syndrome_5_(NS5)_[MIM:611553]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._{ECO:0000269|PubMed:17603482,_ECO:0000269|PubMed:17603483,_ECO:0000269|PubMed:20683980}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_LEOPARD_syndrome_2_(LPRD2)_[MIM:611554]:_A_disorder_characterized_by_lentigines,_electrocardiographic_conduction_abnormalities,_ocular_hypertelorism,_pulmonic_stenosis,_abnormalities_of_genitalia,_retardation_of_growth,_and_sensorineural_deafness._{ECO:0000269|PubMed:17603483}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Cardiomyopathy,_dilated_1NN_(CMD1NN)_[MIM:615916]:_A_disorder_characterized_by_ventricular_dilation_and_impaired_systolic_function,_resulting_in_congestive_heart_failure_and_arrhythmia._Patients_are_at_risk_of_premature_death._{ECO:0000269|PubMed:24777450}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_In_skeletal_muscle,_isoform_1_is_more_abundant_than_isoform_2._{ECO:0000269|PubMed:1886707}.\x3b_	ovary\x3bumbilical_cord\x3bsympathetic_chain\x3bskin\x3bretina\x3bbone_marrow\x3bprostate\x3boptic_nerve\x3bfrontal_lobe\x3bcochlea\x3bendometrium\x3bgerminal_center\x3bbladder\x3bbrain\x3bheart\x3bcartilage\x3bspinal_cord\x3badrenal_cortex\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bmacula_lutea\x3bvisual_apparatus\x3bliver\x3balveolus\x3bspleen\x3bcervix\x3bmammary_gland\x3bperipheral_nerve\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3buterus\x3bwhole_body\x3boesophagus\x3bbone\x3btestis\x3bspinal_ganglion\x3bpineal_gland\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bislets_of_Langerhans\x3bhypothalamus\x3bmuscle\x3bpancreas\x3blung\x3btrachea\x3bplacenta\x3bamnion\x3bkidney\x3bstomach\x3baorta\x3bthymus\x3b	superior_cervical_ganglion\x3bciliary_ganglion\x3bwhole_blood\x3bskeletal_muscle\x3b	0.99869	0.93060	-0.646543901	16.44255721	87.82499	2.00185	rs11549992	289332	Noonan_syndrome|Noonan_syndrome_with_multiple_lentigines|Rasopathy	MeSH:D009634,MedGen:C0028326,Orphanet:ORPHA648,SNOMED_CT:205824006|MedGen:C0175704,Orphanet:ORPHA500|MedGen:CN166718,Orphanet:ORPHA98733	reviewed_by_expert_panel	Likely_benign	0.116	0.433	T	0.000	0.843	D	1.000	0.810	D	1.245	0.315	L	-0.96	0.756	T	-1.01	0.266	N	-0.648	0.628	T	0.234	0.601	T	0.031	0.531	D	.	.	0.984	0.821	D	c	0.160	0.329	1.000	0.747	0.707	0.730	0	5.3	0.746	7.408	0.791	1.048	0.713	1.000	0.715	0.994	0.587	15.442	0.748	.	.	.	.	.	9.684e-05	0	0	0	0	0	0.0001	0.0010	0.0003	0	0.0004	0.0022	0	0	0.0003	0.0005	6.497e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,481	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0.0028	Likely Benign
3	12641734	12641734	T	C	exonic	RAF1	.	nonsynonymous_SNV	RAF1:NM_002880:exon9:c.A907G:p.T303A	0.999776866110749	0.000223133833869176	5.53819998824154e-11	Raf-1_proto-oncogene,_serine/threonine_kinase	FUNCTION:_Serine/threonine-protein_kinase_that_acts_as_a_regulatory_link_between_the_membrane-associated_Ras_GTPases_and_the_MAPK/ERK_cascade,_and_this_critical_regulatory_link_functions_as_a_switch_determining_cell_fate_decisions_including_proliferation,_differentiation,_apoptosis,_survival_and_oncogenic_transformation._RAF1_activation_initiates_a_mitogen-activated_protein_kinase_(MAPK)_cascade_that_comprises_a_sequential_phosphorylation_of_the_dual-specific_MAPK_kinases_(MAP2K1/MEK1_and_MAP2K2/MEK2)_and_the_extracellular_signal-regulated_kinases_(MAPK3/ERK1_and_MAPK1/ERK2)._The_phosphorylated_form_of_RAF1_(on_residues_Ser-338_and_Ser-339,_by_PAK1)_phosphorylates_BAD/Bcl2-_antagonist_of_cell_death_at_'Ser-75'._Phosphorylates_adenylyl_cyclases:_ADCY2,_ADCY5_and_ADCY6,_resulting_in_their_activation._Phosphorylates_PPP1R12A_resulting_in_inhibition_of_the_phosphatase_activity._Phosphorylates_TNNT2/cardiac_muscle_troponin_T._Can_promote_NF-kB_activation_and_inhibit_signal_transducers_involved_in_motility_(ROCK2),_apoptosis_(MAP3K5/ASK1_and_STK3/MST2),_proliferation_and_angiogenesis_(RB1)._Can_protect_cells_from_apoptosis_also_by_translocating_to_the_mitochondria_where_it_binds_BCL2_and_displaces_BAD/Bcl2-antagonist_of_cell_death._Regulates_Rho_signaling_and_migration,_and_is_required_for_normal_wound_healing._Plays_a_role_in_the_oncogenic_transformation_of_epithelial_cells_via_repression_of_the_TJ_protein,_occludin_(OCLN)_by_inducing_the_up-regulation_of_a_transcriptional_repressor_SNAI2/SLUG,_which_induces_down-regulation_of_OCLN._Restricts_caspase_activation_in_response_to_selected_stimuli,_notably_Fas_stimulation,_pathogen-mediated_macrophage_apoptosis,_and_erythroid_differentiation._{ECO:0000269|PubMed:11427728,_ECO:0000269|PubMed:11719507,_ECO:0000269|PubMed:15385642,_ECO:0000269|PubMed:15618521,_ECO:0000269|PubMed:15849194,_ECO:0000269|PubMed:16892053,_ECO:0000269|PubMed:16924233,_ECO:0000269|PubMed:9360956}.\x3b_	DISEASE:_Noonan_syndrome_5_(NS5)_[MIM:611553]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._{ECO:0000269|PubMed:17603482,_ECO:0000269|PubMed:17603483,_ECO:0000269|PubMed:20683980}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_LEOPARD_syndrome_2_(LPRD2)_[MIM:611554]:_A_disorder_characterized_by_lentigines,_electrocardiographic_conduction_abnormalities,_ocular_hypertelorism,_pulmonic_stenosis,_abnormalities_of_genitalia,_retardation_of_growth,_and_sensorineural_deafness._{ECO:0000269|PubMed:17603483}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Cardiomyopathy,_dilated_1NN_(CMD1NN)_[MIM:615916]:_A_disorder_characterized_by_ventricular_dilation_and_impaired_systolic_function,_resulting_in_congestive_heart_failure_and_arrhythmia._Patients_are_at_risk_of_premature_death._{ECO:0000269|PubMed:24777450}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_In_skeletal_muscle,_isoform_1_is_more_abundant_than_isoform_2._{ECO:0000269|PubMed:1886707}.\x3b_	ovary\x3bumbilical_cord\x3bsympathetic_chain\x3bskin\x3bretina\x3bbone_marrow\x3bprostate\x3boptic_nerve\x3bfrontal_lobe\x3bcochlea\x3bendometrium\x3bgerminal_center\x3bbladder\x3bbrain\x3bheart\x3bcartilage\x3bspinal_cord\x3badrenal_cortex\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bmacula_lutea\x3bvisual_apparatus\x3bliver\x3balveolus\x3bspleen\x3bcervix\x3bmammary_gland\x3bperipheral_nerve\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3buterus\x3bwhole_body\x3boesophagus\x3bbone\x3btestis\x3bspinal_ganglion\x3bpineal_gland\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bislets_of_Langerhans\x3bhypothalamus\x3bmuscle\x3bpancreas\x3blung\x3btrachea\x3bplacenta\x3bamnion\x3bkidney\x3bstomach\x3baorta\x3bthymus\x3b	superior_cervical_ganglion\x3bciliary_ganglion\x3bwhole_blood\x3bskeletal_muscle\x3b	0.99869	0.93060	-0.646543901	16.44255721	87.82499	2.00185	rs775898894	442522	Rasopathy|not_provided	MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN517202	reviewed_by_expert_panel	Likely_benign	0.39	0.208	T	0.000	0.843	D	1	0.810	D	2.595	0.761	M	-0.89	0.748	T	-1.28	0.324	N	-0.591	0.652	T	0.332	0.700	T	0.034	0.558	D	0.128	0.033	0.992	0.934	D	c	0.132	0.315	1.000	0.747	0.722	0.854	0	5.82	0.927	7.197	0.772	1.061	0.807	1.000	0.715	0.999	0.750	14.755	0.690	.	.	.	.	.	.	.	.	.	.	.	.	.	6.499e-05	0	0.0004	0	0	0	1.791e-05	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,480	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0.0028	Likely Benign
10	112724154	112724154	A	C	exonic	SHOC2	.	nonsynonymous_SNV	SHOC2:NM_001269039:exon2:c.A38C:p.E13A,SHOC2:NM_001324336:exon2:c.A38C:p.E13A,SHOC2:NM_007373:exon2:c.A38C:p.E13A,SHOC2:NM_001324337:exon3:c.A38C:p.E13A	0.991705191552454	0.00829295945769003	1.84898985615785e-06	SHOC2_leucine-rich_repeat_scaffold_protein	FUNCTION:_Regulatory_subunit_of_protein_phosphatase_1_(PP1c)_that_acts_as_a_M-Ras/MRAS_effector_and_participates_in_MAPK_pathway_activation._Upon_M-Ras/MRAS_activation,_targets_PP1c_to_specifically_dephosphorylate_the_'Ser-259'_inhibitory_site_of_RAF1_kinase_and_stimulate_RAF1_activity_at_specialized_signaling_complexes._{ECO:0000269|PubMed:10783161,_ECO:0000269|PubMed:16630891,_ECO:0000269|PubMed:25137548}.\x3b_	DISEASE:_Noonan_syndrome-like_disorder_with_loose_anagen_hair_(NSLH)_[MIM:607721]:_A_syndrome_characterized_by_Noonan_dysmorphic_features_such_as_macrocephaly,_high_forehead,_hypertelorism,_palpebral_ptosis,_low-set_and_posteriorly_rotated_ears,_short_and_webbed_neck,_pectus_anomalies,_in_association_with_pluckable,_sparse,_thin_and_slow-growing_hair._{ECO:0000269|PubMed:19684605,_ECO:0000269|PubMed:25137548}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bpineal_body\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bcornea\x3bnasopharynx\x3bplacenta\x3bmacula_lutea\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bcervix\x3bkidney\x3bmammary_gland\x3bstomach\x3b	superior_cervical_ganglion\x3btestis_-_seminiferous_tubule\x3bprefrontal_cortex\x3btestis\x3btrigeminal_ganglion\x3b	0.46401	0.24608	-0.183570861	39.95046001	30.58108	0.97282	rs730881018	179140	Rasopathy|not_specified	MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374	reviewed_by_expert_panel	Likely_benign	0.0	0.912	D	0.000	0.843	D	1	0.810	D	1.95	0.526	M	1.17	0.379	T	-0.6	0.189	N	-1.057	0.126	T	0.052	0.219	T	0.018	0.396	T	0.281	0.237	0.991	0.912	D	c	0.263	0.439	1.000	0.747	0.732	0.924	0	5.77	0.910	8.947	0.927	1.083	0.853	1.000	0.715	0.996	0.625	16.096	0.808	.	.	.	.	.	3.231e-05	0	0.0012	0	0	0	0	0	0.0001	0	0.0009	0	0	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,599	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0.0028	Likely Benign
3	12660097	12660097	C	T	exonic	RAF1	.	nonsynonymous_SNV	RAF1:NM_002880:exon2:c.G124A:p.A42T	0.999776866110749	0.000223133833869176	5.53819998824154e-11	Raf-1_proto-oncogene,_serine/threonine_kinase	FUNCTION:_Serine/threonine-protein_kinase_that_acts_as_a_regulatory_link_between_the_membrane-associated_Ras_GTPases_and_the_MAPK/ERK_cascade,_and_this_critical_regulatory_link_functions_as_a_switch_determining_cell_fate_decisions_including_proliferation,_differentiation,_apoptosis,_survival_and_oncogenic_transformation._RAF1_activation_initiates_a_mitogen-activated_protein_kinase_(MAPK)_cascade_that_comprises_a_sequential_phosphorylation_of_the_dual-specific_MAPK_kinases_(MAP2K1/MEK1_and_MAP2K2/MEK2)_and_the_extracellular_signal-regulated_kinases_(MAPK3/ERK1_and_MAPK1/ERK2)._The_phosphorylated_form_of_RAF1_(on_residues_Ser-338_and_Ser-339,_by_PAK1)_phosphorylates_BAD/Bcl2-_antagonist_of_cell_death_at_'Ser-75'._Phosphorylates_adenylyl_cyclases:_ADCY2,_ADCY5_and_ADCY6,_resulting_in_their_activation._Phosphorylates_PPP1R12A_resulting_in_inhibition_of_the_phosphatase_activity._Phosphorylates_TNNT2/cardiac_muscle_troponin_T._Can_promote_NF-kB_activation_and_inhibit_signal_transducers_involved_in_motility_(ROCK2),_apoptosis_(MAP3K5/ASK1_and_STK3/MST2),_proliferation_and_angiogenesis_(RB1)._Can_protect_cells_from_apoptosis_also_by_translocating_to_the_mitochondria_where_it_binds_BCL2_and_displaces_BAD/Bcl2-antagonist_of_cell_death._Regulates_Rho_signaling_and_migration,_and_is_required_for_normal_wound_healing._Plays_a_role_in_the_oncogenic_transformation_of_epithelial_cells_via_repression_of_the_TJ_protein,_occludin_(OCLN)_by_inducing_the_up-regulation_of_a_transcriptional_repressor_SNAI2/SLUG,_which_induces_down-regulation_of_OCLN._Restricts_caspase_activation_in_response_to_selected_stimuli,_notably_Fas_stimulation,_pathogen-mediated_macrophage_apoptosis,_and_erythroid_differentiation._{ECO:0000269|PubMed:11427728,_ECO:0000269|PubMed:11719507,_ECO:0000269|PubMed:15385642,_ECO:0000269|PubMed:15618521,_ECO:0000269|PubMed:15849194,_ECO:0000269|PubMed:16892053,_ECO:0000269|PubMed:16924233,_ECO:0000269|PubMed:9360956}.\x3b_	DISEASE:_Noonan_syndrome_5_(NS5)_[MIM:611553]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._{ECO:0000269|PubMed:17603482,_ECO:0000269|PubMed:17603483,_ECO:0000269|PubMed:20683980}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_LEOPARD_syndrome_2_(LPRD2)_[MIM:611554]:_A_disorder_characterized_by_lentigines,_electrocardiographic_conduction_abnormalities,_ocular_hypertelorism,_pulmonic_stenosis,_abnormalities_of_genitalia,_retardation_of_growth,_and_sensorineural_deafness._{ECO:0000269|PubMed:17603483}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Cardiomyopathy,_dilated_1NN_(CMD1NN)_[MIM:615916]:_A_disorder_characterized_by_ventricular_dilation_and_impaired_systolic_function,_resulting_in_congestive_heart_failure_and_arrhythmia._Patients_are_at_risk_of_premature_death._{ECO:0000269|PubMed:24777450}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_In_skeletal_muscle,_isoform_1_is_more_abundant_than_isoform_2._{ECO:0000269|PubMed:1886707}.\x3b_	ovary\x3bumbilical_cord\x3bsympathetic_chain\x3bskin\x3bretina\x3bbone_marrow\x3bprostate\x3boptic_nerve\x3bfrontal_lobe\x3bcochlea\x3bendometrium\x3bgerminal_center\x3bbladder\x3bbrain\x3bheart\x3bcartilage\x3bspinal_cord\x3badrenal_cortex\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bmacula_lutea\x3bvisual_apparatus\x3bliver\x3balveolus\x3bspleen\x3bcervix\x3bmammary_gland\x3bperipheral_nerve\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3buterus\x3bwhole_body\x3boesophagus\x3bbone\x3btestis\x3bspinal_ganglion\x3bpineal_gland\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bislets_of_Langerhans\x3bhypothalamus\x3bmuscle\x3bpancreas\x3blung\x3btrachea\x3bplacenta\x3bamnion\x3bkidney\x3bstomach\x3baorta\x3bthymus\x3b	superior_cervical_ganglion\x3bciliary_ganglion\x3bwhole_blood\x3bskeletal_muscle\x3b	0.99869	0.93060	-0.646543901	16.44255721	87.82499	2.00185	rs200856000	442524	Rasopathy	MedGen:CN166718,Orphanet:ORPHA98733	reviewed_by_expert_panel	Likely_benign	0.123	0.427	T	0.000	0.843	D	1.000	0.810	D	1.245	0.315	L	-0.9	0.749	T	-0.15	0.093	N	-0.708	0.601	T	0.248	0.617	T	0.021	0.437	T	.	.	0.929	0.566	D	c	0.165	0.361	1.000	0.747	0.707	0.730	0	6.17	0.997	3.921	0.559	0.935	0.490	1.000	0.715	0.997	0.653	20.879	0.999	.	.	.	.	.	9.684e-05	0	0	0	0	0	0.0001	0.0010	0.0003	0	0.0004	0.0022	0	0	0.0003	0.0005	6.497e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,482	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1	0	0	0.0014	Likely Benign
11	76890889	76890889	G	A	exonic	MYO7A	.	nonsynonymous_SNV	MYO7A:NM_000260:exon21:c.G2476A:p.A826T,MYO7A:NM_001127179:exon21:c.G2476A:p.A826T,MYO7A:NM_001127180:exon21:c.G2476A:p.A826T	5.37673856270135e-25	0.207164598627406	0.792835401372594	myosin_VIIA	FUNCTION:_Myosins_are_actin-based_motor_molecules_with_ATPase_activity._Unconventional_myosins_serve_in_intracellular_movements._Their_highly_divergent_tails_bind_to_membranous_compartments,_which_are_then_moved_relative_to_actin_filaments._In_the_retina,_plays_an_important_role_in_the_renewal_of_the_outer_photoreceptor_disks._Plays_an_important_role_in_the_distribution_and_migration_of_retinal_pigment_epithelial_(RPE)_melanosomes_and_phagosomes,_and_in_the_regulation_of_opsin_transport_in_retinal_photoreceptors._In_the_inner_ear,_plays_an_important_role_in_differentiation,_morphogenesis_and_organization_of_cochlear_hair_cell_bundles._Involved_in_hair-cell_vesicle_trafficking_of_aminoglycosides,_which_are_known_to_induce_ototoxicity_(By_similarity)._Motor_protein_that_is_a_part_of_the_functional_network_formed_by_USH1C,_USH1G,_CDH23_and_MYO7A_that_mediates_mechanotransduction_in_cochlear_hair_cells._Required_for_normal_hearing._{ECO:0000250,_ECO:0000269|PubMed:19643958,_ECO:0000269|PubMed:21493626,_ECO:0000269|PubMed:21687988,_ECO:0000269|PubMed:21709241}.\x3b_	DISEASE:_Usher_syndrome_1B_(USH1B)_[MIM:276900]:_USH_is_a_genetically_heterogeneous_condition_characterized_by_the_association_of_retinitis_pigmentosa_with_sensorineural_deafness._Age_at_onset_and_differences_in_auditory_and_vestibular_function_distinguish_Usher_syndrome_type_1_(USH1),_Usher_syndrome_type_2_(USH2)_and_Usher_syndrome_type_3_(USH3)._USH1_is_characterized_by_profound_congenital_sensorineural_deafness,_absent_vestibular_function_and_prepubertal_onset_of_progressive_retinitis_pigmentosa_leading_to_blindness._{ECO:0000269|PubMed:10094549,_ECO:0000269|PubMed:10364543,_ECO:0000269|PubMed:10447383,_ECO:0000269|PubMed:10930322,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:15660226,_ECO:0000269|PubMed:16679490,_ECO:0000269|PubMed:23559863,_ECO:0000269|PubMed:24831256,_ECO:0000269|PubMed:25798947,_ECO:0000269|PubMed:7870171,_ECO:0000269|PubMed:8900236,_ECO:0000269|PubMed:9002678,_ECO:0000269|PubMed:9382091,_ECO:0000269|PubMed:9718356}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_recessive,_2_(DFNB2)_[MIM:600060]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:9171832,_ECO:0000269|PubMed:9171833}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_dominant,_11_(DFNA11)_[MIM:601317]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._DFNA11_is_characterized_by_onset_after_complete_speech_acquisition_and_subsequent_gradual_progression._{ECO:0000269|PubMed:15121790,_ECO:0000269|PubMed:15221449,_ECO:0000269|PubMed:15300860,_ECO:0000269|PubMed:9354784}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dDefects_in_MYO7A_may_be_a_cause_of_Leber_congenital_amaurosis_(LCA),_a_severe_dystrophy_of_the_retina,_typically_becoming_evident_in_the_first_years_of_life._Visual_function_is_usually_poor_and_often_accompanied_by_nystagmus,_sluggish_or_near-_absent_pupillary_responses,_photophobia,_high_hyperopia_and_keratoconus.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_the_pigment_epithelium_and_the_photoreceptor_cells_of_the_retina._Also_found_in_kidney,_liver,_testis,_cochlea,_lymphocytes._Not_expressed_in_brain._{ECO:0000269|PubMed:19643958,_ECO:0000269|PubMed:21493626,_ECO:0000269|PubMed:21709241}.\x3b_	unclassifiable_(Anatomical_System)\x3bmedulla_oblongata\x3bovary\x3bcolon\x3bparathyroid\x3bchoroid\x3bretina\x3bbreast\x3buterus\x3bprostate\x3boptic_nerve\x3blung\x3bendometrium\x3badrenal_gland\x3bthyroid\x3bplacenta\x3bvisual_apparatus\x3bliver\x3btestis\x3bspleen\x3bgerminal_center\x3bkidney\x3bbrain\x3bpineal_gland\x3bperipheral_nerve\x3b	superior_cervical_ganglion\x3bsubthalamic_nucleus\x3btestis_-_seminiferous_tubule\x3badrenal_gland\x3badrenal_cortex\x3btestis\x3bciliary_ganglion\x3bpons\x3batrioventricular_node\x3btrigeminal_ganglion\x3bskeletal_muscle\x3b	0.12096	0.33881	-2.513092117	0.925925926	4945.67513	14.33992	rs368341987	178187	Usher_syndrome,_type_1|Deafness,_autosomal_recessive_2|not_specified|MYO7A-Related_Disorders|Nonsyndromic_Hearing_Loss,_Dominant	MedGen:C1568247,OMIM:276900,Orphanet:ORPHA231169|MedGen:C1838701,OMIM:600060|MedGen:CN169374|MedGen:CN239407|MedGen:CN239435	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.002	0.784	D	0.000	0.559	D	0.992	0.416	D	1.04	0.263	L	-0.62	0.860	T	-2.51	0.545	D	0.029	0.828	D	0.471	0.796	T	0.160	0.840	D	.	.	0.988	0.863	D	c	0.227	0.318	1.000	0.747	0.554	0.283	0	4.48	0.538	8.141	0.895	0.988	0.601	1.000	0.715	0.802	0.337	13.514	0.608	IQ_motif,_EF-hand_binding_site\x3bIQ_motif,_EF-hand_binding_site|P-loop_containing_nucleoside_triphosphate_hydrolase	.	.	.	.	0.0004	0.0001	0	0	0.0006	0	0.0006	0	0.0012	0.0003	4.203e-05	0	9.99e-05	0	0.0003	0.0003	0.0063	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,631	0	0	0	0	0	1	1	0	0	0	1	1	1	1	0	0	0	0	0	0	0	0.025	Benign
10	73490271	73490271	A	G	exonic	CDH23	.	nonsynonymous_SNV	CDH23:NM_001171930:exon30:c.A3625G:p.T1209A,CDH23:NM_022124:exon30:c.A3625G:p.T1209A	0.0506929591139338	0.949268622794338	3.84180917276542e-05	cadherin-related_23	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells._CDH23_is_required_for_establishing_and/or_maintaining_the_proper_organization_of_the_stereocilia_bundle_of_hair_cells_in_the_cochlea_and_the_vestibule_during_late_embryonic/early_postnatal_development._It_is_part_of_the_functional_network_formed_by_USH1C,_USH1G,_CDH23_and_MYO7A_that_mediates_mechanotransduction_in_cochlear_hair_cells._Required_for_normal_hearing.\x3b_	DISEASE:_Usher_syndrome_1D_(USH1D)_[MIM:601067]:_USH_is_a_genetically_heterogeneous_condition_characterized_by_the_association_of_retinitis_pigmentosa_with_sensorineural_deafness._Age_at_onset_and_differences_in_auditory_and_vestibular_function_distinguish_Usher_syndrome_type_1_(USH1),_Usher_syndrome_type_2_(USH2)_and_Usher_syndrome_type_3_(USH3)._USH1_is_characterized_by_profound_congenital_sensorineural_deafness,_absent_vestibular_function_and_prepubertal_onset_of_progressive_retinitis_pigmentosa_leading_to_blindness._{ECO:0000269|PubMed:11138009,_ECO:0000269|PubMed:12075507,_ECO:0000269|PubMed:15660226,_ECO:0000269|PubMed:16679490,_ECO:0000269|PubMed:18429043}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Usher_syndrome_1D/F_(USH1DF)_[MIM:601067]:_USH1DF_patients_are_heterozygous_for_mutations_in_CDH23_and_PCDH15,_indicating_a_digenic_inheritance_pattern._{ECO:0000269|PubMed:15537665}._Note\x3dThe_disease_is_caused_by_mutations_affecting_distinct_genetic_loci,_including_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_recessive,_12_(DFNB12)_[MIM:601386]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:11090341,_ECO:0000269|PubMed:12075507,_ECO:0000269|PubMed:12522556,_ECO:0000269|PubMed:15829536,_ECO:0000269|PubMed:16679490,_ECO:0000269|PubMed:17850630,_ECO:0000269|PubMed:22899989,_ECO:0000269|PubMed:24767429}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Particularly_strong_expression_in_the_retina._Found_also_in_the_cochlea.\x3b_	medulla_oblongata\x3bovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bfovea_centralis\x3bchoroid\x3bskin\x3bbone_marrow\x3bretina\x3bprostate\x3boptic_nerve\x3bbone\x3btestis\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bpharynx\x3bblood\x3blens\x3bbreast\x3bpancreas\x3blung\x3bmacula_lutea\x3bvisual_apparatus\x3bliver\x3bspleen\x3bkidney\x3bstomach\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bsubthalamic_nucleus\x3btestis_-_interstitial\x3bglobus_pallidus\x3bciliary_ganglion\x3bpons\x3batrioventricular_node\x3btrigeminal_ganglion\x3bcerebellum\x3b	0.32126	0.20307	-1.837761842	2.05826846	23222.44281	31.45196	rs41281314	19966	Usher_syndrome,_type_1|Usher_syndrome,_type_1D|not_specified|Nonsyndromic_Hearing_Loss,_Recessive|not_provided	MedGen:C1568247,OMIM:276900,Orphanet:ORPHA231169|MedGen:C1832845,OMIM:601067|MedGen:CN169374|MedGen:CN239439|MedGen:CN517202	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	.	.	.	0.000	0.629	N	1	0.810	D	0.605	0.157	N	.	.	.	.	.	.	-1.163	0.007	T	0.001	0.003	T	.	.	.	.	.	0.840	0.428	D	c	-0.136	-0.017	1.000	0.747	0.495	0.175	0	3.19	0.356	6.151	0.714	1.199	0.960	1.000	0.715	1.000	0.888	9.482	0.379	Cadherin-like\x3bCadherin|Cadherin-like	.	.	.	.	0.0397	0.1373	0.0155	0	0	0.0006	0.0007	0.0071	0.0107	0.1472	0.0076	0	0	0.0004	0.0006	0.0073	9.747e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,498	0	0	0	0	0	1	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0.0028	Benign
16	68856041	68856041	G	A	exonic	CDH1	.	nonsynonymous_SNV	CDH1:NM_001317184:exon11:c.G1666A:p.A556T,CDH1:NM_001317185:exon12:c.G301A:p.A101T,CDH1:NM_004360:exon12:c.G1849A:p.A617T	0.338547688109087	0.661426839739286	2.54721516269318e-05	cadherin_1	FUNCTION:_Cadherins_are_calcium-dependent_cell_adhesion_proteins._They_preferentially_interact_with_themselves_in_a_homophilic_manner_in_connecting_cells\x3b_cadherins_may_thus_contribute_to_the_sorting_of_heterogeneous_cell_types._CDH1_is_involved_in_mechanisms_regulating_cell-cell_adhesions,_mobility_and_proliferation_of_epithelial_cells._Has_a_potent_invasive_suppressor_role._It_is_a_ligand_for_integrin_alpha-E/beta-7._{ECO:0000269|PubMed:16417575}.\x3b_	DISEASE:_Hereditary_diffuse_gastric_cancer_(HDGC)_[MIM:137215]:_A_cancer_predisposition_syndrome_with_increased_susceptibility_to_diffuse_gastric_cancer._Diffuse_gastric_cancer_is_a_malignant_disease_characterized_by_poorly_differentiated_infiltrating_lesions_resulting_in_thickening_of_the_stomach._Malignant_tumors_start_in_the_stomach,_can_spread_to_the_esophagus_or_the_small_intestine,_and_can_extend_through_the_stomach_wall_to_nearby_lymph_nodes_and_organs._It_also_can_metastasize_to_other_parts_of_the_body._{ECO:0000269|PubMed:10319582,_ECO:0000269|PubMed:12216071}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry._Heterozygous_CDH1_germline_mutations_are_responsible_for_familial_cases_of_diffuse_gastric_cancer._Somatic_mutations_has_also_been_found_in_patients_with_sporadic_diffuse_gastric_cancer_and_lobular_breast_cancer.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Ovarian_cancer_(OC)_[MIM:167000]:_The_term_ovarian_cancer_defines_malignancies_originating_from_ovarian_tissue._Although_many_histologic_types_of_ovarian_tumors_have_been_described,_epithelial_ovarian_carcinoma_is_the_most_common_form._Ovarian_cancers_are_often_asymptomatic_and_the_recognized_signs_and_symptoms,_even_of_late-stage_disease,_are_vague._Consequently,_most_patients_are_diagnosed_with_advanced_disease._{ECO:0000269|PubMed:8075649}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Breast_cancer,_lobular_(LBC)_[MIM:137215]:_A_type_of_breast_cancer_that_begins_in_the_milk-producing_glands_(lobules)_of_the_breast._{ECO:0000269|PubMed:17660459}._Note\x3dThe_gene_represented_in_this_entry_may_be_involved_in_disease_pathogenesis.\x3b_	TISSUE_SPECIFICITY:_Non-neural_epithelial_tissues.\x3b_	ovary\x3brectum\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bcochlea\x3bendometrium\x3blarynx\x3bthyroid\x3bbrain\x3bpineal_gland\x3bbladder\x3bgall_bladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3btongue\x3bislets_of_Langerhans\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3badrenal_gland\x3bepididymis\x3bplacenta\x3bmacula_lutea\x3bhypopharynx\x3bliver\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3b	dorsal_root_ganglion\x3bolfactory_bulb\x3bsalivary_gland\x3bbeta_cell_islets\x3bfetal_thyroid\x3bskin\x3bprostate\x3bpancreas\x3bfetal_liver\x3blung\x3btrachea\x3bthyroid\x3bplacenta\x3bfetal_lung\x3bkidney\x3b	0.82520	0.93422	-1.061810361	7.519462137	122.67172	2.41215	rs33935154	27271	Endometrial_carcinoma|Hereditary_cancer-predisposing_syndrome|Hereditary_diffuse_gastric_cancer|not_specified|not_provided	Human_Phenotype_Ontology:HP:0012114,MedGen:C0476089,OMIM:608089,SNOMED_CT:254878006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708349,OMIM:137215,Orphanet:ORPHA26106|MedGen:CN169374|MedGen:CN517202	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	0.513	0.192	T	0.103	0.198	N	1	0.090	N	1.495	0.376	L	0.53	0.551	T	-0.72	0.204	N	-0.932	0.439	T	0.027	0.115	T	.	.	.	.	.	0.015	0.049	N	c	-0.617	-0.596	1.000	0.480	0.707	0.730	0	3.5	0.390	1.253	0.323	0.065	0.171	0.001	0.137	0.946	0.421	8.250	0.307	Cadherin|Cadherin-like	.	.	.	.	0.0127	0.0442	0.0036	0	0	0	0.0002	0.0020	0.0033	0.0452	0.0030	0	0	4.484e-05	0.0002	0.0011	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,914	0	0	0	0	0	1	0	0	0	0	0	1	1	1	0	0	0	1	0	0	0	0.0014	Benign
11	76866991	76866991	C	T	exonic	MYO7A	.	synonymous_SNV	MYO7A:NM_000260:exon5:c.C324T:p.Y108Y,MYO7A:NM_001127179:exon5:c.C324T:p.Y108Y,MYO7A:NM_001127180:exon5:c.C324T:p.Y108Y	5.37673856270135e-25	0.207164598627406	0.792835401372594	myosin_VIIA	FUNCTION:_Myosins_are_actin-based_motor_molecules_with_ATPase_activity._Unconventional_myosins_serve_in_intracellular_movements._Their_highly_divergent_tails_bind_to_membranous_compartments,_which_are_then_moved_relative_to_actin_filaments._In_the_retina,_plays_an_important_role_in_the_renewal_of_the_outer_photoreceptor_disks._Plays_an_important_role_in_the_distribution_and_migration_of_retinal_pigment_epithelial_(RPE)_melanosomes_and_phagosomes,_and_in_the_regulation_of_opsin_transport_in_retinal_photoreceptors._In_the_inner_ear,_plays_an_important_role_in_differentiation,_morphogenesis_and_organization_of_cochlear_hair_cell_bundles._Involved_in_hair-cell_vesicle_trafficking_of_aminoglycosides,_which_are_known_to_induce_ototoxicity_(By_similarity)._Motor_protein_that_is_a_part_of_the_functional_network_formed_by_USH1C,_USH1G,_CDH23_and_MYO7A_that_mediates_mechanotransduction_in_cochlear_hair_cells._Required_for_normal_hearing._{ECO:0000250,_ECO:0000269|PubMed:19643958,_ECO:0000269|PubMed:21493626,_ECO:0000269|PubMed:21687988,_ECO:0000269|PubMed:21709241}.\x3b_	DISEASE:_Usher_syndrome_1B_(USH1B)_[MIM:276900]:_USH_is_a_genetically_heterogeneous_condition_characterized_by_the_association_of_retinitis_pigmentosa_with_sensorineural_deafness._Age_at_onset_and_differences_in_auditory_and_vestibular_function_distinguish_Usher_syndrome_type_1_(USH1),_Usher_syndrome_type_2_(USH2)_and_Usher_syndrome_type_3_(USH3)._USH1_is_characterized_by_profound_congenital_sensorineural_deafness,_absent_vestibular_function_and_prepubertal_onset_of_progressive_retinitis_pigmentosa_leading_to_blindness._{ECO:0000269|PubMed:10094549,_ECO:0000269|PubMed:10364543,_ECO:0000269|PubMed:10447383,_ECO:0000269|PubMed:10930322,_ECO:0000269|PubMed:12112664,_ECO:0000269|PubMed:15660226,_ECO:0000269|PubMed:16679490,_ECO:0000269|PubMed:23559863,_ECO:0000269|PubMed:24831256,_ECO:0000269|PubMed:25798947,_ECO:0000269|PubMed:7870171,_ECO:0000269|PubMed:8900236,_ECO:0000269|PubMed:9002678,_ECO:0000269|PubMed:9382091,_ECO:0000269|PubMed:9718356}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_recessive,_2_(DFNB2)_[MIM:600060]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:9171832,_ECO:0000269|PubMed:9171833}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_dominant,_11_(DFNA11)_[MIM:601317]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._DFNA11_is_characterized_by_onset_after_complete_speech_acquisition_and_subsequent_gradual_progression._{ECO:0000269|PubMed:15121790,_ECO:0000269|PubMed:15221449,_ECO:0000269|PubMed:15300860,_ECO:0000269|PubMed:9354784}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dDefects_in_MYO7A_may_be_a_cause_of_Leber_congenital_amaurosis_(LCA),_a_severe_dystrophy_of_the_retina,_typically_becoming_evident_in_the_first_years_of_life._Visual_function_is_usually_poor_and_often_accompanied_by_nystagmus,_sluggish_or_near-_absent_pupillary_responses,_photophobia,_high_hyperopia_and_keratoconus.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_the_pigment_epithelium_and_the_photoreceptor_cells_of_the_retina._Also_found_in_kidney,_liver,_testis,_cochlea,_lymphocytes._Not_expressed_in_brain._{ECO:0000269|PubMed:19643958,_ECO:0000269|PubMed:21493626,_ECO:0000269|PubMed:21709241}.\x3b_	unclassifiable_(Anatomical_System)\x3bmedulla_oblongata\x3bovary\x3bcolon\x3bparathyroid\x3bchoroid\x3bretina\x3bbreast\x3buterus\x3bprostate\x3boptic_nerve\x3blung\x3bendometrium\x3badrenal_gland\x3bthyroid\x3bplacenta\x3bvisual_apparatus\x3bliver\x3btestis\x3bspleen\x3bgerminal_center\x3bkidney\x3bbrain\x3bpineal_gland\x3bperipheral_nerve\x3b	superior_cervical_ganglion\x3bsubthalamic_nucleus\x3btestis_-_seminiferous_tubule\x3badrenal_gland\x3badrenal_cortex\x3btestis\x3bciliary_ganglion\x3bpons\x3batrioventricular_node\x3btrigeminal_ganglion\x3bskeletal_muscle\x3b	0.12096	0.33881	-2.513092117	0.925925926	4945.67513	14.33992	rs116892396	52371	Retinitis_pigmentosa-deafness_syndrome|not_specified|Nonsyndromic_Hearing_Loss,_Dominant|Nonsyndromic_Hearing_Loss,_Recessive	MedGen:CN033130,OMIM:500004,SNOMED_CT:57838006|MedGen:CN169374|MedGen:CN239435|MedGen:CN239439	criteria_provided,_multiple_submitters,_no_conflicts	Benign/Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0008	0	0	0	0.0161	0	0	0	0.0011	0	0	0	0.0161	0	0	0.0004	3.333e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,627	0	0	0	0	0	0	1	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0.0014	Benign
21	36206858	36206858	G	A	exonic	RUNX1	.	synonymous_SNV	RUNX1:NM_001001890:exon4:c.C573T:p.S191S,RUNX1:NM_001122607:exon4:c.C573T:p.S191S,RUNX1:NM_001754:exon7:c.C654T:p.S218S	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	rs145230602	243611	Familial_platelet_disorder_with_associated_myeloid_malignancy	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290	criteria_provided,_multiple_submitters,_no_conflicts	Benign/Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0003	0.0003	0	0.0066	0	0	0.0002	0	0.0005	0.0007	0.0011	0.0027	0	0	0.0004	0.0013	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,957	0	0	0	0	0	0	1	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0.0014	Benign
21	36164606	36164606	G	A	exonic	RUNX1	.	synonymous_SNV	RUNX1:NM_001001890:exon6:c.C1188T:p.R396R,RUNX1:NM_001754:exon9:c.C1269T:p.R423R	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	rs544247912	243602	Familial_platelet_disorder_with_associated_myeloid_malignancy	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290	criteria_provided,_multiple_submitters,_no_conflicts	Benign/Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0003	0	0	0	0	0	0.0006	0	0.0007	0	0.0003	0.0069	0	0	0.0006	0.0014	8.731e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,947	0	0	0	0	0	0	1	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0.0014	Benign
15	66782108	66782112	CTATT	C	UTR3	SNAPC5	NM_006049:c.*968_*965delAATA	.	.	1.40204453241569e-05	0.125603911120239	0.874382068434436	small_nuclear_RNA_activating_complex_polypeptide_5	FUNCTION:_Part_of_the_SNAPc_complex_required_for_the_transcription_of_both_RNA_polymerase_II_and_III_small-nuclear_RNA_genes._Binds_to_the_proximal_sequence_element_(PSE),_a_non-TATA-box_basal_promoter_element_common_to_these_2_types_of_genes._Recruits_TBP_and_BRF2_to_the_U6_snRNA_TATA_box.\x3b_	.	.	lymphoreticular\x3bovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bvein\x3bskin\x3bbone_marrow\x3bretina\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bfrontal_lobe\x3blarynx\x3bthyroid\x3bbone\x3btestis\x3bgerminal_center\x3bbladder\x3bbrain\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bheart\x3bislets_of_Langerhans\x3bhypothalamus\x3bpharynx\x3bblood\x3blens\x3bbreast\x3bbile_duct\x3bpancreas\x3blung\x3badrenal_gland\x3bnasopharynx\x3bplacenta\x3bvisual_apparatus\x3bhippocampus\x3bmacula_lutea\x3bliver\x3balveolus\x3bhead_and_neck\x3bcervix\x3bkidney\x3bstomach\x3b	atrioventricular_node\x3bskeletal_muscle\x3bcingulate_cortex\x3b	0.08216	0.11262	-0.09720619	46.20193442	24.24987	0.79777	rs397516788	53753	Noonan_syndrome|Cardio-facio-cutaneous_syndrome|Rasopathy|not_specified	MeSH:D009634,MedGen:C0028326,Orphanet:ORPHA648,SNOMED_CT:205824006|MedGen:C1275081,Orphanet:ORPHA1340,SNOMED_CT:403770008|MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374	reviewed_by_expert_panel	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0018	0.0006	0.0048	0	0	0.0003	0.0031	0.0010	0.0022	0.0005	0.0019	0.0060	0	0.0002	0.0034	0.0024	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,886	0	0	0	0	0	0	1	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0.0014	Benign
21	36259324	36259324	A	G	exonic	RUNX1	.	nonsynonymous_SNV	RUNX1:NM_001001890:exon1:c.T86C:p.L29S,RUNX1:NM_001122607:exon1:c.T86C:p.L29S,RUNX1:NM_001754:exon4:c.T167C:p.L56S	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	rs111527738	243617	Familial_platelet_disorder_with_associated_myeloid_malignancy|not_specified	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290|MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Benign/Likely_benign	0.513	0.087	T	0.013	0.289	N	0.905	0.362	D	0.93	0.236	L	-4.07	0.992	D	-0.54	0.221	N	0.797	0.944	D	0.895	0.965	D	.	.	.	.	.	0.903	0.511	D	c	0.104	0.224	1.000	0.747	0.405	0.054	1	5.04	0.672	3.338	0.516	1.088	0.866	1.000	0.715	0.999	0.750	14.769	0.691	Runt_domain|p53-like_transcription_factor,_DNA-binding|p53/RUNT-type_transcription_factor,_DNA-binding_domain	.	.	.	.	0.0120	0.0034	0.0060	0	0	0.0138	0.0182	0.0143	0.0153	0.0026	0.0107	0.0018	0.0001	0.0152	0.0173	0.0161	0.0315	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,985	0	0	0	0	0	1	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0.0014	Benign
21	36259125	36259125	T	C	intronic	RUNX1	.	.	.	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	rs199881885	257458	Familial_platelet_disorder_with_associated_myeloid_malignancy|not_specified	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290|MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0041	0.0010	0.0060	0.0033	0	0.0075	0.0054	0.0061	0.0048	0.0009	0.0036	0.0029	0	0.0058	0.0075	0.0072	0.0007	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,976	0	0	0	0	0	0	1	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0.0007	Benign
10	112771421	112771421	A	G	exonic	SHOC2	.	nonsynonymous_SNV	SHOC2:NM_001269039:exon8:c.A1456G:p.S486G,SHOC2:NM_001324336:exon9:c.A1594G:p.S532G,SHOC2:NM_007373:exon9:c.A1594G:p.S532G,SHOC2:NM_001324337:exon10:c.A1594G:p.S532G	0.991705191552454	0.00829295945769003	1.84898985615785e-06	SHOC2_leucine-rich_repeat_scaffold_protein	FUNCTION:_Regulatory_subunit_of_protein_phosphatase_1_(PP1c)_that_acts_as_a_M-Ras/MRAS_effector_and_participates_in_MAPK_pathway_activation._Upon_M-Ras/MRAS_activation,_targets_PP1c_to_specifically_dephosphorylate_the_'Ser-259'_inhibitory_site_of_RAF1_kinase_and_stimulate_RAF1_activity_at_specialized_signaling_complexes._{ECO:0000269|PubMed:10783161,_ECO:0000269|PubMed:16630891,_ECO:0000269|PubMed:25137548}.\x3b_	DISEASE:_Noonan_syndrome-like_disorder_with_loose_anagen_hair_(NSLH)_[MIM:607721]:_A_syndrome_characterized_by_Noonan_dysmorphic_features_such_as_macrocephaly,_high_forehead,_hypertelorism,_palpebral_ptosis,_low-set_and_posteriorly_rotated_ears,_short_and_webbed_neck,_pectus_anomalies,_in_association_with_pluckable,_sparse,_thin_and_slow-growing_hair._{ECO:0000269|PubMed:19684605,_ECO:0000269|PubMed:25137548}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bpineal_body\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bcornea\x3bnasopharynx\x3bplacenta\x3bmacula_lutea\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bcervix\x3bkidney\x3bmammary_gland\x3bstomach\x3b	superior_cervical_ganglion\x3btestis_-_seminiferous_tubule\x3bprefrontal_cortex\x3btestis\x3btrigeminal_ganglion\x3b	0.46401	0.24608	-0.183570861	39.95046001	30.58108	0.97282	rs145463534	142813	Noonan_syndrome-like_disorder_with_loose_anagen_hair_1|Rasopathy|not_specified	MedGen:C1843181,OMIM:607721|MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374	reviewed_by_expert_panel	Benign	0.133	0.264	T	0.000	0.843	N	1.000	0.548	D	0.86	0.214	L	1.86	0.845	T	-1.61	0.414	N	-0.330	0.742	T	0.449	0.784	T	.	.	.	.	.	0.949	0.623	D	c	0.135	0.162	0.186	0.179	0.706	0.609	0	1.35	0.210	6.232	0.721	1.199	0.960	1.000	0.715	0.994	0.587	7.225	0.250	Leucine-rich_repeat_domain,_L_domain-like	.	.	.	.	0.0038	0.0134	0.0024	0	0	0	0	0	0.0009	0.0129	0.0004	0	0	0	0	0.0009	6.497e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,608	0	0	0	0	0	1	0	0	0	0	0	0	1	0	1	0	0	1	0	0	0	0.0007	Benign
19	4101261	4101261	C	T	exonic	MAP2K2	.	synonymous_SNV	MAP2K2:NM_030662:exon5:c.G546A:p.A182A	0.86326115931858	0.136320885012997	0.00041795566842237	mitogen-activated_protein_kinase_kinase_2	FUNCTION:_Catalyzes_the_concomitant_phosphorylation_of_a_threonine_and_a_tyrosine_residue_in_a_Thr-Glu-Tyr_sequence_located_in_MAP_kinases._Activates_the_ERK1_and_ERK2_MAP_kinases_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Cardiofaciocutaneous_syndrome_4_(CFC4)_[MIM:615280]:_A_form_of_cardiofaciocutaneous_syndrome,_a_multiple_congenital_anomaly_disorder_characterized_by_a_distinctive_facial_appearance,_heart_defects_and_mental_retardation._Heart_defects_include_pulmonic_stenosis,_atrial_septal_defects_and_hypertrophic_cardiomyopathy._Some_affected_individuals_present_with_ectodermal_abnormalities_such_as_sparse,_friable_hair,_hyperkeratotic_skin_lesions_and_a_generalized_ichthyosis-like_condition._Typical_facial_features_are_similar_to_Noonan_syndrome._They_include_high_forehead_with_bitemporal_constriction,_hypoplastic_supraorbital_ridges,_downslanting_palpebral_fissures,_a_depressed_nasal_bridge,_and_posteriorly_angulated_ears_with_prominent_helices._{ECO:0000269|PubMed:16439621,_ECO:0000269|PubMed:18042262,_ECO:0000269|PubMed:20358587}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	medulla_oblongata\x3bsmooth_muscle\x3bovary\x3bsalivary_gland\x3bsympathetic_chain\x3bcolon\x3bparathyroid\x3bskin\x3buterus\x3bprostate\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bmuscle\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbile_duct\x3bpancreas\x3blung\x3badrenal_gland\x3bplacenta\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	amygdala\x3bprefrontal_cortex\x3btestis\x3bpons\x3bcingulate_cortex\x3b	0.88489	0.51187	-0.800872469	12.33191791	40.94266	1.19949	rs141402203	141861	Rasopathy|not_specified	MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374	reviewed_by_expert_panel	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0005	0.0015	0	0	0.0006	0	0	0	0.0002	0.0014	0.0001	0	0.0005	0	8.284e-05	0.0002	3.957e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,933	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0.0003	Benign
19	4099300	4099300	T	C	exonic	MAP2K2	.	nonsynonymous_SNV	MAP2K2:NM_030662:exon7:c.A818G:p.K273R	0.86326115931858	0.136320885012997	0.00041795566842237	mitogen-activated_protein_kinase_kinase_2	FUNCTION:_Catalyzes_the_concomitant_phosphorylation_of_a_threonine_and_a_tyrosine_residue_in_a_Thr-Glu-Tyr_sequence_located_in_MAP_kinases._Activates_the_ERK1_and_ERK2_MAP_kinases_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Cardiofaciocutaneous_syndrome_4_(CFC4)_[MIM:615280]:_A_form_of_cardiofaciocutaneous_syndrome,_a_multiple_congenital_anomaly_disorder_characterized_by_a_distinctive_facial_appearance,_heart_defects_and_mental_retardation._Heart_defects_include_pulmonic_stenosis,_atrial_septal_defects_and_hypertrophic_cardiomyopathy._Some_affected_individuals_present_with_ectodermal_abnormalities_such_as_sparse,_friable_hair,_hyperkeratotic_skin_lesions_and_a_generalized_ichthyosis-like_condition._Typical_facial_features_are_similar_to_Noonan_syndrome._They_include_high_forehead_with_bitemporal_constriction,_hypoplastic_supraorbital_ridges,_downslanting_palpebral_fissures,_a_depressed_nasal_bridge,_and_posteriorly_angulated_ears_with_prominent_helices._{ECO:0000269|PubMed:16439621,_ECO:0000269|PubMed:18042262,_ECO:0000269|PubMed:20358587}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	medulla_oblongata\x3bsmooth_muscle\x3bovary\x3bsalivary_gland\x3bsympathetic_chain\x3bcolon\x3bparathyroid\x3bskin\x3buterus\x3bprostate\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bmuscle\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbile_duct\x3bpancreas\x3blung\x3badrenal_gland\x3bplacenta\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	amygdala\x3bprefrontal_cortex\x3btestis\x3bpons\x3bcingulate_cortex\x3b	0.88489	0.51187	-0.800872469	12.33191791	40.94266	1.19949	rs539555837	49294	Rasopathy|not_specified	MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374	reviewed_by_expert_panel	Likely_benign	0.169	0.232	T	0.000	0.843	N	1.000	0.511	D	0.375	0.121	N	-0.15	0.652	T	-1.43	0.352	N	-0.970	0.372	T	0.137	0.454	T	0.017	0.383	T	.	.	0.933	0.577	D	c	-0.262	-0.077	1.000	0.747	0.707	0.730	0	4.53	0.548	2.195	0.421	1.061	0.807	1.000	0.715	0.996	0.625	12.181	0.533	Protein_kinase_domain|Protein_kinase-like_domain	.	.	.	.	3.234e-05	0	0	0	0	0	6.674e-05	0	7.31e-05	0	0.0003	0	0	0	4.789e-05	0.0002	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,928	0	0	0	0	0	1	0	0	0	0	0	0	0	1	1	0	0	1	1	0	0	0.0003	Benign
21	36231763	36231763	G	A	intronic	RUNX1	.	.	.	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	rs186585782	350636	Familial_platelet_disorder_with_associated_myeloid_malignancy	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290	criteria_provided,_multiple_submitters,_no_conflicts	Benign/Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0	0	0.0060	0	0	0	0	0.0315	0.0043	0.0122	0.0034	0	0	0	0	0.0320	0.0008	0.0031	6.497e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,959	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0.0003	Benign
10	112724573	112724573	C	T	exonic	SHOC2	.	synonymous_SNV	SHOC2:NM_001269039:exon2:c.C457T:p.L153L,SHOC2:NM_001324336:exon2:c.C457T:p.L153L,SHOC2:NM_007373:exon2:c.C457T:p.L153L,SHOC2:NM_001324337:exon3:c.C457T:p.L153L	0.991705191552454	0.00829295945769003	1.84898985615785e-06	SHOC2_leucine-rich_repeat_scaffold_protein	FUNCTION:_Regulatory_subunit_of_protein_phosphatase_1_(PP1c)_that_acts_as_a_M-Ras/MRAS_effector_and_participates_in_MAPK_pathway_activation._Upon_M-Ras/MRAS_activation,_targets_PP1c_to_specifically_dephosphorylate_the_'Ser-259'_inhibitory_site_of_RAF1_kinase_and_stimulate_RAF1_activity_at_specialized_signaling_complexes._{ECO:0000269|PubMed:10783161,_ECO:0000269|PubMed:16630891,_ECO:0000269|PubMed:25137548}.\x3b_	DISEASE:_Noonan_syndrome-like_disorder_with_loose_anagen_hair_(NSLH)_[MIM:607721]:_A_syndrome_characterized_by_Noonan_dysmorphic_features_such_as_macrocephaly,_high_forehead,_hypertelorism,_palpebral_ptosis,_low-set_and_posteriorly_rotated_ears,_short_and_webbed_neck,_pectus_anomalies,_in_association_with_pluckable,_sparse,_thin_and_slow-growing_hair._{ECO:0000269|PubMed:19684605,_ECO:0000269|PubMed:25137548}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bpineal_body\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bcornea\x3bnasopharynx\x3bplacenta\x3bmacula_lutea\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bcervix\x3bkidney\x3bmammary_gland\x3bstomach\x3b	superior_cervical_ganglion\x3btestis_-_seminiferous_tubule\x3bprefrontal_cortex\x3btestis\x3btrigeminal_ganglion\x3b	0.46401	0.24608	-0.183570861	39.95046001	30.58108	0.97282	rs34081996	142807	Noonan_syndrome-like_disorder_with_loose_anagen_hair_1|Rasopathy|not_specified	MedGen:C1843181,OMIM:607721|MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374	reviewed_by_expert_panel	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0126	0.0028	0.0108	0	0	0.0272	0.0162	0.0183	0.0130	0.0027	0.0064	0.0034	0.0001	0.0295	0.0183	0.0146	0.0042	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,602	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0.0003	Benign
21	36164486	36164486	G	C	exonic	RUNX1	.	synonymous_SNV	RUNX1:NM_001001890:exon6:c.C1308G:p.P436P,RUNX1:NM_001754:exon9:c.C1389G:p.P463P	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	rs61750222	257453	Familial_platelet_disorder_with_associated_myeloid_malignancy|not_specified	MedGen:C1832388,OMIM:601399,Orphanet:ORPHA71290|MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0421	0.1231	0.0415	0.06	0.0229	0.0012	0.0081	0.0166	0.0310	0.1179	0.0556	0.0624	0.0218	0.0018	0.0091	0.0300	0.0294	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,945	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0.0003	Benign
19	4117579	4117579	G	A	exonic	MAP2K2	.	synonymous_SNV	MAP2K2:NM_030662:exon2:c.C141T:p.D47D	0.86326115931858	0.136320885012997	0.00041795566842237	mitogen-activated_protein_kinase_kinase_2	FUNCTION:_Catalyzes_the_concomitant_phosphorylation_of_a_threonine_and_a_tyrosine_residue_in_a_Thr-Glu-Tyr_sequence_located_in_MAP_kinases._Activates_the_ERK1_and_ERK2_MAP_kinases_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Cardiofaciocutaneous_syndrome_4_(CFC4)_[MIM:615280]:_A_form_of_cardiofaciocutaneous_syndrome,_a_multiple_congenital_anomaly_disorder_characterized_by_a_distinctive_facial_appearance,_heart_defects_and_mental_retardation._Heart_defects_include_pulmonic_stenosis,_atrial_septal_defects_and_hypertrophic_cardiomyopathy._Some_affected_individuals_present_with_ectodermal_abnormalities_such_as_sparse,_friable_hair,_hyperkeratotic_skin_lesions_and_a_generalized_ichthyosis-like_condition._Typical_facial_features_are_similar_to_Noonan_syndrome._They_include_high_forehead_with_bitemporal_constriction,_hypoplastic_supraorbital_ridges,_downslanting_palpebral_fissures,_a_depressed_nasal_bridge,_and_posteriorly_angulated_ears_with_prominent_helices._{ECO:0000269|PubMed:16439621,_ECO:0000269|PubMed:18042262,_ECO:0000269|PubMed:20358587}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	medulla_oblongata\x3bsmooth_muscle\x3bovary\x3bsalivary_gland\x3bsympathetic_chain\x3bcolon\x3bparathyroid\x3bskin\x3buterus\x3bprostate\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bmuscle\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbile_duct\x3bpancreas\x3blung\x3badrenal_gland\x3bplacenta\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	amygdala\x3bprefrontal_cortex\x3btestis\x3bpons\x3bcingulate_cortex\x3b	0.88489	0.51187	-0.800872469	12.33191791	40.94266	1.19949	rs201526172	442541	Rasopathy	MedGen:CN166718,Orphanet:ORPHA98733	reviewed_by_expert_panel	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9.693e-05	0	0	0	0.0019	0	0	0	8.529e-05	0	0	0	0.0008	0	4.476e-05	0	6.497e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,941	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0.0003	Benign
19	4117495	4117495	G	A	exonic	MAP2K2	.	synonymous_SNV	MAP2K2:NM_030662:exon2:c.C225T:p.I75I	0.86326115931858	0.136320885012997	0.00041795566842237	mitogen-activated_protein_kinase_kinase_2	FUNCTION:_Catalyzes_the_concomitant_phosphorylation_of_a_threonine_and_a_tyrosine_residue_in_a_Thr-Glu-Tyr_sequence_located_in_MAP_kinases._Activates_the_ERK1_and_ERK2_MAP_kinases_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Cardiofaciocutaneous_syndrome_4_(CFC4)_[MIM:615280]:_A_form_of_cardiofaciocutaneous_syndrome,_a_multiple_congenital_anomaly_disorder_characterized_by_a_distinctive_facial_appearance,_heart_defects_and_mental_retardation._Heart_defects_include_pulmonic_stenosis,_atrial_septal_defects_and_hypertrophic_cardiomyopathy._Some_affected_individuals_present_with_ectodermal_abnormalities_such_as_sparse,_friable_hair,_hyperkeratotic_skin_lesions_and_a_generalized_ichthyosis-like_condition._Typical_facial_features_are_similar_to_Noonan_syndrome._They_include_high_forehead_with_bitemporal_constriction,_hypoplastic_supraorbital_ridges,_downslanting_palpebral_fissures,_a_depressed_nasal_bridge,_and_posteriorly_angulated_ears_with_prominent_helices._{ECO:0000269|PubMed:16439621,_ECO:0000269|PubMed:18042262,_ECO:0000269|PubMed:20358587}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	medulla_oblongata\x3bsmooth_muscle\x3bovary\x3bsalivary_gland\x3bsympathetic_chain\x3bcolon\x3bparathyroid\x3bskin\x3buterus\x3bprostate\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bmuscle\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbile_duct\x3bpancreas\x3blung\x3badrenal_gland\x3bplacenta\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	amygdala\x3bprefrontal_cortex\x3btestis\x3bpons\x3bcingulate_cortex\x3b	0.88489	0.51187	-0.800872469	12.33191791	40.94266	1.19949	rs561400866	442540	Rasopathy	MedGen:CN166718,Orphanet:ORPHA98733	reviewed_by_expert_panel	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0002	0	0	0	0	0	0	0.0002	0.0014	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,938	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0.0003	Benign
19	4117429	4117429	G	T	exonic	MAP2K2	.	synonymous_SNV	MAP2K2:NM_030662:exon2:c.C291A:p.I97I	0.86326115931858	0.136320885012997	0.00041795566842237	mitogen-activated_protein_kinase_kinase_2	FUNCTION:_Catalyzes_the_concomitant_phosphorylation_of_a_threonine_and_a_tyrosine_residue_in_a_Thr-Glu-Tyr_sequence_located_in_MAP_kinases._Activates_the_ERK1_and_ERK2_MAP_kinases_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Cardiofaciocutaneous_syndrome_4_(CFC4)_[MIM:615280]:_A_form_of_cardiofaciocutaneous_syndrome,_a_multiple_congenital_anomaly_disorder_characterized_by_a_distinctive_facial_appearance,_heart_defects_and_mental_retardation._Heart_defects_include_pulmonic_stenosis,_atrial_septal_defects_and_hypertrophic_cardiomyopathy._Some_affected_individuals_present_with_ectodermal_abnormalities_such_as_sparse,_friable_hair,_hyperkeratotic_skin_lesions_and_a_generalized_ichthyosis-like_condition._Typical_facial_features_are_similar_to_Noonan_syndrome._They_include_high_forehead_with_bitemporal_constriction,_hypoplastic_supraorbital_ridges,_downslanting_palpebral_fissures,_a_depressed_nasal_bridge,_and_posteriorly_angulated_ears_with_prominent_helices._{ECO:0000269|PubMed:16439621,_ECO:0000269|PubMed:18042262,_ECO:0000269|PubMed:20358587}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	medulla_oblongata\x3bsmooth_muscle\x3bovary\x3bsalivary_gland\x3bsympathetic_chain\x3bcolon\x3bparathyroid\x3bskin\x3buterus\x3bprostate\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bmuscle\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbile_duct\x3bpancreas\x3blung\x3badrenal_gland\x3bplacenta\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	amygdala\x3bprefrontal_cortex\x3btestis\x3bpons\x3bcingulate_cortex\x3b	0.88489	0.51187	-0.800872469	12.33191791	40.94266	1.19949	rs200918323	49257	Rasopathy	MedGen:CN166718,Orphanet:ORPHA98733	reviewed_by_expert_panel	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0001	0	0	0	0.0025	0	0	0	0.0002	0	0	0	0.0027	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,936	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0.0003	Benign
3	12660102	12660102	C	T	exonic	RAF1	.	nonsynonymous_SNV	RAF1:NM_002880:exon2:c.G119A:p.R40H	0.999776866110749	0.000223133833869176	5.53819998824154e-11	Raf-1_proto-oncogene,_serine/threonine_kinase	FUNCTION:_Serine/threonine-protein_kinase_that_acts_as_a_regulatory_link_between_the_membrane-associated_Ras_GTPases_and_the_MAPK/ERK_cascade,_and_this_critical_regulatory_link_functions_as_a_switch_determining_cell_fate_decisions_including_proliferation,_differentiation,_apoptosis,_survival_and_oncogenic_transformation._RAF1_activation_initiates_a_mitogen-activated_protein_kinase_(MAPK)_cascade_that_comprises_a_sequential_phosphorylation_of_the_dual-specific_MAPK_kinases_(MAP2K1/MEK1_and_MAP2K2/MEK2)_and_the_extracellular_signal-regulated_kinases_(MAPK3/ERK1_and_MAPK1/ERK2)._The_phosphorylated_form_of_RAF1_(on_residues_Ser-338_and_Ser-339,_by_PAK1)_phosphorylates_BAD/Bcl2-_antagonist_of_cell_death_at_'Ser-75'._Phosphorylates_adenylyl_cyclases:_ADCY2,_ADCY5_and_ADCY6,_resulting_in_their_activation._Phosphorylates_PPP1R12A_resulting_in_inhibition_of_the_phosphatase_activity._Phosphorylates_TNNT2/cardiac_muscle_troponin_T._Can_promote_NF-kB_activation_and_inhibit_signal_transducers_involved_in_motility_(ROCK2),_apoptosis_(MAP3K5/ASK1_and_STK3/MST2),_proliferation_and_angiogenesis_(RB1)._Can_protect_cells_from_apoptosis_also_by_translocating_to_the_mitochondria_where_it_binds_BCL2_and_displaces_BAD/Bcl2-antagonist_of_cell_death._Regulates_Rho_signaling_and_migration,_and_is_required_for_normal_wound_healing._Plays_a_role_in_the_oncogenic_transformation_of_epithelial_cells_via_repression_of_the_TJ_protein,_occludin_(OCLN)_by_inducing_the_up-regulation_of_a_transcriptional_repressor_SNAI2/SLUG,_which_induces_down-regulation_of_OCLN._Restricts_caspase_activation_in_response_to_selected_stimuli,_notably_Fas_stimulation,_pathogen-mediated_macrophage_apoptosis,_and_erythroid_differentiation._{ECO:0000269|PubMed:11427728,_ECO:0000269|PubMed:11719507,_ECO:0000269|PubMed:15385642,_ECO:0000269|PubMed:15618521,_ECO:0000269|PubMed:15849194,_ECO:0000269|PubMed:16892053,_ECO:0000269|PubMed:16924233,_ECO:0000269|PubMed:9360956}.\x3b_	DISEASE:_Noonan_syndrome_5_(NS5)_[MIM:611553]:_A_form_of_Noonan_syndrome,_a_disease_characterized_by_short_stature,_facial_dysmorphic_features_such_as_hypertelorism,_a_downward_eyeslant_and_low-set_posteriorly_rotated_ears,_and_a_high_incidence_of_congenital_heart_defects_and_hypertrophic_cardiomyopathy._Other_features_can_include_a_short_neck_with_webbing_or_redundancy_of_skin,_deafness,_motor_delay,_variable_intellectual_deficits,_multiple_skeletal_defects,_cryptorchidism,_and_bleeding_diathesis._Individuals_with_Noonan_syndrome_are_at_risk_of_juvenile_myelomonocytic_leukemia,_a_myeloproliferative_disorder_characterized_by_excessive_production_of_myelomonocytic_cells._{ECO:0000269|PubMed:17603482,_ECO:0000269|PubMed:17603483,_ECO:0000269|PubMed:20683980}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_LEOPARD_syndrome_2_(LPRD2)_[MIM:611554]:_A_disorder_characterized_by_lentigines,_electrocardiographic_conduction_abnormalities,_ocular_hypertelorism,_pulmonic_stenosis,_abnormalities_of_genitalia,_retardation_of_growth,_and_sensorineural_deafness._{ECO:0000269|PubMed:17603483}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Cardiomyopathy,_dilated_1NN_(CMD1NN)_[MIM:615916]:_A_disorder_characterized_by_ventricular_dilation_and_impaired_systolic_function,_resulting_in_congestive_heart_failure_and_arrhythmia._Patients_are_at_risk_of_premature_death._{ECO:0000269|PubMed:24777450}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_In_skeletal_muscle,_isoform_1_is_more_abundant_than_isoform_2._{ECO:0000269|PubMed:1886707}.\x3b_	ovary\x3bumbilical_cord\x3bsympathetic_chain\x3bskin\x3bretina\x3bbone_marrow\x3bprostate\x3boptic_nerve\x3bfrontal_lobe\x3bcochlea\x3bendometrium\x3bgerminal_center\x3bbladder\x3bbrain\x3bheart\x3bcartilage\x3bspinal_cord\x3badrenal_cortex\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bmacula_lutea\x3bvisual_apparatus\x3bliver\x3balveolus\x3bspleen\x3bcervix\x3bmammary_gland\x3bperipheral_nerve\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3buterus\x3bwhole_body\x3boesophagus\x3bbone\x3btestis\x3bspinal_ganglion\x3bpineal_gland\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bislets_of_Langerhans\x3bhypothalamus\x3bmuscle\x3bpancreas\x3blung\x3btrachea\x3bplacenta\x3bamnion\x3bkidney\x3bstomach\x3baorta\x3bthymus\x3b	superior_cervical_ganglion\x3bciliary_ganglion\x3bwhole_blood\x3bskeletal_muscle\x3b	0.99869	0.93060	-0.646543901	16.44255721	87.82499	2.00185	rs192632236	49055	Noonan_syndrome|Noonan_syndrome_with_multiple_lentigines|Rasopathy|not_specified|Cardiovascular_phenotype	MeSH:D009634,MedGen:C0028326,Orphanet:ORPHA648,SNOMED_CT:205824006|MedGen:C0175704,Orphanet:ORPHA500|MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374|MedGen:CN230736	reviewed_by_expert_panel	Benign	0.007	0.599	D	0.000	0.843	D	1	0.810	D	1.355	0.339	L	-1.01	0.764	T	-0.86	0.234	N	-0.671	0.618	T	0.221	0.585	T	0.017	0.389	T	.	.	0.982	0.800	D	c	0.184	0.394	1.0	0.983	0.707	0.730	0	6.17	0.997	5.768	0.683	0.935	0.490	1.000	0.715	1.000	0.888	20.879	0.999	.	.	.	.	.	6.459e-05	0	0.0024	0	0	0	0	0	0.0012	0	0.0085	0	0	0	8.951e-06	0.0005	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,483	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0.0003	Benign
19	4099271	4099271	C	A	exonic	MAP2K2	.	nonsynonymous_SNV	MAP2K2:NM_030662:exon7:c.G847T:p.V283L	0.86326115931858	0.136320885012997	0.00041795566842237	mitogen-activated_protein_kinase_kinase_2	FUNCTION:_Catalyzes_the_concomitant_phosphorylation_of_a_threonine_and_a_tyrosine_residue_in_a_Thr-Glu-Tyr_sequence_located_in_MAP_kinases._Activates_the_ERK1_and_ERK2_MAP_kinases_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Cardiofaciocutaneous_syndrome_4_(CFC4)_[MIM:615280]:_A_form_of_cardiofaciocutaneous_syndrome,_a_multiple_congenital_anomaly_disorder_characterized_by_a_distinctive_facial_appearance,_heart_defects_and_mental_retardation._Heart_defects_include_pulmonic_stenosis,_atrial_septal_defects_and_hypertrophic_cardiomyopathy._Some_affected_individuals_present_with_ectodermal_abnormalities_such_as_sparse,_friable_hair,_hyperkeratotic_skin_lesions_and_a_generalized_ichthyosis-like_condition._Typical_facial_features_are_similar_to_Noonan_syndrome._They_include_high_forehead_with_bitemporal_constriction,_hypoplastic_supraorbital_ridges,_downslanting_palpebral_fissures,_a_depressed_nasal_bridge,_and_posteriorly_angulated_ears_with_prominent_helices._{ECO:0000269|PubMed:16439621,_ECO:0000269|PubMed:18042262,_ECO:0000269|PubMed:20358587}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	medulla_oblongata\x3bsmooth_muscle\x3bovary\x3bsalivary_gland\x3bsympathetic_chain\x3bcolon\x3bparathyroid\x3bskin\x3buterus\x3bprostate\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bmuscle\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbile_duct\x3bpancreas\x3blung\x3badrenal_gland\x3bplacenta\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	amygdala\x3bprefrontal_cortex\x3btestis\x3bpons\x3bcingulate_cortex\x3b	0.88489	0.51187	-0.800872469	12.33191791	40.94266	1.19949	rs185999703	442539	Rasopathy	MedGen:CN166718,Orphanet:ORPHA98733	reviewed_by_expert_panel	Likely_benign	0.405	0.103	T	0.119	0.191	N	0.501	0.317	D	-0.09	0.047	N	-0.1	0.643	T	-0.31	0.121	N	-1.012	0.262	T	0.083	0.325	T	0.044	0.612	D	.	.	0.322	0.243	N	c	-1.185	-1.184	0.965	0.287	0.707	0.730	0	-2.13	0.067	0.017	0.132	-0.451	0.056	0.002	0.151	0.096	0.187	7.021	0.239	Protein_kinase_domain|Protein_kinase-like_domain	.	.	.	.	3.236e-05	0	0	0	0.0006	0	0	0	4.386e-05	0	0	0	0.0006	0	0	0	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,926	0	0	0	0	0	1	0	0	0	0	0	0	0	1	1	0	0	1	1	0	0	0.0003	Benign
19	4094469	4094469	C	T	exonic	MAP2K2	.	synonymous_SNV	MAP2K2:NM_030662:exon10:c.G1074A:p.A358A	0.86326115931858	0.136320885012997	0.00041795566842237	mitogen-activated_protein_kinase_kinase_2	FUNCTION:_Catalyzes_the_concomitant_phosphorylation_of_a_threonine_and_a_tyrosine_residue_in_a_Thr-Glu-Tyr_sequence_located_in_MAP_kinases._Activates_the_ERK1_and_ERK2_MAP_kinases_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Cardiofaciocutaneous_syndrome_4_(CFC4)_[MIM:615280]:_A_form_of_cardiofaciocutaneous_syndrome,_a_multiple_congenital_anomaly_disorder_characterized_by_a_distinctive_facial_appearance,_heart_defects_and_mental_retardation._Heart_defects_include_pulmonic_stenosis,_atrial_septal_defects_and_hypertrophic_cardiomyopathy._Some_affected_individuals_present_with_ectodermal_abnormalities_such_as_sparse,_friable_hair,_hyperkeratotic_skin_lesions_and_a_generalized_ichthyosis-like_condition._Typical_facial_features_are_similar_to_Noonan_syndrome._They_include_high_forehead_with_bitemporal_constriction,_hypoplastic_supraorbital_ridges,_downslanting_palpebral_fissures,_a_depressed_nasal_bridge,_and_posteriorly_angulated_ears_with_prominent_helices._{ECO:0000269|PubMed:16439621,_ECO:0000269|PubMed:18042262,_ECO:0000269|PubMed:20358587}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	medulla_oblongata\x3bsmooth_muscle\x3bovary\x3bsalivary_gland\x3bsympathetic_chain\x3bcolon\x3bparathyroid\x3bskin\x3buterus\x3bprostate\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bmuscle\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbile_duct\x3bpancreas\x3blung\x3badrenal_gland\x3bplacenta\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	amygdala\x3bprefrontal_cortex\x3btestis\x3bpons\x3bcingulate_cortex\x3b	0.88489	0.51187	-0.800872469	12.33191791	40.94266	1.19949	rs140896887	257127	Rasopathy|not_specified	MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374	reviewed_by_expert_panel	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0008	0.0026	0	0	0	0	6.684e-05	0	0.0001	0.0015	7.825e-05	0	0	0	1.408e-05	0	4.148e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,924	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0.0003	Benign
10	112769023	112769023	C	T	exonic	SHOC2	.	synonymous_SNV	SHOC2:NM_001269039:exon6:c.C1164T:p.N388N,SHOC2:NM_001324336:exon7:c.C1302T:p.N434N,SHOC2:NM_007373:exon7:c.C1302T:p.N434N,SHOC2:NM_001324337:exon8:c.C1302T:p.N434N	0.991705191552454	0.00829295945769003	1.84898985615785e-06	SHOC2_leucine-rich_repeat_scaffold_protein	FUNCTION:_Regulatory_subunit_of_protein_phosphatase_1_(PP1c)_that_acts_as_a_M-Ras/MRAS_effector_and_participates_in_MAPK_pathway_activation._Upon_M-Ras/MRAS_activation,_targets_PP1c_to_specifically_dephosphorylate_the_'Ser-259'_inhibitory_site_of_RAF1_kinase_and_stimulate_RAF1_activity_at_specialized_signaling_complexes._{ECO:0000269|PubMed:10783161,_ECO:0000269|PubMed:16630891,_ECO:0000269|PubMed:25137548}.\x3b_	DISEASE:_Noonan_syndrome-like_disorder_with_loose_anagen_hair_(NSLH)_[MIM:607721]:_A_syndrome_characterized_by_Noonan_dysmorphic_features_such_as_macrocephaly,_high_forehead,_hypertelorism,_palpebral_ptosis,_low-set_and_posteriorly_rotated_ears,_short_and_webbed_neck,_pectus_anomalies,_in_association_with_pluckable,_sparse,_thin_and_slow-growing_hair._{ECO:0000269|PubMed:19684605,_ECO:0000269|PubMed:25137548}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	ovary\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bfovea_centralis\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bpineal_body\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bcornea\x3bnasopharynx\x3bplacenta\x3bmacula_lutea\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bcervix\x3bkidney\x3bmammary_gland\x3bstomach\x3b	superior_cervical_ganglion\x3btestis_-_seminiferous_tubule\x3bprefrontal_cortex\x3btestis\x3btrigeminal_ganglion\x3b	0.46401	0.24608	-0.183570861	39.95046001	30.58108	0.97282	rs146147503	142811	Rasopathy|not_specified	MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374	reviewed_by_expert_panel	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0018	0.0063	0	0	0	0	6.676e-05	0.0010	0.0007	0.0096	0.0003	0	0	0	3.618e-05	0.0006	0	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,607	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0.0003	Benign
15	66777315	66777315	G	GTC	intronic	MAP2K1	.	.	.	0.994501270366062	0.00549805295620231	6.76677735529064e-07	mitogen-activated_protein_kinase_kinase_1	FUNCTION:_Dual_specificity_protein_kinase_which_acts_as_an_essential_component_of_the_MAP_kinase_signal_transduction_pathway._Binding_of_extracellular_ligands_such_as_growth_factors,_cytokines_and_hormones_to_their_cell-surface_receptors_activates_RAS_and_this_initiates_RAF1_activation._RAF1_then_further_activates_the_dual-specificity_protein_kinases_MAP2K1/MEK1_and_MAP2K2/MEK2._Both_MAP2K1/MEK1_and_MAP2K2/MEK2_function_specifically_in_the_MAPK/ERK_cascade,_and_catalyze_the_concomitant_phosphorylation_of_a_threonine_and_a_tyrosine_residue_in_a_Thr-Glu-Tyr_sequence_located_in_the_extracellular_signal-regulated_kinases_MAPK3/ERK1_and_MAPK1/ERK2,_leading_to_their_activation_and_further_transduction_of_the_signal_within_the_MAPK/ERK_cascade._Depending_on_the_cellular_context,_this_pathway_mediates_diverse_biological_functions_such_as_cell_growth,_adhesion,_survival_and_differentiation,_predominantly_through_the_regulation_of_transcription,_metabolism_and_cytoskeletal_rearrangements._One_target_of_the_MAPK/ERK_cascade_is_peroxisome_proliferator-_activated_receptor_gamma_(PPARG),_a_nuclear_receptor_that_promotes_differentiation_and_apoptosis._MAP2K1/MEK1_has_been_shown_to_export_PPARG_from_the_nucleus._The_MAPK/ERK_cascade_is_also_involved_in_the_regulation_of_endosomal_dynamics,_including_lysosome_processing_and_endosome_cycling_through_the_perinuclear_recycling_compartment_(PNRC),_as_well_as_in_the_fragmentation_of_the_Golgi_apparatus_during_mitosis._{ECO:0000269|PubMed:14737111,_ECO:0000269|PubMed:17101779}.\x3b_	DISEASE:_Cardiofaciocutaneous_syndrome_3_(CFC3)_[MIM:615279]:_A_form_of_cardiofaciocutaneous_syndrome,_a_multiple_congenital_anomaly_disorder_characterized_by_a_distinctive_facial_appearance,_heart_defects_and_mental_retardation._Heart_defects_include_pulmonic_stenosis,_atrial_septal_defects_and_hypertrophic_cardiomyopathy._Some_affected_individuals_present_with_ectodermal_abnormalities_such_as_sparse,_friable_hair,_hyperkeratotic_skin_lesions_and_a_generalized_ichthyosis-like_condition._Typical_facial_features_are_similar_to_Noonan_syndrome._They_include_high_forehead_with_bitemporal_constriction,_hypoplastic_supraorbital_ridges,_downslanting_palpebral_fissures,_a_depressed_nasal_bridge,_and_posteriorly_angulated_ears_with_prominent_helices._Distinctive_features_of_CFC3_include_macrostomia_and_horizontal_shape_of_palpebral_fissures._{ECO:0000269|PubMed:16439621,_ECO:0000269|PubMed:18042262}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Widely_expressed,_with_extremely_low_levels_in_brain._{ECO:0000269|PubMed:1281467}.\x3b_	ovary\x3bsympathetic_chain\x3bskin\x3bbone_marrow\x3bretina\x3bprostate\x3boptic_nerve\x3bendometrium\x3bthyroid\x3bgerminal_center\x3bbladder\x3bbrain\x3bheart\x3bcartilage\x3btongue\x3bpineal_body\x3bpharynx\x3bblood\x3blens\x3bskeletal_muscle\x3bbreast\x3btrabecular_meshwork\x3bvisual_apparatus\x3bmacula_lutea\x3bliver\x3bspleen\x3bmammary_gland\x3bsalivary_gland\x3bintestine\x3bcolon\x3bparathyroid\x3bchoroid\x3bfovea_centralis\x3buterus\x3bwhole_body\x3bbone\x3btestis\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bislets_of_Langerhans\x3bhypothalamus\x3bpancreas\x3blung\x3bnasopharynx\x3bplacenta\x3bhippocampus\x3bhead_and_neck\x3bkidney\x3bstomach\x3baorta\x3bthymus\x3b	whole_brain\x3bamygdala\x3bthalamus\x3boccipital_lobe\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3bhypothalamus\x3btemporal_lobe\x3bcaudate_nucleus\x3bsubthalamic_nucleus\x3bprefrontal_cortex\x3bglobus_pallidus\x3bcingulate_cortex\x3bparietal_lobe\x3bcerebellum\x3b	0.94061	0.84890	-0.449946534	24.00330267	4.89315	0.18138	rs113913469	99984	Noonan_syndrome|Cardio-facio-cutaneous_syndrome|Rasopathy|not_specified|not_provided	MeSH:D009634,MedGen:C0028326,Orphanet:ORPHA648,SNOMED_CT:205824006|MedGen:C1275081,Orphanet:ORPHA1340,SNOMED_CT:403770008|MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374|MedGen:CN517202	reviewed_by_expert_panel	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0127	0.0442	0.0012	0	0	0	0.0002	0.0031	0.0036	0.0499	0.0027	0	0	0	0.0002	0.0018	3.249e-05	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,885	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0.0003	Benign
19	4117480	4117480	C	T	exonic	MAP2K2	.	synonymous_SNV	MAP2K2:NM_030662:exon2:c.G240A:p.A80A	0.86326115931858	0.136320885012997	0.00041795566842237	mitogen-activated_protein_kinase_kinase_2	FUNCTION:_Catalyzes_the_concomitant_phosphorylation_of_a_threonine_and_a_tyrosine_residue_in_a_Thr-Glu-Tyr_sequence_located_in_MAP_kinases._Activates_the_ERK1_and_ERK2_MAP_kinases_(By_similarity)._{ECO:0000250}.\x3b_	DISEASE:_Cardiofaciocutaneous_syndrome_4_(CFC4)_[MIM:615280]:_A_form_of_cardiofaciocutaneous_syndrome,_a_multiple_congenital_anomaly_disorder_characterized_by_a_distinctive_facial_appearance,_heart_defects_and_mental_retardation._Heart_defects_include_pulmonic_stenosis,_atrial_septal_defects_and_hypertrophic_cardiomyopathy._Some_affected_individuals_present_with_ectodermal_abnormalities_such_as_sparse,_friable_hair,_hyperkeratotic_skin_lesions_and_a_generalized_ichthyosis-like_condition._Typical_facial_features_are_similar_to_Noonan_syndrome._They_include_high_forehead_with_bitemporal_constriction,_hypoplastic_supraorbital_ridges,_downslanting_palpebral_fissures,_a_depressed_nasal_bridge,_and_posteriorly_angulated_ears_with_prominent_helices._{ECO:0000269|PubMed:16439621,_ECO:0000269|PubMed:18042262,_ECO:0000269|PubMed:20358587}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	medulla_oblongata\x3bsmooth_muscle\x3bovary\x3bsalivary_gland\x3bsympathetic_chain\x3bcolon\x3bparathyroid\x3bskin\x3buterus\x3bprostate\x3bwhole_body\x3bfrontal_lobe\x3bendometrium\x3bbone\x3bthyroid\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3blymph_node\x3bcartilage\x3bheart\x3bislets_of_Langerhans\x3bmuscle\x3badrenal_cortex\x3bblood\x3blens\x3bskeletal_muscle\x3bbile_duct\x3bpancreas\x3blung\x3badrenal_gland\x3bplacenta\x3bvisual_apparatus\x3bhippocampus\x3bliver\x3bspleen\x3bhead_and_neck\x3bcervix\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	amygdala\x3bprefrontal_cortex\x3btestis\x3bpons\x3bcingulate_cortex\x3b	0.88489	0.51187	-0.800872469	12.33191791	40.94266	1.19949	rs543217722	377711	Rasopathy|not_specified|not_provided	MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374|MedGen:CN517202	reviewed_by_expert_panel	Likely_benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3.231e-05	0	0	0	0	0	6.668e-05	0	0.0001	6.539e-05	0.0002	0	0	0	8.956e-06	0	0.0009	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,937	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1	0	0	0.0002	Benign
11	120989335	120989335	A	G	exonic	TECTA	.	nonsynonymous_SNV	TECTA:NM_005422:exon6:c.A1111G:p.R371G	1.06498565113514e-12	0.999989745526101	1.02544728344311e-05	tectorin_alpha	FUNCTION:_One_of_the_major_non-collagenous_components_of_the_tectorial_membrane_(By_similarity)._The_tectorial_membrane_is_an_extracellular_matrix_of_the_inner_ear_that_covers_the_neuroepithelium_of_the_cochlea_and_contacts_the_stereocilia_bundles_of_specialized_sensory_hair_cells._Sound_induces_movement_of_these_hair_cells_relative_to_the_tectorial_membrane,_deflects_the_stereocilia_and_leads_to_fluctuations_in_hair-cell_membrane_potential,_transducing_sound_into_electrical_signals._{ECO:0000250}.\x3b_	DISEASE:_Deafness,_autosomal_dominant,_12_(DFNA12)_[MIM:601543]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:10196713,_ECO:0000269|PubMed:10987647,_ECO:0000269|PubMed:12162770,_ECO:0000269|PubMed:15319541,_ECO:0000269|PubMed:16718611,_ECO:0000269|PubMed:17661817,_ECO:0000269|PubMed:20947814,_ECO:0000269|PubMed:21520338,_ECO:0000269|PubMed:9590290}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Deafness,_autosomal_recessive,_21_(DFNB21)_[MIM:603629]:_A_form_of_non-syndromic_sensorineural_hearing_loss._Sensorineural_deafness_results_from_damage_to_the_neural_receptors_of_the_inner_ear,_the_nerve_pathways_to_the_brain,_or_the_area_of_the_brain_that_receives_sound_information._{ECO:0000269|PubMed:12746400,_ECO:0000269|PubMed:9949200}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	liver\x3btestis\x3bspleen\x3bblood\x3bbrain\x3b	superior_cervical_ganglion\x3batrioventricular_node\x3bskeletal_muscle\x3b	0.64735	0.20702	-2.430013277	1.032083038	4846.67098	14.13953	rs612969	54481	not_specified|Nonsyndromic_Hearing_Loss,_Dominant|Nonsyndromic_Hearing_Loss,_Recessive	MedGen:CN169374|MedGen:CN239435|MedGen:CN239439	criteria_provided,_multiple_submitters,_no_conflicts	Benign	1.0	0.010	T	0.000	0.629	N	1.000	0.198	P	-2.505	0.001	N	0.36	0.579	T	6.13	0.000	N	-0.909	0.470	T	0.000	0.000	T	.	.	.	.	.	0.058	0.116	N	c	-1.015	-0.761	0.806	0.242	0.516	0.203	0	3.86	0.435	4.963	0.632	0.138	0.222	1.000	0.715	0.687	0.306	11.718	0.507	von_Willebrand_factor,_type_D_domain	.	.	.	.	0.4906	0.6807	0.3289	0.3775	0.2255	0.4734	0.4288	0.4173	0.3975	0.6868	0.3321	0.3629	0.2514	0.4627	0.4130	0.3850	0.3168	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,633	0	0	0	0	0	1	0	0	0	0	0	0	1	1	0	0	0	1	0	0	1	0.0	Benign auto
14	23889445	23889445	T	TG	splicing	MYH7	NM_000257:exon27:c.3337-2->C	.	.	0.000145766291646031	0.999854233523213	1.85141250905742e-10	myosin,_heavy_chain_7,_cardiac_muscle,_beta	FUNCTION:_Muscle_contraction.\x3b_	DISEASE:_Cardiomyopathy,_familial_hypertrophic_1_(CMH1)_[MIM:192600]:_A_hereditary_heart_disorder_characterized_by_ventricular_hypertrophy,_which_is_usually_asymmetric_and_often_involves_the_interventricular_septum._The_symptoms_include_dyspnea,_syncope,_collapse,_palpitations,_and_chest_pain._They_can_be_readily_provoked_by_exercise._The_disorder_has_inter-_and_intrafamilial_variability_ranging_from_benign_to_malignant_forms_with_high_risk_of_cardiac_failure_and_sudden_cardiac_death._{ECO:0000269|PubMed:10065021,_ECO:0000269|PubMed:10329202,_ECO:0000269|PubMed:10521296,_ECO:0000269|PubMed:10563488,_ECO:0000269|PubMed:10679957,_ECO:0000269|PubMed:10862102,_ECO:0000269|PubMed:11113006,_ECO:0000269|PubMed:11133230,_ECO:0000269|PubMed:11214007,_ECO:0000269|PubMed:11424919,_ECO:0000269|PubMed:11733062,_ECO:0000269|PubMed:11861413,_ECO:0000269|PubMed:11968089,_ECO:0000269|PubMed:12081993,_ECO:0000269|PubMed:12566107,_ECO:0000269|PubMed:12590187,_ECO:0000269|PubMed:12707239,_ECO:0000269|PubMed:12818575,_ECO:0000269|PubMed:12820698,_ECO:0000269|PubMed:12951062,_ECO:0000269|PubMed:12974739,_ECO:0000269|PubMed:12975413,_ECO:0000269|PubMed:1417858,_ECO:0000269|PubMed:15358028,_ECO:0000269|PubMed:15483641,_ECO:0000269|PubMed:1552912,_ECO:0000269|PubMed:15563892,_ECO:0000269|PubMed:15856146,_ECO:0000269|PubMed:15858117,_ECO:0000269|PubMed:16199542,_ECO:0000269|PubMed:16267253,_ECO:0000269|PubMed:1638703,_ECO:0000269|PubMed:16650083,_ECO:0000269|PubMed:16938236,_ECO:0000269|PubMed:17372140,_ECO:0000269|PubMed:18175163,_ECO:0000269|PubMed:18403758,_ECO:0000269|PubMed:1975517,_ECO:0000269|PubMed:25182012,_ECO:0000269|PubMed:7581410,_ECO:0000269|PubMed:7731997,_ECO:0000269|PubMed:7848441,_ECO:0000269|PubMed:7874131,_ECO:0000269|PubMed:8250038,_ECO:0000269|PubMed:8254035,_ECO:0000269|PubMed:8268932,_ECO:0000269|PubMed:8282798,_ECO:0000269|PubMed:8343162,_ECO:0000269|PubMed:8435239,_ECO:0000269|PubMed:8483915,_ECO:0000269|PubMed:8655135,_ECO:0000269|PubMed:8899546,_ECO:0000269|PubMed:9544842,_ECO:0000269|PubMed:9822100,_ECO:0000269|PubMed:9829907}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Myopathy,_myosin_storage,_autosomal_dominant_(MSMA)_[MIM:608358]:_A_rare_congenital_myopathy_characterized_by_subsarcolemmal_hyalinized_bodies_in_type_1_muscle_fibers._{ECO:0000269|PubMed:14520662,_ECO:0000269|PubMed:15136674,_ECO:0000269|PubMed:16684601,_ECO:0000269|PubMed:17336526}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Scapuloperoneal_myopathy_MYH7-related_(SPMM)_[MIM:181430]:_Progressive_muscular_atrophia_beginning_in_the_lower_legs_and_affecting_the_shoulder_region_earlier_and_more_severely_than_distal_arm._{ECO:0000269|PubMed:17336526}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Cardiomyopathy,_dilated_1S_(CMD1S)_[MIM:613426]:_A_disorder_characterized_by_ventricular_dilation_and_impaired_systolic_function,_resulting_in_congestive_heart_failure_and_arrhythmia._Patients_are_at_risk_of_premature_death._{ECO:0000269|PubMed:11106718,_ECO:0000269|PubMed:12379228,_ECO:0000269|PubMed:15769782,_ECO:0000269|PubMed:18506004,_ECO:0000269|PubMed:21127202,_ECO:0000269|PubMed:21846512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Myopathy,_distal,_1_(MPD1)_[MIM:160500]:_A_muscular_disorder_characterized_by_early-onset_selective_weakness_of_the_great_toe_and_ankle_dorsiflexors,_followed_by_weakness_of_the_finger_extensors._Mild_proximal_weakness_occasionally_develops_years_later_after_the_onset_of_the_disease._{ECO:0000269|PubMed:15322983,_ECO:0000269|PubMed:17548557}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Myopathy,_myosin_storage,_autosomal_recessive_(MSMB)_[MIM:255160]:_An_autosomal_recessive_form_of_myosin_storage_myopathy,_a_muscle_disease_characterized_by_subsarcolemmal_accumulation_of_hyalinized_bodies_in_type_1_muscle_fibers._MSMB_clinical_features_include_muscle_weakness,_type_II_respiratory_failure_and_cardiac_failure,_due_to_hypertrophic_cardiomyopathy._{ECO:0000269|PubMed:25666907}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Both_wild_type_and_variant_Gln-403_are_detected_in_skeletal_muscle_(at_protein_level)._{ECO:0000269|PubMed:8514894}.\x3b_	unclassifiable_(Anatomical_System)\x3bgreater_omentum\x3bmyocardium\x3bprostate\x3blung\x3bheart\x3blarynx\x3bmuscle\x3btestis\x3bhead_and_neck\x3bskeletal_muscle\x3bperipheral_nerve\x3b	heart\x3btongue\x3bskeletal_muscle\x3b	0.43904	0.16764	-3.644803418	0.283085633	108.56923	2.26118	rs45504498	52126	Hypertrophic_cardiomyopathy|Scapuloperoneal_myopathy|Left_ventricular_noncompaction_cardiomyopathy|Myosin_storage_myopathy|Paroxysmal_familial_ventricular_fibrillation_1|Familial_hypertrophic_cardiomyopathy_1|Myopathy,_distal,_1|not_specified|Cardiovascular_phenotype|Dilated_Cardiomyopathy,_Dominant	Human_Phenotype_Ontology:HP:0001639,MedGen:C0007194,Orphanet:ORPHA217569|Human_Phenotype_Ontology:HP:0009054,MedGen:C2931268|Human_Phenotype_Ontology:HP:0011664,MedGen:C4021133|MedGen:C1842160,OMIM:608358,SNOMED_CT:699267007|MedGen:C2751898,OMIM:603829|MedGen:C3495498,OMIM:192600|MedGen:CN074249,OMIM:160500,Orphanet:ORPHA59135|MedGen:CN169374|MedGen:CN230736|MedGen:CN239310	reviewed_by_expert_panel	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0596	0.0297	0.0550	0.1047	0.0637	0.0826	0.0704	0.0643	0.0151	0.0083	0.0166	0.0113	0.0269	0.0110	0.0129	0.0239	0.0208	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,876	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	1	0.0	Benign auto
12	103306550	103306550	A	G	intronic	PAH	.	.	.	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs17842947	98643	Phenylketonuria|not_specified|not_provided	MedGen:C0031485,OMIM:261600,Orphanet:ORPHA716,SNOMED_CT:154735006|MedGen:CN169374|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.1901	0.2900	0.4031	0.1722	0.0727	0.0973	0.1571	0.1575	0.2015	0.2985	0.4412	0.2207	0.0833	0.0949	0.1556	0.1933	0.1967	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,828	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0.0	Benign auto
10	89720907	89720907	T	G	intronic	PTEN	.	.	.	0.975506865848027	0.0244877796497562	5.35450221699976e-06	phosphatase_and_tensin_homolog	FUNCTION:_Tumor_suppressor._Acts_as_a_dual-specificity_protein_phosphatase,_dephosphorylating_tyrosine-,_serine-_and_threonine-_phosphorylated_proteins._Also_acts_as_a_lipid_phosphatase,_removing_the_phosphate_in_the_D3_position_of_the_inositol_ring_from_phosphatidylinositol_3,4,5-trisphosphate,_phosphatidylinositol_3,4-diphosphate,_phosphatidylinositol_3-_phosphate_and_inositol_1,3,4,5-tetrakisphosphate_with_order_of_substrate_preference_in_vitro_PtdIns(3,4,5)P3_>_PtdIns(3,4)P2_>_PtdIns3P_>_Ins(1,3,4,5)P4._The_lipid_phosphatase_activity_is_critical_for_its_tumor_suppressor_function._Antagonizes_the_PI3K-_AKT/PKB_signaling_pathway_by_dephosphorylating_phosphoinositides_and_thereby_modulating_cell_cycle_progression_and_cell_survival._The_unphosphorylated_form_cooperates_with_AIP1_to_suppress_AKT1_activation._Dephosphorylates_tyrosine-phosphorylated_focal_adhesion_kinase_and_inhibits_cell_migration_and_integrin-mediated_cell_spreading_and_focal_adhesion_formation._Plays_a_role_as_a_key_modulator_of_the_AKT-mTOR_signaling_pathway_controlling_the_tempo_of_the_process_of_newborn_neurons_integration_during_adult_neurogenesis,_including_correct_neuron_positioning,_dendritic_development_and_synapse_formation._May_be_a_negative_regulator_of_insulin_signaling_and_glucose_metabolism_in_adipose_tissue._The_nuclear_monoubiquitinated_form_possesses_greater_apoptotic_potential,_whereas_the_cytoplasmic_nonubiquitinated_form_induces_less_tumor_suppressive_ability._In_motile_cells,_suppresses_the_formation_of_lateral_pseudopods_and_thereby_promotes_cell_polarization_and_directed_movement.\x3b_	DISEASE:_Cowden_syndrome_1_(CWS1)_[MIM:158350]:_An_autosomal_dominant_hamartomatous_polyposis_syndrome_with_age-related_penetrance._Cowden_syndrome_is_characterized_by_hamartomatous_lesions_affecting_derivatives_of_ectodermal,_mesodermal_and_endodermal_layers,_macrocephaly,_facial_trichilemmomas_(benign_tumors_of_the_hair_follicle_infundibulum),_acral_keratoses,_papillomatous_papules,_and_elevated_risk_for_development_of_several_types_of_malignancy,_particularly_breast_carcinoma_in_women_and_thyroid_carcinoma_in_both_men_and_women._Colon_cancer_and_renal_cell_carcinoma_have_also_been_reported._Hamartomas_can_be_found_in_virtually_every_organ,_but_most_commonly_in_the_skin,_gastrointestinal_tract,_breast_and_thyroid._{ECO:0000269|PubMed:10051160,_ECO:0000269|PubMed:10234502,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9140396,_ECO:0000269|PubMed:9259288,_ECO:0000269|PubMed:9345101,_ECO:0000269|PubMed:9399897,_ECO:0000269|PubMed:9425889,_ECO:0000269|PubMed:9600246,_ECO:0000269|PubMed:9735393,_ECO:0000269|PubMed:9797362,_ECO:0000269|PubMed:9832031,_ECO:0000269|PubMed:9915974}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Lhermitte-Duclos_disease_(LDD)_[MIM:158350]:_A_rare_disease_characterized_by_the_occurrence_of_a_slowly_enlarging_mass_within_the_cerebellar_cortex_corresponding_histologically_to_a_cerebellar_hamartoma._It_manifests,_most_commonly_in_the_third_and_fourth_decades_of_life,_with_increased_intracranial_pressure,_headache,_nausea,_cerebellar_dysfunction,_occlusive_hydrocephalus,_ataxia,_visual_disturbances_and_other_cranial_nerve_palsies._Various_associated_abnormalities_may_be_present_such_as_megalencephaly,_microgyria,_hydromyelia,_polydactyly,_partial_gigantism,_macroglossia._LDD_is_part_of_the_PTEN_hamartoma_tumor_syndromes_spectrum_that_also_includes_Cowden_syndrome._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Bannayan-Riley-Ruvalcaba_syndrome_(BRRS)_[MIM:153480]:_A_rare_hamartomatous_disorder_characterized_by_macrocephaly_and_multiple_hemangiomas_as_well_as_subcutaneous_and_visceral_lipomas._It_belongs_to_the_family_of_hamartomatous_polyposis_syndromes_that_includes_Peutz_Jeghers_syndrome,_juvenile_polyposis,_and_Cowden_syndrome._{ECO:0000269|PubMed:10400993,_ECO:0000269|PubMed:11494117,_ECO:0000269|PubMed:9241266,_ECO:0000269|PubMed:9467011}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Squamous_cell_carcinoma_of_the_head_and_neck_(HNSCC)_[MIM:275355]:_A_non-melanoma_skin_cancer_affecting_the_head_and_neck._The_hallmark_of_cutaneous_SCC_is_malignant_transformation_of_normal_epidermal_keratinocytes._{ECO:0000269|PubMed:11801303}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Endometrial_cancer_(ENDMC)_[MIM:608089]:_A_malignancy_of_endometrium,_the_mucous_lining_of_the_uterus._Most_endometrial_cancers_are_adenocarcinomas,_cancers_that_begin_in_cells_that_make_and_release_mucus_and_other_fluids._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dPTEN_mutations_are_found_in_a_subset_of_patients_with_Proteus_syndrome,_a_genetically_heterogeneous_condition._The_molecular_diagnosis_of_PTEN_mutation_positive_cases_classifies_Proteus_syndrome_patients_as_part_of_the_PTEN_hamartoma_syndrome_spectrum._As_such,_patients_surviving_the_early_years_of_Proteus_syndrome_are_likely_at_a_greater_risk_of_developing_malignancies.\x3b_DISEASE:_Glioma_2_(GLM2)_[MIM:613028]:_Gliomas_are_benign_or_malignant_central_nervous_system_neoplasms_derived_from_glial_cells._They_comprise_astrocytomas_and_glioblastoma_multiforme_that_are_derived_from_astrocytes,_oligodendrogliomas_derived_from_oligodendrocytes_and_ependymomas_derived_from_ependymocytes._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_VACTERL_association_with_hydrocephalus_(VACTERL-H)_[MIM:276950]:_VACTERL_is_an_acronym_for_vertebral_anomalies,_anal_atresia,_congenital_cardiac_disease,_tracheoesophageal_fistula,_renal_anomalies,_radial_dysplasia,_and_other_limb_defects._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Prostate_cancer_(PC)_[MIM:176807]:_A_malignancy_originating_in_tissues_of_the_prostate._Most_prostate_cancers_are_adenocarcinomas_that_develop_in_the_acini_of_the_prostatic_ducts._Other_rare_histopathologic_types_of_prostate_cancer_that_occur_in_approximately_5%_of_patients_include_small_cell_carcinoma,_mucinous_carcinoma,_prostatic_ductal_carcinoma,_transitional_cell_carcinoma,_squamous_cell_carcinoma,_basal_cell_carcinoma,_adenoid_cystic_carcinoma_(basaloid),_signet-ring_cell_carcinoma_and_neuroendocrine_carcinoma._{ECO:0000269|PubMed:9072974}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Macrocephaly/autism_syndrome_(MCEPHAS)_[MIM:605309]:_Patients_have_autism_spectrum_disorders_and_macrocephaly,_with_head_circumferences_ranging_from_+2.5_to_+8_SD_for_age_and_sex_(average_head_circumference_+4.0_SD)._{ECO:0000269|PubMed:15805158}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_microdeletion_of_chromosome_10q23_involving_BMPR1A_and_PTEN_is_a_cause_of_chromosome_10q23_deletion_syndrome,_which_shows_overlapping_features_of_the_following_three_disorders:_Bannayan-Zonana_syndrome,_Cowden_disease_and_juvenile_polyposis_syndrome.\x3b_	TISSUE_SPECIFICITY:_Expressed_at_a_relatively_high_level_in_all_adult_tissues,_including_heart,_brain,_placenta,_lung,_liver,_muscle,_kidney_and_pancreas._{ECO:0000269|PubMed:9090379}.\x3b_	.	.	0.21037	0.94603	-0.229483771	36.86010852	3.61036	0.13188	rs555895	98717	not_specified	MedGen:CN169374	criteria_provided,_multiple_submitters,_no_conflicts	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.3864	0.4945	0.4277	0.4133	0.4926	0.3432	0.3217	0.3480	0.3726	0.5005	0.4584	0.3706	0.4882	0.3428	0.3349	0.3783	0.3089	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,591	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0.0	Benign auto
21	36206932	36206932	G	A	intronic	RUNX1	.	.	.	0.449323606506754	0.54937349793652	0.00130289555672611	runt_related_transcription_factor_1	FUNCTION:_CBF_binds_to_the_core_site,_5'-PYGPYGGT-3',_of_a_number_of_enhancers_and_promoters,_including_murine_leukemia_virus,_polyomavirus_enhancer,_T-cell_receptor_enhancers,_LCK,_IL-3_and_GM-CSF_promoters._The_alpha_subunit_binds_DNA_and_appears_to_have_a_role_in_the_development_of_normal_hematopoiesis._Isoform_AML-1L_interferes_with_the_transactivation_activity_of_RUNX1._Acts_synergistically_with_ELF4_to_transactivate_the_IL-3_promoter_and_with_ELF2_to_transactivate_the_mouse_BLK_promoter._Inhibits_KAT6B-_dependent_transcriptional_activation._Controls_the_anergy_and_suppressive_function_of_regulatory_T-cells_(Treg)_by_associating_with_FOXP3._Activates_the_expression_of_IL2_and_IFNG_and_down-_regulates_the_expression_of_TNFRSF18,_IL2RA_and_CTLA4,_in_conventional_T-cells_(PubMed:17377532)._{ECO:0000269|PubMed:10207087,_ECO:0000269|PubMed:11965546,_ECO:0000269|PubMed:14970218,_ECO:0000269|PubMed:17377532,_ECO:0000269|PubMed:17431401}.\x3b_	DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_M2_type_acute_myeloid_leukemia_(AML-M2)._Translocation_t(8\x3b21)(q22\x3bq22)_with_RUNX1T1.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_therapy-related_myelodysplastic_syndrome_(T-MDS)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelogenous_leukemia_(CML)._Translocation_t(3\x3b21)(q26\x3bq22)_with_EAP_or_MECOM.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_childhood_acute_lymphoblastic_leukemia_(ALL)._Translocation_t(12\x3b21)(p13\x3bq22)_with_TEL._The_translocation_fuses_the_3'-end_of_TEL_to_the_alternate_5'-exon_of_AML-1H.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1_is_found_in_acute_leukemia._Translocation_t(11,21)(q13\x3bq22)_that_forms_a_MACROD1-RUNX1_fusion_protein.\x3b_DISEASE:_Familial_platelet_disorder_with_associated_myeloid_malignancy_(FPDMM)_[MIM:601399]:_Autosomal_dominant_disease_characterized_by_qualitative_and_quantitative_platelet_defects,_and_propensity_to_develop_acute_myelogenous_leukemia._{ECO:0000269|PubMed:10508512}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_found_in_therapy-related_myeloid_malignancies._Translocation_t(16\x3b21)(q24\x3bq22)_that_forms_a_RUNX1-CBFA2T3_fusion_protein.\x3b_DISEASE:_Note\x3dA_chromosomal_aberration_involving_RUNX1/AML1_is_a_cause_of_chronic_myelomonocytic_leukemia._Inversion_inv(21)(q21\x3bq22)_with_USP16.\x3b_	TISSUE_SPECIFICITY:_Expressed_in_all_tissues_examined_except_brain_and_heart._Highest_levels_in_thymus,_bone_marrow_and_peripheral_blood.\x3b_	myocardium\x3bsmooth_muscle\x3bovary\x3bcolon\x3bparathyroid\x3bskin\x3bbone_marrow\x3buterus\x3bprostate\x3boptic_nerve\x3bwhole_body\x3bendometrium\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bbladder\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bpharynx\x3bblood\x3bskeletal_muscle\x3bbreast\x3bpancreas\x3blung\x3bepididymis\x3bnasopharynx\x3bplacenta\x3balveolus\x3bliver\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bthymus\x3b	dorsal_root_ganglion\x3bsuperior_cervical_ganglion\x3bmedulla_oblongata\x3bcerebellum_peduncles\x3batrioventricular_node\x3bpons\x3bcaudate_nucleus\x3bskeletal_muscle\x3bbone_marrow\x3bfetal_liver\x3btestis_-_seminiferous_tubule\x3bglobus_pallidus\x3bciliary_ganglion\x3btrigeminal_ganglion\x3bcingulate_cortex\x3b	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	rs11702841	257457	not_specified	MedGen:CN169374	criteria_provided,_single_submitter	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,958	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0.0	Benign auto
12	103246700	103246700	C	T	exonic	PAH	.	synonymous_SNV	PAH:NM_000277:exon7:c.G735A:p.V245V	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs1042503	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.2257	0.0512	0.2112	0.29	0.7509	0.3059	0.2460	0.3119	0.2898	0.0395	0.2094	0.2824	0.7537	0.3055	0.2515	0.2836	0.3730	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,750	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0.0	Benign auto
12	103240630	103240630	C	A	intronic	PAH	.	.	.	1.19519744629961e-10	0.307448665079143	0.692551334801337	phenylalanine_hydroxylase	.	DISEASE:_Phenylketonuria_(PKU)_[MIM:261600]:_Autosomal_recessive_inborn_error_of_phenylalanine_metabolism,_due_to_severe_phenylalanine_hydroxylase_deficiency._It_is_characterized_by_blood_concentrations_of_phenylalanine_persistently_above_1200_mumol_(normal_concentration_100_mumol)_which_usually_causes_mental_retardation_(unless_low_phenylalanine_diet_is_introduced_early_in_life)._They_tend_to_have_light_pigmentation,_rashes_similar_to_eczema,_epilepsy,_extreme_hyperactivity,_psychotic_states_and_an_unpleasant_'mousy'_odor._{ECO:0000269|PubMed:10200057,_ECO:0000269|PubMed:10679941,_ECO:0000269|PubMed:11180595,_ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11461196,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1355066,_ECO:0000269|PubMed:1363837,_ECO:0000269|PubMed:1363838,_ECO:0000269|PubMed:1671810,_ECO:0000269|PubMed:1672290,_ECO:0000269|PubMed:1672294,_ECO:0000269|PubMed:1679030,_ECO:0000269|PubMed:1709636,_ECO:0000269|PubMed:1975559,_ECO:0000269|PubMed:2014802,_ECO:0000269|PubMed:22513348,_ECO:0000269|PubMed:22526846,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:2564729,_ECO:0000269|PubMed:2615649,_ECO:0000269|PubMed:2840952,_ECO:0000269|PubMed:7833954,_ECO:0000269|PubMed:8068076,_ECO:0000269|PubMed:8406445,_ECO:0000269|PubMed:8889590,_ECO:0000269|PubMed:9048935,_ECO:0000269|PubMed:9101291,_ECO:0000269|PubMed:9452061,_ECO:0000269|PubMed:9452062,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9600453,_ECO:0000269|PubMed:9792407,_ECO:0000269|PubMed:9950317}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Non-phenylketonuria_hyperphenylalaninemia_(Non-PKU_HPA)_[MIM:261600]:_Mild_form_of_phenylalanine_hydroxylase_deficiency_characterized_by_phenylalanine_levels_persistently_below_600_mumol,_which_allows_normal_intellectual_and_behavioral_development_without_treatment._Non-PKU_HPA_is_usually_caused_by_the_combined_effect_of_a_mild_hyperphenylalaninemia_mutation_and_a_severe_one._{ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hyperphenylalaninemia_(HPA)_[MIM:261600]:_Mildest_form_of_phenylalanine_hydroxylase_deficiency._{ECO:0000269|PubMed:11385716,_ECO:0000269|PubMed:11935335,_ECO:0000269|PubMed:12501224,_ECO:0000269|PubMed:1358789,_ECO:0000269|PubMed:23792259,_ECO:0000269|PubMed:8088845,_ECO:0000269|PubMed:8098245,_ECO:0000269|PubMed:9521426,_ECO:0000269|PubMed:9852673}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	.	unclassifiable_(Anatomical_System)\x3blung\x3bwhole_body\x3bislets_of_Langerhans\x3bliver\x3btestis\x3bspleen\x3bkidney\x3bmammary_gland\x3bgall_bladder\x3b	superior_cervical_ganglion\x3bfetal_liver\x3bliver\x3bciliary_ganglion\x3bkidney\x3b	0.13031	0.85678	-0.709045403	14.673272	115.70583	2.33963	rs1522306	98662	not_specified|not_provided	MedGen:CN169374|MedGen:CN517202	criteria_provided,_multiple_submitters,_no_conflicts	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.3704	0.2733	0.2792	0.3377	0.0595	0.4931	0.4359	0.3957	0.3533	0.2708	0.2431	0.3306	0.0555	0.4898	0.4207	0.3629	0.3448	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,680	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0.0	Benign auto
11	534242	534242	A	G	exonic	HRAS	.	synonymous_SNV	HRAS:NM_001130442:exon2:c.T81C:p.H27H,HRAS:NM_005343:exon2:c.T81C:p.H27H,HRAS:NM_176795:exon2:c.T81C:p.H27H	0.00794104930284198	0.785285637637198	0.20677331305996	Harvey_rat_sarcoma_viral_oncogene_homolog	FUNCTION:_Ras_proteins_bind_GDP/GTP_and_possess_intrinsic_GTPase_activity._{ECO:0000269|PubMed:12740440,_ECO:0000269|PubMed:14500341,_ECO:0000269|PubMed:9020151}.\x3b_	DISEASE:_Costello_syndrome_(CSTLO)_[MIM:218040]:_A_rare_condition_characterized_by_prenatally_increased_growth,_postnatal_growth_deficiency,_mental_retardation,_distinctive_facial_appearance,_cardiovascular_abnormalities_(typically_pulmonic_stenosis,_hypertrophic_cardiomyopathy_and/or_atrial_tachycardia),_tumor_predisposition,_skin_and_musculoskeletal_abnormalities._{ECO:0000269|PubMed:16170316,_ECO:0000269|PubMed:16329078,_ECO:0000269|PubMed:16443854,_ECO:0000269|PubMed:17054105,_ECO:0000269|PubMed:18039947,_ECO:0000269|PubMed:18247425,_ECO:0000269|PubMed:19995790}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Congenital_myopathy_with_excess_of_muscle_spindles_(CMEMS)_[MIM:218040]:_Variant_of_Costello_syndrome._{ECO:0000269|PubMed:17412879}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Hurthle_cell_thyroid_carcinoma_(HCTC)_[MIM:607464]:_A_rare_type_of_thyroid_cancer_accounting_for_only_about_3-10%_of_all_differentiated_thyroid_cancers._These_neoplasms_are_considered_a_variant_of_follicular_carcinoma_of_the_thyroid_and_are_referred_to_as_follicular_carcinoma,_oxyphilic_type._{ECO:0000269|PubMed:12727991}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Note\x3dMutations_which_change_positions_12,_13_or_61_activate_the_potential_of_HRAS_to_transform_cultured_cells_and_are_implicated_in_a_variety_of_human_tumors._{ECO:0000269|PubMed:3670300}.\x3b_DISEASE:_Bladder_cancer_(BLC)_[MIM:109800]:_A_malignancy_originating_in_tissues_of_the_urinary_bladder._It_often_presents_with_multiple_tumors_appearing_at_different_times_and_at_different_sites_in_the_bladder._Most_bladder_cancers_are_transitional_cell_carcinomas_that_begin_in_cells_that_normally_make_up_the_inner_lining_of_the_bladder._Other_types_of_bladder_cancer_include_squamous_cell_carcinoma_(cancer_that_begins_in_thin,_flat_cells)_and_adenocarcinoma_(cancer_that_begins_in_cells_that_make_and_release_mucus_and_other_fluids)._Bladder_cancer_is_a_complex_disorder_with_both_genetic_and_environmental_influences._{ECO:0000269|PubMed:6298635,_ECO:0000269|PubMed:6844927}._Note\x3dDisease_susceptibility_is_associated_with_variations_affecting_the_gene_represented_in_this_entry.\x3b_DISEASE:_Schimmelpenning-Feuerstein-Mims_syndrome_(SFM)_[MIM:163200]:_A_disease_characterized_by_sebaceous_nevi,_often_on_the_face,_associated_with_variable_ipsilateral_abnormalities_of_the_central_nervous_system,_ocular_anomalies,_and_skeletal_defects._Many_oral_manifestations_have_been_reported,_not_only_including_hypoplastic_and_malformed_teeth,_and_mucosal_papillomatosis,_but_also_ankyloglossia,_hemihyperplastic_tongue,_intraoral_nevus,_giant_cell_granuloma,_ameloblastoma,_bone_cysts,_follicular_cysts,_oligodontia,_and_odontodysplasia._Sebaceous_nevi_follow_the_lines_of_Blaschko_and_these_can_continue_as_linear_intraoral_lesions,_as_in_mucosal_papillomatosis._{ECO:0000269|PubMed:22683711}._Note\x3dThe_disease_is_caused_by_mutations_affecting_the_gene_represented_in_this_entry.\x3b_	TISSUE_SPECIFICITY:_Widely_expressed._{ECO:0000269|PubMed:14500341}.\x3b_	ovary\x3bdevelopmental\x3bcolon\x3bchoroid\x3bskin\x3bretina\x3bbone_marrow\x3buterus\x3boptic_nerve\x3bwhole_body\x3boesophagus\x3bendometrium\x3bthyroid\x3bbone\x3biris\x3btestis\x3bgerminal_center\x3bbrain\x3bunclassifiable_(Anatomical_System)\x3bcartilage\x3bheart\x3btongue\x3bislets_of_Langerhans\x3bhypothalamus\x3bblood\x3blens\x3bskeletal_muscle\x3blung\x3bplacenta\x3bvisual_apparatus\x3bhypopharynx\x3bspleen\x3bhead_and_neck\x3bkidney\x3bmammary_gland\x3bstomach\x3bcerebellum\x3b	whole_brain\x3bmedulla_oblongata\x3btrigeminal_ganglion\x3b	0.99944	0.99980	-0.339715008	30.06605331	4.91473	0.18207	rs12628	48901	Rasopathy|not_specified|not_provided	MedGen:CN166718,Orphanet:ORPHA98733|MedGen:CN169374|MedGen:CN517202	reviewed_by_expert_panel	Benign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.3432	0.3836	0.3600	0.2616	0.2135	0.2675	0.3542	0.3134	0.3157	0.3789	0.3814	0.2712	0.1885	0.2675	0.3384	0.3086	0.2520	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,623	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	1	0.0	Benign auto
